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GENERAL CARE
There are aspects o f general care that apply to all newborns regardless 
of gestational age or medical condition. This chapter deals with the general 
care that newborns receive during the four phases o f their hospitalization: 
delivery, transition, the hospital stay, and discharge. Infection control and 
general laboratory evaluation are also discussed.
CORD CLAMPING
AND CORD BLOOD COLLECTION
After delivery of the infant's head, the obstetrician must clear the in­
fant's airway. During the 30 to 60 seconds o f suctioning, usually before 
clamping the cord, the infant is held at the level o f the introitus or abdomen 
to prevent a significant shift of his blood volume. Consequences of a sig­
nificant shift toward the infant include polycythemia, circulatory volume 
overload, and hyperbilirubinemia, and these generally outweigh any poten­
tial advantage of augmenting the infant's iron reserve. Stripping the umbili­
cal cord to enhance placental transfusion to the infant is reserved for infre­
quent instances of severe fetal hypo-volemia. As soon as possible after suc­
tioning, the cord is clamped and cut 4 to 5 cm from the infant's abdomen. 
After the infant is dried and stabilized and if the umbilical base appears 
normal, an umbilical clamp is secured to the cord 1 to 2 cm distal to the ab­
dominal wall, and any excess length is cut. If the base appears fuller than 
normal, suggesting an omphalocele, or if catheterization of umbilical ves­
sels is likely, it is helpful to clamp the cord more distally. Notation should 
be made if fewer than three umbilical vessels exist.
After delivery o f the placenta, blood may be collected for laboratory 
tests by direct needle aspiration o f the fetal vessels in the cord or on the fe­
tal placental surface. Allowing placental blood to drip from the cord directly 
into laboratory tubes before placental delivery may contaminate the speci­
men if there is not a free flow. Fetal or placental blood should not clot for at 
least 15 minutes after cord clamping.
TEMPERATURE CONTROL
At delivery, the infant moves from a warm environment in utero into 
a much cooler delivery room. Although this immediate cold stress helps the 
infant initiate breathing, prolonged cold stress is dangerous. Because the 
neonate is particularly vulnerable to hypothermia, she requires exquisite at­
tention to her environmental support. She should be placed on a heated radi­
ant warmer bed, dried with warm linens, and swaddled in clean ones, with a 
stockinet cap covering her head. If the parent holding the infant wishes to 
unwrap and inspect her, a radiant warmer should be placed over the parent 
and baby. Common potential sources of cold stress in the first few hours in-
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elude cold oxygen used in resuscitation, un-warmed transport incubators, 
environmental drafts, and the initial weighing, bathing, and examination.
IDENTIFICATION AND SECURITY
Footprinting, palmprinting, or fingerprinting are the traditional meth­
ods of documenting a newborn's identity. Despite evidence that these meth­
ods are unreliable, local regulations may require them. Before leaving the 
delivery room, each infant should be identified by wrist and ankle bands 
that indicate his mother's name and hospital identification number and the 
infant's hospital number and date of birth. The mother should wear a band 
with identical information; the father may do so as well. Any time an infant 
is released to a parent, the matching bands must be verified. Parents should 
verify the identity of anyone asking to take their infant from their room. Be­
cause of the variety of personnel and visitors in maternity, nursery, and 
postpartum areas, all hospitals should follow strict security precautions to 
ensure the safety of each newborn.
INFECTION CONTROL
Because bacterial and viral infections can be devastating to neonates, 
prevention and early detection are mainstays of general care. Meticulous at­
tention to infection control is essential, because newborns are at risk for in­
fections acquired from their mothers, their environment, and the personnel 
providing their care.
Careful hand washing is the mainstay of infection control. Before en­
tering the nursery, personnel should scrub their hands and forearms to the 
elbows with a sponge and an antiseptic preparation such as iodophor, chlor- 
hexidine, or hexachlorophene. Hands should be washed and dried before 
and after handling each baby and after touching any object likely to be con­
taminated.
If there is the potential for contact with blood or body fluids, person­
nel should protect themselves and other patients by following universal pre­
cautions. This means simply wearing gloves for diaper changes and phle­
botomy. For more invasive procedures, gown, mask, goggles, and gloves 
are appropriate. Contaminated linens and clothing should be disposed of 
properly.
Cover gowns have traditionally been used in nursery and postpartum 
units, but gowning decreases neither bacterial colonization of the infant's 
nose or umbilicus nor the incidence of sepsis. Gowns are valuable for pro­
tecting the caregiver's clothing and where universal precautions apply, but 
their routine use is unnecessary. The fact that ungowned visitors pose no 
greater risk to healthy newborns has also brought into question the tradi­
tional use of scrub attire in nurseries; it remains necessary for personnel 
who attend deliveries.
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Providing each infant with his own clothing, diapers, and bulb syringe 
limits cross-contamination and essentially isolates each infant with his own 
equipment. It is common practice to wipe equipment such as stethoscopes 
with alcohol between uses on multiple infants. There is no convincing evi­
dence that this decreases colonization or cross-contamination, but like 
gowning, if the practice reminds personnel to practice careful hand washing, 
it is valuable. Nursery linens and infant clothing may be routinely laun­
dered; autoclaving is unnecessary.
Separating infants into cohort groups by age, which allows complete 
cleaning of a nursery module as that cohort is discharged, is an effective 
means of preventing the spread of pathogens. Cohorting can be routine or 
instituted after an outbreak occurs.
ADMISSION PROCEDURES
After initial stabilization the infant is transferred to an area where her 
adaptation to extrauterine life can be monitored while routine admission 
procedures are performed. This area may be in a specialized nursery, the 
routine care nursery, or the postpartum recovery room. Its staff should be 
attuned to the subtleties of newborn adaptation and familiar with aberrations 
of medical history, physical examination, or laboratory data that may neces­
sitate immediate involvement of the infant's physician.
TRANSITION AND INITIAL PHYSICAL ASSESSMENT
The transition period classically refers to the first 6 to 12 hours of 
life, during which a healthy newborn goes through predictable patterns of 
alertness, vital sign changes, and gastrointestinal activity. Sick, stressed, or 
premature infants do not follow the predictable patterns. Proper interpreta­
tion o f the changing physical findings in the first few hours depends on fa­
miliarity with these normal patterns.
Increasingly, the term "transition" is used interchangeably with "adap­
tation." Physiologic adaptation to extrauterine life occurs over the first 24 
hours and is considered complete when vital signs, feeding, and gastrointes­
tinal and renal function are normal. Infants with delayed or prolonged tran­
sitions may have persistent tachypnea, delayed hunger and feeding, or diffi­
culty maintaining their temperature. Differentiating an otherwise healthy in­
fant with delayed transition from an ill infant with similar symptoms is 
sometimes difficult. Because time alone cures one and harms the other, it is 
crucial to make an accurate observation.
An initial assessment o f the newborn includes measurement of vital 
signs (e.g., heart rate, respiratory rate, temperature), body measurements 
(e.g., weight, length, head circumference, sometimes chest and abdominal 
circumference), and a complete physical examination. Assessment o f vital 
signs, behavior, and activity continues at least every half hour until remain­
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ing stable for 2 hours. Although the AAP suggests that the apparently nor­
mal infant should be examined by 12 to 18 hours of age by the responsible 
physician, many newborns are not seen by physicians until almost 24 hours 
of age. There is much reliance on astute nurses whose experience and judg­
ment are invaluable in the newborn's initial care.
VITAMIN К
Because of poor placental transport of vitamin К and an absence of 
intestinal flora to produce it, newborns have low levels of active vitamin In­
dependent clotting factors. This insufficiency may present clinically as a 
spontaneous bleeding diathesis, notably as gastrointestinal, skin, or intrac­
ranial hemorrhage. Hem-orrhagic disease of the newborn, a potentially le­
thal disorder, has an incidence of 0.25% to 1.7%; breastfed infants and in­
fants of mothers taking anticonvul-sants are at highest risk. Although effec­
tively treated with vitamin К and blood products, the disease can be pre­
vented by the administration of 0.5 to 1 mg of vitamin K, given intramuscu­
larly within 1 hour of birth. Oral vitamin К is effective, although there is no 
consensus on optimal dosage. Careful documentation o f vitamin К admini­
stration is important.
EYE PROPHYLAXIS
The prevention of neonatal gonococcal ophthalmia was the original 
impetus for newborn eye prophylaxis. Chlamydia, although causing a less 
serious ophthalmia, is the more prevalent ocular pathogen acquired by the 
newborn from the maternal genital tract. Penicillinase-producing gonococci 
(PPGC) are becoming prevalent. Acceptable agents for eye prophylaxis are 
1% silver nitrate, 0.5% erythromycin, and 1% tetracycline. Erythromycin 
and tetracycline have direct antibiotic effects; silver nitrate causes a chemi­
cal conjunctivitis, producing an inflammatory response with a secondary an­
tibiotic effect. Each agent has limitations in its spectrum of activity. All are 
effective against sensitive gonococci; silver nitrate is the most effective 
against PPGC; no agent works particularly well against Chlamydia.
All agents are instilled into the lower conjunctival sac, and the lids 
are massaged to distribute the medication. Excess medication can be wiped 
away, but the eyes should not be flushed. To allow for uninhibited mutual 
gazing and parent-infant bonding in the delivery room, eye prophylaxis may 
be delayed until admission to the nursery, where it can be carefully adminis­
tered and documented. However, it should not be delayed longer than 1 
hour. Topical antimicrobial therapy is insufficient prophylaxis for infants of 
mothers with active gonococcal infections at delivery, and these infants 
must receive parenteral therapy as well.
Although evidence suggests that ocular prophylaxis is not necessary 
for infants delivered by cesarean section after fewer than 3 hours of rup­
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tured membranes, the AAP recommends prophylaxis for all infants, regard­
less of route of delivery.
GENERAL LABORATORY EVALUATION
MATERNAL EVALUATION
Several screening blood tests are recommended for all pregnant 
women:
• hemoglobin and hematocrit levels
• serologic test for syphilis (STS)
• blood group, Rh type, and indirect Coombs test
• rubella IgG
• hepatitis В surface antigen (HBsAg)
• a-fetoprotein.
In at-risk populations, screening for human immunodeficiency virus 
(HIV) and illicit drugs is routine, and STS in the third trimester and at deliv­
ery are recommended. The results of the tests should be available to the in­
fant's caregivers as early diagnostic or therapeutic actions may be necessary. 
There should be a standard manner in which this information is transmitted to 
the infant's chart. Any other abnormalities or problems during the pregnancy 
should be also be noted on the chart.
NEONATAL EVALUATION
The value of routine laboratory evaluations on all patients admitted to 
hospitals is a subject of debate. Previous recommendations for newborns 
have included blood type and direct Coombs test, serologic test for syphilis, 
hemoglobin and hematocrit, glucose or rapid blood glucose screen, urinaly­
sis, and the newborn metabolic screen. Of these, only the metabolic screen 
should be performed on every infant; other tests are necessary as indicated in 
the text that follows.
BLOOD TYPE AND COOMBS TEST
The infants at risk for hemolytic disease due to Rh type or major blood 
group incompatibility are Rh-positive infants of Rh-negative mothers and 
type A or В infants of type О mothers. The Rh status of any infant born to an 
Rh-negative mother should be determined to identify candidates for maternal 
immunoprophylaxis; even if an Rh-positive baby is unaffected by Rh disease, 
RhoGAM (i.e., anti-Rh IgG) should be given to the mother postpartum to 
protect future Rh-positive fetuses. Blood typing all infants of type О mothers 
is more controversial. Infants with clinically significant hemolysis due to 
ABO incompatibility usually have only mild anemia; hyperbilirubinemia is 
the major problem. In the past, infants of type О mothers were observed for 
the development of jaundice; type and Coombs status were determined if
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jaundice occurred. Because of the current practice of discharging the mother 
and infant as early as 24 hours postpartum, further observation of the infant 
for jaundice is not feasible, and it is helpful to know the blood type of these 
infants before discharge. Direct Coombs-negative type A or В infants have 
hemoglobin values, reticulocyte counts, and bilirubin levels comparable to 
those of type О infants. Coombs-positive infants usually have lower hemo­
globin values and higher reticulocyte counts and bilirubin levels, indicating 
more hemolysis. Coombs testing should be done on the cord blood of all type 
A or В infants of type О mothers. Cord or serum bilirubin levels, hemoglobin 
and hematocrit testing, and reticulocyte counts are optional unless therapy for 
hyperbilirubinemia is likely or indicated.
GLUCOSE SCREENING
The incidence of hypoglycemia is decreasing as newborns are fed 
sooner after birth and as maternal diabetes is better controlled. Selected 
screening of infants who are at risk by virtue of history or size is appropriate. 
Any infant with symptoms attributable to hypoglycemia should have a glu­
cose test. Rapid glucose screening tests are technique dependent; those that 
use reagent strips demonstrating color change may be inaccurate at high he­
moglobin and hematocrit levels. Abnormal results should be confirmed by 
standard whole blood glucose assays.
HEMOGLOBIN AND HEMATOCRIT DETERMINATIONS
There is little justification for routine hemoglobin and hematocrit de­
terminations on a single infant with no evidence of anemia or polycythemia 
by history or physical examination. Monochorionic twins, however, are at 
risk for twin-to-twin transfusion and its attendant complications; therefore 
same-gender twins should each have blood drawn for hemoglobin and hema­
tocrit tests.
NEWBORN SCREENING PROGRAMS
Programs are in place for neonatal screening for rare but potentially 
devastating disorders that are difficult to detect clinically, but for which there 
are dramatic benefits from early intervention. These disorders include phen­
ylketonuria and congenital hypothyroidism. Most of the hospitals in the 
United States also screen for galactosemia, and some screen for other meta­
bolic diseases and for hemoglobinopathies that are amenable to early preven­
tive health measures. The techniques and the timing for sampling vary; most 
programs require a sample shortly after birth and 2 weeks later. Because 
some assays measure metabolites of ingested substrates, it is advantageous to 
have feedings well established; blood is usually drawn on the morning of dis­
charge. There should be a routine procedure in place for ensuring that each 
screen sample is drawn, with follow-up for abnormal results.
s
THE HOSPITAL STAY
The practice of an infant spending long periods of time in his mother's 
room (i.e., rooming-in) has gained favor and forced reconsideration of prac­
tices based on fears of detriment to the infant not kept in a restricted nursery 
environment controlled for hygiene, attire, and visitors. Rooming-in has be­
come a necessity with the shortening of postpartum hospital stay, because 
new mothers staying in hospital only 24 to 36 hours simply cannot become 
comfortable with infant care if contact with their infants is limited.
Although relaxation of old restrictions allows infants to be outside the 
nursery, attention still must be given to providing a safe environment. Par­
ticular dangers are cold-induced stress, falls, and removal of the infant from 
the mother's care by unauthorized persons.
When the infant is with her mother, she should enjoy the same level of 
nursing care she would have within the nursery. This includes a general 
physical assessment and measurement of vital signs at least every 8 hours; 
recording of feeding volume, frequency, and behavior; recording of urine and 
stool output; cord and circumcision care; and any other procedures deemed 
necessary. The mother's assistance in all appropriate areas is desirable, be­
cause this helps ensure her competence in the care of her infant. The infant's 
bassinet should contain all clothing and equipment necessary for her care.
BATHING AND DRESSING
After achieving temperature stability, the infant with an apparently 
normal transition can be bathed. Although vernix has lubricating and antiin- 
fectious properties that make its presence desirable, removing it for cosmetic 
purposes is routine. Bathing also removes gross maternal blood, minimizing 
exposure of the infant and his caregivers to blood-borne viruses such as hepa­
titis В virus (HBV), herpes simplex virus, and HIV. In infants whose mater­
nal history is unclear or positive for one of these viruses, injections should be 
delayed until after the initial bath.
Warm water alone is sufficient for bathing most infants; a mild, non- 
medicated soap or chlorhexidine gluconate may be used. Hexachlorophene, 
which can be absorbed through intact skin and cause neurotoxicity, is not 
recommended for routine bathing. Care must be taken during bathing to 
minimize heat loss. After the bath, the infant is returned to the radiant 
warmer; when his temperature is stable, he is dressed in a diaper, shirt, and 
hat; wrapped in a double blanket; and transferred to an open bassinet. After 
24 hours, most infants can maintain normal temperatures without a hat or 
second blanket.
Before discharge, the mother should understand how to bathe her baby 
safely. A mild soap and shampoo can be used sparingly. Special baby soaps 
and lotions are expensive and unnecessary for infant skin care. Twice-weekly
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baths are usually sufficient. Overbathing dries and cracks skin; a mild hand 
lotion - not oil or ointment - can be applied if necessary. * • ? _■
Babies are often overdressed for their environments. The infant should 
be dressed in clothing that the parent would find comfortable, with one extra 
layer and a hat added in cool weather. Protection from direct and indirect 
sunlight is important, because infant skin burns easily.
Frequent diaper changing affords the best protection from diaper rash; 
creams, pastes, wipes, lotions, and powders are generally unnecessary. Warm 
water rinsing cleanses most soiled skin, with mild soap added as necessary. 
Diaper wipes are best reserved for times away from home when no sink is 
available. Air drying before rediapering helps keep the skin healthy. A prod­
uct that adheres to the skin as a barrier to urine and stool should be applied to 
macerated skin; healthy skin needs nothing. Parents wishing to use powder 
should apply a nontalc, cornstarch type by hand; shaking the powder onto the 
baby may cause power-aspiration pneumonitis. Neither cloth nor disposable 
diapers enjoy a clear advantage in maintaining infant skin health.
UMBILICAL CORD CARE
After the first bath, the umbilical cord and surrounding skin are treated 
topically to decrease invasive bacterial colonization. Acceptable agents in­
clude triple dye, alcohol, bacitracin, silver sulfadiazine, and povidone-iodine. 
Thereafter, the cord remnant is left exposed outside the diaper to dry and 
mummify. The cord clamp can be safely removed after 24 hours.
Although it is unclear that any particular subsequent treatment shortens 
the time of cord attachment, it is common practice to wipe the cord at least 
daily, usually with alcohol. The alcohol is applied underneath the dried cord 
to the stillmoist areas. A luldly foul smell, slight oozing, a drop or two of 
dood, or a thin rim of erythema on the surrounding abdominal skin are nor­
mal.
FEEDING
Healthy infants tolerate feeding during transition; early feeding may 
prevent or minimize hypoglycemia. Vigorous infants without problems may 
nurse in the delivery room. Formula-fed infants are offered the first feeding 
after stabilization in the admission nursery. Because any newborn may have 
an uncoordinated suck and swallow reflex or an inapparent anomaly predis­
posing to aspiration, the formula-fed infant should take a few sips of sterile 
water before the formula. If aspirated, glucose water causes as severe a 
chemical pneumonitis as formula, and plain water is therefore recommended. 
Subsequently, the infant can be fed room-temperature iron-fortified formula. 
Breast-fed infants need not receive sterile water before the first nursing, be­
cause aspiration of colostrum is fairly benign.
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Most mothers decide long before delivery whether they will breast or 
formula feed their infants. Although breast milk is superior to formula, no 
mother should be subject to disapproval if she chooses to bottle feed. Be­
cause there remain many misunderstandings among first-time mothers about 
feeding, correcting misinformation is important.
On the first day of life, the breast-fed baby may latch onto the breast 
and nurse only briefly. Nursing becomes more vigorous in the second 24 
hours, and by the third day, each session should last 10 to 15 minutes on each 
breast. Similarly, the formula-fed infant, who takes only 15 to 30 mL every 3 
to 4 hours on day 1, increases to 75 to 90 mL by day 4 or 5. Except when a 
more consistent glucose intake is required, babies should be fed on demand, 
when they are awake and hungry, rather than in accordance with a dictated 
schedule. There is no value in routinely supplementing the breast-fed infant 
with feedings of water, glucose water, or formula. In fact, this practice may 
discourage breast-feeding.
Parents of bottle-fed infants should know how to prepare and store 
formula, know how to clean bottles and nipples, and understand the range of 
normal feeding volumes. Breast-feeding mothers need instruction about the 
mechanics of nursing, techniques for awakening and encouraging a sleepy 
baby, pumping and storing expressed milk, formula supplementation, and nu­
trition during lactation. Much of this instruction should occur prenatally, 
when the mother is interested and energetic. It should be supplemented in the 
hospital by nurses, physicians, or lactation specialists who can reinforce pre­
vious learning and ensure that the mother and her infant are doing well at dis­
charge. Videotapes can supplement reading material. Mothers should know 
whom to contact and when to call if breast-feeding is not going well at home. 
Many pediatricians schedule office visits for breast-fed babies within a few 
days of discharge; by this time, mother's milk supply should be adequate to 
stop postnatal weight loss.
VOIDING AND STOOLING
Ninety-one percent of normal newborns void in the first 16 hours of 
life. Failure to do so by 24 hours should evoke concern but not panic. An ap­
parently well infant is unlikely to have serious disease and can be managed 
expectantly. Similarly, 99% of term newborns pass a stool in the first 24 
hours; 76% of premature infants do so, with 99% passing a stool by 48 hours. 
As feeding is established, meconium stools give way to frothy, lighter transi­
tional stools and then to a typical, seedy, yellow-green stool. Infants may 
produce stool in small quantities at each feeding because of the gastrocolic 
reflex; less frequent stools should be more voluminous. In the breast-fed in­
fant, scanty, infrequent stools indicate poor caloric intake.
и
BEHAVIOR
Sleeping, in approximately 4-hour cycles, occupies 20 to 22 hours of a 
typical newborn's day; the remainder is spent feeding and in the quiet alert 
state. Crying is minimal. Parents may be concerned that their baby is inac­
tive, particularly in the first 2 days. Despite extended sleeping, the newborn 
has a sophisticated array of behavioral responses to various stimuli, and cer­
tain aspects of later behavior patterns or personalities can be predicted by re­
sponses evoked on early examinations. The knowledgeable caregiver can 
help strengthen the parent-infant bond by guiding the parents in choosing ap­
propriate responses to their infant's behavioral cues.
JAUNDICE
Two-thirds of all babies appear jaundiced during their hospital stays. 
Although the causes of jaundice are myriad and the pathophysiology com­
plex, most jaundiced infants are normal, and their jaundice abates without ill 
effects. Excess bilirubin resulting from hemolytic disease appears to be the 
only common cause of jaundice that should raise concern. The screening rec­
ommendations for Rh and ABO disease were discussed earlier. After hemo­
lysis is excluded as a cause of moderate jaundice (bilirubin < 25 mg/dL) in a 
healthy, term infant younger than 1 week of age, further diagnostic and 
therapeutic procedures are unnecessary if there is follow-up to determine a 
return to normal.
Jaundiced, breast-fed newborns have higher bilirubin levels than for­
mula-fed infants. This difference disappears if infants are nursed every 2 to 3 
hours, rather than every 3 to 4 hours. Frequent nursing has the added benefit 
of increasing the mother's milk supply and avoiding the problems caused by 
supplementation.
RISKS OF PERINATALLY ACQUIRED INFECTION
SEPSIS
Neonatal sepsis is a relatively rare but potentially lethal disease. Condi­
tions that place an infant at increased risk for sepsis include the following; 
many of these risk factors are additive:
• prolonged rupture of the fetal membranes
• maternal chorioamnionitis, usually involving maternal fever, leu­
kocytosis, uterine tenderness orirritability, purulent cervical discharge 
or foulsmelling amniotic fluid, or fetal tachycardia
• maternal colonization with group В streptococci
• prematurity
• maternal urinary tract infection
• perinatal asphyxia, unless clearly associated with a noninfectious 
cause, such as abruption
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• male gender.
Infants who manifest even subtle clinical signs of sepsis deserve full 
evaluation and antibiotic therapy. Otherwise healthy infants with risk factors 
for sepsis pose a dilemma. Most of these clinically well infants are not in­
fected, but because neonatal sepsis can be rapidly lethal, it must be promptly 
treated.
The laboratory evaluation of the possibly septic infant is complicated 
by several unique problems: low sensitivity of blood cultures; lack of cere­
brospinal fluid pleocytosis in proven meningitis; variability of leukocyte 
counts; and the use of intrapartum antibiotics. There are several approaches 
to the evaluation and treatment of at-risk, asymptomatic neonates. Although 
there is little agreement on the validity of specific approaches, especially 
when confounded by maternal antibiotics, an approach weighing risk factors 
and laboratory results is reasonable.
POSITIVE MATERNAL SEROLOGIC TEST FOR SYPHILIS
As the prevalence of syphilis in the general population rises, so does 
the incidence of congenital syphilis. Recommendations for selected screening 
of pregnant women or infants at risk have failed to detect all infected infants. 
All mother-infant pairs should be screened. The Centers for Disease Control 
(CDC) recommends vigilance regarding the mother's STS:
Pregnant women should be screened early in pregnancy... In areas 
o f  high syphilis prevalence, or in patients at high risk, screening should 
be repeated in the third trimester and again at delivery... An infant 
should not be released from the hospital until the serologic status o f  its 
mother is known.
The CDC's recommendations for infant evaluation depend on the pe­
diatrician's knowledge of the mother's serologies and treatment throughout 
pregnancy. The physician should evaluate the infant if the mother has a posi­
tive STS confirmed by a treponemal test (e.g., the fluorescent treponemal an­
tibody absorption test) and was untreated, had poorly documented treatment, 
was treated with a drug other than penicillin, was treated within 1 month of 
delivery, or was treated adequately but did not demonstrate at least a fourfold 
fall in STS titer afterward, whether due to insufficient follow-up or treatment 
failure.
Evaluation of the infant includes several measures:
• complete physical examination
• STS (the same test performed on the mother so that liters can be 
compared)
• lumbar puncture for analysis of cells, protein, and VDRL
• long-bone radiographs
• any other test clinically indicated.
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Differentiating between early infection and passive transfer of maternal 
antibody is problematic in the infant with an otherwise negative workup, be­
cause there is no reliable assay for IgM antitreponemal antibodies. The rec­
ommendations for treatment and follow-up are necessarily conservative. 
Moreover, excluding the diagnosis of neurosyphilis can be so difficult that 
therapy must be sufficient to treat it.
POSITIVE MATERNAL TEST
FOR HEPATITIS В SURFACE ANTIGEN
The HBsAg-positive mother can transmit HBV perinatally to her new­
born. The spectrum of disease manifestations in the infant range from asymp­
tomatic seroconversion to fulminant, fatal hepatitis. Perinatally infected in­
fants are at particular risk of becoming chronic carriers, and even if free of 
chronic hepatitis, they are at increased risk of developing later cirrhosis or 
hepatocellular carcinoma. Because immunopro phylaxis against HBV initi­
ated at birth is 98% to 99% effective in preventing virus acquisition by the 
infant, identification of HBsAg-positive pregnant women is essential. Confin­
ing testing to high-risk women (e.g., Asian or African race, intravenous drug 
abuse, multiple sexual partners) misses 50% of those who are HBsAg- 
positive, and therefore, "routine screening is recommended for all women
Treatment of the infant whose mother is HBsAg-positive consists of 
immediate, thorough bathing; administration of 0.5 mL of hepatitis В im­
mune globulin (HBIG) intramuscularly within 12 hours of birth; and the first 
dose of hepatitis В vaccine (0.5 mL, regardless of the product used) intra­
muscularly, concurrently with HBIG but at a different site. Subsequent doses 
of vaccine are given at 1 and 6 months of age. No special isolation is neces­
sary. Although HBV is found in breast milk, breast-fed infants, even if not 
receiving immunoprophylaxis, are not at increased risk of acquiring HBV in­
fection, and breast-feeding is therefore allowed.
A hepatitis В immunization series is recommended for all infants, in­
cluding those of HBsAg-negative mothers. The first dose may be adminis­
tered at birth, although alternate schedules are acceptable. If the maternal 
HBsAg status is unknown at delivery, the infant should receive 0.5 mL of 
hepatitis В vaccine within 12 hours of birth. If the mother is subsequently 
found to be HBsAg-positive, HBIG should be given as soon as possible and 
no later than 7 days of age, and the vaccine series continued. If the mother is 
found to be HBsAg-negative, HBIG is unnecessary, and completion of the 
immunization series should follow recommended schedules and dosing.
POSITIVE MATERNAL TEST
FOR HUMAN IMMUNODEFICIENCY VIRUS
Vertical transmission of HIV from mother to infant occurs transplacen- 
tally and intrapartum, with an attack rate estimated at 30% to 35%, but per­
haps as high as 50%, particularly with previous delivery of an infected in-
fant.' ' Maternal antibodies are passively transferred to the infant and are de­
tectable for 15 to 18 months. Diagnosis of HIV infection rests on sequential 
antibody testing of the infant to detect a rising titer. Amplification of HIV 
proviral DNA by means of the polymerase chain reaction may allow for di­
agnosis of infected infants shortly after birth. All exposed infants need com­
prehensive follow-up.
There are documented cases of infants acquiring HIV infection through 
breast-feeding. Though the AAP recognizes that the "additional risk, if any, 
of transmission of the virus to an infant through breast-feeding appears to be 
small," it recommends, "where alternative effective sources of feeding are 
available, an HIV-infected woman should be counseled not to breast feed." 
No special isolation for mother or infant is necessary as long as universal 
precautions are followed.
MATERNAL DRUG USE
Maternal use of cocaine should be suspected if newborn infants have 
congenital anomalies, particularly those that can be explained by vascular 
disruption; irritability, abnormal behavior, seizures, or cerebral infarction; in 
all cases of placental abruption; and in cases of premature labor, unless oth­
erwise explained. Cocaine metabolites can be detected in neonatal urine after 
they have been cleared from maternal urine; a positive infant screen identifies 
drug use even if the maternal screen is negative. Cocaine-exposed infants do 
not go through a predictable pattern of drug withdrawal seen with opiate use. 
They are at risk for apnea, but there is no consensus regarding monitoring of 
these babies after discharge.
The use of other illicit drugs and of alcohol abounds, with changes to 
new drugs occurring an-interest and availability fluctuate. Suspicious mater­
nal or infant behavior should prompt investigation of drug use. Social ser­
vices support should be available for the drug-using mother and her infant.
Mothers who use drugs are at increased risk for all sexually transmit­
ted diseases.
THE POSTDATE INFANT
As the end of gestation approaches, the ability of the uteroplacental 
unit to nourish the fetus may deteriorate. The fetus may stop growing or lose 
weight. The fetus may respond to excessive hypoxia in utero by brisk hema­
topoiesis or may tolerate labor and delivery poorly, requiring nonroutine ob­
stetric intervention or neonatal resuscitation. Postnatal sequelae can include 
polycythemia, hypoglycemia, meconium aspiration syndrome, and the vari­
ous consequences of asphyxia, including persistent pulmonary hypertension.
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MULTIPLE GESTATIONS
"We are faced with the undeniable fact that the human species is not 
designed to carry more than a single fetus in utero with any degree of bio­
logic grace." Twins have a mortality rate four times that of singletons, and 
that risk increases with increasing number of fetuses. Most twin pairs are 
somewhat growth retarded; approximately one-half are also premature. Con­
genital anomalies may be more common in monozygotic twins than in single- 
tons; thest twins are also at risk for twin-to-twin transfusion and its conse­
quences.' Parents of twins need special support; referring them to literature 
and support groups prenatally may help them recognize and cope better with 
the stresses of having two infants. Special help with breast-feeding may be 
necessary. Caregivers must remember to assess and treat twins as individuals 
and should encourage the family to do so as well. Parents of a sick or dying 
twin grieve as deeply as do parents of singletons; that the other twin is alive 
and well does not diminish their grief and worry.
CYANOTIC SPELL
Although the true incidence of the cyanotic or dusky spell in appar­
ently well infants is unknown, personnel who work in well-baby nurseries see 
these episodes regularly. The otherwise healthy-appearing infant can have a 
problem as simple as spitting-up or one as potentially devastating as apnea, 
sepsis, or intracranial hemorrhage. Sorting through the various diagnostic 
possibilities demands an accurate description of the event, the activities im­
mediately before and after it, and any intervention performed. Particular at­
tention should be paid to the cardiac, respiratory, and neurologic examination 
of the infant. Continuous cardiopulmonary monitoring and pulse oximetry 
may be necessary to help define the problem and guide the workup.
DISCHARGE
CAR AND HOME SAFETY
Car safety should start before birth with parental acquisition of an ap­
proved child safety seat. Because these seats are often used improperly, hos­
pital personnel should know the principles of their use and ensure that the 
babies discharged from their care are properly protected. Every hospital 
should have resources on site or readily available in the community for fami­
lies without safety seats so that they may obtain them before discharge.
Literature or videotaped material regarding home safety for infants 
should be available to parents. Topics addressed should include bums, falls, 
aspiration and strangulation, bottle propping, and control of siblings and pets.
HOME ROUTINES AND VISITORS
Newborns do not have routines, which, combined with the recovering 
mother's fatigue, makes the first few weeks at home exhausting. Moreover, 
newborns are particularly susceptible to infection. For these reasons, parents
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should be discouraged from having a houseful of visitors or taking trips out 
of the home that could expose the infant to the general public. All energies 
should be directed at new baby care and feeding until the postpartum recov­
ery is complete and a reasonably predictable feeding schedule established.
DISCHARGE TIME AND FOLLOW-UP
Discharge from the hospital should be dictated by the well-being of the 
mother and her infant, rather than by any other considerations. Both mother 
and infant should be sufficiently recovered from delivery so that continuous 
observation is no longer necessary; the mother should understand her 
postpartum care and be healthy enough to undertake it; and the parents 
should understand the care of their infant and how to obtain help if necessary. 
For the multipa-rous, vaginally delivered woman with a healthy, term infant 
and help at home, this length of time may be less than 24 hours. Obstetric, 
neonatal, and social considerations may preclude a rapid discharge.
All infants should have follow-up arrangements documented before 
discharge. Those who are discharged within 24 hours of delivery should be 
examined within 2 to 3 days; others should be seen no later than 2 weeks of 
age. As with time of discharge, time for follow-up should be individualized, 
with consideration given for type of feeding, infant birth weight, maternal 
and infant blood types, parental experience, and the hospital duration and 
course.
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NUTRITION
FEEDING THE FULL-TERM INFANT
The science of feeding is not very old, and even today, much of what is 
practiced is based on what seems to work or not work. As Dr. Frank Oski 
pointed out, infant feeding practices are the longest, uncontrolled experiment 
lacking informed consent in the history of medicine. Despite these reserva­
tions, it is likely that there are several correct ways to feed full-term and pre­
term infants.
SCHEDULING OF FEEDINGS
Because approximately 2000 feedings occur in the first year of life, it 
is best that they bring enjoyment to both mother and infant. In the first few 
days of life, full-term healthy infants feed at more frequent intervals until the 
sucking and swallowing mechanism is well developed and there is milk let­
down. Thereafter, they usually settle into a schedule of every 3 to 4 hours, 
with sleep occurring about 60% of the time. Trying to wake an infant for 
feeding to create a better schedule will probably result in only small amounts 
of milk taken and tension in the caregivers. Infants needing a more controlled 
schedule are those with a poor suck and swallow reflex, chronic lung disease, 
or gastrostomies, for which careful calculations of intake are necessary to en­
sure growth. Breast-fed infants feed more frequently, often every 2 to 3 
hours. Their intake is unknown but should be calculated by careful weighing 
before and after feedings only if the infant does not thrive. Feedings more 
frequent than every 2 hours should be discouraged.
For an obese infant, after the newborn period, the diet should be calcu­
lated and restricted in caloric intake. Low-caloric-density foods can be substi­
tuted (e.g., vegetables substituted for fruits, dinners in place of pure meats), 
but skim milk should not be used in the first year of life. Even obese infants 
should receive at least 85 kcal/kg with a proper nutrient intake. As the infant 
gets older, the number of feedings decrease, and by 6 months, the number of 
meals should approach three to four daily.
BREAST VERSUS BOTTLE FEEDING
All healthy women should be helpfully encouraged to breast-feed their 
full-term infants. For various reasons, a woman may not want to do so; she 
should not be made to feel guilty. Breast-feeding declined through the late 
1980s. The largest decline was seen in young, unmarried, African-American 
women of lower income, although the decline was not limited to this group.
Despite the advent of modified cow-milk formula, no artificial formula 
has been found to equal breast milk. Since large numbers of women in indus­
trial nations now breast feed, it appears that their infants have a lower inci­
dence than formula-fed infants of gastrointestinal and nongastrointestinal dis­
eases, including otitis media, bacteremia, pneumonia, meningitis, and urinary
is
tract infection. Infants in nonin-dustrial nations must still be breast-fed for 
survival.
The advantages of breast-feeding are many. Human milk is always at 
the correct temperature and requires no sterilization; the protein content is 
lower than in formula but of high quality, gives a small curd, and is easily di­
gestible; the fats are well absorbed; the carbohydrate is relatively high in lac­
tose but causes few problems; breast milk imparts a gram-positive intestinal 
flora rather than gram-negative; antibodies passed by way of the milk to the 
infant help prevent infection; the potential psychologic benefit to mother and 
child is obvious.
There are few instances in which breast-feeding should not be encour­
aged. Even temporary disorders, such as engorgement or mastitis, may be 
improved by continuing feeding. Breast-feeding is recommended for the first 
year of life, adding beikost (i.e., solids) during the second 6 months. Certain 
diseases (e.g., galactosemia, alactasia) call for formula substitutes containing 
no lactose. There are drugs taken by the mother that are contraindicated dur­
ing breast-feeding and some agents merely require temporary cessation.
Although mothers who are positive for hepatitis В antigen and those 
with cytomegalovirus infection may be at risk for transmission of these or­
ganisms through their breast milk, the risk does not seem to outweigh the 
benefits. The exact infectivity o f sero positive mothers for human immunode­
ficiency virus-1 (HIV-1) is unknown. There is evidence that transmission is 
possible. IgG and IgA antibodies to HIV-1 are found in milk from seroposi­
tive women, indicating the virus can elicit a local immune response. Whether 
the antibodies have any protective effect is unknown. In some instances, 
mothers are too sick to breast-feed; in others, drug intake (e.g., cocaine, her­
oin, phencyclidine) may preclude breast-feeding. Although no definite rec­
ommendations can be made for an HIV-positive mother, caution should be 
taken.
Investigators from Finland have found slower gains in lengths in full- 
term infants exclusively breast-fed through the first year of life. In the United 
States, limiting intake to breast milk without adding solids in the first year 
would be unusual and offers no advantages.
GUIDELINES FOR FORMULA SELECTION
A few basic guidelines should be considered in choosing the appropri­
ate feeding for an infant. The diet should have the following characteristics:
•contain sufficient calories and essential nutrients
• be digestible
• contain a reasonable distribution of calories
•avoid potential problems suspected from a family history.
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CALORIES AND ESSENTIAL NUTRIENTS
Underprovision of calories causes tissue breakdown, diverting other 
food substances into energy production. However, the traditionally taught ca­
loric requirement of 120 kcal/kg/day may be an overestimation for some full- 
term infants. Adequate weight gains of as much as 30 g/day have been ob­
served with as low as 90 kcal/kg/day, particularly in infants with decreased 
activity. Fluid volumes carrying these calories average 150 mL/kg, but the 
full-term infant fed ad libitum may exceed this. Both fluid and calories need 
to be calculated only for the newborn with poor or excessive weight gain if 
there is consideration of adjusting caloric concentration. Protein requirements 
for the normal full-term infant are probably overestimated at 2.2 g/kg/day. 
Essential nutrients for weight gain are contained in human milk and most 
commercially prepared infant formulas, with the occasional exception of 
some vitamins.
DIGESTIBILITY
A digestible diet should contain protein, carbohydrates, and fat in 
forms that have superior nutritive value and allow minimal fecal losses. Hu­
man milk still appears to be the best overall. Although its protein content is 
low (1.1%), the excellent lactalbumin-casein ratio (4:1) makes for small 
curds and easy digestibility. The variety of nucleotides may enhance the im­
mune system, gut growth, and lipid metabolism. The modified cow milk in 
most routinely used infant formulas is an adequate source of nutrients. Some 
formulas have protein resembling that of breast milk (e.g., 60% whey and 
40% casein).
Although use of soy protein formulas produces adequate growth of 
full-term infants, these formulas contain only one-third of their available ni­
trogen as essential or semiessential amino acids. For optimal growth, infants 
need approximately 10% more calories if they take soy formulas rather than 
human milk or bovine protein formulas. With soy formulas, because of bind­
ing with phytase, fat losses are increased in the stool, as are the losses of 
various minerals, vitamins, and trace elements. The predominant use of a soy 
formula has been in infants with presumed cow-milk allergy and in those 
who require a supplement to breast-feeding. Evidence suggests that serum 
IgG antibodies to soy proteins are formed as quickly or even more quickly 
than antibodies to cow-milk protein. It is likely that IgE antibodies are more 
important in giving allergic manfestations. Soy formula should not be used 
without specific indications.
Casein hydrolysate formulas are satisfactory sources of nitrogen. Their 
osmolarity is low because glucose polymers have been substituted for su­
crose, making them well tolerated. Their main use should be reserved for 
cow-milk or soy allergy. They are not needed for refeeding an infant after
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gastroenteritis, bowel surgery, or necrotizing enterocolitis. Anaphy-laxis in 
response to hydrolysates has been reported.
The most commonly used infant formulas contain lactose, glucose 
polymers, or a combination as their major carbohydrates. They are generally 
well tolerated. Infants fed human milk or formulas with added vegetable oils 
(e g., com, coconut, soy, oleo), normally excrete less than 1 g fat/kg/day. In­
fants fed whole cow milk in many instances excrete fat in excess of 2 
g/kg/day, and those fed evaporated milk without additional carbohydrates 
lose between 1 and 2 g/kg/day. Fat absorption is least satisfactory in the first
10 days of life and then increases rapidly. Medium-chain triglyceride (MCT)
011 has excellent absorption very early in life, although it may slow gastric 
emptying time.
DISTRIBUTION OF CALORIES
An appropriate distribution of calories for good infant nutrition is 7% 
to 16% protein, 35% to 55% fat, and 35% to 65% carbohydrate. Most avail­
able infant formulas provide this distribution even if combined with various 
strained foods that are very low in fats. Only commercially prepared cow 
milk in regular or lowered fat concentrations, evaporated milk, and certain 
formulas designed for older infants have distributions of calories outside the 
optimal ranges, with a decrease in fat or carbohydrate and an increase in pro­
tein. In the late 1970s, Fomon and others reported that cow milk could be 
used without problems after the first 6 months of life as part of a mixed diet. 
It was later shown that blood loss was still apparent through the gastrointesti­
nal tract for infants on cow milk after 6 months of age. Cow milk should be 
avoided as routine diet for infants younger than 1 year of age. The formulas 
for older infants and cow milk are also hazardous if abnormal losses are en­
countered (e . g diarrhea, vomiting, excessive temperature) because of their 
high solute load. The use of standard infant formula through the first year of 
life that is supplemented after 4 to 6 months with infant foods has been ade­
quate, and there seems to be little use for formulas designed for the older in­
fant.
IRON FORTIFICATION
Iron deficiency has remained one of the most common causes of ane­
mia in infancy and childhood despite widespread availability of iron-fortified 
formulas, supplements, and cereals. Although a full-term infant is born with 
adequate iron reserves, these stores begin to deplete at about 4 months of age, 
and deficiency appears between 6 and 9 months, particularly in lower socio­
economic groups. Without iron supplementation, there must be a large intake 
of commercial dried cereals, which are not well absorbed. The American 
Academy of Pediatrics (AAP) suggests 1 mg/kg/day for the full-term infant 
by 4 months of age and 2 mg/kg/day for preterm infants no later than 2
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months of age. Differing opinions exist about iron supplementation in the 
breast-feeding infant. By 6 months of age, breast-fed infants have decreased 
iron stores, and by 9 months, some become deficient. ' In light of increasing 
reports of the effect of iron therapy on improvement of behavioral perform­
ance in nonanemic but iron-deficient infants and lowered mental and motor 
functioning in a 5-year follow-up of children who had hemoglobin levels less 
than or equal to 10.0 g/dL during infancy, it appears prudent to supplement 
breast-fed infants.
Hesitation to give iron supplements or iron-fortified formulas has been 
based on poorly documented reports of gastrointestinal symptoms and low 
incidences of anemia in middle-class patients. However, controlled studies 
suggest no differences in symptoms between infants fed formulas with iron 
and those given formulas without iron. Controversy also exists about whether 
administration of iron increases the risk of infection in the neonate, because 
iron saturates the binding sites of lactoferrin and interferes with its bacterio­
static function. It appears that the infection risk is more related to other fac­
tors, such as malnutrition and organisms to which an infant is exposed, than 
to iron, and I concur with the AAP recommendation for supplementation.
FLUORIDE SUPPLEMENTATION
Fluoride acts to strengthen dental enamel and is incorporated in the 
mineralization stage and through direct surface contact after eruption. Fluo­
ride is well absorbed from foods, but best from sodium fluoride supplements. 
Formula made with water fluoridated to levels of 3 ppm or higher provides 
the AAP recommendation of 0.3 to 0.7 mg/L/day. If the water contains less, 
0.25 mg/day should be started in the first 2 weeks of life.28 There is no indi­
cation that the preterm infant needs are any different. Any infant exclusively 
on human milk, ready-to-feed formula, or formula made with bottled water 
should receive fluoride supplementation.
MINOR PROBLEMS AND DIETARY MANIPULATION
The pediatrician frequently encounters spitting-up and changes in stool 
pattern in a bottle-fed infant. If there is sufficient growth, these problems do 
not merit formula changes. The physician can treat mild constipation by add­
ing light or dark Karo syrup to the formula or prune juice or solid foods to the 
diet. Severe constipation requiring the constant use of suppositories should be 
investigated. Loose stools may be helped by elimination of some carbohy­
drate from the diet or by changing the carbohydrate source.
Many infants spit up small amounts of formula.
This can result from overfeeding, determined by a careful dietary his­
tory. The exact incidence of gastroesophageal reflux in infancy is unknown, 
but it is estimated to be very high. Medical treatment that includes prone po­
sitioning at a 30° angle, thickening of feedings, and perhaps the use of be-
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bethanechol or metodopramide usually helps in all but the most severe cases. 
Projectile, bile-stained, or persistent vomiting with poor weight earn requires 
immediate investigation.
FEEDING THE PREMATURE INFANT
Although advances in management of premature infants have resulted 
in a lower mortality rate, feeding the premature infant still is a precise nurs­
ing and nutritional art because of the special liabilities of the infant. The aim 
of feeding should be to approximate intrauterine growth and mineral storage, 
a goal that is frequently impossible. The ideal growth rate remains unknown 
in the preterm extrauterine environment.
The premature infant faces several nutritional problems:
• poor suck and swallowing coordination until at least 34 weeks of 
gestation
• a relatively high caloric requirement with initially small gastric ca­
pacity
• poor gag reflexes, leading to aspiration
• immature and often incompetent esophagogastric sphincter, leading 
to reflux
• decreased intestinal enzyme secretion, which may affect nutrient 
absorption
• decreased secretion, absorption, and bile-acid pools
• decreased bowel motility, particularly if not fed enterally
• blunted gastrointestinal hormonal responses if given parenteral nu­
trition.
EARLY LOW-VOLUME FEEDING
The optimal time for initiating enteral feeding in the preterm infant is 
unknown. Larger, healthy infants weighing more than 1500 g can usually be 
fed within hours of birth after stabilization. The critical problem is when to 
feed a very-low-birth-weight (VLBW) infant weighing less than 1500 g and 
the micropremie weighing less than 1000 g. Caloric intake can easily be 
given early by means of parenteral nutrition, although gut villous involution 
can occur within 3 days in neonatal animals receiving intravenous calories. 
There is no conclusive evidence that feeding should be delayed in viable 
premature infants. All unstable infants, whatever their size, should not be en­
terally fed until stable. After stabilization, minimal or low-volume feeds 
should be considered as soon as possible. In several studies, infants fed ear­
lier tended toward decreases in days to discharge, days on parenteral nutri­
tion, and days, to regain birth weight, and they showed no significant in­
crease in necrotizing enterocolitis.
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SCHEDULING FEEDINGS
There is no evidence to suggest that the first few feedings of any infant 
must be sterile water or 5% dextrose, because it is aspirated gastric contents 
with acid that is harmful. Upper intestinal obstruction in the full-term infant 
is usually detected before the first feed. If not, a mature, normal infant is gen­
erally capable of protecting his airways should he experience emesis. Preterm 
infants older than 34 weeks of gestation are similar to full-term infants; those 
more immature have usually had radiographs that included the abdomen to 
rule out obstruction. Breast milk or the formula of choice may be given full 
strength for the full-term infant and generally one-quarter to one-half strength 
for the preterm infant at the first feed. Table 1 shows suggested intervals, 
amounts, and times to full feeds.
Gastric capacities differ, but residuals should be measured before each 
feeding only in small preterm infants. If the amount retained in the stomach 
equals the anticipated feeding, nothing should be given. If there is less on iso­
lated measurements, an additional increment to equal the desired total may be 
given with the refed residual aspirate. Because increasing residuals, with or 
without distention, may be an early indication of partial obstruction, ileus, or 
necrotizing enterocolitis, further feedings should be given only I with cau­
tion.
Table 1
Oral feeding schedule for low-birth-weight infant
Weight < 1000 g 1001-1500g 1501-2000 g > 2000 g
T im e S u b ­
s ta n c e
A m o u n t F re­
q u ency
A m o u n t F re ­
q u en cy
A m o u n t F re­
q u en cy
A m o u n t F re ­
q u en cy
F irs t
f e e d in g
1 /2
s tr e n g th  
h u m a n  
m ilk  o r  
1 /4
s tr e n g th
f o rm u la
1-2
m L /k g
l - 2 h 2 -3
m L /k g
2 h 3 - 4
m L /k g
2 -3  h 10
m L /k g
( f u l l -
s t r e n g th )
3 h
S u b s e ­
q u e n t
f e e d ­
in g s ,
1 2 -7 2 h
F o r ­
m u la  o r  
1 /2  to  
f u ll -  
s tr e n g th  
h u m a n  
m ilk
I n c r e a s e  
l m L  
e v e ry  
o th e r  
f e e d in g  
to  m a x i ­
m u m  o f  
5 m L
2 h I n c r e a s e  
l m L  
e v e ry  
o th e r  
f e e d in g  
to  m a x i ­
m u m  o f  
lO m L
2 h I n c r e a s e  
2  m L  
e v e ry  
o th e r  
f e e d in g  
to  m a x i ­
m u m  o f  
1 5 m L
2 - 3 h I n c r e a s e  
5 m L  
e v e ry  
o th e r  
f e e d in g  
to  m a x i ­
m u m  o f  
2 0 m L
3 h
F in a l 
f e e d in g  
s c h e d ­
u le ,  1 80  
m L /k g
F u l l-  
s tr e n g th  
f o r m u la  
o r  h u ­
m a n  
m ilk
1 0 -1 5
m L
2 h 2 0 - 2 8
m L
2 - 3 h 2 8 - 3 7
m L
3h 3 7 - 5 0  
m L , th e n  
a d  id i-  
tu m
3 - 4 h
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SPECIAL REQUIREMENTS
A premature infant has a number of special requirements that differ 
from those of a fiill-term infant because the latter can usually be fed ad libi­
tum with breast milk or formula with little need for special calculations.
ENTERAL ENERGY AND PROTEIN INTAKE
It has been difficult to settle on the ideal energy and protein allowances 
for preterm infants because of the many variables involved, including tem­
perature stresses, activity, degree of illness, infection, malnutrition, and needs 
for catch-up growth. Data on adults suggest that nitrogen is used better in the 
presence of extra energy. Studies in the 1960s and 1970s reported the most 
rapid weight gain of LBW infants with protein intakes between 3 and 5 
g/kg/day. Goldman and colleagues suggested that excess protein might be in­
jurious to the developing nervous system. Unfortunately, virtually all these 
studies contained a mixture of true preterm and small-for-gestational-age in­
fants, whose requirements differ. Kashyap and associates studied three 
groups of true premature infants with various protein and energy intakes. The 
rates of weight gain and nitrogen retention in the high-protein groups were 
greater. In the group with the highest intake (3.9 g/ kg/day) the excess gain 
was mainly fat. These data suggest an intake of at least 3 g/100 kcal/day (3.6 
g/kg) or roughly 30 kcal/g of protein taken enterally is sufficient.
The LBW infant who can take feeds soon after birth requires a protein 
intake of at least 2.8 g/kg/day.
LBW infants who do not receive protein in the first few days lose at 
least 1% of their endogenous protein stores daily. If protein intake is 
delayed, it must be increased to account for early losses.
It appears that maintenance energy in LBW infants is 50 to 60 
kcal/kg/day, and allowances for stress, loss through stool, and 
growth would require an additional 50 to 60 kcal/kg/day. Barring 
any excess needs because of chronic disease or malab-sorption, 
more than 120 kcal/kg/day is probably unnecessary.
There has been increasing interest in the use of preterm breast milk in 
neonatal intensive care units. Raiha and colleagues showed that the quality of 
protein (i.e., whey versus casein) made a difference in serum amino acid lev­
els, ammonia levels, urea nitrogen, and the incidence of acidosis. Although 
these studies were of considerable importance, there was little focus on min­
eral status, lowered serum proteins in infants fed pooled breast milk, and less 
weight gain. Others have found that preterm infants fed pooled or preterm 
breast milk without fortification grew less well. Additional investigations fo­
cused on the increased protein content of preterm milk compared with full- 
term human milk. Only one study found no real increase when controlling for 
24-hour volume. Because of differences existing in collection of milk, fore­
milk and hindmilk, ongoing changes of the milk during subsequent weeks,
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and daily variation in nutrients, the content of preterm milk should never be 
taken for granted. Preterm infants receiving human milk, particularly, should 
be monitored for nutritional status.
CARBOHYDRATES
Carbohydrates, particularly glucose, is one of the body's main energy 
nutrients and is essential to the brain for normal metabolism. There is a need 
for glucose or galactose as lactose at all times, and yet there are no specific 
requirements. Carbohydrate intravenously promotes efficient nitrogen reten­
tion; the same could be expected of enteral intake. Galactose is needed for 
glycogen storage and for provision of glucose during the fasting state. The 
preterm infant is much more likely to become hypoglycemic, so keeping 
within the suggested energy guidelines seems appropriate.
LIPrDS
Lipids, like carbohydrates, are a major source for growth, metabolism, 
and muscle activity. It now appears that two long-chain unsaturated fatty ac­
ids, linoleic acid (o>6 18:2) and a-linolenic acid (co3 18:3), are essential for 
the preterm infant and that deficiency of the latter is subtle. Linoleic acid 
elongates and saturates to become the precursor of arachidonic acid; linolenic 
acid is metabolized to eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) by the same mechanism. Eicosapentaenoic and DHA may pro­
vide structure to the phospholipid layer, influencing important membrane 
functions. Docosahexaenoic acid and EPA is present in breast milk; formula- 
fed infants have levels that decrease slowly with time. Uauy and colleagues 
studied 83 preterm infants weighing between 1000 and 1500g who were 
given breast milk, preterm formula with only linoleic acid, preterm formula 
containing linoleic and linolenic acids, or an experimental preterm formula 
containing fish oil that supplemented EPA and DHA similar to quantities 
found in human milk. After discharge, the infants received 5 months of full- 
term formulas with corresponding fatty acid intake. The infants fed formula 
with fish oil showed DHA levels similar to infants fed breast milk, and those 
fed the formula with linoleic and linolenic acids had lower levels, suggesting 
that they were not able to metabolize sufficient DHA In addition, their retinal 
function was not as good as the other group.
The AAP suggests that 3% of energy intake should be linoleic acid. 
The European Society for Pediatric Gastroenterology and Nutrition proposed 
that essential fatty acids (i.e., both EFAs) be added to preterm infant formu­
las. Uauy found that fish oil seems to be well tolerated by preterm infants. He 
makes the following recommendations for intake:
Total EFA content should be set at 4% to 5% of energy intake but may 
go as high as 12% safely with linoleic acid at 0.5 to 0.7g/kg/day and 
a-linolenic acid at 70 to 150 mg/kg/day.
26
Because enzymes to convert a-lirtolenic add to DHA may be subopti- 
mal, DHA at doses of 35 to 75 mg/kg/day should be given.
Linoleic acid intake should not exceed 12% of total energy, because an 
excess may inhibit the formation of linolenic acid. The ratio of co6 to 
co3 fatty acids should be in the range of 5:1 to 15:1.56 It appears that 
formula manufacturers are considering this suggestion.
Carnitine synthesis may be limited in the preterm infant. It facilitates 
the transport of long-chain fatty acids across the inner mitochondrial mem­
brane. Fortunately, breast milk has high levels of carnitine, and most formu­
las have been supplemented, and it is only an issue if infants receive car­
nitine-deficient total parenteral nutrition (TPN) solutions.
VITAMINS AND IRON
Although most formulas contain vitamins and are adequate for the full- 
term infant, preterm infants may require additional supplements. Table 2 
shows the suggested intakes. Intramuscular vitamin К (0.5 to 1 mg) should be 
given to all infants at birth.
Vitamin E deficiency was first described in 1967 by Oski, who found 
preterm infants with an anemia unresponsive to iron, high reticulocyte 
counts, increased hydrogen peroxide hemolysis, and puffy feet. Until 1985, it 
was generally accepted that 25 IU of vitamin E and 2 mg/kg/day of iron 
could be given simultaneously to the preterm infant. However, Gross and 
Gabriel showed that vitamin E levels were inadequate in preterm infants at 6 
weeks of age if iron-fortified formulas were given but not if the infants were 
receiving preterm or mature human milk with iron. Vitamin E levels should 
be followed weekly to biweekly and supplements given as needed. Up to 75 
lU/day have been needed by some infants to maintain normal levels. Iron is 
started at 36 to 40 weeks except in the smallest infants (<1000 g) in whom 
iron and ferritin levels are checked before starting iron at approximately 40 
weeks of corrected age. If iron and ferritin levels are sufficient, supplementa­
tion may be delayed if needed.
Table 2
Preterm vitamin supplementation for human milk and formulas
Source of Nourishment Daily Supplement
Entamil Premature Formula+ (Mead Johnson)
Special care formula4 (Ross Laboratories) 0.5 mL Poly-vi-sol
Human milk 1 mL Poly-vi-sol
Pregestimil, Nutramigen, Portagen 1 mL Poly-vi-sol
The relation of vitamin E to retinopathy of prematurity (ROP) in pre­
term infants weighing less than 1500 g has been an ongoing investigation for 
the past 20 years. Several studies showed a decrease in incidence and severity
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of ROP if large amounts of vitamin E were supplemented. Subsequently, a 
large, controlled study showed no significant change in the incidence of ROP 
with prophylactic vitamin E but did show an increased incidence of necrotiz­
ing enterocolitis and retinal hemorrhages. Another showed a decreased over­
all incidence of ROP but an increase in necrotizing enterocolitis and sepsis. 
Two studies have suggested that because regression of ROP is so common, 
prophylaxis is not reasonable. Johnson and colleagues have suggested that 
treatment of ROP with vitamin E may be helpful and deserves further study.
Premature infants, particularly those who are critically ill, have low vi­
tamin A levels. This is a result of their missing the last trimester of placental 
transfer compounded by the fact that vitamin A added to parenteral nutrition 
adheres to plastic tubing. Vitamin A deficiency is characterized by reduced 
wound healing, increased squamous metaplasia in lung tissue, increased inci­
dence of infection, night blindness, and xerophthalmia. In 1985, Shenai 
showed that infants with bronchopulmonary dysplasia (BPD) had lower 
plasma vitamin A levels than those with no lung disease. A controlled study 
was subsequently performed in which infants with an estimated 90% risk of 
developing BPD were given 2000 IU of vitamin A intramuscularly on day 1 
and then every other day for 14 doses. All infants received routine vitamin A 
with their parenteral or enteral nutrition. The control infants had an 85% in­
cidence of BPD, and the treated infants had a 45% incidence. The need for 
ventilation on day 28 was decreased from 55% in the controls to 21% in the 
treated group; ROP decreased from 60% to 26%. For the small preterm infant 
(<1250 g), we suggest starting early supplementation of vitamin A with close 
monitoring of serum levels to determine dosage.
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ACUTE RESPIRATORY DISORDERS
Successful adaptation to air breathing at the time of birth is the culmi­
nation of an orderly process of growth and differentiation of pulmonary cells, 
leading to alveolar and capillary surfaces capable of providing oxygen and 
eliminating carbon dioxide. Failure to achieve adequate gas exchange at birth 
represents a major cause of perinatal morbidity and mortality. This chapter 
reviews the common disorders of neonatal respiratory adaptation, including 
respiratory distress syndrome (RDS), pulmonary meconium aspiration syn­
drome (MAS), pulmonary hypertension, pneumonia, air leak, pulmonary 
hemorrhage, and other causes of acute respiratory dysfunction in the perinatal 
period. The clinical manifestations and therapy of these disorders are dis­
cussed in the context of the morphologic, biochemical, and physiologic fac­
tors critical to normal pulmonary growth, maturation, and function in the 
newborn.
HUMAN LUNG DEVELOPMENT
Human lung development can be divided in to five distinct of organo­
genesis. The first is an early embryonic period (3-7 weeks of gestation), dur­
ing which lung development is initiated and major airways are formed. The 
second is a pseudoglandular period (5 -1 7  weeks of gestation), during which 
the bronchial tree and acinar tubules develop. The third is a canalicular pe­
riod (1 6 - 2 6  weeks of gestation), during which vascularization of the sur­
rounding mesenchyme with formation of the air-blood barrier occurs, and cy- 
todifferentiation of bronchiolar and alveolar epithelial cells is initiated. The 
fourth is a saccular period (24 -  38 weeks of gestation), during which 
enlargement of the peripheral air spaces with development of primitive sac- 
like alveoli and thick interalveolar septa occurs. The fifth is an alveolar pe­
riod (36 weeks of gestation to 3 years of age), during which formation of thin 
secondary alveolar septa and remodeling of the capillary bed is initiated, giv­
ing rise to the mature alveolar organization of the adult lung.
The human lung is a derivative of the primitive foregut and appears by 
3 weeks (i.e., 22 days) of gestation as an enlargement of the caudal end of the 
laryngotracheal sulcus located in the median pharyngeal groove, which is an 
outgrowth of the ventral wall of the primitive esophagus. During the fourth 
week (i.e., 26-28 days) of gestation, the respiratory primordium enlarges and 
subdivides into the left and right main stem bronchi. As the primitive lung 
continues to grow caudally, it expands into the mesenchyme surrounding the 
primitive foregut and becomes separated from the esophagus by a band of 
mesenchymal tissue called the tracheo-esophageal septum. Between 4 and 5 
weeks of gestation, the lobar buds arise as the left and right primary bronchi 
subdivide to produce the secondary, or lobar, bronchi. Further subdivision of 
lobar bronchi into tertiary or segmental bronchi occurs during the sixth week
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of gestation, with the lung taking on a lobulated appearance as the segmental 
buds are formed. The developing respiratory tract is lined by endodermally 
derived epithelium that forms conducting airways and alveoli. Surrounding 
mesoderm is composed of mesenchymal cells that differentiate into connec­
tive tissue components, such as blood vessels, fibroblasts, smooth muscle 
cells, and cartilage.
Preacinar blood vessels first appear at the end of week 4. Pulmonary 
arteries arise from the sixth pair of aortic arches and grow into the mesen­
chyme, where they accompany developing airways, segmenting with each 
bronchial subdivision. Pulmonary veins develop as outgrowths of the atrial 
portion of the heart and are enveloped by mesenchyme. Intraacinar arteries 
and veins develop later, in parallel with alveolar formation.
The pseudoglandular stage of fetal lung development extends from 
about 7 to 16 weeks of gestation and is marked by the formation of the bron­
chial portion of the lung. This occurs through a process known as branching 
morphogenesis, during which the segmental tubules of the developing lung 
undergo repetitive lateral and terminal dichotomous branching to from the 
primitive bronchial tree. By week 16 of gestation, the segmental bronchi have 
subdivided to produce 16 to 25 generations of bronchial tubules ending in the 
terminal bronchioles. These bronchial tubules are lined initially by a pseu- 
dostratified columnar epithelium containing large pools of glycogen. A 
prominent basement membrane underlies the epithelium, and mesenchymal 
cells adjacent to these tubules differentiate into fibroblasts and become 
organized, aligning themselves in a circumferential orientation perpendicular 
to the long axis of the bronchial tubules. As branching progresses, 
pseudostratified columnar epithelium is reduced to a tall columnar 
epithelium, especially in distal regions of the bronchial tree. During this 
period, cytodifferentiation of the airway epithelium occurs in a centrifugal 
direction with ciliated, nonciliated, goblet, and basal cells appearing first in 
the more proximal airways. Cartilarge, smooth muscle cells, and mucous 
glands are also found in the trachea during the pseudoglandular stage of 
development and extend as far as the segmental bronchi.
The canalicular stage of lung development extends from week 16 to 24 
of gestation. By the end of week 16, the terminal bronchioles have divided 
into two or more respiratory bronchioles that have subdivided into small clus­
ters of short acinar tubules and buds lined by cuboidal epithelium. These 
structures undergo further differentiation to become the adult respiratory 
unit, or pulmonary acinus, consisting of the alveolated respiratory bronchiole, 
alveolar ducts, and alveoli. Clusters of acinar tubules and buds grow further 
by lengthening, subdividing, and widening at the expence of the surrounding 
mesenchyme. This peripheral growth is accompanied by intraacinar capillar­
ies, which align themselves around the air spaces, establishing with the over- 
lying cuboidal epithelium. During this period, type II epithelial cell differen-
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tiation occurs in acinar tubules with formation of intracellular multivesicular 
bodies and, later, multilamellar bodies, the storage form of pulmonary surfac­
tant phospholipids. Type I epithelial cell differentiation occurs in conjunction 
with the establishment of the air-blood barrier wherever endothelial cells of 
the developing capillary system come into contact with the overlying acinar 
epithelial cells.
During the saccular stage, which extends from week 24 to 38 of gesta­
tion, the terminal clusters of acinar tubules and buds begin to dilate and ex­
pand into thin, smooth-walled, transitory saccules and ducts that later become 
the true alveolar ducts and alveoli of the adult. During this period, there is a 
marked reduction in the amount of interstitial tissue. Intersaccular and inter- 
ductal septa develop that contain a delicate network of collagen fibers and in- 
traacinar capillary bed. Near the end of this period, elastin is deposited in ar­
eas where future interalveolar septa will form. Increasing amounts of tubular 
myelin, the secretory form of pulmonary surfactant, are seen in the air spaces.
The alveolar period, which extends from 36 weeks of gestation to be­
tween 2 to 8 years of age, is the last stage of lung development and is marked 
by the formation of secondary alveolar septa partitioning the transitory ducts 
and succules into true alveolar ducts and alveoli. This process of alveolariza- 
tion greatly increases the surface area of the lung available for gas exchange. 
Between 20 to 70 million alveoli are formed before birth, and the postnatal 
formation of additional alveoli increases their number to between 300 to 400 
million by 2 to 8 years of age. At the beginning of this period, the secondary 
interalveolar septa consist of short buds or projections of connective tissue 
that contain a double capillary network and interstitial cells that actively syn­
thesizing collagen and elastic fibers. By 5 months of age, these secondary in­
teralveolar septa have lengthened and thinned and contain only a single capil­
lary network. This suggests that alveolar formation occurs rapidly after birth 
and may be complete within the first 12 to 24 months of life. Further growth 
of the lung occurs by expansion and further subdivision of the alveolar spaces 
by tertiary interalveolar septa. From birth to adulthood, the conducting air­
ways increase in length and diameter, while airspace and capillary volume 
increase coordinately at the expense of interstitial volume.
DEVELOPMENTAL ANOMALIES
Each of these stages of lung development comprises distinct changes in 
tissue organization and differentiation that are important for subsequent 
growth and maturation of the lung. Structural and functional defects in lung 
development at birth can often be traced to arrested or aberrant development 
during one of these periods of organogenesis. Developmental anomalies of 
the lung occur through defective division and differentiation of the lung bud 
or of the left or right bronchial bud. Pulmonary agenesis, bronchial malfor­
mations, tracheoesophageal fistulas, tracheomalacia, bronchomalacia, ectopic
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lobes, and congenital pulmonary cysts arise during the embryonic and pseu- 
doglandular stages of lung development. Clinical disorders related to pulmo­
nary hypoplasia and respiratory insufficiency are associated with later peri­
ods of development. Pulmonary hypoplasia can be caused by a reduction of 
space within the pleural cavity, usually as a consequence of another primary 
developmental defect, such as congenital diaphragmatic hernia, or by a 
reduction in the amount of amniotic fluid due to prolonged rupture of mem­
branes or in association with renal dysgenesis (i.e., Potter syndrome). Respi­
ratory distress syndrome and bronchopulmonary dysplasia are associated 
with premature birth at a time when biochemical functions (e g., surfactant 
production) and structural functions (e.g., elasticity) of the lung are still un­
derdeveloped.
THE SURFACTANT SYSTEM
The unique physical-chemical boundary between the alveolar gases 
and the highly solvated molecules at the apical surface of the respiratory epi­
thelium generates a region of high surface tension produced by the unequal 
distribution of molecular forces among water molecules at an air-liquid inter­
face. Surface-active material at this interface in the alveoli provides surface 
tension, lowering activity that contributes to the remarkable pressure- 
volume associations characteristic o f the lung. This surface-active material, 
called surfactant, has been subject to intense study in recent decades.
Deficiency or dysfunction of pulmonary surfactant plays a critical 
role in the pathogenesis of respiratory diseases in the newborn period. Pul­
monary surfactant exists in a variety of physical forms when isolated from 
the alveolar wash of the lung. These physical forms include lamellated and 
vesicular forms and highly organized tubular myelin. Tubular myelin is 
highly surface active and, although composed predominately of phospholip­
ids, its unique structure depends on Ca2+ and lung surfactant proteins A (SP- 
A) and В (SP-B). Tubular myelin represents the major extracellular pool of 
surfactant from which a lipid monolayer is generated to produce an interface 
between the hydrated cellular surfaces and alveolar gas.
Lamellated and vesicular forms of surfactant represent nascent or 
catabolic forms of surfactant material; the latter is taken up by type II 
epithelial cells and recycled. SP-A, SP-B, and surfactant protein C (SP-C) 
play important roles in the organization and function of the surfactant com­
plex regulating surfactant recycling and secretion. Alveolar surfactant con­
centrations are tightly controlled by a variety of mechanisms that modulate 
lipid and protein synthesis, storage, secretion, and recycling.
COMPOSITION OF SURFACTANT
Pulmonary surfactant is composed primarily of the phospholipids 
phosphatidylcholine and phosphati-dylglycerol. These lipid molecules are
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enriched in dipalmitoyl acyl groups attached to a glycerol backbone that 
pack tightly and generate low surface pressures. Rapid spreading and stabil­
ity of pulmonary surfactant is achieved by the interactions of surfactant pro­
teins and phospholipids. Surfactant is synthesized and secreted by type II 
epithelial cells in the alveolus. Synthesis of phosphatidylcholine, surfactant 
proteins, and lamellar bodies, an intracellular storage form of pulmonary 
surfactant, increases with advancing gestation. Lamellar bodies are secreted 
into the lung liquid that contributes to the amniotic fluid. The measurement 
of amniotic fluid phosphatidylcholine, disaturated phosphatidylcholine, 
posphatidylglycerol, or the surfactant proteins has provided useful bio­
chemical markers that predict lung maturation and the adequacy of lung 
function at birth (e.g., lecithin-sphingomyelin [L-S] ratio and phosphatidyl- 
glycerol values). Surfactant function can be assessed by a variety of physi­
cal and physiologic tests that generally measure its ability to reduce surface 
tension at an air-liquid interface and to spread rapidly during dynamic com­
pression and expansion. The Wilhelmy balance, Langmuir trough, pulsating 
bubbleometer, and a variety of animal models have been used to assess the 
efficacy of surfactant and surfactant replacements.
FIG. 1. Pulmonary surfactant components are expressed as a percentage of the 
total weight.
Choi - cholesterol; DG - diacylglycerol; DPPC - dipalmitoylphosphatidyl- 
choline; PA - phosphatidic acid; PC - phosphatidylcholine; PE - phosphati- 
dylethanolamine; PG - phosphatidylglycerol; PI - phosphatidylinositol; SM, - 
sphingomyelin.
CONTROL OF SURFACTANT SYNTHESIS AND SECRETION 
Synthesis of pulmonary surfactant is closely linked to the morphol­
ogic and biochemical differentiation of alveolar type II cells in the periph­
eral respiratory epithelium. Interactions between mesenchymal and epithe­
lial cells, mediated by direct cell-cell contact or by paracrine factors, con­
tribute to the differentiation process. Endocrine factors also modulate the 
differentiation of type II epithelial cells and the synthesis of surfactant com-
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ponents. In vivo and in vitro evidence supports the role of glucocorticoids in 
the modulation of morphologic differentiation and production of phosphol­
ipids and surfactant proteins by the lung.
PHOSPHOLIPID SYNTHESIS
Phosphatidylcholine is produced by type II epithelial cells using ex­
tracellular substrate and the glycogen stores that accumulate in the pre-type 
II cells of the fetal lung. Metabolic pathways producing phosphatidylcholine 
depend on the production of phosphatidic acid and a glycerophosphate 
backbone; the latter is produced as an intermediate of the glycolytic path­
way. The synthesis of phosphatidylcholine involves the deacylation of 
phosphatidic acid and its reaction with cytidine diphosphocholine (CDP- 
choline).
Disaturated forms of phosphatidylcholine may be formed de novo, us­
ing disaturated acyl precursors or by remodeling (i.e., salvage pathway) of 
phospho-lipids by deacylation and reacylation reactions. Production of 
CDP-choline is critical to phosphatidylcholine synthesis and is achieved by 
phosphorylation of choline and transfer to cytidine triphosphate in a reac­
tion dependent on choline kinase and choline phosphate cytidylyltrans- 
ferase. The activities of many of the enzymes in the synthetic pathway for 
phosphatidylcholine increase with advancing gestation in the lung, generally 
increasing in the last third of gestation.
GLUCOCORTICOID ENHANCEMENT
A variety of hormonal factors influence the rate of production of the 
enzymes controlling phosphatidylcholine synthesis in the developing lung. 
Glucocorticoids are the most clinically relevant and useful of these agents. 
Studies in fetal lambs and humans demonstrated that administration of glu­
cocorticoid to the dam or mother resulted in precocious respiratory function 
in prematurely born offspring. The initial clinical studies of Liggins and 
Howie demonstrated that maternal administration of glucocorticoid de­
creased the incidence of respiratory distress in premature infants. Although 
the precise mechanisms by which glucocorticoids induce pulmonary 
maturation and lung function in premature infants have not been discerned, 
increased phosphatidylcholine synthesis and morphologic remodeling of the 
alveolar architecture, including the thinning o f interstitial components of the 
fetal lung, are observed after glucocorticoid treatment. Glucocorticoids 
regulate several genes that are associated with the differentiation of the fetal 
lung, including the genes encoding enzymes involved in the synthesis of 
phosphatidylcholine and the surfactant proteins. The effects of glucocorti­
coid on lung cell differentiation are mediated in part by glucocorticoid re­
ceptors, which when occupied by hormones, influence gene transcription 
and mRNA stability, altering the abundance of the proteins synthesized by 
pulmonary cells.
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OTHER HORMONAL INFLUENCES
Thyroid hormones (i.e., T3, T4), thyrotropin-releasing hormone 
(TRH), estrogens, prolactin, epidermal growth factor, ^-adrenergic agents, 
and other agents that enhance cellular cAMP levels influence pulmonary 
maturation or biochemical indices of pulmonary maturation. T3 and T4 in­
crease the synthesis of phospholipids in mammalian lung but do not readily 
cross the placenta. Recent studies of TRH support its role for prevention of 
chronic lung disease in premature infants. The mechanisms of action of 
TRH have not been clarified, but its action does not appear directly related 
to stimulation of surfactant synthesis.
SURFACTANT SECRETION
Surfactant is stored within type II cells in large lipid-rich organelles 
called lamellar bodies. Secretion of lamellar bodies occurs by a process of 
exocytosis that is regulated by a number of physical and hormonal factors. 
Stretch, the mode of ventilation, and the labor process enhance surfactant 
secretion and extracellular surfactant pool sizes at birth. Catecholamines, 
purinoceptor agonists (e.g., adenosine triphosphate) that activate protein ki­
nases, and Ca2+ ionophores enhance phospholipid secretion by type II cells 
in vitro. SP-A, hyperglycemia and hyperinsulinemia inhibit surfactant phos­
pholipid secretion. Newly secreted surfactant enters the extracellular space 
and undergoes dramatic structural reorganization to form tubular myelin, a 
process dependent on SP-A, Ca2+, phospholipids, and SP-B. Phospholipids 
must move from tubular myelin to form a monolayer at the air liquid inter­
face.
SURFACTANT RECYCLING
The process of inflation and deflation produces spent forms of surfac­
tant phospholipids that are taken up by type II cells and reused. SP-A, SP-B, 
and SP-C enhance the reuptake of phospholipids in vitro. Surfactant phos­
pholipid is reused at fast rates. In the adult rabbit lung, the half-life of sur­
factant phospholipids is approximately 8 hours, and in newborn animals, the 
half-life is 3.5 days. The intracellular and extracellular pools of surfactant 
are generally larger in the newborn animal than in adults. A relatively small 
fraction of the alveolar surfactant pool is cleared by catabolism and alveolar 
macrophages, with most of the surfactant phospholipid recycled by type II 
cells. Exogenously administered surfactant is reused efficiently by adult and 
newborn lungs. The effects of surfactant replacement therapy are therefore 
related to the direct surface-tension-lowering properties of surfactant intro­
duced into the airway and to the recycling of exogenous phospholipids by 
type II cells.
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THE ROLE OF SURFACTANT IN LUNG DISEASE
Quantitative and qualitative abnormalities o f pulmonary surfactant 
contribute to the pathogenesis of lung disease in the newborn infant. In 
premature infants, deficiency in surfactant production and secretion de­
crease intracellular and extracellular pools of surfactant, leading to alveolar 
surfactant insufficiency and atelectasis. Qualitative abnormalities of surfac­
tant are also associated with many types of lung injury. Alveolar-capillary 
leak, hemorrhage, pulmonary edema, and alveolar cell injury fill the alveo­
lus with proteina-ceous material that inactivates surfactant. Serum and non­
serum proteins, including albumin, fibrinogen, hemoglobin, and meconium, 
are potent inactivators of pulmonary surfactant in vivo and in vitro. SP-A, 
SP-B, and SP-C act synergistically to stabilize the surface properties of 
phospholipids in the presence of these inactivating proteins. Inhibitory fac­
tors associated with surfactant dysfunction in acute lung injury can be over­
come by the administration of exogenous surfactants that contain the surfac­
tant proteins.
SURFACTANT REPLACEMENT
The first successful surfactant replacement therapy in humans was re­
ported in 1980. Natural synthetic and semisynthetic surfactants have been 
successfully administered into the lungs of premature infants for treatment 
of RDS and are being tested for therapy of other lung diseases. Surfactant 
replacement has become standard for prevention and treatment of RDS. 
Animal surfactant preparations containing phospholipids, SP-B, and SP-C 
(e . g Survanta, Curosurf, Infrasurf) and synthetic preparations composed 
primarily of phospholipids mixed with spreading agents (e.g., Exosurf) are 
in clinical use. The surfactant preparations containing surfactant proteins 
provide highly surface active material to the alveolus. Surfactant replace­
ment also contributes to the pool size of surfactant phospholipids, providing 
substrate for surfactant synthesis by means of the recycling pathways.
RESPIRATORY DISTRESS SYNDROME
Respiratory distress syndrome, previously called hyaline membrane 
disease, is a common cause of morbidity and mortality associated with pre­
mature delivery. Respiratory distress syndrome is a developmental disorder 
rather than a disease process per se, and it is usually associated with prema­
ture birth. The incidence and severity of RDS generally increases with de­
creasing gestational age at birth and is usually worse in male infants. Infants 
of diabetic mothers with poor metabolic control and infants born after fetal 
asphyxia, maternofetal hemorrhage, or in pregnancies complicated by mul­
tiple births are at higher risk for RDS. Respiratory distress syndrome affects 
approximately 20,000 to 30,000 infants each year in the United States and 
complicates approximately 1% of pregnancies. Approximately 50% of the
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infants born between 26 and 28 weeks of gestation develop RDS, and fewer 
than 20% to 30% of premature infants at 30 to 31 weeks have the disorder.
CLINICAL PRESENTATION
Infants with RDS present at birth or within several hours after birth 
with clinical signs of respiratory distress that include tachypnea, grunting, 
retractions, and cyanosis accompanied by increasing oxygen requirements. 
Physical findings include rales, poor air exchange, use of accessory muscles 
of breathing, nasal flaring, and abnormal patterns of respiration that I may 
be complicated by apnea. Chest radiographs are characterized by atelectasis, 
air bronchograms, and diffuse reticular-granular infiltrates, often progress­
ing to severe bilateral opacity characterized by the term "white-out" (Fig. 2). 
Radiographic patterns in RDS are variable and may not reflect the degree of 
respiratory compromise.
FIG. 2. This premature infant presented with grunting, retractions, 
and cyanosis after delivery. The diffuse reticular-granular opacifica­
tion, air bronchograms, and decreased lung volumes in the chest x- 
ray film indicate respiratory distress syndrome.
The infant attempts to maintain alveolar volume by prolonging and 
increasing expiratory pressures by breathing against a partially closed glot­
tis, causing the grunting noise characteristic of RDS but often seen in other 
respiratory disorders. Increasing oxygen requirements and the need for ven­
tilatory support often occur rapidly in the first 24 hours of life and continue 
for several days thereafter. The clinical course depends on the severity of 
RDS and the size and maturity of the infant at birth. In uncomplicated RDS, 
typically seen in more mature infants, recovery is rapid and infants gener­
ally no longer require oxygen or ventilatory support after the first week of 
life. The most premature infants are at greatest risk for severe RDS and fre-
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quently develop complications, including central nervous system (CNS) 
hemorrhage, patent ductus arteriosus (PDA), air leak, and infection, which 
contribute to prolonged requirements for oxygen and ventilatory support.
PATHOLOGY
Pathologic findings early in the course of RDS include atelectasis, 
pulmonary edema, pulmonary vascular congestion, pulmonary hemorrhage, 
and evidence of direct injury to the respiratory epithelium. Epithelial cell 
injury is especially evident in the bronchiolar region of the lung. Histologic 
findings include the presence of hyaline membranes, the characteristic eosi­
nophilic material derived from bronchial and bronchiolar injury to epithelial 
cells. Alveolar spaces are generally not inflated, and at autopsy, the lungs of 
infants with RDS are often airless on passive deflation. Leukocytic infiltra­
tion is not observed early in the course of RDS unless complicated by infec­
tion. Pulmonary edema, hemorrhage, and hemorrhagic edema are common 
pathologic features in RDS, especially if the clinical course is further com­
plicated by PDA and congestive heart failure.
PATHOPHYSIOLOGY
Quantitative and qualitative abnormalities of the pulmonary surfactant 
system are critical to the pathogenesis of RDS in premature infants. Lack of 
pulmonary surfactant leads to progressive atelectasis, loss of functional re­
sidual capacity, alterations in ventilation-perfusion ratio, and uneven distri­
bution of ventilation. RDS is further complicated by the relatively weak 
respiratory muscles and the compliant chest wall of the premature infant 
that impair alveolar ventilation. Diminished oxygenation, cyanosis, and res­
piratory and metabolic acidosis contribute to increased pulmonary vascular 
resistance (PVR). Right-to-left shunting through the ductus arteriosus, fo­
ramen ovale, and intrapulmonary ventilation-per-fusion mismatch further 
exacerbate hypoxemia.
PREVENTION
Although the incidence of premature birth in the United States (i.e., 
approximately 7%) has not changed significantly in recent decades, the in­
cidence of severe RDS has decreased at each gestational age as advances in 
maternal care and strict attention to avoidance of asphyxia and infection at 
birth have become standard treatment. Careful fetal monitoring, treatment of 
underlying maternal disorders, use of amniotic fluid L-S or other biochemi­
cal indicators of fetal lung maturity, and administration of tocolytics and 
maternal glucocorticoids have decreased the incidence of RDS. Surfactant 
replacement further decreases the incidence and severity of RDS. Rapid res­
toration of blood volume after hemorrhage and correction and avoidance of 
anemia, acidosis, and hypothermia improve the clinical outcomes in RDS. 
Positive-pressure ventilation and continuous positive airway pressure
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(CPAP) improve the course of severe RDS but do not prevent the disease 
itself.
TREATMENT
Postnatal therapy of RDS begins with careful assessment and resusci­
tation. Adequate ventilation, oxygenation, circulation, and temperature must 
be assured before transfer of the infant from the delivery room to the appro­
priate site of care. Surfactant replacement therapy may be initiated at birth 
in infants at risk for RDS or thereafter, as symptoms of RDS are established 
and the diagnosis of RDS is confirmed. Ventilatory management of neonatal 
respiratory disorders has been reviewed.
Adequacy of ventilation and oxygenation must be established as soon 
as possible to avoid pulmonary vasoconstriction, further ventilation- 
perfusion abnormalities, and atelectasis. Positive-pressure ventilation, 
CPAP, and oxygen therapy may be required at any time during the course of 
RDS and must be readily available to the infant. Close monitoring of pH, 
oxygen saturation, PC02 and P 0 2 by transcutaneous monitors and by arte­
rial catheterization or sampling of arterialized capillary blood is critical in 
guiding mechanical ventilation and ambient oxygen requirements. Surfac­
tant replacement therapy is provided through the endotracheal tube and is 
often used several times during the early course of RDS to maintain pulmo­
nary function. Exogenous surfactants are given by intratracheal instillation 
of doses of approximately 100 mg o f phospholipid per 1 kg of body weight.
Mild or moderate RDS can be managed by CPAP applied by mask, 
nasal cannula, nasal prongs, or endotracheal or nasopharyngeal tubes. In 
general, 3 to 6 cm of H20  pressure is applied to the infant's airway. Oxy­
genation and effort of breathing are usually rapidly improved by CPAP. 
Rapid fluctuations in blood gases may occur, requiring careful monitoring 
of PC02 and P 0 2. As forced inspiratory oxygen requirements decrease dur­
ing recovery, airway pressure is decreased, and the infant is weaned to head 
hood or nasal cannula oxygen. Apnea, inadequacy of ventilation, atelectasis, 
mucous plugging, hyperaeration, or air leak may complicate the care of in­
fants with RDS.
Careful attention to the mechanical details of the application of CPAP 
or mechanical respirators is required. Mandatory ventilation should be insti­
tuted well in advance of respiratory failure and severe respirator)' acidosis 
to avoid severe hypoxemia and atelectasis. Ventilation is maintained 
through an endotracheal tube, which can be placed nasally or orally, for de­
livery of oxygen and positive pressure. Pressure-cycled ventilators are most 
frequently used in the NICU and are controlled by setting positive inspira­
tory pressure, rate, inspiratory-expiratory times, and positive end-expiratory 
pressures (PEEP). Volume-cycled ventilators, in which fixed volumes are 
delivered to define the respiratory cycle, are used less frequently in the
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newborn. As in all respiratory therapy, critical attention to adequacy of ven­
tilation, as assessed by PO2 , PC02, pH , and transcutaneous oxygen satura­
tion, is required on an almost continual basis to adjust to the rapid changes 
in respiratory status occurring in these critically ill infants. Barotrauma and 
oxygen toxicity to the lung represent significant pulmonary complications in 
the therapy of RDS. Excesses in ventilation, peak or mean airway pressure, 
and oxygen therapy should be avoided. Because hyperoxia is associated 
with retrolental fibroplasia, a major cause of blindness in premature infants, 
arterial P 02 must be carefully monitored, generally maintaining P 0 2 be­
tween 50 to 80 torr. Although other forms of ventilation such as high- 
frequency or jet ventilators have been used successfully for the treatment of 
RDS, these therapies should be considered experimental except for severely 
affected infants whose ventilation has not been supported by conventional 
mandatory ventilation and surfactant therapy.
COMPLICATIONS
Central nervous system hemorrhage, intraventricular hemorrhage 
(IVH), and PDA represent significant clinical problems affecting the care of 
infants with RDS. Patent ductus arteriosus and subsequent congestive heart 
failure and pulmonary edema further compromise respiratory function, de­
creasing pulmonary compliance and perhaps inactivating pulmonary surfac­
tant. Prompt diagnosis and medical or surgical treatment of PDA is indi­
cated during the treatment of RDS. Acute CNS hemorrhage is often associ­
ated with shock, pulmonary compromise, and pulmonary hemorrhage. Fluc­
tuations in respiratory status may contribute to IVH and can be minimized 
by careful attention to respiratory care and by judicious use of sedation. In­
travenous fluids and administration of oral feedings must be adjusted care­
fully during acute and convalescent care of infants with RDS. Excessive 
fluid administration impairs pulmonary function and increases the risk of 
PDA.
MECONIUM ASPIRATION SYNDROME
Meconium-stained amniotic fluid (MSAF) occurs in approximately 
12% of live births. The cause, pathophysiology, and treatment of MSAF and 
MAS have been reviewed.
Meconium first appears in the fetal ileum between 10 and 16 weeks of 
gestation as a viscous, green liquid composed of gastrointestinal secretions, 
cellular debris, bile and pancreatic juice, mucus, blood, lanugo, and vernix. 
Meconium is approximately 72% to 80% water. The dry weight composi­
tion consists primarily of mucopolysaccharides, with less protein and lipid. 
Although intestinal meconium appears very early in gestation, MSAF rarely 
occurs at less than 38 weeks of gestation. Incidence of MSAF increases 
thereafter, and approximately 30% of new-borns have MSAF after 42 weeks
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of gestation. The increased incidence of MSAF with advancing gestational 
age probably reflects the maturation of peristalsis in the fetal intestine. Mo- 
tilin, an intestinal peptide that stimulates contraction of the intestinal mus­
cle, is in lower concentrations in the intestine of premature versus post-term 
infants. Umbilical cord motilin concentration is higher in infants who have 
passed meconium compared with infants with clear amniotic fluid. Intesti­
nal parasympathetic innervation and myelination also increase throughout 
gestation and may play a role in the amplified passage of meconium in late 
gestation.
Passage of meconium may be a normal physiologic event, but it is as­
sociated with fetal asphyxia and decreased umbilical venous blood P 0 2 
(Fig. 3). The gasping respiratory efforts accompanying fetal asphyxia are 
thought to contribute to the entry of meconium into the respiratory tract, 
causing MAS. Experimentally, intestinal ischemia produces a transient pe­
riod of hyperperistalsis and relaxation of anal sphincter tone, leading to the 
passage of meconium. Intestinal ischemia is augmented in the fetus by the 
diving reflex that shunts blood preferentially to the brain and heart and 
away from the visceral organs during hypoxia.
MATERNAL-FETAL COMPROMISE
FIG. 3. Pathogenesis of meconium aspiration syndrome.
An association between MSAF, fetal compromise, and perinatal mor­
bidity has been clearly demonstrated. However, most infants with MSAF do 
not have lower Apgar scores, more acidosis, or clinical illness than infants 
born with clear amniotic fluid. When normal fetal heart rate patterns are ob­
served in cases of MSAF, the neonatal outcome is generally comparable to 
deliveries with clear amniotic fluid. Neonatal outcomes of deliveries com­
plicated by MSAF associated with fetal tachycardia and decreased fetal 
heart rate variability are similar to those of non-meconium-stained infants 
with similar abnormalities of fetal heart rate. Meconium staining may indi-
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cate fetal compromise and demands critical evaluation o f fetal well-being. 
However, in infants with a normal fetal heart rate pattern, MSAF generally 
carries a low risk for perinatal morbidity.
CLINICAL PRESENTATION
Meconium found below the vocal cords defines MAS, which occurs 
in approximately 35% of live births with MSAF or in approximately 4% of 
all live births. Meconium aspiration syndrome describes a wide spectrum of 
respiratory disease, ranging from mild respiratory distress to severe disease 
and death despite mechanical ventilation. Meconium aspiration syndrome 
usually presents as respiratory distress and hypoxemia soon after birth. 
Pulmonaiy hypertension is frequently observed in infants with severe MAS.
The chest radiographs of infants with MAS demonstrate coarse infil­
trates, widespread consolidation, or areas of hyperaeration. Pleural effusions 
are detected in approximately 30% of infants with MAS. Pneumothorax or 
pneumomediastinum occur in approximately 25% of severely affected in­
fants.
PATHOLOGY
Postmortem examination of lungs from infants with severe MAS re­
veals meconium, vemix, fetal squa-mous cells and cellular debris in the air 
spaces from the airways to the alveoli. An inflammatory response with po­
lymorphonuclear leukocytes, macrophages, and alveolar edema may be ob­
served, but large quantities of meconium may be present without histologic 
signs of inflammation. Hyaline membrane formation, pulmonary hemor­
rhage, and necrosis of pulmonary microvasculature and parenchyma can oc­
cur. Platelet-rich microthrombi in small arterioles and increased musculari- 
zation of distal arterioles have been described in some infants dying of 
MAS.
PATHOPHYSIOLOGY
The pulmonary abnormalities in MAS are related primarily to acute 
airway obstruction, decreased lung tissue compliance, and parenchymal 
lung damage. Instillation of meconium into adult rabbit and newborn dog 
tracheas causes acute mechanical obstruction of proximal and distal air­
ways. A ball-valve mechanism producing partial airway obstruction con­
tributes to air trapping, which results in increased anteroposterior chest di­
ameter, increased expiratory lung resistance, and increased functional resid­
ual capacity. Complete obstruction of small airways may result in regional 
atelectasis and ventilation-perfusion inequalities. Disruption of surfactant 
function by serum and nonserum proteins and fatty acids contributes to ate­
lectasis, decreased compliance, and resulting hypoxia. In more than one-half 
of the infants with severe MAS, pulmonary hypertension with right-to-left 
shunting contributes to the characteristically severe hypoxemia. Perinatal
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tal asphyxia is a critical underlying factor in the pathogenesis of MAS, in­
creasing the risks for pulmonary hypertension and meconium aspiration.
PREVENTION
Before the late 1970s, it was thought that aspiration of amniotic fluid 
and meconium occurred during the first few breaths after delivery. Therapy 
was aimed at preventing MAS at the time of delivery by suctioning of the 
nasopharynx before delivery of the shoulders and before the first breath. 
The trachea was immediately intubated and suctioned to limit aspiration of 
meconium from the oropharynx and trachea, a procedure that remains stan­
dard in most institutions. Mortality from MAS was decreased when the tra­
chea was suctioned immediately after birth.
Meconium aspiration syndrome continued to occur in infants who are 
adequately suctioned in the delivery room. Aspiration of meconium or am­
niotic fluid in utero probably occurred in some infants with MAS, particu­
larly in those with perinatal asphyxia. Generally, fetal lung fluid flows out­
wardly from the lungs into the amniotic sac. However, studies with radi­
opaque contrast and Cr-labeled erythrocytes injected into the amniotic sac 
demonstrated that some amniotic fluid enters the fetal lung in the nonas- 
phyxiated human fetus. Fetal gasping may be a critical factor in entry of 
meconium into the lung before birth. Gasping associated with inhalation of 
amniotic fluid or meconium occurs in fetal lambs, rhesus monkeys, and hu­
mans in response to fetal asphyxia after compression of the umbilical cord 
or maternal aorta, Antenatal diagnosis and treatment of fetal asphyxia is 
therefore critical for prevention of MAS. Amniomfusion, particularly in 
cases of oligohydramnios, may decrease morbidity related to MAS by de­
creasing cord compression and diluting the meconium, potentially minimiz­
ing its toxicity after aspiration.
Concerns about infection risks to delivery room staff and mechanical 
injury to the infant related to aggressive suctioning and intubation have 
been raised. The use of direct tracheal suctioning for all meconium-stained 
infants is undergoing reevaluation. Meanwhile, clearing the airway and es­
tablishing respiration and oxygenation remain basic to the resuscitation of 
all infants.
TREATMENT
Postnatal therapy for MAS begins with continuous observation and 
monitoring of infants at risk. Pulmonary vasoconstriction is associated with 
MAS, and rapid correction of hypoxemia and acidosis is critical. Chest 
physiotherapy and suctioning may be useful if there is airway obstruction 
and the infant maintains adequate oxygenation during such therapy. Con­
tinuous monitoring of oxygenation by transcutaneous oxygen monitoring or 
pulse oximetry and assessment of P 0 2, PC02 and pH  by arterial catheteriza­
tion should be used to guide the use of oxygen therapy and mechanical ven-
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tilation. The presence and severity of pulmonary hypertension should be 
evaluated. Mechanical ventilation to achieve respiratory alkalosis and infu­
sion of sodium bicarbonate to produce a metabolic alkalosis may improve 
oxygenation.
VENTILATORY SUPPORT
Although improvement in oxygenation was observed in patients with 
MAS treated with 4 to 7 cm H20 PEEP, further studies to confirm the safety 
and efficacy of positive end-expiratory pressure in MAS are needed. Me­
chanical ventilation is often required in severe MAS and must be managed 
carefully. Continuous positive airway pressure or PEEP may aggravate 
hyperinflation associated with MAS and should be used with caution. Pneu­
mothorax or pneumomediastinum occur frequently during the course of 
MAS and may occur before the application of positive-pressure ventilation. 
Lengthening the expiratory time of the ventilatory cycle may minimize hy­
perinflation. Oscillation and high-frequency jet ventilation have been used 
in the treatment of MAS, but reports of their safety and efficacy in MAS are 
conflicting.
OTHER THERAPEUTIC CONSIDERATIONS
Therapy of the infant with MAS includes careful observation and vig­
orous treatment of other sequelae of neonatal asphyxia, including tempera­
ture instability, hypoglycemia, hypocalcemia, hypotension, and decreased 
cardiac function. Specific therapy directed to the sequelae from multiorgan 
hypoxemia and ischemia, including reduced renal function, reduced liver 
production of clotting factors, hypoalbuminemia, cerebral edema, and sei­
zures, may be required.
Extracorporeal membrane oxygenation (ECMO) has been used suc­
cessfully in treatment of severe MAS refractory to ventilatory therapy. 
Broad-spectrum antibiotics are routinely used in the therapy o f MAS in in­
fants with abnormal radiographic findings and respiratory distress. Treat­
ment of acute MAS with glucocorticoids has not been beneficial. The use of 
exogenous surfactant for therapy of MAS is under active investigation.
PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN
Gersony and colleagues described hypoxemia in two infants with 
"persistent physiologic characteristics of the fetal circulation (PFC) in the 
absence of recognizable cardiac, pulmonary, hematologic, or central nerv­
ous system disease.' Because the placenta is no longer present and the 
ductus arteriosus may or may not be patent, the term persistent pulmonary 
hypertension of the newborn (PPHN) is now used to describe this disorder. 
The pathophysiology of PPHN is related to a failure to make the transition 
from high PVR and low pulmonary blood flow characteristic of the fetus to
44
the relatively low PVR and high pulmonary blood flow of the postnatal in­
fant. The clinical syndrome of PPHN has been reviewed.
PATHOPHYSIOLOGY
The pathophysiology of PPHN can best be understood within the 
framework of the current knowledge of the transitional circulation. Normal 
transition occurs in four phases: the in utero phase, the immediate phase oc­
curring in the first minutes after birth, the fast phase developing in the first 
12 to 24 hours, and the final phase, which requires days or months to com­
plete.
I N  U T E R O  CIRCULATION
The in utero phase (i.e., phase 1) is characterized by PVR that ex­
ceeds systemic vascular resistance, resulting in right atrial and ventricular 
pressures exceeding left atrial and ventricular pressures. As a result of this 
pressure differential, more than one-third of the oxygenated blood returning 
from the placenta through the inferior vena cava streams across the patent 
foramen ovale, is ejected from the left ventricle, and perfuses the head and 
neck vessels and the lower body. Venous blood returning through the supe­
rior vena cava preferentially flows into the right ventricle and main pulmo­
nary artery. A small amount of this deox-ygenated blood, comprising ap­
proximately 8% of the cardiac output with a P 0 2 less than 20 torr, does per­
fuse the lungs, but because of elevated PVR, most is shunted across the 
PDA to mix with the blood returning in the inferior vena cava. The lower 
body is perfused with relatively less well oxygenated blood than the head 
and neck. Because of the large right-to-left shunt, blood bypasses the lungs 
in utero. Persistence of the elevated PVR after birth without the benefit of 
placental oxygenation results in the profound hypoxemia characteristic of 
PPHN. The mechanisms that maintain the fetal state of high PVR are under 
study. Pulmonary vasoconstriction induced by hypoxia, alterations in nitric 
oxide and arachidonic acid metabolism, and systemic acidosis probably 
contribute to physiologic abnormalities in PPHN.
IMMEDIATE PHASE
The second stage of normal transition, the immediate phase, is ac­
complished in the first minute after birth when the fluid-filled fetal lungs are 
distended with air during the first breath. A rapid decrease in PVR occurs 
with the mechanical distention of the pulmonary vascular bed, allowing 
more oxygenated blood to perfuse the lungs. The entry of air into the alveoli 
improves the oxygenation of the pulmonary vascular bed, further decreasing 
PVR.
FAST PHASE
The fast phase of the transitional circulation occurs for 12 to 24 hours 
after birth and accounts for the greatest reduction in PVR. The drop in PVR
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has been associated with the production of vasodilators, such as prostacy­
clin and endothelial-derived relaxing factor (i.e., nitric oxide). Prostacyclin 
is produced in the neonatal lung in response to the initiation of ventilation. 
Pretreatment of the fetal lamb with cyclooxy-genase inhibitor decreased 
prostacyclin production and prevented the late fall in PVR. The role of cy­
clooxygenase and prostacyclin in the transitional circulation may have 
clinical implications. Persistent pulmonary hypertension of the newborn has 
been observed in infants of mothers receiving aspirin or nonsteroidal antiin­
flammatory agents that inhibit cyclooxygenase activity. Pulmonary produc­
tion of potent vasodilatory leukotrienes also occurs during the initiation of 
ventilation.
FINAL PHASE
The final phase of the neonatal pulmonary vascular transition in­
volves remodeling of the pulmonary vascular musculature. In the normal 
fetal and term lung, fully muscularized, thick-walled preacinar arteries ex­
tend to the level of the terminal bronchioles. Intraacinar and alveolar wall 
arteries are not muscularized. Within days after delivery, medial wall thick­
ness of preacinar vessels smaller than 250 pm in diameter decreases, and 
within months, medial wall thickness of vessels larger than 250 and smaller 
than 500 pm also decreases. Hypoxia at birth prevents the remodeling of the 
smooth muscle of the preacinar bronchiolar arteries. High flow states and in 
utero hypoxia stimulate cells of the intraacinar and alveolar arteries to dif­
ferentiate into smooth muscle and connective tissue, resulting in abnormally 
thickened and reactive arteriolar musculature. Increased muscularization of 
the pulmonary arteries has been described in infants dying of severe MAS 
with PPHN.
ETIOLOGY
Persistent pulmonary hypertension of the newborn has a variety of 
causes that can be classified by the predominant abnormality involved. The 
clinician needs to recognize the subclasses of PPHN. Because of the avail­
ability of ECMO therapy, assessment of the clinical severity of PPHN helps 
determine the need for referral to tertiary care nurseries with ECMO capabil­
ity.
CLINICAL PRESENTATION
Clinically, PPHN presents as labile hypoxemia that is disproportion­
ate to the extent of pulmonary paren-chymal disease. Infants with PPHN are 
commonly appropriate for gestational age and near term. The perinatal his­
tory frequently includes factors associated with perinatal asphyxia. Clinical 
symptoms include tachypnea, respiratory distress, and often rapidly pro­
gressive cyanosis, particularly in response to stimulation of the infant. The 
cardiovascular examination may be normal or may reveal a right ventricular 
heave, closely split or single loud S2, and tricuspid regurgitation suggesting 
that pulmonary arterial pressure is equal to or greater than systemic arterial
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pressure. Differential diagnosis of PPHN includes severe pulmonary paren­
chymal disease, such as severe MAS, RDS, pneumonia, or hemorrhage, and 
congenital heart disease, such as transposition of the great arteries. Critical 
pulmonic stenosis, hypoplastic left ventricle, or severe coarctation should be 
considered I in the differential diagnosis. Methods used to differentiate 
PPHN from pulmonary parenchymal disease or cardiac disease are outlined 
in Table 3.
Table 3
Diagnostic evaluation of severe neonatal hyperoxia
Test Method Result Suggested Diagnosis
Hyperoxia Expose to 100% FiCh Pa02 increases to > Pulmonary parenchy-
for 5-10 min 100 torr
Pa02 increases to < 20 
torr
mal disease 
Persistent pulmonary 
hypertension or cya- 
tonic congenital heart 
disease
Hyperventilation- Mechanical ventila- PaCh increases to > Pulmonary parenchy-
hyperoxia tion with 100% Fi02 
and respiratory rate
100 torr without hy­
perventilation
mal disease
100-150 bpm Pa02 increases at a 
critical PC02, often to 
< 25 torr
No increase in Pa02 
despite hyperventila­
tion
Persistent pulmonary 
hypertension
Cyatonic congenital 
heart disease or se­
vere, fixed pulmonary 
hypertension
Simultaneous preduc- Compare PO2 of right Preductal РОг> 15 + Patent ductus arteri-
tal-postductal PO2 arm or shoulder to that 
of lower abdomen or 
extremities
postductal PO2 osus with right-to-left 
shunt
Echocardiography M-mode Increased RVPEP and 
RVET
Right ventricular sys­
tolic time invertal ra­
tio (RVSTI 
RVPEP/RVET > 0,5) 
predicts PPHN
Venous contrast injec­
tion
Simultaneously ap­
pears in PA and LA
Patent foramen ovale
Two-dimensional Deviation of intraatrial Increased pulmonary
echocardiography septum to left; rule out 
congenital heart defect
arterial pressure
Doppler Failure of acceleration 
of systolic blood flow 
between large main 
pulmonary artery and 
small peripheral pul­
monary artery
Suggests right-to-left 
PDA or intracardiac 
shunt
1.A - left atrium; PA - pulmonary artery; PDA - patent ductus arteries; PPHN - 
persistent pulmonary hypertension of the newborn; RVET - right ventricular ejec­
tion time; RVPEP - right ventricular ejection period.
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The oxygenation of infants with severe pulmonary parenchymal dis­
ease generally improves after treatment with oxygen or mechanical ventila­
tion. Infants with PPHN often have little or no parenchymal lung disease. 
They are easily ventilated but remain hvpoxic despite high ambient forced 
inspiratory oxygen. Cyanotic congenital heart disease (CCHD) is usually 
associated with fixed, structural mixing of venous and arterial blood. In in­
fants with CCHD, hypoxemia is generally unresponsive to increased exoge­
nous oxygen or mechanical ventilation. Diagnosis of PPHN can be compli­
cated by the coexistence of pulmonary hypertension, parenchymal lung dis­
ease, or CCHD. Echocardiography is useful in the diagnosis of structural 
heart disease in this clinical setting.
THERAPY
Supportive medical management includes correction of underlying 
abnormalities that may include polycythemia, hypoglycemia, hypothermia, 
diaphragmatic hernia, or CCHD. Metabolic acidosis and hypotension should 
be corrected by adequate replacement of intravascular volume and admini­
stration of sodium bicarbonate or pressors.
Specific therapy for PPHN is aimed at increasing pulmonary blood 
flow and decreasing right-to-left shunting. High ambient oxygen and me­
chanical ventilation are the pulmonary therapeutic interventions for treat­
ment of PPHN. Ligation is not useful for treating PDA, and it may be det­
rimental. Cardiac failure may occur after PDA ligation as the right ventricle 
fails in the face of high afterload without the safety valve of the patent duc­
tus. Because shunting between the pulmonary and systemic circulations de­
pends on the relative pressures of each system, optimal therapy should de­
crease pulmonary artery pressure while increasing or not changing systemic 
arterial pressure and cardiac output.
Infants with severe PPHN are often sensitive to activity and agitation. 
Transcutaneous and intravascular monitoring equipment should be used and 
stimulation minimized during the care of these infants. Muscle relaxants 
(e.g., pancuronium) and sedatives are frequently beneficial but should be 
used with caution because paralysis may further compromise ventilation and 
may mask clinical signs of respiratory insufficiency. Sedatives should be 
chosen to minimize cardiovascular side-effects. Infants with PPHN, espe­
cially if asphyxiated or septic, frequently develop systemic hypotension and 
signs of cardiac failure. Elevated right heart pressure due to increased PVR, 
poor venous return secondary to high intrathoracic pressures during me­
chanical ventilation, and previous asphyxia may contribute to myocardial 
dysfunction. The hematocrit should be maintained at or above 45%, and 
volume expanders, such as salt-poor albumin, Plasmanate, or normal saline, 
may be used to support the circulation. Dopamine and other pressors are 
commonly used for refractory hypotension.
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RESPIRATORY AND METABOLIC ALKALOSIS
The often dramatic response of infants with PPHN to respiratory or 
metabolic alkalosis supports their use in the care of infants with severe 
PPHN. The degree of pulmonary parenchymal disease and risk of baro­
trauma may affect the clinical choice of inducing respiratory or metabolic 
alkalosis. It may be necessary to lower PC02 and raise the pH to 7.55 or 
above with hyperventilation and sodium bicarbonate to treat severe pulmo­
nary vasoconstriction. Sustaining PC02 at less than 20 torr is not advocated. 
Excessive mechanical ventilation with over distention of the lung may in­
crease right-to-left shunting. Pulmonary baro-trauma associated with ag­
gressive ventilation should not be underestimated. Hypocarbic alkalosis, by 
shifting the hemoglobin-oxygen dissociation curve, may also compromise 
the release of oxygen at the tissue level. Hyperoxia and hypocarbia may ad­
versely affect cerebral blood flow. Weaning from ventilation and alkaliniza- 
tion must proceed with caution, because dramatic lability of P 02 is often 
observed in infants with PPHN.
PULMONARY VASODILATOR THERAPY
Pharmacologic agents such as tolazoline and nitro-prusside have been 
used for pulmonary vasodilation. Tolazoline has been used most commonly, 
but its vasodilatory effects are unpredictable, and systemic vasodilation is 
frequently observed. Inhalation of nitric oxide is undergoing clinical evalua­
tion for the treatment of PPHN. Volume infusion and vasopressors should 
be readily available, if not used prophy-lactically, to treat systemic hypoten­
sion. Tolazoline has not been shown to influence survival of infants with 
PPHN.
LONG-TERM OUTCOME
Most infants treated for PPHN have few residual respiratory symp­
toms or neurologic or developmental sequelae by 1 year of age. Infants with 
more seal vere parenchymal disease may have persistent or chronic tachyp­
nea and bronchospasm. Infants with severe MAS and PPHN have an in­
creased risk for chronic pulmonary sequelae. Continued oxygen therapy, 
bronchodilators, diuretics, and enhanced nutrition may be necessary to treat 
residual disease and establish adequate growth. Hearing, vision, and neu­
rologic development should be followed closely in infants treated for 
PPHN, especially if severely asphyxiated.
PNEUMONIA
Pneumonia remains a significant cause of morbidity and mortality for 
preterm and term infants. The incidence of pneumonia in NICU patients ex­
ceeds 10%, and mortality of perinatally acquired pneumonia remains ap­
proximately 20%. Pneumonia may be acquired transplacentally, during the 
birth process, or postnatally, and it is caused by a variety of pathogens, in-
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eluding viruses, bacteria, and fungi. Unique environmental and host factors 
predispose the neonate to pulmonary infections. The increased susceptibility 
of neonates for pneumonia may be related to immaturity of mucociliary 
clearance, small size of the conducting airways, and lowered host defenses. 
Invasive procedures, such as tracheal intubation, barotrauma, and hyperoxic 
damage to the respiratory tract, may further impair resistance to pneumonia. 
The nosocomial flora of the hospital nursery, whether derived from nursery 
equipment or the unwashed hands of caregivers, are important vectors of 
pathogenic organisms.
TRANSPLACENTAL VIRAL PNEUMONIAS
Pneumonia acquired through the transplacental route is most com­
monly of viral origin. Rubella, varicella-zoster, cytomegalovirus (CMV), 
herpes simplex virus (HSV), and human immunodeficiency virus (HIV) are 
acquired by this route.
Table 4
Primary pathogens of neonatal pneumonia
Vector Viruses Bacteria Other Agents
Transplacental Rubella
Varicella-zoster
HIV
CMV
HSV
L. monocytogenes
M. tuberculosis 
T. pallidium
Perinatal HSV
CMV
Group В streptococci 
Gram-negative enteric 
(i.e., E. coli, Kleb­
siella)
C. trachomatis 
U. urealyticum
Postnatal CMV
HSV
Community based (i.e., RSV, 
influenza, parainfluenza)
S. aureus 
P. aeruginosa 
Flavobacterium 
S. marcescens
C. albicans
HIV - human immunodeficiency virus; CMV - cytomegalovirus; HSV - herpes simplex virus;
RSV - respiratory syncytial virus.
Transplacentally acquired pneumonitis is also associated with adeno­
viral, enter oviral and influenza viral infections. Viral pneumonia is usually 
part of a systemic illness, reflecting hematogenous spread from the mother. 
Severity and onset of respiratory symptoms varies from respiratory failure 
at delivery to chronic pneumonia evolving months after birth.
Fetal infection may result from a primary maternal infection acquired 
during pregnancy or from reactivation of a latent infection. In utero trans­
mission of rubella occurs as a result of primary infection acquired during 
pregnancy. Transmission of varicella-zoster, HSV, and CMV occurs as a
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result of primary or recurrent maternal infection. The timing of maternal in­
fection in relation to birth is often a critical factor in outcome. Congenital 
varicella typically develops when primary maternal chickenpox occurs 
within the 21 days preceding parturition. If maternal varicella occurs less 
than 5 days before birth, antepartum transfer of maternal antibody to the fe­
tus is minimal, increasing the risk of systemic varicella infection in the neo­
nate. Varicella pneumonia usually presents 2 to 4 days after the onset of the 
exanthem. Although varicella pneumonia is often self-limited, it can cause 
significant mortality and morbidity. Treatment with varicella-zoster immune 
globulin within 72 hours of birth improves clinical outcome in neonates ex­
posed to varicella. Pneumonitis is not a common presentation in congenital 
CMV or herpes, but it is more common in perinatally acquired CMV and 
HSV. Pulmonary disease caused by transplacental transfer of the HIV virus 
generally presents after the neonatal period.
TRANSPLACENTAL BACTERIAL PNEUMONIAS
Transplacental bacterial infections are less common causes of pneu­
monia. Listeria monocytogenes, Mycobacterium tuberculosis, and Tre­
ponema pallidum are the most common organisms. Maternal listeriosis 
classically presents with a flulike syndrome, with fever and chills occurring 
up to 2 weeks before delivery. Pre-term labor and meconium staining of 
amniotic fluid, even in preterm infants, are common. Early-onset listeriosis 
generally presents soon after birth with respiratory distress and pneumonia. 
Radiographic findings are nonspecific, consisting of peribronchial or wide­
spread infiltrates. Congenital tuberculosis occurs most commonly in infants 
born to women with primary infections. Respiratory symptoms in neonatal 
tuberculosis typically present at 2 to 4 weeks of age. Transplacental transfer 
of T. palladium occurs most commonly during primary or secondary mater­
nal infection, usually after 20 weeks of gestation. Pneumonia alba refers to 
the pale, firm, and enlarged lungs seen at autopsy in congenital syphilis. Al­
though pulmonary involvement is uncommon, the recent increase in the in­
cidence of primary and secondary syphilis should heighten physician 
awareness of all manifestations of congenital syphilis.
PNEUMONIA ACQUIRED IN THE PERINATAL PERIOD
Neonatal pneumonia is most commonly acquired during the process 
of labor and delivery. Infection occurs from organisms ascending from the 
genital tract after rupture of fetal membranes or acquired during passage of 
the infant through the birth canal. Respiratory symptoms are often present at 
delivery or have their onset in the first few days of life. Despite the abun­
dance and heterogeneity of organisms in the genital tract, only a few com­
monly cause pneumonia.
In U.S. nurseries, group В streptococcus (GBS) is the most frequently 
identified organism causing neonatal pneumonia. The second largest group
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of organisms to produce early-onset sepsis or pneumonia are the gram­
negative enteric bacilli: Escherichia coli, Klebsiella, Enterobacter, and Pro­
teus species. Herpes simplex and CNV are the most common viral agents 
causing early-onset pneumonia. Pneumonia caused by Chlamydia 
trachomatis, usually begins at 2 to 8 weeks of age with upper respiratory 
tract symptoms, a staccato cough, and apnea. Antecedent conjunctival in­
fection is common but not always observed. Interstitial pneumonitis and 
hyperinflation are associated with chlamydial pneumonia. U. urealyticum is 
a common inhabitant of the lower genital tract of women and is frequently 
associated with histologic evidence of chorioamnionitis. U. urealyticum is a 
cause of acute congenital pneumonia and has also been associated with 
chronic lung disease in infants.
PNEUMONIA ACQUIRED IN THE POSTNATAL PERIOD
Newborns exposed to respiratory equipment or humidified incubators 
are at risk for respiratory infection by Pseudomonas species, Flavo- 
baderium, Klebsiella, or Serratia marcescens. Direct contamination by the 
hands of caretakers due to inadequate hand washing is associated with out­
breaks of Staphylococcus aureus and gram-negative enteric organisms. Cy­
tomegalovirus that is acquired postnatally through blood products or breast 
milk commonly presents as a pneumonitis. Onset of CMV disease is usually 
4 to 12 weeks after exposure, presenting with tachypnea, cough, and upper 
respiratory symptoms.
Neonatal HSV infection is most often associated with HSV type II. 
However, data from the National Institute of Allergy and Infectious Disease 
indicate that 30% of symptomatic neonatal HSV infections were caused by 
HSV type I. Postnatal infection from HSV generally occurs from orolabial, 
oropharyngeal or breast lesions. Community based respiratory pathogens, 
including respiratory syncyticial virus, influenza, parainfluenza, and entero­
viruses, occur in the nursery. Pneumonia resulting from epidemic outbreaks 
of various enteroviral agents, including echovirus 22 and coxsackievirus 
type B, is often associated with other clinical manifestation of enteroviral 
disease. Risk factors for nosocomial fungal infections include very low birth 
weight, prolonged antibiotic therapy, intubation, central line catheter 
placement, intravenous alimentation, and corticosteroids. Pneumonia caused 
by Candida albicans usually presents in the context of disseminated disease.
Disruption of alveolar capillary permeability and cell injury results in 
leakage of proteins into the alveolus that further inactivate pulmonary sur­
factant, leading to atelectasis. The decreased compliance, atelectasis, and 
hypoxemia seen in pneumonia are often indistinguishable from findings in 
surfactant-deficient lungs in premature infants. The chest radiographic find­
ings in RDS and neonatal pneumonia may be identical, although broncho­
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pneumonia and pleural effusions are more common in GBS and other bacte­
rial causes of neonatal pneumonia than in RDS.
SUPPURATIVE PNEUMONIA
Staphylococcus aureus, enteric bacilli, such as Klebsiella pneumo­
niae, E. coli, and Pseudomonas species, and fungi can cause suppurative 
pneumonia. An intense inflammatory response often occurs in the lungs 
during these bacterial infections. Necrosis of lung parenchyma, microab­
scess formation, and partial obstruction o f terminal bronchioles results in 
thin-walled, air-filled pneumatoceles. Spontaneous rupture of these struc­
tures can produce pneumothorax. Micro-abcesses may consolidate into lar­
ger cavities or rupture to the pleural space causing empyema. Pneumonia 
may be focal or may consolidate to produce large confluent abscesses. Per­
fusion of consolidated lung tissue causes venous admixture and hypoxemia.
INTERSTITIAL PNEUMONITIS
Interstitial pneumonitis is typically caused by a virus and character­
ized by interstitial inflammation, edema, mononuclear infiltration, and sep­
tal hyper-plasia. Alveolar spaces may remain uninvolved, but in severe 
cases, a serous exudate containing desquamated pneumocytes and macro­
phages may be associated with hyaline membrane formation. Septal wall 
necrosis may occur, adding a component of hemorrhage to the inflammatory 
exudate. Alveolar capillary block associated with the inflammation may im­
pair respiratory function. Cytomegalovirus, HSV, varicella-zoster, rubella, 
HIV, enteroviruses, and the community-based pathogens, such as respira­
tory syncytial, influenza, and parainfluenza viruses, are commonly associ­
ated with interstitial pneumonitis.
GROUP В STREPTOCOCCAL PNEUMONIA
During the 1970‘, GBS pneumonia emerged as the predominant 
pathogen causing neonatal sepsis and pneumonia. The incidence of GBS in­
fection in the first week of life varies from 1.3 to 3 per 1000 live births. De­
spite increased awareness of the disease, GBS infection continues to be as­
sociated with mortality rates of 10% to 30%.
Group В streptococci are commonly found in genital and intestinal 
flora of 10% to 20% of pregnant women. For women with positive GBS 
cultures at delivery, the infant colonization rate is approximately 50%. Of 
colonized infants, only 0.5% to 2% develop invasive disease. Risk of infec­
tion is inversely related to birth weight. Maternal factors increasing the risk 
of infection include the concentration of genital GBS and the level of ma­
ternal, type-specific GBS antibodies. Prolonged rupture of membranes (i.e., 
>24 hours), chorioamnionitis, and use of fetal monitoring devices increase 
the risk of GBS disease.
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Intrapartum chemoprophylaxis may prevent early onset neonatal GBS 
disease. Efficacy of intrapartum treatment was demonstrated in high-risk 
pregnancies with documented prenatal GBS colonization and premature la­
bor, rupture of membranes for more than 12 hours, or intrapartum fever.
Early-onset GBS disease usually presents within the first week of life. 
Septicemia (30%-40%), meningitis (30%), and pneumonia (30%-40%) are 
the most common presentations. Regardless of the primary site of involve­
ment, 90% of affected infants present with respiratory distress. Radio- 
graphic features of GBS infection may be indistinguishable from RDS, al­
though pleural effusions may help differentiate GBS from RDS. In two- 
thirds of affected infants, increased vascular markings or patchy infiltrates 
are observed on the initial chest radiographs. Respiratory distress in the ab­
sence of radiographic abnormalities may be associated with pulmonary vas­
cular hypertension and hypoxemia. Late-onset GBS usually presents from 1 
to 6 weeks after birth and is commonly associated with meningitis.
Respiratory failure in GBS pneumonia results from hyaline membrane 
formation, atelectasis, and pulmonary hypertension. Pulmonary hyperten­
sion is proposed to be mediated by high-molecular-weight polysaccharide 
exotoxin. In animals, infusion of GBS exotoxin results in an initial increase 
in pulmonary vascular pressures and fever, followed by a second phase 
characterized by granulocytopenia, granulocyte trapping in the lung, and in­
creased pulmonary vascular permeability.
Isolation of GBS from cultures of blood, cerebro-spinal fluid, or sup­
purative foci (i.e., pleural fluid) is diagnostic of GBS infection. Surface cul­
tures of skin or mucous membranes may not be of clinical significance. La­
tex particle agglutination is a rapid diagnostic test that provides presumptive 
diagnosis of GBS disease pending the outcome of bacterial cultures. Antim­
icrobial therapy is usually instituted before an organism is identified and 
consists of a penicillin and an aminoglycoside. After the organism is identi­
fied and meningitis is excluded, therapy can continue with penicillin alone 
at 200,000 U/kg/day, usually for 10 to 14 days. Extensive supportive care, 
including oxygen, mechanical ventilation, and cardiovascular support, may 
also be required in treating an overwhelming infection.
PNEUMOTHORAX, PNEUMOMEDIASTINUM,
AND PNEUMOPERICARDIUM
Infants with pneumothorax often present with grunting, tachypnea, 
cyanosis, and retractions. Accumulated air may collapse the lung or shift the 
mediastinum to the side opposite the air leak. A shift of the trachea or point 
of maximal impulse and decreased breath sounds on the affected side may 
be found on clinical examination. Pneumothoraces fall into two major 
groups: spontaneous pneumothorax in otherwise healthy, full-term infants, 
which most often occurs within minutes of birth, and pneumothorax in in­
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fants with significant pulmonary disease, which frequently occurs several 
days after birth, during therapy for pulmonary diseasef Щ h) ■
Prompt recognition of air leak is essential for effective therapy. Un­
expected changes in ventilatory requirements or status and abrupt fall in 
blood pressure, heart rate, respiratory rate, and P 0 2 may indicate an air leak. 
Transillumination of the thorax can be useful in the diagnosis of pneu­
mothorax and its response to therapy. Treatment of tension pneumothorax 
requires immediate surgical drainage and placement of a chest tube. For 
treatment of pneumothorax that does not involve tension or cardiovascular 
compromise, inhalation of 100% oxygen, usually for 6 to 12 hours, can be 
used in term infants as a nitrogen wash-out method. Premature infants 
should not be treated with hyperoxia, because they are at risk for retrolental 
fibroplasia. Noncompromising pneumomediastinum and pneumopericar­
dium can also be managed with 100% oxygen therapy. Tension pneumop­
ericardium is life threatening, must be drained surgically, and is associated 
with a high incidence of morbidity and mortality.
FIG. 4. A full-term infant bom by a difficult breech delivery presented 
shortly after birth with crepitus in the neck area, tachypnea, grunting, and re­
tractions. An an-teroposterior chest x-ray film demonstrates bilateral pneu­
mothorax under tension on the left. The heart and mediastinum are com­
pressed and shifted to the right. The left pleural air herniates across the mid­
line. The left diaphragm is depressed and inverted. Subcutaneous emphysema 
is seen in the soft tissues of the neck.
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CARDIAC DISEASE
During the past 10 years, the practice of neonatal cardiology has been 
revolutionized by advances made in diagnostic echocardiography. An infant 
suspected of having heart disease undergoes an echocardiographic examina­
tion, and based on the resulting anatomic diagnosis, a treatment program is 
devised that may include observation, use of pharmacologic agents, and 
surgical or catheter interventions. Because of greater diagnostic precision 
and improvements in surgical and catheterization treatments, overall mortal­
ity rates for managing neonates with cardiac disease have improved.
Discussion in this chapter is limited to the neonatal period; for further 
details about the cardiac problems of survivors, standard texts of pediatric 
cardiology should be consulted.
INCIDENCE
The incidence of congenital heart disease has been most reliably es­
timated to be 7.5 per 1000 live births. However, the statistic of most interest 
in planning services for babies with heart disease is the number who are ill 
enough to require some medical action. Considering only those sick enough 
to require cardiac catheterization or cardiac surgery or to have died with 
heart disease, there are approximately 2.7 sick cardiac infants per 1000 
births. Almost one-half of these infants are first seen before the second 
week of life.
MORTALITY
After a philosophy of aggressive palliation was adopted, the infant 
cardiac fatality rate fell to 0.8 of 1000 births. Since then, the mortalities in 
neonates with specific cardiac lesions are improved, but the data required to 
calculate mortality per 1000 live births are not available for recent years. 
We think that survival figures are the best they ever have been, even though 
neonatal death from congenital heart disease accounts for most neonatal 
deaths in hospitals.
The importance of prematurity and of associated noncardiac anoma­
lies in neonatal cardiac deaths has been emphasized and influences the po­
tential for salvaging infants with cardiac disease (Table 5). In some situa­
tions, the mortality attributable to these problems is considerable.
SURVIVAL
With few exceptions, there is a cardiac operation or catheter interven­
tion that can improve the quality of life or lengthen the life of a child with 
heart disease. For many years, it has been a matter of conviction among car­
diologists that any improvement in survival was worth the effort, emotional 
drain, and cost, particularly because later progress in the field often allowed 
unexpected secondary interventions which provided even longer survival.
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The palliative shunt operations of 20 years ago unexpectedly produced can­
didates for later Fontan procedures. The central principle continues to be 
where there is life, there is hope.
An infant with an uncorrectable cardiac problem may survive because 
of a palliative operation but have no expectation of reaching adulthood. 
Similarly, the cardiac problem may be totally corrected, but in the process, 
the baby may suffer central nervous system damage. Correction of a cardiac 
defect in a child with crippling noncardiac anomalies can scarcely be cate­
gorized as salvaging the baby. However, with heroic treatment, a child may 
survive severe myocardial disease and be completely normal, and a cardiac 
operation can often cure the patient.
Table 5
Rank order of cardiac diagnoses and first-year mortality by birth weight
Birth Weight > 2.5 kg (n = 1552) Birth Weight < 2.5 kg (n = 230)
Frequency
(%)
Diagnosis Mortality
(%)
Frequency
(%)
Diagnosis Mortality
(%)
17 d-TGA 9 16 VSD 5
14 VSD 2 14 PDA 9
S PDA S 7 MYO 6
7 HLV 50 7 COARC 38
7 TF 16 6 TF 28
6 COARC 18 6 MAL 31
5 ASD2 1 6 TRI 8
5 PS 1 5 d-TGA 17
4 MAL 28 5 ASD2 0
4 TRI 1 4 PS 0/9
4 ECD 17 3 HLV 3/8
3 MYO 6 3 ECD 2/7
2 AS 26 2 ТА 2/5
2 ТА 19 2 TAPVR 2/5
2 TRUNC 24 2 AS 0/5
1 PA + IVS 14 2 TRUNC 2/5
I TAPVR 11 1 SV 1/2
1 SV 31 1 PA + IVS 1/2
1 l-TGA 0/6 1 l-TGA 0/1
6 Other 16 8 Other 28
100 Total 13 100 Total 18
AS - aortic stenosis; ASD2 - atrial septal defect, COARC - coarctation of the aorta; D- 
TGA - D-transposition of the great arteries; ECD - endocardial cushion defects; HLV - 
hypoplastic left heart syndrome; L-TGA - L-transposition of the great arteries; MAL- 
malpositions; MYO - cardiomy-opathy; PDA - patent ductus arteriosus, PA + IVS - 
pulmonary atresia and intact interventricular septum; PS - valvar pulmonary stenosis; 
SV - single ventricle; ТА - tricuspid atresia; TAPVR - total anomalous pulmonary 
veins; TF - tetralogy of Fallot; TGA - transposition of the great arteries; TR1 - tricus­
pid valve diseases; TRUNC - truncus arteriosus; VSD - ventricular septal defect.
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The pros and cons of treating a child who has crippling extracardiac 
defects must be discussed with the parents in understandable language. The 
long-range future of patients undergoing cardiac transplantation, Fontan op­
erations, shunting operations, Senning operations, or intracardiac repair re­
quires detailed discussion. These procedures have late complications. The 
possibility that brain injury or other injury may be acquired in the process of 
treatment should be understood. The expected physical capabilities of the 
patient after treatment should be delineated. After the physician is confident 
that the parents thoroughly understand the known facts, he or she is free to 
express an opinion about what may be best for the child. Almost invariably, 
the family, trusting their doctor, follows the advice.
The many surgical procedures and modifications of procedures, their 
early and late complications. Virtually all procedures have some late prob­
lems, often delayed until adulthood.
Confusing this situation is the inherent tendency of pediatricians to 
consider the struggle to be won if the child can be coaxed to adulthood. The 
goal is to provide for a satisfying life for many years after childhood. Many 
children with cardiac disease survive to 20 years of age only to succumb in 
the next decade.
ETIOLOGY
Parents ask why their baby was born with a cardiac abnormality and 
whether it is likely to recur with a subsequent pregnancy. In most cases, the 
specific cause of the cardiac anomaly is unknown. Evidence suggests that 
extrinsic perturbations, genetic predisposition, and chance play roles. Diag­
nostic frequency year by year, state by state, and hospital by hospital has 
been relatively constant, and any etiologie theory must account for this phe­
nomenon. Fetal exposure to specific environmental, pharmacologic, bio­
chemical, and infectious factors may increase the risk for developing a car­
diac abnormality (Table 6). However, in individual cases, it is usually diffi­
cult or impossible to identify specific extrinsic factors.
Table 6
Possible teratogens for congenital heart disease
Environmental
agents
High altitude, trichloroethylene, irradiation
Drugs Ethanol, hydantoin, valproic acid, trimethadione, primi­
done, carbamazepine, lithium, thalidomide, retinoic 
acid, antineoplastic agents • >, amphetamine, cocaine
Metabolic factors Maternal diabetes, maternal phenylketonuria
Immune factors Maternal autoimmune disease, including lupus erthema- 
tosus
Infectious agents Rubella, mumps , cytomegalovirus
It is generally accepted that these prenatal factors increase the risk for congenital 
heart disease.
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Epidemiologic findings suggest that genetic factors play a role in iso­
lated congenital malformations, but alone, they are not sufficient to explain 
causation in most cases. Rarely, all affected children in a family have the 
same cardiac defect. Few congenital cardiac diseases have clear mendelian 
inheritance, but hypertrophic cardiomyopathy is an exception. Approxi­
mately one-third of patients with congenital heart disease have a positive 
family history of congenital cardiac abnormalities. It is rare for both frater­
nal twins to have heart disease, but as many as 25% of identical twins both 
have cardiac abnormalities. The risk in siblings may be higher with some 
lesions, particularly left heart obstructive lesions, such as coarctation and 
hypoplastic left heart syndrome. If one parent has congenital heart disease, 
the risk to the offspring may be higher if the mother is the one affected.
Some lesions are predominantly associated with the sex of the infant. 
Boys more commonly have coarctation of the aorta, aortic stenosis, and 
transposition of the great arteries, and girls are prone to have atrial septal 
defect and patent ductus arteriosus.
Approximately 8% to 13% of children with cardiac anomalies have 
inheritable syndromes with associated cardiovascular abnormalities (e.g., 
Marfan syndrome), and 13% have chromosomal syndromes associated with 
cardiovascular malformation (Table 7). The association of Down syndrome 
and heart anomalies, especially endocardial cushion defect, is common (Ta­
ble 8). Clinical identification of a syndrome associated with congenital heart 
disease or vice versa should prompt an investigation for possible associated 
defects.
Table 7
Incidence of severe associated noncardiac anomalies among infants with 
___  heart disease
Diagnosis Incidence (%)
Endocardial cushion defect 43
Patent ductus arteriosus 31
Ventricular septal defect 24
Malpositions 13
Tetralogy of Fallot 10
Coarctation of aorta 9
Pulmonary atresia with infact septum 1
Transposition of the great arteries 1
The tendency for various cardiac anomalies to occur together suggests 
common embryogenesis. For example, infundibular pulmonary stenosis is 
associated with ventricular septal defect, but valvar pulmonary stenosis is 
not. Similarly, the association of non-cardiac anomalies and specific forms 
of heart disease (e.g., asplenia, polysplenia) can be recognized. A single 
event may result in characteristic complex cardiac malformation by altering
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or killing embryonic primordial cells, such as in the neural crest or endocar­
dial cushion, before formation of cardiac structures in the conotruncus or 
atrioventricular valves. Malformation of a specific structure may alter blood 
flow patterns and vascular growth downstream. Certain cardiac lesions are 
associated with prematurity or low birth weight. Because closure of the ven­
tricular septum may be delayed until the first months of life, it is not 
surprising that there is a somewhat greater incidence of ventricular septal 
defect among premature infants. The increased incidence of patent ductus 
arteriosus in prematurely born infants can be viewed as the result of birth 
long before the programmed time for closure of the ductus. Hypoxemia of 
pulmonary origin also promotes ductal patency.
PHYSIOLOGY
Extensive information about the circulatory physiology of the fetus 
and newborn has accumulated.
FETAL CIRCULATION
The circulation before birth consists of parallel circuits. Blood in the 
aorta may follow several routes to a capillary bed in the fetus or the pla­
centa, back to the heart, passing through either ventricle, and out again to 
the aorta. The stream of newly oxygenated blood from the placenta passes 
through the umbilical vein, the ductus venosus, the inferior vena cava, and 
the right atrium. Unlike the circulation after birth, the streams of oxygen­
ated and unoxygenated blood are not separated, although the more oxygen­
ated blood from the inferior vena cava tends to be diverted through the fo­
ramen ovale into the left atrium. Blood from the left ventricle entering the 
ascending aorta and coronary and carotid circulations is somewhat higher in 
oxygen than that entering the descending aorta from the right ventricle by 
way of the ductus arteriosus.
Because of the parallel arrangement of the ventricles, the potential of 
each ventricle for pumping different amounts of blood exists. Normally, the 
volume pumped by the right ventricle is thought to be about 62% of the 
combined output of both ventricles. Because both ventricles pump against 
the systemic resistance, the level of pressure in the two ventricles is compa­
rable. The resistance to blood flow through the lungs is relatively great; 
only minimal flow through the lungs occurs in utero and almost all of the 
right ventricular output into the pulmonary artery passes through the ductus 
arteriosus to the descending aorta.
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Table 8
Congenital disorders associated with cardiac disease
D i s o r d e r
P e rce n t o f  
p a tien ts  
w ith  ca r­
d iac  d is ­
ease
T y p e s  o f  c a r d i a c  a b n o r m a l i t i e s
P r i m a r y  i s o l a te d  c a r d i a c  d i s o r d e r s
H y p e r t r o p h ic  c a rd io m y o p a th y 1 00 H y p e r t r o p h ic  c a r d io m y o p a th y
R o m a n o - W a r d  S y n d ro m e 1 00 P r o lo n g e d  О Т  in te r v a l ,  V T ,  s u d d e n  b e a tl i
A u t o s o m a l  D o m i n a n t  S y n d r o m e s
d e  L a n g e 3 0 V S D , A S D , P D A , A S ,  E F E
H o l t -O ra m  c a rd ia c - l im b  s y n d ro m e 1 00 A S D
M a r f a n  s y n d ro m e 6 7 - 1 0 0 A o r t ic  a n e u ry s m , A R ,  M R , T R ,  p r o la p s e ,  d y s ­
rh y th m ia s
N o o n a n  s y n d ro m e 6 7 P S ,  A S D , h y p e r t r o p h ic  c a rd io m y o p a th y ,  V S D , 
P D A , L A D
O s ie r - W e b e r - R e n d u  h e m o r r h a g ic  te la n g ie c ­
ta s ia
1 5 -2 5 P u lm o n a r y  a n d  s y s te m ic  a r t e r io v e n o u s  m a lf o r ­
m a t io n s
S h p r in tz e n  v e lo c a r d io f a c ia l  s y n d ro m e 8 0 V S D , T F ,  r ig h t  a o r t i c  a rc h ,  a b e r r a n t  le f t  s u b ­
c la v ia n  a r te ry
T r e a c h e r  C o l l in s  m a n d ib u lo fa c ia l  d y s o s to s is U n c o m ­
m o n
A S D , V S D , P D A
T u b e r o u s  s c le r o s i s 3 0 C a r d ia c  r h a b d o m y o m a s
A u t o s o m a l  R e c e s s iv e  S y n d r o m e s
C a r p e n te r 3 3 P D A ,  P S ,  V S D , T F ,  T G A
E l l i s -v a n  C r e v e ld  c h o n d ro e c to d e r m a l  d y s ­
p la s ia
5 0 - 6 0 S in g le  a t r iu m , p r im u m  A S D , C O  A R C , s m a ll  
L V , C H F
M u c o p o ly s a c c h a r id o s i s > 5 0 M y o c a r d ia l  h y p e r t r o p h y ,  c c o r o n a r y  d i s e a s e ,  A R , 
M R , T R ,  C H F
P o m p e  g ly c o g e n o ly s is  ty p e  II 10 0 M y o c a r d ia l  h y p e r t r o p h y ,  E F E ,  s h o r t  P R ,  C H F
S m ith -L e m l i- O p i tz  s y n d ro m e ,  ty p e s  I a n d  II 2 0 /1 0 0 V S D , P D A , A S D , T F
T h r o m b o c y to p e n ia  w ith  a b s e n t  ra d i i 3 3 A S D , T F
X - L i n k e d  S y n d r o m e s
D u c h e n n e  m u s c u la r  d y s tr o p h y  | C o m m o n  | C a r d io m y o p a th y
C h r o m o s o m a l  D i s o r d e r s
T r is o m y  21 ( D o w n  s y n d ro m e ) 4 0 - 5 0 A V  c a n a l ,  V S D , P D A , A S D  p r im u m , T F
T r is o m y  18 ( E d w a r d  s y n d ro m e ) 9 0 - 1 0 0 V S D , p o ly v a lv u la r  d i s e a s e ,  A S D , P D A
T r is o m y  13 ( P a ta u  s y n d ro m e ) 8 0 P D A , V S D , A S D , d e t r o c a r d i a .  C O A R C , A S , P S
X O  ( T u r n e r  s y n d ro m e ) 4 5 C O A R C , b ic u s p id  a o r t ic  v a lv e ,  a o r t ic  a n e u ry s m
S y n d r o m e s  W i t h  U n k n o w n  E t io lo g y
В e s k w i th - W ie d e m a n n  s y n d ro m e 1 6 -9 2 C a r d io m e g a ly ,  A S D ,  V S D , P D A , T F
C a r d io f a c ia l  ( a s y m m e tr ic  c ry in g  f a c ie s )  
s y n d ro m e )
5 - 1 0 V S D
C H A R G E  a s s o c ia tio n 6 5 - 7 5 T F ,  D O R V , A S D , V S D , P D A  C A R C , A V  c a n a l
D iG e o r g e  s y n d ro m e 5 0 + I n te r ru p e d  a o r t ic  a rc h ,  t ru n c u s  a r t e r io s u s ,  T F
G o ld e n h a r  f a c io a u r ic u lo v e r te b r a l  s p e c tru m 5 - 8 0 V S D , P D A  A S D , C O A R C ,  P S
R u b in s te in - T a y b i  s y n d ro m e 3 5 V S D , P D A  A S D , C O A R C ,  P S
V A S T E R L  a s s o c ia tio n 10 V S D , A S D , T F
W il l ia m s  s y n d ro m e 5 0 - 8 0 S u p r a v a lv a r  A S ,  b r a n c h  P S ,  V S D , h y p o p la s t ic  
a o r ta
AR- aortic valve regurgitation; AS - aortic stenosis; ASD - atrial septal defect; AV - atrioventricu­
lar; CHF - congestive heart failure; COARC - coarctation of the aorta; DORV - double-outlet right 
ventricle; HFE - endocardial fibroelastosis; LAD - left axis deviation; LV - left ventricle; MR - mi­
tral valve regurgitation; PDA - patent ductus arteriosus; PS - pulmonary stenosis; TF - tetralogy of 
Fallot; TGA - transposition of the great arteries; TR - tricuspid valve regurgitation; VSD - ventricu­
lar septal defect; VT - ventricular tachycardia.
61
The parallel arrangement of the ventricles allows fetal survival de­
spite a wide variety of cardiac lesions. With total obstruction of either ven­
tricle, the other ventricle assumes the entire cardiac output with surprising 
success. Reversal of the pulmonary arterial and aortic streams of blood, as 
occurs in transposition of the great arteries, produces no deleterious effect 
on the fetus. The birth weights of these babies are rarely less than average 
and often greater. Even lesions that cause increased fetal cardiac work, such 
as central nervous system arteriovenous fistulae, are tolerated well. The 
ability to withstand gross intrauterine circulatory abnormality is partially a 
result of simultaneous development of the anomaly and adaptation to it. De­
spite the remarkable ability to adapt, grow, and survive, the fetus is affected 
by limitations in myocardial contractility in direct proportion to their sever­
ity. Because of the virtual exclusion of the lungs from the circulation, fetal 
congestive heart failure manifests as generalized edema. A fetus with myo­
cardial dysfunction of any cause may be born with anasarca. The interplay 
between the metabolic effects of congestion in the fetus and the possible 
compensatory role of the placenta is not understood. Because lesions that 
may be expected to cause gross intrauterine difficulty are tolerated surpris­
ingly well, the postulate that the placenta helps compensate for the meta­
bolic abnormalities resulting from congestive heart failure is tenable.
CIRCULATORY ADJUSTMENTS AT BIRTH
With the first breath, the resistance to pulmonary blood flow drops 
sharply. The oxygen content of the left heart and systemic circulation rap­
idly reaches levels well above that of the fetal circulation. The oxygen satu­
ration in the ascending fetal aorta is about 65%; immediately after birth, it 
rises to about 93%. The ductus venosus functionally closes, establishing the 
portal circulation as an independent loop between two capillary beds. With 
removal of the low resistance placenta, systemic resistance stabilizes at a 
higher level. The relative fall in the pulmonary resistance and rise in the 
systemic resistance results in a transitory left-to-right shunt through the duc­
tus arteriosus.
The ductus becomes functionally closed toward the end of the first 
day of life, becoming anatomically obliterated at about 10 days of age. Even 
among cya-notic newborns who are duct dependent, the ductus may inexo­
rably close, often severing the infant's only source of pulmonary blood flow 
(e.g., pulmonary atresia). The mechanisms causing closure of the ductus ar­
teriosus are not completely understood but involve decreased prostaglandins 
and increased blood oxygen. Prostaglandin levels in the blood decrease at 
birth due to removal of the placental source of production from the circula­
tion and increase in perfusion of the lungs, where prostaglandins are me­
tabolized. Persistent patency of the ductus arteriosus in the neo nate with 
duct-dependent cardiovascular lesions can be achieved by infusion of pros­
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taglandin E, and pharmacologic closure of the histologically normal duct in 
the preterm infant can be hastened by inhibition of prostaglandin synthesis 
with indomethacin.
At birth, the left ventricle abruptly becomes the sole supplier of sys­
temic blood flow, and the volume that it pumps is fractionally increased. 
The left-to-right shunt through the ductus arteriosus adds further volume 
work, and the elevated systemic resistance must be overcome. Although this 
is a stressful time for the left ventricle, the magnitude of these suddenly ac­
quired burdens is not so great that detectable left ventricular difficulties are 
seen normally, but any impairment of myocardial function may be magni­
fied as a consequence. Myocardial disease as a cause of symptoms is more 
common in the first days of life than at any other time during infancy; 25% 
of infants with myocardial disease presented in the first week of life. Hy­
poxic-ischemic myocardial dysfunction after delivery can be recognized by 
means of echocardiography. Recovery from severe left ventricciar failure in 
the neonatal period is often surprisingly good.
At birth, the volume of blood to be pumped by the right ventricle de­
creases to the level of the systemic blood flow; right ventricular pressure 
falls as a result of the decrease in pulmonary resistance and closure of the 
ductus arteriosus. Although left ventricular work increases, right ventricular 
work decreases.
Before birth, the two ventricles share in supplying systemic blood 
flow and placental flow, and after birth, the two ventricles sequentially and 
independently handle the entire cardiac output. Effectively, each ventricle 
pumps blood in amounts comparable to those that it pumped in utero, de­
spite a reduction by 50% in the amount of blood pumped through the aorta 
after removal of the placenta. Although this arrangement results in each 
ventricle pumping comparable amounts of blood before and after birth, a 
central nervous system arteriovenous fistula, because of the shift from 
parallel to serial ven tricular pumping, causes an acute increase in the 
volume of work for each ventricle, despite a constant flow through the 
fistula. These babies often die immediately after birth, despite normal 
growtlFimcttieiMal closure of the foramen ovale occurs soon after birth, 
largely as a result of increased left atrial volume and pressure secondary to 
the increased pulmonary venous return, to the ductal left-to-right shunt, and 
the developing differences in diastolic pressure of the two ventricles. Anat­
omic closure normally is delayed for months or years. Among infants with 
cardiac defects, lesions with increased right atrial pressure favor indefinite 
patency of the foramen ovale (e.g., pulmonary stenosis), but abnormally in­
creased left atrial pressure promotes early anatomic closure (e.g., ventricular 
septal defect).
Before birth, the pulmonary arterioles are relatively muscular and 
constricted. With the first breath, total pulmonary resistance falls rapidly
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because of the un-kinking of the vessels with expansion of the lungs and be­
cause of the vasodilatory effect of inspired oxygen. The muscular constric­
tion relaxes, and gradually during the subsequent days and weeks, the mus­
cular wall of the pulmonary arterioles thins. During the first weeks of life, 
the muscular arterioles retain a significant capacity for constriction. Pulmo­
nary alveolar hypoxia normally produces an increase in pulmonary artery 
pressure at all ages, but in the young infant, the response is more profound 
and occurs more rapidly. The discovery of pulmonary hypertension equal to 
or greater than systemic pressure is a familiar observation in a sick baby.
PREMATURITY
The events at birth and in the neonatal period are modified in direct 
relation to the degree of prematurity. The muscular coat of the pulmonary 
arterioles develops late in gestation; the more premature the infant, the less 
muscular are the pulmonary arterioles at birth. The most notable conse­
quence of this is that the difference between systemic and pulmonary resis­
tance after birth is greater among premature than among normal infants. 
Shunting through a ductus arteriosus is often audible. The hypoxia so com­
mon among premature infants may be one of the factors that delays closure 
of the ductus, and as a result, ductal murmurs are more common. The pro­
pensity of the ductus to close at around 41 weeks after conception is clini­
cally recognized. Among older infants with persistently patent ductus, the 
incidence of prematurity is greater than expected.
The prolonged ductal shunting in the premature infant would proba­
bly be of no consequence except that ductal shunting is often associated 
with respiratory distress. The ductal shunt causes increased pulmonary 
blood volume in an infant already severely ill with respiratory distress and 
sometimes causes left ventricular failure. Medical or surgical interruption of 
the ductus may have an appreciable effect on morbidity and mortality. 
However, it is our view that the ductus is rarely the sole problem in symp­
tomatic neonates; it is instead an additional problem in an already serious 
situation. Patent ductus is found equally among premature male and female 
infants and is considered to be persistent patency of the normal ductus. Pat­
ent ductus unassociated with prematurity is an anomaly and is predomi­
nantly encountered in female infants (2:1).
RECOGNITION OF CLINICAL FEATURES
Only a few infants are born in hospitals equipped for all eventualities. 
To allow time for transfer to a specially equipped and staffed cardiac center, 
recognition that the baby has heart disease must be early enough to allow 
time for transportation, diagnostic workup, and treatment, including cardiac 
catheterization and surgery. The infrequent use of echocardiography to rec­
ognize heart disease in infants in remote areas has often been unsatisfactory.
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Cases of delayed transfer of babies because of erroneous diagnoses of inop­
erable congenital heart disease and erroneous reassurance that there is no 
significant lesion have been encountered. With limited experience in the di­
agnosis of congenital heart disease in neonates, it may be best to transport 
the infant to the nearest center for echocardiographic examination or to for­
ward a tape of the examination for a second opinion if the echo- 
cardiographer is primarily experienced in examining adults.
MURMURS
Hearing a murmur is the most common means of recognizing infant 
heart disease. Evaluation includes assessment of the infant's well-being, 
respiratory work, precordial activity, perfusion, pulses and blood pressure in 
the extremities, splitting of the second heart sound, and murmur intensity, 
quality, and pitch. A chest radiograph and electrocardiogram (ECG) should 
be obtained. The murmurs of valvar regurgitation and stenosis are audible 
immediately after birth, and the murmurs of septal defects are usually de­
layed days, for as long as several months in the case of atrial septal defects. 
A two-dimensional echocardiogram is obtained if cardiac disease is sus­
pected. This technique demonstrates the anatomic basis for the murmur, oc­
casionally uncovering a potentially lethal lesion in advance of symptoms.
CYANOSIS
Much more threatening than a murmur is the presence of cyanosis. 
Cyanosis without pulmonary disease is almost invariably the result of a se­
rious cardiac abnormality. Cyanosis may result from poor mixing of parallel 
circulation because of transposition of the great arteries; right-to-left shunt­
ing because of pulmonary outflow obstruction (e.g., tetralogy of Fallot, 
critical pulmonary stenosis, tricuspid atresia); or intracardiac mixing {e.g., 
total anomalous pulmonary venous connection, truncus arteriosus, single 
ventricle, hypoplastic left heart syndrome). Especially in the first week of 
life, cyanosis may be the sole evidence of an important cardiac lesion. One- 
third of infants with potentially lethal congenital heart disease have cyanosis 
as their major symptom; another one-third have cyanosis associated with 
respiratory symptoms.
Prompt cardiac evaluation of all cyanotic babies is mandatory, be­
cause most of these lesions are amenable to surgery. The clinical recogni­
tion of cyanosis is influenced by the baby's hemoglobin. An anemic infant 
may have severe arterial oxygen unsaturation without obvious cyanosis, and 
infants with polycythemia may appear cyanotic with normal arterial oxygen 
levels. Hypothermic infants may seem blue; babies viewed in fluorescent 
lighting may appear blue; and blue surroundings may make the estimation 
of cyanosis more difficult. Persistent cyanosis due to hypoglycemia or met­
hemoglobinemia is rare.
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RESPIRATORY SYMPTOMS
Cardiac disability may result in pulmonary vascular engorgement, 
pulmonary venous hypertension, and pulmonary edema. Grandmothers and 
multiparas often observe that the baby had always breathed too fast. There 
is no doubt that persistent respiratory rates of 60 per minute or greater, often 
with persistently increased depth of respirations, commonly precede hearing 
a murmur and may presage deterioration to gross dyspnea and congestive 
heart failure. Persistent tachypnea may be the first clue to heart disease or 
lung disease; a chest radiograph may provide the answer.
DIAGNOSTIC FEATURES
The number of cardiac lesions that cause serious disability among 
newborns is great. Ventricular septal defects are the most common, but the 
largest category requiring hospitalization in the first 2 weeks of life is o- 
transposition of the great arteries. Among the lesions causing symptoms in 
this age group are coarctation of the aorta and the hypoplastic left heart 
syndrome.
AGE OF PRESENTATION
It is clinically useful to keep in mind the usual time of presentation of 
infants with various cardiac anomalies. Although ventricular septal defect is 
by far the commonest congenital heart lesion discovered in neonates, trans­
position of the great arteries, coarctation of the aorta, and the hypoplastic 
left heart syndrome are the most common life-threatening anomalies pre­
senting in the first week of life. Among those whose problem is cyanosis, 
transposition of the great arteries is the leading cause for admission through 
the third week of life; after that time, tetralogy of Fallot becomes the domi­
nant cause of cyanosis for the rest of childhood. Among neonatal cardiac 
patients admitted because of respiratory symptoms, the hypoplastic left 
heart syndrome is the leading cause in the first week, complex coarctations 
lead in the second week, and thereafter, ventricular septal defect becomes 
the main cause for symptomatic admission.
NONCARDIAC ANOMALIES AND LOW BIRTH WEIGHT
It is useful to know the relative frequency of the cardiac diagnostic 
possibilities among low birth weight babies and among those who have 
other anomalies. Among premature infants, patent ductus arteriosus, coarc­
tation of the aorta, and ventricular septal defect are more commonly 
encountered. Chromosomal abnormalities and congenital syndromes may 
also be associated with cardiac malformations (e.g., Down syndrome).
ACUTE LUNG DISEASE AND CARDIAC DISEASE
The differential diagnosis between primary lung disease and heart 
disease causing pulmonary edema is difficult. A chest radiograph may sug-
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gest lung disease, particularly if the findings are asymmetric, but in the 
presence of diffuse symmetrical changes possibly compatible with pulmo­
nary edema, caution is necessary. Treatment for a pulmonary problem, with 
initial limited improvement in oxygenation, may confuse the picture. The 
correct diagnosis is delayed until the persistent poor response to oxygen and 
positive-pressure ventilation alerts the physician to the possibility that heart 
disease may detect right-to-left shunting through a ductus arteriosus caused 
by lung disease. Administration of oxygen may decrease pulmonary resis­
tance and increase pulmonary flow, providing higher oxygen levels in a 
cyanotic child with a large pulmonary flow and congestive heart failure. Ar­
terial P 02 typically does not improve significantly in response to 100% 
oxygen in infants with PPHN. Comparison of the P 02 measured in blood 
from the right radial artery or temporal artery with the P02 measured in 
blood from the umbilical arterial catheter may help to clarify the diagnosis 
in these conditions.
With the above exceptions, the infant who responds to breathing pure 
oxygen with a marked rise in arterial P 02 to 250 torr or more has lung dis­
ease, and the infant who does not raise his preductal arterial P02 above 100 
torr has heart disease. If doubt persists, the physician can make the diagno­
sis with two-dimensional echocardiography by establishing that the cardiac 
anatomy is normal or sufficiently abnormal to account for a critically ill 
baby.
Apparent diffuse pulmonary disease in a full-term baby, particularly 
if the chest radiograph is conceivably compatible with pulmonary edema, 
should be viewed with caution. Two-dimensional echocardiography usually 
solves the dilemma. Anomalous pulmonary venous drainage below the dia­
phragm may be missed on electrocardiography.
CHRONIC PULMONARY HYPERTENSION AND COR PULMONALE
In the past, the term cor pulmonale was used to describe the circula­
tory physiology resulting from chronic lung disease, and pediatric cardiolo­
gists are using this terminology less often than previously. Cor pulmonale is 
the association of right ventricular hypertrophy with pulmonary hyperten­
sion secondary to ventilatory or pulmonary disease. It frequently presents as 
symptoms of congestive heart failure with pulmonary disease. Patients with 
cor pulmonale have a structurally normal heart and must be differentiated 
from those with pulmonary hypertension as a consequence of intracardiac 
shunts or pulmonary venous obstruction (e . g mitral stenosis, cor triatria- 
tum). The most frequent cause in infants has been broncho-pulmonary dys­
plasia, although a large number of other causes, including airway obstruc­
tion, central hypoventilation, pulmonary hypoplasia, and diaphragmatic ab­
normalities, also occur.
67
Pathophysiology. The pulmonary artery pressure is controlled by 
vascular resistance that is a function of the average luminal size and number 
of small pulmonary arteries. The number of vessels may be con-genitally 
diminished by pulmonary hypoplasia or by acquired pulmonary parenchy­
mal damage. The amount of small pulmonary artery musculature and the 
distance that it extends along the vessel determines the extent to which con­
striction may cause obstruction. The required muscle to prevent more than 
minimal pulmonary flow before birth is still present, although relaxed, after 
birth and can profoundly re-constrict with elevation of pulmonary resistance 
and pulmonary hypertension under the appropriate circumstances. The pul­
monary vascular resistance is often labile with the potential for development 
of pulmonary hypertension above the level of normal systemic pressure for 
that patient.
The circumstances that may stimulate constriction include alveolar 
hypoxia (e.g., perinatal asphyxia, pulmonary parenchymal disease, airway 
obstruction, high altitude), acidemia, increased pulmonary venous pressure 
(e.g., left ventricular diastolic dysfunction), and bacteremia (e.g., strepto­
coccal infection). Polycythemia may also increase resistance. Increases in 
cardiac output with exertion, fever, or anemia can elevate pulmonary artery 
pressure beyond that caused by fixed resistance.
Chronic pulmonary hypertension results in right ventricular hypertro­
phy and, if severe, right ventricular diastolic dysfunction and dilation. In 
addition to pulmonary hypertension, bronchopulmonary dysplasia also is 
frequently associated with systemic hypertension. The cause of the systemic 
hypertension is complex and may involve exposure to aortic catheters, re­
flex responses to pulmonary arterial hypertension, and altered pulmonary 
metabolism of vasoactive substances. Systemic hypertension causes left 
ventricular hypertrophy. Shifting of the interventricular septal position, 
caused by elevated intraventricular pressure and biventricular hypertrophy, 
may impair the diastolic compliance of both ventricles and lead to increased 
sensitivity to intra-vascular volume in the systemic and pulmonary circula­
tions. Acute exacerbations of pulmonary hypertension may further increase 
the right ventricular diastolic pressure and shift the intraventricular septum 
leftward, leading to additional biatrial hypertension and edema.
The pulmonary hypertension and cardiac sequelae seen with bron­
chopulmonary dysplasia generally appear to resolve when the pulmonary 
parenchymal disease resolves. In contrast, permanent pulmonary vascular 
change (i.e., Eisenmenger syndrome) occurs in patients with congenital 
heart disease after 1 or more years of exposure to a large left-to-right shunt 
with pulmonary artery hypertension.
C linical Findings. Variable hepatomegaly and systemic venous 
congestion secondary to right atrial hypertension are predominant findings. 
Elevated left atrial pressure, especially in the presence of pulmonary paren-
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hvmai disease, may predispose to pulmonary symptoms and rales. The 
. ht ventricular impulse may be increased and the second heart sound loud 
and appear single. There may be a relatively soft murmur from tricuspid re- 
uurgitation, but a prominent murmur is not common and suggests possible 
congenital heart disease instead.
Two mechanisms produce cyanosis in patients with pulmonary hyper­
tension with normally arranged cardiac structures. In the usual case of a 
patent foramen ovale (PFO), elevation of the pressure in the right atrium 
may allow right-to-left shunting and cyanosis. At first, this is likely to be 
transitory because right atrial pressure also depends on the level of exertion. 
Persistent cyanosis at rest, although not necessarily dangerous in itself, may 
suggest serious pulmonary hypertension if there is shunting right-to-left 
across the foramen ovale. Alternatively, cyanosis may be the result of alveo­
lar dysfunction or intrapulmonary shunting with less than normal oxygen 
saturation in the pulmonary veins. In this case, cyanosis is a direct function 
of the extent of parenchymal involvement.
The degree of pulmonary artery hypertension and cardiac symptoms 
may vary with labile ventilatory or pulmonary conditions. The diagnosis of 
cor pulmonale may be justified with moderate elevation of pulmonary artery 
pressure because there may be the potential for symptomatic marked pul­
monary hypertension on other occasions.
Infants with bronchopulmonary dysplasia appear to be at increased 
risk for sudden death. Multiple factors may contribute, including pulmonary 
hypertension. Death from pulmonary hypertension is perhaps best docu­
mented in older patients with primary pulmonary hypertension. Some of 
these patients suddenly die, having been relatively well, often after episodes 
of fainting. The pulmonary hypertension can be acutely aggravated if there 
is alveolar hypoxia from mucus plugs, bronchospasm, upper airway obstruc­
tion, or intercurrent infection. Cardiac output is sharply limited by acutely 
elevated afterload; the patient collapses, and may develop fatal dysrhythmia. 
Babies with bronchopulmonary dysplasia are at risk for such problems. Pa­
tients who can develop a right-to-left shunt have a blow-off-valve effect that 
limits the height of the pulmonary pressure, providing some cardiac output 
while producing cyanosis.
Diagnostic Assessm ent. Noninvasive measurement of pulmonary 
Wery pressure has been used as a method to follow the course of pulmonary 
Parenchymal disease with pulmonary hypertension. The ECG signs of right 
ventricular hypertrophy have been useful in some patients, but in others, the 
ectncal conductance anteriorly is altered by lung disease. A variety of 
^ocardiographic methods, some remarkably precise, some not so accurate, 
most applicable to particular circumstances, are discussed later in this 
everu one technique in use is generally accepted and applicable in 
™ patient. Sedation, often necessary for technically acceptable studies in
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older, active babies, may depress ventilation and should be used with cav 
tion. Externally measured pulmonary artery pressures are not precise, bi 
they provide an estimation of the truth and should be used as such as 
guide to therapy.
Treatment. The treatment of pulmonary hypertension secondary t 
pulmonary or ventilatory disease is directed primarily at the underlying dij. 
order. Although oxygen in high amounts may be toxic, its judicious chronic 
use as a potent pulmonary vasodilator may be useful. Bronchodilators and 
diuretics may be helpful for treating pulmonary parenchymal disease. Digfc 
talis has not been found to be beneficial in most infants with congestive 
symptoms. Nifedipine is useful in some older children with primary pulmo. 
nary hypertension, but its routine use in infants with bronchopulmonary 
dysplasia has not been established.
Differential Diagnosis. In patients with pulmonary hypertension, 
even those with lung disease, the presence of congenital heart disease 
should be sought. The absence of a loud murmur does not exclude a septal 
defect or patent ductus arteriosus in the presence of elevated pulmonary 
vascular resistance. Because many of the symptoms of cor pulmonale over­
lap those of congenital heart disease, echocardiography has been useful for 
excluding occult cardiovascular lesions that could lead to irreversible Eis- 
enmenger syndrome. However, echocardiography used in cases of lung dis­
ease frequently faces the problem of poor ultrasound windows. These limi­
tations should be realized, and the results correlated with other findings.
DIAGNOSTIC TOOLS
The clinical diagnosis of congenital heart disease frequently requires 
the use of ECG and chest radiographs. The transcutaneous measurement of 
partial pressure of oxygen or oxygen saturation is useful, particularly after 
the umbilical artery is no longer a source of arterial blood. A variety of in­
struments useful in measuring blood pressure are available.
ECHOCARDIOGRAPHY
Two-dimensional echocardiography with color Doppler ultrasound al­
lows excellent analysis o f the intracardiac anatomy in small infants. Neo­
nates are particularly good candidates for echocardiographic imaging be­
cause they are less active and have excellent echocardiographic imaging 
windows. Contrast echocardiography with injection of agitated saline or al­
bumin into intravenous or umbilical artery catheters can serve as a useful 
adjunct to color Doppler to visualize the presence and direction of blood 
flow in patent ductus arteriosus, septal defects, systemic venous anomalies, 
and arteriovenous malformation. Pulsed and continuous wave Doppler tech­
niques enable estimation of some physiologic parameters such as the pres­
sure gradient across stenotic valves, septal defects, and patent ductus arteri­
osus. In the common case of tricuspid regurgitation, right ventricular peak 
systolic pressure may be estimated by Doppler measurement of the magni­
tude of the pressure gradient between the right ventricle and right atrium 
and the addition of right atrial V-wave pressure, whether assumed or di­
rectly measured through an umbilical vein catheter (usually 3-10 torr). 
Right ventricular systolic pressure relative to left ventricular pressure can 
also be qualitatively assessed by the curvature of the interventricular sep­
tum.
The shortening fraction of the left ventricular internal short axis di­
mension is used to assess left ventricular systolic function. The shortening 
fraction measures left ventricular performance, which is a function of con­
tractility, afterload, preload, and heart rate. The relative end systolic wall 
stress velocity of fiber shortening is an index of contractility that can be 
measured using directed M-mode echocardiography, indirect central pulse 
tracing, and phonocardiography that in the physiologic range appears to be 
independent of preload and takes afterload and heart rate into account. Both 
techniques are impaired when right ventricular hypertension results in flat­
tening of the interventricular septal curvature in systole.
CARDIAC CATHETERIZATION AND ANGIOGRAPHY
The miniaturization of standard catheterization and angiographic 
techniques for the study of infants was accomplished in the early 1970.. In­
fant cardiac catheterization has become a technical art demanding specific 
training and experience. The neonate undergoing study is ill, often critically 
ill, and may have a widely fluctuating physiologic state. The combinations 
of lesions encountered in this age group are large, and the natural mortality 
rate is high. To perform a therapeutic procedure or to extract the vital diag­
nostic information with the least danger to the patient requires vigilance 
against a multitude of treacherous pitfalls and a finely honed sense of the 
cost and benefit of each maneuver contemplated.
Catheterization is rarely used to learn the basic anatomy of the heart. 
It is used to perform specific therapeutic interventions or provide specific 
data unavailable through echocardiography that are useful in planning sur­
gery. What is the pulmonary artery anatomy and pressure? What is the anat­
omy of systemic-to-pulmonary collaterals. Is catheter closure of the collat­
erals possible? What is the coronary anatomy? Is there a pressure gradient?
Catheterization for an acyanotic infant in congestive heart failure is 
better delayed until the pulmonary vascular resistance has decreased and the 
full effect of the medications has been appreciated. Duct-dependent infants 
with a closing ductus arteriosus are best managed with an infusion of pros­
taglandin ei, begun before and continued throughout the catheterization.
Death within 48 hours of cardiac catheterization is rare (0.1%) among 
children after the first months of life. Earlier in infancy, the risk is difficult
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to estimate because of the high natural mortality rates associated with the 
lesions encountered and the association of cardiac catheterization with car­
diac surgery. In the first week of life, death within 48 hours of catheteriza­
tion is 15 times greater than in the fourth week of life. The conclusion that 
this mortality parallels the natural mortality of the lesions is inescapable. 
Although this provides a universal excuse for a lamentable outcome, the po­
tential for procedural error is undeniably greater in the sick newborn.
If only unequivocally demonstrable damage to the infant is counted, 
the risk is quite small. We estimate the mortality rate directly attributable to 
cardiac catheterization to be 1% to 2% in the neonatal period. Morbidity, 
such as blood loss, electrolyte imbalance, angiographic myocardial stains, 
hypothermia, and acidosis, occurs during these studies and influences the 
outcome of subsequent cardiac surgery.
MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging can detect intrathoracic structures, such 
as peripheral pulmonary arteries, systemic-to-pulmonary collateral vessels, 
and the postoperative aortic arch, that often are not adequately imaged by 
echocardiography. Use of the available diagnostic tools in conjunction with 
the history and physical examination enables precise diagnosis without re­
sorting to diagnostic cardiac catheterization in most neonates.
MANAGEMENT PROCEDURES FOR SEVERE CARDIAC DISEASE
An infant in difficulty because of heart disease in the first days of life 
has the potential for rapid deterioration. Too often, the baby looks as though 
he will survive but is near death hours later. The earlier symptoms appear, 
the faster deterioration can take place. By the time the infant has reached 1 
or 2 months of age, concern about sudden shifts in status is less warranted. 
The earlier an infant develops symptoms, the more rapidly the physician 
must respond.
Infants who present with severe cyanosis in the first days to 2 weeks 
of life may do so because right ventricular outflow is critically obstructed 
and pulmonary blood flow depends on a closing ductus arteriosus, or be­
cause the great arteries are transposed and require a ductus arteriosus for 
adequate mixing of the pulmonary and systemic circulations. Babies with 
congestive heart failure in the first week of life often have obstructed left 
ventricular or aortic outflow, with descending aortic flow supplied by a 
closing ductus arteriosus. In these babies, survival may depend on persistent 
patency of the ductus arteriosus; dependency should be suspected and pros­
taglandin ei therapy considered. If possible, echocardiography should be 
used to confirm a specific anatomic diagnosis, but this may not be available 
in many primary care facilities, and the infant's condition may prohibit 
transport to a facility where echocardiography is available. Duct depend­
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ency (e.g., pulmonary atresia, hypoplastic left heart syndrome) or a lesion 
that is significantly worsening because of ductal closure (e.g., o- 
transposition of the great arteries, critical pulmonary stenosis with P 0 2 < 
25, critical aortic stenosis, coarctation with congestive heart failure) can be 
suspected from a physical examination, ECG, and chest radiograph, and 
prostaglandin Ej therapy can be initiated even if echocardiography is not 
available. The usual starting dose of 0.1 pg/kg/ minute can frequently be re­
duced to 0.05 to 0.02 /pg/ kg/minute after stabilization. The occurrence of 
relatively common side-effects, particularly apnea, vasodilation with hy­
potension, and fever should be anticipated. Intubation of infants receiving 
prostaglandins before transport anticipates the risk of apnea.
Despite prostaglandin therapy, these critically ill infants may have 
low cardiac output that may respond to the correction of common metabolic 
perturbations including hypothermia, intravascular hypovolemia, hypocal­
cemia, and hypoglycemia, but frequently, inotropic support is needed (Ta­
bles 9 and 10). Placement of an umbilical venous catheter may allow meas­
urement of central venous pressure to guide fluid therapy and permit ad­
ministration of concentrated infusions of dextrose, calcium, and \ as-oactive 
amines. Hyperventilation should be avoided in babies with certain lesions in 
which the pulmonary and systemic circulations are in parallel, such as hy­
poplastic left heart syndrome. Hyperventilation and oxygen administration 
in these babies can drop pulmonary vascular resistance to low levels, result­
ing in runoff into the pulmonary vasculature, systemic hypotension, and low 
output. After appropriate steps to correct contributing metabolic abnormali­
ties, fluid can be given in 5- to 10-mL/kg doses until adequate response is 
achieved or circulatory congestion occurs Infusion of dopamine or dobuta- 
mine (5-20 | pg//kg minute) should be added to support pump function as 
needed. Higher doses or continuous infusion of epinephrine, amrinone, or 
isoproterenol can be considered to support refractory neonates until surgical 
palliation can be achieved. Digitalis preparations are much less desirable for 
acute inotropic support of critically ill infants who have variable renal and 
hepatic functions and electrolyte status. The acyanotic cardiac infant who 
develops symptoms of increased respiratory work and poor feeding after 2 
to 4 weeks of life often has congestive heart failure due to decreasing pul­
monary vascular resistance and increasing left-to-right shunt. Rarely, these 
infants have left-sided obstructive lesions or myocardial disease (e.g., 
anomalous left coronary artery). In infants with isolated left-to-right shunts, 
a vigorous trial of diuretics, digoxin, and caloric supplementation may be 
rewarding. Afterload reduction may be beneficial in some infants. Gener­
ally, the younger the baby, the more difficult it is to achieve persistent im­
provement.
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Table 9
Common oral drugs for the treatment of congestive heart failure
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THERAPEUTIC CATHETERIZATION
The creation of atrial septal defects, dilation of obstructed valves or 
vessels, occlusion of undesirable vessels, and myocardial biopsies are com­
monly performed in older children. It is not unreasonable to assume that 
conditions such as pulmonary stenosis, coarctation of the aorta, aortic steno­
sis, and patent ductus arteriosus will soon be amenable to comparable 
treatment in the newborn period.
SURGERY
Heart disease in neonates is often life threatening and requires sur­
gery. Early recognition, safe transport to a cardiac center, accurate diagno­
sis, and an experienced surgical team are needed for success. Anesthesiolo­
gists familiar with the problems of neonatal cardiac patients and a well- 
equipped intensive care unit with trained personnel contribute to successful 
management of these babies. The postoperative care requires fine adjust­
ment of blood volume, body temperature, fluid, electrolyte balance, blood
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pH, P 0 2 and PC02. Close cooperation between the cardiologists, intensiv- 
ists, and surgeons responsible for the care of these infants is mandatory.
Table 10
Intravenous vasoactive drugs
D r u g
D o s e
p g /k g /
m in
A c t io n P r e ­
lo a d
S y s -
te m ic
R e s is
ta n c e
P u l ­
m o n ­
a ry
R e s is
t a n c e
C o n
t r a c
t i l -
i ty
H e a r t
R a te
U s e T o x i lc i ty
D o p a ­
m in e
2 -5
5 - 1 0
D, Pi 
D, P, о
+/-1
i
+ / - i
I . T T
0
t
T
TT
+/-T
TT
t  C O , 
t  B P
T a c h y c a r d i a ,  d y s -  
r y th m ia s ,  n e c r o s i s  
w i th  e x t r a v a s a t io n ,  j  
r e n a l  b lo o d  f lo w  at 
h i g h e r  d o s e s
D o b u -
ta m in e
2 - 2 0 P i ,  m ild  
B 2, a
+/-1 i i TT T T C O T a c h y c a r d i a ,  d y s -  
r y th m ia s ,  n e c r o s i s  
w i th  e x t r a v a s a t io n
E p in e p
h r in e
0 .0 5 -
1.0
a ,  Pi .  Pi i .T I ,  ГТ i , t TTT TTT T c o ,  
T b p , 
T H R
T a c h y c a r d i a ,  d y s -  
r y th m ia s ,  n e c r o s i s  
w i th  e x t r a v a s a t io n ,  |  
r e n a l  b l o o d  f lo w
I s o p r o -
t e r o n o l
0 . 0 5 -
2 . 0
P 1 . P 2 1 i t i TTT TTT T C O ,  
T H R
M a r k e d  h y p o te n s io n  
ta c h y c a r d i a ,  d y s -  
r y th m ia s ,  w h e n  v o l ­
u m e  d e p le te d
A m r i-
n o n e
5 - 1 0
( lo a d :
1 O m g
/
k g )
P h o s ­
p h o d i ­
e s te r a s e
in h ib i t io n
1 u I . T T T 0 t с о T h r o m b o c y to p e n ia ,
d y s r y th m ia s
N i t r o -
p r u s -
s id e
0 . 5 - 5 E D R F -  
l ik e  a c ­
t io n
u Ш 1 0 T t c o ,
r  B P
H y p o te n s io n ,  V /Q  
m is m a tc h ,  t h io c y ­
a n a te  t o x ic i ty
N i t r o ­
g ly c e r in
1-5 E D R F -  
l ik e  a c ­
t io n
Ш u 1 0 T T с о ,
1 p r e ­
lo a d
H y p o te n s io n ,  V /Q  
m is m a tc h ,  m e th e m o ­
g lo b in e m ia
P h e n y l ­
e p h r in e
0 .5 -
4 .0
a T T T t T +/-T + / - I T F ,
c y a ­
n o t ic
s p e l l s
C a r d ia c  o u tp u t  j  r e ­
n a l  b lo o d  f lo w
+/- may or may not; | - decrease; t - increase; « - alpha-adrenergic; 0 - adrenergic; BP - blood pres­
sure CO cardiac output; D - dopaminergic, EDRF - endothelial-denved relaxing factor, HR - heart 
rate, TF - tetralogy of Fallot, V/Q - pulmonary ventilation-perfusion ratio.
The timing of surgical intervention depends on the anatomic diagno­
sis and the likelihood of success. Only neonates who are in danger of death 
are candidates for immediate cardiac surgery.
In the past, there were two schools of thought concerning surgical 
management of infants critically ill with heart disease. The older view was 
that a life-saving, palliative operation should be done in infancy, followed
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months or years later with a reparative operation. This concept is being 
challenged by the conviction that single-stage repair should be used if pos­
sible. The justification for this view is the demonstrably acceptable mortal­
ity, avoidance of the double jeopardy of two cardiac operations, and the in­
creasing evidence that early repair results in improved cardiac status and 
neurologic function. Recent mortality data continue to support single-stage 
repair.
ACYANOTIC LESIONS
Lesions associated with normal pulmonary flow include coarctation 
of the aorta, aortic stenosis, myocardial disease, and tricuspid valve disease. 
Acyanotic lesions usually associated with increased pulmonary blood flow 
include ventricular septal defect, patent ductus arteriosus, atrial septal de­
fect, endocardial cushion defects, L-transposition of the great arteries, and 
arteriovenous malformations.
COARCTATION OF THE AORTA
For clinical, prognostic, and probably etiologie reasons, coarctation of 
the aorta is best considered in two separate categories: simple and complex. 
Simple coarctation is usually a discrete constriction of the aortic isthmic 
area, occasionally associated with a patent ductus arteriosus inserting just at 
or below it. The complex malformation involves tubular hypoplasia of the 
aortic arch with or without discrete aortic narrowing, a patent ductus arteri­
osus, and one or more of the following lesions: ventricular septal defect, en­
docardial cushion defect, aortic stenosis, sub-aortic stenosis, mitral stenosis 
or regurgitation, hypoplasia of the left ventricle and ascending aorta, and 
endocardial fibroelastosis. This amalgam of left-sided involvement may be 
secondary to intrauterine low flow through the left heart, with consequent 
under-development and hypoplasia extending from the left atrium to the 
aortic isthmus. The aortic arch may be atretic and completely interrupted as 
in DiGeorge syndrome. In simple and complex coarctations, there are great 
variations possible in the extent and location of the coarctation.
Coarctation occurs in 6% of newborns with heart disease. It is one of 
the common causes of congestive failure in the neonate. It is more common 
in male and premature infants. Girls sometimes have Turner syndrome. 
Among symptomatic infants, 82% have complex coarctation, and 18% have 
simple coarctation. Severe extracardiac anomalies, usually renal or gastroin­
testinal, occur in 6% of these patients.
PATHOPHYSIOLOGY
Simple Coarctation. The isthmus is normally smaller than the as­
cending or descending aorta in newborn infants with simple coarctation be­
cause only 25% of the combined ventricular output during fetal life passes 
through the isthmus into the descending aorta, whereas approximately 60%
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passes through the ductus arteriosus to the descending aorta. After birth, the | 
isthmus gradually grows, but in simple coarctation, a curtainlike constrict­
ing band develops at the point of connection to the ductus arteriosus.
Table 11
Findings in acyanotic 0- to 2-week-old neonates with congestive 
heart failure'"
Diagnosis Physical Examination Radiographic findings Electrocardiographic
findings
Coarctation J. Leg pulses and leg BP, solf 
SEM in back, +/- click, S3, 
+/- differential cyanosis, 
shocklike sepsis picture
t Heart size, pulmo­
nary edema
+/- RVH, develops 
LVH, BVH
Critical aortic 
stenosis
Shock, i pulses and perfu­
sion, SEM, click, S3, single 
S2
j Heart size, pulmo­
nary edema
LVH, T-wave abnor­
malities
Patent ductus 
arteriosus in 
premature in­
fant
Heave, J, pulses, [ pulse 
pressure, continuous or SRM
t Heart size (LV, LA), 
t pulmonary arterial 
markings
Develops RVH, LVH, 
BVH
Cardiomyo-
hathy
4 Pulses, i  perfusion, J. pulse 
pressure, T HR, SRM
Large globular heart, 
pulmonary edema
J. or T voltage, T-wave 
changes, Q waves in 
ALCA
Critical pulmo­
nary stenosis
SEM, click, single S2 most 
have cyanosis
Normal or f pulmo­
nary arterial markings, 
RAE
QRS axis 0°-90u, 
LVH, develops RVH
Systemic arte­
riovenous
Heave, t  pulses, wide pulse 
pressure, soft SEM or SRM, 
bruit, +/- cyanosis
t Heart size, t pulmo­
nary arterial markings
develops RVH, LVH, 
BVH
"Congestive heart failure with cyanosis may be due to hypoplastic left heart syndrome, transposition 
of the great arteries, truncus arteriosus, total anomalous pulmonary venous connection, pulmonary 
atresia with tetralogy, tricuspid atresia, Ebstein malformation, or persistent pulmonary hypertension 
+/- - may or may not be present; 4 - decreased; f -  increased; ALCA - anamolous left coronary ar­
tery, BVH - biventricular hypertrophy; HR - heart rate; LA - left atrium; LV - left ventricle, LVH - 
left ventricular hypertrophy; RAE - right atrial enlargement; RVH - right ventricular hypertrophy, S2 
- second heart sound; S 3 - third heart sound; SEM - systolic ejection murmur; SRM, systolic regur­
gitant murmur.
The coarctation may become more severe in the neonatal period, as 
constriction of the adjacent ductal tissue occurs. During childhood, there 
maybe progressive hypertrophy and endothelial thickening at the coarcta­
tion site, possibly engendered by high flow velocity at the narrowed point. 
Collateral circulation may be present at birth. In simple coarctation, the in­
creased resistance to flow results in a pressure overload on the left ventricle 
to which a volume load may be added if there is a patent ductus arteriosus. 
With a gradual fall in pulmonary vascular resistance after birth, there is a 
reversal of flow through the ductus arteriosus from the aorta to the pulmo­
nary artery, and a considerable left-to-right shunt may exist. If the increased
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pressure and volume load exceeds the ability of the heart to compensate by 
hypertrophy or dilation, congestive failure with diminution of systemic out­
put ensues. Left ventricular end-diastolic pressure is elevated with conse­
quent increase in left atrial filling pressure, increased pulmonary venous 
pressure, and development of pulmonary edema. The increased pulmonary 
venous pressure also produces pulmonary artery hypertension and right 
heart failure.
Table 12
Findings in acyanotic 2-to 8-week-old neonates with congestive heart failure
Diagnosis Physical Examination Radiographic findings Electrocardiographic
findings
Ventricular septal 
defect*
Heave, harsh SRM, +/- 
S3 , +/- diastolic rumble, 
normal pulses
t Heart size (RV, LV, 
LA), T pulmonary arterial 
markings
Defelops RAE, RVH, 
LVH, BVH
Endocardial 
cushion defect
Same as ventricular sep­
tal defect, fixed split S2
Same as ventricular sep­
tal defect
Left axis deviation, 
defelops RAE, RVH, 
LVH, BVH
Atrial septal de­
fect
Hyperdynamic pre- 
cordium, soft SEM, +/- 
diastolic rumble
f Heart size (RV, normal 
LV and LA), |  pulmo­
nary arterial markings
Defelops RAD, RVH
Patent ductus ar­
teriosus in full- 
term infants
Same as presentation at 
0-2 weeks of age
Cardiomyopathy Same as presentation at 
0-2 weeks of age
* Murmur may be present earlier than 2 weeks of age, and congestive heart failure may 
occur earlier in premature infants.
+/- - may or may not be present; J - decreased; f  - increased; BVH - biventricular hyper­
trophy; LA - left atrium, LV - left ventricle; LVH - left ventricular hypertrophy; RAD - 
right axis deviation; RAE - right atrial enlargement, RV - right ventricle; RVH - right 
ventricular hypertrophy; S2 - second heart sound; S3 - third heart sound; SRM - systolic 
regurgitant murmur.
Complex Coarctation. Complex coarctation is characterized by 
pulmonary artery hypertension with a ductus arteriosus supplying the de­
scending aorta, usually a large intracardiac left-to-right shunt, and increased 
pulmonary flow. The right-sided structures are dilated and hypertrophied. 
There is a pressure and volume overload on both ventricles and congestive 
heart failure. In cases of a large ventricular septal defect and patent ductus 
arteriosus, the systolic pressures in the pulmonary artery, descending aorta, 
ascending aorta, and right ventricle are identical. Peripheral pulse pressure 
is normal, and the pulses are equal throughout. With ductal closure or con­
striction, the femoral pulsations dimmish. If the coarctation is severe, perfu­
sion to the lower one-half of the body, previously supplied by the open duc­
tus, is reduced, and manifestations of shock, renal and mesenteric hypoper­
fusion, and metabolic acidosis develop.
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CLINICAL FINDINGS
Infants with isolated discrete coarctation may be asymptomatic, al­
though some develop congestive heart failure, usually after the age of 1 
month. The femoral pulses are absent or diminished and significantly de­
layed compared with brachial pulses. Left brachial pulses may be decreased 
if the left subclavian arises at or below the coarctation. Systolic blood pres­
sure in the upper extremities is higher than in the lower extremities, but 
marked hypertension is uncommon. Pulse pressure in the lower extremities 
is narrow, often 10 to 15 ton. An ultrasonic flow probe or external blood 
pressure monitor may be helpful. Ss is often prominent, and there may be an 
apical systolic ejection click. A systolic ejection murmur is usually heard 
best at the left interscapular area over the back, but it may be audible at the 
left upper sternal border. A continuous murmur suggests a left-to-righB 
shunt across the ductus arteriosus. Manifestations ofl congestive heart fail­
ure are those of combined lefitl and right heart failure. The chest radiograph 
showji cardiac enlargement and pulmonary venous congection. The ECG 
usually reveals right ventricular hypertrophy in the early months and left 
ventricular hypertrophy later. Echocardiographic visualization of the aortic 
arch usually shows the site, length, and severity of coarctation and the aortic 
arch branching pattern. There is characteristically a constriction from the 
outer posterior curvature of the aortic wall, and an I anterior periductal shelf 
may be identified. An instantaneous systolic gradient may be derived from 
the velocities across the coarctation but may underestimate the severity of 
the lesion if cardiac output is depressed. The descending aortic flow has a 
characteristically diminished systolic upstroke velocity and I prolonged an­
tegrade flow.
Infants with severe isolated and complex coarctation usually present 
with congestive heart failure in the early neonatal period. Generally, the 
younger the infant, the more severe and complex are the combined malfor­
mations. In addition to the findings described for simple coarctation, there is 
evidence of a large left-to-right shunt and pulmonary artery hypertension. 
Femoral pulsations may wax and wane, depending on ductal patency. This 
in itself is a useful diagnostic sign. A pansystolic murmur of a septal defect 
or mitral regurgitation may be found. Ductal closure may result in a criti­
cally ill baby with poor perfusion, metabolic acidosis, and possibly dissemi­
nated intravascular coagulation, necrotizing entero-colitis, and renal and he­
patic dysfunction. The chest radiographs show considerable cardiac en­
largement, pulmonary plethora, and edema (Fig. 5). The ECG shows right 
axis deviation, right atrial hypertrophy, right ventricular hypertrophy, and 
often diminished left ventricular forces. In addition to the aortic arch anat­
omy, echocardiography often reveals associated lesions, including mitral 
and aortic stenosis, ventricular septal defect, subaortic obstruction, and 
conotruncal abnormalities.
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FIG. 5. A chest radiograph of a 1-day-old infant with complex coarctation of the aorta shows
marked cardiac enlargement and pulmonary vascular engorgement.
TREATMENT
All neonates with congestive heart failure thought to have coarctation 
of the aorta should be promptly hospitalized, treated, and examined by 
echocardiography. Many infants with complex coarctation become symp­
tomatic because of constriction of the ductus arteriosus. Prostaglandin ei in­
fusion can dilate the ductus, restore systemic perfusion, improve metabolic 
abnormalities, and provide time to study the anatomy and arrange for sur­
gery. Inotropic support with intravenous dopamine or adrenergic agents is 
often needed. In critically ill babies, there may be adverse ischemic conse­
quences for the gastrointestinal, renal, hepatic, and coagulation systems. 
Echocardiography usually provides the anatomic detail needed for surgery. 
Cardiac catheterization, digital subtraction angiography, or magnetic reso­
nance imaging (MRI) may be useful for additional delineation of the aortic 
arch and intracardiac anatomy.
After an initial period of clinical improvement, rapid deterioration 
may occur, and surgery should not be unduly delayed. The surgical proce­
dures employed depend on the severity of the lesion and include resection 
of the coarctation with primary anastomosis, subclavian or prosthetic patch 
aortoplasty, or construction of a conduit from the ascending to descending 
aorta; division of the patent ductus arteriosus; and intracardiac repair or 
banding of the pulmonary artery if there is a large ventricular septal defect. 
In some older infants with simple coarctation who respond well to medical 
therapy, surgery may be delayed. The mortality rate for infants with compli­
cated coarctation is 85% without surgery. Surgery increases the survival 
rate to 85%. Regardless of the type o f coarctation, the mortality is related to 
age of presentation and is higher for those with duct-dependent descending 
aortic flow. The survivors need close medical supervision throughout child­
hood and may require other operations for various associated abnormalities 
at a later time. Those who undergo surgical coarctation repair early in in­
fancy may develop restenosis later, which may require reoperation or cathe-
so
ter balloon dilation. The role of catheter balloon dilation of unoperated pri­
mary discrete coarctation is being investigated. It can offer palliation in the 
complex critically ill infant.
DIFFERENTIAL DIAGNOSIS
Aortic arch obstruction should be suspected in any critically ill term 
baby with a septiclike shock. A thorough examination, including careful 
palpation of all peripheral pulses and blood pressure measurement, should 
lead to the correct diagnosis. Infants presenting before 1 month of age usu­
ally have severe or complex coarctation. Complete interruption of the aortic 
arch is usually associated with a ventricular septal defect and a systemic 
patent ductus arteriosus and is clinically indistinguishable from complicated 
coarctation. It is frequently seen as part of DiGeorge syndrome, which may 
have additional manifestations of hypocalcemia, absent thymic shadow on 
the initial chest radiograph, and possible impaired immune response to 
transfused viable nonirradiated leukocytes. The presence of a ductus arteri­
osus supplying the descending aorta may be demonstrated by the finding of 
a lower arterial P02 in the legs than in the arms. The hypoplastic left heart 
syndrome produces a similar shocklike picture or congestive failure in the 
first week as the ductus arteriosus closes. In these patients, there is cyanosis, 
the peripheral pulses are diminished throughout, and the ECG shows 
marked diminution in left ventricular forces.
AORTIC STENOSIS
Symptomatic isolated aortic stenosis in infancy is rare and almost in­
variably valvar rather than supravalvar or subvalvar. Only the most severe 
aortic valve obstruction produces symptoms in early infancy. The symptoms 
are those of congestive heart failure, pulmonary edema, and sometimes pe­
ripheral vascular collapse. The baby may appear ashen and cyanotic if the 
pulmonary edema is severe. The cardinal features are tachypnea, a blowing 
stenotic murmur at the upper right or middle left sternal border, an apical 
early systolic click resembling a split Sj, cardiac enlargement and pulmo­
nary venous congestion on chest radiographs, biventricular hypertrophy 
with T-wave changes on the ECG, and a deformed immobile aortic valve 
with commissural fusion on the echocardio-gram. In severe aortic obstruc­
tion, transvalvar flow is diminished, and the systolic murmur and the Dop­
pler-derived pressure gradient are of low amplitude and do not reflect the 
severity of the lesion. On the echocardiogram, the left ventricle appears hy- 
pertro-phied and may have small or dilated internal dimensions and poor or 
hyperdynamic systolic function. Some patients may have coarctation and 
mitral valve abnormalities.
Initial treatm ent o f  critical stenosis consists o f  adm inistration o f  ino­
tropic support, oxygen, and frequently prostaglandin ei, followed as soon as 
feasible by cardiac catheterization and balloon valvuloplasty or surgical
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valvotomy. Although most infants with critical aortic stenosis survive val­
vuloplasty or valvotomy, some have associated endocardial fibroelastosis or 
very small left ventricles that limit their survival. The asymptomatic infant 
with auscultatory findings of aortic stenosis and those after valvuloplasty 
require continued follow-up, because valvar aortic stenosis frequently re­
curs.
MYOCARDIAL DISEASE
Several diseases with different causes but with common clinical 
manifestations and pathophysiology affect the myocardium of the neonate 
(Table 13). These may be functionally grouped as dilated, hypertrophic, and 
restrictive cardiomyopathy. The relatively rare primary myocardial disor­
ders include viral myocarditis, neuromuscular diseases, nonobstructive and 
obstructive hypertrophic cardiomyopathies, and glycogen storage disease 
(i.e., Pompe disease).
Dilated cardiomyopathies are characterized by cardiac dilation, di­
minished contractility, and congestive heart failure. There is frequently 
some insult to the myocardium that results in myocardial dysfunction, stun­
ning, or necrosis, often with interstitial fibrosis leading to impaired systolic 
contractility and diastolic compliance. Ventricular dilation, as a result of the 
Frank-Starling phenomenon, and tachycardia occur in the attempt to main­
tain cardiac output despite diminished systolic shortening fraction. Pulmo­
nary edema may develop, and cardiac output is often diminished. Unlike 
older children, neonates with dilated cardiomyopathy frequently have an 
identifiable cause.
A condition commonly encountered with neonatal cardiomyopathy is 
severe birth asphyxia. Hypoxemia and ischemia, often with pulmonary hy­
pertension, lactic acidemia, hypercarbia, hypothermia, hypocalcemia, ane­
mia, or polycythemia, may contribute to the myocardial dysfunction. 
Treatment consists of correction of coexistent metabolic abnormalities, sup­
porting the myocardium with intravenous inotropic agents (e.g., dopamine, 
dobutamine, epinephrine, amrinone), using antidysrhythmics as needed, and 
judiciously providing fluids to maintain cardiac output while minimizing 
edema. Other neonatal disorders associated with significant myocardial dys­
function are sepsis (e.g., endotoxemia, exotoxemia) and persistence of fetal 
pulmonary hypertension. In addition to supportive measures, antibiotics, 
hyperventilation, paralysis, sedation, and vasodilators may be employed. In 
cases with severe but presumably self-limited cardiopulmonary failure re­
fractory to conventional therapy, venoarterial extracorporeal membrane 
oxygenation has been used with success. Although serious complications 
continue to exist, ECMO has become a standard treatment for critically ill 
neonates with self-limited cardiopulmonary failure.
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Table 13
Neonatal cardiomyopathies
Dilated Cardiomyopathies
Asphyxia-induced Persistent pulmonary hypertension
Hypoglycemia Hypothermia
Polycythemia Chloramphenicol
Adriamycin Myocarditis (e g., coxsackie B, echo, rubella, 
and human immunodeficiency viruses)
Anomalous origin of left coronary ar­
tery
Arrhythmogenic right ventricular dysplasia
Maternal connective tissue disease 
(e g., systemic lupus erythematous)
T achycardia-induced
Sepsis (e g., endotoxemia, exotoxemia) Hypophosphatemia
Hypocalcemia Carnitine deficiency
Hypertrophic Cardiomyopathies
Maternal diabetes melli- Hypertrophic cardiomyopathy Pheochromocytoma 
tus (i.e., idiopathic)
Infiltrative Cardiomyopathies
Pompe glucogen storage disease | Mucopolysaccharidoses
Neonatal viral myocarditis is an often fulminant disease frequently 
associated with hepatitis and encephalitis. The most commonly identified 
causes are rubella virus, echovirus, and Coxsackie virus, particularly type B. 
In individual cases, the cause is frequently not determined despite culturing 
of nasopharyngeal, tracheal, and stool swabs and serologic tests. The infec­
tion may be acquired perinatally or postnatally. Treatments including ster­
oids, y-globulin, interferon, and ribavirin have been under investigation in 
biopsy-proven myocarditides, but supportive measures are the mainstay of 
treatment. Several other viruses, bacteria, mycoplasma, rickettsiae, spiro­
chetes, and fungi rarely cause myocarditis. Myocarditis because of an auto­
immune reaction may occur with maternal lupus erythematosus. Maternal 
IgG Ro antibodies cross the placenta, bind to the fetal myocardium, and 
may block conduction or cause cardiomyopathy. Steroids may be beneficial 
in this disease.
The diagnosis of anomalous origin of the left coronary artery from the 
pulmonary artery should be considered in all children with dilated cardio­
myopathy, particularly if there is an ECG pattern of anterolateral myocar­
dial infarction. The anomalous origin of the left coronary artery can usually 
be seen on echocardiography, although angiography may be needed in some 
cases. Treatment is surgical and is usually successful.
Chronic supraventricular and ventricular tachycardia can lead to per­
sistent myocardial dysfunction with the picture of cardiomyopathy.
Chronic therapy is supportive and aimed at control of the congestive 
heart failure and arrhythmias. Digitalization should be carried out with cau­
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tion and orally if possible in infants with myocarditis, because they may be 
unduly susceptible to drug-induced dysrhythmias. Therapy should be main­
tained until cardiac enlargement subsides. Afterload reduction with angio­
tensin-converting enzyme (ACE) inhibitors can produce significant benefit. 
Cardiac transplantation may be considered if the course is fulminant.
Although sometimes a severe disorder in infants, the hypertrophic 
cardiomyopathy of infants of diabetic mothers is generally self-limited. Hy­
pertrophic cardiomyopathy in infants of diabetic mothers is thought to be a 
result of a myocardial trophic response to fetal hyperinsulinemia provoked 
by trans-placental passage of high maternal glucose loads. Clinical findings 
include a systolic ejection murmur and, rarely, evidence of congestive heart 
failure. There is an increased risk of structural heart disease. Echocardi­
ography reveals left ventricular hypertrophy that is sometimes severe, usu­
ally with involvement of the septum, and occasionally with outflow obstruc­
tion (Fig. 6). Treatment is supportive, Digoxin may worsen outflow obstruc­
tion and is contraindicated if the obstruction is severe.
FIG. 6. Echocardiographic parasternal long axis view of a diabetic mother's 
infant with severe hypertrophic cardiomyopathy and subaortic ventricular 
septal defect. - ventricular septal defect; AV - aortic valve, IVS - inter­
ventricular septum; LA - left atrium, LV - left ventricle; RV - right ventricle.
Idiopathic hypertrophic cardiomyopathy is a multi-gene disorder in­
herited as an autosomal condition with variable penetrance. This disorder is 
characterized by marked left ventricular hypertrophy associated with myo­
cyte hypertrophy and disarray. There is a propensity for development of left 
ventricular outflow or intracavitary systolic gradients, symptoms o f conges­
tive heart failure due to poor diastolic chamber compliance, ventricular dys­
rhythmias, and sudden death. There can be significant progression with 
time, and a normal echocardiogram at birth may not exclude the possibility
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for phenotypic expression later in life. Those presenting at birth appear to 
have the poorest prognosis. Inotropic agents and diuretics are potentially 
harmful and generally not used. Calcium channel blockers decrease the sys­
tolic pressure gradient, improve diastolic compliance, and may improve 
survival in adults. Because of hazards associated with calcium channel 
blockers in infants, their use in infants less than 1 year of age remains in- 
vesti-gational. Propranolol improves symptoms but has no effect on the 
progression of hypertrophy or survival. Ventricular septal myotomy or 
myomectomy may improve symptoms in those refractory to medical treat­
ment. Holter monitoring for ventricular dysrhyth-mias should be routinely 
performed and amiodarone considered in those with ventricular tachycardia 
or syncope. Cardiac transplantation may be considered in severely affected 
refractory patients.
Infiltrative disorders of the myocardium such as Pompe glycogen 
storage disease can present with clinical, ECG, and echocardiographic fea­
tures resembling in many ways hypertrophic cardiomyopathy. Distinguish­
ing features sometimes include skeletal muscular hypotonia, protruding 
tongue, short PR interval, left ventricular hypertrophy, and normal or dimin­
ished systolic function. Pompe disease is uniformly fatal.
TRICUSPID VALVE DISEASE
An abnormally functioning but anatomically normal tricuspid valve is 
a common finding in the newborn period. There may be right ventricular 
myocardial disease; perhaps asphyxial cardiomyopathy, which causes tri­
cuspid regurgitation; or PPHN or pulmonary hypertension resulting from 
pulmonary parenchyma! disease. Whether there is primary myocardial dys­
function or pulmonary hypertension and secondary right ventricular dys­
function, there is secondary tricuspid regurgitation of a normal tricuspid 
valve. If there is right ventricular diastolic dysfunction, there may be right- 
to-left shunting through a PFO. The explanation for a lower sternal murmur 
is documented by echocardiography and managed with observation, because 
tricuspid regurgitation of this type tends to regress as the underlying prob­
lem resolves.
VENTRICULAR SEPTAL DEFECT
Interventricular septal defects may be small or large, single or multi­
ple, and isolated or associated with other cardiovascular malformations. 
They are an integral part of complex congenital heart disease lesions, such 
as tetralogy of Fallot, truncus arteriosus, double-outlet right ventricle, and 
atrioventricular canal, and they have been associated with virtually every 
other known congenital cardiac malformation. The defect occurs most 
commonly in the membranous septum, less often in the low portion of the 
muscular septum, rarely beneath the pulmonary valve, and rarely posteriorly 
adjacent to the tricuspid valve. Ventricular septal defects are the most corn-
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mon of the congenital cardiac lesions, and even though only 10% of ven-" 
tricular septal defects cause symptoms, they remain the most common Cause 
of congestive heart failure after the second week of life. Extracardiac mal­
formations occur in 24% of the patients.
PATHOPHYSIOLOGY
The common small ventricular septal defect does not produce symp­
toms, but a moderate or large defect in a neonate may cause significant he­
modynamic alterations. If the defect is large, there is equilibration of right 
and left ventricular pressures and pulmonary hypertension. The decreasing 
pulmonary resistance after birth allows an increasing left-to-right shunt 
through the defect. The normal regression of pulmonary resistance in the 
first week of life is usually delayed in these babies. Nonetheless, sufficient 
reduction in pulmonary resistance occurs by the second week of life to 
cause symptoms in many patients. Others, presumably with smaller defects 
or further delay in the reduction of pulmonary vascular resistance, develop 
symptoms as late as 3 to 4 months of age.
Symptoms are the result of congestive heart failure or superimposed 
pulmonary problems such as pneumonia or atelectasis. Congestive heart 
failure is caused by the recirculation of large amounts of blood through the 
heart and lungs while simultaneously attempting to meet the demand for 
systemic flow.
Mechanical pressure by enlarged structures, particularly the left pul­
monary artery and atrium, may result in bronchial obstruction and pulmo­
nary atelectasis. The added effect of pulmonary congestion, which produces 
decreased lung compliance, makes the infants with a large left-to-right 
shunt susceptible to recurrent respiratory airway obstruction and infections. 
Because pulmonary vascular resistance is lower in premature infants at 
birth, the development of symptoms from a ventricular septal defect occurs 
earlier.
Gradual improvement and diminution in pulmonary blood flow in an 
infant with a moderate or large ventricular defect may occur if there is an 
anatomic decrease in the size of the defect. Many defects spontaneously 
close and most—particularly muscular and membranous defects—become 
smaller with time. During childhood, but rarely in infancy, there may be 
progressive and irreversible development of anatomic obstructive changes 
in the pulmonary arterioles.
CLINICAL FINDINGS
A small ventricular septal defect is characterized by a readily audible 
harsh systolic murmur, which is loudest at the lower left sternal border. In­
fants with large septal defects develop congestive failure in the first few 
months of life with symptoms of tachypnea (i.e., rate consistently &60), fa-
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tigue with feeding, decreased oral intake, excessive diaphoresis, and recur­
rent respiratory infections. Gross dyspnea is a late manifestation. Weight 
gain lags considerably behind height maturation. The infant often presents 
with a respiratory infection that may precipitate or mask underlying conges­
tive failure. On examination, the infant is scrawny and tachypneic. The pe­
ripheral pulses are rapid and may be slightly bounding. The cardiac impulse 
is hyperdynamic. If pulmonary artery hypertension exists, the second heart 
sound may be single with an accentuated pulmonary closure. A gallop 
sound may be heard and is often associated with a mid-diastolic rumble. 
The systolic murmur is heard best at the lower left sternal border but is usu­
ally transmitted well to the entire precordium. There is hepatomegaly and 
frequently pulmonary wheezing and rales. Peripheral edema is rare.
A chest radiograph shows considerable cardiac enlargement, in­
creased pulmonary blood flow, and sometimes pulmonary edema. The main 
pulmonary artery segment and left atrium are often enlarged. Atelectasis 
and parenchymal infiltrates are common. The ECG usually reveals left ven­
tricular hypertrophy, and if the lesion is associated with pulmonary artery 
hypertension, right ventricular hypertrophy is detected. The echocardiogram 
can demonstrate the size, location, and number of ventricular septal defects. 
Associated lesions not appreciated on physical examination, including atrial 
septal defect, patent ductus arteriosus, coarctation of the aorta, and left and 
right ventricular outflow obstructions, are revealed by echocardiography. 
Right ventricular and pulmonary hypertension can be assessed from the 
curvature of the interventricular septum and by Doppler measurement of the 
instantaneous systolic pressure gradient across the defect. Some degree of 
tri-cuspid regurgitation often allows estimation of the right ventricular pres­
sure from the pressure gradient between the right ventricle and right atrium. 
Large defects show evidence of left ventricular volume overload with large 
left atrial and left ventricular dimensions and hyperdynamic left ventricular 
function.
TREATMENT
An infant with a small ventricular septal defect requires no specific 
treatment but should be followed. Some infants with large defects have or 
develop progressive pulmonary stenosis that prohibits left-to-right shunting, 
cardiomegaly, and congestive heart failure. These babies may develop the 
features of the tetralogy of Fallot. Any evidence of increasing right ven­
tricular hypertrophy on the ECG suggests the development of pulmonary 
stenosis or increasing pulmonary vascular resistance and the need for care­
ful reevaluation. In infants with congestive heart failure, intensive medical 
therapy with the administration of digitalis and diuretics may produce con­
siderable improvement. Systemic afterload reduction with ACE inhibitors 
(e.g., captopril) may be beneficial in some refractory patients. If there are
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any pulmonary complications, antibiotics, brortchodilators, and pulmonary 
physiotherapy should be employed as appropriate. The use of high-caloric 
formulas may be helpful. The total ad libitum oral intake should not be re­
stricted, because growth failure and small size are a common issue in these 
infants.
The infant who develops congestive failure or who has evidence of 
pulmonary artery hypertension may require cardiac catheterization to con­
firm the hemodynamics and determine the possible coexistence of other 
cardiac lesions. Palliative or corrective surgery is indicated if the infant 
does not grow despite intensive medical therapy after a reasonable period of 
observation, requires repeated hospitalizations for respiratory infections, or 
has persistent significant pulmonary artery hypertension after 6 months of 
age. Primary repair in infants entails cardiopulmonary bypass, possible deep 
hypothermic circulatory arrest, and in most patients, closure through the tri­
cuspid valve. Some patients require right or left ventriculotomy. Of infants 
born with isolated, large defects requiring closure in the first year of life, 
10% die, usually as a consequence of associated severe extra-cardiac con­
genital anomalies, pulmonary complications, or prematurity. The long-term 
prognosis after transatrial surgical closure of isolated ventricular septal de­
fects in the first year o f life is excellent, with essentially normal hemody­
namics and a small risk for symptomatic dysrhythmias for most patients.
DIFFERENTIAL DIAGNOSIS
In the neonate, the murmur of a small ventricular septal defect may be 
difficult to differentiate from that caused by an obstructive lesion or atrio­
ventricular valve regurgitation (i.e., mitral or tricuspid regurgitation). Other 
malformations resulting in a large lefit-to-right shunt and congestive failure 
are often difficult to differentiate clinically and should be excluded by 
echocardiography.
PATENT DUCTUS ARTERIOSUS
The ductus arteriosus, arising from the distal dorsal sixth aortic arch, 
is well developed by the sixth week of gestation and forms a bridge between 
the pulmonary artery and the dorsal aorta, inserting at the aortic isthmus. At 
term, it is a muscular contractile structure. In the full-term infant, functional 
closure occurs during the first day of life. Persistence of patency of the duc­
tus arteriosus alone or in association with other cardiovascular lesions may 
produce no symptoms or severe hemodynamic changes, depending on its 
size.
Isolated patent ductus arteriosus, without hyaline membrane disease, 
is common, accounting for 3.9% of all newborns symptomatic with heart 
disease. It is more prevalent in female than male infants. Patent ductus ar­
teriosus is a frequent complication of hyaline membrane disease in the pre­
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mature infant, in surviving premature infants, and in infants born at high al­
titudes; in these patients, there is no sex difference. It is common in combi­
nation with other congenital heart lesions (e.g., coarctation of the aorta, ven­
tricular septal defect, vascular ring). It occurs in 60 to 70% of infants born 
with congenital rubella.
PATHOPHYSIOLOGY
At birth, ductal constriction is caused by multiple factors, the most 
important of which appears to be increased oxygen tension, the levels of 
circulating prostaglandins, and available ductus muscle mass. Prostaglandin 
ei is used to dilate a closing ductus in several forms of congenital heart dis­
ease in which patency of the ductus arteriosus is necessary to support pul­
monary or systemic blood flow. Delayed closure frequently occurs in pre­
mature infants with respiratory distress syndrome. Indomethacin, an inhibi­
tor of prostaglandin synthesis, is used to promote closure of the ductus in 
this situation. The ductus arteriosus that remains patent in the term infant is 
abnormal and not susceptible to pharmacologic closure.
Within the first hours after birth, with a fall in pulmonary vascular re­
sistance and a rise in systemic resistance, a left-to-right shunt may develop 
through the ductus arteriosus. A small right-to-left or bidirectional shunt 
may occur. If spontaneous closure does not occur and the ductus is small, 
the left-to-right shunt remains small. However, a moderate-sized patent duc­
tus arteriosus is usually associated with a significant left-to-right shunt, left 
ventricular volume overload, increased left ventricular end-diastolic volume 
and pressure, elevation of left atrial pressure, and the development of con­
gestive heart failure. Increased pulmonary blood flow elevates the left ven­
tricular stroke volume, increases systolic pressure, produces wide pulse 
pressure, and generates bounding peripheral pulsations.
The premature infant may fail earlier because of incomplete devel­
opment of the medial musculature in the small pulmonary arterioles. The 
contractile function of the heart, required to handle the increased volume 
load, may be incompletely developed. Among those with respiratory dis­
tress syndrome, there may be an initial period of improvement as the pul­
monary status improves, followed by clinical deterioration as left-to-right 
shunting through the ductus arteriosus increases.
A large patent ductus arteriosus produces pulmonary artery hyperten­
sion because the pressure is transmitted directly from the aorta to the pulmo­
nary artery through the large defect. Those with moderate and large ducts 
are prone to the development of pulmonary vascular obstructive disease at a 
later age.
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CLINICAL FINDINGS
In the neonate with a patent ductus arteriosus, as ir all left-to-right 
shunts, the elevated but decreasing pulmonary vascular resistance determines 
the clinical manifestations. The classic continuous (i.e., Gibson) murmur is 
heard infrequently, except in some small premature infants. There is usually a 
crescendo systolic murmur, often with clicks, sometimes detectably spilling 
into diastole. Often, S2 is not clearly audible The infant with a large patent 
ductus arteriosus has bounding peripheral pulses, wide pulse pressure, and 
hyperactive cardiac impulse at the apex. There may be an apical diastolic 
rumble. The child may have symptoms and signs of congestive heart failure, 
poor weight gain, and recurrent pulmonary infections. In a full-term infant 
with a large patent ductus arteriosus, overt failure usually does not develop 
until 3 to 6 weeks of age, but in premature infants, it may occur earlier.
The chest radiograph shows cardiac enlargement, pulmonary plethora, 
a prominent main pulmonary artery, and left atrial enlargement. The ECG 
reveals left ventricular hypertrophy, occasionally left atrial hypertrophy, and 
in severe failure, ST-T wave changes. Echocardiography demonstrates the 
ductus arteriosus, its size, and the direction of the flow across the defect. 
Disturbed flow in the pulmonary artery, seen best with color Doppler tech­
niques, is particularly helpful in identifying a patent ductus arteriosus. Con­
tinuous-wave Doppler allows measurement of the pressure gradient across 
the defect and thereby, estimation of pulmonary pressure. Large defects show 
evidence of left heart volume overload and a large left atrium and left ventri­
cle, and right ventricular hypertension with flattening of the interventricular 
septum curvature.
If there is associated pulmonary disease, the pulmonary resistance 
may be high, allowing only right-to-left shunting, which does not produce a 
murmur. Right-to-left ductal shunting also occurs with left heart obstructive 
lesions and coarctation of the aorta. If suspected, echocardiography should 
be used to exclude these lesions before treatment.
TREATMENT
The full-term and premature infant with a persistent patent ductus ar­
teriosus and no evidence of cardiovascular embarrassment should be fol­
lowed and catheter closure or surgical division of the ductus performed be­
tween 6 months and 1 year of age. Term infants with congestive heart failure 
should be digitalized, and if necessary, diuretics should be added. In the sick 
neonate, clinical differentiation from other lesions is often possible using 
echocardiography. Careful transfusion of packed erythrocytes in the anemic 
premature diminishes the left ventricular volume overload and may hasten 
ductal closure by increasing the arterial oxygen content.
Among preterm infants with significant patent ductus arteriosus, in- 
domethacin treatment produces closure in approximately 85% of patients. In-
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domethacin can cause deterioration of renal and platelet function and should 
be avoided if there is significant renal dysfunction, thrombocytopenia, or 
bleeding. The ductus arteriosus occasionally reopens after initially successful 
indomethacin treatment and may respond to a second course of treatment. 
Failure of indomethacin does not adversely affect subsequent surgery. Surgi­
cal interruption of the ductus arteriosus is indicated, regardless of age or 
weight in any infant with a persistent hemodynamically significant left-to- 
right shunt, particularly if there is pulmonary artery hypertension. Surgical 
mortality is low, and dramatic improvement often occurs. The procedure is 
performed using a left thoracotomy in the intensive care nursery or the op­
erating room under intravenous or inhalation general anesthesia. Catheter 
closure is not yet technically achievable in neonates and preterm small infants.
DIFFERENTIAL DIAGNOSIS
The infant with congestive failure and a large left-to-right shunt caused 
by a ventricular septal defect may be clinically indistinguishable from the 
one with a large patent ductus arteriosus. Other lesions that may result in a 
large aortic runoff and mimic a patent ductus arteriosus include truncus arte­
riosus, hemitruivcus (i.e., right pulmonary artery from the ascending aorta), 
aortopulmonary window, aneurysm of the sinus of Valsalva, and a large 
systemic arteriovenous fistula, usually intracranial or hepatic.
ATRIAL SEPTAL DEFECT SECUNDUM
Virtually all babies have a PFO at birth. Many PFOs become function­
ally closed within hours of birth, but most allow the passage of a catheter at 
least for the first months of life and sometimes for the rest of the person's 
life. This is important to the neonatologist, because umbilical vein catheters 
tend to follow the course of the circulation for the preceding 9 months and 
may pass through the foramen ovale into the left heart, providing erroneous 
measures of oxygen levels and allowing passage of undiluted intravenously 
injected materials straight to the brain, occasionally with disastrous re­
sults.
An opening in the atrial septum is a relatively common anomaly, but 
rarely causes symptoms or a murmur loud enough to attract attention in in­
fants. Some of these defects are discovered because of concern initiated by 
extracardiac anomalies, and an echocardiogram is ordered. Others are dis­
covered during workup for failure to thrive, but most are found because a 
murmur of pulmonary stenosis is heard. This murmur is thought to be pro­
duced by the excess flow across the pulmonary valve caused by the left-to- 
right shunt resulting from an atrial septal defect. Because there is rarely con­
gestive heart failure, treatment consists of observation until the child is older, 
when if the defect persists, it may be closed by surgical or catheter techniques. 
Surprising numbers of these defects spontaneously close in the first years of
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life, raising the question about whether some were patent foramina ovale mis­
interpreted at echocardiography. Rarely, a large atrial septal defect is associated 
with an early decrease in the pulmonary resistance and a large left-to-right 
shunt in the first months of life. Growth failure and congestive heart failure 
may raise the question of early cardiac surgery. This is a treacherous situation 
because any left-sided heart disease (e.g., myocardial disease) may have upset 
the balance of bilateral atrial outflow resistance, causing the left-to-right shunt. 
Surgical closure of the defect may uncover the additional problem of myocar­
dial failure, with a disastrous outcome. The simple rule of thumb is to under­
take surgery for isolated atrial septal in early infancy with great caution.
ENDOCARDIAL CUSHION DEFECTS
Defects of endocardial cushion development may be partial, resulting in 
an ostium primum atrial defect, or complete, resulting in additional deficiency 
of the interventricular septum and a common atrioventricu-lar valve (i.e., com­
plete atrioventricular canal). The atrioventricular valves, particularly the ante­
rior mitral valve leaflet, are usually malformed, deficient, or abnormally at­
tached to the ventricular septum. With ostium primum defect, there is usually 
a cleft in the mitral valve and frequently mitral regurgitation. In complete 
atrioventricular canal, the primitive atrioventricular valve floats like a sail over 
both ventricles. This malformation results in a large communication between 
the right and left atria and the right and left ventricles. Significant mitral in­
competence or tricus-pid incompetence is less common than in those with only 
an ostium primum defect. Occasionally, but more often in those without 
trisomy 21, the mitral valve has abnormal chordal attachments and is 
stenotic. The large atrioventricular valve is rarely primarily centered over one 
ventricle, and the contralat-eral ventricle is much smaller than normal. Endo­
cardial cushion defects as primary lesions account for 4% of all newborns with 
serious heart disease.
Forty percent of infants with Down syndrome have congenital heart dis­
ease, predominantly complete atrioventricular canals. Because babies who 
have Down syndrome have a tendency to underventilate, causing pulmonary 
venous oxygen unsaturation, they may have pulmonary hypertension that, 
associated with a common atrioventricular canal, may limit left-to-right 
shunting to amounts that do not produce a murmur. All infants with Down 
syndrome should be examined for congenital heart disease. An ECG to show 
the leftward superior axis of the atrioventricular canal or an echocardio­
gram to show the anatomy is routinely required in the workup o f these
PATHOPHYSIOLOGY
The hemodynamic consequence of an ostium pri/mum atrial septal 
defect is volume overload, which is caused by a left-to-right shunt across 
the atrial septal defect or regurgitation from the left ventricle to the right
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atrium through the cleft mitral valve. The large volume load, particularly 
if aggravated by an additional overload caused by mitral regurgitation, re­
sults in congestive heart failure, which is often severe. Streaming o f infe­
rior vena cava blood across the large, low-lying defect and cleft common 
valve leads to mild systemic arterial oxygen unsaturation. In complete 
atrioventricular canal, there is an additional left-to-right shunt through a 
ventricular septal defect and right ventricular and pulmonary artery hy­
pertension at a systemic level. Infants with pulmonary artery hyperten­
sion are particularly susceptible to the development of pulmonary vascu­
lar obstructive disease and its complications in later childhood.
There was no murmur. At catheterization of the girl at 6 months of age while breath­
ing room air, the pulmonary resistance was high; there was no left-to-right shunt, and 
she had arterial oxygen unsaturation. (B) When breathing oxygen, a large left-to-right 
shunt developed and the estimated pulmonary resistance fell sharply. The percentages 
indicate oxygen saturation; the numbers in italics are pressure measurements.
CLINICAL FINDINGS
Infants with ostium primum atrial septal defects who are sympto­
matic in the neonatal period usually have severe mitral regurgitation. 
Growth retardation may be marked, and weight lags considerably behind 
height maturation. Recurrent pulmonary infections are common. With 
atrioventricular canal, there is frequently mild cyanosis. Cardiac impulse is 
hyper-dynamic, and Si is obscured by a loud pansystolic murmur audible 
at the apex or left sternal border. There is usually pulmonary hypertension, 
and the S2 is accentuated. A loud S3 and an apical middiastolic rumble are 
often heard. Occasionally, particularly among neonates with Down syn­
drome, there may be no perceptible auscultatory abnormality. The chest ra­
diograph shows cardiac enlargement, sometimes out of proportion to the
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increased pulmonary vasculature, attributable to the large atria. The main 
pulmonary artery segment is prominent, and there is pulmonary vascular 
engorgement. The ECG characteristically shows a left superior QRS axis in 
the frontal plane, commonly 0° to -60° in primum defects and -60° to - 
100° in complete canal with a small Q wave in lead aVL. Significant right 
ventricular hypertrophy usually indicates right ventricular hypertension 
(Fig. 8). Echocardiography demonstrates the anatomic features relevant to 
surgical repair, including the anatomy of the atrioventricular valve with its 
chordal attachments, papillary muscles, ventricular relationships, and pos­
sible regurgitation or stenosis of the atrioventricular valves (Fig. 9). Patients 
with complete atrioventricular canals may require cardiac catheterization to 
determine the pulmonary vascular resistance and the presence of associated 
lesions. Selective left ventriculography in the case of complete atrioventricu­
lar canal shows a posterior inlet ventricular septal defect straddled by a 
common atrioventricular valve and a goose-neck sign in the left ventricular 
outflow. The latter results from diastolic anterior movement of the superior 
segment of the anterior mitral valve leaflet, producing an elongated and 
horizontal left ventricular outflow tract.
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FIG. 8. Electrocardiogram of infant with endocardia! cushion defect shows the characteris­
tic left axis deviation.
TREATMENT
In many patients, palliative or corrective surgery has to be performed in 
infancy because of refractory congestive heart failure or pulmonary hyperten­
sion. Treatment with digitalis and diuretics may result in sufficient improve­
ment in growth and respiratory work to delay operative repair for several 
months. In some with refractory symptoms of congestive heart failure, after­
load reduction may help. In infants with complete atrioventricular canals, there
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is pulmonary artery hypertension, and surgery is mandatory within the first 
year to prevent irreversible pulmonary vascular changes.
Primary complete repair is the preferred treatment. This entails cardio­
pulmonary bypass, atriotomy, patch closure of the atrial and ventricular septal 
defects, and attachment of the common valve leaflet to the patch or patches. In 
infants with refractory congestive heart failure weighing less than 2.5 to 3 kg 
or those with serious confounding noncardiac illness (e.g., duodenal atresia), 
pulmonary artery banding may be helpful, with complete repair accomplished 
later. Children with isolated uncomplicated ostium primum atrial septal de­
fects and few symptoms can undergo complete repair without cardiac cathe- 
teriza-tion at several years of age. The long-term prognosis after surgery is ex­
cellent. There is often some postoperative regurgitation of the atrioventricular 
valve, but in most infants, this is not a significant problem. Systemic vasodila­
tors can reduce the volume of regurgitation and may help preserve ventricular 
function in patients with significant postoperative mitral regurgitation. Late 
dysrhythmias occasionally occur. When there is severe mitral regurgitation, 
closure of the septal defect with valvuloplasty may result in clinical improve­
ment, but residual mitral regurgitation may later require valve replacement. 
Without surgery, the prognosis is poor. Only 50% of patients with endocardial 
cushion defects who become symptomatic in the first month of life survive be­
yond 1 year of age without surgical treatment, and many of these have con­
siderable delays in growth.
FIG. 9. Echocardiographic apical four-chamber view of an infant with trisomy 21 
and complete atrioventricular canal defect. < - primum atrial septal defect; > - poste­
rior inlet ventricular septal defect; LA - left atrium, LV - left ventricle; RA - right 
atrium; RV - right ventricle.
L-TRANSPOSITION OF THE GREAT ARTERIES
In L-transposition of the great arteries with situs solitus, also called cor­
rected transposition, the circulation is physiologically corrected. The systemic
95
venous blood enters the right atrium and flows into a right-sided, morphologi­
cally left, ventricle and out to the pulmonary artery. Pulmonary venous blood 
returns to the left atrium and by way of the tricuspid valve into the left-sided, 
morphologically right, ventricle to the aorta. The aorta is abnormally posi­
tioned, anterior and usually to the left of the pulmonary artery. The hemody­
namic changes in patients with L-transposition of the great arteries are caused 
by the commonly associated cardiac abnormalities that include ventricular sep­
tal defect (50%), single ventricle (42%), pulmonary stenosis or atresia (45%), 
and left atrio-ventricular valve regurgitation (23%). Conduction disturbances 
and arrhythmias, particularly complete heart block, are common, and this di­
agnosis should always be considered for a newborn with complete heart block. 
Medical management and surgery are directed toward correction or palliation 
of the associated cardiovascular malformations, such as closure of the ventricu­
lar septal defect, pulmonary valvotomy, and a cardiac pacemaker if needed.
ARTERIOVENOUS MALFORMATIONS
Malformation of the developing peripheral vascular system can result in 
abnormal connections of arteries, arterioles, and capillaries to the venous sys­
tem (i.e., arteriovenous fistulae) that create a large shunt. These fistulae can 
involve vessels of any size and location. Capillary hemangiomas involve ongo­
ing abnormal neovascularization. Although most infants with arteriovenous 
malformations have no other cardiovascular anomaly, abnormal congenital sys- 
temic-to-pulmonary vascular corrections can occur with tetralogy of Fallot 
with pulmonary atresia, partial anomalous pulmonary venous connection (i.e., 
scimitar syndrome), and bronchopulmonary sequestration. Some infants with 
prolonged respiratory disease complicated by pneumothorax requiring multi­
ple chest tubes may develop collateral vessels from systemic arteries in the 
chest wall to the pulmonary arteries, resulting in a left-to-right shunt physio­
logically mimicking a patent ductus arteriosus but usually heard in a differ­
ent location.
PATHOPHYSIOLOGY
Although most infants do not develop cardiovascular symptoms, a large 
systemic arteriovenous malformation can result in significant left-to-right shunt 
and congestive heart failure. Symptomatic babies usually have connections of 
relatively large arteries and veins in the cerebral or hepatic vasculature. Pulmo­
nary arteriovenous malformations result in an intrapulmonary right-to-left 
shunt and cyanosis, but they do not produce congestive heart failure.
CLINICAL FINDINGS
Arteriovenous fistula is one of the few cardiovascular defects that may 
produce severe congestive heart failure in the first day of life. Cardiovascular 
shock may be the predominant clinical picture. There may be a hyperdynamic 
precordium and pulses, flow murmur, severe congestive heart failure, and
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cyanosis. Bruits over the fontanelle, posterior neck, or abdomen may be audi­
ble, and there may be an enlarged head or liver. Echocardiography can dem­
onstrate biventricular dilation and sometimes an enlarged cava with increased 
flow. Arterial contrast injection demonstrates systemic arteriovenous fistulae. 
Systemic venous or pulmonary artery injection of contrast demonstrates pul­
monary arteriovenous malformations. Ultrasonography, computed tomogra­
phy, MRI, and angiography may be useful in finding and delineating the le­
sion.
TREATMENT
Malformations causing congestive heart failure usually do not sponta­
neously improve, except for capillary malformations that may respond to 
steroid or antiangiogenic drugs such as interferon. Large vessel malformations 
require mechanical occlusion. Surgery carries a considerable risk, and tran­
scatheter occlusion with a variety of devices, including coils and detachable 
balloons, has been successful in many, usually older patients.
CYANOTIC LESIONS
The differential diagnosis of cyanotic heart disease includes many dis­
orders (Table 14). Lesions usually associated with normal or decreased pul­
monary flow include the tetralogy of Fallot, pulmonary stenosis, tricuspid 
atresia, pulmonary atresia with intact ventricular septum, and Ebstein dis­
ease. Cyanotic lesions usually associated with increased pulmonary vascular 
markings include D-transposition of the great arteries, hypoplastic left 
heart syndrome, total anomalous pulmonary veins, truncus arteriosus, sin­
gle ventricle, and malpositions.
TETRALOGY OF FALLOT
The tetralogy of Fallot is characterized by a large ventricular septal de­
fect and infundibular pulmonary stenosis or pulmonary atresia. The right ven­
tricular in-fimdibulum is hypoplastic and narrow, and right ventricular hy­
pertrophy is evident. There is often considerable valvar pulmonary stenosis, 
hypoplasia of the pulmonary arteries, a relatively large ascending aorta, and 
a right aortic arch (25%). In infants with pulmonary atresia, pulmonary 
perfusion occurs by way of a patent ductus arteriosus or by systemic to 
pulmonary arterial collateral vessels. Five percent of patients have abnor­
mal coronary distribution that may influence later surgical correction. 
Tetralogy is one of the most common cyanotic congenital heart lesions 
presenting in the newborn period and is occasionally (10%) associated with 
severe extracardiac malformations.
PATHOPHYSIOLOGY
Depending on the severity of right ventricular outflow obstruction, 
there may be intracardiac left-to-right or right-to-left shunt and hypoxemia.
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Table 14
Differential diagnosis of cyanotic heart disease
Diagnosis Physical Examination Radiographic findings Electrocardio­
graphic findings
Hypoplastic left 
heart syndrome
Single S2, |  respiratory 
work, |  pulse ampli­
tude, J. perfusion, +/- 
SRM
T Pulmonary arterial mark­
ings, cardiomegaly
Develops LV force 
usually, develops 
RAE, RAD, RVH
Transposition of 
great arteries 
(IVS, VSD)
Split S2, +/- murmur, 
+/- t  respiratory work 
(i.e., peaceful cyanosis)
t  Pulmonary arterial mark­
ings, +/- cardiomegaly with 
narrow mediastinum (i.e., 
“egg on a string”)
Develops RAE, 
RAD, RVH
Truncus arteri­
osus
Split S2, +/- multiple 
clicks, soft to loud 
SEM, +/- DRM, t  res­
piratory work
t  Pulmonary arterial mark­
ings, cardiomegaly
Develops RAE, 
RAD, RVH
Total anomalous 
pulmonary ve­
nous connection
Narrow S2 split, +/- 
murmur, T respiratory 
work
t Pulmonary venous mark­
ings, t  diffuse interstitial 
markings
Develops RAE, 
RAD, RVH
Tricuspid atresia 
Without PS
Split S2, heave, SRM t Pulmonary arterial mark­
ings, cardiomegaly
Left axis deviation
With PS Single S2, SEM i Pulmonary arterial mark­
ings, +/- cardiomegaly
Tetralogy of Fal­
lot
With PS
Single S2, SEM +/- 1 Pulmonary arterial 
markings, +/- bootshaped 
heart
Develops RAE, 
RAD, RVH
With PA Single S2, continuous 
murmur, LSB back, 
axillae
T, J Pulmonary arterial mark­
ings and heart size
Pulmonary 
stenosis (IVS or 
SV)
Single S2, click, SEM [ Pulmonary arterial mark­
ings
In IVS QRS axis 0- 
100, Develops 
RAE, RAD, RVH
Pulmonary 
atresia (IVS or 
SV)
Single S2,soft SRM i Pulmonary arterial mark­
ings
In IVS QRS axis 0- 
80, 1 RV forces, +/- 
develops Q waves
Persistent pul­
monary hyper­
tension
Narrow split or single 
S2, j  S2 loudness, +/- 
SRM
i Pulmonary arterial mark­
ings, +/- parenchymal infil­
trates, +/- cardiomegaly
Develops RAE, 
RAD, RVH
•Single ventricle is usually associated with transposition of the great arteries, and in the ab­
sence of PS or PA, it presents similar to transposition with ventricular septal defects.
+/- - may or may not be present; |  - decreased; T - increased; BVH - biventricular hypertrophy; 
DRM - diastolic regurgitant murmur; IVS - intact ventricular septum; LSB - left sternal border; 
LV - left ventricle; PA - pulmonary atresia, PS - pulmonary stenosis; RAD - right axis devia­
tion; RAE - right atrial enlargement; RV - right ventricle; RVH - right ventricular hypertrophy; 
SEM - systolic ejection murmur; SRM - systolic regurgitant murmur; SV - single ventricle; 
VSD - ventricular septal defect.
Pressures equalize between the ventricles through the large septal de­
fect. The amount of pulmonary blood flow depends on the severity of right 
ventricular outflow obstruction, the systemic vascular resistance, existence
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of a ductus arteriosus, and the possible presence of systemic to pulmonary 
arterial collateral supply to the lung. The extent of systemic venous admix­
ture (i.e., right-to-left shunt by way of the septal defect) is directly related to 
the severity of the pulmonary stenosis and inversely related to the systemic 
vascular resistance. The peripheral arterial oxygen saturation depends on the 
amount of venous admixture and the absolute pulmonary flow. For exam­
ple, in pulmonary atresia with a ventricular septal defect, the entire right 
heart output passes right to left through the ventricular defect, and pulmo­
nary flow is supplied by a ductus arteriosus or collateral vessels and is usu­
ally less than normal. Cyanosis is the result. If the newborn has large aor- 
topulmonaiy collateral vessels perfusing the lung, pulmonary blood flow 
may be large, and the infant may be barely cyanotic and rarely may have 
congestive heart failure.
Tetralogy of Fallot is a progressive lesion. Twenty-five percent of pa­
tients are clinically cyanotic at birth, 75% are affected by 1 year, and by 20 
years of age, almost all have become cyanotic. Infundibular hypoplasia and 
stenosis is progressive, and with time, complete atresia can occur. A patent 
ductus arte-riosus usually closes within the first week of life, resulting in se­
vere and often sudden hypoxemia or cyanotic spells.
Hypoxemia, particularly of rapid onset such as during a hyperpneic 
spell secondary to a temper tantrum with infundibular spasm, to systemic 
vasodilation after meal or bath, or to constriction of a ductus arte-riosus, may 
initiate a fall in systemic vascular resistance, metabolic acidosis, and further 
hypoxemia and hyperpnea. Hyperventilatory compensation for the meta­
bolic acidosis may be ineffective because of inadequate pulmonary blood 
flow. The self-aggravating cycle of increasing hypoxemia and metabolic aci­
dosis can produce coma and convulsions.
CLINICAL FINDINGS
Various degrees of cyanosis and mild tachypnea are often observed 
soon after delivery. If hypoxemia is severe, the infant may be hypotonic and 
hypotensive with a slow heart rate. Hyperpneic spells characterized by a 
sudden onset of irritability, hyperpnea, and increasing cyanosis may develop. 
Spells may end in a loss of consciousness, seizures, cerebral injury, hemi- 
paresis, or death. The disappearance of a previously heard right ventricular 
outflow systolic murmur with increased cyanosis suggests a spell and consti­
tutes an indication for immediate therapy.
There is a systolic murmur at the left sternal border, and the second 
heart sound is single. In a newborn with pulmonary atresia, the systolic 
murmur is absent; there may be a constant apical systolic ejection click and 
prominent continuous murmurs of a patent ductus arteriosus or aortopul­
monary collaterals, audible at the base, in the axillae, or over the back. A 
patent ductus arteriosus usually does not cause continuous murmur in the
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first months of life, therefore, the presence of murmurs with cyanosis and a 
single S2 in a neonate strongly suggests tetralogy of Fallot with pulmonary 
atresia. Delay in height, weight, and skeletal maturation is common, but 
some infants flourish despite severe hypoxemia. Some young infants with 
the anatomic but acyanotic tetralogy of Fallot experience congestive heart 
failure, later recovering from congestion and becoming cyanotic. Rarely, 
congestive heart failure is seen in an infant with pulmonary atresia and very 
large aortopulmonary collaterals. Although subacute bacterial endocarditis 
and brain abscess are common in older children with tetralogy of Fallot, 
these complications are extremely rare in infancy. However, spontaneous 
cerebrovascular accidents are common, particularly in infants with severe hy­
poxemia and relative anemia (<6-8 g/dL of oxyhemoglobin).
The chest radiograph shows a normal-sized heart, sometimes with right 
ventricular enlargement resulting in an upturned apex and an absent or dimin­
ished main pulmonary artery segment (r'.e., boot-shaped heart), diminution of 
the pulmonary vasculature, and in 25%, the aorta arching to the right. The 
ECG demonstrates right axis deviation, right atrial hypertrophy, and right ven­
tricular hypertrophy, but at birth, it may be difficult to differentiate from nor­
mally prominent right ventricular forces. The echocardiogram shows anterior, 
leftward deviation of the infundibular septum, creating subpulmonary stenosis 
and a malalignment ventricular septal defect with a large overriding aortic 
root (Fig. 10). Additional ventricular or atrial septal defects, central pulmo­
nary artery hypoplasia, and coronary artery anatomy can often be assessed by 
echocardiography but may require cardiac catheterization. Determining the 
possible presence of distal pulmonary artery stenosis and the anatomy of sys­
temic arterial to pulmonary arterial collaterals requires angiography.
TREATMENT
Treatment depends on the severity of the lesion. The newborn with 
tetralogy of Fallot and little or mild cyanosis should be carefully observed and 
repeated transcutaneous measurements of systemic oxygen saturation made 
until a stable level is apparent. Hyperpneic spells should be treated with oxy­
gen, intramuscular or subcutaneous morphine sulfate (0.1 mg/ kg), intrave­
nous administration of saline boluses and sodium bicarbonate (approximately 
1 mmol/kg), and if needed, phenylephrine (0.1 mg/kg subcutaneously; 5-20 
pg/kg by intravenous bolus; 0.1-0.5 pg/kg/minute by intravenous infusion) ti­
trated to elevate systemic vascular resistance and pressure. Prostaglandin ei 
may open a ductus arteriosus in the cyanotic newborn infant and improve 
pulmonary perfusion. Prcypranolol may be of some value in treating the infant 
with a reactive infundibulum. The hemoglobin concentration should be main­
tained high enough to permit adequate oxygen transport. The occurrence of a 
single hyperpneic spell is an indication for surgery, possibly as an emergency 
procedure.
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In the past, critically ill infants who required surgery underwent pallia­
tive procedures, usually a shunt between the subclavian artery and branch 
pulmonary artery (i.e., Blalock-Taussig). The shunt was ligated during a 
reparative operation when the child was older. Infants with uncomplicated 
tetralogy of Fallot requiring surgery now undergo one-stage reparative proce­
dures with excellent results. The right ventricular outflow tract is enlarged 
with a pericardial patch, and the ventricular septal defect is closed with a Da­
cron patch. There are several potential sequelae, including late dysrhythmias, 
but most patients with uncomplicated tetralogy of Fallot have an asympto­
matic long-term course. Those with anomalous origin of the left anterior de­
scending coronary from the right coronary artery and those with pulmonary 
atresia and hypoplastic distorted pulmonary arteries may require a palliative 
shunt with a more definitive repair, entailing a conduit from the right ventricle 
to the pulmonary artery when the child is older.
In general, the earlier severe hypoxemia develops, the more severe is 
the tetralogy of Fallot and the poorer the prognosis without surgery. The over­
all mortality rate without surgery is approximately 35% by 1 year of age.
FIG. 10. Echocardiographic (A) subxiphoid and (B) parasternal short axis views of an infant 
with tetralogy of Fallot. Anterior deviation of the conal septum (above the arrow ) is associ­
ated with malalignment ventricular septal defect and obstruction of the right ventricular out­
flow. (—»- ventricular septal defect; :- narrowed right ventricular outflow; ANT- anterior; 
AV- aortic valve; LA- left atrium; LV- left ventricle; LVOT- left ventricular outflow tract; 
PA- pulmonary artery; RA- right atrium; RV- right venticie.)
DIFFERENTIAL DIAGNOSIS
The features of cyanosis, a harsh systolic ejection murmur, chest radio- 
graphic findings of diminished pulmonary vasculature with a normal-sized 
heart, and ECG evidence of right ventricular hypertrophy are characteristic of 
tetralogy of Fallot (see Table 14). The same findings with a continuous mur­
mur suggest tetralogy of Fallot with pulmonary atresia. A few infants with
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tetralogy of Fallot and an underdeveloped pulmonary valve present with a 
characteristic to-and-fro murmur (i.e., steam engine sound) and severe respira­
tory distress caused by bronchial or tracheal compression by aneurysmally 
dilated pulmonary arteries.
PULMONARY STENOSIS
Pulmonary stenosis is probably the most common form of congenital 
heart disease discovered by hearing a murmur. The abnormality is often a nar­
rowing of the proximal pulmonary artery branches though minor obstructions 
at the pulmonary valve are equally common. Even minimal obstruction (<10 
torr across the obstruction) produces a readily audible murmur, frequently re­
sulting in a request for an echocardiogram. Rarely, valvar obstruction is se­
vere enough to require intervention. Symptomatic peripheral pulmonary 
stenosis is rare and is usually associated with other problems, such as tetral­
ogy of Fallot, Williams syndrome, and infants bom of mothers with rubella.
The common valvar and proximal peripheral pulmonary arteiy obstruc­
tions are usually mild and can be located by echocardiography. Infundibular 
(i.e., subvalvar) obstruction as an isolated lesion is rare; its presence usually 
indicates an associated ventricular defect. Severe valvar obstruction may oc­
cur with cyanosis because of right-to-left shunting through a foramen ovale or 
may present with the findings of right-sided congestive heart failure. If the ob­
struction is severe, the valve is immobile, and there is dilation and hypertro­
phy of the right ventricle; the velocity measured across the pulmonary valve 
by Doppler technique indicates a high pressure gradient.
Only reassurance and observation are required for the mild stenoses be­
cause progressive obstruction is rare. Moderate obstructions in early infancy 
become progressively worse with growth, and the patients should be periodi­
cally examined with this in mind. The severe obstructions are relieved by 
catheter balloon dilation or surgery. Bacterial endocarditis is rare, but the ad­
ministration of antibiotics for prophylaxis prior to the procedure is rec­
ommended.
TRICUSPID ATRESIA
Tricuspid atresia is a relatively uncommon disease that is character­
ized by absence of the tricuspid valve. Except in rare cases, no valve exists, 
and tricuspid agenesis is therefore a more precise description of this anom­
aly.
PATHOPHYSIOLOGY
The entire systemic venous return (i.e., cardiac output) enters the 
right atrium and exits through the foramen ovale to the left heart. The sys­
temic and pulmonary venous streams are mixed in the left atrium. After pas­
sage to the left ventricle, the cardiac output passes to the aorta, and an 
amount equal to the pulmonary flow gains access to the pulmonary artery
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through a ventricular septal defect, a diminutive right ventricle, and various 
degrees of pulmonary stenosis. Flow to the pulmonary artery is limited by 
the size of the ventricular defect or the amount of pulmonary stenosis. Occa­
sionally, the great vessels are transposed, with the aorta arising from the 
right ventricle, and the systemic output may be limited by the size of the 
ventricular defect. The level of cyanosis is determined by the amount of pul­
monary blood flow. In early infancy, the pulmonary blood flow can be in­
creased by a patent ductus arteriosus and subsequent Blalock-Taussig shunt. 
The ultimate goal is to provide the connections for Fontan physiology. Sev­
eral methods of connecting the systemic venous return directly to the pulmo­
nary arteries are used. In effect, the pulmonary circulation is supplied by pas­
sive flow, bypassing the heart. The normal postnatal elevation in pulmonary 
vascular resistance prevents this from being successful in young infants. In 
older children, these operations are surprisingly successful and last many 
years, although just how long remains to be determined.
CLINICAL FINDINGS
The babies are discovered to have cyanosis during the first months of 
life. Some have a systolic murmur; diastolic murmurs are rare. On chest ra­
diographs, the heart is usually of normal size or minimally enlarged, and the 
pulmonary vasculature is diminished. Unlike most other cyanotic lesions, the 
ECG shows a leftward superior axis similar to endocardial cushion defects 
but usually with diminished right precordial forces. The diagnosis is readily 
confirmed by echocardiographic identification of a diminutive right ventricle, 
an absent tricuspid valve, and right-to-left flow through the foramen ovale.
TREATMENT
Infants with severe obstruction of blood flow through the ventricular 
septal defect and right ventricle may require infusion of prostaglandin ei prior 
to palliative surgery. A shunt from an aortic branch to pulmonary artery al­
lows an excessively cyanotic infant to grow. Sometime after the age of 1 to 3 
years, variations on the Fontan operation are possible. About 75% of infants 
with tricuspid atresia survive with Fontan physiology.
Rarely, in an infant with a large ventricular defect and no pulmonary 
stenosis, the pulmonary blood flow may be excessive enough to cause con­
gestive heart failure. Anticongestive medications are usually sufficient to al­
low growth, although a pulmonary artery banding procedure may be neces­
sary to diminish pulmonary vascular pressure and resistance.
PULMONARY ATRESIA WITH INTACT VENTRICULAR SEPTUM
When the pulmonary valve is atretic and there is no ventricular septal 
defect, blood cannot pass through the right ventricle in the fetus, and the right 
ventricle cavity is frequently coarsely trabeculated and the size of a prune pit.
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There is membranous pulmonary valvar atresia and, in approximately one- 
third of the cases, associated infundibular stenosis, hypoplasia or atresia. The 
tricuspid valve annulus is small and may be stenotic or incompetent. There 
are often fistulous tracts connecting the right ventricular sinus to the distal 
coronary arteries, commonly with proximal coronary artery stenosis and 
myocardial fibrosis. The pulmonary arteries are of adequate size and are per­
fused through a patent ductus arteriosus or rarely through aortopulmonary 
collaterals. An interatrial communication is essential to survival. Pulmonary 
atresia with an intact ventricular septum is rarely associated with other car­
diovascular or somatic malformations.
PATHOPHYSIOLOGY
The major hemodynamic consequences of pulmonary atresia with in­
tact septum is the obligatory right-to-left passage o f the total systemic ve­
nous return through the foramen ovale to the left atrium. A patent ductus 
arteriosus provides the only entrance to the pulmonary circulation. As it 
closes, pulmonary perfusion is greatly reduced and results in severe hy­
poxemia, metabolic acidosis, and death. The right ventricle, despite its se­
vere hypoplasia and poor compliance, usually generates suprasystemic 
pressures. This is probably true in utero as well, and explains the frequent 
tricuspid incompetence with right atrial enlargement and the development 
of fistulae that drain blood from the right ventricle into the coronary artery.
Surgical establishment o f continuity between the right ventricle and the 
pulmonary artery may result in sufficient decompression of the right ven­
tricle to cause hypoperfusion of coronary beds supplied by fistulae from 
the right ventricle to coronary artery. There is often proximal coronary ar­
tery obstruction, in which case right ventricular decompression may reduce 
coronary blood flow enough to produce myocardial infarction. The size of 
the infarct and its impact directly correlate with the area of distribution of 
the coronary vessel involved.
CLINICAL FINDINGS
Most infants with pulmonary atresia are critically ill within the first 
week of life because of severe hy-poxemia. With postnatal ductal constric­
tion, severe cyanosis, hypotension, bradycardia, hypotonia, and marked 
acidosis occur. Signs of right-sided failure may develop but are usually ab­
sent. The precordium is quiet, and there is no thrill. S2 is single, and there is 
often a pansystolic murmur of tricuspid incompetence. On the chest radio­
graph, the heart may appear mildly enlarged, the lung fields are ischemic, 
and the aortic arch is on the left (Fig. 11). The ECG usually reveals a QRS 
axis in the frontal plane between 0° and 80°, absent or diminished right ven­
tricular forces, and a pattern of left ventricular hypertrophy.
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An echocardiogram shows normal or somewhat enlarged left-sided 
structures, a small tricuspid valve and right ventricle, and atresia of the 
pulmonary valve. If there is membranous atresia of the pulmonary valve, 
the membrane moves like a true valve, and the diagnosis cannot be made 
with certainty without a Doppler flow examination. Color Doppler can help 
to delineate fistulas between the right ventricle and the coronary arteries. Af­
ter the presumptive diagnosis is made, prostaglandins can be given to di­
late the ductus arteriosus and increase pulmonary blood flow. There should 
be rapid improvement in oxygenation and relief of acidosis. Cardiac cathe- 
teri/Zation is indicated as soon as the diagnosis is made. Selective ventricu­
lography and ascending aortography to delineate the coronary arteries are 
essential for planning surgery.
FIG. 11. A chest radiograph shows decreased pulmonary vascularity and mild cardio- 
megaly in a 1-day-old infant with pulmonary atresia and an intact ventricular septum.
TREATMENT
After stabilization with prostaglandins, the treatment of choice is sur­
gery, which is indicated as soon as feasible after the anatomy is established 
by catheterization. For infants with an adequately sized right ventricle, pul­
monary valvotomy or valvectomy is performed. Some infants may require 
placement of a patch across the right ventricular outflow tract and valve an­
nulus for adequate relief of obstruction. In infants with severe right ventricu­
lar hypoplasia and a noncompliant right ventricle, a systemic-to-pulmonary 
shunt also may be necessary for relief o f  hypoxmia. After a period during 
which the right ventricular capacity and compliance improves and the pul­
monary vascular resistance decreases, these infants may no longer require 
shunts for maintenance of adequate pulmonary blood flow. Even infants with 
initially diminutive right ventricular chambers usually demonstrate some 
growth of the chamber if flow through the ventricle is provided by estab­
lishing continuity between the right ventricle and pulmonary artery. The 
right ventricle cannot be decompressed in infants who have fistulas between 
the right ventricle and coronary arteries and stenoses involving at least 
two separate proximal coronary vessels, without risk of fatal infarction. 
These infants may require a staged approach with an initial neonatal shunt
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and a later Fontan-type cavopulmonary anastomosis or transplantation. 
Without therapy, the malformation is usually fatal, and with surgical treat­
ment, about 75% of these newborns survive to 1 year o f age.
DIFFERENTIAL DIAGNOSIS
Pulmonary atresia with an intact septum should be differentiated 
from others causing severe cyanosis in the first week of life. Tetralogy of 
Fallot or pulmonary atresia with a ventricular septal defect and transposition 
of the great arteries with an intact ventricular septum are associated with 
ECG evidence of right ventricular hypertrophy. Infants with tricuspid atresia 
or endocardial cushion defect and pulmonary stenosis have a superior fron­
tal plane axis on the ECG. Critical valvar pulmonary stenosis is accompanied 
by a systolic ejection murmur, congestive heart failure, moderate or marked 
cardiac enlargement, and right ventricular hypertrophy. Critical pulmonary 
stenosis with a diminutive right ventricle can be delineated by echocardi­
ography. In Ebstein anomaly of the tricuspid valve, the precordium is quiet, 
and cardiac enlargement is severe (Fig. 12).
EBSTEIN DISEASE
Examples of Ebstein disease are encountered rarely in the newborn pe­
riod. The septal leaflet of the tricuspid valve is displaced downward and ad­
heres to the ventricular septum to various degrees. The result is a spectrum 
of dysfunctioning tricuspid valves that are regurgitant and sometimes 
stenotic. The dysfunction is compounded by the fact that the right atrium 
and right ventricle contract at different times, and there is an area of atrial- 
ized ventricle or ventricularized atrium, depending on the point of view. 
This discordant pumping of parts of each chamber contributes to the 
dysfunction. Those with severe prenatal tricuspid regurgitation often have 
massive cardiomegaly and may have pulmonary hypoplasia. The effective 
right ventricular volume is reduced, and there is limited passage of blood 
through the right ventricle. Some blood escapes through the PFO, causing 
cyanosis. The severity of the defect can be described by the degree of 
cyanosis that, in the newborn period, can be severe because of the 
concomitant unresolved elevation of the pulmonary vascular resistance left 
over from fetal life. As the newborn’s pulmonary vascular resistance 
regresses, the cyanosis often improves, sometimes markedly, although 
babies with severe re-gurgitation and pulmonary hypoplasia have a high 
mortality rate. After surviving the newborn period, the course is determined 
by the degree of abnormality; some patients survive into late adulthood 
without important limitation, but others remain cyanotic and prone to 
arrhytEbskasn disease is recognized because of minimal systolic or diastolic 
murmurs, extra heart sounds, absent to severe cyanosis, and cardiomegaly 
that may vary from minimal to some of the largest hearts encountered in the
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newborn period (see Fig. 12). The diagnosis is established by echocardi­
ography. Treatment is usually supportive. The pediatrician can recognize 
that the degree of displacement of the tricuspid valve may be so slight that 
the diagnosis becomes a matter of definition, which is not firmly established 
for this rare disease. The diagnosis of mild Ebstein disease may be errone­
ous and is of no known importance.
FIG. 12. A chest radiograph of a 1-day-old cyanotic infant with Ebstein anomaly of the
tricuspid valve shows marked cardiomegaly.
D-TRANSPOSITION OF THE GREAT ARTERIES
With transposition of the great arteries, the aorta arises from and 
above the right ventricle and the pulmonary artery from the left ventricle. In 
the commonest form, D-transposition, the aorta is anterior to and to the 
right of the pulmonary artery, rather than in its normal rightward and poste­
rior position.
Transposition of the great arteries is one of the commonest congenital 
heart lesions presenting in the newborn period and is a frequent cause of 
death among unoperated neonates with congenital heart disease. The male- 
female ratio is 1.8:1, and the average birth weight is greater than that for 
other patients with congenital heart disease, although not for the general 
population. Transposition is frequently associated with other cardiac ab­
normalities, including ventricular septal defect, patent ductus arteriosus, 
hypoplastic right ventricle, and coarctation.
PATHOPHYSIOLOGY
The systemic and pulmonary circulations are normally in series with 
each other, but in complete transposition, the circulations are in parallel. 
Systemic venous blood returns to the right atrium, enters the right ventri­
cle, and exits through the aorta. Pulmonary venous blood, coming from the 
iung, enters theleft atrium and the left ventricle, and then returns to the pul­
monary arteries and the lungs. Without some communication between the 
pulmonary and systemic circulations, survival is impossible; oxygenated blood 
cannot be delivered to the systemic circulation, nor can systemic venous
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blood pick up oxygen in the lung. An atrial communication, ventricular de­
fect, or patent ductus arteriosus, singly or in combination, may provide for 
mixing between the circulations (Fig. 13). The foramen ovale and ductus ar­
teriosus, both normally patent in the fetus, usually close soon after birth. In­
fants with transposition and intact ventricular septum become extremely 
cyanotic within the first few hours or days after delivery, as closure of the fo­
ramen ovale and ductus arteriosus occurs and mixing between the circula­
tions diminishes (Fig. 14). The severe hypoxemia may lead to metabolic 
acidcvsis. Survival depends on prompt supportive medical care and 
reestablishment of patency of the ductus arteriosus and interatrial 
communication to improve mixing and oxygenation.
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50/8
FIG. 13. Transposition of the great arteries with a single membranous ventricular septal 
defect in a l-month-old baby who had mild cyanosis and controlled congestive heart fail­
ure. There is equilibration of pressure between the ventricles and elevation of left-sided 
diastolic pressures. After balloon septostomy, the arterial saturation rose to 75%. The 
percentages indicate oxygen saturation; the numbers in italics are pressure measurements.
Infants born with transposition and a large ventricular septal defect 
are less cyanotic because the ventricular defect allows mixing. These ba­
bies may not be recognized in the newborn period but appear in subse­
quent months with congestive failure. The combination of a large pulmo­
nary flow, pulmonary hypertension, and elevation of left atrial pressure 
leads to the development of congestive heart failure (see Fig. 13) and later 
pulmonary vascular obstructive disease. Anatomic changes during the 
first few months of life may result in important hemodynamic I changes. A 
large ventricular septal defect may spontaneously diminish in size or close, 
reducing mixing I and increasing hypoxemia. Increasing pulmonary I
stenosis may decrease pulmonary flow, and thereby 1 improve congestive 
heart failure. Atrial septal defects I created by balloon septostomy and 
those made by surgical septectomy may spontaneously diminish in size or 
close.
SVC  PUL VEINS
FIG. 14. Transposition with intact ventricular septum in a 1-day-old girl who was cya­
notic at birth. At catheteriza/tion, she had less than systemic pressure in the left (i.e., 
pulmonary) ventricle. The patent ductus arteriosus shunts felood into the pulmonary cir­
cuit, and the foramen ovale shunts an equal amount out of the pulmonary circuit. If this 
were not the case, blood would pile up on one side of the circulation in a matter of min­
utes. If the ductus spontaneously closed/ the infant's condition would become precarious. 
If the ductus were dilated with prostaglandins, the infant would become pinker but might 
experience respirator)' difficulty because of excess pulmonary flow. The percentages in­
dicate oxygen saturation; the numbers in italics are pressure measurements.
CLINICAL FINDINGS
In infants with an intact ventricular septum, cyanosis accompanied by 
mild tachypnea develops soon after birth. Often the infants, though tachyp- 
neic, do not seem distressed (i.e., peaceful cyanosis). The cardiac examina­
tion, chest radiograph, and ECG may be normal. The heart sounds are nor­
mal, and there maybe no significant murmur. The ECG may show some 
excessive right ventricular forces.
On a plain chest radiograph, the heart and pulmonary vascularity may 
be initially normal, although at a few weeks of age, cardiac enlargement, a 
narrow mediastinum, and pulmonary plethora are detected. One of the most 
important diagnostic tests is the determination of arterial partial pressure of 
oxygen (Pa02) in room air and after the inhalation of 100% oxygen for a 10- 
minute period. Failure of the PaO (often <30 torr) to rise significantly is 
strong presumptive evidence for complete transposition. Failure to raise 
systemic arterial 0 2 tension significantly is due to inadequate mixing be­
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tween the pulmonary and systemic circulations. Subcostal echocardiogra­
phy reveals that the great artery arising from the left ventricle has an ab­
normal superior course and then bifurcates into the right and left pulmo­
nary artery. The right ventricle gives rise to a great artery that passes rela­
tively straight superiorly to the posterior arching aorta (Fig. 15). The patency 
of the foramen ovale and ductus arteriosus and the coronary anatomy can 
be assessed.
An infant with transposition and a large ventricular septal defect usu­
ally presents with congestive failure and mild cyanosis between 3 to 6 
weeks of age. Poor weight gain, tachypnea, and excessive diaphoresis are 
evident, and wheezing is common. A loud S3 may produce a gallop rhythm, 
and there is a loud systolic murmur at the lower left sternal border, often as­
sociated with a mid-diastolic flow rumble. Rales may be audible in the 
lungs. The ECG reveals right axis deviation and right atrial and right ven­
tricular hypertrophy. Infrequently, if the right ventricle is hypoplastic, right 
ventricular forces may be absent or reduced, and left ventricular hypertro­
phy is observed. The chest radiograph characteristically shows consider­
able cardiomegaly and pulmonary plethora, Echocar-diography should iden­
tify the location of the ventricular septal defect and its relation to the great 
arteries and the atrioventricular valves and complex associated problems, 
including straddling or abnormal tricuspid valve, hypoplastic right ventricle, 
valvar or subvalvar pulmonary stenosis, coarctation of the aorta, juxtaposi­
tion of the atrial appendages, and anomalous systemic or pulmonary venous 
drainage.
FIG. 15. Echocardiographic subxiphoid view of a neonate with transposition of the great 
arteries. (AO - aorta, ARCH- aortic arch; LA- left atrium; LV- left ventricle; PA- pulmo­
nary artery; RV- right ventricle; < TV- tricuspid valve.)
TREATMENT
After the diagnosis of transposition and intact ventricular septum is es­
tablished by echocardiography, cardiac catheterization is scheduled. Infusion 
of prostaglandin ei to open and maintain patency of the ductus arteriosus
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may improve mixing and systemic oxygenation. Because prostaglandin ei 
may cause apxiea and vasodilation, support with mechanical ventilation, vol­
ume infusion, and sometimes inotropic agents may be required. Some babies 
require, and most do better with, a widely open atrial defect. Balloon atrial 
septostomy usually results in considerable clinical improvement. The anat­
omy of the coronary arteries and associated lesions may also be established 
by catheterization. Echocardiography is also used and advocated by many. 
The type of surgical procedure employed depends on the associated cardiac 
defects. In recent years, there has been renewed interest in "anatomic repair" 
or arterial switch operations in neonates with uncomplicated transposition. 
The aorta and pulmonary arteries are transected and the distal vessels re­
joined to provide normal physiologic connections. A button of proximal aor­
tic tissue surrounding each coronary artery origin is cut, and both coronaries 
with the surrounding aortic button are attached to the neoaorta. Although 
short-term results are similar to the Senning or Mustard atrial switch opera­
tions, midterm results suggest that it is superior to the atrial baffle procedures 
that have long-term difficulties with tricuspid valve and right ventricular 
function and dysrhytlwriias. Atrial baffle procedures are still used if there is 
difficult intracardiac or coronary anatomy.
Without therapy, 95% of infants born with transpositions die within I 
year. With aggressive medical and surgical treatment, mortality has been re­
duced to less than 10%.
DIFFERENTIAL DIAGNOSIS
Most infants with transposition and intact ventricular septum are readily 
recognized as cyanotic infants without significant murmurs and little respira­
tory distress. The diagnosis of transposition of the great arteries is rarely diffi­
cult and is confused only if other abnormalities, such as straddling tricuspid 
valve, hypoplastic right ventricle, coarctation of the aorta, or pulmonary steno­
sis, exist (see Table 14). Depending on the type and severity of the associated 
cardiac malformations, the clinical symptoms and findings in infants with 
complicated transposition of the great arteries may closely resemble those of 
almost any other cyanotic heart lesion.
The clinical picture in infants with transposition of the great arteries, 
ventricular septal defect, and pulmonary stenosis or atresia is virtually indis­
tinguishable from that of tetralogy of Fallot or pulmonary atresia with a ven­
tricular septal defect. If D-transposition of the great arteries is associated with a 
large ventricular septal defect and limited cyanosis, it is sometimes mistaken 
for other lesions with a large left-to-right shunt, such as a ventricular septal de­
fect with normal aortic root or total anomalous pulmonary venous return 
without obstruction. The absence of cyanosis identifies the former, and echo­
cardiography can differentiate all of these anomalies.
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HYPOPLASTIC LEFT HEART SYNDROME
The hypoplastic left heart syndrome encompasses a variety of specific 
cardiovascular malformations producing similar hemodynamic and clinical 
manifestations, including aortic atresia, mitral atresia, premature closure of the 
foramen ovale, hypoplastic left ventricle with critical mitral stenosis, and aortic 
stenosis. Some cases of severe complex coarctation are also included in this 
category. The left heart chamber is usually very small, and endocardial fibroe­
lastosis is common. Hypoplastic left heart syndrome occurs in 10.2% of in­
fants with serious heart disease and is one of the most common lesions present­
ing in the first week of life. It is less common in very premature infants (<1.85 
kg). It is usually an isolated lesion, although it has been described in associa­
tion with autosomal trisomy syndromes and in infants of diabetic mothers. 
Familial cases occur.
PATHOPHYSIOLOGY
Obstruction or atresia of the mitral or aortic valves limits or prevents 
flow through the left heart. The systemic venous return enters the right heart 
and is ejected into the pulmonary artery. The systemic circulation is largely or 
totally supplied by right-to-left flow through the ductus arteriosus. Blood trav­
ersing the lung enters the left atrium, flows through an in-teratrial defect or 
dilated PFO, and returns to the right atrium to join the incoming systemic ve­
nous return. Complete mixing takes place in the right atrium, with similar 
oxygen saturation measured in the right ventricle, pulmonary artery, and aorta. 
With little or no egress through the left heart, pulmonary flow must pass left- 
to-right through an interatrial communication. Any limitation of flow through 
the atrial septum produces pulmonary venous hypertension.
The maintenance of adequate systemic circulation requires patency of 
the ductus arteriosus. In aortic atresia, the ascending aorta, brachiocephalic 
vessels, and coronary arteries are perfused in a retrograde fashion with blood 
originating from the patent ductus arteriosus. Spontaneous constriction of the 
ductus results in low systemic blood flow, poor coronary perfusion, conges­
tive failure, and shock with simultaneous flooding of the pulmonary circula­
tion. Closure of the ductus leads to immediate death because of poor perfusion, 
metabolic acidosis, electrolyte imbalance, and coagulation abnormalities.
CLINICAL FINDINGS
These infants become symptomatic within the first week of life. Conges­
tive failure and a shocklike picture may develop precipitously. The baby be­
comes ashen gray with poor peripheral perfusion, and all pulses are weak. 
Ductal constriction may be intermittent, with femoral pulses intermittently 
palpable. Symptoms and signs of congestive failure are associated with hy­
potension and, terminally, with bradycardia. S2 is usually single, and a gallop is 
heard. The chest radiograph shows cardiac enlargement and pulmonary pleth­
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ora, and the ECG usually demonstrates right axis deviation, right atrial hyper­
trophy, right ventricular hypertrophy, and markedly diminished or absent left 
ventricular forces. The diagnosis can be made with echocardiography by 
demonstrating a very small or unrecognizable left ventricle. The ascending 
aorta is small with retrograde flow in cases of aortic atresia, and there is fre­
quently a discrete juxta-ductal coarctation.
TREATMENT
Without surgery, the mortality rate is 98% by 1 year of age. There are a 
few survivors with mitral atresia or hypoplasia of the left ventricle with severe 
aortic or mitral stenosis. Advances in cardiac surgery have encouraged several 
approaches to infants with this condition. Palliative surgery can be performed 
in the newborn period after stabilization with prostagland/n E, inotropic 
agents, volume infusion, and bicarbonate. Hyperventilation (i.e., arterial par­
tial pressure of carbon dioxide (РаСОг < 40 torr) and unnecessary supple­
mental oxygen administration should be avoided, because these measures 
may lead to a decrease in pulmonary vascular resistance and preferential 
flow of the right ventricular output into the pulmonary vascular bed instead 
of across the ductus to the systemic vasculature, worsening the shock.
Surgical therapy consists of an attempt to convert the circulation to 
Fontan-type physiology or to transplant a new heart. A first-stage procedure 
anastomoses the transected main pulmonary artery to the aortic arch, ligates 
the ductus arteriosus, supplies perfusion to the distal oversewn pulmonary 
artery by creation of a modified Blalock-Taussig or direct central systemic to 
pulmonary artery shunt, and leaves an atrial septectomy to allow unimpeded 
pulmonary venous return to the right atrium. The long-term outlook depends 
on the ability of the right ventricle to support the systemic circulation while 
the pulmonary circulation is supplied relatively directly with systemic ve­
nous return through a cavopulmonary anastomosis at a second-stage Fontan- 
type procedure. The perinatal and first-stage surgical mortality rate is between 
25% and 40%, and overall during the firsts years, it is as high as 50% to 
75%. Long-range survival is undetermined.
Cardiac transplantation has been used as an alternative approach with 
good survival, but there is limited timely availability of neonatal donors and 
limited documentation of long-range survival.
Neither reconstructive surgery leading to a Fontan procedure or car­
diac transplantation can be viewed as curative. Both methods of treatment 
have high fiscal and emotional costs.
DIFFERENTIAL DIAGNOSIS
The clinical picture of the hypoplastic left heart syndrome may be 
simulated by respiratory distress syndrome, interrupted aortic arch, severe
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complex coarctation, early neonatal myocarditis, isolated critical valvar aor­
tic stenosis, sepsis or some inherited metabolic disorders (see Table 14).
TOTAL ANOMALOUS PULMONARY VEINS
In the event of failure to connect the common pulmonary vein to the 
left atrium in the embryo, communications are established with available 
systemic venous channels that then drain the pulmonary veins, Anatomi­
cally abnormal drainage may be supracardiac (i.e., into the right or left su­
perior vena cava), intracardiac (i.e., into the coronary sinus, right atrium), 
or sub-diaphragmatic (i.e., through the inferior vena cava or porta hepatis). 
Mixed sites of drainage occur in approximately 10% of these patients. A 
PFO or atrial septal defect is invariably present. Anomalous pulmonary 
venous return is often associated with heterotaxy.
Although total anomalous venous return accounts for only 2% of 
newborns with serious cardiac disease, it is an important lesion because it 
is potentially curable and often misdiagnosed as pulmonary disease.
PATHOPHYSIOLOGY
Infants with anomalous pulmonary venous drainage can be divided 
into two major categories on the basis of the hemodynamic changes pro­
duced: those with nonobstructed veins and those with obstructed veins. 
Nonobstmcted pulmonary veins entering the systemic venous circula­
tion or directly into the right heart result in a large left-to-right shunt, 
congestive heart failure, and pulmonary artery hypertension. Systemic 
output is maintained through an interatrial communication. Despite the 
obligatory right-to-left shunt through the atrium, the large pulmonary 
blood flow mixing with the systemic venous return at the right atrium al­
lows a reasonable peripheral oxygen tension and produces only mild 
cyanosis.
If pulmonary venous return is obstructed, the circulatory effects 
are different. The obstruction may take the form o f increased resistance 
to flow produced by a long, common, pulmonary venous channel or lo­
calized intrinsic or extrinsic obstruction. Sub-diaphragmatic anomalous 
pulmonary venous return is usually obstructed by constriction of the 
ductus venosus, obstructing flow into the inferior vena cava (Fig. 16). 
Obstruction to supracardiac pulmonary venous return may occur because 
of compression of the common pulmonary venous channel between the 
left primary bronchus and left pulmonary artery or because of narrowing 
at the entry of the common pulmonary vein into the right superior vena 
cava. Obstruction at the foramen ovale is uncommon. After birth, signifi­
cant resistance to flow through the pulmonary veins becomes evident, 
causing pulmonary venous hypertension, pulmonary edema, marked pul­
monary artery hypertension, and severe cyanosis. The arterial oxygen tension
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is low because the contribution of fully oxygenated blood to the right atrial 
mixing is less than in the unobstructed form of this disorder.
FIG. 16. (A) A chest radiograph of a 3-day-old infant with obstructed total anomalous 
pulmonary venous drainage shows a ground-glass appearance of the lungs and normal 
heart size. A similar clinical picture may be seen in respiratory distress syndrome. (B) 
Postmortem angiography shows obstruction of the common pulmonaiy venous channel 
below the diaphragm (arrow)
CLINICAL FINDINGS
Infants with total anomalous pulmonary venous return without signifi­
cant obstruction usually become symptomatic after the neonatal period, when 
the pulmonary vascular resistance decreases and a large left-to-right shunt 
and congestive heart failure develop. They are mildly cyanotic, often have 
congestive heart failure, and have a large heart revealed on chest radiographs.
Infants with obstructed pulmonary venous return are usually critically 
ill, cyanotic, and tachypneic within the first week of life. There is congestive 
heart failure and poor peripheral perfusion. Heart size, as seen on the chest 
radiograph, is often normal, and there is evidence of pulmonary edema. The 
clinical and the radiographic pictures may resemble hyaline membrane dis­
ease or diffuse pneumonia complicated by PPHN. The ECG shows right axis 
deviation, right atrial hypertrophy, and right ventricular hypertrophy. The 
findings on two-dimensional and color Doppler echocardiography include 
absence of pulmonary venous connections to the left atrium, right-to-left 
bulging of the interatrial septum, right-to-left in-teratrial shunt, and pulmo­
nary venous confluence posterior to the left atrium connecting to a systemic 
venous channel. The diagnosis, especially if there is partial anomalous ve­
nous drainage below the diaphragm, may be missed altogether using echo­
cardiography; however, this error is becoming less common with recent ad­
vances in instrumentation. The triad of severe cyanosis and a roentgeno- 
graphic picture of a normal heart size associated with pulmonary edema is 
characteristic. Surgical success is related to the anatomy (e.g., results are 
poorest in the mixed variety) and to the age of onset of symptoms, as in pa­
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tients with the infradiaphragmatic type. The success rate is better for in­
fants with intracardiac drainage.
TREATMENT
The treatment of total anomalous pulmonary veins is surgical. Under 
deep hypothermic circulatory arrest, continuity or redirection of the pulmo­
nary venous drainage into the left atrium is established. Although inotropic 
agents, diuretics, and supportive medical treatment are used, infants with se­
verely obstructed anomalous venous return require immediate surgical inter­
vention. Prostaglandin ei therapy is not beneficial and can lead to dramatic 
worsening of the pulmonary edema. In most patients, surgery can be done on 
the basis of information from echocardiography without the delays and risks 
involved with cardiac catheterization. If there are associated complex con­
genital anomalies (e.g., heterotaxy syndrome) or intrinsic pulmonary vein 
stenosis is suspected, preoperative catheterization is needed. Those with un­
obstructed pulmonary veins and congestive heart failure with relatively nor­
mal pulmonary artery pressure may improve considerably on medical treat­
ment, and corrective surgery may be delayed for a few weeks. Among those 
without additional lesions, the postoperative survivors have an excellent 
prognosis for a relatively normal life. A few infants develop pulmonary vein 
stenosis and dysrhythmias postoperatively, and close follow-up is mandatory 
for several years.
DIFFERENTIAL DIAGNOSIS
Respiratory distress syndrome and interstitial pneumonia were clini­
cally indistinguishable from obstructed total anomalous pulmonary venous 
return until the advent of echocardiography. Any suggestion of an atypical 
course mandates echocardiography, particularly if there is equally diffuse in­
volvement of both lungs and any suggestion of a murmur. Two-dimensional 
echocardiography shows the anomalous common venous connections and ob­
structions and other cardiac lesions are excluded.
TRUNCUS ARTERIOSUS
Failure of the truncus arteriosus to divide into the aorta and main pul­
monary artery results in the clinical problem described as truncus arteriosus. 
The only arterial vessel arising from the heart is the truncus. There is one se­
milunar valve that may have extra valve leaflets and is often incompetent and 
rarely stenotic. The pulmonary arteries are supplied from the truncus by ab­
normal connections arising along the trunk. Classifications in vogue are 
based on the level at which the pulmonary vessels take off, but they are not 
especially pertinent to the physiology and the clinical picture. Almost univer­
sally, there is a ventricular septal defect, usually in the subaortic septum, 
similar to that seen in tetralogy of Fallot. There is a high incidence of associ­
ated extracardiac congenital anomalies (e.g., DiGeorge syndrome).
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PATHOPHYSIOLOGY
Because of the large ventricular defect and the common arterial trunk, 
the systemic and pulmonary ve>~- nous returns are mixed, and the patient is 
cyanotic. I The degree of cyanosis is determined by the pulmonary flow, 
which is a function of obstruction in the proximal pulmonary arteries. These 
obstructions are common, rarely severe, and located at the junction of the 
pulmonary artery and the trunk. If there is no obstruction, which is likely, 
there is excessive pulmonary flow, development of congestive heart failure, 
and poor survival without surgery. Without surgery, irreversible pulmonary 
vascular disease is likely to develop as early as the patient's first birthday. 
Congestive heart failure is less of a problem if there is branch pulmonary ar­
tery stenosis, although the degree of cyanosis is greater. The branch obstruc­
tion may cause problems after surgery.
CLINICAL FINDINGS
Infants with truncus arteriosus resemble those with ventricular defect 
more than the other cyanotic defects. Except cyanosis, which may be mild, 
development of symptoms is delayed until the pulmonary vascular resistance 
has resolved enough to allow a large pulmonary flow and the features of a 
left-to-right shunt. Tachypnea and the other signs of congestion predominate, 
although cyanosis may be recognized and documented in the first days of 
life. There is usually a murmur that sounds like a ventricular defect, the pe­
ripheral pulses are bounding, and other signs of an aortic runoff may be elic­
ited. The S2 is loud and single, and systolic clicks may be heard. On chest ra­
diographs, the heart is enlarged, and the pulmonary vasculature is engorged. 
The EKG inexplicably varies, showing right, left, or combined ventricular 
hypertrophy.
TREATMENT
Anticongestive measures to control congestion and promote growth are 
rarely successful. Surgical correction is usually undertaken within the first 2 
to 6 weeks of life. Although banding of the pulmonary arteries on both sides 
is possible and is sometimes the only choice, it is easy to understand the dif­
ficulty of applying bands on each side equally. For this reason and because of 
empirically poor results, most centers perform one-stage repair in infancy. 
This surgery consists of separating the pulmonary arteries from the trunk, es­
tablishing a conduit from the right ventricle to the pulmonary arteries, and 
closing the ventricular defect. It is too early to know the long-range outcome 
of this type of repair. The semilunar valve of the trunk is a known factor and 
may rarely be sufficiently incompetent to influence the outcome. Iatrogenic 
or natural branch pulmonary artery stenosis may be an important determinant 
of outcome.
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SINGLE VENTRICLE
There are few patients who have only one ventricle. Most patients 
characterized as having a single ventricle have one dominant ventricle and a 
second diminutive structure that is often characterized as an outflow cham­
ber. Because of the similarity to tricuspid atresia, some physicians have pre­
ferred the term uruiventricular heart to describe all patients -with a function­
ally single ventricle, whether they have two atrio-ventricular valves, tricuspid 
atresia, or mitral atresia. Seventy percent of these patients have a single left 
ventricle with a rudimentary right ventricular outflow chamber in the L- 
transposed position. The right ventricular outflow chamber leads to an ante­
rior and leftward aorta, similar to that seen in corrected transposition. Pulmo­
nary stenosis coexists in 50% of these patients. Almost any other cardiac 
anomaly may be associated with single ventricle.
PATHOPHYSIOLOGY
Depending on the presence of pulmonary stenosis, the clinical picture 
may be dominated by cyanosis or congestive heart failure, or the patient may 
be mildly cyanotic and otherwise asymptomatic. The problems peculiar to 
corrected transposition, such as the tendency to develop complete heart block 
or develop an incompetent atrioventricular valve (usually the left), are risks. 
The connection between the single ventricle and the outflow chamber (i.e., 
ventricular defect) tends to get smaller with time in approximately 50% of 
patients. This has the physiologic effect of subaor/tic stenosis and must be 
considered in any management program.
CLINICAL FINDINGS
The patient usually is visibly cyanotic during the neonatal period. 
Sometimes those with excessive pulmonary blood flow, minimal cyanosis, 
and congestive heart failure present later because of growth failure or 
tachypnea. Most have systolic murmurs from pulmonary stenosis, atrioven­
tricular valve regurgitation, or from other associated defects. The diagnosis is 
made by echocardiography. Cardiac catheterization is used preoperatively to 
confirm details that may influence surgical success.
TREATMENT
The ultimate goal of management is to provide a cavopulmonary or 
atriopulmonary anastomosis (e.g., Fontan procedure). Rare patients who have 
perfectly balanced pulmonary and systemic circulations and are only mildly 
cyanotic and virtually asymptomatic fare well with no surgery for years. 
Most require a pulmonary artery band to limit pulmonary flow or a shunt 
procedure to increase pulmonary flow and arterial oxygenation until a Fontan 
procedure (i.e., direct connection of systemic venous return to the pulmonary 
arteries) can be performed.
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MALPOSITIONS
The term malposition is used to describe misplacement of the heart 
(e.g., ectopia cordis), but it usually indicates concomitant heterotaxy (i.e., 
discordant sid-edness) and is used to describe patients with dextrocardia with 
situs solitus of the abdominal organs and levocardia with abdominal situs in­
versus (i.e., isolated levocardia). Ambiguous location of the abdominal con­
tents, as seen in the asplenia and polysplenia syndromes, is also described as 
malpositioning (Fig. 17). If the heart is displaced into the right chest because 
of pulmonary disease or diaphragmatic hernia or if there is total situs inversus 
(i.e., situs inversus universalis), there is no heterotaxy. Because this form of 
dextrocardia is rare and it is not always immediately possible to be confident 
that all organs are inverse, dextrocardia with abdominal situs inversus is usu­
ally discussed with the malpositions. The discussion is brief, because situs 
inversus universalis is rare and the heart may be anatomically normal, unlike 
the more common forms of malposition.
For practical purposes, evidence of abnormal sicLedness is primarily of 
consequence to the neonatologist and the pediatrician as a way to discover 
patients who have particularly difficult combinations of congenital heart le­
sions. Whether heterotaxy is discovered by physical examination because of 
abnormal sidedness of the abdominal contents or because the heart is located 
in the right chest on physical examination or chest radiographs, the result is 
the same. After the question has been raised and regardless of the clinical ap­
pearance of the baby, it is safest to proceed with a detailed workup. There is 
no consistent pattern of congenital cardiac defects associated with the differ­
ent varieties of malposition that allows the physician to propose specific car­
diac abnormalities based on the finding of dextrocardia or isolated levo­
cardia. About all that can be confidently stated is that there is a high probabil­
ity that life-threatening abnormalities exist and that the patient should be 
promptly turned over to a cardiac team that has the facilities and experience 
to handle the problem.
FIG. 17. A chest radiograph of a neonate 
with asplenia syndrome, tricuspid atresia, 
transposition of the great arteries, and a right 
aortic arch. The liver and stomach are on the 
right side.
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The cardiologists must sort out the combination of great vein, cardiac 
chamber, and great artery anomalies on a segment-to-segment basis, delineat­
ing the connections of the various segments of the heart. The cardiologist de­
rives little diagnostic value from the nature of the malposition, other than to 
recognize that there is no practical alternative to painstaking and detailed 
evaluation of the cardiac anatomy and physiology using all the tools avail­
able. The combined information from echocardiography and cardiac cathe­
terization is usually sufficient to propose a plan of surgical palliation, some­
times delaying full understanding of the anatomy until a later date.
Table 15
Common abnormalities in asplenia and polysplenia syndromes
Asplenia Polysplenia
Isolated levocardia or dextrocardia 
Visceral isomerism (midline liver and 
stomach)
Transposition of the great arteries 
Double-outlet right ventricle 
Total anomalous pulmonary venous re­
turn
Endocardial cushion defect 
Pulmonary atresia or pulmonary stenosis 
Single ventricle 
Bilateral superior vena cava 
Absent coronary sinus 
Ipsilateral inferior vena cava and ab­
dominal aorta
P-wave axis of atrial inversion 
Bilateral eparterial bronchi 
Bilateral trilobed lung
Dextrocardia or levocardia 
Absent inferior vena cava (renal to he­
patic segment)
Endocardial cushion defect 
Total anomalous pulmonary venous re­
turn
Coronary sinus rhythm 
Bilateral hyparterial bronchi
RHYTHM DISTURBANCES
Although any rhythm disturbance may occur in utero or in early in­
fancy, those most commonly encountered include sinus tachycardia and bra­
dycardia, premature atrial contractions, paroxysmal atrial tachycardia, and 
less commonly, atrial flutter and complete heart block. Atrial dysrhythmias 
are common, but those of ventricular origin are rare. In infants, wide- 
complex tachycardia is considered to be ventricular tachycardia, and digoxin 
is contraindicated. Acute life-threatening rhythm disturbances, such as ven­
tricular fibrillation, ventricular tachycardia, sinus arrest, and extreme brady­
cardia, usually occur as a terminal event in a systemic illness or in association 
with severe hypoxemia, acidosis, electrolyte disturbance, or drug toxicity 
(e.g., digitalis). Isolated ectopic atrial beats, atrial bigeminy, and nodal escape 
beats are only rarely associated with tachycardia and usually are of no serious 
consequence.
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Tachydysrhythmias must be differentiated from sinus tachycardia, 
which can occur with serious illness, fever, anemia, or pain at rates up to 230 
beats per minute (bpm). Faster rates and those with wide complex or an 
abrupt onset and termination are tachy-dysrhythmias. Sustained bradycardia 
at less than 70 bpm in neonates is abnormal. Noncardiac causes such as gas­
troesophageal reflux leading to vagal stimulation are common. Cardiac 
causes, including non-conducted atrial premature beats and second- or third- 
degree atrioventricular block, should be sought.
SUPRAVENTRICULAR TACHYCARDIA
Supraventricular tachycardia is a common rhythm disturbance in early 
infancy. It is frequently associated with an accessory atrioventricular bypass 
tract that is concealed during sinus rhythm because all conduction is passing 
through the normal pathway or manifested (i.e., Wolff-Parkinson-White syn­
drome) because antegrade conduction in sinus rhythm passes to the ventricle 
through the bypass tract and the atrioventricular node. Other causes include 
reentry within dual atrioventricular nodal pathways, ectopic atrial foci and 
atrial flutter. Cardiac malformation (e . g Ebstein disease, corrected transposi­
tion of the great arteries), tumors, and myocarditis are predisposing factors in 
a few patients. Onset of the tachycardia at less than 4 months of age carries a 
better prognosis, and recurrence is unlikely after 1 year of age.
Electrocardiographically, the arrhythmia is characterized by a rate of 
over 230 bpm, abnormal or unidentifiable P waves that may be superimposed 
on the T waves, and normal QRS morphology with constant RR interval. The 
arrhythmia usually starts and ceases abruptly. The infant may be asympto­
matic initially, but then he or she becomes irritable and fussy and refuses 
feeding. Congestive heart failure develops in approximately 20% after 36 
hours and in 50% after 48 hours. Rapid bolus of intravenous adenosine 
(0.075 mg/kg, increased to 0.15 mg/kg if needed) is the treatment of choice 
for most infants. Adenosine rapidly and briefly blocks atrioventricular nodal 
conduction, interrupting atrioventricular bypass and atrioventricular node re­
entry tachycardias, and it effects brief, dramatic drops in heart rate and pres­
sure with conversion. Side-effects appear to be rare.
Esophageal overdrive atrial pacing is also highly successful and offers 
the opportunity to obtain diagnostic atrial ECGs of the tachycardia and sinus 
rhythm. Intravenous verapamil should be avoided in infants younger than 1 
year of age because of reports of cardiovascular collapse and profound bra­
dycardia. Digoxin, preferably by the parenteral route if the infant is acutely 
ill, usually abolishes the arrhythmia within 6 to 12 hours. It has the advantage 
of improving myocardial contractility. Vagal stimulation maneuvers (e.g., ice 
to face, gagging) can be attempted while medications are being drawn up, but 
these are less often successful in neonates than older children. Synchronized 
direct current (DC) cardiover-sion with a DC defibrillator starting with 0.5-
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1.0 W-seconds/kg of body weight may be necessary for some infants refrac­
tory to adenosine if overdrive pacing is not readily available and prompt con­
version is needed.
Because recurrence within 3 months is common, chronic preventative 
treatment is recommended. The recommended medications used in chronic 
management schemes differ among institutions. Without manifest Wolff- 
Parkinson-White syndrome, most physicians treat with digoxin, and if break­
through occurs, they add or switch to propranolol followed by switching to 
oral verapamil, type LA agents (e.g., quinidine, procainamide, disopyramide) 
or type IC agents (e.g., flecainide) in various orders. The recommended 
schemes will change as more data about existing medications and new medi­
cations become available. If there is Wolff-Parkinson-White syndrome, most 
physicians will not use digoxin without electrophysiologic testing, because it 
may quicken antegrade conduction across the bypass tract in some patients. 
The administration of chronic suppressive medications such as propranolol or 
digitalis should be continued for approximately 6 months to 1 year after the 
last episode of arrhythmia. Esopha-geal electrophysiology studies with pro­
grammed atrial stimuli can be used to determine probability of recurrence on 
medications or after medications have been discontinued for those with reen­
try supraventricular tachycardia.
Infants with supraventricular tachycardia may be recognized in utero 
by a rapid fetal heart rate. If the arrhythmia has been present for some time, 
these infants may develop hydrops. In utero, the administration of digoxin, 
flecainide, or quinidine to the mother or procainamide or amiodarone directly 
into the umbilical vein may be effective.
ATRIAL FLUTTER
Atrial flutter is less common than other types of paroxysmal supraven­
tricular tachycardia and may be idiopathic or associated with the same con­
genital heart lesions as those producing paroxysmal supraventricular tachy­
cardia. Congestive heart failure is rare because some degree of atrioventricu­
lar block is present. The atrial rate may be 200 to 380 bpm. With a 2:1 block, 
the ventricular rate at the highest atrial rate would be 190 bpm, a rate insuffi­
cient to produce congestive failure in infancy. The rare infant without a block 
may have a rapid rate and shock. The ECG tracing reveals flutter waves, of­
ten seen best in leads II or V,. The RR interval is constant unless the atrio­
ventricular block changes. If the diagnosis is not certain from surface ECG, 
transesophageal atrial ECG can demonstrate the P waves, and intravenous 
adenosine may be used to alter transiently the atrioventricular block. The 
treatments of choice are overdrive atrial pacing from the esophagus or di­
goxin and, if necessary, cardioversion by DC countershock (initial dose = 5- 
10 W-seconds). Adenosine, although diagnostically helpful, does not con­
vert atrial flutter. Maintenance therapy with digoxin should probably be con­
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tinued for 6 months to 1 year. The addition of quinidine or propranolol may 
be necessary.
COMPLETE ATRIOVENTRICULAR BLOCK
In complete heart block, the ventricular rate is slower than and inde­
pendent of the atrial rate. The arrhythmia is not infrequently recognized in 
utero. In approximately 50% of infants with congenital heart block, there is 
an associated cardiovascular malformation (e.g., corrected transposition of 
the great arteries, ventricular septal defect, atrial septal defect). Myocarditis 
and fibrosis of the atrioventricular node or His bundle are etiologie factors. 
There is an association between maternal connective tissue disorders, particu­
larly systemic lupus erythematosus, and congenital complete heart block. 
Testing of the mother for anti-nuclear antibodies may be indicated. Complete 
heart block may occur as a complication of cardiac surgery, particularly in 
the correction of endocardial cushion defects, tetralogy of Fallot, and ven­
tricular septal defects.
Most infants with congenital heart block and no other cardiac problems 
are asymptomatic and require no immediate therapy. Symptoms are usually 
related to the severity of the associated cardiovascular malformation and the 
degree of bradycardia. Infants without hemodynamically significant cardiac 
malformation tolerate bradycardia well, grow, and develop normally. Exami­
nation usually reveals cardiac enlargement due to an increased left ventricular 
end-diastolic volume. A systolic ejection murmur and apical mid-diastolic 
rumble are common. The ECG is usually characterized by normal atrial rate 
and P-wave configuration, independent ventricular rate with long but equal 
RR intervals, and abnormal or wide QRS complex. Syncopal (i.e., Stokes- 
Adams) episodes may occur, but the initial episode is rarely fatal. The ven­
tricular rate tends to decrease with increasing age. Patients with syncope or 
near syncope, congestive heart failure, or postsurgical block should be elec­
trically paced with epicardial wires. Medical therapy with isoproterenol (Isu- 
prel) or atropine or with a transcutaneous or transvenous pacemaker is help­
ful in the acute situation or in preparation for sureerv.
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GASTROINTESTINAL DISIASE
Although most pediatric gastroenterologists are uncomfortable with 
primary care of the sick premature infant, they often are valuable consultants 
to the neonatologist. In evaluating a complex gastrointestinal or hepatobiliary 
problem, a gastroenterologist often uses an organ system-specific 
developmental pathophysiologic approach. In looking at a problem from a 
somewhat different perspective than the neonatologist, the opinion of the 
consultant may augment the analysis of the primary physician. It remains the 
responsibility of the neonatologist to put the consultant's view into 
perspective as it relates to the other complex problems of the sick infant.
The gastroenterologist also may offer his or her skills in invasive pro­
cedures to aid in the diagnosis of gastrointestinal and liver disease. Upper and 
lower gastrointestinal endoscopy, liver biopsy, rectal suction biopsy, and 
esophageal, antroduodenal, and anorectal motility studies, and even endo­
scopic retrograde cholangiopancreatography can be performed in term infants 
and, depending on the skill and training of the gastroenterologist, in prema­
ture infants as well.
Finally, in some institutions, gastroenterologists with special expertise 
in nutrition provide assistance in nutritional support of parenteral nutrition- 
dependent or malnourished infants. Their role becomes especially important 
in infants with gastrointestinal or liver disease who may require long-term 
follow-up, such as the infant with progressive liver disease, or home par­
enteral nutrition, such as the infant with short bowel syndrome.
DEVELOPMENT OF THE GASTROINTESTINAL TRACT
Subsequent to the development of the individual organs of the 
gastrointestinal tract, specialized features of the system begin to become 
apparent, mostly in the second and third trimester. At approximately 14 
weeks of gestation, differentiation of the pancreatic endocrine and exocrine 
tissues begins, and crypts and villi begin to form in the small intestine. A few 
weeks later, the colon, initially populated with villi similar to those in the 
small intestine, begins to develop its more characteristic surface with gradual 
loss of villi. As these morphologic changes occur, numerous functional 
processes begin, some of which mature early in utero, some only at birth, and 
some during the first year of life.
CARBOHYDRATE ABSORPTION
The functional maturation of the digestive process is complex. There 
are marked differences in maturation of the digestive and absorptive proc­
esses of different nutrients (Table ] $}. In the neonate, most dietary carbohy­
drate is presented in the form of lactose, the predominant carbohydrate in vir­
tually all mammalian milk. Lactose and other disaccharides are digested by
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enzymes located on the brush border membrane in mature enterocytes; those 
enterocytes located on the midportions and distal portions of the small intes­
tinal villi. Component monosaccharides are released after hydrolysis by dis- 
accharidases. Lactase hydrolyzes lactose to glucose and galactose, and both 
subsequently are transported by active carrier-mediated transport. Other dis- 
accharidases include maltase, which hydrolyzes maltose to two glucose units, 
glucoamylase, which hydrolyzes glucose oligosaccharides to glucose mono­
mers, and sucrase, which hydrolyzes sucrose to fructose and glucose. Sucrase 
is actually a double enzyme, the other part of the molecule being isomaltase, 
which hydrolyzes a-1-6 bonds of а-limit dextrins. Disaccharidase activities 
are highest in the proximal and midjejunum and decrease distally.
Table 16
Digestive and absorptive function in infants relative to adults
Process Premature infant Full-term infant Adult
Salivary enzymes Normal Normal Normal
Gastric acid production 1 J. To normal Normal
Bile acid secretion u 1_______ 1
Pancreatic enzyme production 11 _______1__ Normal
Lactase production 1 Normal Normal
Sucrase and isomaltase pro­
duction
Normal Normal Normal
i - decreased
Lactase activity develops later in gestation than the other disacchari- 
dases. Lactase activity is low until the final weeks of gestation. Although 
other disaccharidase levels can be detected somewhat earlier in gestation, and 
reach nearly adult levels between 26 and 34 weeks of gestational age, lactase 
levels are only 30% of full-term levels by that point in gestation. Because of 
the delayed maturation of lactase, specialized infant formulas for preterm in­
fants have been designed with a significant percentage of carbohydrate pre­
sented as sucrose or glucose polymers rather than lactose. The predominant 
enzyme for digestion of starches and glucose polymers is pancreatic amylase, 
which is nearly absent during the first 4 to 6 months of life and gradually ma­
tures during the latter one-half of the first year. An alternative pathway must 
therefore exist for the digestion of these glucose polymers.
Salivary glands produce an amylase that may be important in the diges­
tion of complex carbohydrates in the newborn. This enzyme is detectable at 
20 weeks of gestation and is present in significant quantities in premature in­
fants. As with pancreatic amylase, however, the ability of the newborn to se­
crete salivary amylase is substantially reduced and matures throughout the 
first year of life. Salivary amylase is inactivated by gastric acid, but probably
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retains some activity in the stomach of premature infants. Glucoamylase is a 
brush border enzyme capable of digesting glucose units from the nonreducing 
ends of starch and dextrin. Glucoamylase is present in neonates and infants at 
50% to 100% of adult levels.
Finally, it is probable that some malabsorbed carbohydrate is digested 
in the colon through the colon salvage pathway. Colonic anaerobic bacteria 
are capable of metabolizing carbohydrates to produce short-chain fatty acids 
that are then absorbed through the colonic mucosa. Considering the relative 
pancreatic insufficiency and lactase deficiency in the newborn infant, the co­
lon salvage pathway may be an important mechanism by which infants ab­
sorb carbohydrates.
FAT ABSORPTION
Fat absorption is a complex process, primarily because fat is insoluble 
in the aqueous environment of the small intestinal lumen. Solubilization, 
therefore, is an important part of the fat assimilation process.
The first phase of fat absorption is that of enzymatic digestion or 
lipolysis. Because most dietary fat is present in the form of triglycerides, oth­
erwise known as triasylglycerols, these must first be hydrolyzed by pancre­
atic lipase. Phospholipids are hydrolyzed concurrently by pancreatic phos­
pholipase. Colipase, a cofactor secreted by the pancreas, also is required, fa­
cilitating the action of lipase by binding to bile salt-lipid surfaces and 
improving the interaction of lipase with triglyceride. The efficiency of this 
process is augmented by the release of cholecystokinin (CCK) from the duo­
denal epithelium, which occurs in response to the presence of lipid and pro­
tein in the duodenum. Cholecystokinin stimulates pancreatic secretion, gall­
bladder contraction, and simultaneous relaxation of the sphincter of Oddi, to 
mix large quantities of bile acids and digestive juices with lipids. Pancreatic 
lipase levels are reduced in preterm infants and intrauterine growth-retarded 
infants, significantly impairing lipolysis. Lingual lipase, secreted from the 
salivary glands, may facilitate lipolysis in the premature infant and partially 
compensate for the infant's relative pancreatic insufficiency. Nonetheless, fat 
absorption is significantly impaired in newborn infants and, to a greater ex­
tent, in premature infants, due at least in part to pancreatic insufficiency.
Closely linked with the process of enzymatic digestion of fats is micel­
lar solubilization by bile acids. Bile add molecules are complex structures 
with both hydrophobic and hydrophilic ends. Bile acids interface with lipids 
to render them water soluble by positioning the hydrophobic portion in close 
proximity to the lipid globules while allowing the hydrophilic portion to re­
main free to interact with the aqueous environment. Lipids then become en­
closed in disc-shaped water-soluble micelles that contain fatty acids, 
monoglycerides, phospholipids, cholesterol, and fat-soluble vitamins.
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Solubilization is particularly important because of the presence of the 
intestine's unstirred water layer. This stagnant layer of water overlies the mi­
crovillus membrane of the intestinal epithelial cells and is the primary barrier 
to lipid transport. The actual thickness of the unstirred water layer is complex 
and difficult to measure, but the layer is significantly reduced by the constant 
agitation of the fluid in the gastrointestinal tract due to gut motility and villus 
contraction. Because of the convolutions in the small intestine caused by the 
presence of villi and microvilli, the total surface area available to interface 
between the intestinal surface and the unstirred layer is much greater than the 
interface between the unstirred water layer and the aqueous intraluminal en­
vironment. Penetration through the unstirred layer by the disc-shaped mi­
celles is the rate-limiting step for lipid absorption. Disease processes that in­
crease the unstirred layer thickness will markedly inhibit fat absorption in 
much the same manner as disease states that render the supply of bile acids 
inadequate for micellar solubilization. Bile acids commonly are deficient in 
cholestatic liver diseases such as neonatal hepatitis or biliary atresia and in 
rare cases of congenital bile acid deficiency. Bile acids are deconjugated rap­
idly and reabsorbed in the presence of small intestinal bacterial overgrowth. 
Bile acid deficiency may therefore occur in patients with disorders that cause 
intestinal stasis and bacterial overgrowth such as short bowel syndrome. In 
disorders of mucosal injury, the unstirred layer thickness may be increased, 
making penetration of the fat-containing micelles difficult and further exac­
erbating fat malabsorption.
Bile acids are extremely important in the fat absorption process. In the 
absence of bile acids, only about one third of dietary triglycerides, a very 
small percentage of fatty acids, and virtually no cholesterol or fat-soluble vi­
tamins are absorbed. Medium-chain triglycerides may be better absorbed be­
cause of their enhanced water solubility, which allows penetration of the un­
stirred water layer without micellar solubilization. In both preterm and term 
infants, bile acid synthesis is limited and the bile salt pool size is low. More­
over, preterm infants may have an ineffective bile salt transport process in the 
distal ileum, resulting in impaired enterohepatic circulation of bile salts. Con­
sequently, the bile acid concentration may be less than adequate for the for­
mation of micelles and solubilization of fat. Thus, penetration of the unstirred 
layer is less efficient in the term infant and further impaired in the preterm 
infant compared to adults.
After lipids are enclosed in the bile acid micelle and reach the lipid bi­
layer membrane of the small intestinal mucosal cell, absorption into the cell 
occurs by passive diffusion. Because of the convolutions of the gastrointesti­
nal tract, a large surface area exists for lipid assimilation. In the absence of 
disease, this process progresses in the term and preterm infant relatively un­
inhibited. In disorders in which the absorptive surface area is reduced or 
damaged, however, such as short bowel syndrome or any form of diffuse en­
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terocolitis, fat, carbohydrate, and, to a limited degree, protein are malab- 
sorbed.
Within the enterocyte, monoglycerides and esterified fatty acids are 
immediately resynthesized to triglycerides. These triglycerides, along with 
apoproteins, phospholipids, free cholesterol, some diglycerides, and esterified 
cholesterol are stabilized within chylomicrons. The outer structure of the chy­
lomicron then fuses with the basolateral membrane and is extruded into the 
lamina propria, where it is carried by the lacteals and lymphatic channels and 
deposited into the bloodstream.
PROTEIN ABSORPTION
The assimilation of protein begins in the stomach through the action of 
hydrochloric acid and pepsin. The maturational aspects of this process have 
been the subject of substantial study and some controversy. Conflicting data 
exist as to the status of acid secretion in the newborn infant. Newborn infants 
appear to be capable of secreting acid, although the process is somewhat im­
mature. In premature infants, it is probable that the process is impaired to a 
greater extent. Pepsinogen, the proenzyme for pepsin, which facilitates pro­
tein digestion in the stomach, is secreted in preterm infants, but in much 
lower concentrations than in term infants.
The gastric aspects of protein digestion are relatively inconsequential, 
compared to the much more complete process in the small intestine. En- 
terokinase, produced in the duodenal mucosa, activates the pancreatic prote­
olytic enzyme trypsinogen, converting it to trypsin, which then activates es­
sentially all of the other enzymes involved in protein digestion. Enterokinase 
levels have been demonstrated in human fetuses as early as 21 weeks of ges­
tation. Enterokinase secretion is diminished during fetal development, how­
ever, and is only 10% of adult levels in the term newborn. In addition, pan­
creatic and duodenal proteolytic enzymes are present in preterm and term in­
fants in lower concentrations than in older children and in adults. These en­
zymes initiate hydrolysis of proteins, and the hydrolysis process is completed 
by brush border and cytosolic peptidases. Protein is absorbed in the form of 
amino acids and dipeptides through active transport processes that appear to 
be well developed by 28 weeks of gestational age. Despite the relative imma­
turity of multiple phases of the protein assimilation process, both preterm and 
term infants are quite capable of absorbing adequate quantities of dietary pro­
tein. In small infants, the protein malabsorption resulting from mucosal injury 
is probably far less consequential than the malabsorption of the other major 
macronutrients.
MICRONUTRIENT ABSORPTION
Absorption of micronutrients matures at varying rates in infancy. Wa­
ter is absorbed passively in response to sodium and other electrolytes, as it is 
in older children and adults. Experimental evidence suggests that the intesti­
ne
nal epithelium may be more secretory during early infancy, and the increased 
susceptibility of infants to diarrheal disorders probably is at least partially re­
lated to this process.
Mineral absorption depends on the form in which the mineral is pre­
sented to the infant. Iron, for example, is absorbed extremely well from 
breast milk. Even the preterm infant is capable of absorbing nearly 50% of 
the iron in breast milk, whereas only a small percentage of iron is absorbed 
from cow-milk formulas, necessitating iron supplementation. Calcium and 
phosphorous also are well absorbed from breast milk. Magnesium, copper, 
and, to a lesser extent, zinc are well absorbed by both term and preterm in­
fants. In general, minerals are absorbed somewhat better from breast milk 
than from cow milk. Most vitamins appear to be absorbed adequately in both 
term and preterm infants, although fat-soluble vitamin deficiency is common 
in disorders affecting fat absorption, especially disorders causing bile acid 
deficiency.
GUT MOTILITY
Although nutrient assimilation is heavily dependent on the develop­
ment of digestive and absorptive function, actual feeding depends greatly on 
the maturation of gut motility. Neuroblasts migrate in a cranial-to-caudal di­
rection between weeks 5 and 12 of gestation. There is gradual maturation of 
gut motility throughout the fetal period and the first several years of postnatal 
life. In the fetus, normal propulsive motility in the gut probably does not ap­
pear until approximately 30 weeks of age. Interdigestive phenomena, known 
as migrating motor complexes, can be demonstrated by approximately 33 
weeks of gestation. Motor activity in the neonatal gut differs significantly 
from that in adults, in that the propagation rate of the migrating motor com­
plex is substantially slower in neonates, and the complex is not abolished by 
feeding as in older children.
Sucking and swallowing reflexes begin early during fetal development, 
but the maturation of the process is not completed until after birth. The fetus 
is able to swallow amniotic fluid as early as 11 to 12 weeks of gestation. Ac­
tual sucking probably does not occur until approximately 18 to 24 weeks. 
This type of sucking is termed nonnutritive sucking, differentiating it from 
the more effective nutritive sucking mechanism that develops by 34 to 35 
weeks of gestation. The onset of nutritive sucking closely parallels a rapid 
increase in growth of the fetal stomach, and the acquisition of mature patterns 
of gastric antral and small intestinal motility.
By the time a term infant is bom, sucking movements are followed in 
an orderly progression by swallowing, esophageal peristalsis, relaxation of 
the lower esophageal sphincter, and relaxation of the gastric fundus. The first 
stage of swallowing is an involuntary reflex in both the term and preterm in­
fant.
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Some data suggest that nonnutritive sucking may play an important 
role in weight gain in preterm infants. The mechanism of this effect may be 
related to maturational changes in the infant gastrointestinal tract, and suck­
ing may facilitate gastric emptying and other gastrointestinal functions, pri­
marily through stimulation of secretion of gastrointestinal regulatory pep­
tides.
Maturation of gastrointestinal motility may have important implica­
tions for a number of conditions. Gastroesophageal reflux is common in both 
term and preterm infants, and probably relates to diminished lower esophag­
eal sphincter function or inappropriate relaxation of the lower esophageal 
sphincter, often in association with delayed gastric emptying. The maturation 
of both lower esophageal sphincter function and gastric emptying has been 
studied extensively, with somewhat equivocal results. Depending on the 
technique used to measure sphincter function, the lower esophageal sphincter 
tone has been shown to be either low or normal in both preterm and term in­
fants. Hypertonic carbohydrate solutions appear to delay gastric emptying in 
infants, much as they do in adults.
GASTROINTESTINAL HORMONES AND ENTERIC NEUROPEFTIDES
Gastrointestinal peptide hormones appear to play an important role in 
the structural and functional development of the gut, as well as in the control 
of alimentary functions. The function of a vast endocrine system is integrated 
with that of the enteric nervous system, which itself uses other regulatory 
peptides as local messengers.
Endocrine cells producing gastrin, somatostatin, motilin, and glucose- 
dependent insulinotrophic peptide (GIF) are detectable in the fetus at 8 weeks 
of gestation, with gastrin- and somatostatin-producing cells being most nu­
merous. By 14 weeks, all of the endocrine cell types are present in the intes­
tinal mucosa, although the anatomic distribution is more widespread than that 
seen in the adult. By the end of the second trimester, the distribution of gut 
endocrine cells resembles that of the adult. Peptidergic nerves are first de­
monstrable in the myenteric plexus at about 12 weeks of gestation, correlat­
ing with the known developmental pattern of enteric nerve plexuses. These 
enteric nerves then migrate through to the submucous plexus. By the third 
trimester, all of the regulatory peptide systems are well developed. At birth, 
the molecular forms of the gastrointestinal regulatory peptides and their dis­
tribution in the gut are similar to those of the adult.
Surges of gut hormones appear to be responsible for the marked 
growth and functional change that occur in the alimentary tract in early neo­
natal life. Substantial changes in gastrointestinal hormone secretion are seen 
during this period, triggered by the switch from intravenous to enteral feed­
ing.
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Gastrin is an important regulator of gastric secretion and also is trophic 
to the gastric mucosa. At birth, cord blood levels of gastrin are already four 
or five times higher than those in the adult, and prefeed basal levels remain 
elevated for several weeks. Furthermore, gastrin levels increase in response 
to the first milk feed. After 3 or 4 weeks of life, basal gastrin levels decline, a 
change accompanied by development of marked feeding responses. Gastric 
acid is detectable in the stomach at birth and reaches a peak in the first day or 
two of life. Thereafter, acid output decreases for a period of about a month in 
spite of the hypergastrinemia and rapid growth of the stomach. It has been 
suggested that the lack of responsiveness to gastrin could be due to a lack of 
receptors in the oxyntic gland mucosa.
Basal levels of the duodenal hormone, secretin, are higher at birth than 
in adults, and during the first 3 weeks of life a more marked postprandial re­
sponse develops than is seen in the adult. Because secretin is considered to be 
a major factor in triggering the neutralization of acid chyme entering the 
duodenum, the increase in circulating secretin levels may be of considerable 
importance in mucosal protection during this period. It is notable that the 
postnatal surge of secretin, unlike that of the other alimentary hormones, oc­
curs even in the absence of feeding, indicating the importance of this mucosal 
cytoprotective function.
Cholecystokinin, released from the upper small intestine, stimulates 
pancreatic enzyme secretion and contracts the gallbladder. In addition, CCK 
has marked trophic effects on the pancreas and appears to be responsible for 
regeneration after resection or acute pancreatitis. The observed postnatal 
surge of plasma CCK concentrations may therefore be of importance in 
stimulating growth of this organ.
Also released from the small intestine, motilin is a hormonal peptide 
with powerful motor functions. These motor functions include acceleration of 
gastric emptying and stimulation of the interdigestive myoelectric complexes 
during the interprandial period. Motilin concentrations are low in cord blood, 
but preprandial basal concentrations show a massive postnatal surge that 
peaks at around 2 weeks of postnatal life. This peak is enhanced, but delayed, 
in preterm neonates. It is likely that this increase in circulating motilin con­
centrations is responsible for the known increase in motor activity of the gut 
that occurs during the neonatal period. Interdigestive motor complexes ap­
pear normal at birth in the term infant, but interdigestive cycles are incom­
plete in preterm neonates. Premature babies exhibit abnormal motor activity, 
with periods of motor quiescence and non-propagating contractions. Thus, 
motor activity is more immature in preterm infants than in term infants. The 
relationship between maturation of the migrating motor complexes arid the 
late postnatal surge of motilin in preterm neonates is not clear.
The jejunal hormone, QIP, is thought to be largely responsible for the 
postprandial increase in circulating insulin levels. Basal QIP concentrations
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are low at birth and increase gradually throughout the first month of life, to­
gether with the development of a marked postfeeding QIP response similar to 
that seen in the adult after ingestion of a mixed meal. The development of the 
QIP response to feeding in neonates is mirrored by the postprandial insulin 
response, which increases through the first month of life to maintain glucose 
homeostasis.
Neurotensin is an ileal peptide that has inhibitory effects on gastric se­
cretion and motility. Plasma neurotensin concentrations are higher in the neo­
nate than in the adult, and an enhanced postprandial response develops in the 
first month of life. Both reduction of gastric secretion and slowing of the rate 
of gastric emptying will decrease the rate at which acid chyme enters the 
duodenum and, therefore, will result in a more steady absorption of nutrients 
from the gut. Thus, neurotensin may be important in the adaptation of the 
neonate to enteral nutrition.
Peptide YY is an important hormone from the distal intestine that in­
hibits gastric emptying and slows small bowel transit. Peptide YY also inhib­
its gastric and small bowel secretion, leading to an increase in net absorption. 
Concentrations of PYY are elevated in cord blood and rise postnatally to a 
peak within the first 2 weeks postpartum. At their peak, plasma PYY concen­
trations are about 50 times higher than fasting levels in normal adults. There 
is evidence to suggest that gastric emptying and intestinal transit are rapid 
during the first week of life, both in term and preterm infants. The triggering 
mechanism for the changes that then take place is unknown, but it is likely 
that factors such as PYY play a role. In addition, the very potent inhibitory 
effect of PYY on gastric secretion may account for the prevention of hyper­
secretion of acid during the early neonatal period, in spite of the marked hy- 
pergastrinemia.
Plasma enteroglucagon concentrations show a very marked postnatal 
surge, which peaks within the first week and is associated with the develop­
ment of a marked postprandial response. As an increased rate of small intes­
tinal mucosal growth is known to occur during this period, it can be specu­
lated that the increase of this trophic hormone is important in neonatal ali­
mentary maturation. The resulting mucosal growth increases the absorptive 
area for the uptake of nutrients from the gut lumen.
Temporally, the postnatal surges of gut hormones parallel the changes 
in gastrointestinal function that accompany the introduction of enteral feed­
ing in the infant. It is therefore of considerable interest that these surges are 
not seen in infants who have never received enteral feeding. Concentrations 
of all gut hormones, with the exception of secretin, remain low in infants re­
ceiving only parenteral nutrition.
Precise mechanisms control the secretion of each gut hormone, and the 
amount of a particular peptide liberated by a meal is adequate to stimulate the 
appropriate digestive response. For example, a meal rich in long-chain
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triglycerides will evoke a large CCK response, not seen with medium-chain 
fats. The high circulating levels of CCK in turn stimulate the pancreatic en­
zyme secretion and, by gallbladder contraction, release the bile salts neces­
sary for digestion of the long-chain fat. Medium-chain triglycerides, on the 
other hand, are rapidly hydrolyzed by lingual and gastric lipases; they are wa­
ter soluble, do not require micelle formation, and are rapidly absorbed. Thus, 
bile salts and pancreatic enzymes are not required for digestion of medium- 
chain triglycerides, and a large CCK response is not seen when they are in­
gested. The gut endocrine system, with its sparse distribution of overlapping 
cell types, is designed to produce an integrated digestive response to the dis­
continuous stimulation of ingested food. Because the type of food presented 
can influence the integrated hormonal response, it is apparent that differences 
in nutrition in early neonatal life may result in changes in the growth and 
functional development of the neonatal alimentary tract.
Although the fetus makes little demand on its gastrointestinal tract, the 
situation changes dramatically at birth, when demand for nutrients necessi­
tates the rapid maturation of the alimentary tract. This development of the 
gastrointestinal tract is characterized by the integrated maturation of its many 
functions. The observation, however, that premature infants make a satisfac­
tory transition from intravenous nutrition through the placenta to extrauterine 
enteral feeding suggests that external influences can exert a substantial influ­
ence. The massive postnatal surges in circulating levels of hormones, which 
have trophic as well as secretory and motor functions, is compelling circum­
stantial evidence of a profound gut endocrine influence on alimentary devel­
opment. ’ This is supported further by the observation that these hormonal 
surges are not seen in sick infants who are on parenteral nutrition and have 
not been fed orally. It is likely that failure of secretion of trophic gut hor­
mones is responsible for the hypoplastic gut and pancreas that accompany 
parenteral nutrition. Appropriate enteral stimuli or hormone replacement 
eventually may alleviate this problem.
ABNORMALITIES OF THE GASTROINTESTINAL TRACT
To avoid repetition, an attempt has been made to confine the abnor­
malities described in this section to those that might require consultation by a 
pediatric gastroenterologist. Some overlap with general surgery has been al­
lowed, however, to avoid extensive cross-referencing.
ABDOMINAL WALL DEFECTS
Major defects of the abdominal wall, omphalocele and gastroschisis, 
are relatively uncommon malformations occurring in approximately 1 of 
6000 live births. In either case, a portion of the infant's gastrointestinal tract 
remains outside the abdominal cavity at birth. Omphalocele is a failure of the 
extraembryonic intestine to reenter the abdominal cavity through the umbili­
cus, a developmental anomaly that occurs between weeks 10 and 12 of gesta-
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tional age. The defect therefore includes the umbilicus, and the viscera typi­
cally are covered with a peritoneal sac. Occasionally, the sac may rupture, 
making the disorder difficult to distinguish clinically from gastroschisis. Gas- 
troschisis is an actual defect in the abdominal wall that occurs lateral to the 
umbilicus. The infant with gastroschisis has a normal umbilical cord not in­
volved in the defect. Both defects may occur in the presence of other intesti­
nal anomalies. Malrotation is present in association with omphalocele. Al­
though intestinal atresias are more commonly found in gastroschisis, atresias 
may be associated with either anomaly. Abdominal wall defects frequently 
are diagnosed prenatally by fetal ultrasound. The preferred route of delivery 
remains controversial and may depend on the size of the defect. Vaginal de­
livery may be acceptable for small defects, and cesarean section may be pre­
ferred in cases with large defects.
Gastroschisis or omphalocele requires immediate pediatric surgical 
consultation. Fluid losses and hypothermia are of primary immediate con­
cern, especially in the case of gastroschisis, since no membrane covers the 
bowel. Large fluid and heat losses are common and intravenous fluid re­
placement should be initiated immediately. The defect should be wrapped, 
using warm, sterile, moist saline gauze, with care taken to prevent twisting 
and infarction of the bowel.
Postoperative management includes sedation and mechanical ventila­
tion for at least 48 to 72 hours because of increased intraabdominal pressure. 
During the postoperative period, gut motility is slow to return, especially in 
the case of gastroschisis. Patients with gastroschisis may demonstrate slug­
gish motility for up to 8 months, and a protracted course of parenteral nutri­
tion commonly is required. Delayed onset of necrotizing enterocolitis (NEC) 
is not uncommon, and should be suspected if bloody stools are observed.
DISORDERS OF THE ESOPHAGUS
GASTROESOPHAGEAL REFLUX
Gastroesophageal reflux is the most common esophageal disorder in 
the neonatal period. Gastric contents normally are retained within the stom­
ach through the action of the lower esophageal sphincter, a zone of high pres­
sure in the distal esophagus that remains tonically contracted except during 
deglutition. The anatomy of the stomach and esophagus, and their relation­
ship to the diaphragm and related structures, may play a secondary role in re­
taining gastric contents within the stomach. Although considerable contro­
versy exists, there is evidence to suggest that the lower esophageal sphincter 
may be fully functional in the normal full-term infant. Some evidence sug­
gests that sphincter pressure may be decreased, either continuously or inter­
mittently, in infants with gastroesophageal reflux, facilitating reflux of gastric 
contents into the esophagus. There is considerable controversy over the inci­
dence of reflux in the premature infant. Reflux appears relatively more corn-
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mon, but some data suggest that the lower esophageal sphincter may be com­
petent. Delayed gastric emptying and other motility problems also may play a 
role in reflux in premature infants.
In adults and older children, chronic esophagitis due to reflux of acid 
into the distal esophagus is the major concern with gastroesophageal reflux. 
During the neonatal period, however, esophagitis rarely occurs. Reflux typi­
cally presents with continual regurgitation and spitting up or vomiting of 
small quantities of formula after eating, but also may present with apnea and 
bradycardia. Recurrent aspiration during reflux episodes may result in pneu­
monitis or exacerbation of preexisting neonatal pulmonary disease. If enough 
formula is regurgitated, the infant may fail to thrive. In neonates, reflux also 
may be associated with delayed gastric emptying. As in older children, reflux 
is encountered more frequently in infants with neurologic abnormalities.
Gastroesophageal reflux may exist as a primary disorder due to lower 
esophageal sphincter incompetence or intermittent relaxation, or may be a 
manifestation of another disorder. First of all, it must be realized that gastroe­
sophageal reflux may occur physiologically in all infants, although not with 
thefrequency and severity of pathologic reflux. Any disorder that limits gas­
tric emptying or causes a partial proximal small intestinal obstruction, such as 
annular pancreas or pyloric stenosis, will result in some gastroesophageal re­
flux. Small bowel disorders, including milk protein enterocolitis or infectious 
enteritis, will cause vomiting and regurgitation— in essence, gastroesophag­
eal reflux. Finally, a variety of systemic disorders, including certain inborn 
errors of metabolism, chronic infection, chronic renal disease, and increased 
intracranial pressure all may result in chronic emesis similar to gastroe­
sophageal reflux. Drugs, such as xanthines, which may be given because of 
apnea or lung disease, decrease lower esophageal sphincter pressure and may 
exacerbate or even cause reflux.
Several diagnostic studies are available to diagnose gastroesophageal 
reflux in infants; however, these studies as a rule do not separate primary 
from secondary' causes. For example, an infant with milk protein enterocolitis 
or pyloric stenosis will test positively for gastroesophageal reflux by any of 
the available studies. The most widely available test for reflux is an upper 
gastrointestinal series. An upper gastrointestinal series is preferable to a bar­
ium swallow, since the latter only examines esophageal motility. The stom­
ach must be filled with barium to assess the patient accurately for reflux. Un­
fortunately, assessing a child for gastroesophageal reflux radio-graphically 
lacks sensitivity because of the short time interval during which the child is 
observed, and lacks specificity because of the likelihood of physiologic re­
flux occurring during performance of an upper gastrointestinal series. There­
fore, the primary role of an upper gastrointestinal series is to exclude gastric 
outlet lesions such as pyloric stenosis or proximal small bowel partial ob­
structions such as duodenal webs or annular pancreas.
135
Twenty-four-hour pH  monitoring is the most widely accepted means of 
assessing gastroesophageal reflux. The pH  probe is placed approximately 2 
cm proximal to the lower esophageal sphincter, and distal esophageal pH  is 
recorded over a 24-hour period. The infant must be bolus-fed during the 
study, to ensure adequate gastric distention to simulate the physiologic state. 
Considerable controversy exists over appropriate feeding for children during 
24-hour pH monitoring. The inconsistency of acid secretion in small infants 
makes the procedure much less reliable during the neonatal period, and, con­
sequently, simultaneous measurement of intragastric pH often is helpful in 
determining the validity of the study.
A Tc scintiscan may be used to screen for gastroesophageal reflux, al­
though this technique is not considered as reliable as 24-hour pH monitoring. 
The technique is useful, however, for measuring gastric emptying delay, 
which may coexist with gastroesophageal reflux in a number of infants. En­
doscopy with biopsy is a useful technique for detecting reflux in older in­
fants; however, endoscopic biopsies are less useful during the neonatal period 
because pathologic reflux has not had sufficient time to cause esophageal 
mucosal injury. In older children, the presence of intraepithelial eosinophils 
suggests reflux, but this sign cannot be relied on in neonates, and biopsy 
specimens frequently are normal.
Treatment of gastroesophageal reflux is based on the severity of symp­
toms. If the child is thriving well, and the major complaint is frequent regur­
gitation and spitting, the infant may be placed prone on an incline at ap­
proximately 30° with the head higher than the feet. It has been demonstrated 
that children positioned in this manner will reflux less frequently. Although it 
may take several weeks for symptoms to resolve, the risk of esophagitis is 
lessened and reflux tends to resolve more quickly. If the volume of reflux is 
severe and the infant is chronically irritable, has evidence of esophagitis, or is 
failing to thrive, then inhibition of gastric acid secretion with agents such as 
antacids or H; receptor antagonists may be necessary. Both cimetidine and 
ranitidine are available in liquid preparations, and work well. Data suggest 
that aluminum antacids may elevate serum aluminum levels in small infants. 
Bethanechol, a parasympathomimetic agent, has been demonstrated to in­
crease lower esophageal sphincter resting tone and improve weight gain in 
infants with failure to thrive secondary to gastroesophageal reflux. Unfortu­
nately, bethanechol may have associated central nervous system side-effects 
such as irritability and sleeplessness. Metoclopramide also has been used to 
treat gastroesophageal reflux in infants. The effectiveness of metoclopramide 
is controversial, and it probably is most helpful when delayed gastric empty­
ing coexists with reflux. Some clinicians thicken infants' formula with cereal. 
Although this may reduce spitting, it usually does not reduce reflux or its 
complications and results in nutrient imbalance in the infant's carefully for­
mulated diet.
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Gastroesophageal reflux may be treated successfully with surgical fun- 
doplication in approximately 95% of cases. The most common surgical pro­
cedures include the Nissen fundoplication, in which the stomach is wrapped 
and sutured 360° around the distal esophagus, and the Thai fundoplication, 
which consists of a 270° wrap. Complications, including gaseous distention 
of the stomach and dumping syndrome, may be less common with the Thai 
procedure. Indications for an operation for gastroesophageal reflux include 
recurrent aspiration pneumonia, failure to thrive secondary to severe vomit­
ing unresponsive to in-hospital medical management, or apparent life- 
threatening apnea events associated with gastroesophageal reflux.
Differential diagnosis of the typical neonate with chronic recurrent 
vomiting includes, in addition to gastroesophageal reflux, two major catego­
ries of disease. The first is upper gastrointestinal anomalies, including pyloric 
stenosis. Virtually all of these can be eliminated by upper gastrointestinal 
contrast studies; pyloric stenosis can be excluded adequately by ultra­
sonography in the hands of an experienced pediatric ultrasonographer. The 
second major diagnostic category is formula protein intolerance. Infants with 
formula protein intolerance commonly vomit, especially those with signifi­
cant small bowel mucosal disease. Such infants often are irritable and usually 
have loose, Hematest-positive stools. Proctoscopic examinations of the rec­
tum usually demonstrate colitis. This disorder is discussed in detail later in 
this chapter.
ESOPHAGEAL ANOMALIES
The other major category of esophageal disease that presents in the 
neonatal period is tracheoesophageal fistula or esophageal atresia. These 
anomalies occur in approximately 1 in 4000 live births. In addition to a pre­
natal history of polyhydramnios, increased salivation with coughing, chok­
ing, and cyanosis shortly after birth should raise the suspicion of tracheoe­
sophageal fistula-esophageal atresia. The most common variety is that of 
atresia with the distal esophageal pouch connected to the trachea through a 
fistula. Such infants frequently have a stomach distended with air, and respi­
ratory symptoms due to tracheal aspiration of refluxed gastric acid. Immedi­
ate pediatric surgical consultation is required.
After surgery, gastroesophageal reflux is a virtual certainty. Patients 
with tracheoesophageal fistula or esophageal atresia have incompetent lower 
esophageal sphincter function as well as aperistaltic contractions in the 
midesophagus. Although swallowing usually proceeds without much diffi­
culty, gastroesophageal reflux with chronic esophagitis and occasionally 
stricture formation are frequent long-term complications. Subsequent eso­
phageal dilatations and fundoplication may be necessary.
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DISORDERS OF THE STOMACH AND DUODENUM
CONGENITAL ANOMALIES
Congenital anomalies of the upper gastrointestinal tract frequently pre­
sent with vomiting. The most common is pyloric stenosis, which occurs in 
approximately 1 in every 500 live births. The disease is most common in 
Caucasian males. A positive family history often is present. Pyloric stenosis 
usually presents with nonbilious projectile vomiting during the third to fourth 
week of life. The disorder often is insidious in onset. After emesis, infants are 
hungry and will attempt to eat to compensate for malnutrition. Eventually, 
nutrition deteriorates and infants become dehydrated and alkalotic secondary 
to chronic vomiting of the acidic gastric contents. Unconjugated hyper­
bilirubinemia is present in a small percentage. Patients with pyloric stenosis 
have normal or firm stools, in contrast to infants with formula protein intoler­
ance, who usually have loose stools with evidence of malabsorption, inflam­
mation, or both. Serum electrolytes reveal potassium and chloride deficiency 
and metabolic alkalosis. Physical examination demonstrates visible peristalsis 
in the epigastric region. Careful palpation of the abdomen while feeding may 
reveal a pyloric olive. The olive can be felt best when the stomach is empty, 
particularly just after vomiting. Diagnosis usually is confirmed by an upper 
gastrointestinal series or ultrasonography, or in the case of ambiguity, both, 
before proceeding with surgical intervention.
Before operative correction of the pyloric stenosis, infants should be 
rehydrated intravenously and the electrolyte imbalance and alkalosis cor­
rected. Surgical correction consists of longitudinal incision of the hypertro­
phied muscle (i.e., pyloromyotomy). After the operation is completed, the pa­
tient usually can be fed within 6 to 12 hours. Pyloric stenosis has been noted 
to recur in rare cases. Nonoperative medical management of pyloric stenosis, 
consisting of anticholinergic drugs and small frequent feedings, occasionally 
may be helpful. This therapy, sometimes used in Europe, is rarely used in 
North America because of the excellent results of surgical intervention.
Other rare gastric anomalies also may present in the neonatal period. 
Various forms of gastric atresia or hypoplasia have been described, most of 
which present with vomiting at or shortly after birth. Congenital microgastria 
may occur in association with a variety of other anomalies, including limb 
abnormalities, asplenia, megaesophagus, situs inversus, midgut malrotation, 
and cardiac anomalies. After major reconstructive surgery of the stomach, 
prognosis may be quite good.
ACID PEPTIC DISEASE
Acid peptic disease may be seen in newborn infants. Ulcers in children 
occur most commonly in the neonatal period or during the second decade of 
life. In newborn infants, ulcers, whether gastric or duodenal, usually present 
with hematemesis. Occasionally, blood loss may be substantial, manifested
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by symptoms of hypovolemia and shock. Differential diagnosis of hemate- 
mesis in the newborn includes swallowed maternal blood, or blood ingested 
from a cracked nipple through breast-feeding. In an otherwise stable infant, 
this differentiation can be made by assaying for fetal hemoglobin in the vom­
ited gastric contents.
Diagnosis of peptic ulcer disease in the neonate requires endoscopy. 
Radiographic studies rarely are useful because the lesions are quite superfi­
cial and difficult to image radiographically. Endoscopy can be performed 
easily in a newborn infant by a skilled pediatric endoscopist using appropri­
ate equipment. The smallest pediatric upper gastrointestinal endoscopes can 
be used safely in term infants, with little sedation and without general anes­
thesia. The minimum size of the infant that can be safely endoscoped varies 
with the skill of the endoscopist, but endoscopy often also can be performed 
safely in larger premature babies. A bronchoscope can be used in smaller in­
fants, although the examination usually is unsatisfactory. Although ulcera­
tions may be identified anywhere in the stomach and the duodenum, multiple 
superficial gastric lesions are most common in newborn infants. Ulcers may 
be primary, or secondary as in the case of drugs known to irritate the upper 
gastrointestinal tract, such as steroids or theophylline. Treatment with antac­
ids, or preferably H2 receptor antagonists such as cimetidine or raniti-dine, 
for a period of 2 to 6 weeks results in complete healing of the lesion. Secon­
dary ulcers may be treated in a similar fashion. In this instance, continuation 
of the offending agent requires careful assessment of the risk-benefit ratio, 
because lesions will heal more rapidly if the agents are discontinued.
Spontaneous gastric perforation is a rare occurrence in the newborn. It 
occurs most commonly during the first 5 days of life, especially in infants 
subjected to severe stress or hypoxia. The constellation of symptoms typi­
cally includes a sudden deterioration in clinical status between the second 
and fifth day of life, characterized by refusal to eat, vomiting, abdominal dis­
tention, and respiratory distress. Free intraperitoneal air and fluid are demon­
strable on plain radiographs of the abdomen. Immediate surgical consultation 
should be sought.
DISORDERS OF THE SMALL INTESTINE
CONGENITAL ANOMALIES
Of the various small intestinal disorders that present in the neonatal pe­
riod, congenital anomalies that produce obstruction are likely to present ear­
liest. Patients present with bilious vomiting, abdominal distention, and occa­
sionally obstipation. Bilious vomiting associated with the passage of blood 
through the rectum suggests vascular compromise of the small intestine, ne­
cessitating immediate surgical intervention.
Malrotation or nonrotation of the gut is an anatomic defect produced 
by incomplete rotation and fixation of the embryonic intestine after return 
from its extraabdominal location at about week 10 of gestation. During de-
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velopment, the intestine rotates 270° around the axis of the superior mesen­
teric artery to place the cecum in the right lower quadrant. When the cecum 
fails to rotate completely, the mesenteric attachment of the small intestine is 
limited to that supporting the superior mesenteric artery and vein. This per­
mits the bowel to twist on itself and produces a midgut volvulus. In the mal- 
rotated colon, adhesive bands, otherwise known as Ladd bands, stretch ante­
riorly from the right peritoneal gutter over the duodenum, where they can 
produce obstruction. Rotational anomalies may be associated with other in­
testinal anomalies, usually duodenal stenosis or atresia or other small intesti­
nal atresias. Cardiac, esophageal, urinary, and anal anomalies also may be 
present. Rotational abnormalities should be considered in the differential di­
agnosis of a high intestinal obstruction identified radiographically. Unfortu­
nately, the diagnosis often is missed by plain abdominal radiographs because 
air may be present in several loops of bowel distal to the obstruction. Rota­
tional abnormalities are identified more easily with an upper gastrointestinal 
series, or barium enema. The radiographic hallmark of malrotation is the 
identification of the cecum in the upper abdomen or to the left of the midline, 
Symptomatic rotational abnormalities require urgent surgical exploration, 
since a volvulus may result in loss of the entire midgut within hours of pres­
entation due to vascular occlusion.
Jejunal or ileal atresias range from membranous obstructions to com­
plete atresia. Atresias can be single or multiple. An apple peel or Christmas 
tree deformity of the superior mesenteric artery results in an extensive jejuna 
atresia followed by multiple ileal atresias that are vascularly supplied by a 
branch of the ileocolic artery. Unlike duodenal atresia relatively few anoma­
lies are associated with ileal atresia. Cystic fibrosis, however, is present in 
approximately 20% of infants with jejunoileal atresia.
Small intestinal atresias in the neonatal period present with bilious 
vomiting. The degree of abdominal distention varies with the site of the 
atresia. If the atresia is distal, vomiting may be delayed for up to 24 hours af­
ter birth. Depending on the location of the atresia, varying numbers of dilated 
loops of bowel with air fluid levels may be present on abdominal radio­
graphs. Because it is difficult to differentiate small intestine from colon on 
plain abdominal radiographs in newborns, a contrast enema should be per­
formed to exclude colonic lesions and obstructions. Contrast enemas also are 
helpful in excluding disorders such as meconium plug syndrome or associ­
ated rotational abnormalities.
MECONIUM ILEUS
Meconium ileus occurs almost exclusively in patients with cystic fi­
brosis. It is caused by abnormally viscid mucus glycoprotein in meconium. 
Approximately 10% to 20% of patients with cystic fibrosis have meconium 
ileus as the first sign of their disease. Pathologically, the lumen of the distal
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small intestine is obstructed by an accumulation of abnormal meconium. In­
fants present with bilious vomiting and abdominal distention during the first 
2 days of life. A palpable sausagelike mass may be present, and rectal exami­
nation may identify hard, dry, graytan meconium. Abdominal radiographs 
demonstrate some evidence of complete obstruction, but the radiologic hall­
mark is the soap-bubble appearance of trapped air within the tenacious me­
conium in the distal small bowel. A water-soluble contrast enema occasion­
ally is therapeutic in disrupting the meconium obstruction. Care shoud be 
taken to avoid dehydration, since contrast substances are hypertonic and can 
result in massive pooling of fluid within the bowel lumen. Surgical iterven- 
tion is required if the contrast enema is unsuccessful.
Other disorders related to meconium may be seen in the neonatal pe­
riod. Meconium peritonitis may occur when intrauterine bowel perforation, 
secondary to obstruction, has resulted in leakage of sterile meconium into the 
peritoneal cavity. Common causes include atresia, volvulus, stenosis, cystic 
fibrosis, meconium ileus, and Hirschsprung disease. Small flecks of intraab­
dominal calcification may be identified radiographically. Ascites occasion­
ally occurs, but may resolve spontaneously unless secondary infection devel­
ops. In severe cases, meconium peritonitis can result in adhesions that require 
surgical intervention.
NECROTIZING ENTEROCOLITIS
Probably the most serious gastrointestinal disorder occurring in neo­
nates is NEC. Because NEC appears predominantly in sick, low-birth-weight 
infants, the incidence has increased in recent years as the mortality rate for 
the very-low-birth-weight infant has decreased. It has been estimated that 
90% of cases occur in premature infants and that NEC may develop in 1% to 
10% of infants hospitalized in neonatal intensive care units. Significant inter­
center differences in the prevalence of NEC have been reported. The mortal­
ity rates vary from 10% to 50%. The age o f onset of NEC is related to birth 
weight and gestational age. Smaller, more immature infants (<26 weeks of 
gestation) tend to have NEC at art older age than larger, more mature (>31 
weeks of age) infants. Thus, the more premature the infant, the longer the du­
ration of risk.
The etiology of NEC is not fully known. Multiple factors appear to be 
involved, including hypoxia, acidosis, and hypotension, which may lead to 
ischemic damage of the mucosal barrier of the small intestine. Secondary 
bacterial invasion of the mucosa may be involved in the pathogenesis of 
pneumatosis intestinalis. Moreover, NEC has been observed to occur in epi­
demics in neonatal intensive care units, further supporting the role of micro­
bial agents in pathogenesis. A number of conditions may predispose the lar­
ger infant to development of NEC, including cyanotic congenital heart dis­
ease, obstructive lesions of the systemic cardiac outflow (e.g., hypoplastic
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left heart, coarctation of the aorta), polycythemia, umbilical catheters, ex­
change transfusions, perinatal asphyxia, maternal preeclampsia, and maternal 
use of cocaine. Infants with patent ductus arteriosus also seem to be at greater 
risk. In this case, oxygenated blood is shunted from the intestine. A ll of these 
factors suggest that mucosal injury and ischemia are important in the devel­
opment of NEC. The role of inflammatory mediators, such as tumor necrosis 
factor-а and platelet-activating factor, and oxygen free radicals also have re­
ceived attention.
Rapid onset of enteral feeding may be a risk factor for NEC, because 
of changes in enteric blood flow and oxygen requirements during feeding. 
Necrotizing enterocolitis is occasionally, but rarely, reported in infants who 
have never been enterally fed. Several factors related to enteral feeding have 
been studied and a number of theories have been proposed on how enteral 
feedings might precipitate NEC. Hyperosmolar formulas have been impli­
cated in the production of NEC, but these formulas differed from standard 
formulas in other ways as well. In addition, most hyperosmolar formulas 
have been reformulated to minimize this risk. Formula feedings seem to pre­
dispose to NEC more than breast-feeding, suggesting that breast milk factors, 
including growth factors, antibodies, and cellular immune factors, might be 
protective. It also is likely that formula within the gastrointestinal tract may 
provide a substrate for bacterial proliferation. The role of bacterial invasion 
in this disease has been well recognized, but is likely to be a secondary event 
after compromise of the intestinal mucosal barrier.
The shunting of blood away from the intestine in a fashion similar to 
the diving reflex in aquatic mammals has been postulated as a potential 
mechanism for producing the initial gut ischemia. This reflex might occur in 
response to a hypoxic episode, and has been studied extensively in animal 
models.
The association of NEC with prematurity implicates immaturity of the 
intestinal mucosal barrier. A number of factors that affect the mucosal barrier 
are immature in premature infants, including acid output, intestinal motility, 
and enzyme production. Immaturity of the microvillus membrane itself, as 
well as differences in the mucus secreted by the small intestine, may play a 
significant role. The mucosal immune system is immature, and less secretory 
IgA is produced. Recent interest has arisen in the possible role of oral immu­
noglobulin administration for prophylaxis against NEC.
The reported gastrointestinal hormone abnormalities in NEC patients 
are difficult to interpret because of the spectrum of ages at which the disease 
develops, the randomness of blood sample timing, and the variation in quan­
tity of enteral feedings. Concentrations of GIP, neurotensin, and enterogluca- 
gon in infants with NEC are lower than those of fed normal infants of compa­
rable age, but gastrirv, motilin, and pancreatic polypeptide (PP) levels appear 
to be normal.
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Clinical presentations vary widely. Abdominal distention usually is one 
of the earliest and most consistent clinical signs. Other symptoms include 
bloody stools, apnea, bradycardia, lethargy, shock, and retention of gastric 
contents due to poor gastric emptying. Thrombocytopenia, neutropenia, and 
metabolic acidosis may develop during bowel ischemia. Not every patient 
has every sign, however, and clinical presentation may vary markedly. Diag­
nosis is confirmed by radiographic demonstration of pneumatosis intestinalis 
or portal hepatic venous air. Nonspecific radiographic findings include 
thickening of the bowel wall, dilated loops of bowel, and ascites. The 
presence of reducing substances in the stool, due to carbohydrate 
malabsorption, may be an early finding in NEC, as may increased di- 
antitrypsin levels, which indicate protein-losing enteropathy.
Suspicion of NEC dictates that all enteral feedings should be discon­
tinued. An orogastric tube is placed routinely to relieve distention of the ali­
mentary tract. Intravenous access must be secured to provide fluid and elec­
trolytes and nutrition, since the patient will not be fed enterally for an ex­
tended period of time. Intravenous antibiotics are administered to provide 
coverage for enteric organisms. Inclusion of specific antianaerobic agents 
does not appear to be helpful. The duration of oral intake restriction depends 
on the clinical status. Patients who merely have poor feeding with increased 
residuals, and the presence of minimal radiographic findings, may be fed 
within 48 to 72 hours. In the presence of pneumatosis intestinalis and marked 
abdominal distention, 2 weeks of parenteral nutrition may be required before 
judicious gradual reintroduction of enteral feedings is considered.
Throughout the course of the disease, frequent radiographic evaluation 
of the abdomen for evidence of intestinal perforation is required. Apnea, bra­
dycardia, abdominal wall discoloration or edema, or a sudden increase in in­
traabdominal girth should give rise to the suspicion of bowel perforation. In 
the presence of perforation, surgical intervention should occur immediately. 
Frequent laboratory evaluations include a complete blood count and platelet 
count to look for thrombocytopenia and neutropenia, both of which suggest 
deterioration. In infants with severe inflammation of the small intestine, large 
volumes of fluid and electrolytes or blood products may be required to main­
tain perfusion and blood pressure. This is especially true in infants in whom 
severe metabolic acidosis develops secondary to poor perfusion. Ventilatory 
support may be necessary.
Infants who require surgical intervention are at risk for short bowel 
syndrome and a variety of complications associated with total parenteral nu­
trition (TPN). In a number of infants, the mucosal inflammatory process may 
progress to transmural necrosis that may, if it does not lead to perforation, re­
sult in fibroblast proliferation, granulation tissue, and stricture formation. 
Stricture formation in the distal small intestine and colon is a relatively com­
mon complication following NEC. Some clinicians routinely study the gas-
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trointestinal tract radiographically after NEC has been treated medically. It is 
not uncommon to find asymptomatic ileal stenosis or colonic stenosis in such 
patients. If symptoms of partial obstruction, such as abdominal distention, 
failure to thrive, or poor feeding develop in infants who have recovered from 
a bout of NEC, contrast studies are indicated.
SHORT BOWEL SYNDROME
Short bowel syndrome is defined as a malabsorptive state that occurs 
after bowel resection. Infants with short bowel syndrome fall into two catego­
ries: those with congenital anomalies (e.g., gastroschisis, apple peel anomaly 
of the superior mesenteric artery, intestinal atresia) and anatomically normal 
patients who undergo bowel resection for NEC. The latter group tend to have 
fewer complications and a better prognosis, when equal lengths of residual 
small intestine remain.
After massive resection of the small intestine, the remaining small 
bowel undergoes an adaptation process characterized by epithelial hyperpla­
sia. Within 1 to 2 days after resection, enterocytes begin replicating in the 
crypts. Gradual morphologic changes occur in the small intestine, including a 
marked lengthening of villi that results in increased mucosal surface area. 
This is followed by an increase in absorptive capacity that eventually enables 
many to survive without parenteral nutrition. The adaptation process is grad­
ual, however, and may require weeks to years.
The major gut hormone changes seen after ileal resection are marked 
increases in plasma levels of PYY, enteroglucagon, and motilin. Increases of 
the putative trophic hormone, enteroglucagon, and of PYY, which inhibits 
gastric and small intestinal secretion and delays intestinal transit, are appro­
priate responses in this condition. Preservation, or even enhancement of the 
PYY response would be valuable in diminishing the rapid transit and diarrhea 
associated with this condition. Studies in experimental animals have revealed 
that improvements in transit and fluid absorption are temporally related to the 
increase in PYY response that occurs after bowel resection.
Mucosal hyperplasia does not occur in the absence of enteral nutrition. 
In fact, mucosal atrophy may result if the patient is nourished only parenter- 
ally. Enteral nutrition stimulates intestinal adaptation by several mechanisms. 
Highly unsaturated long-chain fats stimulate intestinal adaptation to a greater 
extent than protein or carbohydrate; the mechanism by which this occurs is 
poorly understood. Nonetheless, careful attention to the provision of adequate 
enteral nutrition is important.
Management of the short bowel syndrome is a multistage process. Dur­
ing the early postoperative period, use of parenteral nutrition and careful at­
tention to fluid and electrolyte abnormalities are essential. High-volume os­
tomy losses must be replaced with a solution of comparable electrolyte
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content to obviate the need for frequent changes in electrolyte concentration 
in parenteral nutrition solutions.
The presence of an ostomy may create additional problems. These vary 
somewhat, depending on whether the ostomy is in the ileum, in which 
thevolume output is likely to be much greater, or in the colon, in which stool 
consistency may vary markedly based on whether the ostomy was placed 
proximally or distally. If available, the services of an enterostomal therapist, 
with special training in rehabilitation of infants and children with ostomies, 
will assist the parents in understanding the implications of the ostomy. The 
ostomy should be placed away from sites such as the iliac crest, costal mar­
gin, or umbilicus so that ostomy appliances will fit easily.
Most ostomy devices consist of an adhesive, nonallergenic wafer de­
vice with a flange that allows the transparent drainage pouch to be secured to 
it over the stoma. The pouch is easily removed for draining by snapping it off 
the wafer, or it can be emptied through a drainage port at the bottom of the 
bag. When leakage occurs beneath the wafer, the device should be removed, 
and careful skin care around the ostomy is necessary. The skin should be 
washed gently with a soft cloth, moistened with mild soap and tepid water. 
The skin should then be dried thoroughly after cleansing. Many protective 
ointments and powders are available to apply around the stoma area to pre­
vent skin breakdown. If skin irritation is present, tincture of benzoin or ster­
oid preparations available in spray form may be used. The pouches often are 
reusable, and may be washed with mild soap and water and soaked in a de­
odorant solution to control odor problems. Appropriate teaching will prevent 
many of the other problems encountered by ostomy patients such as skin ex­
coriation, minor stoma bleeding, stoma prolapse, and odor. Additional 
ostomy problems include prolapse and stenosis. The latter should be sus­
pected in the presence of abdominal distention and vomiting. In either situa­
tion, the surgeon should be notified.
When enteral feeds are started, a slow continuous infusion of a dilute 
elemental formula generally works best. The lactose-free preparations with 
hydrolyzed protein are rapidly absorbed, yet provide adequate stimulation of 
intestinal adaptation. Stool losses must be monitored carefully. A marked in­
crease in fluid losses or significant evidence of carbohydrate malabsorption 
manifested by a low stool pW or positive stool-reducing substances are con­
traindications for further increasing the enteral infusion. Enteral infusions are 
increased as tolerated, and parenteral nutrition is decreased in a gradual iso­
caloric fashion. Patients can then be weaned to intermittent parenteral nutri­
tion and prepared for home parenteral nutrition therapy. Intermittent par­
enteral nutrition allows provision of parenteral nutrients at night, primarily 
for the convenience of caregivers. Parenteral nutrition initially is discontin­
ued only for short periods of time, usually 4 to 6 hours, each day. In small in­
fants, this usually is delayed until the patient can tolerate approximately 20%
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of calorie intake enterally to avoid hypoglycemia when he or she is not re­
ceiving parenteral nutrition. The duration of parenteral nutrition can be de­
creased gradually until all parenteral nutrition infuses over 10 to 12 hours at 
night. It is wise to taper the parenteral nutrition rates up and down when plac­
ing a patient on or off of parenteral nutrition, to prevent fluctuation in serum 
glucose levels. Home parenteral nutrition has markedly reduced the cost of 
long-term management of short bowel syndrome patients and also has de­
creased family stresses and nosocomial infections. It has become a standard 
therapy in patients with short bowel syndrome, and prolonged hospitaliza­
tions rarely are necessary. To minimize complications, careful training of 
home nursing personnel is essential and coordination of activity between 
physician and nursing staff must be tightly controlled.
Continuous enteral infusions are used in patients in short bowel syn­
drome for several reasons. The percentage of calories absorbed from the con­
tinuous infusion is greater than that possible with bolus feedings, because 
transport carrier proteins are continually saturated. Continuous infusion pro­
vides constant stimulation of mucosal adaptation and reduces the need for 
parenteral calories, decreasing the risk of parenteral nutrition liver disease. 
Children should be fed small quantities of formula orally, so as to learn to 
suck and swallow. Eventually, solids can be fed around the nasogastric tube. 
These manipulations often will speed the transition from continuous enteral 
to oral feeding later in the course of therapy.
Numerous chronic complications arise in the treatment of short bowel 
syndrome, including bacterial overgrowth, nutritional deficiency states, wa­
tery diarrhea, parenteral nutrition liver disease, and catheter-related problems. 
Bacterial overgrowth is defined as increased bacterial content in the small in­
testine. Complications from bacterial overgrowth include increased malab­
sorption, d-lactic acidosis and colitislike or ileitislike syndrome. Normal 
small bowel bacterial counts vary from 103/mL proximally to much greater 
numbers in the ileum. Normal antegrade peristalsis and gastric and mucosal 
immune factors prevent excess bacterial proliferation. In short bowel syn­
drome, because of disruption of normal anatomy and motility, overgrowth is 
likely and bacterial counts usually exceed 10s/mL. Bacterial overgrowth 
should be suspected whenever motility is slowed, bowel is dilated, or the 
ileocecal valve is absent. Organisms typically include facultative bacteria and 
anaerobes. Bacteria deconjugate bile salts, causing them to be reabsorbed, 
depleting the bile salt pool, impairing micelle solubilization, and resulting in 
steatorrhea and malabsorption of fat-soluble vitamins. More important, bacte­
rial overgrowth causes mucosal inflammation, exacerbating malabsorption of 
all nutrients. Protein-losing enteropathy and loss of immunoglobulins may 
occur. Bacteria may compete with the host for nutrients, such as vitamin B)2
Screening for bacterial overgrowth can be done with a fasting breath 
hydrogen or glucose breath hydrogen test, or by detecting the presence of in-
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dican in the urine. Measurement of breath hydrogen is a simple test in infants 
and children, although collection of samples in the neonate requires special 
care. A fasting breath hydrogen level greater than 42 ppm is seen only in 
small bowel bacterial overgrowth. A breath hydrogen level greater than 20 
ppm after the administration of 2 g/kg of oral glucose, with measurement at 
15-minute intervals after ingestion, suggests bacterial overgrowth. Measure­
ment of indican in the urine is a simple screening test for bacterial over­
growth, because bacteria convert dietary tryptophan to indican. Unfortu­
nately, indicanuria may occur in other conditions, and the technique lacks 
sensitivity. Bacterial overgrowth can be definitively diagnosed by culture of 
aspirates from the small intestine. Small intestinal biopsies demonstrating in­
flammatory changes suggest bacterial overgrowth.
Accumulation of o-lactate in the bloodstream results in neurologic 
symptoms varying from frank disorientation to coma. Bacterial overgrowth 
may cause colitislike or ileitislike syndrome with large ulcerations character­
istic of Crohn disease, but without granulomas. Broad-spectrum oral antibiot­
ics (e.g., metronidazole, gentamicin and so on) and antiinflammatory agents 
often are beneficial. Broad-spectrum antimicrobial coverage should be di­
rected at the organisms present, usually anaerobes. Antimotility agents may 
improve nutrient contact with the mucosa by lengthening transit time, but 
tend to exacerbate bacterial overgrowth and should be used with caution.
Secretory diarrhea may be a problem in some children with short 
bowel syndrome. This may be related to hypergastrinemia, which often oc­
curs after resection. Because the tight junctions in the ileum are less perme­
able than the jejunum, the ileum plays a major role in fluid and electrolyte 
conservation, and ileal resections are more likely to result in major fluid and 
electrolyte losses than jejunal resections. Because most infants with NEC 
have ileal disease, this is a major problem in neonates after bowel resection: 
Ileal resection also results in malabsorption of bile acids, because the ileum is 
the primary site for bile acid reabsorption. Malabsorption of bile acids into 
the colon may cause fluid secretion and watery diarrhea, which may respond 
to a bile-acid-binding resin such as cholestyramine. Unfortunately, cho­
lestyramine may further deplete the bile acid pool, exacerbating steatorrhea.
Nutritional deficiency states may occur after parenteral nutrition is dis­
continued, including deficiencies of fat-soluble vitamins A, D, and E, and the 
minerals iron, zinc, calcium, and magnesium.
Parenteral nutrition hepatobiliary tract disease is the major complica­
tion that may result in death in infants with short bowel syndrome. The 
mechanism by which the liver injury occurs is unknown. In mostinstances, 
enteral administration of a significant percentage of calories, usually between 
20% and 30% of total requirements, reduces the risk of parenteral nutrition 
liver disease.
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Cholelithiasis develops in approximately 20% of infants receiving par­
enteral nutrition for short bowel syndrome because of malabsorption of bile 
acids, altered bilirubin metabolism, and gallbladder stasis. Cholangitis may 
occur in the presence of partial obstruction. Early cholecystectomy should be 
considered if patients are symptomatic with elevated direct bilirubin and liver 
enzymes.
Catheter-related infections and thrombosis are common in infants re­
quiring long-term parenteral nutrition. In our experience, catheter-related in­
fections rarely are due to intestinal bacterial overgrowth and most commonly 
are related to catheter care technique. Diligent parental instruction in catheter 
care and in the signs and symptoms of sepsis is extremely important.
During later stages of therapy, additional surgery may be indicated. 
One of the first questions usually concerns whether to close a stoma that was 
formed at the time of initial surgery. If the colon remains, and especially if 
ileum exists as well, reconnecting an ostomy may substantially conserve fluid 
and electrolytes, but also may result in perianal disease. In infants with di­
lated segments of proximal bowel, resecting a tight anastomosis or tapering 
the bowel to improve flow of luminal contents often reduces bacterial over­
growth. A number of procedures have been designed to slow transit time, in­
cluding reverse segments of bowel, one-way valves, or colon interposition, 
but none is considered reliably effective, and all may increase bacterial over­
growth.
A procedure to increase the length of the bowel has been devised that 
involves transecting the bowel longitudinally, preserving the blood supply to 
both sides of the bowel, and creating a segment about twice the length and 
one-half of the diameter. This allows reducing the diameter of the bowel 
without any loss of mucosal surface area. Because it does not actually in­
crease the mucosal surface area, it is indicated primarily to reduce bacterial 
overgrowth without losing absorptive surface in infants with dilated bowel. 
Our experience has been quite rewarding with this procedure, with 12 of 14 
recent patients demonstrating significant improvement and several becoming 
independent of parenteral nutrition after surgery. It should not, however, be 
performed in neonates, because it is successful only after significant bowel 
dilation has occurred.
Intestinal transplantation has become available, but remains experi­
mental. Rejection and sepsis have been the major obstacles to success. Com­
bined liver-bowel transplants in children with irreversible, severe TPN- 
associated liver disease and short bowel syndrome have achieved some suc­
cess. Further experience with intestinal transplantation must be gained before 
its role in the treatment of short bowel syndrome can be determined.
It is possible for infants to survive without transplantation or perma­
nent parenteral nutrition with surprisingly short segments of bowel. As a gen­
eral rule, patients with greater than 25 cm of bowel at the time of neonatal re­
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section who have an ileocecal I valve, or with greater than 40 cm of bowel at 
the time of neonatal resection who have no ileocecal valve, have a reasonable 
chance of eventually becoming in dependent of parenteral nutrition. The ileo­
cecal valve appears to play a major role in determining the long-term progno­
sis, primarily because of its ability to exclude colonic bacteria from entering 
the small bowel and perhaps its ability to delay transit through the small in­
testine.
MUCOSAL INJURY DISORDERS
Because of the limited small intestinal reserve in small infants, small 
intestinal disease is perhaps most catastrophic in infancy. In small intestinal 
injury, all nutrients are malabsorbed. Most symptoms, however, are related to 
carbohydrate malabsorption because of the osmotic diarrhea produced when 
these malabsorbed molecules are broken down further by intestinal bacteria 
into smaller and smaller osmotically active particles. The osmotic gradient 
overrides the ability of the ileum and colon to reabsorb fluid effectively, and 
watery diarrhea ensues.
Measurement of stool pH  and reducing substances is an ideal means to 
screen for small bowel mucosal disease in infancy. When carbohydrates are 
malabsorbed and broken down into organic acids by colonic bacteria, the 
stool pH drops below 5.5. Stool pH can be measured easily with litmus paper, 
simply by inserting the paper into the stool. Measurement of reducing sub­
stances in stool can be done by placing five drops of stool and ten drops of 
water into a test tube and dropping in a Clinitest (Ames, Elkhart, IN) tablet. 
Positive reducing substances in stool confirms the presence of carbohydrate 
malabsorption. Patients receiving formulas that are predominantly sucrose 
are less likely to demonstrate positive reducing substances in their stools be­
cause sucrose is a nonreducing carbohydrate.
INFECTIOUS DIARRHEA
During the neonatal period, infectious diseases of the small intestine 
are relatively uncommon. A number of viruses may cause diarrhea in small 
infants, including rotavirus, enteric adenoviruses, and enteroviruses. Viral 
gastroenteritis usually presents with watery stools with evidence of carbohy­
drate malabsorption. The predominant mucosal injury in viral gastroenteritis 
is in the proximal jejunum, where carbohydrates are absorbed. In contrast, 
bacterial pathogens generally produce more distal injury that involves the co­
lon and results in Hematest-positive stools that contain leukocytes (Table 15). 
Bacterial causes of diarrhea include Salmonella sp, Shigella sp, invasive Es­
cherichia coil, and Campylobacter jejuni. Clostridium difficile infection pre­
dominantly involves the large intestine, and in severe cases, produces 
pseudo-membranous colitis. Infection with C. difficile usually follows a 
course of broad-spectrum antibiotics. Severe watery or bloody diarrhea and
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colonic perforation may occur. Diagnosis is difficult in neonates because a 
very high percentage of small infants carry C. difficile without evidence of 
disease.
Table 17
Screening stool studies in infectious diarrhea
Bacterial Viral
Clinitest - +
PH > <
Hematest +++ -
Leukocytes +++ -
negative; + - negative or positive; +++ - strongly positive.
HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED DISEASE
Human immunodeficiency virus (HIV) in infants results in a variety of 
gastrointestinal problems. Failure to thrive is not uncommon. Chronic diar­
rhea and generalized lymphadenopathy often are present. Other common 
presentations include asymptomatic hepatosplenomegaly, which may occur 
in conjunction with severe interstitial pneumonia and hy­
pergammaglobulinemia.
Chronic diarrhea in infants with acquired immunodeficiency syndrome 
(AIDS) presents a very difficult management problem. Diarrhea may result 
from opportunistic infections, tumors, including Kaposi sarcoma and lym­
phoma, and direct HIV infection of the gut. Opportunistic organisms include 
viral agents (e.g., cytomegalovirus, rotavirus, herpes simplex, coxsackievirus, 
adenovirus), bacterial pathogens (e.g., Salmonella sp, Campylobacter-like 
organisms, Listeria sp, Mycobacterium avium-intracellulare, Plesiomonas 
shigelloides), fungal pathogens (e.g., Candida sp, Aspergillus sp), and para­
sitic pathogens (e.g., Cryptosporidium, Strongyloides sp, Giardia sp, amoe- 
bas, Isospora belli}. A broad spectrum of endoscopic and histologic findings 
is possible because of the diverse nature of the disease. Extensive viral and 
bacterial cultures and examinations for ova and parasites are warranted in in­
fants and children with AIDS.
Treatment consists of therapy directed at any specific infectious patho­
gen identified, coupled with use of parenteral and enteral nutrition. As in al­
most all chronic enteropathies, primary attention should be given to continu­
ous enteral infusion with an elemental diet or protein hydrolysate formula. If 
malabsorption develops in the patient, as indicated by stools testing positive 
for reducing substances or manifesting a pH below 5.5, supplemental par­
enteral nutrition is needed to provide the remainder of caloric and other nutri­
tional needs. The presence of a significant secretory component of the diar­
rhea may make treatment difficult, may complicate the use of continuous en­
teral infusion, and may require careful attention to intake and output of fluid 
and electrolytes to maintain biochemical homeostasis.
1 50
HORMONAL CHANGES IN DIARRHEA
Infective diarrhea in infants is associated with a massive increase in 
circulating concentrations of motilin, enteroglucagon, and PYY. These ab­
normalities resolve once the patients are better. The gut endocrine system in 
infants, however, responds in a manner different from that of adults. In in­
fants with diarrhea, plasma motilin concentrations exceed those that are 
known to accelerate gastric emptying and increase small bowel motility. Mo­
tilin is therefore likely to be involved in the motor abnormalities associated 
with this condition. A hormonally triggered increase in transit rate may con­
stitute a defense mechanisms to rid the bowel of pathogens and secreted tox­
ins. The extremely high enteroglucagon levels in neonatal infective diarrhea 
appear to be related to the extent of mucosal injury and its repair. Measure­
ment of selected gut hormones may give information on the extent of muco­
sal damage, or the presence of ongoing pathologic change.
FORMULA PROTEIN INTOLERANCE
One of the most common causes of chronic diarrhea in small infants is 
formula protein-induced enterocolitis. Small bowel involvement (i.e., enteri­
tis), colon involvement (i.e., colitis), or concomitant small bowel and colon 
involvement are possible with this disorder. Protein-induced mucosal injury 
has been reported with cow-milk protein, soy protein, breast milk, and even 
beef protein. We have observed infants who have manifested intolerance to 
protein hydrolysate formulas, and responded therapeutically to amino acid 
formulations such as Tolerex or Vivonex.
Infants typically present before 3 months of age with bright red blood 
in the stool, which may be normal or loose in consistency depending on the 
extent of inflammation. Sigmoidoscopic examination may reveal gross fri­
ability or may appear normal until the mucosa is wiped with a cotton swab, at 
which time the mucosa readily bleeds. Rectal biopsy confirms inflammation, 
with the combination of polymorphonuclear leukocytes and eosinophils in 
the lamina pro-pria. Stools may test positive for occult blood and may con­
tain leukocytes. If the inflammation extends into the small intestine, carbohy­
drate malabsorption may occur, infants will have watery diarrhea, and stools 
will be acidic {pH < 5.5) and test positive for reducing substances. Small in­
testinal biopsy will demonstrate varying degrees of mucosal injury, with 
shortening and blunting of the villi, inflammatory infiltrates, and an increase 
in mitotic activity in the crypts. Disaccharidase levels in the mucosal biopsies 
often are reduced.
Other symptoms that may occur as a result of formula protein-induced 
enterocolitis are vomiting and irritability. Infants with formula protein intol­
erance commonly vomit, especially those with small intestinal disease. It of­
ten is difficult to differentiate this disorder from gastroesophageal reflux, be­
cause both groups may present with irritability; however, babies with formula
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protein sensitivity commonly have loose stools and abnormal sigmoidoscopic 
examinations. This is an important .distinction because the treatment is vastly 
different. Irritability, not dissimilar from infantile colic, may occur in infants 
with formula protein intolerance. In infantile colic, the irritability classically 
occurs at a specific time of the day and responds symptomatically to repeti­
tive stimuli. Infants with irritability secondary to formula protein intolerance 
usually are inconsolably irritable, often feed poorly, have loose stools, spit 
up, and have abnormal sigmoidoscopic examinations or other evidence of 
small intestinal or colonic inflammation. A careful histoiy and physical ex­
amination and appropriate laboratory studies can be quite specific in differen­
tiating the two disorders.
Infants who manifest signs and symptoms of formula protein intoler­
ance should be placed on a protein hydrolysate formula such as Nutramigen, 
Pre-gestimil, or Alimentum because a high percentage also will be intolerant 
of soy formula. A small percentage of infants who do not respond to these 
formulas may improve on an amino acid formulation such as Tolerex or Vi- 
vonex. These formulas are constituted for adults, and may not be appropriate 
for use in small infants. The addition of extra vitamins, minerals, and essen­
tial fatty acids should be considered if the formulas are to be used long-term. 
It is frequently administered Tolerex diluted from normal adult strength (1 
cal/mL) to 0.67 cal/mL and place the children on supplemental infant vita­
mins plus 5 to 10 mL of bolus safflower oil daily to prevent essential fatty 
acid deficiency.
Most infants with formula protein intolerance will outgrow their sensi­
tivity by 1 year of age. Powell has described a specific challenge procedure to 
confirm the diagnosis of cow-milk protein intolerance. Patients should not 
have received the suspected antigen for at least 2 weeks before testing and 
should be asymptomatic. A standard dose (100 mL of cow milk or soy for­
mula) is administered and the child is monitored carefully for reaction. Stool 
specimens are analyzed for occult blood, leukocytes, and reducing sugars, 
and a leukocyte count is obtained 6 to 8 hourslater. The test is considered 
positive if diarrhea develops within 24 hours, leukocytes or blood appear in 
stools, or the leukocyte count rises by over 4000 cells/ mL over baseline. Ap­
proximately 20% of the infants have a delayed reaction. If the child originally 
had evidence of severe milk protein sensitivity, it is wise to hospitalize the 
infant, start with small volumes (5-10 mL) of formula, and gradually to in­
crease the volume to avoid severe mucosal injuiy, anaphylaxis, and shock.
INTRACTABLE DIARRHEA OF INFANCY
A state of persistent diarrhea and malabsorption despite the institution 
of a protein hydrolysate formula and in the absence of infectious pathogens is 
referred to as intractable or protracted diarrhea of infancy. These patients 
demonstrate a variety of histologic abnormalities on small intestinal biopsy,
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including blunting or flattening of the villi, increased mononuclear cells with 
occasional polymorphonudear infiltrates, cuboidalization of the surface epi­
thelium, and a mild to moderate increase in mitotic activity in the crypts. His­
tologic lesions vary substantially, however, and correlate poorly with ulti­
mate prognosis. Such infants have chronic weight loss and progressive mal­
nutrition unless appropriate therapy is instituted. Initial therapy involves slow 
institution of a continuous enteral infusion of a diluted elemental formula 
such as Pregestimil or Alimentum. The rate is rapidly advanced to approxi­
mately 150 ml/kg/ day or more, provided the child is not on supplemental 
parenteral nutrition. The concentration of the formula is then sequentially ad­
vanced over 3 to 4 days, until the patient is tolerating full caloric require­
ments and gaining weight. During this time, stool pH and reducing sub­
stances are monitored and evidence of carbohydrate malabsorption suggests 
failure of enteral feedings. If this occurs, a period of parenteral nutrition is 
indicated, usually through a central venous catheter, with gradual reintroduc­
tion of enteral feedings by continuous infusion. In treating such infants, it is 
important to avoid using formulas that contain intact milk or soy protein, be­
cause the likelihood of protein sensitivity in such infants is high and further 
mucosal injury may result. Lengthy periods of parenteral or continuous en­
teral infusion may be necessary, but the ultimate prognosis is good.
In addition to intractable (i.e., protracted) diarrhea associated with 
formula protein intolerance, other rare syndromes have been reported to re­
sult in mucosal injury and chronic diarrhea. One is congenital microvillus at­
rophy or microvillus inclusion disease, a disorder with hypoplastic atrophy of 
the villi and shortening or depletion of micro villi. This disorder requires 
electron microscopic diagnosis and has a very poor prognosis. Severe pro­
tracted diarrhea also may be associated with autoimmune enteropathy; how­
ever, this disorder usually presents outside the immediate neonatal period. 
Mucosal lesions are se vere and the prognosis also is poor. Infants with this 
disorder often have multiorgan autoantibodies, including gut epithelium, and 
frequently have pancreatic involvement with hyperglycemia or hypoglyce­
mia.
DISORDERS OF THE COLON
CONGENITAL ANOMALIES
There is substantial overlap in small bowel and colonic disease in neo­
nates. Many of the congenital anomalies involve both the small and large in­
testine, and certain mucosal injury disorders, including formula protein en­
terocolitis and NEC, can involve both the small intestine and colon. There are 
some disorders that affect the colon primarily, however. Most are congenital 
and involve anatomic obstructions, such as atresias, or dysmotility, such as 
Hirschsprung disease.
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ANATOMIC LESIONS
Colonic stenosis or atresia is a rare event, often associated with other 
skeletal anomalies. Colonic duplication also is a rare entity, which may pre­
sent with delayed symptoms of obstruction. Duplications usually are cystic, 
gradually enlarging masses, located posterior to the rectum, which may be 
confused with tumors.
MOTILITY DISORDERS
More frequent are the disorders that present with delayed passage of 
meconium secondary to dysmotility. Meconium plug syndrome is one such 
entity, in which inspissated meconium in the distal colon results in obstruc­
tion and dilatation proximally. Delayed passage of meconium is the present­
ing symptom, and barium enema examination reveals a large plug of me­
conium that often is evacuated after the barium enema. Normal feeding and 
stooling usually follows removal of the obstruction, but 20% to 30% of pa­
tients with meconium plug syndrome have Hirschsprung disease. If symp­
toms recur after removal of the meconium plug, rectal suction biopsy is indi­
cated.
Delayed passage of meconium also may occur with the neonatal small 
left colon syndrome. Radiographic examination of these infants demonstrates 
normal to dilated proximal colon with constricted or smaller distal colon, 
with the constricted area usually beginning around the splenic flexure. The 
line of demarcation is much more abrupt than is seen in neonatal Hirsch­
sprung disease. The disorder is more common in infants of diabetic mothers, 
as well as infants of mothers with hyperthyroidism. It usually resolves spon­
taneously, although placement of a colostomy may be necessary until normal 
motility returns. Colonic motility will eventually return, usually within 2 to 
12 weeks, and the colostomy may be closed at that time.
Hirschsprung disease, or congenital aganglionic megacolon, occurs in 
approximately 1 in 5000 live births, more commonly in males than in fe­
males. The risk of recurrence in families is reported to be as high as 10%, 
higher in infants with total aganglionosis. The frequency is ten times higher 
in infants with trisomy 21. The disease is caused by a congenital absence of 
the ganglion cells in both the submucous and myenteric plexuses. Ganglion 
cells regulate normal colonic peristaltic activity. The absence of ganglion 
cells results in an inability of the bowel to undergo coordinated relaxation. 
Impaired migration of neural crest cells into the distal colon is thought to be 
the mechanism through which Hirschsprung disease develops, although there 
is some controversy about this. The disorder almost always involves the dis­
tal rectum, but the extent varies substantially. There also is controversy as to 
whether or not skip areas can occur. A few such cases have been reported, 
but they appear to be extremely rare. In most instances, involvement does not 
extend proximal to the sigmoid colon. In very rare instances, the involvement
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may extend beyond the colon into the small intestine. The further the lesion 
extends, the more difficult the medical management becomes.
Most cases of Hirschsprung disease are not diagnosed in the neonatal 
period. When they are, the most common clinical presentation is delayed pas­
sage of meconium, with passage of the first stool beyond 24 hours of age. 
This presentation probably is common but often overlooked. Infants also may 
appear irritable, with poor feeding and failure to thrive—unfortunately, the 
typical presentation of a wide variety of small bowel and colonic disorders.
Some infants with Hirschsprung disease may present with a life- 
threatening complication—acute enterocolitis. Toxic megacolon is common. 
Although enterocolitis may occur in the newborn period, it more commonly 
presents at 2 to 3 months of age. Mortality remains around 50%. The disorder 
presents with sudden or gradual onset of diarrhea, followed by bloody stools 
and eventually the clinical appearance of neonatal sepsis. The clinical overlap 
between infectious enterocolitis or formula protein-induced enterocolitis is 
such that Hirschsprung enterocolitis also must be considered in the differen­
tial diagnosis of these more common entities. Patients who present with 
bloody diarrhea in the neonatal period and have negative stool cultures, and 
who do not respond quickly to protein hydrolysate formula, need to have a 
rectal biopsy performed. If Hirschsprung disease is suspected, surgical con­
sultation should be obtained immediately, and attempts should be made to 
decompress the colon with a rectal tube or rectal irrigation. A decompressing 
colostomy should be placed as soon as feasible.
Diagnosis of Hirschsprung disease usually rests with rectal suction bi­
opsy. A small biopsy tube is inserted into the rectum and a small piece of tis­
sue is removed from a point 2 cm proximal to the mucocutaneous junction. If 
the biopsy is obtained higher, patients with low-segment Hirschsprung dis­
ease may be missed, and if the biopsy is taken more distaliy it will be ob­
tained in the hypoganglionic zone, an area in which ganglion cells are nor­
mally sparse, resulting in a false-positive biopsy for Hirschsprung disease. 
The biopsy must be deep enough to contain sufficient submucosa to identify 
ganglion cells. Superficial biopsies are inadequate to diagnose Hirschsprung 
disease. Because ganglion cells are sparse, the biopsy must be serially sec­
tioned and 60 to 80 sections of tissue examined. Ganglion cells in newborns 
are somewhat immature and difficult to identify. Thus, a rectal suction biopsy 
is a reliable diagnostic tool, provided the biopsy is obtained from an appro­
priate location and depth and an experienced gastroenterologist or pathologist 
interprets the biopsy. If results are equivocal, a full-thickness biopsy may be 
performed to establish the diagnosis.
Diagnosis also can be made by inflating a balloon in the distal rectum 
and measuring relaxation of the internal anal sphincter, a process impaired in 
Hirschsprung disease. Although this technique is less commonly performed, 
those who are skillful in its use believe it is as reliable as rectal biopsy. In
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contrast, barium enema examination in the newborn is highly unreliable in 
the diagnosis of Hirschsprung disease because the transition zone has yet to 
develop. Therefore, proximal colonic dilation usually is not apparent in the 
neonate, and the clinician must look for irregular contractions in the recto­
sigmoid as the primary hallmark of Hirschsprung disease.
Treatment begins with placement of a decompressing colostomy proxi­
mal to the transition zone between ganglionic and aganglionic bowel. 
Definitive surgery usually is done at 8 to 12 months of age. A number of dif­
ferent operations have been devised in which the aganglionic bowel is re­
moved and the ganglionic bowel attached into the distal rectum. Surgical 
treatment generally is successful in restoring long-term fecal continence.
Patients with total colonic Hirschsprung disease present major difficul­
ties in postoperative fluid and electrolyte balance. Infants frequently require 
prolonged courses of parenteral nutrition. Parents should be warned about the 
protracted nature of the disease, and infants should be observed closely for 
fluid, electrolyte, and nutritional problems.
Several rare intestinal motility disorders present in the neonatal period. 
Transient hypomotility occurs in some premature infants, and is characterized 
by markedly delayed gastric emptying and absent or diminished small bowel 
motility. In most instances, these abnormalities gradually resolve with time; 
support with parenteral nutrition coupled with intermittent attempts at feed­
ing is all that is indicated. Alterations in calcium and magnesium metabolism 
such as parathyroid dysfunction, or hypothyroidism can cause diminished 
motility, and these disorders should be excluded in infants with apparent mo­
tility disorders. Occasionally, infants with chronic idiopathic intestinal pseu­
doobstruction syndrome can present during infancy. This term applies to a 
number of neuropathic and myopathic disorders that result in chronic pro­
gressive gastrointestinal hvpomotility. A variety of histologic lesions have 
been described, and the prognosis for improvement is poor. Occasionally, the 
disorder also may involve the urinary tract, with associated megalocystis and 
mega-ureter.
PANCREATIC DISORDERS
CYSTIC FIBROSIS
Disorders of the pancreas uncommonly present during the neonatal pe­
riod. The most common is cystic fibrosis, which occurs in approximately 1 in 
1600 Caucasian live births. This autosomal recessive disorder usually pre­
sents later in childhood with failure to thrive or chronic pulmonary disease, 
but may present with meconium ileus in the neonatal period. After the ob­
struction has been relieved, therapy consists of compensating for the pancre­
atic insufficiency through use of elemental formulas such as Pregestimil or 
Alimentum that contain hydrolyzed protein as their protein source and me­
dium-chain tnglycer-ides as part of their lipid component. Medium-chain
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triglycerides do not require digestion by pancreatic enzymes for absorption 
and, consequently, may facilitate nutrient assimilation in infants with pancre­
atic insufficiency. Despite the use of elemental formulas, replacement pan­
creatic enzyme therapy from birth is necessary to aid the digestion of 
endogenously secreted proteins.
In children with pancreatic insufficiency due to cystic fibrosis the re­
lease of the pancreatic hormone PP is almost totally abolished. Fasting PP 
levels are low and the normal response to milk feeding is absent. Plasma in­
sulin and GIP responses are significantly reduced in cystic fibrosis patients, 
compared to control subjects, even though the early glucose rise is greater in 
the former group. Reduced GIP secretion in response to feeding may exacer­
bate the glucose intolerance that accompanies pancreatic destruction. Al­
though plasma enteroglucagon concentrations are elevated in cystic fibrosis, 
levels of other hormones such as gastrin, secretin, motilin, and glucagon are 
quite normal.
The second most common cause of pancreatic insufficiency in infancy 
is Shwachman syndrome, a disorder characterized by pancreatic insufficiency 
and bone marrow dysfunction with cyclic neutropenia. This rare disorder 
should be considered in infants with steatorrhea and neutropenia. Extremely 
rare isolated defects in pancreatic enzyme secretion, including trypsinogen 
and lipase, also have been reported.
DISORDERS OF THE LIVER
The liver is a complex organ serving multiple metabolic functions. 
From a digestive standpoint, its primary function is that of an exocrine organ 
producing bile for the emulsification of fats. Postnatally, the liver receives its 
blood from two separate sources, approximately 25% from the hepatic artery, 
and 75% from the portal vein. The portal vein drains the splanchnic bed and 
allows the liver the opportunity to regulate and metabolize substances ab­
sorbed by the intestine and hormones produced in the gastrointestinal tract.
Bile is composed primarily of water. The concentration of solids in the 
bile are increased threefold by the gallbladder. The fetal liver is capable of 
synthesizing bile acids from cholesterol slowly, and the rate of synthesis in­
creases progressively throughout gestation. The major bile salt in newborns is 
taurocholate. Conjugation of bile salts with glycine in preference to taurine 
gradually increases, and by adulthood, most bile salts are conjugated with 
glycine. The bile acid pool is very small in the preterm infant, but gradually 
increases in the newborn and matures throughout infancy. This relatively 
small bile acid pool results in reduced bile salt secretion and, in addition to 
the relative pancreatic insufficiency, plays a role in the less efficient absorp­
tion of fat in the newborn infant. Bile adds are reabsorbed in the ileum 
through an active transport mechanism. There is some passive transport of
157
bile acids in the jejunum and colon as well. In the fetus, taurocholate is ab­
sorbed passively and active ileal transport appears after birth.
CHOLESTATIC LIVER DISEASE
Most liver diseases in the neonatal period present with cholestasis, or 
conjugated hyperbilirubinemja. Although in older children and adults, eleva­
tion of the amino transferase (i.e., transaminase) enzymes is considered the 
hallmark of hepatocellular injury, neonates may have significant hepatocellu­
lar injury even in the presence of normal amino transferase levels. There are 
many causes of prolonged conjugated hyperbilirubinemia in the neonatal pe­
riod. These can be subdivided into general categories, including infectious 
disorders; toxic insults such as parenteral nutrition and sepsis; metabolic dis­
orders; anatomic disorders, including congenital hepatic fibrosis and chole­
dochal cyst; and idiopathic infantile cholangiopathies, including primarily 
biliary atresia and neonatal hepatitis.
Neonatal Hepatitis and Biliary Atresia. After extensive evaluation of 
the infant with cholestasis, a diagnosis of either extrahepatic biliary atresia or 
idiopathic neonatal hepatitis is made in 70% to 80% of cases. Current think­
ing suggests that neonatal hepatitis and biliary atresia form a continuum of a 
pathophysiologic process directed at various levels of the hepatobiliary tract. 
Inflammation in the bile duct epithelium may result in sclerosis and oblitera­
tion of the bile ducts and manifest itself as extrahepatic biliary atresia. Pri­
mary hepatocellular inflammation is more likely to result in neonatal hepati­
tis. Reovirus type III has been found in a number of infants with both idio­
pathic neonatal hepatitis and biliary atresia. This virus has been implicated as 
a causative agent in both disorders, although there is evidence that raises 
questions about this hypothesis.
Idiopathic neonatal hepatitis is slightly more common than biliary atre­
sia. Both sporadic and familial varieties exist. Neonatal hepatitis, unlike 
biliary atresia, is more common in low-birth-weight infants. Jaundice devel­
ops during the first week of life in most cases. A wide variety of clinical 
presentations may occur, from severe failure to thrive or fulminant hepatic 
failure to asymptomatic jaundice. Acholic stools are uncommon, but may oc­
cur if cholestasis is severe. Physical examination reveals a firm, enlarged 
liver and occasionally splenomegaly. The presence of other signs of congeni­
tal infection may point toward a more specific diagnosis. Liver biopsy may 
be helpful in making the diagnosis, but the histologic findings are relatively 
nonspecific. In most cases, neonatal hepatitis can be differentiated success­
fully from biliary atresia by percutaneous liver biopsy. Clinical management 
is directed toward nutritional support and medical management of clinical 
complications such as ascites or pruritus. The prognosis is variable, with one- 
half of the cases resolving with little or no sequelae. Life-threatening chronic 
liver disease may necessitate liver transplantation.
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Extrahepatic biliary atresia accounts for about one third of cases of 
neonatal cholestasis. Familial cases are uncommon, as are cases in premature 
infants. Patients typically present with jaundice during the first or second 
week of life. Acholic stools are more common than in neonatal hepatitis. The 
liver is firm and enlarged, and splenomegaly may be present, as in neonatal 
hepatitis. Infants often appear clinically well, although progressive liver in­
jury results in nutritional deficiencies, failure to thrive, and ascites.
Differentiation between neonatal hepatitis and biliary atresia has been 
the subject of controversy over the years. Serum amino transferase (i.e., 
transaminase) levels are notoriously unreliable indicators of neonatal liver 
disease and may be normal even in some patients with neonatal hepatitis. Ex­
tremely elevated y-glutamyl transferase levels are suggestive of the marked 
bile ductular proliferation found in biliary atresia. Liver biopsy demonstrates 
inflammatory obliteration of the extrahepatic biliary tree, with bile stasis and 
bile ductular proliferation in the liver. Histologic features may overlap with 
neonatal hepatitis, particularly early in the course of the disease making it 
difficult to differentiate. Histologic transition from neonatal hepatitis to bil­
iary atresia has been reported, and may be a relatively common phenomenon. 
The duodenal intubation and aspiration test is a simple, rapid, inexpensive 
method to check for patency of the extrahepatic biliary tree. Collection of 12 
2-hour ali-quots of duodenal drainage from a feeding tube placed in the duo­
denum over a 24-hour period suggests biliary atresia if no yellow fluid is pre­
sent. Aspiration of bile-stained fluid from the duodenum suggests patency of 
the extrahepatic biliary tract. This test is sensitive and specific for the evalua­
tion of infantile cholestasis. The test has reliability comparable to or better 
than radionuclide imaging with scans, which may give abnormal results in 
neonatal hepatitis during periods of severe cholestasis. Reliability of the ra­
dionuclide studies may be improved by measurement of duodenal fluid 
counts collected by a simple string test. The combination of liver biopsy and 
imaging study or duodenal drainage usually is used to determine whether the 
patient is more likely to have biliary atresia or neonatal hepatitis. If bile 
drainage cannot be confirmed or the typical histologic picture of neonatal 
hepatitis is not apparent on liver biopsy, then surgical exploration and intra­
operative cholangiography usually is performed to establish a final diagnosis.
If the patient has biliary atresia, a hepatoportoen-terostomy with Roux- 
en-Y enteroanastamosis (i.e., Kasai procedure) is performed to attempt bile 
drainage. The Kasai procedure rarely alters the long-term outcome of biliary 
atresia, but may delay the necessity of liver transplantation. For this reason, 
some advocate not performing a Kasai procedure. Most, however, believe 
that performing the procedure does not worsen the prognosis at transplant 
and may allow the child to live longer so that a more suitable liver donor may 
be located before transplantation. For those infants with progressive liver dis­
ease after the Kasai procedure, every attempt must be made to optimize their
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condition before transplantation. Deficiencies of the fat-soluble vitamins (i.e., 
A, D, E, K) require supplementation. Nutritional deficiencies are treated by 
using formulas containing medium-chain triglycerides. Salt and protein re­
striction may become necessary, as liver failure progresses.
Hepatic transplantation is the definitive treatment for biliary atresia and 
results in long-term survival in 70% to 85% of infants.
Other Causes of Cholestasis. Rare causes of cholestasis must be ex­
cluded before confirming the diagnosis of neonatal hepatitis or biliary atresia 
(Table 16). Infectious diseases such as cytomegalovirus, hepatitis B, HIV, 
rubella, herpes, toxoplasmosis, and syphilis should be excluded by standard 
sero-logic or culture techniques. Metabolic disorders to be considered include 
tyrosinemia, galactosemia, and hereditary fructose intolerance. Obtaining 
urine for reducing substances to exclude galactosemia and hereditary fructose 
intolerance, and succinyl acetone to exclude tyrosinemia should be done im­
mediately Anatomic disorders such as choledochal cysts can be diagnosed by 
ultrasonography. Other causes such as TPN cholestasis or sepsis should be 
considered, based on the clinical presentation.
Occasionally, liver biopsy will demonstrate a marked reduction in the 
number of intrahepatic bile ducts, revealing a disorder known as paucity of 
the intrahepatic bile ducts or intrahepatic biliary hypoplasia. Some of these 
patients fall into the category of Alagille syndrome, also known as syndro- 
matic paucity or arteriohepatic dysplasia. These patients exhibit unusual fa­
cial characteristics, ocular abnormalities including posterior embryotoxon 
(i.e., prominent Schwalbe line), pulmonic stenosis, and vertebral arch defects, 
including anterior vertebral arch fusion with butterfly vertebrae. Careful car­
diac examination, examination of the eyes by an ophthalmologist, and radio- 
graphic examination of the lumbosacral spine should be obtained in patients 
with suspected Alagille syndrome who have a paucity of intralobular bile 
ducts. Prognosis for long-term survival in syndromatic patients is relatively 
good.
Table 18
Steps in evaluating neonatal cholestasis
1. Determine that hyperbilirubinemia is predominantly direct
2. Exclude metabolic and infectious causes of cholestasis
3. Perform ultrasound to exclude anatomic lesions
4. Obtain percutaneous liver biopsy and hepatobiliary scan or 
duodenal drainage study
5. Explore whether studies suggest biliary atresia, and perform Ka-
___sai procedure if indicated________________________________
There are patients with nonsyndromatic paucity who have liver biopsy 
findings similar to those with Alagille syndrome. In general, these patients
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have a much poorer prognosis than those with syndromatic paucity. Life- 
threatening cirrhosis develops in many, and these patients may require he­
patic transplantation. As in biliary atresia, liver transplantation has markedly 
changed the prognosis for these patients.
A number of infectious disorders, both viral and bacterial, may present 
during the neonatal period, and a specific diagnosis should be sought in such 
instances. Hepatitis В typically is found in infants whose mothers were in­
fected during the third trimester. As many as 60% to 90% of infants bom to 
hepatitis В surface antigen-positive mothers may be infected. Transmission 
from mother to infant most commonly occurs at the time of delivery. Mothers 
who are hepatitis В antigen-positive are at extremely high risk to transmit 
hepatitis В virus to their infants. In addition, mothers who are chronic carriers 
of hepatitis В surface antigen also may infect their infants. Most hepatitis В 
in infancy is asymptomatic. Abnormal liver tests develop at approximately 6 
to 8 weeks of age, and may persist for up to a year. Nearly 50% of these chil­
dren remain hepatitis В surface antigen-positive, and are at risk for develop­
ing hepatocellular carcinoma. Such children should be screened annually 
with a-fetoprotein levels for evidence of liver cancer, unless their hepatitis В 
surface antigen determinations revert to negative. Maternal screening for 
hepatitis В surface antigen is essential to prevent perinatal transmission of 
hepatitis B. Neonates born to mothers who are hepatitis В antigen-positive 
should receive hepatitis В hyperimmune globulin, 0.5 mL intramuscularly at 
the time of birth, and hepatitis В vaccine within 12 hours of birth. Booster 
immunizations with hepatitis В vaccine are recommended at 1 and 6 months 
of age.
Several other viruses may produce hepatitis during the neonatal period. 
Hepatitis A may develop in infants of mothers with active icteric hepatitis A 
at the time of delivery. Hepatitis C, formerly known as parenterally transmit­
ted non-A, non-B hepatitis, commonly is transmitted through blood contact 
and produces a clinical spectrum similar to hepatitis B. Serologic tests are 
available to detect hepatitis C, and its relationship to neonatal liver disease 
probably will be known in the near future. Other viruses, such as Epstein- 
Barr virus, cytomegalovirus, HIV, rubella, herpes simplex, coxsackievirus, 
and adenoviruses may cause a wide spectrum of neonatal liver disease. In 
most instances, infection with these viruses results in spontaneous resolution 
without chronic injury.
Bacteria also may produce neonatal liver injury, because invasion of 
the liver may occur. Specific hepatic infection may result from certain bacte­
rial diseases such as syphilis and listeriosis, as well as the parasitic disorder 
toxoplasmosis.
A number of metabolic diseases may present with neonatal cholestasis. 
The most common is a,-antitrypsin deficiency. Alpha i -antitrypsin is the ma­
jor protease inhibitor in the hepatocyte. Deficiency of a t-antitrypsin occurs in
161
a number of inheritable phenotypes. These Pi or protease inhibitor pheno­
types can be determined. Type ZZ produces the most complete deficiency 
state and most cases of liver disease. It is estimated that 10% to 20% of type 
ZZ patients develop liver disease. Isolated cases of type MZ and MS also 
have been reported with liver injury. The ZZ phenotype is inherited through 
an autosomal recessive mechanism and occurs in 1 in 2000 live births. Pa­
tients can be identified by the measurement of a very low ctiantitrypsin level 
in the blood. Diagnosis is confirmed by the determination of the ZZ pheno­
type, plus the classic histologic findings of periodic add-Schiff-positive, dia­
stase-resistant granules on liver biopsy.
Liver disease may develop in patients with cystic fibrosis, although 
very few of these present during the neonatal period. Measurement of sweat 
chloride to exclude cy stic fibrosis, however, should be part of the evaluation 
of neonatal liver disease.
Three metabolic diseases present with rather fulminant neonatal liver 
disease. These include galactosemia, hereditary fructose intolerance, and 
tyro-sinemia. These disorders should be expected when coagulation abnor­
malities appear inappropriately severe relative to the apparent degree of liver 
disease. Patients with galactosemia have positive urinary reducing substances 
if they are being fed lactose at the time of screening. Patients with hereditary 
fructose intolerance also may test positive. Patients with tyro-sinemia can be 
screened by measuring succinyl acetone content in the urine. Plasma and 
urine amino acids will demonstrate marked elevations of tyrosine, although 
this may be a nonspecific finding in any infant with neonatal liver disease. 
Patients with galactosemia respond to a galactose-free diet, and liver injury 
usually resolves spontaneously. Neonatal sepsis is a frequent occurrence in 
these infants and precautions should be taken. Patients with tyrosinemia 
commonly undergo progressive liver and renal dysfunction and are candi­
dates for emergent liver transplantation once the diagnosis is made.
Several lipid storage diseases produce neonatal liver disease. Niemann- 
Pick disease, Wolman disease, cholesterolester storage disease, and Gaucher 
disease are included in this group. Most present with an insidious onset later 
in life.
A number of disorders exist in which peroxisomal dysfunction occurs. 
The most common is Zellweger syndrome, the cerebrohepatorenal syndrome. 
These patients present with cholestasis, hepatomegaly, hypotonia, and dys­
morphic features, and may be diagnosed by demonstration of very-long-chain 
fatty acids in the serum.
Defects in the urea cycle may present with hyperammonemia during 
the first 2 days of life. A sepsislike picture with vomiting, lethargy, seizures, 
and coma suggests this diagnosis. The most common form is ornithine tran- 
scarbamylase deficiency. Serum ammonia levels are very high, provided the 
infant is being fed protein. Diagnosis depends on plasma and urinary amino
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acid levels, and liver biopsy must be assayed for specific enzymes. Protein 
intake should be restricted and liver transplantation should be considered. 
Transient hyperammonemia of the newborn also has been reported with 
spontaneous resolution and no long-term neurologic sequelae. Permanent 
resolution of the hyperammonemia usually occurs by 2 weeks of age.
Cholestasis may occur in any patient on chronic parenteral nutrition, 
but it is far more common in sick premature infants who receive parenteral 
nutrition for long periods of time. The mechanism by which the liver injury 
occurs is unknown and perhaps multifactorial. Several risk factors have been 
identified, however, including recurrent infections, prematurity, and lack of 
enteral feeding. Certain components of parenteral solutions have been impli­
cated in causing liver injury. Excessive caloric administration may play a 
role. Certain amino acids may be more hepatotoxic, although many of these 
data are derived from animal studies. Higher doses of protein may result in a 
more rapid rise in bilirubin, but does not appear to alter ultimate risk of de­
velopment of liver disease. Available intravenous lipid preparations do not 
appear to cause cholestasis, and may in fact be beneficial in thL regard.
The reason premature infants are more susceptible to liver disease 
while on parenteral nutrition probably is related to developmental immaturity 
of several hepatobiliary processes. These infants have reduced and altered 
bile acid synthesis, decreased bile acid pool size, and therefore decreased in­
tra-luminal bile acids. Gallbladder function also is impaired. Bile acid 
reabsorption from the small bowel is underdeveloped. The premature liver 
also is less capable of detoxifying potentially toxic secondary bile acids.
Lack of enteral feeding definitely predisposes to parenteral nutrition 
cholestasis. Gastrointestinal hormones that stimulate bile flow depend on en­
teral feeding for their release. Reduced gut motility in the unused bowel may 
contribute to bacterial proliferation and the resultant production of toxic sec­
ondary bile acids. Infection, especially gastrointestinal, and gastrointestinal 
surgery may potentiate the liver injury through related mechanisms. Limited 
amounts of enteral feeding, as tolerated, may be very beneficial in preventing 
liver injury in the parenteral nutrition-dependent infant.
Diagnosis of parenteral nutrition liver disease depends on exclusion of 
other causes of cholestasis in the parenteral nutrition-dependent patient. 
Separation of this disorder from other causes of cholestasis is difficult using 
standard laboratory tests. Histologic study is nonspecific, but may be helpful 
in making the diagnosis. The disease often is reversible once parenteral nutri­
tion is discontinued. It occasionally may progress to cirrhosis, and hepatocel­
lular carcinoma has been reported.
Treatment is best accomplished by discontinuing parenteral nutrition. 
If this cannot be accomplished, the following steps should be taken:
1. Reevaluate solutions to ensure they are appropriately formulated 
and balanced.
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2. Use low-dose enteral feedings as tolerated to stimulate bile flow 
and gut motility.
3. Cycle the parenteral nutrition so that it is given over only part of the 
day.
4. Use amino acid solutions specially formulated for infants.
Other potential therapies, yet unproven, include choleretics such as 
phenobarbital or ursodeoxycholic acid, hormone stimulation of bile flow, and 
bowel prokinetic agents. Success with combined intestinal-liver transplants 
suggests that this procedure may play an important role in infants with end- 
stage parenteral nutrition liver disease.
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JAUNDICE
Jaundice is the most common and one of the most vexing problems 
that can occur in the newborn. Although most jaundiced infants are other­
wise perfectly healthy, they make neonatologists anxious because bilirubin 
is potentially toxic to the central nervous system.
Jaundice occurs when the liver cannot clear sufficient bilirubin from 
the plasma. When the problem is excessive bilirubin formation or limited 
uptake and conjugation, unconjugated (i.e., indirect-reacting) bilirubin ap­
pears in the blood. When bilirubin glucuronide excretion is impaired (i.e., 
cholestasis), conjugated monoglucuronide and diglucuronide (i.e., direct- 
reacting) bilirubin accumulate in plasma and, because of their solubility, 
also appear in the urine. Reverse-phase high-performance liquid chromatog­
raphy permits the identification of an additional form of direct-reacting 
bilirubin, which appears to be formed nonenzymatically from conjugated 
bilirubin and is irreversibly bound to albumin (Fig. 18). This fourth frac­
tion—unconjugated, monoglucuronide, and diglucuronide being the first 
three—5-bilirubin, reacts directly with the diazo reagent and is covalently 
bound to albumin to form a biliprotein. Covalent bonds exist between atom 
pairs that can complete their electronic shells by sharing electrons. Cova­
lent binding to albumin prevents filtration by the glomerulus; thus, 5- 
bilirubin does not appear in the urine but tends to form an increasing per­
centage of the total bilirubin during recovery from cholestatic jaundice. The 
presence of this fraction explains the previously puzzling observation that, 
in some cases, during recovery from cholestatic jaundice, bilirubin disap­
pears from the urine while the plasma remains icteric. In neonates with indi­
rect hyperbilirubinemia, 5-bilirubin normally represents 5% or less of total 
bilirubin, but in neonates with direct hyperbilirubinemia, 10% to 73% of total 
bilirubin may be present as 5-bilirubin. 'The concentration of 5-bilirubin in the 
newborn appears to be related to the duration rather than the cause of the 
jaundice. The fetus can also produce 5-bilirubin, which was found to repre­
sent 13% of total bilirubin at age 6 hours in an infant with neonatal giant­
cell hepatitis. Because of its tight binding to albumin, 5-bilirubin might pre­
vent the binding of unconjugated bilirubin to albumin and potentially contrib­
ute to bilirubin toxicity.
Other bile pigment species are also found in the blood of patients with 
cholestatic liver disease. Bilirubin glucuronides are prone to internal rear­
rangement (i.e., acyl migration). In this reaction, the bilirubin moves rapidly 
back and forth from one OH group of the glucuronic acid to an adjacent 
group. Each glucuronide of bilirubin can therefore “spawn a whole family of 
new compounds that still contain the same proportions of bilirubin and sugar 
as the parent, but which are not, strictly speaking, glucuronides.” The blood 
from patients with cholestatic jaundice may therefore contain “bilirubin,
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bilirubin glucuronides, rearranged glucuronides, and biliproteins—not simply 
a trio, or quartet, but a whole orchestra of bilirubin derivatives in which the 
glucuronides are not necessarily predominant.” With the exception of bilirubin 
itself,, all these substances react directly with the diazo reagent.
bil-alb <
FIG. 18. A chromatogram of serum from an adult pa-it with cholestatic jaundice (BIL- 
ALB - albumin-bound lirubin; DI - diconjugated bilirubin; MONO - monocon-jted 
bilirubin, UNCONJ - unconjugated bilirubin.
In most jaundiced neonates, only unconjugated bilirubin is found in the 
blood, and the accumulated bilirubin is distributed by the circulation 
throughout body and produces clinical jaundice. It is generally assumed that 
to cross intact cell membrane barriers the bilirubin must be free, or dissoci­
ated, from its albumin binding. Unconjugated bilirubin also binds to certain 
membrane and cell phospholipids.
In severe jaundice, crystals or precipitates of bilirubin may form, 
which might contribute to the toxicity of the pigment. The total bilirubin 
space has not been measured in a newborn, but studies in normal adults sug­
gest that it is at least twice the plasma volume. In severe, prolonged jaundice, 
vast quantities of bilirubin are sequestered in the extravascular tissues—far 
more than can be accommodated in the plasma—and this is not reflected by 
the serum bilirubin concentration.
FORMATION. STRUCTURE. AND PROPERTIES OF BILIRUBIN 
Bilirubin is the end product of the catabolism of iron protoporphyrin or 
heme, of which the major source is circulating hemoglobin. The formation of 
bilirubin from hemoglobin involves removal of the iron and protein moieties 
followed by an oxidative process catalyzed by the enzyme microsomal heme 
oxygenase in which the a-methene bridge of the heme porphyrin ring is 
opened and carbon monoxide and biliverdin are formed (Fig. 19). The iron is 
salvaged and carbon monoxide excreted by the lungs, leaving the blue-green
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pigment biliverdin IXa. Biliverdin can be readily excreted in bile, but in 
mammals it is reduced to bilirubin by NADPH-dependent biliverdin reduc­
tase. Because it is derived from cleavage at the a position of the heme ring of 
ferroprotoporphyrin IX, the product thus formed is known as bilirubin IXa 
(see Fig. 19).
JH B ILIV E R D INR E D U C TA S E
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FIG. 19. Biosynthesis of bilirubin. (From Lightner VIcDonagh AF).
Why a readily excreted, nontoxic molecule (i.e., biliverdin) is con­
verted into a poorly excreted toxic molecule (i.e., bilirubin) is not clear but 
might be explained by the fact that biliverdin is poorly transported by the 
placenta. If biliverdin were the end product of heme catabolism, it would be 
trapped on the fetal side of the placenta, yielding fluorescent blue-green in­
fants. In addition, bilirubin appears to have an important role as an antioxi­
dant, which may be beneficial to the newborn.
HOOC COOH
FIG. 20. The chemical structure of bilirubin. (From McDonagh AF, Lightner DA.
A linear representation of bilirubin is shown in Figure 20. Trace 
amounts of other bilirubin isomers, including bilirubin IXp, IXy, 1X5, are 
found in human bile, and bilirubin exists in the plasma in a variety of forms
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that determine its biologic properties. The ionic species of bilirubin are 
shown in Figure 21.
FIG. 21. Ionic species of bilirubin. (A) The dianion combines with two protons and 
forms (B) bilirubin acid, which is then stabilized internally by (C) the formation of in­
tramolecular hydrogen bonds.
X-ray diffraction studies and nuclear magnetic resonance spectroscopy 
show one stable (i.e., ridgetile) conformation of bilirubin. It is likely that this 
is the prevalent structure in plasma because it is consistent with the biologic 
properties of bilirubin. In this conformation, the bilirubin molecule is stabi­
lized by the presence of intramolecular hydrogen bonds, and the hydrophilic 
polar COOH and NH groups are not available for the attachment of water. 
The hydrophobic hydrocarbon groups are on the perimeter, rendering the 
molecule insoluble in water but soluble in nonpolar solvents, such as chloro­
form. Under these circumstances, bilirubin behaves like other lipophilic sub­
stances (e.g., dioxin, poly-chlorinated biphenyls)— it is difficult to excrete 
but crosses biologic membranes, such as the placenta, blood-brain barrier, 
and hepatocyte plasma membrane, easily. Brodersen questioned the long-held 
belief that bilirubin is lipophilic, although he found that bilirubin forms a 
complex with phosphatidylcholine (i.e., lecithin), a major component of cell 
membranes. McDonagh argues that the biologic properties are entirely con­
sistent with those of a lipophil, and this has been confirmed by recent studies.
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In an alkaline medium, after the structure is opened and the hydrogen­
bonding groups are exposed (see Fig. 21), the molecule can form a soluble 
sodium or potassium salt. The addition of methanol or ethanol interferes with 
the hydrogen bonding and results in an immediate diazo reaction—the basis 
for the measurement of indirect bilirubin by the Van den Bergh reaction.
FETAL BILIRUBIN METABOLISM
BILIRUBIN IN AMNIOTIC FLUID
Bilirubin can be detected in normal amniotic fluid after about 12 weeks 
of gestation, but it disappears by 36 to 37 weeks. Increased levels of bilirubin 
in the amniotic fluid are observed in the presence of fetal unconjugated hy­
perbilirubinemia and can be used to predict the severity of Rh hemolytic dis­
ease. Increased amniotic fluid bilirubin levels and bile acid concentrations are 
found in the presence of fetal intestinal obstruction if the obstruction occurs 
distal to the ampulla of Vater, but not in the presence of esophageal or pylo­
ric atresia.
It is not known precisely how bilirubin gets into the amniotic fluid. 
Suggested routes include tracheobronchial secretions; excretion by way of 
the mucosa of the upper gastrointestinal tract or the fetal urine and me­
conium; diffusion across the umbilical cord and fetal skin; and transfer from 
the maternal circulation. The most likely of these mechanisms appears to be 
the first. Studies in rabbits demonstrate a correlation between increased se­
rum unconjugated bilirubin concentrations and increased tracheal fluid 
bilirubin concentrations.
BILIRUBIN PRODUCTION, HEPATIC FUNCTION,
AND PLACENTAL TRANSFER
The rate of bilirubin production in the fetus has not been determined, 
but it is reasonable to assume that it is at least as great as that in the newborn.
In early fetal life, plasma albumin concentrations are low, but bilirubin 
binds to a-fetoprotein. The ability of human fetal liver to remove bilirubin 
from the circulation and to conjugate bilirubin is severely limited, although 
some uridine diphosphoglucuronosyl transferase (UDPGT) activity can be 
detected by 16 weeks of gestation. Until recently, a detailed analysis of the 
development of human hepatic UDPGT had not been performed because, be­
fore the introduction of high-pressure liquid chromatography, it was not pos­
sible to measure very low concentrations of bilirubin glucuronide. Onishi and 
colleagues studied the prenatal and postnatal development of UDPGT activ­
ity in the livers of fetuses after elective abortions, in preterm and full-term 
infants at autopsy, and in laparotomy samples obtained from infants and 
adults. Between 17 and 30 weeks of gestation, alhough UDPGT activity was 
only 0.1% of adult values, bilirubin glucuronide was detected, indicating that 
the UDPGT is active in vivo. Between 30 and 40 weeks of gestation, UDPGT
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activity in fetuses and in preterm and full-term newborns surviving less than 
7 days increased tenfold to 1 % of adult values. After birth, however, activity 
increased exponentially, reaching adult levels by 6 to 14 weeks. Marked 
postnatal development of UDPGT activity occurs in infants who survive 
more than 8 days and is independent of gestation.
Bilirubin pigment in fetal bile also has been studied in detail. Until 14 
weeks of gestation, no bile pigments are detectable. Between 14 and 15 
weeks of gestation, bilirubin IXP is the only bile pigment detected, and it is 
the predominant bilirubin up to 20 weeks of gestation; although between 16 
and 17 weeks of gestation, some unconjugated bilirubin IXa is present. Be­
tween 20 and 30 weeks of gestation, bilirubin IXa glucuronide appears, and 
at 30 weeks of gestation, monoconjugates of bilirubin IXa are the predomi­
nant types of bilirubin present. In the full-term fetus, bilirubin IXa monoglu­
curonide is the major bilirubin derivative.
The major route of fetal bilirubin excretion is across the placenta. Be­
cause virtually all the fetal plasma bilirubin is unconjugated, it is readily 
transferred across the placenta to the maternal circulation, where it is ex­
creted by the maternal liver. Using high-performance liquid chromatography, 
Rosenthal measured serum bilirubin concentrations in umbilical arterial and 
venous blood in full-term infants at birth. In all samples, bilirubin consisted 
entirely of unconjugated pigment. The mean serum bilirubin level in umbili­
cal arterial blood was 5.1 ±1.8 mg/dL (86.6 ± 31.2 /unoI/L), and it was 2.7 ±
0.7 mg/dL (45.6 ± 12.6 /rmol/L) in umbilical venous blood. The bilirubin 
concentration in blood flowing from the fetus to the placenta was nearly 
twice that of blood returning from the placenta to the fetus, indicating that the 
placenta clears bilirubin efficiently from the fetal circulation. Mean maternal 
serum bilirubin concentrations were 0.5 ± .16 mg/dL (7.7 ± 2.8 /rmol/L), con­
firming the gradient of bilirubin flow from the fetus to the mother. Thus, the 
newborn is rarely bom jaundiced, except in the presence of severe hemolytic 
disease, when there may be an accumulation of unconjugated bilirubin in the 
fetus. Conjugated bilirubin is not transferred across the placenta, and it may 
also accumulate in the fetal plasma and other tissues.
MATERNAL HYPERBILIRUBINEMIA AND ITS EFFECT
ON THE FETUS
Obstetricians and pediatricians occasionally are confronted with a 
pregnant mother who has hyperbilirubinemia as a result of hemolytic anemia 
or liver disease. Reported cases in the literature provide evidence for transfer 
of unconjugated bilirubin from the mother to her fetus. In four cases, mothers 
developed cholestatic jaundice with elevations of both direct and indirect se­
rum bilirubin concentrations. In all four, the indirect bilirubin levels in the 
umbilical cord blood were similar to the maternal serum level, with a differ­
ence of 1 to 3.8 mg/dL (17-65 pmol/L); large differences of 9.3 to 20.2 
mg/dL (159-345 pmol/L) were found in the direct bilirubin levels. These data
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are consistent with the transfer of unconjugated but not conjugated bilirubin 
from mother to fetus. They do not, however, rule out the possibility that the 
elevation in maternal bilirubin concentration prevented the normal transfer of 
fetal unconjugated bilirubin across the placenta. In two pregnant mothers 
with homozygous sickle-cell anemia, the development of a crisis led to an 
acute elevation of indirect bilirubin to levels of 13 and 15 mg/dL (222 and 
257 pmol/L), respectively, at the time of delivery. Cord blood concentrations 
in these infants, however, were only 1 and 1.6 mg/dL (32 and 27 pmol/L), 
respectively. This suggests that transfer of bilirubin between the maternal and 
fetal circulations may be relatively slow. Of the cases described, two infants 
died. In one, the autopsy findings revealed no evidence of kemicterus. The 
other infant expired on the first day, and clinical signs of kernicterus were 
said to have developed. No further clinical details were provided, however, 
nor was there any autopsy information. The other infants survived. One was 
reported to be normal at 14 months of age, and the other was followed only to 
age 3 months. In the two infants whose mothers had only indirect hyper­
bilirubinemia, no follow-up data were provided. Thus, no conclusions can be 
reached regarding the possible effect of maternal hyperbilirubinemia on the 
developmental outcome of the offspring.
Maternal hyperbilirubinemia may have other adverse effects on repro­
duction. Of 28 pregnancies in women with Dubin-Johnson syndrome, only 9 
resulted in normal deliveries and normal infants. Whether this represents a 
causative association is speculative. The jaundiced female Gunn rat is fre­
quently infertile, and plasma bilirubin levels are lower in those rats that do 
conceive. Davis and colleagues fed activated charcoal to jaundiced Gunn rats 
and found that this was effective in reducing the plasma bilirubin levels by as 
much as 40%. Forty-eight percent of charcoal-fed, versus 1% of control fe­
male rats, that were continuously mated produced a live litter. These findings 
support the possibility of an adverse effect of bilirubin on reproduction in the 
female Gunn rat.
NEONATAL BILIRUBIN METABOLISM
BILIRUBIN PRODUCTION
The normal destruction of circulating erythrocytes accounts for about 
75% of the daily bilirubin production in the newborn. Senescent erythrocytes 
are removed and destroyed in the reticuloendothelial system, where the he­
moglobin is catabolized and converted to bilirubin. One g of hemoglobin 
yields 35 mg of bilirubin.
A significant contribution (25% or more) to the daily production of 
bilirubin in the neonate comes from sources other than effete erythrocytes 
(Fig. 22). These sources are collectively known as the early - labeled peak of 
bile pigment, a description based on the observation of an early peak of ra­
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dioactivity that appears as labeled stercobilin in the stool within minutes to 
days after the administration of labeled glycine or 8-aminolevulinic acid. This 
early bilirubin consists of two major components:
1. A nonerythropoietic component resulting from the turnover of nonhe­
moglobin heme protein and free heme, primarily in the liver.
2. An erythropoietic component arising primarily from ineffective 
erythropoiesis and the destruction of immature erythrocyte precursors, 
eitherin the bone marrow or soon after release into the circulation.
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FIG. 22. Neonatal bile pigment metabolism. (R E. - reticuloendothelial; RBC - eryth­
rocyte.)
TRANSPORT AND HEPATIC UPTAKE OF BILIRUBIN 
Once bilirubin leaves the reticuloendothelial system, it is transported in 
the plasma and bound reversibly to albumin at a high-affinity primary bind­
ing site with a binding constant of 6.8 x 107тоГ '. AtpH 7A, the solubility of 
bilirubin is low—about 4 nm/L (0.24 mg/dL)—and at the bilirubin levels 
normally found in infants and adults, bilirubin must be boundto its carrier,
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albumin, so that the concentration of unbound (i.e., free) bilirubin remains 
low.
The parenchymal cells of the liver have a selective and highly efficient 
capacity for removing unconjugated bilirubin from the plasma, but exactly 
how this is achieved remains controversial. When the bilirubin-albumin com­
plex reaches the plasma membrane of the hepatocyte, a proportion of the 
bilirubin, but not the albumin, is transferred across the cell membrane into the 
hepatocyte, where it is bound to soluble proteins. The transfer of bilirubin 
from plasma to the liver cell is carrier-mediated. Intracellularly, bilirubin 
binds, in part, to ligandin (i.e., Y protein, glutathione S-transferase B) and 
possibly other cytosolic-binding proteins.
Bilirubin flux across the hepatocyte membrane is bidirectional; in nor­
mal adults, about 40% of the bilirubin taken up by the hepatocytes in a single 
pass through the liver refluxes, unchanged, back into plasma. Although 
ligandin does not appear to participate directly in the hepatic uptake of 
bilirubin, it probably decreases the efflux of bilirubin back into the plasma, 
thus increasing net hepatic uptake. The administration of phenobarbital in­
creases the concentration of ligandin and provides more intracellular biding 
sites for bilirubin. Bilirubin might also be transported intracellularly by direct 
membrane-to-membrane transfer.
CONJUGATION AND EXCRETION OF BILIRUBIN
Because of its hydrogen-bonded conformation (see Formation, Struc­
ture, and Properties of Bilirubin), conjugated (i.e., indirect-reacting) bilirubin 
is nonpolar and insoluble in aqueous solutions at pH 7.4 and must be con­
verted to its water-soluble conjugate (i.e., direct-reacting bilirubin) before it 
can be excreted. This is achieved when bilirubin is combined enzymatically 
with a sugar, glucoronic acid, producing a new pigment that is more water- 
soluble and sufficiently polar to be excreted into the bile or filtered through 
the kidney. Esterification with glucuronic acid leads to the formation of one 
of the two isomers of bilirubin monoglucuronide (i.e., C8 or C l2) or diglu- 
curonide, if esterification occurs in both the C8 and C12 positions of the car­
boxyl groups of the propionic acid side chains.
Formation of the monoglucuronide is catalyzed by the enzyme hepatic 
urdine diphosphoglucuronosyl transferase (UDPGT), primarily located in the 
rough and smooth endoplasmic reticulum. The nomenclature for the 
bilirubin-conjugating enzyme has changed from uridine diphosphoglucuronyl 
transferase to UDPGT. Bilirubin UDPGT belongs to a family of UDPG Г 
isoenzymes that metabolize endogenous compounds and various food chemi­
cals in most tissues. This nomenclature is preferred because the enzyme that 
glucuronodates bilirubin catalyzes the transfer of a glucuronosyl group.
Conversion of both monoglucuronide isomers (i.e., C8 and C12) to di- 
glucuronide also is mediated by UDPGT, although the capacity of the en-
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zyme system for in vitro diglucuronide formation appears to be much lower 
than that for monoglucuronide synthesis. This may explain why patients with 
Gilbert syndrome or Crigler-Najjar type II disease have more monoglucuron­
ide than diglucuronide present in their bile. Nevertheless, bilirubin diglu­
curonide is the major pigment found in normal human and rat bile. The rea­
son for this is not clear, and the precise mechanism for the in vivo formation 
of bilirubin diglucoronide remains uncertain.
Rosenthal and colleagues used high performance liquid chromatogra­
phy to measure serum bilirubin conjugates. In healthy adults, pregnant 
women at term and in cord bloods from uncomplicated deliveries, total 
bilirubin concentrations did not exceed 2 mg/dL, and the bilirubin was en­
tirely unconjugated. In contrast, serum bilirubin concentrations in cord blood 
samples from infants with blood-group incompatibility and intrauterine hy­
poxia exceeded 2 mg/dL and contained conjugated bilirubin. These data con­
firm that in the presence of elevated bilirubin concentrations in utero, 
bilirubin UDPGT activity can be induced prematurely. In both premature and 
full-term infants, measurable amounts of esterified bilirubin appeared within 
24 to 48 hours after birth. A distinct sequence of conjugating activity appears 
to occur, with monoconjugated bilirubin appearing in the serum during the 
first 24 to 48 hours followed by the diconjugated esters, which represent 21% 
of the total esters by the third day. The predominant bilirubin conjugate frac­
tion observed is the C8 monoester. These conjugates are detectable once the 
total serum bilirubin level exceeds 2 mg/dL. Bilirubin esters were also de­
tected in serum samples of a premature infant of only 25 weeks of gestation, 
and conjugated bilirubin levels were higher in the serum of full-term infants 
than premature infants. The entire conjugated fraction, however, normally 
accounts for only 2% to 5% of the total bilirubin.
The fact that conjugates do not appear until the total serum bilirubin 
level increases suggests that bilirubin plays an important role in the initiation 
of its own conjugation after birth. The ratio of conjugated to total bilirubin 
remains constant during the period of physiologic jaundice. If cholestasis 
were present, the conjugated bilirubin fraction would be expected to increase 
progressively, but accumulation of conjugated bilirubin does not contribute 
significantly to physiologic jaundice. This differs from observations of bile 
acid transport in human newborns. Newborns have elevated serum bile acid 
concentrations, impaired bile acid uptake, and impaired transport and excre­
tion of organic anions.
TRANSFER OF BILIRUBIN INTO BILE AND INTESTINAL TRANSPORT
After conjugation, bilirubin is excreted rapidly into the bile canaliculi 
by the liver cell, a process that requires metabolic work for the active trans­
port of bilirubin across a large concentration gradient. Canalicular excretion, 
like bilirubin uptake, appears to be a carrier-mediated process that is satur-
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able and is rate-limiting in the overall transport of bilirubin from blood to 
bile. Interference with this process is probably responsible for the hyper- 
bilirubi-nemia associated with hepatocellular disorders such as hepatitis.
Once in the small intestine, conjugated bilirubin is not reabsorbed. In 
the healthy adult, it is largely reduced by the action of colonic bacteria to a 
series of colorless tetrapyrroles, collectively known as urobilinogen. The 
term stercobilinogen, synonymous with urobilinogen, is no longer used. An 
insignificant amount is hydrolyzed to unconjugated bilirubin and reabsorbed 
by way of the enterohepatic circulation. In the newborn, however, this en- 
terohepatic circulation of bilirubin may be significant. In conditions involv­
ing high plasma bilirubin levels and poor hepatic excretion, there is a gradi­
ent for unconjugated bilirubin from the plasma to the intestinal lumen, and 
significant amounts of unconjugated bilirubin may be cleared by diffusion 
across the intestinal wall. Figure 22 summarizes bile pigment metabolism in 
the newborn.
Recent reviews of the chemistry and metabolism of bilirubin can be 
found elsewhere.
PHYSIOLOGIC MECHANISMS OF NEONATAL JAUNDICE
INCREASED BILIRUBIN LOAD ON THE LIVER CELL
BILIRUBIN PRODUCTION
Measurements of carbon monoxide, which is produced in equimolar 
quantities with bilirubin, show that the normal newborn produces an average 
of 8 to 10 mg/kg (137-171 pmol/L) of bilirubin per day. Similar rates of 
bilirubin production have been found in low-birth-weight infants. This is 
more than twice the rate of normal daily bilirubin production in the adult and 
is explained by the fact that the neonate has a higher circulating erythrocyte 
volume, a shorter mean erythrocyte life span, and a larger early-labeled 
bilirubin peak. Bilirubin production decreases with increasing postnatal age 
but is still about twice the adult rate by age 2 weeks.
ENTEROHEPATIC CIRCULATION
The newborn probably reabsorbs much larger quantities of unconju­
gated bilirubin, by way of the enterohepatic circulation, than does the adult. 
Infants have fewer bacteria in the small and large bowel and greater activity 
of the deconjugating enzyme, /i-glucuronidase. As a result, conjugated 
bilirubin, which is not reabsorbed, is not converted to urobilinogen but is hy­
drolyzed to unconjugated bilirubin, which is then reabsorbed, thus increasing 
the bilirubin load on an already stressed liver. Studies in newborn humans 
and monkeys suggest that the enterohepatic circulation of bilirubin is a sig­
nificant contributor to physiologic jaundice.
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D E C R E A S E D  C L E A R A N C E  O F  B IL I R U B IN  F R O M  T H E  P L A S M A
UPTAKE
Ligandin, the predominant bilirubin-binding protein in the human liver 
cell, is deficient in the liver of newborn monkeys. It reaches adult levels by 5 
days of age, coinciding with a fall in bilirubin levels and a normal hepatic up­
take of sulfobromophthalein. The administration of phenobarbital enhances 
hepatic uptake of sulfobromophthalein and simultaneously increases the con­
centration of ligandin. Although this suggests that impaired uptake may con­
tribute to the pathogenesis of physiologic jaundice, uptake does not appear to 
be rate-limiting during phase I (see Physiologic Jaundice); however, it may 
be important during phase II, the low-grade but more persistent stage of 
physiologic jaundice.
CONJUGATION
Deficient glucuronosyl transferase activity, with resultant impairment 
of bilirubin conjugation, has long been considered a major cause of physiol­
ogic jaundice. Studies in full-term newborn rhesus monkeys revealed virtu­
ally no hepatic glucuronosyl transferase activity in the first 24 hours. Activity 
increased over the next 48 hours, coincident with a decline in serum bilirubin 
levels (i.e., descending curve of phase I). By 48 hours, activity levels were 
close to those of the adult, but enzyme maturation in two premature infants 
was markedly delayed. In a single postmature monkey, activity at 4 hours of 
age was 10 times greater than that of full-term animals of comparable age. In 
human infants, the early postnatal increase in serum bilirubin appears to play 
an important role in the initiation of bilirubin conjugation.
The administration of phenobarbital (5 mg/kg/day for 6 weeks) to 
pregnant monkeys and in similar dosage to their infants increased hepatic 
glucuronosyl transferase activity by almost threefold—sufficient to abolish 
completely phase I physiologic jaundice. Using high-pressure liquid chroma­
tography, Onishi and colleagues studied the activity of UDPGT toward 
bilirubin in human subjects. Liver samples were obtained from patients who 
underwent laparotomy or from autopsies of infants. In the first 10 days of 
life, UDPGT activity in full-term and premature neonates was usually less 
than 0.1% of adult values, although some infants showed activity between
0.1% and 1%. Thereafter, UDPGT activity increased at an exponential rate, 
reaching adult values by 6 to 14 weeks of age, after which it remained con­
stant. The postnatal increase in UDPGT activity was independent of the in­
fants' gestation. These observations are consistent with the pivotal role of de­
ficient glucuronosyl transferase activity and bilirubin conjugation in the first 
phase of neonatal jaundice.
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EXCRETION
The absence of an elevated serum level of conjugated bilirubin in 
physiologic jaundice suggests that, under normal circumstances, the neonatal 
liver cell is capable of excreting the bilirubin that it has just conjugated. Nev­
ertheless, the ability of the newborn liver to excrete conjugated bilirubin and 
other anions (e.g., drugs, hormones) is more limited than that of the older 
child or adult and may become rate-limiting when the bilirubin load is sig­
nificantly increased. Thus, when intrauterine hyperbilirubinemia occurs, usu­
ally as a result of isoimmunization, it is not uncommon to find an elevated 
serum level of conjugated bilirubin.
EPIDEMIOLOGY OF NEOKATAL JAUNDICE
Various factors in the epidemiology of neonatal jaundice are described 
in Table 19.
Table 19
Epidemiology of neonatal jaundice
| ; c Effect on Neonatal Serum Bilirubin Levels
В Associated Factors Increase Decrease No Effectk Race East Aslan African Amerl-Щ .. Native American Greek canШ Genetic or famiiial Previous siting with jaundice
|l Maternal Primipara1 , 
Older mothers
Smoking
r .
1
Diabetes
Hypertension
Oral contraceptive use at time of 
conception
First-trimester bleeding 
Decreased plasma zinc level
, Drugs administered to mother Oxytocin Phenobarbital Beta-adrenergic
l i , Diazepam Meperidine agents
| Epidural anesthesia Reserpine
I  :
Promethazine Aspirin
Chloral hydrate
Heroin
Phenytoin
Antipyrine
Alcohol
! Labor and deii very
r
Premature rupture of membranes Fetal distress
Forceps delivery 
Vacuum extraction 
Breech delivery
Low Apgar scores
infant
r :■jp
r
Low birth weight
Prematurity
Male gender
Delayed cord clamping
Elevated cord blood bilirubin level
Delayed meconium passage
Breast-feeding
Caloric deprivation
Larger weight loss after birth
Low serum zinc and magnesium
1 Drugs administered to infant Choral hydrate
f Other Altitude
*
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GENETIC, ETHNIC, AND FAMILIAL INFLUENCES 
East Asian and Native American infants have mean maximal serum 
bilirubin concentrations that are significantly higher than those of Caucasian 
populations. Measurements of carbon monoxide production and blood car- 
boxyhemoglobin levels suggest that increased bilirubin production is an im­
portant factor contributing to hyperbilirubinemia in these infants.
In certain areas of Greece, there is a remarkably high incidence of 
idiopathic hyperbilirubinemia and an increased incidence of kernicterus. Al­
though glucose-6-phosphate dehydrogenase (G6PD) deficiency is more 
common in East Asian and Greek infants, it does not account for these star­
tling differences in the incidence and severity of hyperbilirubinemia. Japa­
nese infants living in the United States have a much higher incidence of hy­
perbilirubinemia and higher mean bilirubin levels than do their American 
counterparts, but infants bom in Australia of parents who have emigrated 
from Greece do not have higher bilirubin levels than Australian infants. Envi­
ronmental rather than genetic factors appear to be important in this popula­
tion. Black infants in the United States and in Great Britain have lower 
bilirubin levels than Caucasian infants (Table 20).
Neonatal jaundice runs in families, which suggests that, to some ex­
tent, the risk of jaundice is genetically determined. Khoury and colleagues 
studied 3301 infants and found that if previous siblings had a serum bilirubin 
level higher than 12 mg/dL (205 pmol/L) or higher than 15 mg/dL (257 
pmol/L), the risk of similar bilirubin levels in subsequent siblings was 3.1 
and 12.5 times greater, respectively, than in siblings of infants who did not 
have that degree of jaundice. Nielsen and colleagues also found a highly sig­
nificant correlation between the peak bilirubin levels of siblings.
Table 20
Effect of race on the incidence of hyperbilirubinemia
P e a k  b i l i ru b in  c o n -  
c e n tr a t io n  ( m g /d L )
P e r c e n ta ___________
R e f e re n c e sE a s t  A s ia n C a u c a s ia n A f r ic a n  A m e r ic a n
> 1 0 4 9 2 0 12 L in  e t  a l. 198 5
> 1 2 13 7 F r ie d m a n  e t  al 1 9 7 8
> 1 3 2 3 10 4 N e w m a n  1 9 9 0
6 4 H a r d y  1 9 7 9
> 1 5 19 7 2 L in  e t  a l. 19 8 5
•About 7% of infants in this study were bom at <37 weeks of gestation or weighed <2S00 g; 
t Includes preterm and low-birth-weight infants from total population of 12,461 (percent­
age unknown);
4  AH infants weighed >2500 g.
MATERNAL FACTORS 
SMOKING
Most studies suggest that infants of mothers who smoke during preg­
nancy have lower serum bilirubin levels than infants of nonsmokers, but oth-
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ers have not found this. Women who smoked at least one pack of cigarettes 
per day had a lower risk of having a child with hyperbilirubinemia than those 
who smoked less. The data are confounded by the finding that women who 
smoke are much less likely to breast-feed and that the incidence of breast­
feeding is inversely related to the number of cigarettes smoked per day. 
Breast-fed infants have higher serum bilirubin levels than bottle-fed infants.
DIABETES
As a group, infants of insulin-dependent diabetic mothers are more 
likely to become jaundiced than control infants, but closer scrutiny suggests 
that hyperbilirubinemia in infants born to insulin-dependent diabetic mothers 
occurs mainly in those that are large for their gestational age or have an in­
creased birth weight-length ratio. A direct relation has been found between 
the amount of carbon monoxide excreted—an index of bilirubin produc­
tion—and the degree of macrosomia in these infants; those who are large for 
their gestational age, but not those appropriate for their gestational age, have 
significantly higher bilirubin and carboxyhemoglobin levels than control in­
fants. These studies suggest that increased bilirubin production contributes to 
the hyperbilirubinemia of macrosomic infants of insulin-dependent diabetic 
mothers.
Ineffective erythropoiesis and polycythemia are probably responsible 
for the increased bilirubin production found in these infants. Infants of dia­
betic mothers have high erythropoietin levels and evidence of increased 
erythropoiesis; as many as 24% of macrosomic infants of insulin-dependent 
diabetic mothers are polycythemic. In addition, diabetic mothers have a 
threefold greater concentration of (3-glucuronidase in their breast milk than 
nondiabetic mothers.88 This enzyme enhances the enterohepatic circulation 
of bilirubin and could be an additional contributor to hyperbilirubinemia in 
breast-fed infants of insulin-dependent diabetic mothers.
OTHER FACTORS
Hyperbilirubinemia has been associated with pr/miparous mothers in 
some studies, but not in others. Gale and colleagues found a significant asso­
ciation between neonatal jaundice and increasing maternal age; teenage 
mothers had the lowest risk for hyperbilirubinemia.
EFFECT OF EVENTS DURING LABOR AND DELIVERY
INDUCTION OF LABOR BY OXYTOCIN
The potential association between hyperbilirubinemia and the use of 
oxytocin to induce or augment labor has interested a surprising number of in­
vestigators, and several authors have reported an increased incidence of neo­
natal hyperbilirubinemia after induction of labor with oxytocin. Caution must 
be exercised in interpreting positive results because of the possibility that the
179
oxytocin-induced groups in these studies contained a greater number of less 
mature infants. Using linear logistic regression analysis in a prospective 
study of 739 infants, Lange and colleagues found a marginal effect of oxyto­
cic agents but a highly significant influence of gestational age on the risk of 
jaundice. Three controlled trials compared the incidence of hyperbilirubine­
mia in full-term infants after induction of labor with prostaglandin E2 or oxy­
tocin. There was a 30% increase in the incidence of jaundice, with bilirubin 
levels higher than 10 mg dL (171-205 pmol/L) in infants of mothers who re­
ceived oxytocin.
The mechanism for the putative increase in serum bilirubin in associa­
tion with oxytocin administration is unknown. It is possible that, in many 
cases, infants delivered after oxytocin induction are less mature than those 
delivered spontaneously. Others have suggested that hyperbilirubinemia is 
the result of hemolysis following erythrocyte swelling and loss of deform- 
ability. Oxytocin is known to exert an antidiuretic effect, and it is commonly 
administered with relatively large quantities of electrolyte-free dextrose solu­
tions. The infants bom to these mothers show significant hyponatremia, hy- 
poosmolality, and enhanced osmotic fragility of erythrocytes. These infants 
also have lower hematocrits, decreased plasma haptoglobin, and increased 
plasma lactate dehydrogenase activity compared with those born after spon­
taneous labor. With this hemolytic mechanism in mind, Johnson and col­
leagues administered minimal amounts of free water to mothers receiving 
oxytocin. They observed no hyperbilirubinemia in the infants. The use of es­
tradiol for cervical ripening has produced conflicting effects on serum 
bilirubin levels.
ANESTHESIA AND ANALGESIA
Epidural anesthesia, specifically, bupivacaine, has been associated with 
neonatal jaundice in most studies but not in others. Anesthetic agents readily 
cross the placenta and produce measurable blood levels in the newborn. 
Bupivacaine, but not lidocaine or mepivacaine, significantly reduced erythro­
cyte filterability in vitro and erythrocyte survival in the rat. In a controlled 
trial, bupivacaine and lidocaine epidural anesthetics were compared; there 
was no difference in neonatal bilirubin levels.
Johnson and colleagues found a significant association between the 
maternal use of promethazine hydrochloride and the risk of neonatal jaun­
dice. In other studies, maternal administration of promethazine, propiomaz- 
ine, methotrimeprazine, meperidine, and chlorpromazine had no effect on 
neonatal bilirubin levels.
OTHER DRUGS
Drew and Kitchen investigated the effect of the administration of vari­
ous pharmacologic agents to the mothers of 1107 infants. Administration of
iso
narcotic agents, barbiturates, aspirin, chloral hydrate, reserpine, and pheny- 
toin-sodium was associated with lower serum bilirubin concentrations, the 
use of diazepam, which raised mean bilirubin levels by <1 mg/dL, and oxyto­
cin led to higher bilirubin levels. Note that the finding of a lower bilirubin 
concentration in association with the administration of a drug could imply an 
adverse effect of the drug on bilirubin-albumin binding, with potentially dele­
terious results. Antipyrine administered to mothers before delivery decreases 
neonatal bilirubin levels, and infants of heroin-addicted mothers have lower 
bilirubin levels. Phenobarbital, if given in a sufficient dose to the mother, 
lowers serum bilirubin levels significantly in the first week of life.
Singhi and colleagues randomly assigned mothers in labor to receive 
no fluids or intravenous dextrose water. Serum bilirubin levels were signifi­
cantly higher in the intravenous dextrose water group, and 60% of the jaun­
diced neonates in that group were considered to have frank hyponatremia. 
The mechanism here may be similar to that suggested for the use of fluids 
with oxytocin.
Controlled trials of the use of cimetidine and intrapartum administra­
tion of vitamin К to the mother have found no effect on neonatal jaundice.
The use of antenatal betamethasone to accelerate lung maturation did 
not increase neonatal serum bilirubin levels, but antenatal dexamethasone 
was associated with an increase in the incidence of bilirubin levels higher 
than 15 mg/dL (257 pmol/L) in a group of premature infants.
TOCOLYSIS
Beta-adrenergic agents used for tocolysis in labor are not associated 
with higher bilirubin levels or an increase in bilirubin production.
Because an increase in bilirubin production was observed in rats given 
nicardipine, women in preterm labor were randomly assigned to receive 
nifedipine or ritodrine or ritodrine and terbutaline. Carboxyhemoglobin levels 
in these infants and the need for phototherapy were similar.
DELIVERY MODE
Full-term Japanese infants delivered vaginally had significantly higher 
serum bilirubin levels throughout the first week of life than those delivered 
by cesarean section. In a controlled trial, however, the incidence of hyper­
bilirubinemia was similar in low-birth-weight infants delivered vaginally or 
by cesarean section. In the study by Yamauchi and Yamanouchi, infants born 
by cesarean section had significantly lower hematocrits than those bom vagi­
nally—probably due to the fact that placental transfusion is essentially absent 
in infants born by cesarean section. When compared with forceps delivery, 
the use of vacuum extraction does not appear to increase the risk of jaundice, 
although epidemiologic studies have found an association between vacuum 
extraction and hyperbilirubinemia.
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PLACENTAL TRANSFUSION AND HYPERVISCOSITY
The catabolism of 1 g of hemoglobin produces 35 mg (60 pmol) of 
bilirubin, so that it is reasonable to assume that a high hematocrit is a risk 
factor for neonatal jaundice. In controlled trials of the effect of exchange 
transfusion on hyperviscosity, infants with polycythemia and hyperviscosity 
were randomly assigned to receive either partial exchange transfusions or 
symptomatic treatment. The authors state that the mean bilirubin levels and 
the incidence of hyperbilirubinemia were similar in the treated and control 
infants, although serum bilirubin levels were not provided.
The volume of placental transfusion is determined by the time of cord 
clamping as well as the distance that the infant is held below the introitus be­
fore the cord is clamped. Controlled trials, in which full-term newborns were 
randomly assigned to have their cords clamped immediately or 5 minutes af­
ter delivery, showed mixed results. In two studies, infants were held 15 cm 
below the introitus before clamping. Neither study demonstrated any effect. 
In the study by Saigal and colleagues, infants were held 30 cm below the in­
troitus in the delayed group; this study showed the most significant effects in 
both full-term and preterm infants. Mean bilirubin levels at age 72 hours 
were 7.7 mg/dL (132 pmol/L) in the delayed-clamping group, compared with 
3.2 mg/dL (55 pmoI/L) in the early-clamping group. In preterm infants, 38% 
of infants in the delayed-clamping group had serum bilirubin levels that ex­
ceeded 15 mg/dL (257 pmol/L), compared with 6% in the early-clamping 
group.
CORD BLOOD BILIRUBIN LEVELS
The association between the level of bilirubin in the cord blood and the 
risk of hyperbilirubinemia in infants with Rh erythroblastosis is well known. 
In newborns with ABO incompatibility, a cord bilirubin level higher than 4 
mg/dL (68 gmol/L) was highly predictive of a subsequent serum bilirubin 
level higher than 16 mg/dL (274 pmol/L).151 Cord blood bilirubin levels are 
also related to subsequent bilirubin levels in infants without hemolysis. 
Knudsen found that 36% of infants who required phototherapy had a cord 
blood bilirubin level higher than 2.3 mg/dL (14 pmol/ L), compared with 
4.1% of jaundiced infants who did not require phototherapy. Knudsen and 
Lebech measured bilirubin concentrations in the mother and in the infant's 
umbilical cord blood at the time of delivery. Compared with nonjaundiced 
infants, infants who subsequently became jaundiced had significantly higher 
transplacental bilirubin gradients and cord blood bilirubin levels, and the se­
rum bilirubin levels in their mothers were also significantly greater. Meas­
urements of serum albumin concentrations and reserve albumin concentra­
tion, which is a measurement of bilirubin-binding capacity, were similar in 
jaundiced and nonjaundiced infants, suggesting that the increased cord 
bilirubin in the infants who later became jaundiced was the result of either
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increased fetal bilirubin production or decreased removal of bilirubin from 
the maternal circulation, and not a difference in albumin binding. Combining 
maternal and cord bilirubin levels at delivery provided a better prediction of 
neonatal jaundice than the cord bilirubin levels alone.
NEONATAL FACTORS
BIRTH WEIGHT AND GESTATION
Low-birth-weight and decreasing gestational age highly correlated 
with an increased risk for hyperbilirubinemia, and infants who are only 
slightly premature are at significantly greater risk for hyperbilirubinemia than 
full-term infants. At 37 weeks of gestation, newborns were four times more 
likely to have a serum bilirubin level of 13 mg/dL (222 pmol/L) or higher 
than were those at 40 weeks gestation.
GENDER
As a group, male infants consistently have higher bilirubin levels than 
females.
FEEDING, WEIGHT LOSS, AND CALORIC INTAKE
Caloric intake is known to affect bilirubin metabolism; decreased ca­
loric intake is associated with increased serum bilirubin levels. Early feeding 
might also decrease intestinal transit time and decrease the enterohepatic cir­
culation of bilirubin. Low-birth-weight infants fed in the first few hours after 
birth have significantly lower serum bilirubin levels than those fed at 12 to 48 
hours and an intake of 120 cal/kg/day for the first 5 days produces lower se­
rum bilirubin levels than 60 cal/kg/day. On the other hand, early intravenous 
feeding has little effect when compared with early or late oral feeding. In the 
National Institute of Child Health and Human Development (NIC'HHD) pho­
totherapy study, infants who received 90 or fewer cal/kg/day had signifi­
cantly higher bilirubin concentrations than those fed more than 90 cal/kg/day, 
and phototherapy was less effective when calorie and fluid intakes were low.
Consistent with the caloric effect on neonatal jaundice, a significant 
association has been found between hyperbilirubinemia and weight loss in 
the first few days after birth.
Several mechanisms might explain the inverse association between ca­
loric intake and serum bilirubin levels. In adults with a low-calorie intake, the 
predominant mechanism appears to be a decrease in hepatic clearance of 
bilirubin from the plasma. Fasting- or insulin-induced hypoglycemia in­
creases the activity of heme oxygenase and, possibly, bilirubin production, in 
rats but caloric deprivation in animals, human adults, and newborns is not ac­
companied by an increase in carbon monoxide production. During fasting, 
nonesterified fatty add levels increase and may impede hepatic clearance of 
bilirubin. Nonesterified fatty acids may affect bilirubin uptake by interfering
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with the receptors on the hepatic cell membrane. Nonesterified fatty acids 
also compete with unconjugated bilirubin binding by ligandin and may de­
crease bilirubin clearance by inhibiting glucuronosyl transferase activity.
The effects of parenteral nutrition and protein intake on the develop­
ment of cholestatic jaundice are well known. Compared with infants fed hu­
man milk or formula, those receiving intravenous glucose and amino acid 
solutions are more likely to develop conjugated hyperbilirubinemia. A high- 
protein intake (3.6 g/kg/day versus 2.3 g/kg/day) is associated with higher 
peak direct serum bilirubin levels and earlier onset of cholestatic jaundice.
TYPE OF DIET
When the diet of Gunn rats was changed from the standard laboratory 
diet to one composed predominantly of carbohydrate or protein, the plasma 
bilirubin concentration doubled over a period of 3 days. Rats fed a soybean 
oil lipid emulsion (i.e., intralipid) showed a slight decrease in plasma 
bilirubin levels. Gourley and colleagues evaluated the effect of diet on fecal 
output and neonatal jaundice in infants fed human milk or infant formulas. 
Infants who consumed a casein-hydrolysate formula had significantly lower 
bilirubin levels from days 10 through 18 than those fed standard casein or 
whey-predominant formulas. The cumulative stool output of the infants fed 
the caseinhydrolysate was lower than that of the infants fed the other formu­
las, suggesting that factors other than stool output and its effect on the en- 
terohepatic circulation must explain these observations. The authors state that 
they have preliminary findings to indicate that casein-hydrolysate formula 
inhibits figlucuronidase and may thus decrease the amount of bilirubin ab­
sorbed by the enterohepatic circulation.
BREAST-FEEDIMG AND JAUNDICE
A strong association has been found between breastfeeding and an in­
creased incidence of neonatal hyperbilirubinemia. In 1963, Newman and 
Gross, and in 1964, Arias and colleagues, described a syndrome of hyper­
bilirubinemia associated with breastfeeding. These infants, all full-term and 
healthy, had jaundice in the first week of life that did not resolve but per­
sisted into the second and third week, achieving a maximal level of 10 to 30 
mg/dL (171-513 pmol/ L) by 10 to 15 days after birth. If breast-feeding con­
tinued, elevated levels persisted for 4 to 10 days, then declined slowly, reach­
ing normal values by 3 to 12 weeks of age. If breast-feeding was interrupted, 
serum bilirubin levels fell within 48 hours. This condition became known as 
the breast-milk jaundice syndrome.
In addition to this syndrome, there is convincing epidemiologic evi­
dence that serum bilirubin levels during the first 3 to 5 days after birth are 
significantly higher in breast-fed than in formula-fed infants. In a pooled 
analysis of 12 studies comparing bilirubin levels in over 8000 newborns, se-
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rum bilirubin levels of 12 mg/dL (205 pmol/L) or higher occurred in 12.9% 
of breast-fed infants and 4% of formula-fed infants (p < 0.000001), and levels 
15 mg/dL (257 pmol/L) or higher occurred in 2% of the breast-fed infants 
and in 0.3% of the formula-fed infants. Thus, breast-fed infants are about 
three times more likely to develop moderate jaundice and six times more 
likely to develop severe jaundice than formula-fed newborns. In a study of 
2416 consecutive infants in a well-baby nursery, serum bilirubin levels of 13 
mg/dL (222 pmol/L) or higher occurred in 9% of breast-fed and 2.2% of 
formula-fed infants. The corresponding percentages for bilirubin levels of 12 
mg/dL (205 pmol/L) or higher were 3.6% for bottle-fed versus 12.1% for 
breast-fed infants. In these infants, the 95th percentile for maximal serum 
bilirubin before hospital discharge in the breastfed group was 14.5 mg/dL 
(248 pmol/L), compared with 11.4 mg/dL (195 pmol/L) in the bottle-fed 
group. Eighty percent of the infants whose serum bilirubin concentrations 
were 13 mg/dL (222 pmol/L) or higher were breast-fed, compared with 47% 
of those whose maximal bilirubin level was lower than 13 mg/dL. Of the in­
fants in whom no apparent cause for hyperbilirubinemia was found, 83% 
were breastfed.
In a more recent study, 306 infants admitted to a pediatric ward within 
21 days of birth with severe indirect hyperbilirubinemia were identified; the 
mean serum bilirubin level was 18.5 mg/dL (316 pmol/L). Seventy-seven 
percent of these infants were fully breast-fed and 14% partially breast-fed. 
Average age at the time of readmission to hospital was 5 days; 91.5% were 
admitted in the first week, 8% between 8 and 14 days, and 0.5% after 14 
days.
The jaundice associated with breast-feeding may appear early (2-4 
days of age) or later (4-7 days of age). The early-onset jaundice has been 
called breastfeeding jaundice syndrome, and the late-onset form has been 
called breast-milk jaundice syndrome. So much overlap exists between these 
two entities, however, that the distinction between early- and late-onset 
breast-milk jaundice may be more artificial than real, although some feel that 
the two conditions can be distinguished by their pathophysiology.
Evidence against two distinct syndromes comes from studies of the 
natural history of jaundice in the breast-fed infant. In addition to having 
higher bilirubin levels in the first 3 to 5 days, as a group, breast-fed infants 
have serum bilirubin levels that are higher than formula-fed infants for at 
least 3 to 6 weeks. These infants are the same infants who have high bilirubin 
levels in the first week of life, so it is hard to believe that those still jaundiced 
at 2 to 3 weeks of age represent a distinct group.
Jaundice associated with breast milk has also been described in prema­
ture infants. Lucas and Baker studied 186 preterm infants who weighed less 
than 1850 g at birth. These infants were randomly assigned to receive either 
banked donor breast milk or a preterm infant formula. Those fed banked
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breast milk had significantly higher peak bilirubin concentrations and more 
prolonged jaundice than infants fed the preterm formula, and those fed breast 
milk were over four times more likely to achieve plasma bilirubin levels 
above 11.7 mg/dL (200 pmol/L). This effect was also seen in sick, ventilated 
infants who weighed less than 1500 g and whose enteral intake during the 
first week was only 200 mL.
The pathogenesis of breast-milk jaundice has been reviewed in detail, 
and the suggested mechanisms are listed in Table 21.
Table 21
Suggested pathophysiology of jaundice associated with breast-feeding
Decreased Bilirubin Clearance by the Liver
Decreased caloric intake
Inhibitory substances in breast milk 
Pregnanediol 
Free fatty acids 
Other inhibitors 
Genetic factors
Increased Intestinal Reabsorption of Bilirubin
Delayed meconium passage
Decreased formation o f urobilinogen
Beta-glucuronidase
Bile acid abnormalities___________________________
Bilirubin Production
Breast-fed infants do not produce more bilirubin than formula-fed in­
fants. Measurements of carbon monoxide production, an index of bilirubin 
production show no differences between breast- and bottle-fed infants.
Decreased Bilirubin Clearance by the Liver
Decreased Caloric Intake
As discussed previously, a decreased caloric intake is associated with 
increased serum bilirubin levels. In the first few days after birth, breast-fed 
infants consume less calories than formula-fed infants, and there is a signifi­
cant association between hyperbilirubinemia and weight loss in the first few 
days after birth. Also, during fasting, NEFA levels increase and may impede 
hepatic clearance of bilirubin.
Inhibitory Substances in Breast Milk
Pregnanediol. The original observations of Arias and Gartner sug­
gested that a progestational steroid, З-а-20-p-pregnanediol, which is present 
in the milk of certain mothers, was responsible for inhibiting bilirubin conju­
gation in vitro and could also cause hyperbilirubinemia when administered to 
full-term infants. Although others have confirmed the inhibitory properties of
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breast milk from certain mothers, they have not found this particular steroid 
to be the offending compound.
Lipase and Free Fatty Acids. Nonesterified fatty acids inhibit bilirubin 
conjugation. These free fatty acids may be liberated as a result of the lipolytic 
action of breast-milk lipase on triglycerides. Both lipoprotein lipase (LPL) 
and bile salt-stimulated lipase are found in human milk. Bile salt-stimulated 
lipase is about 100 times more active than LPL, requires exposure to bile 
salts, and is important in the digestion of milk fat. Lipoprotein lipase does not 
appear to have much activity in normal human milk, and observations regard­
ing the role of LPL activity and NEFAs in neonatal jaundice are conflicting. 
Some investigators have found elevated LPL activity in the milk of mothers 
of infants with the breast-milk jaundice syndrome, but others have found no 
difference in LPL activity in milk samples from mothers of jaundiced and 
non-jaundiced infants. Alonso and colleagues found no relation between in­
fant bilirubin levels and either NEFA levels in fresh human milk or the abil­
ity of the milk to inhibit glucuronosyl transferase activity in -vitro. Nonesteri­
fied fatty acids accumulate in stored milk, and there is a relation between free 
fatty acid levels and the inhibition of glucuronosyl transferase. Foliot and col­
leagues found that milk from mothers of jaundiced infants, when stored at 
4°C, strongly inhibited bilirubin conjugation, but when assayed immediately 
after thawing, had no inhibitory effect. Breast-milk lipase activity normally 
increases significantly from day 3 to day 21. Thus, failure to use age-matched 
controls produces misleading results.
Uhari and colleagues assigned 332 breast-feeding mothers to receive a 
diet containing a low or high polyunsaturated-saturated fatty acid ratio. Al­
though there were significant differences in breast milk and maternal and in­
fant serum levels of oleate, linoleate, and linolenate, which was previously 
shown to inhibit bilirubin conjugation, there were no significant differences 
in neonatal serum bilirubin levels. Intake of specific dietary fatty acids does 
not appear to be related to neonatal jaundice.
Other Possible Inhibitors. Many factors are involved in the control of 
glucuronosyl transferase activity, including compounds such as metal irons, 
steroids, and nucleotides. Nucleotides might inhibit bilirubin clearance and 
play a role in the pathogenesis of breast-milk jaundice. Genetic factors must 
also be considered. Navajo infants have a high incidence of unconjugated hy­
perbilirubinemia, which is exaggerated in those who are breastfed. In these 
breast-feeding mothers, an inhibitor of glucuronosyl transferase activity was 
found in colostrum and breast milk in the first 3 days after birth, and the de­
gree of inhibition observed was related to the elevation of serum bilirubin.
Intestinal Reabsorption of Bilirubin
Direct and indirect evidence support the conclusion that an increase in 
intestinal absorption of bilirubin is the most important mechanism responsi-
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ble for the jaundice associated with breast-feeding. Bilirubin is present in fe­
tal bile as early as 14 to 15 weeks of gestation and, by 20 to 30 weeks of ges­
tation, bilirubin conjugates appear. The cumulative excretion of bilirubin dur­
ing fetal life accounts for the fact that significant quantities of bilirubin are 
found in meconium; it has been estimated that about 100 to 200 mg of 
bilirubin is present in the meconium of a normal 3-kg infant. This is about 4 
to 7 times more bilirubin than the infant will produce daily from the normal 
catabolism of heme, and delay in meconium passage leads to higher serum 
bilirubin levels. In the first few days of life, breast-fed infants pass less stool 
by weight, and their stools contain less bilirubin than those of formula-fed 
infants. Since there is no difference in the rate of bilirubin production, the 
implication is that breast-fed infants reabsorb more bilirubin through the gut 
than do formula-fed infants. Gourley and colleagues evaluated the effect of 
diet on feces and jaundice during the first 3 weeks of life. They found that 
breast-fed infants produced lower-weight individual wet and dry stools than 
formula-fed infants and that the cumulative wet and dry stool output was also 
lower in the breast-fed infants. In these infants, a decrease in serum bilirubin 
levels from day 3 to day 21 correlated positively with the 21-day total wet 
and dry cumulative stool weights. They concluded that the quantity of stool 
excreted is related to decreases in serum bilirubin levels in infants fed human 
milk. Infants fed human milk passed stool significantly less frequently than 
infants fed casein-predominant formulas, while those fed casein hydrolysate 
formulas passed less stool, cumulatively, than those fed whey-predominant or 
casein-predominant formulas. There was no difference between the cumula­
tive wet or dry stool output during the first 3 weeks of life in infants fed ca­
sein hydrolysate formulas or human milk. Gartner and colleagues instilled 
unconjugated bilirubin into the duodenum of adult rats. When the bilirubin 
was given with phosphate buffer, 25% of the administered dose was absorbed 
and excreted in bile within.5 hours,' ~ ' When the bilirubin was ad­
ministered with human milk or cow milk, absorption was less than 2%; how­
ever, when bilirubin was administered in milk from mothers of infants with 
the breast-milk jaundice syndrome, absorption was 25% during the first 5 
hours and persisted for an additional 11 hours, leading to a total absorption of 
65% of the administered dose. Thus, milk from mothers of infants with 
breast-milk jaundice appeared to enhance the enterohepatic circulation of 
bilirubin.
Alonso and colleagues collected milk from unse-lected, normal moth­
ers and serum from their infants at 16.3 ± 2.4 days. When the bilirubin was 
administered with a bicarbonate buffer, 25.29% ± 4% was absorbed. Absorp­
tion was 4.67% ± 2.4% when given with Similac formula and 7.7% ± 2.9% 
when given with fresh human milk. They also found a positive correlation 
between the percentage of bilirubin.absorbed when administered with human 
milk and the serum bilirubin level in the infant being fed that milk. These
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data provide additional confirmation that enhanced intestinal absorption of 
bilirubin contributes to the jaundice associated with breast-feeding. These 
studies also confirm that cow milk inhibits re-absorption of bilirubin, which 
explains why interrupting breast-feeding or supplementing breast-feeding 
with formula generally lowers serum bilirubin levels.
Alonso and colleagues also analyzed the breast milk for P- 
glucuronidase, NEFAs, and the ability of the milk to inhibit glucuronosyl 
transferase activity of rat liver microsomes in vitro. None of these measure­
ments correlated with the infant's serum bilirubin.
Urobilinogen Formation. Once in the small intestine, conjugated 
bilirubin is not reabsorbed. In a healthy adult, it is largely reduced by the ac­
tion of colonic bacteria, principally clostridium ramosum, to a series of 
tetrapyrroles, collectively known as urobilinogen. As a result, in the adult, 
there is minimal reabsorption of bilirubin from the intestinal tract. At birth, 
however, the fetal gut is sterile, and although there is an increase in the bacte­
rial content of the gut after delivery, the neonatal intestinal flora do not con­
vert conjugated bilirubin to urobilinogen. This leaves bilirubin in the bowel 
and allows it to be deconjugated and become available for reabsorption. The 
bile pigments in newborn stool are similar to those found in duodenal bile. 
Formula-fed infants excrete urobilin in their stools earlier than breast-fed in­
fants, perhaps due to the effect of the feeding on intestinal flora. Thus, the ef­
fect of breast milk on intestinal flora, by slowing the formation of urobilin, 
further enhances the possibility of intestinal reabsorption of bilirubin.
Beta-Glucuronidase. Beta-glucuronidase is an enzyme that cleaves the 
ester-linkage of bilirubin glucuronide, producing unconjugated bilirubin, 
which can then be reabsorbed through the gut. Significant concentrations of 
P-glucuronidase are found in the neonatal intestine. Beta-glucuronidase activ­
ity is also significantly greater in human milk than in infant formulas. Gour- 
ley and Arend found a relation between serum bilirubin levels and breast- 
milk p-glucuronidase activity in the first 3 to 4 days after birth, but others 
have not been able to confirm this. Because the neonate's intestine contains 
large quantities of mucosal p-glucuronidase, the relatively small amounts of 
enzyme in milk would not be expected to add much to the overall activity. 
Nevertheless, Gourley and colleagues suggest that milk p-glucuronidase may 
be a significant additional source of fecal p-glucuronidase. These investiga­
tors also found a correlation between neonatal serum bilirubin levels and p- 
glucuronidase activity in the first stool passed after birth. Finally, Gourley 
and colleagues infused rat bile plus breast milk into the rat's duodenum. Rats 
that received this infusion with saccharolactone, a p-glucuronidase inhibitor, 
excreted significantly less bilirubin in their bile than those that did not re­
ceive saccharolactone, suggesting that inhibition of p-glucuronidase de­
creased the intestinal absorption of bilirubin.
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Bile Acids. Some studies suggest that breast-fed infants with prolonged 
unconjugated hyperbilirubinemia may also have a mild degree of cholestasis. 
Finni and colleagues found elevated serum levels of alkaline phosphatase, 
cholic and chenodeoxycholic acids, and a-fetoprotein in jaundiced, breast-fed 
infants at 1 month of age. Cholic and chenodeoxycholic acids were still sig­
nificantly elevated at 12 months of age, although the alkaline phosphatase 
and a-fetoprotein levels had returned to normal. T araw a and colleagues did 
not find a significant increase in total serum bile acid levels in breast-fed in­
fants with prolonged jaundice. All breast-fed infants, regardless of the pres­
ence or absence of jaundice, had a bile acid pattern dominated by taurine con­
jugates, whereas in bottle-fed infants, glycine conjugates predominated. In 
the jaundiced breast-fed infants, however, the ratio of glycine- to taurine- 
conjugated bile acid was significantly lower than in nonjaundiced infants. 
Lipoprotein X levels were normal in breast-fed jaundiced infants. This pat­
tern of bile acids does not suggest the usual type of cholestasis but indicates 
the possibility of an increased enterohepatic circulation of bile acids in 
breastfed infants. High-performance liquid chromatographic analysis of 
bilirubin in breast-fed and formula-fed infants revealed no differences in 
bilirubin monoconjugates or diconjugates on the third and fifth day of life.
Meconium Passage. Because the enterohepatic circulation of bilirubin 
appears to be an important contributor to neonatal hyperbilirubinemia, in­
creasing the rate of bilirubin evacuation from the bowel should decrease the 
incidence of neonatal jaundice. Two controlled trials tested this hypothesis. 
In one, infants were randomly assigned to have their temperatures taken ei­
ther rectally or in the axilla directly after birth, on the assumption that the in­
sertion of a rectal thermometer would stimulate earlier meconium evacuation, 
which it did. Weisman and colleagues randomly assigned infants to receive 
one-half of an infant suppository within the first hour after birth and then 
every 4 hours until the appearance of the first transitional stool. In both these 
studies, the peak serum bilirubin levels were about 1 mg/dL (17 pmol/ L) 
lower in the treated than in the control groups, and a pooled analysis of the 
data indicates that the effect is significant.
In summary, early and frequent feeding promotes fluid and caloric in­
take and minimizes weight loss. Such feeding also decreases intestinal transit 
time and facilitates early passage of meconium, which decreases the entero­
hepatic circulation of bilirubin. These measures should reduce neonatal 
bilirubin levels.
PHENOLIC DETERGENTS
The use of excessive concentrations of a phenolic disinfectant deter­
gent to clean surfaces in the nursery was associated with an epidemic of neo­
natal hyperbilirubinemia in two hospitals. There was no evidence for hemo­
lysis, and the pathogenesis for the hyperbilirubinemia is not known. Daum
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and colleagues demonstrated inhibition of glucuronosyl transferase activity in 
liver homogenates, but they could not confirm this in vivo using the Gunn 
rat. Doan and colleagues found that use of a phenolic detergent, even when 
used at the manufacturer's recommended concentrations, was associated with 
higher bilirubin levels than those found in infants in a nursery in which a 
nonphenolic quarternary ammonium disinfectant was used. In view of these 
observations, it is recommended that phenolic detergents not be used in the 
nursery1.
TRACE METALS
Plasma zinc levels were significantly lower in neonates with unex­
plained jaundice and their mothers than in controls. The data on magnesium 
levels in these infants are conflicting— increased in one study, but normal in 
another. It is possible that zinc deficiency produces structural defects in the 
erythrocyte membrane and leads to hemolysis.
ALTITUDE
Moore and colleagues observed an association between hyper­
bilirubinemia, with serum bilirubin levels higher than 12 mg/dL (205 
pmol/L), and high altitude. Infants bom at 3100 meters above sea level had 
more than twice the incidence of hyperbilirubinemia than those born at 1600 
meters (32.7% versus 13%) and four times the incidence reported for those 
bom at sea level. The infants born at higher altitudes had higher hematocrits, 
but there was no difference in hematocrits between infants with high bilirubin 
levels and those with low levels at each altitude. The presence of other risk 
factors known to affect serum bilirubin levels was similar in the different 
groups, but the incidence of maternal smoking was, unfortunately, not as­
sessed. Both short- and long-term exposure to high altitudes increases 
bilirubin levels in adults. Possible mechanisms for these observations include 
an increase in bilirubin load due to higher hematocrits, impaired conjugation, 
and impaired excretion of bilirubin.
DRUGS ADMINISTERED TO THE INFANT
Large doses (up to 30 mg) of synthetic vitamin К analogs have been 
associated with significant increases in bilirubin levels and kemicterus. The 
standard dose (1 mg) of intramuscular vitamin ki has no effect on neonatal 
bilirubin levels.
Freeman and colleagues found that infants exposed to pancuronium 
were at greater risk for hyperbilirubinemia (bilirubin-birth weight index > 
0.5). The risk was greatest among exposed infants during the 4 days after the 
last dose of pancuronium. It is possible that pancuronium alters bilirubin me­
tabolism and increases the risk of hyperbilirubinemia in ill newborns. It is
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also possible that the use of pancuronium simply identifies a group of new­
borns who are at higher risk for this complication.
Chloral hydrate, which is widely used as a sedative in neonates and in­
fants, is associated with significant elevations in indirect and direct serum 
bilirubin levels. Chloral hydrate is metabolized to trichloroacetic acid and the 
toxic trichloroethanol, both of which accumulate in the tissues of compro­
mised infants. The half-life of trichloroethanol is 37 hours in the newborn, 
compared with 14 hours in the adult. In ill preterm infants, there is indirect 
evidence of competition by trichloroethanol for hepatic glucuronidation of 
bilirubin. The administration of chloral hydrate is also associated with direct 
hyperbilirubinemia. Infants with direct hyperbilirubinemia had received 
much higher total cumulative doses of chloral hydrate than those that did not 
develop direct hyperbilirubinemia, and the hyperbilirubinemia resolved after 
chloral hydrate was discontinued. Thus, chloral hydrate should be used with 
caution in newborns and particularly low-birth-weight, ventilator-dependent 
infants.
FREE-RADICAL PRODUCTION
Bilirubin appears to have an important physiologic function as an anti­
oxidant and may play a role in the prevention of oxidative membrane damage 
in vivo (see Physiologic Effects of Bilirubin). Although sick newborns might 
be expected to have an exaggerated rise in bilirubin levels, Benaron and Bo­
wen found that this was not the case. Infants with illnesses such as circulatory 
failure, proven sepsis, aspiration syndromes, and asphyxia—conditions be­
lieved to enhance free-radical production—had a significantly lower daily 
rise in mean serum bilirubin levels (2.1 mg/dL, or 36.1 pmol/L) than control 
infants (3.9 mg/dL, or 66.7 pmol/L). Control infants were initially ill but 
proved not to have any active medical disorder. They were selected from in­
fants with myelomeningoceles, other surgical disorders, and suspected sepsis 
that was ruled out by negative studies. Neither group received enteral feed­
ings during the study. If the conditions identified in the study infants actually 
enhance free-radical production, then this finding is consistent with the hy­
pothesis that bilirubin is consumed as an antioxidant. The role of bilirubin as 
an antioxidant is discussed later.
JAUNDICE IN THE HEALTHY NEWBORN
NORMAL SERUM BILIRUBIN LEVELS
Mean bilirubin levels in cord blood range from 1.4 to 1.9 mg/dL (24- 
32 pmol/L), and elevated cord bilirubin levels are associated with an in­
creased risk of hyperbilirubinemia.
The serum bilirubin level was measured routinely at about 48 hours of 
age and repeated daily if the initial level was 10 mg/dL (171 pmol/L) or
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greater until the value decreased below 10 mg/dL. Additional serum bilirubin 
determinations were obtained when clinically indicated.
Normal plasma bilirubin concentrations in human adults range from
0.3 to 1 mg/dL (5-17 pmol/L).248 In 3.3% of infants, maximal serum 
bilirubin levels never exceeded 1 mg/dL (5 pmol/L), and 8.2% had serum 
bilirubin levels that did not exceed 1.5 mg/dL (20 pmol/L).
Table 22
Maximal total serum bilirubin of newborn Caucasian infants by birth weight
DIRECT BILIRUBIN LEVELS
Newman and colleagues analyzed 5255 direct biliru-bin measurements 
performed on full-term infants born at the hospitals of the University of Cali­
fornia, San Francisco (UCSF), and Stanford University. Each institution used 
different methods to measure direct or conjugated bilirubin levels, which al­
most certainly accounts for the fact that the values for the 50th through 95th 
percentiles at UCSF were more than double those at Stanford (Table 2£). The 
measurements of total and direct bilirubin levels are both subject to labora­
tory error, and it is important to recognize that direct bilirubin is not synony­
mous with conjugated bilirubin. Laboratory methods for estimating serum 
bilirubin concentrations are discussed in detail in the section on clinical man­
agement.
PHYSIOLOGIC JAUNDICE
According to the criteria for normal adult serum bilirubin concentra­
tions, about 97% of Caucasian infants with birth weights greater than 2500 g 
have some degree of chemical jaundice, and about two thirds have serum
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bilirubin levels of 5 mg/dL (85 pmol/L) or greater (see Table 24). Because it 
is almost universal during the first week of life, this transient hyper­
bilirubinemia has been called physiologic jaundice. Gartner and colleagues 
studied the newborn rhesus monkey and found that the newborn human and 
monkey develop a similar biphasic pattern of physiologic jaundice. In the 
monkey, phase I is characterized by a rapid increase in serum bilirubin levels 
to 4.5 mg/dL (77 pmol/L) by 19 hours followed by a decline to 1 mg/dL (17 
pmol/L) by 48 hours. In phase II, bilirubin levels remain elevated at 1 mg/dL 
(17 pmol/L) until about 4 days of age, when they decline to normal adult val­
ues.
Table 23
Maximal total serum bilirubin of newborn african-american
There is a similar pattern in the full-term human neonate, but both 
phases last much longer and vary considerably among different racial groups. 
The pattern is also strongly influenced by breast- or formula-feeding (Fig.23). 
Compared with formula-fed infants, breast-fed infants tend to have a more 
rapidly rising and prolonged phase I and a very prolonged phase II that, in 
some infants, may extend for several weeks. As can be seen from Figure 23, 
mean peak serum bilirubin levels in full-term newborns range from about 5.6- 
to 12.8 mg/dL (96-219 pmol/L), depending on the population and feeding 
method. Low-birth-weight infants, if untreated, have exaggerated and pro­
longed hyperbilirubinemia, with peak serum bilirubin levels of 10 to 15 
mg/dL (171-257 pmol/L) on days 5 to 6 (i.e., phase I), then lower concentra-
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tions, which may persist for up to 4 weeks.
Table 24
Maximal total serum bilirubin concentrations before discharge
S t n m U it
Levels
in  n e w b o rn  C au casian  in fa n ts  w e ig h in g  >  2 5 0 0  g  
*1 Warts* |t= 2297) B re e sW  M in ts И 2 Й )  Formula-Fed Infants (n = 1026)
mg/dt IdDobl Mumber Percentage
Cumulative
Percentage Number Percentage
Cumulative
Percentage N u m b e r P e r c e n t a g e
C u m u l a t i v e
P e r c e n t a g e
0-0.9 0-16 51 222 222 29 23 23 2 2 2 .1 4 2 .1 4
1-1.9 17-33 221 9.62 1194 90 7.14 9.44 1 3 0 1 2 .6 7 1 4 .8 2
2-29 34-50 180 7.84 19.68 86 693 1627 9 4 9 .1 6 2 3 .9 8
5-39 51-67 187 8.14 2792 82 6.51 22.78 1 0 5 1 0 .2 3 3 4 .2 1
U 9 68-84 185 8.1 3592 90 7.14 29.92 9 5 9 .2 6 4 3 .4 7
5-59 85-102 204 898 449 98 7.78 37.7 1 0 6 1 0 .3 3 5 3 .8
5 4 9 103-119 241 1049 5529 118 997 47.06 1 2 2 1 1 .9 8 6 5 .6 9
7-7.9 120-136 235 102! 65.52 135 10.71 57.7! 9 9 9 .6 5 7 5 .3 4
8 4 3 137-153 225 9.8 75.32 140 11.11 68.89 8 5 8 .2 9 8 3 .6 3
9-99 151-170 171 744 82.76 104 825 77.14 66 6 .4 3 9 0 .0 6
10-109 171-187 117 509 17.85 77 511 8325 3 9 3 .8 9 3 .8 6
11-119 188-204 87 379 91.64 59 4.68 87.94 2 6 2 .5 3 9 6 .3 9
12-129 205-221 54 295 3393 39 309 91.03 1 4 1 .3 7 9 7 .7 6
13-139 222-238 43 1.87 95.86 35 278 9391 8 0 .7 8 9 8 .5 4
H -148 239-256 30 191 97.17 26 206 9597 2 0 .1 9 9 8 .7 3
15-159 257-273 31 1.35 98.52 24 191 97.78 7 0.68 9 9 .4 2
15-16.9 274-290 16 0.7 9922 16 1.27 99.05 0 0 9 9 .4 2
17-179 291-307 11 9(8 99,7 8 0.63 99.60 3 0 .2 9 9 9 .7 1
11-189 308-324 4 017 9997 2 016 99.64 2 0 .1 9 9 9 .9
19-199 325-341 3 813 Ш 2 016 100 1 0.1 100
Table 25
Maximal direct bilirubin levels in full-term infants at two hospitals
University of 
California, Stanford
San Francisco* Universityi
(n - 4948) (n = 307)
Percentile /xmol/L mg/dL jimol/L mg/dL
50 19 1.1 7 0.4
75 24 1.4 10 0.6
90 32 1.9 14 0.8
95 39 2.3 17 1.0
99 63 3.7 77 4.5
1 95
14
0 1— .— i— .— i— ■— i— .— ■— .— i— .— i— .— i— .—
0 1 2 3 4 5 6 7 8  
Age (days)
FIG. 23. Mean total daily bilirubin concentrations in normal full-term infants. (A) Fitly healthy 
Japanese newborn infants, 37-42 weeks of gestation, all breast-fed. Excludes Rh and ABO in­
compatibility. (D) Two hundred and seventy-five full-term Israeli infants.) 37-41 weeks of ges­
tation, 65% breast-fed, 30% breast- and formula-fed, 5% formula-fed Excludes infants with 
hemolytic disease, respiratory distress, or sepsis. Values estimated from graphic data, (e)- 
Twenty-nine full-term American infants, all formula-fed, about 50% African American and 
50% Caucasian. Values estimated from graphic data.
Jaundice may result from an increased load of bilirubin on the liver 
cell, including that contributed by the enterohepatic circulation, and a de­
crease in the ability of the liver to clear the bilirubin from the plasma as a re­
sult of defective uptake, conjugation, or excretion, singly or in any combina­
tion. Physiologic jaundice is probably the result of the interaction of a num­
ber of these factors (Table 26).
CLINICAL DIAGNOSIS OF JAUNDICE
CEPIIALOPEDAL PROGRESSION
In newborns, jaundice is detected by blanching the skin with digital 
pressure, thus revealing the underlying color of the skin and subcutaneous 
tissue. This dermal icterus is seen first in the face and then progresses in a 
cordad manner to the trunk and extremities.
First observed over 100 years ago, the cephalo-caudal progression of 
dermal icterus may be a useful clinical tool (Fig. 24, Table 27). Kramer stud­
ied the relation between the progression of dermal icterus and serum indirect 
bilirubin levels in 103 American, full-term infants (80% Caucasian). Infants 
whose jaundice was restricted to the face and trunk and did not extend below 
the umbilicus all had serum bilirubin concentrations of about 12 mg/dL (205 
pmol/ L) or less. Those whose hands and feet were jaundiced all had serum 
bilirubin levels in excess of 15 mg/dL (257 pmol/L). Ebbesen did a similar 
study but examined infants in daylight; Kramer's observations were carried
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out under blue-white fluorescent light. Although Ebbesen confirmed the 
usual cephalocaudal progression, distal icterus corresponded with much 
lower bilirubin levels than those found by Kramer.
Table 26
) Possible mechanisms involved in physiologic jaundice
Increased Bilirubin Load on Liver Cell
Increased erythrocyte volume 
Decreased erythrocyte survival 
Increased early-labeled bilirubin 
Increased enterohepatic circulation of bilirubin 
Defective Hepatic Uptake of Bilirubin 
From Plasma
Decreased ligandin (i.e., Y protein)
Binding of Y and Z proteins by other anions 
Decreased relative hepatic uptake deficiency, phase II 
Defective Bilirubin Conjugation 
Decreased uridine diphosphoglucuronosyltransferase activity 
Increased uridine diphosphoglucose dehydrogenase activity 
Defective Bilirubin Excretion
Excretion impaired but not rate-limiting______________________________
FIG. 24. Dermal zones of jaundice
Ebbesen found that if dermal icterus did not progress below the knees, 
serum bilirubin levels never exceeded 6.4 mg/dL (pmoi/L). The differences
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may be related to the different populations studied. Ebbesen studied a mixed 
Scandinavian population of full-term and premature infants. He found no ef­
fect of prematurity on dermal icterus. The cephalocaudal progression of 
jaundice has also been studied using transcutaneous bilirubinometry These 
measurements provide objective confirmation that, at any given bilirubin 
level, the skin in the face is more yellow than that in the foot. Knudsen sug­
gested that the cephalocaudal color difference in newborns is explained by 
conformational changes in the bilirubin-albumin complex. He hypothesizes 
that the yellow color of the skin in icteric newborns is made up of a contribu­
tion from natural skin color, bilirubin-albumin complexes that are located 
outside the vascular space, and precipitated bilirubin acid in phospholipid 
membranes. Bilirubin is formed in the reticuloendothelial system, primarily 
in the liver, spleen, and bone marrow, and once it reaches the plasma, it is 
bound tightly to albumin. The initial binding process is extremely rapid (i.e., 
within 10 msec) and is followed by a train of slow relaxing changes in the 
conformation of the bilirubin-albumin complex. Major conformational 
changes in the bilirubin-albumin complex occur within 1 to 30 seconds, and a 
final conformation is reached 8 minutes after binding. Initially, therefore, 
there is a lower bilirubin-binding affinity to albumin until the final stage of 
conformation has occurred.
Tabh? 2 ?
Indirect serum bilirubin concentration and its relation to the progression of 
dermal icterus in full-term infants
Dermal
Zonet
Bilirubin (mg/100 mL)
Mean ± SD Range Observations
1 5.9 i  0.3 4.3-7.9 13
2 8.9 ± 1.7 5.4-12.2 49
3 11.8 ± 1.8 8.1-16.5 52
4 15.0 ± 1.7 11.1-18.3 45
5 >15 29
♦Includes all infants whose rate of serum bilirubin rise was 0.7 mg/dL/h or less. See figure 24.
Thus, lower bilirubin affinity for albumin is present in the blood im­
mediately after it has left the reticuloendothelial system, but increasing affin­
ity is present as the blood reaches the distal portions of the body. If some o f 
the yellow color of the skin is the result of precipitated bilirubin acid, then, in 
the presence of reduced bilirubin-binding affinity to albumin, there is an in­
crease in precipitation of bilirubin acid and thus an increase in the yellow 
color of the skin. This is more likely to occur in the proximal parts of the 
body because of the conformational changes in the young bilirubin-albumin
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complexes. Consistent with this hypothesis, Knudsen found that there was a 
significant and linear correlation between the cephalocaudal color difference, 
the plasma bilirubin concentration, and the square of the hydrogen ion con­
centration. The cephalocaudal color difference was inversely related to the 
reserve albumin concentration, thus suggesting that the con-formational 
change in the young bilirubin-albumin complex enhances the precipitation of 
bilirubin acid in the skin of the proximal parts of the body. If this is the 
mechanism, then objective measurement of the yellow color of the skin using 
a transcutaneous bilirubinometer could be a better predictor of potential 
bilirubin encephalopathy than a serum bilirubin measurement.
EVALUATING JAUNDICED INFANTS
Because clinical jaundice becomes apparent at serum bilirubin levels 
of about 5 mg/dL (85 pmol/L), 65% of all normal newborns are jaundiced 
during the first week of life. It is therefore important for the physician caring 
for newborns to develop a relatively consistent approach to the investigation 
and management of the jaundiced newborn. Such an approach is suggested 
by the following questions:
Is the jaundice physiologic or nonphysiologic, and, possibly, patho­
logic?
If not physiologic jaundice, what are the possible causes?
Which infants require further investigation, and what investigations
are needed? Is the jaundice a threat to the infant?
What investigations are required to assess the potential danger?
If danger exists, what treatment is appropriate?
DIFFERENTIATING PHYSIOLOGIC FROM NONPHYSIOLOGIC JAUNDICE
The definitions of physiologic and nonphysiologic jaundice are based 
on the natural history of bilirubinemia and normal serum bilirubin levels in 
the first weeks of life. These definitions have led to the establishment of cri­
teria for the evaluation and treatment of jaundiced infants. Some authorities 
advise measuring bilirubin levels in all jaundiced infants. In those with early 
jaundice or bilirubin levels higher than 12 to 13 mg/dL (205-222 fjunoUL), 
additional diagnostic evaluation is recommended.257'259 These recommen­
dations are likely to lead to unnecessary testing of many jaundiced full-term 
infants, and they can do more harm than good.
IDENTIFYING NONPHYSIOLOGIC JAUNDICE
In the past, whenever nonphysiologic jaundice was suspected, standard 
investigations included the following tests:
• serum bilirubin concentration, direct and total
• complete blood cell count, including hemoglobin, reticulocyte 
count, and peripheral smear for erythrocyte morphology
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• blood type and Rh determination of mother and infant and direct 
Coombs test of infant's blood.
Problems with this approach include the following:
First, the data from which definitions of physiologic and nonphysi- 
ologic jaundice are derived are based on bilirubin levels obtained during an 
era when about 25% of infants were breast-fed and most remained in the 
nursery for several days. In most nurseries in the United States today, at least 
50% and sometimes more than 80% of infants are breast-fed, and all vagi- 
nally delivered infants are discharged within 48 hours, necessitating reevalu­
ation of the infant by a health visitor, physician, or parent in the first few 
days after birth.
Second, with few exceptions, the recommended laboratory tests listed 
previously are not particularly helpful. In studies at the Hershey Medical 
Center and UCSF, almost 5000 jaundiced infants who weighed more than 
2500 g were evaluated using the tests listed above. The only diagnoses made 
as a result of the routine investigation of jaundice were polycythemia and 
ABO or Rh immunization. These conditions accounted for jaundice in fewer 
than 20% of infants.
In most circumstances, the Rh type of the mother and her infant is 
known, whether or not the infant is jaundiced. Mothers who have had no an­
tenatal care must have blood typing performed to identify the need for Rh 
immunoglobulin. The diagnosis of ABO isoimmunization is much more dif­
ficult. Although as many as 33% of group A or В infants born to group О 
mothers have anti-A or anti-B antibodies attached to their erythrocytes, only 
a small proportion of these (perhaps 1 in 5) have hyperbilirubinemia or other 
evidence of hemolytic disease. ABO-incompatible Coombs-positive infants 
are about twice as likely as their compatible peers to have a serum bilirubin 
level of more than 12 mg/dL (205 pmol/L), but severe jaundice in these in­
fants is uncommon. The presence of jaundice in an ABO-incompatible, 
Coombs-positive infant does not necessarily mean that the infant has ABO 
hemolytic disease. Because evidence from earlier studies suggests that hy­
perbilirubinemia is more hazardous in the presence of isoimmunization, it is 
probably worthwhile to identify ABO immunization in infants with severe 
jaundice and to treat them more aggressively than infants with nonhemolytic 
jaundice. The rate of rise of serum bilirubin is helpful when some form of 
hemolytic process is being considered, and a bilirubin level of 15 mg/dL (257 
(imol/L) at 30 hours of age would raise concerns that are different from those 
suggested by a similar bilirubin level at 3 to 5 days of age. In certain popula­
tions, the diagnosis of G6PD deficiency or other hereditary hemolytic ane­
mias must be considered as well as other less common causes of jaundice.
No jaundice should be dismissed as physiologic without at least a re­
view of the maternal and infant history, examination of the infant, and if nec­
essary, pursuit of further laboratory investigations. On occasion, jaundice
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may be one sign of serious illness, and the presence of any of the associated 
signs listed in Table 28 demands evaluation and treatment as indicated. The 
problems are that jaundice is common, most of the diseases the tests aim to 
identify are rare, and the tests are neither sensitive nor specific.
Bacterial infection is a recognized cause of hyperbilirubinemia in the 
newborn, and some reports have suggested that unexplained indirect hyper­
bilirubinemia may be the only manifestation of sepsis in otherwise healthy- 
appearing newborns. However, jaundice is rarely the only manifestation of 
bacteremia or incipient sepsis. In 306 newborns admitted to a pediatric ward 
within 21 days of birth with the diagnosis of indirect hyperbilirubinemia 
(peak serum bilirubin levels 18.5 ± 2.8; range 12.7 - 29.1 mg/dL, or 316 ± 
4.8, 217-498 pmol/L), not one case of sepsis was identified (upper 95% 
confidence limit for the risk of sepsis = 1%). If a good screening test for 
sepsis were available, it would be worth looking for in spite of its rarity 
because it is both serious and treatable. As can be seen in Table 3D \  in 
most full-term, jaundiced newborns, no pathologic cause of the jaundice can 
be identified. Jaundice is a common entity, and the finding of a positive 
blood or urine culture in a newborn with indirect hyperbilirubinemia does 
not prove that the infection is the cause of the jaundice. On the other hand, 
infants who exhibit other signs or symptoms (see Table 2  9 ')  deserve 
more careful evaluation, particularly those who have late-onset jaundice af­
ter physiologic icterus has resolved, direct hyperbilirubinemia, or some­
thing in the history, physical examination, or laboratory investigations that 
is out of the ordinary.
Table 28
Danger signs in jaundiced infants
Family history of significant hemolytic disease 
Onset of jaundice in first 24 hours of life 
Onset of jaundice after day 3 of life 
Vomiting 
Lethargy 
Poor feeding 
Fever
High-pitched cry 
Dark urine
Light stools__________________________
MEASURING DIRECT BILIRUBIN CONCENTRATIONS 
In many nurseries, routine determinations of direct bilirubin levels are 
obtained whenever the total bilirubin level exceeds a predetermined level. 
Measurements of direct bilirubin, however, are notoriously inaccurate and 
when used as a screening test in the newborn nursery, direct bilirubin meas­
urements provide a low yield and are nonspecific if the intent is to rule out
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treatable causes of cholestasis, such as biliary atresia or galactosemia. Bil­
iary atresia occurs in 10 of every 100,000 births and galactosemia in about 2 
in 100,000 births. In contrast, 15,000 of 100,000 infants have significant 
jaundice, of whom at least 750 (5%) have a direct bilirubin level above the 
95th percentile. Fortunately, galactosemia can be identified by a routine 
metabolic screen performed in the nursery, and biliary atresia should be di­
agnosed by selective testing of infants with prolonged jaundice (>2 weeks), 
light stools, or dark urine.
Every infant who is jaundiced beyond 2 weeks of age must have a 
measurement of direct bilirubin performed. If this is elevated, the urine 
should be tested for bile and the stool color evaluated. This approach is es­
sential for the early identification of infants with biliary atresia. If these in­
fants are to benefit from the operation of portoenterostomy, surgery must be 
performed before 60 days of age. If an elevated direct bilirubin measure­
ment is obtained while the infant is in the nursery, it must be repeated, if it 
remains elevated, the infant must be investigated for possible causes of cho­
lestatic jaundice (Fig. 25).
PRACTICAL APPROACH TO EVALUATION
Given that jaundice in the newborn nursery is extremely common, but 
only rarely due to a pathologic entity, and recognizing that early neonatal 
discharge has rendered daily evaluation impossible, Newman and Maisels 
suggested two different strategies for the evaluation and follow-up of jaun­
diced infants. Guidelines for evaluation and a diagnostic approach to the 
jaundiced infant are given in Figure 24. Although most routine laboratory 
testing rarely reveals information of importance, jaundice should not be ig­
nored. Particularly in association with other findings, jaundice may be a 
sign of serious illness. Thus, jaundice in an infant should always trigger a 
clinical evaluation to determine whether any danger signs are present. If 
they are, more aggressive evaluation and treatment are indicated.
Since a short postdelivery hospital stay is the norm for newborns and 
the length of stay is likely to become even shorter, it may be advantageous 
to try to identify isoimmunization soon after birth by performing a blood 
type and Coombs test on infants of group О mothers. Such testing is manda­
tory for all infants of Rh-negative mothers. The most frequent cause of iso­
immunization is ABO incompatibility. Although the risk for severe jaundice 
in these infants is low, the identification of ABO isoimmunization suggests 
the need for more careful surveillance, perhaps delaying discharge if outpa­
tient follow-up cannot be ensured. A positive Coombs test is more likely to 
occur on cord blood than on a blood sample drawn several days later. Nev­
ertheless, there is no good evidence that routine testing of infants of group 
О mothers is beneficial, and it increases costs.
2 0 2
JAUNDICEf
MEASURE TOTAL AND DIRECT BUJRUBlNt
JAUNDICE NOT PHYSIOLOGIC
t
BLOOD TYPES. Rh. COOMBS 
HEMATOCRIT 
RED CELL MORPHOLOGY 
RETICULOCYTE COUNT
C*h 'V  Мяк*
FIG. 25. Diagnostic approach to neonatal jaundice.
Table 29
Suggested guidelines for evaluation and follow-up of jaundice 
in full-term infants*
Indications Maneuvers
Rh-negative mothers1
Any jaundice in first 24 hours* 
Jaundice after 24 hours 
Jaundice below umbilicus from 24- 
48 hours
Jaundice below knee
Jaundice in hands or feet 
Infants with evidence of hemolysis
Blood type, group, and Coombs test, 
determined from cord blood 
Serum bilirubin level 
Observe for dermal distribution 
Transcutaneous bilirubin, icterometer 
assessment, or serum bilirubin level 
Transcutaneous bilirubin, icterometer 
assessment, or serum bilirubin level 
Serum bilirubin level 
Follow bilirubin until peak
*Note that these guidelines cannot take into account all possible situations Full-term infants are 
infants of at least 37 weeks of gestation.
tin  some institutions, blood type, group, and Coombs tests are performed on the cord blood of 
infants of all group-O mothers to identify ABO incompatibility. This information could be help­
ful, particularly if follow-up is difficult or uncertain.
•This time period is not immutable. As is clear from Figure 23, many normal infants appear 
slightly jaundiced by 24 hours of age. Nevertheless, if jaundice is present well before 24 hours
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of age, it is almost always due to increased bilirubin production (usually hemolysis), and possi­
ble causes must be sought. Similarly, obvious jaundice appearing at 25 hours of age is more 
likely to be pathologic than jaundice at 48 hours of age. Hemolytic jaundice associated with glu- 
cose-6- phosphate dehydrogenase deficiency can be an exception.
Table 30
Additional laboratory evaluation of the jaunidiced full-term infant
Indications Maneuvers
Suspicion of hemolytic disease or 
anemia (e.g., pallor, early jaundice, or 
ТВ > 14 mg/dL [239 pmol/L] in first 
48 hours of life)
Asian or Mediterranean infants, espe­
cially males, with ТВ > 15 mg/dL 
(257 pmol/L), particularly if late- 
onset jaundice
Jaundice beyond 2 weeks of age
B lo o d  ty p e ,  g r o u p ,  a n d  C o o m b s  te s t ,  i f  n o t  o b ­
ta in e d  w ith  c o r d  b lo o d
Complete blood count and smear 
Reticulocyte count
Glucose-6-phosphate dehydrogenase 
screen
Infant ill
Direct bilirubin level, urine dipstick for 
bilirubin, inspect stools for color 
Check results of newborn thyroid 
screen, evaluate infant for signs or 
symptoms of hypothyroidism 
Direct bilirubin level, check urine for 
reducing substances, check results of 
newborn screen forgalac-tosemia, and 
evaluate for sepsis
Т В  -  t o t a l  b i l i r u b i n  c o n c e n t r a t i o n .
Because most infants are discharged well before the peak serum 
bilirubin has been attained (see Fig.23), it would be reassuring if these in­
fants could be seen at about 3 to 4 days after birth. In some countries, this is 
achieved by a home visit from a nurse. Although nonhemolytic jaundice is 
usually benign, some workers in this field have encountered apparently 
healthy full-term, Coombs-negative infants who were discharged from the 
hospital only to reappear on days 4 to 7 with serum bilirubin levels of 30 
mg/dL (513 pmoI/L) or greater. Some of these infants developed kemic- 
terus. Unfortunately, apart from the epidemiologic and other factors already 
discussed, there is no easy way to identify these infants before they leave 
the hospital, nor is it known how often hyperbilirubinemia of this magnitude 
occurs. To prevent an unknown number of infants from becoming severely 
jaundiced, every infant would have to be seen at age 3 to 4 days, a practice 
that would lead to an increase in costs and other risks (e.g., repeated labora­
tory tests, visits, and treatment in infants who would otherwise have done 
perfectly well).
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Clinical jaundice is easy to recognize in newborns, but the ability of 
physicians and parents to estimate the degree of jaundice varies considera­
bly. For this reason, the use of noninvasive methods for screening jaundiced 
infants should be encouraged. Even the use of these simple devices, how- 
) ever, requires contact between the infant and a health care professional, and 
many infants need to be followed closely for each one that becomes signifi­
cantly jaundiced. If jaundice persists beyond 2 weeks of age, a urinalysis 
with dipstick test for bilirubin and a direct bilirubin measurement should be 
performed to rule out treatable causes of cholestasis.
Some causes of jaundice, such as G6PD deficiency, are particularly 
problematic. In contrast to the jaundice caused by blood-group incompati­
bilities, jaundice in infants with G6PD deficiency commonly does not ap­
pear until the second day of life and often appears much later. Furthermore, 
the risk for jaundice and subsequent neurologic damage probably depends 
on the particular isoenzyme present and on triggering environmental factors 
that may account for the striking differences in the incidence of neonatal 
hyperbilirubinemia in different populations. The risk for kernicterus in 
G6PD-defi-cient infants appears to be similar to that associated with Rh 
disease.
Although they usually weigh more than 2500 g and are treated as 
normal infants in the well-baby nursery, infants who are even slightly pre- 
ninfi;ic (35 37 weeks of gestation) arc much more likely to develop hyper­
bilirubinemia. Gale and colleagues found that infants at 37 weeks of gesta­
tion were four times more likely than those at 40 weeks of gestation to have 
a serum bilirubin level of 13 mg/dL or higher. These slightly premature in­
fants do not feed as well as their full-term peers, particularly if they are 
breast-fed, and they require more careful scrutiny than full-term infants.
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I INDIRECT HYPERBILIRUBINEMIA
The causes of pathologic indirect hyperbilirubinemia in the neonate 
are listed in Table 31.
INCREASED BILIRUBIN LOAD
Hemolytic Disease. The introduction of Rh immunoglobulin has 
dramatically reduced the incidence of erythroblastosis fetalis, and the com­
bination of postpartum and antepartum prophylaxis has reduced the inci­
dence of antepartum sensitization of Rh-negative mothers to 0.17%. Other 
hemolytic processes to be considered include spherocytosis and other mor­
phologic abnormalities of the erythrocyte, in addition to erythrocyte enzyme 
deficiencies. Cord blood screening programs for hemoglo-binopathies per­
mit the diagnosis of sickle-cell disease in the immediate neonatal period.
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Although previous reports suggested an association between sickle-cell dis­
ease and jaundice in the newborn, a matched, case-control study of 68 neo­
nates with sickle-cell disease found no increase in the rate of clinical jaun­
dice and no increase in bilirubin levels in patients with sickle-cell disease 
compared with controls.
Extravascular Blood. Cephalhematomas, intracranial or pulmonary 
hemorrhage, or any occult bleeding may lead to an elevated serum bilirubin 
level from breakdown of the extravascular erythrocytes. In two reports, se­
vere hyperbilirubinemia followed delayed absorption of intraperitoneal 
blood in infants who received fetal transfusions before birth. In both re­
ported cases, despite multiple exchange transfusions, hyperbilirubinemia 
was not controlled until peritoneal lavage was performed.
In the very-low-birth-weight infant, the presence of periventricular- 
intraventricular hemorrhage (PIVH) has been associated with an increase in 
serum bilirubin levels in some studies, but not in others. Amato and col­
leagues studied 88 infants with birth weights less than 1500 g. Phototherapy 
was initiated only when serum bilirubin levels exceeded 12 mg/dL (205 
pmol/L). The incidence of serum bilirubin levels greater than 12 mg/dL was 
39% in the PIVH group and 46.8% in the infants without PIVH. There was 
no difference in the duration of phototherapy in the two groups. Unless pho­
totherapy is withheld, as was done in Amato's study, it is difficult to evalu­
ate the effect of PIVH on serum bilirubin levels, making some studies diffi­
cult to interpret. In infants of less than 1250 g of birth weight, mean serum 
bilirubin levels on day 5 were about 8.0 mg/dL in those with PIVH, com­
pared with levels of 6.2 mg/dL in infants with no hemorrhage. Linear re­
gression analysis showed a significant influence of PIVH on the bilirubin 
birth weight index (i.e., the bilirubin level divided by the birth weight in 
kg), and the effect of PIVH was most prominent in infants with birth 
weighls less than 1000 g.
Table 31
Causes of pathologic indirect hyperbilirubinemia in newborn infants 
Increased Production
Fetomaternal blood group incompatibility; Rh, ABO, and others 
Hereditary spherocytosis 
Nonspherocytic hemolytic anemias
Glucose-6-phosphate dehydrogenase deficiency and drugs 
Pyruvate kinase deficiency 
Other erythrocyte enzyme deficiencies 
Alpha thalassemia 
Beta-y-thalassemia 
Vitamin K3-induced hemolysis 
Sepsis**
Exravasation of blood; petechiae; hematoma; pulmonary, cerebral, or occult hem- 
orrhage _________________________________________________
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Polycythemia
Maternofetal and fetofetal transfusion 
Delayed clamping of cord 
Swallowed blood
Increased enterohepatic circulation of bilirubin 
Pyloric stenosis*
Small or large bowel obstruction or ileus 
Infants of diabetic mothers
Decreased Clearance
Inborn errors of metabolism
Familial nonhemolytic jaundice types 1 and 2 and Gilbert syndrome 
Galactosemia*
Tyrosinemia*
Hypermethioninemia*
Drugs and hormones 
Hypothyroidism 
Hypopituitarism*
Breast-milk jaundice
Prematurity --------------------- .-------- ------ -------------------------
* Decreased clearance also part of pathogenesis, 
t Elevation of direct-reacting bilirubin also occurs.
Polycythemia. The catabolism of 1 g of hemoglobin produces 35 mg 
of bilirubin, and it is reasonable to assume that a high hematocrit is a risk 
factor for neonatal jaundice. Twin-to-twin transfusion, maternofetal transfu­
sion, or other factors that produce elevated hemoglobin levels or an increase 
in the erythrocyte mass should increase the bilirubin load presented to the 
liver Nevertheless, mean bilirubin levels and the incidence of hyper­
bilirubinemia were similar in polycythemic infants randomly assigned to 
receive either partial exchange transfusions or symptomatic treatment (see
Epidemiology). . , ,
Increased Enterohepatic Circulation. Intestinal obstruction or a
delay in bowel transit time increases the enterohepatic circulation by allow­
ing more time for bilirubin deconjugation and reabsorption. Jaundice is 
common in infants with small bowel obstruction and also occurs in infants 
with pyloric stenosis. Correction of the obstruction produces a prompt de­
cline in bilirubin levels.
Infants of Diabetic Mothers. Recent studies suggest that hyper­
bilirubinemia is limited to macrosomic infants of mothers with insulin- 
dependent diabetes and is the result of increased bilirubin production (see 
Epidemiology of Neonatal Jaundice: Maternal Factors).
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D E C R E A S E D  B I L I R U B I N  C L E A R A N C E
Nonhemolytic Unconjugated Hyperbilirubinemia
Three degrees of defect are recognized:
1. Marked defect, characterized by absolute failure o f bilirubin biotrans­
formation through the nor mal pathway
2. Moderate defect, characterized by a marked to moderate decrease in 
the activity of the pathway that responds to inducing agents such as 
phenobarbital
3. Mild defect, characterized by a mild decrease in the activity of the 
pathway reaching clinical significance only under special circum­
stances.
The principal characteristics of these three types are listed in Table 
17.
Type I Glucuronosyl Transferase Deficiency. Type I glucuronosyl 
transferase dificiency is inherited as an autosomal recessive gene and is also 
known as the type I Crigler-Najjar syndrome. Infants with this condition 
have virtually complete absence of hepatic glucuronosyl transferase. They 
develop severe jaundice in the first 2 to 3 days of life, and exchange trans­
fusion is commonly necessary in the first week of life. Subsequently, inten­
sive home phototherapy controls bilirubin levels to some extent, but as 
these children get older, increasing skin thickness and pigmentation and a 
decrease in the surface area-body mass ratio render phototherapy less effec­
tive. Brain damage can occur at any time in the first two decades, and plas­
mapheresis is used to reduce bilirubin concentrations during acute 
exacerbations of hyperbilirubinemia. One 16-year-old boy with type I 
Crigler-Najjar syndrome had 72 plasma exchanges over a period of 28 
months before undergoing orthotopic liver transplantation. Serum bilirubin 
concentrations decline dramatically within hours of liver transplantation 
who develop kernicterus generally have the classic syndrome, 
including choreoathetosis, hearing loss, and severe mental retardation. La- 
brune and colleagues described three children with Crigler-Najjar type I dis­
ease whose first manifestations of kernicterus were seen between the ages 
of 2.5 to 6 years. All three children had the onset of acute cerebellar 
symptoms after an intercurrent infection or, in one case, the interruption of 
phototherapy. The clinical presentation was characterized by gait distur­
bances, ataxia, and dysmetric movements. These features have not been de­
scribed in the typical syndrome of acute bilirubin encephalopathy in the 
neonate (see Bilirubin Toxicity), perhaps because the onset of neurologic 
disease in the neonate is rapid or because it is difficult to detect cerebellar 
symptoms in the neonatal period. Cerebellar symptoms have been described 
as sequelae of kernicterus in some older patients. Gunn rats, the animal 
model for the Crigler-Najjar syndrome, have degenerative lesions of the
2 0 8
brain, of which cerebellar hypoplasia is one of the most striking. In children 
with Crigler-Najjar disease, it is important to manage intercurrent infections 
promptly and to follow bilirubin levels closely.
The diagnosis of Crigler-Najjar syndrome is made most readily by 
high-performance liquid chromatography analysis of serum and bile ob­
tained by a duodenal tube and by evaluating the response to phenobarbital. 
In type I Crigler-Najjar disease, phenobarbital has little or no effect on the 
serum bilirubin concentrations, and bile pigments are found to contain 
about 90% unconjugated bilirubin, 9% monoconjugates, and 1% or less di­
conjugates. In children with type II disease, serum bilirubin levels decrease 
by 27% to 72% during phenobarbital treatment, and the bile pigment con­
sists mainly of monoconjugates (57%), with unconjugated bilirubin and di­
conjugates representing 33% and 10%, respectively.
Type II Qlucuronosyl Transferase Deficiency. This disease is also 
known as type II Crigler-Najjar disease or Arias syndrome. These infants 
generally manifest with less severe jaundice, although severe hyper­
bilirubinemia can occur, and kernicterus has been reported in some in­
fants. Both infants and adults with type II Crigler-Najjar syndrome re­
spond readily to phenobarbital therapy with a sharp decline in serum 
bilirubin levels within 7 to 10 days. This response can be used to differen­
tiate between the two syndromes. The pattern of inheritance for Crigler- 
Najjar type II disease has not been clearly established. Suggested inheri­
tance patterns include an autosomal dominant disease with incomplete 
pene-trance and varied expressivity as well as autosomal recessive inheri­
tance. Labrune and colleagues described a brother and sister who both de­
veloped prolonged indirect hyperbilirubinemia in infancy that was re­
sponsive to phenobarbital therapy. The parents were unrelated, and none of the 
family members had ever been jaundiced. Needle biopsy specimens of the liver 
obtained from both infants and parents revealed markedly reduced hepatic 
glucuronosyl transferase activity in both infants and both parents, suggesting 
autosomal recessive inheritance.
Table 32
Congenital nonhemolytic unconjugated hyperbilirubinemia: 
_________________clinical syndromes___________ _____
Characteristics
Marked (Crigler- 
Najjar Syndrome; 
Arias Туре I)
Moderate 
(Arias Type IX)
Mild
(Gilbert Syn­
drome)
Steady-state serum 
bilirubin
>20 mg/dL <20 mg/dL <5 mg/dL
Range of bilirubin values 
Bilirubin in bile
14-50 mg/dL 5.3-37.6 mg/dL 0.8-10 mg/dL
Total <10 mg/dL (increased 
with phototherapy)
50-100 mg/dL Normal
Conjugated Absent Present(only 
monogl ucuronide)
Present (50% 
monoglucuronide)
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Bilirubin-UDPGT activ­
ity in  vitro
None detected None detected 20%-30% of nor­
mal
Bilirubin clearance Extremely decreased Markedly decreased 20%-30% of nor­
mal
Hepatic bilirubin uptake Normal Normal Reduced
Glucuronide formation Reduced Reduced Reduced?
with other substrates 
Response to phenobarbi- 
tal
Plasma bilirubin Unchanged Decreased but re­
mains above normal 
range
Within normal 
range
Bilirubin-UDPGT activ­
ity
None detected None detected Within normal 
range
Glucuronidation of other 
substrates
Increased from previ­
ous sub-normal levels
Increased from previ­
ous sub-normal levels
Increased
Smooth endoplasmic re- Hypertrophy Hypertrophy Hypertrophy
ticulum
Bilirubin encephalopathy Usually present Uncommon; may oc­
cur only in the 
neonatal period
Not present
Genetics Autosomal recessive; 
pa-rents often re­
lated; both demon­
strate impairment of 
glucuronidation but 
have normal 
bilirubin levels
Heterogeneity of de­
fect distinctly possi­
ble; autoso-mal 
dominant?; double 
heterozygotes?; 
no parental consan­
guinity, abnormal 
glucuronidation or 
Gilbert defect in one 
of the parents
Autosomal 
dominant (het­
erozygotes); usu­
ally one of the 
parents dem­
onstrates similar 
abnormality
UDPGT - UDP glucuronosyltransferase.
Other Inborn Errors of Metabolism
Galactosemia. Galactosemia is a rare disease (worldwide incidence, 
about 1 in 50,000 infants), and jaundice may be one of the presenting fea­
tures; but infants with significant hyperbilirubinemia due to galactosemia 
almost all have some other manifestations of the disease (e.g., vomiting, 
excessive weight loss, hepatomegaly, splenomegaly). Hyperbilirubinemia 
during the first week of life is almost exclusively unconjugated, and the 
conjugated fraction tends to rise during the second week, probably reflect­
ing liver damage. The presence of a positive family history, hepatomegaly, 
lethargy, poor feeding, or other signs of illness merit additional diagnostic 
evaluation, including testing the urine for reducing substances using Clin- 
itest.
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patients with Crigler-Najjar syndrome type I after discharge from neonatal intensive cats unit.
Tyrosinemia and Hypermethioninemia. The relation between these 
inborn errors of metabolism and jaundice is primarily due to the presence 
of neonatal liver disease, which may initially manifest as indirect hyper­
bilirubinemia but which generally is accompanied by some evidence of 
cholestasis (i.e., direct hyperbilirubinemia).
Hypothyroidism. Prolonged indirect hyperbilirubinemia is one of the 
clinical features of congenital hypothyroidism, a condition that must be 
ruled out in any infant who has indirect hyperbilirubinemia beyond 2 to 3 
weeks of age. Although widespread availability of screening programs for 
congenital hypothyroidism should allow early identification of this prob­
lem as a possible cause of jaundice, screening programs do not detect 
every infant, and errors are more likely to occur with early discharge of in­
fants in whom the T4 level may still be spuriously elevated. A single case 
of cholestasis associated with hypothyroidism has been described in a 54- 
year-old woman. The pathogenesis of hyperbilirubinemia associated with 
hypothyroidism is not clear. In hypothyroid rats after thyroidectomy, the 
excretion rates of both unconjugated bilirubin and bilirubin monoconju­
gates were markedly decreased. Hypothyroidism also produced cholestasis 
with a 50% decrease in bile flow and bile salt excretion and an elevation in 
the serum conjugated bilirubin level. On the other hand, there was a sig­
nificant increase in hepatic bilirubin UDPGT activity. Thyroidectomized 
rats actually had significantly lower unconjugated bilirubin concentrations 
and higher concentrations of bilirubin mono-conjugate and diconjugates 
than control rats. Thus, the mechanism for indirect hyperbilirubinemia in 
infants with congenital hypothyroidism is obscure. The administration of
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triiodothyronine to full-term and preterm infants does not lower peak se­
rum bilirubin levels.
DRUGS
The use of pancuronium and chloral hydrate is associated with 
higher bilirubin levels in sick preterm infants, and chloral hydrate is asso­
ciated with an increased risk of direct hyperbilirubinemia.
BREAST-MILK JAUNDICE
See previous section on breast-feeding and jaundice.
PROLONGED INDIRECT HYPERBILIRUBINEMIA
Prolonged indirect hyperbilirubinemia is defined as indirect 
bilirubinemia persisting beyond 2 weeks of age in the full-term infant. The 
causes of prolonged indirect hyperbilirubinemia are listed in Table 33.
Table 33
Causes of prolonged indirect hyperbilirubinemia
Breast-milk jaundice Pyloric stenosis
Hemolytic disease Crigler-Najjar syndrome
Hypothyroidism Extravascular blood
MIXED FORMS OF JAUNDICE
SEPSIS
Jaundice is one sign of bacterial sepsis, and some reports suggest 
that unexplained hyperbilirubinemia may be the only manifestation of sep­
sis in otherwise healthy-appearing newborns. Rooney and colleagues de­
scribed a series of 22 newborns with documented bacterial infection and 
hyperbilirubinemia. In some of these newborns, serum bilirubin levels 
were exceptionally high, at 28.3 to 50 mg/dL (484-855 pmol/L), and sev­
eral had significant elevations of direct-reacting bilirubin. Nevertheless, 
nine infants were said to be "active and well throughout and jaundice was 
the only abnormal clinical finding." In another prospective study of 69 
newborn infants with unexplained hyperbilirubinemia, bacterial infection 
was documented in two infants, both of whom had asymptomatic gram­
negative urinary tract infections. Elevation of direct-reacting bilirubin has 
been described, particularly in infants with urinary tract infections in 
whom jaundice develops after the first week of life.
Under and colleagues identified 93 of a population of 5805 new­
borns who had serum bilirubin levels exceeding 10 mg/dL (171 pmol/L) in 
the first 48 hours afterbirth or 15 mg/dL (257 gmol/L) thereafter. Three 
had positive blood cultures; the organisms identified were Proteus mirabi- 
lis, Bacteroides species, and Klebsiella pneumonias. Apart from the un­
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usual nature of these organisms, all three of these infants had other signs 
indicating that they were not well. One had an increase in serum bilirubin 
of 5.4 mg/dL (92 pmol/L) over 6 hours while the infant received photo­
therapy; another refused feeding; and a third was vomiting.
Should newborns with unexplained hyperbilirubinemia be subjected 
to lumbar puncture and blood and urine cultures even if they appear oth­
erwise well? The finding of a positive blood or urine culture in a newborn 
with indirect hyperbilirubinemia does not prove that the infection is the 
cause of the jaundice. On the other hand, infants who appear sick or who 
have late-onset jaundice after physiologic icterus has resolved, direct hy­
perbilirubinemia, or something else in the history, physical examination, 
or laboratory investigations that is out of the ordinary, should be evaluated 
carefully for possible sepsis.
OTHER CAUSES
Congenital syphilis, the TORCH group of chronic intrauterine infec­
tions (i.e., toxoplasmosis, rubella, cytomegalovirus, herpes simplex), and 
coxsackievirus В infection are the other important causes of mixed jaun­
dice.
BILIRUBIN TOXICITY
PATHOLOGY OF KERNICTERUS
In 1875, Orth observed bilirubin pigment at autopsy in the brains of 
infants who were severely jaundiced. Schmorl subsequently described two 
forms of brain icterus. The first was characterized by a diffuse yellow col­
oration of the entire brain substance. Actually, descriptions of this type of 
bilirubin staining of the brain had already appeared in textbooks of that 
era.328 A second form had not yet "been described in detail, but has been 
mentioned in passing by Orth. In this form, the jaundiced coloration appears 
to be completely circumscribed and... limited to the so-called 'kern' or nu­
clear region of the brain." Full-term infants dying from kemicterus demon­
strate bilirubin staining in a characteristic distribution (Table 34), although a 
variety of patterns have been described, grossly and microscopically. Ker- 
nicteric premature infants and Gunn rats with inherited glucuronosyl trans­
ferase deficiency display a similar topography of neuronal damage. Those 
regions most commonly affected are the basal ganglia, particularly the sub­
thalamic nucleus and the globus pallidus; the hippocampus; the geniculate 
bodies; various brain stem nuclei, including the inferior colliculus, oculo­
motor, vestibular, cochlear, and inferior olivary nuclei; and the cerebellum, 
especially the dentate nucleus and the vermis.
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Tab le  34
Comparative neuropathology of kernicterus
Topography o f Lesions
Full-Term Infants 
Hyperbilirubinemia
Globus pallidus + + +
Subthalamus + + +
Hypothalamus + - -
Horn of Ammon + + +
Reticular zone of the sub­
stantia nigra + + +
Cranial nerve nuclei + + +
Reticular formation + +
Central pontine nuclei 
Interstitial nucleus 
Locus ceruleus + +
Lateral cuneate nucleus of 
the medulla + + +
Cerebellum 
Dentate nuclei + +
Nuclei of roof of fourth 
ventricle + + +
Purkinje cells - + +
Spinal cord + + +
+ - yellow pigment present; - - yellow pigment absent.
Neuronal necrosis is the dominant histopathologic feature after 7 to 
10 days of postnatal life, and, for the most part, its distribution corresponds 
with the distribution of bilirubin staining, although there are some excep­
tions to this rule. For example, intense staining develops in the olivary and 
dentate nuclei, but there is little neuronal necrosis in these regions. The im­
portant areas of neuronal injury (as opposed to staining) include the basal 
ganglia, brain stem oculomotor nuclei, and brain stem auditory pathways, 
especially cochlear nuclei and inferior colliculi. The involvement of these 
regions explains some of the clinical sequelae of bilirubin encephalopathy 
(see Clinical Features of Bilirubin Encephalopathy).
Originally a pathologic diagnosis, and later a well-defined acute and 
chronic neurologic syndrome, kernicterus or bilirubin encephalopathy ap­
pears to be a less well-circumscribed entity that includes nuclear bilirubin 
staining of very-low-birth-weight infants who have died from other causes 
and, possibly, a subtle chronic encephalopathy in which extrapyramidal mo­
tor disturbances and sensorineural hearing deficit are not the predominant 
features.
Full-term infants in whom the aforementioned pathologic manifesta­
tions of kernicterus are seen usually manifest the classic clinical symptoma­
tology of this disorder, including very high serum bilirubin levels, com­
monly higher than 20 mg/dL (342 pmol/L). Yellow staining of the brain,
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however, has been observed in premature infants who manifested none of 
the clinical signs of kernicterus during life and in whom serum bilirubin 
levels remained low. Is this yellow staining actually toxic bilirubin encepha­
lopathy, or is it merely bilirubin staining of brain cells previously damaged 
by hypoxia or ischemia? Turkel and colleagues identified 32 infants with 
kernicterus at autopsy and compared them with 32 control infants of similar 
gestational ages without kernicterus. In the kernicteric infants, although the 
gross pattern of staining followed that of classic kernicterus, the typical his­
tologic changes characteristic of kernicterus were found in only three pa­
tients. These authors suggest that the bilirubin staining they observed was 
probably not the same clinicopathologic entity as the kernicterus of postic- 
teric encephalopathy. Instead of the neuronal degeneration typically seen, 
they found spongy change and gliosis, which both imply nonspecific dam­
age to the brain. This suggests that prior diffuse injury may predispose the 
brain to bilirubin deposition at relatively low levels of serum bilirubin.
Ahdab-Barmada and Moossy found kernicterus in 97 autopsies of 
neonates (95 were younger than 36 weeks of gestation). The neuropathology 
in these infants was strikingly similar to that of classic kernicterus in the 
full-term neonate and in the Gunn rat. In the NICHHD cooperative photo­
therapy study, four low-birth-weight infants had autopsy-proven kemic- 
terus. The neuropathologic findings in these infants were those of classic 
kernicterus.
As can be seen from Table 35, the neuropathology of kernicterus is 
different from that of hypoxic ischemic encephalopathy. Even though in 
some low-birth-weight infants, hypoxic ischemic insults may predispose the 
brain to bilirubin deposition, it appears that kernicterus may occur in low- 
birth-weight infants in the absence of hypoxic-ischemic brain injury.
Autopsies on jaundiced infants reveal bilirubin staining of the aorta, 
pleural fluid, ascitic fluid, or a generalized yellow cast throughout the vis­
cera. The staining is not usually considered a sign of tissue damage unless 
other cytologic changes are found. Bilirubin staining can also be found in 
necrotic tissue anywhere in the body and has been described in the gastroin­
testinal tract, kidney, adrenals, and gonads. In infants with hemolytic dis­
ease, bile plugs are commonly found in the canaliculi between the hepato- 
cytes, especially in the periportal areas. The kidneys may show bilirubin- 
stained tubular casts, bilirubin crystals in the small vessels or in edematous 
interstitium, and renal tubular necrosis. The bilirubin in-farcts (i.e., patches 
of yellow staining in the renal medulla) are probably the result of focal ar­
eas of acute tubular necrosis that have been stained by bilirubin.
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Comparative neuropathology of kernicterus and anoxic-ischemic en­
cephalopathy in the premature neonate ____
Tab le  35
Topography ot L e s io n s * Kern icterus
A n o x ic - Isc h e m ic
Encephalopathy
Cerebral cortex Absent Present
Periventricular white matte' Absent Present
Corpus striatum Globus pailidus Putamen and caudate nuclei
Thalamus Subthalamus Anterior and lateral nuclei
Horn of Ammon Resistant sector (H2-3) Sommer sector (H;)
tfibbrain Interstitial nucleus Inferior colliculi
Nuclei of nerve IIP Nuclei of nerve Hi*
Reticular Dorticn of substantia nigra Compact portion of substantia nigra
Pens Locus ceruleus Basal pontine nuclei
Nuclei of nerves VI, VII Superior olivary complex
Reticular formation5 Reticular formation5
Medulla Vestibular and cochlear nuclei Inferior olivary nuclei 
Superior olivary nuclei
r Cerebellum Purkinje cells" Purkinje cells'
Nuclei of roo? of fourth ventricle Granular cells
♦Only topographic areas considered helpful for differential diagnosis were selected in this table.
5 Whenever neuronal damage involved in the same structure in kernicterus and anoxic-ischemic 
encephalopathy, the cytopathology was different.
In infants dying from hyaline membrane disease, the lungs often ap­
pear grossly yellow or orange, and there is microscopic staining by bilirubin 
of the pulmonary hyaline membranes (i.e., yellow hyaline membrane dis­
ease). Hyaline membranes are formed from necrotic cellular debris and 
transudation of plasma proteins from the capillaries after damage to the al­
veolar epithelium, and it appears likely that the transudate also contains 
bilirubin, which is deposited in the membranes with albumin and other 
plasma molecules.
PATHOPHYSIOLOGY
BILIRUBIN CHEMISTRY AND NEUROTOXICITY
As already discussed in the section on the formation, structure, and 
properties of bilirubin, the bilirubin molecule, in its usual conformation, is 
stabilized by the presence of intramolecular hydrogen bonds that saturate 
the hydrophilic groups of the molecule, leaving no affinities for the attach­
ment of water and rendering it nearly insoluble in water at pH 7.4 (see Figs. 
38-4 and 38-5). In an alkaline medium, the hydrogen bonds are open to 
form a divalent anion that has several hydrophilic groups, resulting in a 
molecule with much greater solubility. Because of its pronounced tendency 
for aggregation, it has been suggested that bilirubin 9a (ZZ) acid is the neu­
rotoxic form of bilirubin. The pH of plasma profoundly affects the solubility 
of bilirubin and its binding to tissue sites. At a pH of 7.4, the limit of 
bilirubin solubility is reached with 0.5 moles of bilirubin per mole of albu­
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min; at a pH of 7, this limit is less than 0.1 mole of bilirubin per mole of al­
bumin. Thus, when the concentration of bilirubin acid exceeds its solubility, 
bilirubin may gradually aggregate and come out of solution. Bilirubin crys­
tals have been found in the brain cells of infants dying from kernicterus, and 
bilirubin in concentrations of 2 mg/dL (34 pmol/ L) has been extracted from 
kernicteric brains. It is likely that even higher concentrations of pigment ex­
ist in the presence of kernicterus. Brodersen and Stern have proposed, there­
fore, that kernicterus occurs when aggregates of precipitated bilirubin acid 
are deposited in the cells of the brain. Wennberg offered a different model 
for the development of bilirubin encephalopathy; he suggested that bilirubin 
monoanion and membranes form reversible complexes and that this mecha­
nism is responsible for the development of bilirubin encephalopathy (Fig.
CELLULAR TOXICITY OF BILIRUBIN
Bilirubin appears to be a cell poison, but exactly how it exerts its 
toxic effect is not known. Cashore reviewed the evidence for bilirubin toxic­
ity to the neuron and summarized several histologic and biophysical find­
ings from different clinical and experimental studies. These studies show a 
range of effects of bilirubin, including binding to cell membranes, decreased 
sodium-potassium exchange and increased water accumulation, axonal 
swelling, lowering of membrane potentials and decreased action potential 
decreased activity of the auditory brain stem response, decreased phos­
phorylation of protein kinase and synapsone 1, decreased tyrosine uptake 
and dopamine synthesis, decreased methionine and thymidine uptake, and 
decreased mitochondrial viability. Bilirubin decreases the rate of tyrosine 
uptake and dopamine synthesis in dopaminergic striatal synaptosomes. 
These effects can be reversed by albumin. No single mechanism of bilirubin 
intoxication has been demonstrated in all cells, and specific studies of me­
tabolism and toxicity have not been performed on basal ganglia cells, the 
cells commonly involved in kernicterus.
Other experimental data are conflicting. In vitro, bilirubin uncouples 
oxidative phosphorylation and blocks the production of ATP, which is re­
quired for the energy-dependent processes in the cell, but studies in guinea 
pigs and piglets infused with high concentrations of bilirubin, did not show 
the changes in glucose metabolism or oxygen consumption consistent with 
mitochondrial injury as the primary pathway of bilirubin toxicity in the in­
tact brain. Bilirubin reduces the responsiveness of cyclic adenosine mono­
phosphate to insulin-stimulated glucose transport, but in whole-brain stud­
ies, glucose transport and glucose metabolism were unaffected. Neverthe­
less, bilirubin infusion in the rat, after osmotic opening of the blood-brain 
barrier, produced a marked increase in the lactate-pyruvate ratio, indicating 
accumulation of NADH, which reflects severe mitochondrial dysfunction.
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FIG. 27. Proposed model of bilirubin transport across biologic membranes. 
The relatively hydrophilic bilirubin monovalent anion H ■ Ф  partitions much 
like a detergent from the aqueous phase to the lipid membrane surface Addi­
tion of the second i f  forms the bilirubin acid H ®  H that enters the lipid phase 
of the membrane. The process reverses as bilirubin emerges at the cytoplasmic 
membrane surface. The symbol indicates the bilirubin dianion. The box
gives typical values for unbound bilirubin concentration (UBC) and the differ­
ent subfractions (molecules per liter) expected at pH 7.4 with a total serum 
bilirubin level of 15 to 20 mg/dL (250-340 pmol/L).
Table 36
Hypothetical model of pathophysiology of bilirubin toxicity 
Site of Bilirubin Uptake Effect on  N e u ro n s  Duration  o f Effect
.Aggregation of bilirubin at nerve 
’< terminalsВУ:" ■ i
Bilirubin binds to cell components
Lowers membrane potentials; de­
creases auditory brain stem con­
duction
i
Impairs substrate transport, neuro-
Usually reversible
Prevented or reversed by equimolar
transmitter synthesis, and mito­
chondrial functions 
i
Dysfunction and death of neurons 
in acute clinical syndrome 
i
Long-term clinical sequelae
albumin
4-
Retrograde uptake of bilirubin by 
v neuronal body
Irreversible
Pyknosis and gliosis of neurons—  
/ bilirubin staining of affected 
•'areas
Irreversible
From Cashore WJ. The neurotoxicity of bilirubin. Clin Perinatal 1990
Changes in energy metabolism produced by hyperbilirubinemia have 
been studied using P nuclear magnetic resonance in vitro and in vivo. It was 
found that hypoxia produced a steady-state reduction of PCr-Pj ratio, and 
the addition of bilirubin lead to a further reduction in the ratio. These 
changes were reversible when the brain slices were exposed to a bilimbin- 
free medium and normoxic conditions were reestablished. These investiga­
tors also evaluated the effects of bilirubin on energy metabolism during hy­
perosmolar opening of the blood-brain barrier in adult rats. Hyper-
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bilirubinemia alone caused no measurable disturbance in the energy me­
tabolism, but after opening of the blood-brain barrier, exposure to serum 
bilirubin levels of about 28 nig/dL (479 pmol/L) produced a decrease in the 
PCr/(PCr + P,) ratio. There was a significant correlation between a reduced 
PCr/(PCr + P,) ratio and brain-tissue bilirubin content.
When toad bladder membranes are exposed to bilirubin, there is a de­
crease in water and sodium transport and a decrease in the epithelial re­
sponse to vasopressin; and in newborn rabbits, bilirubin decreases the phos­
phorylation of protein kinase. These findings illustrate the wide range of re­
sponses found when cells are directly exposed to high bilirubin concentra­
tions.
Mayor and colleagues showed that incubation of synaptosomes with 
bilirubin lowers membrane potential, and Hansen and colleagues also found 
action potentials reduced in brain slices exposed to bilirubin. It is not known 
why bilirubin is preferentially deposited in the basal ganglia, but it is possi­
ble that it may first attach to nerve terminals, thus lowering membrane po­
tentials and decreasing nerve conduction, and, after further exposure, may 
penetrate nerve terminals or axons with retrograde uptake of bilirubin in the 
cell body. Cashore offers a hypothetical format for the progression of 
bilirubin toxicity from the initial, possibly benign stage of bilirubin accumu­
lation at the cell surface to ultimate neuronal damage and permanent seque­
lae (Table 36).
ALBUMIN BINDING AND THE CONCEPT OF FREE BILIRUBIN
Bilirubin (B) is transported in the plasma as a dianion bound reversi­
bly to serum albumin (A): __
B^ + A ^ A B 2-
Binding of bilirubin to the high-affinity site of albumin can be ex­
pressed as follows:
(В2-)(Л)
The association constant (K), derived from the equilibrium concentra­
tions of bound (AB2') and free (B2 ) bilirubin, is about 107 to 108 moles. Al­
bumin has a primary binding site with the capacity for binding up to 1 mole­
cule of bilirubin per molecule of albumin and one or more binding sites with 
much lower affinities. When the bilirubin-albumin ratio exceeds 1, the con­
centration of free or unbound bilirubin increases, but binding at the lower- 
affinity sites continues up to a molar bilirubin-albumin ratio of 3:1. It has 
been widely accepted that bilirubin toxicity occurs when free bilirubin 
enters the brain and binds to cell membranes. The presence of albumin miti­
gates the in vivo and in vitro toxic effects of bilirubin, and drugs, such as 
sulfisoxazole, that decrease albumin binding of bilirubin also increase the 
risk of kernicterus. These observations are consistent with the hypothesis
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that free bilirubin is able to move across the blood-brain barrier, bind to tis­
sues, and damage the cells of the central nervous system. They do not ex­
clude the possibility that, under certain circumstances, albumin-bound 
bilirubin may do the same.
The studies of Wennberg and Hance suggest that if albumin-bound 
bilirubin gains access to the brain in the absence of a disrupted blood-brain 
barrier, it is unlikely that toxic effects will occur. Disruption of the blood- 
brain barrier, on the other hand, permits leakage of the albumin-bilirubin 
complex into the interstitium of the brain. Under these circumstances, the 
brain cells are exposed to the same free bilirubin concentration that exists in 
the serum, and the bilirubin equilibrates with binding sites on albumin and 
cellular membranes. If the free bilirubin is sufficiently high, and the reser­
voirs are sufficiently large, the amount of bilirubin bound to membranes 
might impair neuronal function.
Measurement of Free Bilirubin
Several techniques have been developed for measuring free or loosely 
bound bilirubin and the binding capacity and affinity o f bilirubin for albu­
min. Some of these tests are listed in Table 37, and the subject has been re­
viewed in detail. Acute changes in free bilirubin concentrations, however, 
are probably transient because there is rapid equilibration and redistribution 
of bilirubin between the plasma (i.e., albumin) and the tissues. Thus, al­
though sulfisoxazole administration produces acute changes in binding 
status and an elevation in free bilirubin levels, within a few minutes, the 
concentration of free bilirubin returns to normal. Even under experimental 
conditions that lead to a significant increase in brain bilirubin content, the 
differences in free bilirubin concentrations in the serum between control and 
study animals is small.
Although there is a vast literature dealing with bili-rubin-binding 
tests, none is in general use in clinical decision making. Because one mole­
cule of albumin is capable of binding one molecule of bilirubin tightly at the 
primary binding site, a bilirubin-albumin molar ratio of 1 represents about
8.5 mg of bilirubin per gram of albumin. Thus, a full-term infant with a se­
rum albumin concentration of 3 to 3.5 g/ dL should be able to bind about 25 
to 28 mg/dL of bilirubin (428-479 pmoI/L). The albumin-binding capacity 
of sick, low-birth-weight infants is less than that of full-term infants, and 
their serum albumin levels are often lower. Stevenson and Wennberg sug­
gest using a factor of 7 times the albumin level to predict the binding capac­
ity of bilirubin in a healthy full-term infant and a multiple of 5 to 6 times 
the albumin concentration in sick, low-birth-weight infants.
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Factors Affecting the Binding of Bilirubin to Serum Albumin
This subject has been reviewed in great detail. A few of the factors 
are discussed here.
Fatty Acids. Free fatty acids in plasma may compete with bilirubin for 
) its binding to albumin, but significant interference with bilirubin binding 
probably does not occur until molar ratios of free fatty acids to albumin ex­
ceed 4:1. Brodersen has estimated that at a free fatty acid-albumin ratio of 
6, the free bilirubin concentration increases by a factor of 2.6. Intravenous 
lipid preparations do not displace bilirubin from albumin binding, but they 
produce an increase in free fatty acids that is potentially dangerous. Un­
bound bilirubin concentrations were measured by hematofluorometry in in­
fants receiving 1, 2, or 3 g/kg of intralipid over a 15- to 20-hour period. A 
linear relation was found between the serum free fatty acid-albumin (F-A) 
molar ratio and the concentration of unbound bilirubin, although there was 
considerable scatter. The largest increases in unbound bilirubin were seen in 
infants with an F-A ratio greater than 4, and such ratios tended to occur in 
infants of fewer than 30 weeks of gestation. The infusion of 1 g/kg of in­
tralipid over a 15-hour period in infants of fewer than 30 weeks of gestation 
produced an F-A ratio of less than 3 and minimal increases in unbound 
bilirubin concentrations. With doses of 2 to 3 g/kg, however, higher ratios 
were found. In a recent study, intravenous fat was given as a continuous in­
fusion of 2 g/kg/day for 7 days to infants of 32 weeks or less of gestation 
(mean birth weight, 1200 g). This produced F-A ratios of only 0.1 to 1.8. 
Intralipid has been administered to congenitally jaundiced (i.e., Gunn) rats 
in which the total-body bilirubin pool was uniformly labeled with radioac­
tive bilirubin. Intralipid was found to have no effect on the kinetics of 
bilirubin formation, transport, tissue distribution, or clearance.
pH. The binding of bilirubin to albumin is unaffected by changes in 
the serum pH. Nevertheless, the correction of neonatal acidosis in 11 sick 
newborns appeared to decrease the serum free bilirubin concentration as 
measured by a peroxidase technique. The role of pH, on the other hand, may 
be pivotal in determining the binding of bilirubin to cells and, therefore, its 
deposition in the central nervous system. Bilirubin interaction with rat brain 
synaptosomal membranes is augmented as pH decreases. In addition, a de­
crease in pH reduces the solubility of bilirubin in plasma, encouraging pre­
cipitation of the insoluble acid form. A decrease in pH of 0.3 produces a 
fourfold increase in the concentration of bilirubin acid. Because the acid is 
insoluble in water, deposition of the substance in the tissues is likely in the 
presence of acidosis.
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Table 37
Bilirubin binding tests
Measures Reported as
patkmwith BR and:
' Sephadex column elu-
f*?. lion
. ■ Peroxidase oxidation
Fluorescence quench­
ing
Front-face fluorometry
.Dye binding 
: HA3A and related 
methods
Direct yellow 7
Selective trace ligand 
t ( ,4C-MADOS)
Electron spin resonance
Loosely bound or un­
bound BR
Sephadex methods 
Peroxidase oxidation
, Erythrocyte bilirubin
Paper chromatoelec­
trophoresis
Saturation index
Difference spectroscopy 
Circular dichroism
Adsorption o f  BR on 
Sephadex columns 
Enzyme-catalyzed oxida­
tion of 3R
Fluorescence quenching 
of ALB by BR 
Fluorescence of BR  in 
whole blood
Residual binding of dye, 
compared with a biluru- 
bin-free standard 
Fluorescence of dye and 
its quenching due to 
BR
Dialysis rate of MADDS in 
serum, compared with 
an albumin standard 
Spectral emissions of 
bound versus unbound 
selective ligand
As above 
As above
Adsorption of BR onto 
red blood cells 
Separation of bound and 
unbound BR  on chro­
matography paper 
Percent decrease in opti­
cal density at 460 nm 
caused by addition of 
salicylate
Spectral changes induced 
by saturation of binding 
sites or displacement of 
BR
Binding capacity; loosely 
bound BR 
Free bilirubin 
Binding capacity 
Binding affinity (associa­
tion constant)
Binding capacity 
Binding affinity 
Total BR; bound BR 
Binding capacity (total 
bound)
Saturation index
Reserve dye-binding ca­
pacity
BR-binding capacity
Reserve albumin
Binding capacity 
Reserve BR-loading ca­
pacity
As above
As above, or apparent 
free BR 
Erythrocyte BR
Reserve binding capacity 
Loosely bound BR
Saturation index
Graphic display of spec­
tral changes as per­
centage of baseline
Units*
mg/dL or mmol«L 
nmol/L
mg/dL or mmol/L 
KA
mol BR/mol AL8 
KA
mg/dL
mg/dL
(bound/reserve) x 10
Percent of dye binding 
compared with stan­
dard
mol BR/mol ALB
mmol/L
mol BR/mol ALB 
mol BR/mol ALB
mg/dL or mmol/L 
nmol/L or jxg/dL
mg/dL red blood cell
m g ;dL
vSemiquantitative (diazo­
positive)
Percent decrease in opti­
cal density* at 460 (max­
imum 14%)
mol BR/mol ALB. or %
BR bound or displaced
* For conversion of gram or milligram concentrations to moles, molecular 
weight of bilirubin = 585 and of albumin = 68,000.
ALB, albumin; BR, bilirubin; HABA; hydroxybenzene azobenzoic acid; 
MADDS, monoacetyl diaminodiphenylsulfone.
Drugs. The effect of numerous drugs on bilirubin-albumin binding 
has been tested in vitro using different methods. The measured effect varies 
with the method used; some systems require much greater concentrations of 
the drug than others to demonstrate an increase in unbound bilirubin. For 
example, although sulfisoxazole is clearly capable of displacing bilirubin 
from its binding to albumin, when the serum is diluted 40-fold to perform* 
the peroxidase assay, no displacing effect is found. Drug-displacing effects 
are probably transient. When sulfisoxazole is administered to rats, there is a 
transient increase in free bilirubin concentrations, but this returns to pre­
treatment values despite continued infusion of the displacing drug. Robert-
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son and colleagues reviewed the bilirubin displacing effect of drugs used in 
neonatology. They believe that every drug used in newborns should be 
tested for its effect on bilirubin-albumin binding before these drugs are li­
censed for use in the newborn, although such testing is not required by gov­
ernmental authorities.
Because oral medications are rarely given to sick, preterm infants, 
and topical medications do not lead to concentrations that would effectively 
compete with bilirubin for albumin binding, they do not require testing. 
Other drugs can be excluded from testing either because of low albumin- 
binding (e.g., the aminoglycosides) or low serum concentrations (e.g., thy­
roxine, adrenal hormones, vitamins). Robertson and colleagues arbitrarily 
chose to consider an increase in the free bilirubin concentration of 5% as 
potentially dangerous, and they consider a drug to be a potential displacer if 
it occupies 5% or more of the available albumin. Knowledge of the usual 
peak serum bilirubin concentrations and the percentage of albumin-bound 
drug can also be used to calculate the concentration of bound drug. If the 
bound drug concentration is less than 15 pmol/L, it is unlikely that this drug 
will cause significant displacement of bilirubin.
Robertson and colleagues calculated a maximal displacement factor, 
5, from the KD value, using the following equation:
5 = KDd + 1,
where d is the concentration of free drug in the patient's plasma and 
KD is the displacement constant, which represents the competitive effect of 
the drug with bilirubin for albumin binding. If Kd is 0, then 5 = 1 ,  and the 
drug does not displace bilirubin. If 5 = 1.2, there has been a 20% increase of 
free bilirubin concentration after drug administration. Although an arbitrary 
value of 1.2 has been suggested as the upper permissible limit for bilirubin 
displacement, it is recommended that, as far as possible, drugs with the low­
est 5 values be selected. Appendix H-6 lists the effects of drugs used in neo­
natology on bilirubin-albumin binding. The free drug concentration is calcu­
lated from the serum concentration and the percentage of bound drug as 
taken from existing data in the literature.
Robertson and Brodersen have also evaluated the effect of drug com­
binations on bilirubin-albumin binding. This is important because drug 
combinations are commonly administered to sick neonates, and the data 
show that the bilirubin-displacing effect of these combinations cannot be 
predicted from each drug's effect. For example, the administration of 
aminophylline with vancomycin increased the displacing effect when com­
pared with either drug alone, but the overall effect was still minimal. 
Robertson and Brodersen recommend that, in the absence o f published data, 
drugs should be selected in which therapeutic concentrations are much
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lower than the usual concentration of albumin (about 2.8 mg/dL in a very- 
low-birth-weight newborn infant). Drugs should be selected that are not 
bound to albumin, and simultaneous treatment with several drugs should be 
limited as far as possible.
Other Competing Anions. It is possible that certain unidentified ani­
ons interfere with the albumin binding of bilirubin. Evidence for this is sug­
gested by the failure of exchange transfusion to alter significantly the albu­
min binding of infants' serum despite the fact that exchange transfusion re­
moves bilirubin, replaces much of the infant's serum albumin with bilirubin- 
free albumin, and lowers the free bilirubin level. Anions that interfere with 
albumin binding may not be removed by exchange transfusion.
Clinical Status o f  the Infant. A relation may exist between bilirubin- 
bindmg capacity and the clinical condition and gestational age of the infant. 
In some studies, very premature infants were able to bind less bilirubin per 
mole of albumin than were more mature infants, but in others studies, no re­
lation was found between bilirubin-binding ability and gestational age.
HYPERBILIRUBINEMIA AND BRAIN BILIRUBIN LEVELS
Under normal circumstances, there is a constant influx and efflux of 
bilirubin in and out of the brain, but under experimental conditions, regard­
less of how much bilirubin is infused, it is difficult to get it to stay in the 
brain of healthy animals or to produce electrical central nervous system 
changes. Gross staining of the brain and electrophysiologic changes, how­
ever, occur readily in asphyxiated animals.
Bilirubin is found in the cerebrospinal fluid at a mean concentration 
of 0.24 ± 0.098 mg/dL (4.1 ± 1.7 pmol/L) in normal, full-term infants and 
0.61 ±0.15 mg/dL (10.4 ± 2.6 pmol/L) in preterm infants, and there is a 
correlation between serum bilirubin and spinal fluid bilirubin levels. 
Bilirubin is found in the brain of rats or piglets made hyperbilirubinemic by 
continuous intravenous infusions of bilirubin, but compared with other body 
organs, bilirubin does not get into the brain easily—higher concentrations 
are found in the liver, spleen, fat, and muscle than in the brain.
Genetic factors may be involved in determining the susceptibility of 
patients to bilirubin-induced neurotoxicity. For example, in different strains 
of Gunn rats exposed to similar bilirubin and albumin concentrations, there 
were significant differences in susceptibility to kernicterus and mortality, 
suggesting that genetic or other factors may be important in determining in­
dividual susceptibility to bilirubin toxicity.
BLOOD-BRAIN BARRIER
A blood-brain barrier exists that limits the entry of certain substances 
into the central nervous system. This barrier, at the cerebral blood vessels, is 
due to a continuous lining of endothelial cells connected by tight junctions
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that restrict intercellular diffusion. The blood-brain barrier normally ex­
cludes most water-soluble substances and proteins but is permeable to lipid- 
soluble substances that are not protein-bound. Large molecules, such as al­
bumin, are excluded from the brain but may enter when the brain is made 
permeable by the infusion of a hyper-tonic solution.
EXPERIMENTAL OPENING OF THE BLOOD-BRAIN BARRIER
Levine and colleagues opened the blood-brain barrier on one side of 
the brain in adult rats by infusing hypertonic arabinose into the internal cu 
rotid artery. One minute after the arabinose was given, a bilirubin-albumin 
solution was infused through the femoral vein. Yellow staining of the brain 
occurred on the side on which the blood-brain barrier had been opened by 
the infusion of arabinose. Clearly, the blood concentration of bilirubin, both 
free and bound, on both sides of the brain was identical, yet only one side 
was stained yellow, indicating that entry of bilirubin into the brain was de­
termined by disruption of the blood-brain barrier, not by the level of serum 
free bilirubin. Bratlid and colleagues confirmed Levine's observations using 
a different technique. They induced hyperbilirubinemia in chronically cathe- 
terized rats and produced hyperosmolality by injecting urea. A direct rela­
tion was found between serum osmolality and both brain bilirubin and al­
bumin content.
Wennberg and Hance infused bilirubin into rats whose blood-brain 
barriers had been opened with arabinose. One group of rats received 1.5 
g/kg of human serum albumin before the arabinose solution; the other group 
received saline only. Electroencephalogram (EEG) changes were monitored 
during and after these infusions. Successful opening of the blood-brain bar­
rier was reflected by ipsilateral changes in the EEG. Bilirubin staining of 
the brain occurred when the blood-brain barrier was open, but the staining 
was most intense in the albumin-treated animals. Both the albumin-primed 
and control animals developed EEG changes and differential staining of the 
ipsilateral hemisphere. Electroencephalogram encephalopathy, however, oc­
curred at much lower brain bilirubin concentrations in the control animals, 
where serum binding was poor, than in the albumin-primed rats. When free 
bilirubin levels were low, encephalopathy occurred only when the blood- 
brain barrier was open and permeable to the albumin-bilirubin complex.
Opening of the blood-brain barrier might allow albumin-bound 
bilirubin to bathe the neurons, but whether or not free bilirubin binds to al­
bumin or to cellular membranes may be determined by the binding of 
bilirubin to albumin. At some point, sufficient tissue binding occurs to im­
pair neuronal function. This can be documented by changes in the EEC. It is 
possible, therefore, that both disruption of the blood-brain barrier and the 
levels of free bilirubin may be important in the pathogenesis of bilirubin 
toxicity. This experimental model supports the proposal that yellow staining
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of the brain is not synonymous with bilirubin toxicity and may provide an 
explanation for the neuropathologic observations of Turkel and colleagues. 
Bratlid also measured the brain uptake of bilirubin by rats after a bolus in­
jection of sulfisoxazole. A significant increase in plasma unbound bilirubin 
and brain bilirubin concentration occurred without any increase in brain al­
bumin concentration.
EFFECT OF MATURITY ON BLOOD-BRAIN BARRIER PERMEABILITY
Is the blood-brain barrier of the neonate more permeable to bilirubin 
and albumin than in older children or adults? The immature brain demon­
strates greater passive permeability between the blood and central nervous 
system for lipid-insoluble molecules. Studies in newborn piglets have 
shown that the blood-brain barrier is more permeable to bilirubin in 2-day- 
old than in 2-week-old piglets, while the permeability to albumin does not 
change.
LIPID SOLUBILITY
Lipid-soluble substances that are not protein-bound and gases, such as 
carbon dioxide and oxygen, cross the blood-brain barrier easily, by simple 
diffusion, while water-soluble substances, proteins, and polar compounds 
(i.e., ions) do not. The permeability of the blood-brain barrier to different 
substances is proportional to the octanol-water partition coefficient, a meas­
ure of lipid solubility. Although there has been some debate about whether 
bilirubin can be regarded as a lipid-soluble molecule, studies of blood-brain 
barrier permeability to albumin-bound and free bilirubin, show that, in vivo, 
in relation to the cerebral microvasculature, free bilirubin behaves like a 
lipid-soluble molecule.
MEASUREMENT OF PERMEABILITY
The permeability of the blood-brain barrier to bilirubin has only re­
cently been quantified by Ives and Gardner. Using the single-pass (i.e., 
Oldendorf) and in situ perfusion (i.e., Takasato) techniques in adult male 
rats, these investigators found that for free bilirubin, the brain uptake index 
was 28.5 ± 9.3 and the permeability surface area product was 54.84 ± 36.38 
x 10'4 mL/sec/g. No permeability to albumin-bound bilirubin was demon­
strated.
MECHANISMS FOR TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
Wennberg suggests a mechanism for the transport of bilirubin across 
membranes. This is based on the fact that the partitioning of bilirubin be­
tween water and organic solvents, such as octanol and chloroform, is di­
rectly related to the hydrogen ion concentration. Although Brodersen and 
Stern suggest that tissue uptake of bilirubin involves the precipitation of 
bilirubin acid in phospholipid membranes, Wennberg suggests that bilirubin
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concentrates as the monovalent anion at the cell surface, facilitating the ad­
dition of another hydrogen ion to form bilirubin acid, which enters the lipid 
phase of the membrane. The process reverses as bilirubin emerges at the cy­
toplasmic membrane surface. Thus, although free bilirubin in plasma (i.e., 
water) is thought to be present in the dianion form (B2'), the partitioning 
studies indicate the existence of a bilirubin monoanion or bilirubin acid salt 
(BH ) as well. Once it has crossed the blood-brain barrier, bilirubin proba­
bly enters the brain extracellular space and is bound by albumin or the brain 
cells. Free bilirubin should cross the blood-brain barrier as the monovalent 
ion, while the entry of albumin-bound bilirubin is more restricted.
FACTORS AFFECTING BLOOD-BRAIN BARRIER PERMEABILITY
Anoxia, hypercarbia, and hyperosmolality open the blood-brain bar­
rier and increase the deposition of bilirubin and albumin in the brain, pro­
ducing neurophysiologic and biochemical changes as well as changes in 
brain physiology and energy metabolism. Thus, opening of the blood-brain 
barrier is likely to be one important mechanism in the pathogenesis of ker- 
nicterus, although other mechanisms undoubtedly exist. For example, dur­
ing hypercarbia, the increased bilirubin that is deposited in the brain is pre­
dominantly in the unbound form, although some is also albumin-bound. 
Burgess and colleagues found that the regional deposition of bilirubin in the 
brain of piglets occurs in areas where hypercarbia produces the greatest in­
crease in regional blood flow. Respiratory acidosis increases bilirubin depo­
sition in the brain; metabolic acidosis does not.
REGIONAL LOCALIZATION OF BILIRUBIN WITHIN THE BRAIN
Autopsy findings in infants with erythroblastosis fetalis who died 
from kernicterus show that the regions of the brain most commonly affected 
are the basal ganglia, particularly the subthalamic nucleus and the globus 
pallidus; the hippocampus; the geniculate bodies; various brain stem nuclei; 
and the cerebellum. The distribution of brain bilirubinin in animal studies 
has varied; some investigators found a distinct regional distribution after 
hyperosmolality and hypercarbia, while others did not find a similar re­
gional pattern. Regional differences in brain bilirubin deposition may be re­
lated to blood flow differences in different areas of the brain, the binding 
properties of the bilirubin molecule, and the clearance of bilirubin once it 
has entered the brain (half-life is 1.7 hours in the rat).
Mitochondria in the brain and other tissues contain a highly specific 
bilirubin oxidase that converts bilirubin to biliverdin and other nontoxic 
products. Local breakdown of bilirubin may also have a role in determining 
the distribution and detoxification of bilirubin in the brain. The addition of 
bilirubin oxidase reversed the toxic effects of bilirubin on mouse neuroblas­
toma cells.
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CELLULAR BASIS OF BILIRUBIN TOXICITY
This subject was reviewed by Wennberg and by Bratlid.
pH AND BILIRUBIN SOLUBILITY
Brodersen demonstrated the relation between bilirubin solubility and 
the serum pH and emphasized the importance of bilirubin solubility in de­
termining the binding of bilirubin to cells. As discussed previously, 
bilirubin is reversibly bound to albumin in the form of a dianion (B ).
в 2' + a " ° a b 2l
This binding obeys the laws of mass action, and the concentration of 
bilirubin dianion can be calculated:
b = B/p x 1/K,
where b is the concentration of free bilirubin dianion, В the concen­
tration of bound bilirubin, p the concentration of albumin with a vacant site 
for high-affinity binding of bilirubin, and К the binding constant. В is 
measured as the concentration of unconjugated bilirubin, and p is approxi­
mated as the reserve albumin concentration for binding of monoacetyl dia- 
minodiphenylsulfone. К = 6.8 x 107 M 1 at 37°C. Thus, the concentration of 
free bilirubin in the sample can be calculated from equation 4. At a pH of 
7.4, the solubility of bilirubin is only 7 nmol, and newborns frequently have 
higher concentrations of free bilirubin dianion. Thus, the plasma of new­
borns is supersaturated with respect to bilirubin acid, and this favors a proc­
ess of precipitation of bilirubin. Using this information, an index of plasma 
bilirubin toxicity (I) has been derived:
I = log B/p - 2 pH + 15.5.
As the toxicity index increases, bilirubin deposition in tissues is ex­
pected to occur.
MONOVALENT ANION HYPOTHESIS
Wennberg pointed out that within the range of physiologic pH, the 
binding of bilirubin to albumin is not affected by changes in the hydrogen 
ion concentration, and the reason for increasing tissue uptake of bilirubin 
with decreasing pH must be the result of the interaction of bilirubin with the 
cells, rather than an effect of pH on albumin binding. The linear relation be­
tween hydrogen ion concentration and cell binding indicates that a single 
proton or hydrogen ion is added to bilirubin in the binding process. 
Wennberg suggests that the development of bilirubin encephalopathy is the
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result of the formation of reversible complexes of bilirubin monoanion and 
cell membranes rather than the precipitation of bilirubin acid in phosphol­
ipid membranes, as proposed by Broder-sen and Stern. The hydrogen ion 
dependence of tissue binding for bilirubin can be explained, not by the ef­
fect of pH on bilirubin solubility, but by the conversion of the bilirubin 
dianion (B2') to monovalent anion.
Based on this, it is possible to estimate the relative bilirubin load to 
tissue in equilibrium with plasma bilirubin by measuring the free bilirubin 
concentration and blood pH. Because the free bilirubin level is usually a 
function of the bilirubin-albumin ratio, it is possible to calculate the serum 
bilirubin concentrations that would yield the same tissue bilirubin load at 
varying pH and concentrations of albumin. From Figure 2 8  \  it can be 
seen that an infant with an albumin level of 2.4 g/dL and a pH of 7.3 has the 
same pressure for bilirubin deposition in the brain when the serum bilirubin 
level is 14 mg/dL (239 pmol/L) as another infant who has a bilirubin level 
of 20 mg/dL (342 pmol/L) but an albumin level of 3.3 g/dL and a normal 
pH of 7.35. These calculations assume a normal albumin-binding capacity 
that may not be present in sick, low-birth-weight infants or in the presence 
of competition of drugs or endogenous an-ions. They also cannot take into 
account changes in permeability of the blood-brain barrier, variations in pH 
within the brain, and variations in the susceptibility of the brain cells. Nev­
ertheless, these calculations suggest the importance of attempting to correct 
acidosis in the severely jaundiced infant, particularly, respiratory acidosis, 
since carbon dioxide equilibrates rapidly in the brain. Hypercapnia also in­
creases cerebral blood flow and bilirubin delivery to the brain.
FIG. 28. Serum bilirubin concentrations yield the same tissue bilirubin load at 
varying pH and serum albumin concentrations. The reference exchange trans­
fusion level of 20 mg/dL occurs with an albumin level of 3 3 g/dL and pH of 
7.35.
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Wennberg and colleagues also demonstrated that bilirubin toxicity 
can be augmented and reversed by altering cellular pH. These investigators 
infused bilirubin into premature rhesus monkeys and then exposed them to 
carbon dioxide. At total bilirubin levels of 24 to 29 mg/dL (410-496 
(imol/L; unbound bilirubin levels 2.5 - 3.8 pg/dL), the addition of carbon 
dioxide produced a decrease in arterial pH to 6.86 — 7.04 and changes in 
the brain stem audiometric evoked response (BAER) in 6 of 7 animals. Cor­
rection of the respiratory acidosis produced partial to complete reversal of 
the BAER changes within 3 to 20 minutes, and reexposure to carbon diox­
ide immediately reproduced the BAER abnormality. These data support the 
hypothesis that bilirubin toxicity can be both potentiated and reversed by 
modulating environmental pH.
The monovalent anion hypothesis is consistent with the ready extrac­
tion of tissue-bound bilirubin by exchange transfusion and the reversibility 
of the bilirubin-induced changes in BAER. As illustrated in Figure 38-18 
and discussed previously, this hypothesis suggests that when the monoanion 
enters the lipid core of the membrane, it accepts a second proton, making it 
more lipid-soluble. This proton would be released as bilirubin emerges on 
the opposite surface. If the immature cell membrane has sufficient fluidity, 
bilirubin can pass through in its mono-ionic form; and if membrane fluidity 
is important in determining bilirubin toxicity, pharmacologic intervention 
can affect this. For example, benzyl alcohol increases membrane fluidity, 
and the use of benzyl alcohol appears to be strongly associated with a very
h i g h  incidence of kernicterus in low-birth-weight infants.
Other mechanisms have been determined by which bilirubin might al­
ter membrane function. If tissue binding involves bilirubin acid-lipid com­
plexes, bilirubin might adversely affect membrane function by changing the 
lipid environment of membrane proteins. Bilirubin binding to specific re­
ceptor sites on enzymes might be another mechanism for bilirubin mem­
brane toxicity.
WINDOWS OF VULNERABILITY
The permeability of the blood-brain barrier and the susceptibility of 
the brain to damage from bilirubin or other insults change as maturation oc­
curs. Damage to the Purkinje cells and the cerebellum of Gunn rats was sig­
nificantly mitigated when these rats were exposed to phototherapy on cer­
tain days, while other studies using displacing agents found that bilirubin 
staining of regions of the cerebellum, other than the Purkinje cells, was 
most intense on day 15. Although pathologic kernicterus occurs in very-^ 
low-birth-weight infants, they do not manifest the classic clinical picture, 
this may be due to the differences discussed previously. The distribution 
and type of bilirubin toxicity appear to be dependent on the maturity of the 
brain.
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FIG 29 Possible mechanisms for bilirubin entry into the brain and binding to 
neuronal cell membranes. The different factors affecting this process are also 
indicated. (A - albumin; AB~ - albumin-bilirubin complex; B~ - bilirubin 
monoanion; B2- - bilirubin dianion; BBF - brain-blood flow.
MECHANISMS BY WHICH BILIRUBIN ENTERS THE BRAIN 
Bratlid has provided a schematic presentation of possible mechanisms 
of bilirubin entry into the brain, its binding to neuronal cell membranes, and 
the potential clinical signs that may follow (Fig. 29). Under normal circum­
stances, bilirubin enters the brain. Clinical confirmation of this fact is pro­
vided by the observation that modest elevations of serum bilirubin can pro­
duce clinical and electrophysiologic alterations in healthy full-term infants.
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Such infants demonstrate changes in behavior, characteristics of the cry, and 
changes in the BAER. These changes reverse as the bilirubin level de­
creases.
The second mechanism for bilirubin entry into the brain occurs when 
there is a marked increase in the serum level of unbound bilirubin. In the 
unbound state, bilirubin readily enters the brain and has the potential for 
producing kernicterus. Finally, bilirubin bound to albumin can enter the 
brain through a disrupted blood-brain barrier. Even in the presence of a 
damaged blood-brain barrier, however, on a molar basis, more bilirubin than 
albumin is deposited in the brain. In all these situations, acidosis increases 
deposition of bilirubin in brain cells.
CLINICAL FEATURES OF BILIRUBIN ENCEPHALOPATHY
ACUTE BILIRUBIN ENCEPHALOPATHY OR KERNICTERUS
In classic kernicterus, markedly jaundiced infants progress through 
three fairly distinct clinical phases. In the first few days, the infant becomes 
lethargic, hypotonic, and sucks poorly. Later in the first week, the second 
phase evolves; the infant becomes hypertonic and frequently develops a fe­
ver and a high-pitched cry. The hypertonia involves the extensor muscle 
groups, and most infants exhibit backward arching of the neck (i.e., retro- 
collis) and trunk (i.e., opisthotonus). The fever may be due to diencephalic 
involvement. In the third phase, usually after 1 week, hypertonia subsides 
and is replaced by hypotonia. Infants who manifest hypertonia during the 
second phase invariably develop the clinical features of chronic bilirubin 
encephalopathy. Van Praagh found that those who were consistently neuro- 
logically normal during the first week of life never developed the features of 
chronic encephalopathy, but other investigators found later evidence of 
brain damage in some infants in whom no, or equivocal, manifestations of 
kernicterus were apparent in the newborn.
CHRONIC BILIRUBIN ENCEPHALOPATHY
Temporal Evolution
Byers and colleagues described the temporal evolution of chronic 
bilirubin encephalopathy after neonatal erythroblastosis fetalis. In the first 
year, infants typically feed poorly, develop a high-pitched cry, and are hy­
potonic but have increased deep tendon reflexes, a persistent tonic neck re­
flex, and motor delay. There is a delay in acquisition of motor skills, al­
though most infants walk alone by 5 years of age. The other typical features 
of chronic bilirubin encephalopathy are not usually apparent before 1 year 
of age and often not for several years. These children generally are hypo­
tonic at rest for the first 6 or 7 years. By the time they reach their teens, hy­
pertonia has replaced hypotonia.
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Clinical Features
The classic sequelae of posticteric encephalopathy constitute a tetrad 
consisting of extrapyramidal disturbances, auditory abnormalities, gaze pal­
sies, and dental dysplasia.
Extrapyramidal Disturbances. Athetosis (i.e., involuntary, sinuous, 
writhing movements) may develop as early as 18 months but may be de­
layed as late as 8 or 9 years. If sufficiently severe, athetosis may prevent 
useful limb function. These movements are described as uncontrollable, 
purposeless, involuntary and incoordinate. They may be rapid and jerky 
(choreiform), slow and worm-like (orthodox athetosis) or so slowed by hy­
pertonicity that the patient may assume momentarily fixed attitudes with 
stiffness of the extremities (dystonia). Occasionally, extra-pyramidal rigid­
ity may predominate, rather than involuntary motion. In Perlstein's opinion, 
"the absence of athetosis or of other forms of extrapyramidal dyskinesia, 
makes the diagnosis of post-icteric encephalopathy dubious, if not unten­
able. Severely affected children may also have dysarthria, facial grimacing, 
drooling, and difficulty chewing and swallowing.
Auditory Abnormalities. Some degree of hearing loss is often found in 
children with chronic bilirubin encephalopathy. Pathologic studies and stud­
ies of BAER indicate that injury to the brain stem, specifically the cochlear 
nuclei, is the principal cause of hearing loss, although occasional studies 
suggest possible involvement of the peripheral auditory system as well.
Hyman, Keaster, and colleagues followed 405 survivors of hemolytic 
disease of the newborn and compared 119 children whose maximal indirect 
serum bilirubin levels exceeded 20 mg/dL (342 pmol/L) with 286 who had 
lower bilirubin levels. Those with higher bilirubin levels had three times the 
risk of neurologic abnormality (20% versus 6.6%) and 4.4 times the risk of 
sensorineural hearing loss (9.2% versus 2.1%). All the infants who received 
exchange transfusions, and 16 of the 17 later found to have hearing loss, re­
ceived prophylactic streptomycin, an ototoxic antibiotic. Although infants 
with elevated bilirubin levels had a higher risk of hearing loss even when 
those not receiving streptomycin were excluded from the comparison group, 
it is impossible to exclude effect modification because all infants with high 
bilirubin levels received streptomycin.
Johnston and colleagues followed 129 children who had indirect se­
rum bilirubin levels above 20 mg/dL (342 pmol/L). Ninety-two of these in­
fants had Rh hemolytic disease, and 26 had ABO hemolytic disease. Seven 
children had neurologic sequelae, all of whom had sensorineural hearing 
impairment. All these hearing-impaired infants received exchange transfu­
sions, and six of the seven received streptomycin. Hearing loss is generally 
most severe in the high frequencies, and an association between moderate 
hyperbilirubinemia and subsequent sensorineural hearing loss has been de­
scribed in low-birth-weight infants
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Gaze Abnormalities. Limitation of upward gaze and other gaze ab­
normalities occur, and the fact that full vertical eye movements during the 
doll's-eye maneuver are attained in most affected children suggests that the 
lesion is above the level of the oculomotor nuclei. Some patients have para­
lytic gaze palsies. Supranuclear palsies can be explained by bilirubin depo­
sition and neuronal injury in the rostral mid-brain, and nuclear palsies can 
be explained by damage to the oculomotor nuclei.
Dental Dysplasia. About 75% of children with post-icteric encepha­
lopathy have some degree of dental enamel hypoplasia. A smaller percent­
age have green discoloration of the teeth.
CLINICAL SEQUELAE OF HYPERBILIRUBINEMIA
This subject remains a source of lively debate. Is there evidence for a 
subtle form of bilirubin encephalopathy in otherwise healthy full-term in­
fants? What about preterm infants? What does yellow staining of the brain 
found at autopsy mean in some very-low-birth-weight infants?
Hsia and colleagues and Mollison and Cut-bush first established the 
link between bilirubin levels and brain damage in the early 1950s, when 
they demonstrated that the risk of kernicterus in infants with Rh hemolytic 
disease increased dramatically with rising bilirubin levels and that exchange 
transfusion could markedly reduce the risk. It subsequently became clear 
that in untreated infants with severe hemolytic disease, the incidence of ker­
nicterus (30%-50% in those with the highest bilirubin levels) was much 
higher than the incidence in markedly jaundiced infants without hemolytic 
disease. As a result, there was considerable disagreement about how jaun­
dice in preterm and full-term infants without Rh isoimmunization should be 
treated. Some investigators described clinical and pathologic kernicterus in 
premature infants who did not have hemolytic disease and whose bilirubin 
levels were well below 20 mg/dL (342 pmol/L). In other studies, similar in­
fants did not appear to be at risk unless their serum bilirubin levels were 
well above 20 mg/dL. In some small, sick infants, yellow staining of the 
brain was seen at autopsy, with bilirubin levels less than 10 mg/dL (171 
pmol/L)
Starting in 1967 and continuing into the late 1970s, reports from the 
CPP, a study of 53,000 pregnant women and their offspring, linked moder­
ate elevations of neonatal serum bilirubin to lower developmental scores, 
lower IQ scores, and increased risk of neurologic abnormalities. These find­
ings occurred at levels of bilirubin previously presumed to be safe.
These data and the results of other studies suggested that acute 
bilirubin encephalopathy or classic kernicterus was the most obvious and- 
extreme manifestation of a spectrum of bilirubin toxicity; at the other end of 
the spectrum were more subtle forms of neurotoxicity that occurred at much
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lower bilirubin levels and in the absence of any obvious abnormal clinical 
findings in the neonatal period.
Two subsequent studies found little association between serum 
bilirubin levels and bilirubin staining of the brain of very-low-birth-weight 
infants. The finding that gross bilirubin staining of the brain could occur in 
the absence of the typical microscopic neuronal damage described with ker- 
nicterus called into question the meaning of yellow staining of the brain in 
some very-low-birth-weight infants. Unlike the classic form of fatal kernic- 
terus, these very-low-birth-weight infants, although they may have had ker- 
nicterus, died from other causes.
Rh HEMOLYTIC DISEASES OF THE NEWBORN
A lone controlled trial was done on the treatment of hemolytic disease 
of the newborn. Thirty-two percent of the infants who received a simple 
transfusion died from kernicterus, compared with 10% of those who re­
ceived an exchange transfusion. Some infants in the exchange transfusion 
group died after 1 week of age, but no further deaths occurred in the simple 
transfusion group. Survivors were followed to 6 months of age, and the in­
cidence of brain damage was similar in both groups.
No bilirubin levels were reported in these studies, therefore no con­
clusions can be drawn about the possible relation between serum bilirubin 
levels and fatal kernicterus. There is also no clear statement about how the 
diagnosis of kernicterus was made—clinically, by autopsy, or both. Never­
theless, the study demonstrated beyond reasonable doubt that exchange 
transfusion in infants improved their chance of survival and decreased the 
risk of fatal kernicterus. The results of these studies, combined with the un­
controlled observations of Hsai and colleagues and Mollison and Cutbush, 
established exchange transfusion as the standard treatment for preventing 
kernicterus in infants with erythroblastosis fetalis. These investigators found 
that kernicterus was unlikely to occur if serum bilirubin levels were kept be­
low 20 mg/dL (342 pmol/L), an observation that has been amply confirmed 
by subsequent experience with the treatment of hemolytic disease.
As a complication of hemolytic disease, clinical kernicterus has es­
sentially disappeared in the Western world, and since Rh disease is largely 
preventable, there is no reason to consider any change in this approach. It is 
interesting to recall, however, that these studies were performed on infants 
born in the late 1940s and early 1950s. These infants were commonly as­
phyxiated and seriously ill, and many were delivered prematurely to prevent 
stillbirth. Streptomycin was frequently administered to infants who received 
exchange transfusion. Later experience with Rh hemolytic disease was far 
more encouraging. It would be interesting to reevaluate a similar series of 
infants managed under contemporary conditions of high-risk obstetric and 
neonatal intensive care.
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An 18-year follow-up of 55 boys with a history of neonatal hyper­
bilirubinemia (> 15 mg/dL, or 257 pmol/L) was performed in Norway at the 
time of military draft physical examinations. Compared with the total cohort 
of Norwegian conscripts, there were no significant differences revealed on 
physical examination or tests of vision, hearing, or IQ. As neonates, one- 
half of these boys had positive Coombs tests; and seven boys who had a his­
tory of positive Coombs tests and bilirubin in excess of 15 mg/dL (25 
pmol/L) for more than 5 days had significantly lower IQ scores than the na­
tional average.
FULL-TERM INFANTS WITHOUT HEMOLYSIS
Full-term infants without hemolytic disease appear to be at signifi­
cantly lower risk for bilirubin encephalopathy at bilirubin levels that are 
considered hazardous to infants with hemolytic disease. When the serum 
bilirubin level concentration reached 20 mg/dL (342 pmol/L), Killander and 
colleagues assigned 94 infants alternately to receive or not to receive an ex­
change transfusion. None of these infants had Rh hemolytic disease; 21 
were ABO incompatible, but only 6 had evidence of ABO hemolytic disease 
(3 in the exchange group and 3 in the nonexchange group). Forty-six infants 
received exchange transfusions, and 48 did not (controls). In three control 
and four treated infants, bilirubin levels exceeded 25 mg/dL (428 pmol/L). 
The infants were followed for at least 2 years and underwent detailed physi­
cal and neurologic examinations at a mean age of 27 months. No audiome­
try or IQ testing was done, but a detailed history was obtained with specific 
attention to behavioral abnormalities, hearing and vision impairment, and 
possible deviations in motor performance. The examiners were not blinded. 
With the exception of one infant in the treated group who probably had an 
inherited myopathy, none of the children in either of the groups showed any 
major neurologic abnormalities. There are no other controlled trials that ad­
dress the question of whether or not serum bilirubin levels of 20 mg/ dL are 
harmful to otherwise healthy full-term infants.
The CPP was a multicenter cohort study of 53,043 women who be­
came pregnant in the years 1959 to 1965. Each infant born to these mothers 
and weighing more than 2500 g had a total serum bilirubin drawn at age 48 
± 12 hours. If the initial bilirubin concentration was at least 10 mg/dL (171 
pmol/L), the measurement was repeated daily until the bilirubin level fell 
below 10 mg/dL. The predictor variable in each of the CPP studies is the 
highest total bilirubin value recorded. The infants in this study were fol­
lowed to 8 years of age, during which time they were evaluated with full 
psychometric testing including IQ, formal neurologic evaluations, and 
evaluations of speech and hearing. Unfortunately, some important results 
from the CPP have been published only in monographs and are unfamiliar
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to many in the field because monographs are neither peer-reviewed nor 
listed in the Index Medicus.
In their analysis, Newman and Maisels restricted their attention to 
full-term infants without hemolysis and found that, although statistically 
significant, serum bilirubin levels are not associated with subsequent IQ 
score in any clinically important way. They reached this conclusion by cal­
culating the magnitude of associations (i.e., the effect size) rather than rely­
ing on p values to estimate the importance of reported associations. This is 
necessary because some statistically significant correlations in the CPP oc­
curred only by virtue of the enormous sample size.
To put these effect sizes into perspective and to facilitate comparisons 
of different studies, Newman and Maisels calculated the observed change in 
outcome per 5 mg/dL (85 pmol/L) of serum bilirubin. This figure was chosen 
because it represents the upper limit of what is usually obtained in bilirubin­
lowering interventions used in clinical practice. For example, phototherapy 
introduced at a serum bilirubin level of 18 mg/dL (308 pmol/L) is commonly 
discontinued when the bilirubin reaches 13 mg/dL (222 pmol/L). Exchange 
transfusion results in a drop after rebound of about 30% to 40% of the peak 
bilirubin level. In a group of ABO incompatible infants, tin protoporphyrin 
(SnPP) reduced the mean serum bilirubin by 2 to 3 mg/dL (34-51 pmol/L).
The association of bilirubin level with IQ in the CPP was only about 
one point per 5 mg/dL. This is probably a worst-case estimate because pre­
mature infants and those with hemolysis were not excluded from the study. 
Bilirubin levels were also unrelated to subsequent school performance. Fi­
nally, of nearly 15,000 subjects with complete hearing evaluations at 8 
years of age, no association was found between sensorineural hearing loss 
and serum bilirubin levels.
Thus, even if the observed associations were completely causal and in­
terventions to reduce hyperbilirubinemia could completely eliminate the risk, 
the potential gain in IQ would be only about 0.75 to 1.5 points—an effect 
only about 5% to 10% as large as the effect of race or socioeconomic status. 
The prediction of reduction in definite or suspected neurologic abnormality is 
also small; decreasing the serum bilirubin level from 18 to 13 mg/dL, for ex­
ample, produces a predicted change in the incidence of definite or suspected 
abnormality from 14% to 13%. It is unlikely that a search for new interven­
tions directed at preventing or treating hyperbilirubinemia will be rewarding, 
particularly in full-term infants without hemolysis.
Seidman and colleagues evaluated a group of Israeli army draftees (n 
= 1948) and matched their pre-induction psychologic and physical examina­
tions at age 17 years to their neonatal records. They found an association 
between risk of IQ below 85 and bilirubin level higher than 20 mg/dL (342 
pmol/L) in full-term boys with a negative Coombs test (p = 0.01). This as­
sociation was not found in girls. When adjusted for various confounders, no
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association was found between bilirubin levels and mean IQ score, risk of 
physical or neurologic abnormality, or hearing loss. Seidman and colleagues 
suggest that their finding of a significantly increased risk of low IQ scores 
in association with serum bilirubin levels higher than 20 mg/dL is consistent 
with the concept of a threshold level of bilirubin above which there is sig­
nificant danger. If there were no danger from bilirubin until it reached a cer­
tain threshold, however, one would expect to see an effect of bilirubin on 
the mean IQ of the population.
Newman and Maisels used linear regression analysis to summarize 
the effect of bilirubin on IQ. This could be misleading if the relation be­
tween bilirubin and IQ were nonlinear. Newman and Klebanoff reanalyzed 
the CPP data and found no association between bilirubin and IQ—adpsted 
for confounding variables— in either linear or nonlinear models. They also 
found no effect of peak bilirubin on definite neurologic abnormalities. An 
effect was found, however, on suspected neurologic abnormalities (e.g., mi­
nor muscle and coordination problems and oculomotor abnormalities) at age 
7; these increased from 15% in those with a peak bilirubin level of 10 
mg/dL (171 pmol/L) or higher to 22% at a bilirubin level of 20 mg/ dL (342 
pmol/L; p < 0.001). So far, there is no evidence that treating hyper­
bilirubinemia at these levels has reduced the incidence of these types of 
neurologic problems.
BILIRUBIN-BINDING CAPACITY AND DEVELOPMENTAL OUTCOME
Odell and colleagues examined 32 children 4 to 7 years of age in 
whom bilirubin levels were measured in the neonatal period. They found no 
relation between total serum bilirubin levels and abnormal performance, but 
there was a strong relation between the bilirubin saturation index, which is a 
measure of the saturation of serum bilirubin-binding sites by bilirubin, and 
subsequent abnormality. The effect size observed was remarkable: a risk 
difference of 58% (i.e., brain damage occurred in 76% of those with high 
saturation, compared with 18% of those with low saturation). Sixteen of the 
18 abnormal infants were either premature or had hemolytic disease. Two 
thirds of the infants enrolled were lost to follow-up, raising the possibility 
of substantial bias, and the small sample size could lead to gross overesti­
mation of the effect simply by chance.
Johnson and Boggs reported results of detailed neurologic and psy­
chometric examinations on 83 infants with a history of neonatal jaundice. 
They found a relation between developmental outcome and the HBABA- 
binding test. Infants with binding levels of 50% or less were more likely to 
be considered suspect on neurologic psychometric or speech and hearing 
examinations.
In the NICHHD Cooperative Phototherapy Study, albumin binding of 
bilirubin was measured by the HBABA technique and Sephadex G-25 gel
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column chromatography. Three infants who died were found to have kernic- 
terus at autopsy. Two had one or more abnormal HBABA values (<40%), 
whereas only one infant had positive findings on the Sephadex. No relation 
was found between IQ measured at age 6 years and the results of the bind­
ing tests during the neonatal period.
DURATION OF HYPERBILIRUBINEMIA
Johnson and Boggs also found a relation between peak indirect 
bilirubin levels higher than 15 mg/dL (257 pmol/L) and the risk of neu­
rologic and psychometric abnormalities. The strongest relation, however, 
was with duration of hyperbilirubinemia; the longer the hyperbilirubinemia 
lasted, the greater the risk. Odell and colleagues found that brain-damaged 
infants were exposed to bilirubin levels higher than 15 mg/dL (257 pmol/L) 
for significantly longer than were normal infants. As with Odell's study, 
Johnson and Boggs' data cannot be applied to healthy full-term infants be­
cause 44 (53%) of the infants had hemolytic disease and 27 (33%) were 
premature. In the large NICHHD collaborative phototherapy trial, a 6-year 
follow-up of 224 control infants who did not receive phototherapy and had 
birth weights lower than 2000g showed no association between IQ and 
mean bilirubin level, time and duration of exposure to bilirubin, or measures 
of bilirubin-albumin binding.
It is possible, however, that one explanation for the poor correlation 
between maximal serum bilirubin and outcome is that maximal serum 
bilirubin is only weakly associated with the true risk factor—free serum 
bilirubin or duration of hyperbilirubirtemia. Unfortunately, it is difficult to 
base clinical decisions on binding tests, since they are generally unavailable, 
or on the duration of hyperbilirubinemia, since at the time decisions need to 
be made, the duration is not yet known.
HEARING LOSS AND AUDIOMETRIC EVOKED RESPONSES
The BAER test is an accurate and noninvasive means of assessing the 
functional status of the auditory-nerve and the brain stem auditory pathway. 
The three positive wave forms labeled in the figure are those most easily 
identified in the neonate. The neural generators of the BAER include the 
auditory nerve (i.e., wave I), the cochlear nucleus and superior olive (i.e., 
wave III), and the inferior colliculus (i.e., waves IV and V). The latency for 
wave I represents the peripheral conduction time. Latency of waves III and 
V and the interpeak latency of waves I to III, III to V, and I to V all repre­
sent measurements of central conduction time. The interpeak latency I to V 
is referred to as the brainstem conduction time. Reports also include ampli­
tudes of the wave forms. These may decrease or be lost in response to vari­
ous insults.
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Several studies have evaluated the relation between serum bilirubin 
levels and the BAER. Most have identified an effect of bilirubin on central 
conduction time, although some suggest an effect on the peripheral auditory 
nerve. According to Vohr, the reported differences may be due to the inclu­
sion of both full-term and premature infants, the use of different definitions 
of hyperbilirubinemia, and variations in technique. Histologic studies in in­
fants and Gunn rats suggest involvement of the brain stem auditory nuclei.
The acute changes seen in BAER can be reversed by bilirubin­
lowering interventions (e.g., phototherapy, exchange transfusion). Nakamura 
and colleagues and Esbjorner and colleagues found that abnormalities of the 
BAER were more closely related to the unbound bilirubin levels than to total 
bilirubin levels. In Nakamura's study, abnormalities were present in 89% of 
infants with unbound bilirubin levels of 1 pg/dL or higher, compared with 
42% of those with levels of 0.5 to 0.99 pg/dL and 33% of those with levels of 
0.5 pg/dL or lower.426 On the other hand, Streletz and colleagues were un­
able to demonstrate any relation between serum bilirubin levels and 
prolongation of the BAER central conduction time in a NICU population. 
Prolongation of wave I latency was found in hypoxemic infants. Streletz and 
colleagues also pointed out that middle ear effusion may occur in as many of 
one third of the NICU population and may result in transient BAER abnor­
malities, difficult to distinguish from the changes due to hyperbilirubinemia 
or hypoxemia. Thoma and colleagues studied 85 children with serum 
bilirubin levels between 8.2 and 25 mg/dL (141-430 pmol/L). About 20 in­
fants had serum bilirubin levels that exceeded 20 mg/dL (340 pmol/L), and 
72 had bilirubin levels of 17.5 mg/dL (299 pmol/L) or higher. No correlation 
was found between serum bilirubin concentrations and BAER.
In spite of evidence for acute bilirubin toxicity on the auditory path­
way in full-term and preterm infants, there is virtually no evidence for a risk 
of hearing loss related to hyperbilirubinemia in full-term infants who do not 
have hemolytic disease. In a study of almost 15,000 children who received 
complete hearing evaluations at 8 years of age, the incidence of sensorineu­
ral hearing loss was actually highest in the infants with the lowest bilirubin 
levels, as was the incidence of conductive hearing loss. In their 17-year fol­
low-up study, Seidman and colleagues found no relation between hearing 
loss and hyperbilirubinemia. In the NICHHD controlled trial of photother­
apy, the incidence of sensorineural hearing loss in children followed to age 
6 years was identical in the phototherapy and control groups (1.8% versus 
1.9%). Valaes and colleagues, however, reported a statistically significant 
relation between serum bilirubin levels of 12 mg/dL (205 pmol/L) or higher 
and the risk of sensorineural hearing loss in the children of mothers who en­
rolled in a prenatal phenobarbital trial (relative risk 8.1; p < 0.001). Inter­
pretation of this result is complicated by the lack of information on the se­
verity of hearing loss, how it was measured, whether those measuring it
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were blinded to bilirubin values, and the inclusion of infants with hemolytic 
disease. Although most of the subjects did not have hemolytic disease, of 
the 45 infants with bilirubin values higher than 16 mg/dL (205 pmoI/L), 13 
had ABO incompatibility, 7 were premature, and 1 was G6PD-deficient.
Johnson and colleagues found that deficits in central hearing, speech, 
and language can occur in the absence of pure-tone hearing loss. They also 
noted that these deficits are easier to detect at 7 years of age than at 4 years 
of age and that they correlate more closely with measures of bilirubin bind­
ing than with peak serum bilirubin levels. Johnson also pointed out that in 
their earlier study, there was a high incidence of perceptual dysfunction in 
spite of normal IQ scores. Deficits in central processing can occur in spite 
of a normal hearing threshold and a normal IQ.
CRY ANALYSIS
An abnormal cry is a sign of neurologic distress and has been associ­
ated with acute bilirubin encephalopa-thy. Modest degrees of hyper­
bilirubinemia also affect the infant's cry. Glottal instability appeared in 11 
of 12 infants with serum bilirubin levels between 10 and 20 mg/dL (171- 
342 pmol/L). Using high-speed computer technology, Vohr and colleagues 
found that infants with bilirubin levels of 10 to 20 mg/ dL (171-342 pmol/L) 
had a significant increase in percentage of phonation and in the variability 
of first formant when compared with infants with bilirubin levels lower than 
8 mg/dL (137 pmol/L). They also found that the percentage of phonation 
correlated with the BAER interpeak latency of waves I to III and brain stem 
conduction time (i.e., waves I to IV).
INFANT BEHAVIOR
Investigators have used the Brazelton Neonatal Behavioral Assess­
ment Scale (BNBAS) to evaluate the effect of hyperbilirubinemia on infant 
behavior. Most studies show some effect, although several are confounded 
by the use of phototherapy. Escher-Graub and Fricker used the BNBAS 
with examiners blinded to evaluate behavioral integrity in 76 infants whose 
serum bilirubin levels ranged from 11.7 to 14.6 mg/dL (200-250 pmol/L) 
and compared them with infants with serum bilirubin levels below 5.8 
mg/dL (100 pmol/L). The jaundiced infants scored lower than the controls 
in habituation, orientation, motor performance, regulation of state, and 
autonomic stability. Paludetto and colleagues compared 31 moderately jaun­
diced full-term infants on days 3 and 4 (bilirubin level, 8.4 to 14.3 mg/dL, 
or 144-245 (pmol/L) with nonjaundiced matched controls; they found no 
differences between the two groups. Other investigators have evaluated 
behavior in infants undergoing phototherapy. Telzrow and colleagues and 
Paludetto and colleagues found that infants receiving phototherapy for hy-
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therapy for hyperbilirubinemia scored lower on orientation items when 
compared with controls.
Vohr and colleagues studied 23 jaundiced fu'll-term infants with 
bilirubin levels of 10 to 20 mg/dL (171-342 pmol/L) and compared them 
with 27 whose bilirubin levels were 8 mg/dL (137 pmol/L) or lower on days 
2 to 3. Infants in the jaundiced group had lower BNBAS cluster scores for 
orientation and state regulation. The serum bilirubin level correlates in­
versely with the BNBAS orientation score and state regulation score. The 
orientation cluster score was also inversely correlated with cry dysphona- 
tion and variability of the fundamental frequency.
These studies suggest that mild to moderate elevations of serum 
bilirubin have an effect on neurosensory systems that can be measured and 
documented. Changes in the BAER are mediated by the 8th cranial nerve 
pathway, and cry characteristics by the vagal complex cranial nerves. The 
nuclei of these cranial nerves are located close to one another in the brain 
stem, and bilirubin might affect both areas simultaneously.
PREMATURE INFANTS
It is generally believed that premature infants are at greater risk for 
developing kernicterus or bilirubin encephalopathy than are full-term new­
borns exposed to similar bilirubin levels. The evidence for this, although 
suggestive, is not entirely convincing.
Watchko and Oski provide a historical review of kernicterus in pre­
maturity from the 1950s to the present. Reports during the years 1950 to 
1965 suggested that kernicterus or the clinical sequelae of hyperbilirubine­
mia were unlikely to develop if exchange transfusions were used to main­
tain serum bilirubin levels below 18 to 22 mg/dL (308-376 pmol/ L). Kil- 
lander and colleagues found that premature infants with nonhemolytic hy­
perbilirubinemia did not develop kernicterus or evidence of bilirubin en­
cephalopathy if the serum bilirubin level was maintained below 20 mg/dL 
(342 pmol/L) using exchange transfusions. Shiller and Silverman found no 
association between bilirubin levels and neurologic deficits or mental retar­
dation in their study of premature infants.
Wishingrad and colleagues conducted a prospective randomized study 
of 187 preterm infants with nonhemolytic hyperbilirubinemia, most of 
whom weighed more than 1500 g. One-hundred infants whose serum 
bilirubin levels exceeded 18 mg/dL (308 pmol/L) after 36 hours of age were 
randomly assigned to receive or not to receive an exchange transfusion (50 
in each group). An additional 87 infants whose serum bilirubin concentra­
tions did not exceed 15 mg/dL (257 pmol/L) were selected as a control 
group. There were no differences in the mortality among the three groups. 
In the exchange transfusion group, there was no evidence of kernicterus at 1 
year of age despite the fact that 7 of the 50 infants had levels of indirect
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bilirubin exceeding 24 mg/dL (410 pmol/L). In the no-exchange group, 10 
of the infants had bilirubin levels exceeding 24 mg/dL, and one developed 
fatal kernicterus. This infant had respiratory distress syndrome, edema, and 
a peak indirect serum bilirubin concentration of 27.6 mg/dL (472 pmol/L). 
Lethargy and jitteriness were noted at an indirect serum bilirubin level of 
17.7 mg/dL (303 pmol/L), and a seizure occurred at 22.8 mg/dL (390 
pmol/L). Neurologic assessment of the remaining infants at 1 year of life 
revealed no evidence of kernicterus. The authors concluded that exchange 
transfusions in the management of nonhemolytic hyperbilirubinemia of 
prematurity need not be performed if indirect serum bilirubin levels are be­
low 24 mg/dL. In the one infant who developed fatal kernicterus, however, 
one might question whether intervention at a bilirubin level of 17.7 mg/dL 
(303 pmol/L) might not have been helpful when symptoms of lethargy and 
jitteriness appeared.
Several other studies published during this era failed to demonstrate 
evidence of an association between serum bilirubin levels lower than 20 
mg/dL (342 pmol/L) and developmental outcome in the premature neonate. 
Most of the infants reported in the studies mentioned previously were larger 
(1250-2500 g) and more mature (28-36 weeks of gestation) than the ex­
tremely low-birth-weight infants seen in NICUs.
LOW-BILIRUBIN KERNICTERUS
Between 1958 and 1972, a group of studies reported the occurrence of 
kernicterus at serum bilirubin levels well below 20 mg/dL (342 pmol/L). In 
general, these infants were significantly more premature and of much lower 
birth weight than those previously observed with kernicterus, and some 
were exposed to sulfisoxazole,—subsequently shown in a controlled trial to 
be a powerful displacer of bilirubin from its binding to albumin. As a result 
of these findings, various authors suggested the use of exchange transfu­
sions in preterm infants at serum bilirubin levels of less than 20 mg/dL (342 
pmol/L). The publication of data from the CPP that suggested an association 
between impaired psychomotor performance and bilirubin levels higher 
than 10 to 14 mg/dL (171-239 pmol/L) in low-birth-weight infants provided 
additional support for these recommendations.
Similar guidelines were incorporated into the NICHHD cooperative 
phototherapy study. In this study, infants were randomly assigned to a con­
trol group that received no phototherapy or to a group that received photo­
therapy at predetermined serum bilirubin levels. The criteria for exchange 
transfusion for all infants mandated exchange transfusions at relatively low 
levels of serum bilirubin (10 mg/dL, or 171 pmol/L, in high risk newborns 
with birth weights less than 1250 g). A total of 1339 infants entered the 
study—672 in the phototherapy group and 667 in the control group. Infants 
who weighed less than 2000 g at birth were assigned to receive photother-
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ару at 24 ± 12 hours of age, irrespective of their serum bilirubin levels. In 
this birth weight category, of 462 infants assigned to the phototherapy 
group, only 17.7% had serum bilirubin levels higher than 10 mg/dL (171 
pmol/L), compared with 62.8% of the 460 controls. One-hundred and nine­
teen infants died, and 64% had autopsies performed. Kernicterus was found 
in four infants, all of whom weighed less than 1500 g and had a complicated 
neonatal course. Their peak serum bilirubin levels ranged from 6.5 to 14.2 
mg/dL (111-243 pmol/L). One of these infants was in the phototherapy 
group, and three were in the control group (p = 0.2). The results were com­
plicated by the fact that the infant in the phototherapy group who had ker­
nicterus did not get phototherapy until 43 hours of age and received an ex­
change transfusion at 44 hours of age. The infant died at 7 days of age. If 
this infant is excluded, the p value for the Fisher exact test is .081. The four 
infants who had kernicterus at autopsy had birth weights ranging from 760 
to 1270 g. All were asphyxiated or had hyaline membrane disease, and all 
had some degree of PIVH. Two had periventricular leukomalacia. Since 
36% of those who died did not have autopsies, the interpretation of these 
results remains uncertain.
Surviving infants in the study were followed and evaluated at 1 year 
of age with the Bay ley Scales of Mental and Psychomotor Development and 
at 6 years of age with the Wechsler Verbal and Performance IQ. No differ­
ences were found in the incidence of definite and suspect cerebral palsy, 
clumsy or abnormal movements, hypotonia, or an IQ lower than 70. There 
were no differences between the two groups in growth, speech, hearing loss, 
or evidence of hyperactivity.
Scheldt and colleagues published a 6-year follow-up of 224 control 
children with birth weights lower than 2000 g. None of these infants re­
ceived phototherapy, but bilirubin levels were maintained below specified 
levels by the use of exchange transfusion. No relation was found between 
serum bilirubin levels and the incidence of cerebral palsy, nor was there any 
association between maximal bilirubin level and IQ. IQ was not associated 
with mean bilirubin level, time and duration of exposure to bilirubin, or 
measures of bilirubin-albumin binding.
Because the predictor variable in the NICHHD phototherapy study 
was phototherapy versus no phototherapy, it provides only indirect although 
clinically relevant evidence regarding the question of whether bilirubin af­
fects neurodevelopmental outcome. In fact, because in infants who weighed 
2500 g or more, phototherapy was not begun until the serum bilirubin level 
reached an average of 15.7 mg/dL, the peak serum bilirubin levels in the 
two groups at this birth weight were practically identical. A difference ex­
isted in the duration of hyperbilirubinemia, which can be expressed as a dif­
ference in areas under the two curves of serum bilirubin level plotted 
against age. This difference was about 12.5 mg/dL/day in infants who
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weighed more than 2500 g. In the infants who weighed 2000 to 2499 g and 
in those who weighed less than 2000 g, the differences in peak bilirubin 
levels were about 1 mg/dL and 6 mg/dL, respectively, and the areas under 
the curves were substantially greater in the control infants.
HEARING LOSS IN LOW-BIRTH-WEIGHT INFANTS 
Several epidemiologic studies have identified elevated serum bilirubin 
levels as a risk factor for hearing loss in low-birth-weight survivors of N1- 
CUs. On the other hand, in a study of 975 infants cared for in an intensive 
care nursery, Halpern and colleagues identified craniofacial anomalies, con­
genital perinatal infections, and meconium aspiration as the strongest predic­
tors of hearing loss, especially in full-term infants. They found a negative as­
sociation between hyperbilirubinemia and hearing loss. In a 5-year follow-up 
of 814 infants of less than 32 weeks of gestation or less than 1500 g birth 
weight, van de Bor and colleagues found no association between bilirubin 
levels and hearing loss.
DeVries and colleagues found a significant increase in bilateral sen­
sorineural deafness in infants with birth weights lower than 1500 g who 
were classified as high risk. High-risk criteria included the following:
• Apgar score <5 at 5 minutes, or requirement for intubation lasting 
more than 4 minutes
• intermittent positive-pressure ventilation for more than 24 hours
• hyaline membrane disease requiring ventilation
• pneumothorax
• persistent fetal circulation severe enough to require treatment with to- 
lazoline
• persistent patent ductus arteriosus requiring treatment
• proven infection
• hyperglycemia
• PIVH.
If serum bilirubin levels exceeded 14 mg/dL (240 pmol/L), the inci­
dence of deafness was 36% in these high-risk infants, compared with only 
4% in high-risk infants with birth weights of more than 1500 g (p < 0.05). 
After more aggressive use of phototherapy and exchange transfusion, the 
incidence of sensorineural deafness in this population was reduced to zero.
LOW-BIRTH-WEIGHT INFANTS IN THE 1980s AND 1990s 
In 1980, Kim and colleagues and Turkel and colleagues reviewed the 
risk factors previously suggested to predict the development of kernicterus. 
They were unable to identify any risk factor or group of factors that was as­
sociated with the development of kernicterus in the premature neonate, in­
cluding birth weight less than 1500 g, hypothermia, asphyxia, acidosis, hy- 
poalbuminemia, sepsis, meningitis, drug therapy, and serum bilirubin levels.
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It is likely that there are some risk factors for the development of ker- 
nicterus that are unknown. An excellent example of this possibility is the 
experience reported by Jardine and Rogers. They found that the proportion 
of premature infants with kernicterus who underwent autopsy fell abruptly 
from 31% to 0% when they stopped flushing intravenous catheters with bac­
teriostatic saline that contained benzyl alcohol. In an earlier study from their 
NICU, the incidence of kernicterus diagnosed postmortem among neonates 
of 25 to 32 weeks of gestation was a remarkably high 25%. As mentioned 
previously, benzyl alcohol is an agent that increases membrane fluidity and 
may thus facilitate the passage of bilirubin. At the same institution, 
Watchko and Claasen found only three cases of kernicterus in 72 autopsies 
performed from 1984 through 1991 on newborns of less than 34 weeks of 
gestation who lived at least 48 hours. This sustained decrease in the inci­
dence of kernicterus supports their contention, confirmed by experience in 
most nurseries, that kernicterus in premature newborns has disappeared al­
most completely from the NICU. In Watchko and Claasen's population of 
69 newborns who did not have kernicterus, the peak serum bilirubin level 
ranged from 6.3 to 20.6 mg/dL (108-352 pmol/L), and 56% had peak serum 
bilirubin values higher than those suggested for exchange transfusion by the 
NICHHD phototherapy study guidelines. Thus, kernicterus is an uncommon 
event, even when serum bilirubin levels are allowed to rise above those pre­
viously thought to place the premature infant at risk.
Several studies have failed to document an association between maxi­
mal serum bilirubin levels and developmental outcomes in very-low-birth- 
weight infants. Van de Bor and colleagues found a relation between 
maximal serum bilirubin concentrations in the neonatal period and neurode- 
velopmental outcome at a corrected age of 2 years. The handicaps described 
were not those characteristically found with kernicterus and were mainly 
caused by cerebral palsy. In addition, no relation was found between maxi­
mal serum bilirubin concentrations and hearing defects. In a follow-up of 
the same population at 5 years, in which a remarkable 98% of 831 surviving 
children were evaluated, no significant difference was found in mean 
maximal serum bilirubin concentrations between children with and without 
handicaps. A dose-response relation between maximal serum total bilirubin 
concentration and the risk of adverse outcome was again observed, but after 
correction for seven suspected confounding factors (i.e., gestational age, 
birth weight, intracranial hemorrhage, ventriculomegaly, seizures, bron­
chopulmonary dysplasia, and socioeconomic status), the previously ob­
served association between bilirubin levels and handicap disappeared (odds, 
ratio, 1.2; confidence interval, 0.89 to 1.43 per 50 pmol/L increase of total 
bilirubin). The investigators did find, however, that children who had suf­
fered an intracranial hemorrhage were at significantly greater risk of handi­
cap (odds ratio, 1.84; confidence interval, 1.08 to 3.15 per 50 timol/L in-
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crease of bilirubin). The association between maximal serum bilirubin con­
centration and handicap was most prominent, however, in children with 
grade I hemorrhage. This effect was not seen in the more severe hemor­
rhages, but the number of infants with severe hemorrhages was small. Fur­
thermore, only 109 children (13.4%) had a handicap at 5 years of age; 63 
(7.7%) had a minor and 46 (5.7%) had a major handicap. Failure to achieve 
statistical significance was probably the result of the small number of chil­
dren with handicaps in the 5-year-old cohort.
Although these data are reassuring, few of these infants had markedly 
elevated bilirubin levels. In the study by Graziani and colleagues, only 3 of 
249 infants had a serum bilirubin level higher than 14.6 mg/dL (250 
pmol/L). In van de Bor's study, mean maximal total serum bilirubin levels 
averaged 10.4 mg/dL (178 pmol/L); and in O'shea's study, median bilirubin 
levels were about 9 mg/dL (154 pmol/L). O'shea followed a geographically 
based sample of 495 very-low-birth-weight infants born between January 
1,1985 and December 31,1989 who survived to 1 year of adjusted age. Me­
dian bilirubin levels were about 9 mg/dL, and only 52 infants had a maxi­
mal serum bilirubin level above 11.6 mg/dL (22 pmol/L). Maximal neonatal 
serum bilirubin level was not associated with the risk of developmental 
problems identifiable at 1 year. Although they found an increase in the odds 
ratio for developmental problems of 1.3 for each 50 pmol/L of bilirubin 
similar to that of van de Bor, much of the apparent association was due to 
the confounding effect of neonatal intracranial abnormalities. When the ef­
fect of intracranial abnormalities was controlled using stratified analyses, an 
association between maximal bilirubin level and developmental problems 
was found only among subjects with uncomplicated subependymal or intra­
ventricular hemorrhage.
CLINICAL MANAGEMENT
The clinical diagnosis of jaundice and the use of the cephalopedal 
progression of jaundice to evaluate the infant are discussed in the section 
Clinical Diagnosis if jaundice.
LABORATORY MEASUREMENTS OF BILIRUBIN
METHODS BASED ON THE DIAZO REACTlOn
The reaction of diazotized sulfanilic acid with bilirubin, described by 
Ehrlich in 1883, is the basis for bilirubin measurements in most laborato­
ries. In 1916, van den Bergh and Muller noted that this diazo reagent re­
acted rapidly with serum from patients with cholestatic jaundice, thus meas­
uring the direct-reacting bilirubin, whereas serum from those with hemo­
lytic jaundice required the addition of alcohol to obtain the red-purple de­
rivatives (i.e., azodipyrroles) of the yellow tetrapyrrole, bilirubin. This 
measured the total bilirubin. The basic diazo reactions for total and direct
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bilirubin measurements are shown in Figure 30. The azobilirubins produced 
in these reactions are measured spectrophotometrically at 600 nm. The pres­
ence of accelerators, such as caffeine and methanol, break up the in­
tramolecular hydrogen bonds of unconjugated bilirubin and the unconju­
gated, as well as conjugated, bilirubin reacts rapidly and completely, yield­
ing the total diazo reaction.
Laboratory measurements of serum bilirubin concentrations can be in­
accurate. Two surveys in 1982 disclosed a high level of interlaboratory varia­
tion in the measurements of total and direct serum bilirubin concentrations in 
neonatal sera. In a survey of 67 laboratories in Indiana, bilirubin values of 
10.9 to 24 mg/dL (186-410 pmol/L) were reported for a serum with a mean 
total bilirubin concentration of 18.1 mg/dL (310 pmol/L), and a range of 1.8 
to 9.2 mg/dL (31-157 pmol/L) was found for a mean direct-reacting bilirubin 
of 5.8 mg/dL (99 pmol/L). Watkinson and colleagues also found a high inter­
laboratory variation in Australia and New Zealand. With regard to conjugated 
bilirubin analyses, they concluded that "laboratories are unable to repeat ac­
curately conjugated bilirubin results," which were, at best, "only an approxi­
mation to the true value." Rather than reporting the actual value for conju­
gated bilirubin, they recommended that these results be reported in ranges of 
25 to 50 pmol/L (1.5-3 mg/dL).
Total bilirubin
Conjugated bilirubin Diazotized sulfanilic acid
+ + +
Unconjugated bilirubin Caffeine-benzonate
Azobilirubin A and В 
(Isomers I and II)
Direct bilirubin
Conjugated Bilirubin + Diaz otized sulfanilic acid
_____  Azobilirubin В
(Isomers I and II)
Indirect Bilirubin
Total bilirubin - Direct biliru bin= Indirect Bilirubin
FIG. 30. Basic diazo reactions for determination of total and direct bilirubins.
Indirect bilirubin is obtained by calculation.
When different laboratories measure total bilirubin on standard sam­
ples with identical bilirubin concentrations, the coefficient of variation (i.e., 
the standard deviation divided by the mean) is about 10% when the total 
bilirubin is in the range of 5 to 20 mg/dL (85-342 pmol/L). Coefficients of 
variation within the same laboratory (i.e., on duplicate analyses of the same
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specimen) are only about one-half as large. The American College of Pa­
thologists' proficiency survey, in December 1988, found that the coefficient 
of variation for all methods measuring total bilirubin with a mean of 0.94 
mg/dL (16 pmol/L) was 14.9%, and with a mean of 5.29 mg/dL (90 pmol/L), 
it was 8.1%. Unfortunately, proficiency surveys do not usually provide sam­
ples with bilirubin levels that are relevant to therapeutic decisions in the 
newborn. If the true serum bilirubin is 20 mg/dL (342 pmol/L), a 10% coeffi­
cient of variation between laboratories means that a repeat value could fall 
anywhere between 16 and 24 mg/dL (274-410 pmol/L; assuming 95% confi­
dence limits). Within the same laboratory, however, a repeat measurement 
should fall between 18 and 22 mg/dL (308-376 pmol/L). These results can be 
improved with careful attention to standardization and other details. In Wil­
liam Beaumont Hospital laboratory, the coefficient of variation for a serum 
bilirubin level of 6.7 mg/dL (115 pmol/L) is 2%, and at 17.5 mg/ dL (299 
pmol/L), it is 3%.
DIRECT SPECTROPHOTOMETRY
Direct spectrophotometry is frequently used to measure total bilirubin 
in the newborn. This measurement is based on the fact that bilirubin absorbs 
light at about 454 nm, and hemoglobin absorbs light equally at both 454 nm 
and 540 nm. By subtracting the 540 nm absorbance from the 454 nm ab­
sorbance, effects of hemolysis are eliminated, and only bilirubin absorbance 
is measured. The assay is only suitable for neonatal serum (<2—3 weeks of 
age) because other pigments, notably carotene, appear as infants get older 
and cause interference at 454 nm.
HIGH-PRESSURE LIQUID CHROMATOQRAPHY
Considered the gold standard for bilirubin measurement, reverse- 
phase high-pressure liquid chromatography permits the measurement of all 
four fractions of bilirubin in a small sample. Unfortunately, high-pressure 
liquid chromatography is too elaborate, expensive, and time-consuming for 
the clinical laboratory.
REFLECTIVE SPECTROPHOTOMBTRY
Developed by the Eastman Kodak Company, this method is available 
as an automated procedure using Kodak Ektachem Analizers. The method 
involves the use of two thin film slides, one of which directly measures con­
jugated and unconjugated bilirubin; the second measures total bilirubin (in­
cluding S-bilirubin; Fig. 31).
BILIRUBIN OXIDASE
The enzyme bilirubin oxidase oxidizes both conjugated and unconju­
gated bilirubin to biliverdin. The biliverdin is then oxidized to unknown 
purple compounds. Total bilirubin can be measured accurately by using di-
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rect spectrophotometric techniques before and after treatment of serum with 
bilirubin oxidase. The method can also be used to measure conjugated 
bilirubin. By allowing the reaction involving bilirubin oxidase to occur at 
pH 4.5, only the conjugated forms of bilirubin are measured.
CONJUGATED AHD DIRECT-REACTIMG BILIRUBIN 
Although the two terms are used synonymously, direct-reacting 
bilirubin is not the same as conjugated bilirubin. Direct-reacting bilirubin re­
fers to the bilirubin that reacts directly with diazotized sulfanilic acid (i.e., 
without the addition of an accelerating agent), while conjugated bilirubin re­
fers to bilirubin that has been made water-soluble by binding with glucuronic 
acid in the liver. Although measurements of total bilirubin have lacked preci­
sion and accuracy, this problem is considered more serious in the measure­
ment of direct-reacting and conjugated bilirubin levels. The measured direct- 
reacting bilirubin depends on the concentration of conjugated bilirubin but 
also on other factors, including the amount of time it is allowed to react, the 
concentration of various reagents, and the concentration of unconjugated 
bilirubin. In contrast to total bilirubin, however, for which interlaboratory 
standardization is available through the College of American Pathologists, 
there is no standardization of direct-reacting j bilirubin measurements from 
laboratory to laboratory. An example of this is the study by Newman and col­
leagues, in which measurements of direct-reacting \ bilirubin using the Du­
Pont АСА or Coulter DAC05 analyzer produced direct-reacting bilirubin 
levels in a population of full-term newborns at one hospital that were twice as 
high as those measured in a similar population at another institution, where 
the Kodak Ektachem 700 method was used. As mentioned previously, the 
Ektachem method measures conjugated bilirubin, while the other methods 
measure direct-reacting bilirubin.
Unconjugated Bilirubin (a fraction)
Conjugated Bilirubin (p and у fractions)
Total Bilirubin (a, p, -y and 5 fractions)
Neonatal Bilirubin (a + P + у fractions)
Delta (5) Bilirubin (Total-Neonatal)
FIG. 31. Bilirubin determinations performed by the 
tance spectrophotometric method.
SITE OF BLOOD SAMPLING 
Leslie and colleagues measured total serum bilirubin in paired capil­
lary and venous samples in 118 newborns. Although there was a significant 
correlation between the values, they found that capillary samples were lower 
than the venous bilirubin values when venous levels exceeded 10 mg/dL (171 
pmol/L). Capillary samples were, on average, 0.9 mg/dL (15 pmol/L) lower 
in infants not receiving phototherapy and 0.6 mg/dL (10 pmol/L) lower in
Direct
measurement
J  Calculations
Kodak Ektachem reflec-
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those receiving phototherapy. Eidelman and colleagues also found significant 
differences, but in the opposite direction. Values were higher in capillary 
than venous samples. The reasons for these differences are obscure, but it is 
useful to recall that virtually all the data on bilirubin levels published in the 
literature were obtained from capillary samples. Some data have been derived 
from umbilical artery samples in very-low-birth-weight infants. Whether 
these are similar to capillary values is unknown, but for the purpose of mak­
ing clinical decisions, capillary blood samples for measuring serum bilirubin 
levels remain the gold standard; and whatever the differences between capil­
lary and venous samples may mean, there is no reason to measure the venous 
bilirubin level until there are data identifying the relation between venous 
bilirubin and the risk of kernicterus.
SAMPLING TECHNIQUE
Because of the well-known effects of light on bilirubin, laboratory 
manuals recommend that blood samples be protected from light until the se­
rum is analyzed. Using serum samples with bilirubin levels of 16.0, 11.8, and 
7.9 mg/dL (273, 202, and 135 pmol/L), was found that under the usual labo­
ratory conditions, there was no measurable effect of ambient light on serum 
bilirubin levels for at least 8 hours.
NONINVASIVE MEASUREMENTS OF BILIRUBIN
Two devices have proved useful as screening techniques for gauging 
the depth of jaundice in newborns. The Ingram Icterometer (Cascade Health 
Care Products, Salem, OR) is a piece of transparent plastic (Perspex) on 
which are painted five transverse stripes of graded yellow hue. The instru­
ment is pressed against the nose, the yellow color of the blanched skin is 
matched with the appropriated yellow stripe, and a jaundice score is as­
signed. The Minolta Air Shields Jaundice Meter is a more sophisticated and 
much more costly device. When pressure is applied to the photoprobe of 
this hand-held, rechargeable instrument, a strobe light is generated by a xe­
non tube and passes through a fiberoptic filament, penetrating the blanched 
skin and entering the subcutaneous tissue. The reflected light returns 
through a second fiberoptic bundle to the spectrophotometric module, where 
the intensity of the yellow color, corrected for hemoglobin, is measured and 
displayed as arbitrary units—the transcutaneous bilirubin (TcB) index.
The accuracy and utility of these instruments has been reviewed in 
depth by Schumacher. Measurements with the Minolta Air-Shields Jaundice 
Meter are highly reproducible and related in linear fashion to the total serum 
bilirubin concentration. Although there are some differences in slopes and 
intercepts in different populations, in full-term infants of the same racial 
group, the slopes of the regression lines are remarkably similar. Transcutane­
ous bilirubin measurements are affected by the infant's race, gestational age,
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and birth weight, which limits the use of the jaundice meter in heterogeneous 
populations. When used in selected groups, however, the jaundice meter has 
performed well as a screening device. Because of the bleaching effect of pho­
totherapy on cutaneous bilirubin, transcutaneous bilirubin measurements are 
less reliable in infants receiving phototherapy, although if an area of skin is 
covered with an opaque patch, the relation between the TcB index and the se­
rum bilirubin level improves.
Schumacher used receiver-operating characteristic (ROC) curves to 
compare the merits of these devices. He found that the Minolta Air-Shields 
Jaundice Meter and the Ingram Icterometer performed equally well. Re­
ceiver-operating characteristic curves of visual estimates of jaundice using 
the dermal zones of jaundice indicate that this method is also an effective 
screening tool. An important advantage of Minolta's jaundice meter is the vir­
tual absence of interobserver variability. On the other hand, the jaundice me­
ter sells for about $2500.00, while the Ingram Icterometer costs $20.00. Al­
though none of these methods can replace serum bilirubin measurements, 
they can be recommended as good screening techniques. At William Beau­
mont Hospital, use of the Minolta Air-Shields Jaundice Meter has led to a 
30% reduction in the number of serum bilirubin measurements obtained in 
the well-baby nursey.
Because the major concern regarding bilirubin toxicity is the amount of 
bilirubin in the tissue, rather than the blood, the use of transcutaneous 
bilirubinometry ultimately may prove to be a better predictor of the potential 
for brain damage than serum bilirubin concentrations.
TREATMENT
MECHANISMS AND PRINCIPLES
Hyperbilirubinemia can be treated by exchange transfusion, which 
removes bilirubin mechanically; phototherapy, which converts bilirubin to 
products that can bypass the liver's conjugating system and be excreted in 
the bile or in the urine without further metabolism; and pharmacologic 
agents that interfere with heme degradation, accelerate the normal metabolic 
pathways for bilirubin clearance, or inhibit the enterohepatic circulation of 
bilirubin. Phototherapy is the most common treatment in use for hyper­
bilirubinemia; exchange transfusions generally are reserved for photother­
apy failures. The bilirubin level at which intervention is necessary is still a 
contentious issue.
The background to treatment decisions for hyperbilirubinemia has been 
provided. The basic principles underlying the recommendations given in Ta­
bles 38 as follows:
Full-term infants without hemolytic disease are at a low risk of
bilirubin toxicity.
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Because of the tremendous changes in obstetric and neonatal care in the 
past 40 years, the existing data on the use of exchange transfusion in 
hemolytic disease may not be applicable to infants in the 1990s.
Evidence for treatment efficacy is lacking for many infants.
Treatment is not free of risk.
Table 38
Approaches to the prevention and treatment of jaundice associated
_______________ with breast-feeding_________________
Prevention
1. Encourage frequent nursing (i.e., at least eight times per day)
2. Do not supplement with water or dextrose water 
Treatment Options
Observe
Discontinue nursing, substitute formula
Alternate feedings of breast milk and formula
Discontinue nursing, administer phototherapy
Continue nursing, administer phototherapy___________________
There is a problem with the first principle listed. Except in the most 
obvious circumstances (i.e., major blood group incompatibility with a rapidly 
rising bilirubin level), it is difficult, and sometimes impossible, to rule out an 
underlying hemolytic process. Standard diagnostic tests for hemolysis, such 
as the reticulocyte count, hematocrit, or examination of the peripheral smear, 
are neither sensitive nor specific. Nevertheless, it is reasonable to assume that 
most full-term infants with significant elevations of their serum bilirubin do 
not have hemolytic disease. The possibility of G6PD deficiency must be con­
sidered in areas where this condition is prevalent and in certain ethnic groups. 
These infants cannot be distinguished from the normal population by meas­
urements of hematocrit or reticulocyte count.
Table 39
Approaches to the treatment of hyperbilirubinemia in full-term infants*
Bilirubin  Leve l in m g/dL (pm ol/L) Total S e re u m ’ |
Treatment
No Hemolysis* and 
Infant Well
•ii
Hemolysis Likert 
or Infant Sic* j
Phototherapy8 17-22 (290-325! 13-15 (220-25Sił
Interrupt or modify 17-22 (290-325) Usually not J
nursing, with or 
without photother­
apy
Exchange transfusion* 25-29 (425-500!
indicated f 
,i
{
f
17 -22 ( 290-3701;
* Refers to infants bom at 37 or more weeks of gestation.
t  Consider initiating therapy at these levels. Range is intended to allow discretion based on 
clinical conditions or other circumstances.
f Refers to absence of obvious hemolytic disease due to Rh or ABO incompatibility or glu- 
cose-6-phosphate dehydrogenase deficiency. It may be difficult to rule out ABO hemolytic
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disease as well as other, rarer, causes of hemolysis. Diagnosis of glucose-6-phosphate dehy­
drogenase deficiency requires an awareness of genetic background and should be considered 
in families from Greece, Turkey, Sardinia, China, and Nigeria and in Sephardic Jews from 
Kurdistan, Iraq, Iran, Syria, Turkey, and Buchara.
§ Assumes phototherapy will be used in adequate doses.
|| Phototherapy and modification of breast-feeding are interventions that can be used sepa­
rately or concurrently, depending on physician preference and parental choice.
# Assumes bilirubin continues to rise or remains at these levels in spite of intensive (i.e., dou­
ble) phototherapy. Double phototherapy refers to light placed above and below infant.
RISKS
Phototherapy is an effective method of lowering the serum bilirubin 
concentration, and its use reduces the risk of exchange transfusion, but it has 
not been shown to have any effect on neurologic or developmental outcome. 
Nevertheless, it appears that liberal use of phototherapy in jaundiced prema­
ture newborns has contributed to the virtual disappearance of kemicterus and 
a marked reduction in the need for exchange transfusion in this population.
Table 40
Approaches to the use of phototherapy and exchange transfusion 
in low-birth-weight infants*
Birth W e igh t (g)
Total B ilirub in  Leve l in m g/dL (pm ol/L)*
Phototherapy* E x c h a n g e  T ra n s fu s io n 8
< 15 00 5 -8  (85 -140 ) 1 3 -1 6  (220-275 )
1500-1999 8 -1 2  (140-200 ) 1 6 -1 8  (275-300 )
200 0 -2 499 1 1 -1 4  (190-240 ) 1 8 -2 0  (300-340 )
* Note that these guidelines reflect ranges used in neonatal intensive care units. They cannot 
take into account all possible situations. In some units, prophylactic phototherapy is used for all 
infants who weigh less than 1500 g. Higher intervention levels may be used for small-for- 
gestational-age infants, based on gestational age rather than birth weight 
t  Consider initiating therapy at these levels.
Range allows discretion based on clinical conditions or other circumstances.
Used at these levels and in therapeutic doses, phototherapy should, with few exceptions, elimi­
nate the need for exchange transfusion. There are no data, however, to indicate that photo ther­
apy used in this way will improve developmental outcome.
§ Levels for exchange tranfusion assume that bilirubin continues to rise or remains at these lev­
els in spite of intensive (i.e., double) phototherapy. (Double phototherapy refers to light placed 
above and below infant.)
Table 41
Use of phototherapy in full-term infants with abo hemolytic disease
Age (hours) Total serum 
bilirubin level (mg/dL)
<12 10
12-17 12
18-23 14
>24 15
Phototherapy in full-term infants with hemolytic disease secondary to ABO incompatibility.
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Phototherapy is a relatively benign intervention. On the other hand, in 
full-term newborns, it can lead to separation of the mother and infant, in­
crease parental concern, decrease the likelihood of successful breast-feeding, 
and adversely affect the mother-infant relationship.
Table 42
______ Conditions that may modify intervention for hyperbilirubinemia_____
Immediate Exchange Transfusion 
Clinical signs of bilirubin encephalopathy
Earlier or Prophylactic Phototherapy Due to Increased Procedural Risk of 
Morbidity and Mortality or Technical Difficulty in Performing Exchange 
Transfusion
Serious complication with previous exchange transfusions 
Serious cardiovascular, coagulation, or other disease
Potential graft-ve/\siw-host reaction (e.g., acquired or inherited immunedeficiencies, 
mother exposed to immunosuppressive agents)
Inability to use umbilical vessels (e.g., abdominal surgery, omphalocele)
Earlier Phototherapy or Exchange Transfusion Due to Possible Increased Risk 
o f Bilirubin Toxicity
Serum bilirubin rising more than 1 mg/dL (17 цМ/L) per hour 
Serum albumin <2.5 mg/dL 
Reduced bilirubin-binding capacity, if measured 
Persistent, severe, metabolic or respiratory acidosis*
Persistent, severe hypercapnia*
Persistent, severe hypoxemia*
Sepsis
Very sick low-birth-weight infants_________________
♦Attempt to correct blood gas abnormality.
At a time when pediatricians are trying to promote breast-feeding in 
the face of considerable odds (e.g., early discharge from hospital, the rapid 
return of mothers to the work force, commercial marketing of formulas), at­
tention should be given to an intervention that has a negative impact on the 
nursing mother. Given the low risk for adverse outcome in the nonhemolyz- 
ing full-term infant and the potentially harmful effects of bilirubin-lowering 
interventions (e.g., phototherapy, interrupting breastfeeding) in hundreds of 
thousands of infants throughout the world, pediatricians must be sure that the 
potential benefits of interventions outweigh the risks.
The risk of exchange transfusion includes both risks from the trans­
fused blood and from the procedure. Blood bank screening procedures have 
reduced the risk of acquired immunodeficiency syndrome and hepatitis sig­
nificantly, but this risk is never zero. In experienced hands, the risk of the 
procedure is about 2 to 3 deaths per 1000 procedures overall, and this risk is 
generally restricted to sick, low-birth-weight infants. Experience with ex­
change transfusion is decreasing, and with new interventions in immune 
hemolytic disease, it is likely to decrease even further. It is common for a
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resident to complete a pediatric training program without ever having per­
formed an exchange transfusion. Under the circumstances, the mortality and 
morbility for this procedure might increase in the years ahead.
RECOMMENDATIONS
JAUNDICE ASSOCIATED WITH BREAST-FEEDING
Because of the association between breast-feeding and elevated 
bilirubin levels in the first week of life, attempts have been made to mitigate 
this effect. Observational studies suggest that increasing the frequency of 
breast-fęeding during the first few days after birth decreases maximal serum 
bilirubin values. In a controlled trial, Vain and colleagues randomly assigned 
mothers to one of two feeding schedules, frequent or demand. The mothers in 
the frequent group nursed their infants on average 9.1 ± 1.4 times per day and 
in the demand group, 6.8 ± 1.0 times per day. Serum bilirubin levels, meas­
ured at an average age of 55 hours, were minimally lower in the frequent 
group (0.6 mg/dL, or 10 pmol/L); this did not achieve statistical significance. 
Bilirubin levels in these infants were measured between 48 and 72 hours, and 
it is likely that maximal bilirubin levels had not yet been achieved. Neverthe­
less, these data suggest that increasing the frequency of breast-feeding is 
unlikely to have a significant effect on serum bilirubin levels in the first three 
days of life.
The other intervention commonly used is to provide supplemental 
feedings of water or dextrose water to breast-fed infants. This practice is 
widespread, potentially harmful, and, when studied, has consistently pro­
duced an increase in maximal serum bilirubin levels in the supplemented in­
fants. Kuhr and Paneth showed that dextrose water intake in the first 3 days 
of life was significantly and inversely related to breast-milk intake on the 
fourth day, and those breast-fed infants with a low breast-milk intake on the 
fourth day tended to have higher bilirubin levels. Providing glucose water 
supplements to breast-fed infants not only had no effect on serum bilirubin 
levels but also significantly reduced the number of infants being nursed ex­
clusively at 3 months of age. If supplementation is elected as one intervention 
for jaundice associated with breast-feeding, formula should be chosen. 
Corchia and colleagues studied breast-fed infants who were assigned to be 
supplemented with formula or dextrose water. The formula-supplemented in­
fants were significantly less likely to reach a serum bilirubin level of 12 
mg/dL (205 pmol/L).
Osborn and Bolus developed a protocol for the management of jaun­
diced breast-fed infants. Mothers of infants whose bilirubin levels reached 14 
mg/dL (239 pmol/L) were asked to discontinue breast-feeding, and the infant 
was fed formula every 2 hours. In 87 infants, nursing was interrupted for 24 
to 48 hours, and the bilirubin declined in 81 (93%).
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Amato and colleagues compared the effect of interrupting breast­
feeding with phototherapy when serum bilirubin levels reached 15 mg/dL 
(257 pmol/L). There was no difference between the groups or the amount of 
time needed to reduce the bilirubin to less than 12 mg/dL (205 pmol/L). They 
concluded that interrupting breast-feeding was a reasonable alternative to 
phototherapy.
In a controlled clinical trial, Martinez and colleagues compared the 
effect of four different interventions on hyperbilirubinemia in 125 full-term 
breast-fed infants. When the serum bilirubin level reached 17 mg/dL (291 
pmol/L), the infants were assigned at random to one of four interventions:
1. Continue breast-feeding and observe.
2. Discontinue breast-feeding and substitute formula.
3. Discontinue breast-feeding, substitute formula, and administer photo­
therapy.
4. Continue breast-feeding and administer phototherapy.
The serum bilirubin concentration reached 20 mg/dL (342 pmol/L) in 
24% of infants in group 1, 19% in group 2, 3% in group 3, and 14% in 
group 4 (p = 0.0001 for groups 3 and 4 versus group 1). Phototherapy pro­
duced a significantly greater and more rapid decline in bilirubin than no 
phototherapy.
Although serum bilirubin levels reached 20 mg/dL (342 pmol/L) in 
14% of the group in which phototherapy was administered and breast-feeding 
was continued, compared with 3% of the group in which phototherapy was 
administered and breast-feeding was discontinued, the decline in serum 
bilirubin levels over 48 hours was about the same in both groups. These data 
suggest that it is feasible to allow mothers to continue breast-feeding while 
phototherapy is being administered. When the circumstances permit, parents 
should be given this information and the option of making an informed deci­
sion regarding which intervention they prefer. Many mothers do not want to 
interrupt nursing if at all possible, and the option of doing nothing or provid­
ing phototherapy while nursing is continued should be offered. The availabil­
ity of fiberoptic phototherapy systems also makes this alternative more ap­
pealing to many parents because it obviates the necessity for eye patching 
and permits more maternal-infant contact. If necessary, it also allows for 
double phototherapy, which is significantly more effective than single photo­
therapy.
FULL-TERM NEWBORNS
Most infants who are treated for neonatal jaundice have no identifiable 
pathology and no evidence of hemolytic disease; about 90% of these infants 
are fully or partially breast-fed. Given the low risk of harm, it is reasonable to 
encourage individualization of treatment, taking the preferences and biases of 
the parent and pediatrician into account. This is a more accurate reflection of
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the uncertainty about when to treat jaundiced newborns. The data on which 
these recommendations are based are scant, however, and pediatricians are 
forced to compromise between a desire to avoid unnecessary and potentially 
harmful treatment and a reluctance to accept the possibility of some risk, 
even if this is small.
Recommendations for treatment of full-term infants are given in Table 
39. When phototherapy is used, it should be used in a therapeutic, not ho­
meopathic, dose. There is a strong dose-response relation for phototherapy, 
and a more rapid decline in serum bilirubin can be achieved by increasing the 
dose of light delivered. This is done by placing a standard phototherapy light 
closer to the infant. I do this by placing all full-term infants who receive pho­
totherapy in bassinets, not incubators, and placing the light as close as possi­
ble to the infant. Occasionally, this produces an increase in the infant's tem­
perature, in which case the light is elevated slightly. Exposing a greater sur­
face area to light also lowers bilirubin levels more rapidly, and this is easily 
achieved by using double phototherapy (i.e., placing a infant on a fiberoptic 
blanket with a conventional phototherapy lamp above).
The recommendations for exchange transfusion assume that photother­
apy has failed to keep the bilirubin below the designated levels. In some 
breast-fed infants, the first physician contact after discharge from the hospital 
occurs when the infant presents with significant jaundice. In these infants, a 
trial of phototherapy and interruption of nursing should be attempted even if 
the bilirubin level is 25 mg/dL (428 pmol/L) or higher. At these levels, I usu­
ally interrupt nursing as well, although it is by no means certain that this is 
necessary. Should these measures fail, exchange transfusion is an alternative.
Suggested guidelines for the management of hyperbilirubinemia in 
low-birth-weight infants are provided in Table 40. As discussed previously, 
there has been a remarkable decrease in the incidence of kernicterus found at 
autopsy in infants dying in NICUs. Some of this decrease may be due to the 
liberal use of phototherapy. On the scale of interventions carried out in NI­
CUs, phototherapy is one of the most benign. There is also no question that 
phototherapy dramatically reduces the necessity for exchange transfusion.
Phototherapy is directed primarily at preventing exchange transfusion 
and possible developmental handicap. The suggested association between 
relatively low serum bilirubin levels and cerebral palsy has been questioned, 
however, and even if it were true, there is no evidence that the use of photo­
therapy to treat mild jaundice has prevented any form of handicap. Most neo­
natal units apply phototherapy on a sliding scale—the lower the birth weight, 
the lower the bilirubin level at which phototherapy is introduced. In spite of 
its widespread acceptance, no data are available to support this approach. A 
reasonable justification is that infants weighing less than 1500 g are more 
likely to be sick, acidotic, hypoxic, hypercapnic, or septic, and it seems par­
ticularly pedantic to debate whether or not to introduce phototherapy at a
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bilirubin level of 5 or 6 mg/dL (85 or 103 pmol/L) in an infant weighing 
1000 g. The use of exchange transfusion, on the other hand, merits more 
careful deliberation.
In the NICHHD phototherapy study, maximal bilirubin levels were es­
tablished for each weight group, and exchange transfusions were performed 
in both phototherapy-treated and control infants when these levels were 
reached. These criteria have been widely applied, but their validity has been 
questioned.
With the introduction of more effective means of administering photo­
therapy to low-birth-weight infants, much of the discussion regarding ex­
change transfusion in this population is moot. In our experience, in the very- 
low-birth-weight population, exchange transfusions are a rare event and are 
restricted to those infants who are profoundly bruised or have severe hemo­
lytic disease. Even in these infants, the introduction of more effective photo­
therapy or the use of intravenous y-globulin in hemolytic disease should re­
duce the need for exchange transfusion. Although recommended in certain 
high-risk infants with bilirubin levels as low as 10 to 13 mg/dL (171-222 
pmol/L), exchange transfusion at these bilirubin levels is inefficient. For ex­
ample, an exchange transfusion at 10 mg/dL (171 pmol/L) would probably 
lower the serum bilirubin level to about 5 mg/dL (85 pmol/L). With the usual 
rebound, however, the bilirubin would increase to about 7 mg/dL (120 
pmol/L) within one-half hour of the exchange. Phototherapy is more effective 
than exchange transfusion in achieving prolonged reduction of bilirubin lev­
els in infants with nonhemolytic jaundice.
DIRECT-REACTING BILIRUBIN
The problem of how to deal with the occasional infant who has a high 
total bilirubin level as well as an elevation in direct-reacting bilirubin has 
never been resolved satisfactorily. Because of the evidence that indirect-, and 
not direct-, reacting bilirubin is toxic to the central nervous system, most 
texts in the 1960s and early 1970s provided guidelines for exchange transfu­
sion based on the level of indirect serum bilirubin. More recently, most 
guidelines have either ignored the subject or have referred to total bilirubin 
levels as criteria for treatment. Kernicterus has been described in a full-term 
infant with the bronze-baby syndrome. The maximal total serum bilirubin in 
this infant was 18 mg/dL (308 pmol/L), and the direct-reacting bilirubin was
4.1 mg/dL (17 pmol/L). I have had occasion to review the medical record of 
one full-term infant who developed clinical kernicterus when the total 
bilirubin level was 27.6 mg/dL (472 pmol/L), but the direct bilirubin level 
was 8.7 mg/dL (149 pmol/L). Others have seen similar cases. These are an­
ecdotal observations, but they raise the question of how elevated direct 
bilirubin levels should be handled in assessing the risk of kernicterus. It is 
possible that direct-reacting bilirubin causes competitive displacement of in-
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direct bilirubin from its binding site to albumin. Alternatively, the conditions 
that lead to elevation of direct-reacting bilirubin may produce changes in the 
ability of albumin to bind bilirubin. Gartner and Lee recommend that direct 
bilirubin concentrations should not be subtracted from the total bilirubin level 
unless they amount to more than one-half of the total serum bilirubin concen­
tration. Although this is purely empiric advice, it is reasonable.
HEMOLYTIC DISEASE
In the studies of erythroblastosis fetalis done in the early 1950s, the in­
cidence of kernicterus—30% to 50% in those with the highest bilirubin lev­
els—was much higher than that in markedly jaundiced infants without hemo­
lytic disease.
Not all studies had such negative outcomes, however. Johnston and 
colleagues conducted a 5-year follow-up on 129 infants whose indirect serum 
bilirubin levels were higher than 20 mg/dL (342 pmol/L) in the neonatal pe­
riod. Ninety-two (71%) of these infants had Rh hemolytic disease and 26 
(20%) ABO hemolytic disease. Forty-two infants had indirect serum bilirubin 
levels higher than 25 mg/dL (428 pmol/L). Only one infant developed defi­
nite kernicterus in the neonatal period, although there were 11 cases in which 
kernicterus was suspected because of lethargy, poor feeding, weak cry, and 
mild head retraction. Nine of these children were normal on follow-up ex­
amination at 5 years of age, while two had athetoid neurologic sequelae. Only 
seven children (5.4%) showed any sequelae at 5 years of age. All seven had 
sensorineural hearing impairment, but six of the seven had received strepto­
mycin. Thus, the developmental outcome for infants with erythroblastosis 
may not be nearly as bleak as depicted by the earlier studies.
Why do infants with hemolytic disease appear to be at greater risk for 
bilirubin encephalopathy than infants with similar serum bilirubin levels who 
do not have hemolysis? As far as Rh disease is concerned, the infants re­
ported in the trials of the late 1940s and early 1950s were often asphyxiated 
and severely ill, and many were delivered prematurely to prevent stillbirth, a 
practice later shown to increase the risk of kernicterus. The results of subse­
quent studies in the 1960s were far more encouraging, and given contempo­
rary obstetric and neonatal care, it is highly unlikely that the outcome for 
such infants today would be nearly as gloomy. It has been suggested that one 
mechanism that might account for the increased risk of neurotoxicity in in­
fants with hemolytic disease is the presence of products of erythrocyte de­
struction, such as hematin, which may compete with bilirubin for binding 
sites on albumin. Studies in infants with erythroblastosis show no effect of 
the hemolysis or the level of bilirubin on the newborn's ability to bind hema­
tin. Catterton and colleagues could find no effect of hemolytic disease on the 
albumin-binding capacity, but others have demonstrated a significant adverse 
effect of hematin on bilirubin binding. This only occurred, however, at high
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hematin concentrations (i.e., molar ratio of hematin to bilirubin of 0.5). The 
apparent unbound bilirubin concentration, in control sera and sera from 
Coombs-positive ABO-incompatible infants was identical, suggesting that 
either there was no significant increase of hematin in ABO hemolytic disease 
or the hematin present is insufficient to alter bilirubin binding. Thus, apart 
from the clinical condition of the infant, there is no ready explanation for the 
apparent increase in risk of bilirubin encephalopathy in infants with isoim­
mune hemolytic disease. There is also no obvious explanation for the in­
creased risk of bilirubin encephalopathy in infants with G6PD deficiency.
MANAGEMEMT OF ABO INCOMPATIBILITY
The situation regarding ABO hemolytic disease is less clear than for 
Rh disease, although some studies suggest that the indications for exchange 
transfusion in ABO hemolytic disease could be less stringent. Follow-up 
data for infants with ABO incompatibility are not nearly as extensive as 
those for Rh disease. In one study by Ose and colleagues, developmental re­
tardation or cerebral palsy occurred in 15% of 89 Japanese infants with ap­
parent hemolytic disease whose serum bilirubin levels were between 20 and 
24.9 mg/dL (342-426 pmol/L). Seventy-nine percent of these infants were 
ABO-incompatible and 21% Rh-incompatible. Seven percent weighed less 
than 2500 g.
Osborn and colleagues conducted a prospective evaluation of 476 new­
borns admitted to their well-baby nursery. Forty-seven (10%) were ABO- 
incompatible and had positive indirect Coombs tests measured on the cord 
blood. Three infants were eliminated from the study, which left 44 remaining 
infants. The investigators elected to use phototherapy at the bilirubin levels 
shown in Table 41. Using these criteria, two infants received phototherapy 
for bilirubin levels higher than 10 mg/dL (257 pmol/L) in the first 12 hours 
and two for levels higher than 15 mg/dL (257 prnol/L) after 24 hours. None 
of the infants required an exchange transfusion. Of the 40 untreated infants, 6 
had bilirubin levels that exceeded 12 mg/dL (205 pmol/L). This study con­
firms the clinical observation that although some infants with ABO hemolytic 
disease have rapidly rising serum bilirubin levels in the first 12 hours of life, 
many do not develop significant hyperbilirubinemia subsequently. It should 
also be noted that about 90% of infants who have ABO incompatibility and 
positive Coombs tests do not have hemolytic disease. Standard hematologic 
indices do not predict the degree of hemolysis in ABO-incompatible infants. 
Brouwers and colleagues found that an assay of antibody-dependent cell- 
mediated cytotoxicity (ADCC) in maternal serum was the most sensitive as­
say to predict ABO hemolytic disease. Combining the ADCC assay with an 
assay of the antigen density of A or В antigens on the infant's erythrocytes 
provided the most specificity.
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SEVERE HEMOLYTIC DISEASE
Exchange transfusion remains the only effective therapy in infants 
who have failed phototherapy or other interventions in the management of 
hemolytic disease. Exchange transfusions are indicated in two situations: to 
correct anemia rapidly in infants severely affected with erythroblastosis and 
to treat potential or actual hyperbilirubinemia. In hemolytic anemia, both of 
these conditions may exist.
In the past, various criteria for early or immediate exchange transfu­
sion were proposed for infants with hemolytic disease based on cord blood 
levels of hemoglobin and bilirubin, but these measurements do not predict the 
severity of hyperbilirubinemia with sufficient accuracy to warrant their use as 
therapeutic guidelines. Early studies of the natural history of Rh and ABO 
hemolytic disease allowed us to predict whether or not the serum bilirubin 
concentration would reach 20 mg/dL (342 pmol/L), and rules of thumb were 
developed for exchange transfusion based on serum bilirubin levels at differ­
ent ages. The use of intensive phototherapy and intravenous y-globulin has 
rendered such guidelines irrelevant. If, despite intensive phototherapy, the se­
rum bilirubin level continues to rise rapidly, an exchange transfusion is indi­
cated. The rationale for early intervention is the removal of sensitized eryth­
rocytes from the blood, which aborts the hemolytic process. An early ex­
change transfusion also corrects anemia and removes some bilirubin before 
large amounts are distributed into the extravascular space.
REPEAT EXCHANGE TRANSFUSIONS
In general, the criteria for repeat exchange transfusions should be simi­
lar to those used for the initial exchange. The effect of exchange transfusion 
on unbound bilirubin levels and reserve albumin binding is variable. Some 
authors observed a salutary effect, but others found no effect during or im­
mediately after single or even multiple exchange transfusions.
HYDROPS FETALIS
Obstetric management allows us to anticipate the delivery of infants 
with hydrops fetalis. They suffer significant hypoxia in utero, and women 
who are to deliver such infants should be managed exclusively in perinatal 
centers capable of the full range of obstetric and neonatal intensive care. 
Hydropic infants and those who are obviously pale and asphyxiated demand 
immediate treatment. Otherwise, therapy for jaundice is based on serial 
bilirubin determinations.
The pathogenesis of hydrops fetalis, with its attendant edema and se­
rous effusions, is not clear. Hydrops commonly occurs when the fetal he­
moglobin drops below 6 to 7 g/dL, and hydrops can be reversed with in­
travascular intrauterine transfusions, which raise fetal hemoglobin concen­
trations. In Rh isoimmunization, fetal edema may result from the extensive
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erythropoiesis in the fetal liver that disrupts the portal circulation and im­
pairs albumin synthesis and also from the cardiovascular adaptations that 
are seen in anemic fetuses. Moya and colleagues found that fetuses with se­
vere hydrops had high atrial natriuretic factor concentrations and were also 
significantly more anemic than fetuses with either mild or no hydrops. They 
also found an inverse relation between the hemoglobin and atrial natriuretic 
factor concentrations. This may be the result of atrial natriuretic factor re­
lease induced by hypoxia. Hypoxia produces myocardial dysfunction, which 
increases umbilical venous pressure and leads to a release of atrial natri­
uretic factor. After intravascular transfusion in utero, there was a significant 
decrease in plasma atrial natriuretic factor concentration.
Most authors suggest that infants with hydrops due to hemolysis die 
from congestive heart failure secondary to the severe anemia and that the 
edema is secondary to the heart failure. Studies of premature infants with 
moderate to severe erythroblastosis, however, suggest that chronic congestive 
heart failure is rare at birth in hydropic infants. Central venous pressures, 
measured in the thoracic inferior vena cava, reflect not only blood volume 
but also venous tone, pulmonary vascular resistance, and right ventricular 
dynamics. Elevated pressures probably result from acute intrapartum as­
phyxia and may decline to normal or subnormal levels after correction of aci­
dosis, hypoxia, hypercarbia, and anemia. Severely affected infants die from 
progressive cardiorespiratory failure, in which asphyxia and hyaline mem­
brane disease play a major role. Acute intrapartum asphyxia, superimposed 
on chronic asphyxia in a premature and anemic fetus, leads to delivery of an 
asphyxiated infant with hypoxemia, hypercarbia, and mixed respiratory and 
metabolic acidosis. A high incidence of hyaline membrane disease can be ex­
pected in such infants.
A linear relation has been found between the umbilical cord hematocrit 
and the erythrocyte volume in infants with erythroblastosis, and in nonhemo­
lytic infants, between the hematocrit and the blood volume. No correlation 
was observed, however, between the severity of hydrops fetalis and the in­
fants' blood volumes. In the study by Phibbs and colleagues, the blood vol­
umes of almost all infants were within the normal range of 70 to 90 mL/kg. 
Only one infant, who was severely hydropic, had a significantly elevated 
blood volume (113 mL/kg), whereas in another infant, the blood volume was 
low (48 mL/kg). Not all hydropic infants are severely anemic, but most are 
hypoalbuminemic. These data suggest that low plasma colloid osmotic pres­
sure, as a result of hypoalbuminemia, is another important mechanism in the 
pathogenesis of hydrops.
The management of these infants demands a comprehensive approach 
that includes intensive monitoring and vigorous treatment of asphyxia, acido­
sis, hypoglycemia, and hypothermia. Assisted ventilation is the rule because 
of the frequent presence of hyaline membrane disease, pulmonary edema, and
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chest wall edema. Significant ascites hampers ventilatory efforts and can be 
relieved by paracentesis. Thrombocytopenia and coagulation disorders are 
common. Hydropic infants and those who are severely anemic (i.e., hema­
tocrit < 35%) and asphyxiated demand immediate treatment. An exchange 
transfusion of about 50 mL/kg of packed cells soon after birth raises the he­
matocrit to about 40%. Phlebotomy should not be routinely performed on 
these infants because they are usually normovolemic and may be hypo­
volemic. Furthermore, no manipulations of blood volume should be per­
formed without appropriate measurements of central venous and arterial 
blood pressures. For accurate monitoring of the central venous pressure, 
however, the umbilical venous catheter must enter the inferior vena cava by 
way of the ductus venosus. If the catheter is in a portal vein or the umbilical 
vein, the pressures so measured are meaningless and preclude interpretation 
of the infant's circulatory status. The practice of measuring central venous 
pressure by means of an umbilical vein catheter may lead to serious therapeu­
tic error unless the position of the catheter is confirmed radio-graphically or 
by pressure tracing. In addition, before making therapeutic decisions based 
on measurements of central venous pressure, the physician must also correct 
acidosis, hypercarbia, hypoxia, and anemia. Serum glucose levels should be 
monitored carefully because hypoglycemia is common.
EXCHANGE TRANSFUSION
TYPES OF BLOOD USED
Citrate phosphate dextrose (CPD) is the anticoagulant of choice for 
banked blood in the United States. Heparinized blood, once used exclu­
sively in some centers, has been displaced by the use of component therapy 
and the need to screen all donors for human immunodeficiency virus, hepa­
titis, and so forth. Most blood banks reconstitute blood by adding plasma or 
albumin-saline solutions to stored packed erythrocytes or to previously fro­
zen erythrocytes. Some blood transfusion centers have recommended the 
use of preparations in which packed erythrocytes are suspended in other so­
lutions. There are potential hazards to the use of these solutions. If addi­
tional albumin is not added, a marked depletion in albumin and other 
plasma proteins occurs after exchange transfusion.
METABOLIC COMPLICATIONS
The citrate in CPD blood binds ionic calcium and magnesium and 
produces a significant depression in these divalent cations. The temporary 
hypomagnesemia has not been associated with clinically recognizable prob­
lems, but the depression of calcium ion may produce deleterious hemody­
namic and cardiac effects that are not caused by toxicity of the citrate.
Some physicians administer calcium gluconate during exchange trans­
fusions to counteract the citrate binding, but this does not appear to have any
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significant effect on the serum ionized calcium, although there is a temporary 
increase directly after the calcium is given. In some centers, supplemental 
calcium is never administered, and this has been without apparent ill effects. 
The addition of 0.1 g calcium chloride to 1 U of heparinized CPD blood pre­
vented a fall in ionized calcium in full-term infants, but not in preterm in­
fants. It is probably unnecessary to administer additional calcium to most in­
fants. Clinical tetany is rarely seen during exchange transfusion, which is re­
markable considering the low levels of ionized calcium that occur. Jitteriness, 
crying, and irritability occur but cannot be correlated with levels of ionized 
calcium. Parathormone levels rise initially but then decline during the ex­
change. Citrate phosphate dextrose blood contains 300 to 350 mg/dL of glu­
cose. This stimulates insulin secretion in the infant and may lead to rebound 
hypoglycemia after the exchange. Blood sugar levels should be monitored in 
the first few hours after the procedure.
POTASSIUM IN STORED BLOOD
Potassium levels in stored blood increase rapidly. Levels as high as
9.1 mEq/L occur after 1 day, and levels may exceed 20 mEq/L after 2 days 
of storage. Previously, it was recommended that exchange transfusions be 
performed with blood no more than 4 days old. Such blood may have dra­
matically elevated serum potassium levels. The blood bank can eliminate 
this problem by washing packed erythrocytes before reconstitution with 
fresh-frozen plasma. This produced a mean plasma potassium concentration 
of 4.4 mEq/L or less, even when 5-day-old erythrocytes were used. Use of 
an IBM blood cell processor, however, produced serum potassium levels c f 
about 2 mEq/L. Such levels could result in hypokalemia and cardiac dys­
rhythmia.
BILIRUBIN REBOUND
During the exchange transfusion, bilirubin from the extravascular 
space is drawn into the plasma. Partial equilibration between extravascular 
and plasma bilirubin occurs almost instantaneously, so that by the end of an 
exchange, in which only 13% of the circulating erythrocytes remain, the se­
rum bilirubin is still 45% of the preexchange level. Immediately after the 
exchange, further equilibration takes place, which is complete within 30 
minutes and which produces the early rebound of plasma bilirubin to 60% 
of the preexchange level. Despite exchange transfusion, rapid heme break­
down may continue, producing a further increase in serum bilirubin that 
may necessitate repeat exchange transfusion. This hemolysis may result 
from catabolism of sensitized erythrocytes that exist as pools previously se­
questered in the bone marrow or spleen and therefore not removed by ex­
change transfusion, from production of early-labeled bilirubin, or from the 
hemolysis of transfused erythrocytes.
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EFFICIENCY
The mass of bilirubin removed is related to the plasma bilirubin 
level610 and the size of the exchange transfusion, with the most critical fac­
tor being the amount of plasma removed. A volume of twice the infants' cir­
culating blood volume has generally been recommended (i.e., double-volume 
exchange transfusion). In a randomized trial, however, Amato and colleagues 
compared single-and double-volume exchange transfusions in full-term in­
fants with ABO hemolytic disease and found no difference in the efficiency 
of the exchange. Because of the rapid equilibration between extravascular 
and plasma bilirubin, the rate of the exchange has little effect on the amount 
of bilirubin removed. The extravascular bilirubin concentration decreases at 
the same rate as the plasma bilirubin concentration and cannot be influenced 
by the rate of the exchange. For practical purposes, the size of the blood ali­
quots exchanged also has no significant effect on the efficiency. Therefore, 
exchanging increments of 5 or 10 mL is as efficient as using 20-mL aliquots. 
Withdrawal of 20 mL of blood from a 3000-g infant represents an acute de­
pletion of total blood volume and may cause a decrease in cardiac return, 
cardiac output, and blood pressure, particularly if done rapidly. As the car­
diovascular system is adapting to these changes, an equal volume of blood is 
rapidly reinfused, which reverses the adaptation. This could be repeated 25 to 
30 times during a double-volume exchange. The use of smaller aliquots 
places less stress on the infants's cardiovascular adaptive mechanisms.
ALBUMIN ADMINISTRATION
The administration of albumin before or during an exchange transfu­
sion has produced conflicting results with regard to its effect on the effi­
ciency of the exchange. Some authors reported that 1 g/kg of 25% salt-poor 
albumin, given 1 hour before the exchange, increased the amount of bilirubin 
removed by the exchange, although others did not find this to be the case.
TECHNIQUE
This is described in Allen and Diamond's classic monograph, and more 
recent detailed descriptions also are available. The most commonly used 
technique is the push-pull method, in which a single syringe and special four­
way stopcock are used. Various other techniques have been described, which 
include the use of syringe pumps that mechanically infuse and withdraw 
blood. Simultaneous withdrawal from the umbilical artery and gravity- 
assisted infusion by way of the umbilical vein has also been employed. This 
method adds the hazard of an additional catheter but may be of considerable 
value when dealing with sick infants because it eliminates the swings in 
blood volume and pressure that occur with the push-pull method. A technique 
of exchange transfusion in which peripheral veins are used also has been de­
scribed.
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RATE OF EXCHANGE
Rapid exchange transfusion may aggravate cardiovascular changes, 
may affect cerebral blood flow and intracranial pressure, and may not allow 
time for the liver to metabolize the infused acid and citrate. With adequate 
monitoring and good temperature control, there does not seem to be any need 
to hurry the procedure. Generally, an exchange of twice the blood volume 
should take about 1 to 1.5 hours in any infant. This means a slower rate for 
the smaller and sicker infants.
COMPLICATIONS
Morbidity and Mortality. In the NICHHD collaborative phototherapy 
study, 190 patients received a total of 331 exchange transfusions. One infant 
died within 6 hours of the procedure. He was an 850-g infant with severe 
respiratory distress syndrome and thrombocytopenia. The overall mortality 
for the procedure was 5.3 per 1000 patients and 3 per 1000 procedures. Of 
172 infants who were in good, or critical but stable, clinical condition, none 
died after exchange transfusion. Significant morbidity (e.g., apnea, brady­
cardia, cyanosis, vasospasm with thrombosis) was associated with 5.2% of 
the exchange transfusions. Of infants in whom serious events related to the 
exchange transfusion occurred, all but two were critically ill before the pro­
cedure.
The results of 1472 exchange transfusions with fresh heparinized blood 
in 1069 newborns were reported by Hovi and Siimes. Fourteen infants had a 
major complication during the procedure, including respiratory arrest, pul­
monary edema, cardiac arrest, and bradycardia. The incidence of major com­
plications was 13 in 1000 patients and 9.5 in 1000 procedures. In four infants, 
death was considered possibly related to the exchange transfusion (3.7 in 
1000 patients or 2.7 in 1000 procedures). Remarkably, three of these infants 
died after developing necrotizing enterocolitis between the ages of 2 days and 
3 weeks. One infant died of Pseudotnows septicemia at 5 days of age, after 
five exchange transfusions. Note that in the NICHHD collaborative photo­
therapy study, procedure-related mortality was defined as death occurring 
within 6 hours of the procedure, whereas Hovi and Siimes defined mortality 
as deaths possibly related to exchange transfusions.
Ellis and colleagues surveyed their experience with exchange transfu­
sion over a 27-year period. Before 1965, 19 infants died, but death was con­
sidered inevitable. Seventeen infants had unexplained deaths. Since 1965, 
however, no unexplained death occurred in 1004 infants who underwent ex­
change transfusion.
Necrotizing Enterocolitis. Necrotizing enterocolitis with intestinal 
perforation has been reported following exchange transfusion. This has oc­
curred in both full-term and premature infants and after both single and 
multiple exchanges. The cause remains obscure, and it has been suggested
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that malpositioning of the umbilical venous catheter in the portal system, 
with its close relation to the mesenteric veins, may produce retrograde ob­
structive hemodynamic changes with hemorrhage and thrombosis at the mi- 
crocirculatory level. Studies in piglets demonstrated a significant increase in 
portal venous pressure during the injection phase of the exchange.
In some infants, exchange transfusion may be the primary etiologie 
event, whereas in others, it represents an additional insult to a bowel com­
promised by infection or hypoxia. Black and colleagues present evidence to 
support this possibility. In their study, infants with polycythemia and hyper­
viscosity were randomly assigned to receive partial plasma exchange transfu­
sions or symptomatic care. Eight of 43 hyperviscous infants who received 
partial exchange transfusions developed necrotizing enterocolitis, whereas 
none of the symptomatically treated infants did. Twenty-two (51%) of the in­
fants who received partial exchange transfusions had evidence of some gas­
trointestinal problem, such as abdominal distention, diarrhea, blood in the 
stool, emesis, and signs of systemic illness. Both polycythemia and exchange 
transfusions have been associated with gastrointestinal injury, but the results 
of this study suggest that when both conditions occur in the same patient, the 
risk of serious gastrointestinal problems increases significantly.
Blood-Borne Infection. Exchange transfusion carries the usual risk of 
any blood product. With the screening techniques employed by blood 
banks, however, the risk of acquired immunodeficiency syndrome, hepatitis, 
and cytomegalovirus infection is low.
Graft-versus-Host Disease. Graft-versus-host disease has occurred in 
infants who received intrauterine transfusions and subsequently received 
exchange transfusions after delivery. These infants apparently did not reject 
the donor lymphocytes because the previous introduction of viable lympho­
cytes during intrauterine life had rendered them relatively immunologically 
tolerant. Graft-ver«rs-host disease has also occurred after exchange transfu­
sion in apparently normal, but presumably immunologically compromised, 
newborns. Irradiation of blood before exchange transfusion is advisable for 
immunocom-promised infants and for those who have received intrauterine 
transfusions.
A clinical syndrome of transient maculopapular rash with associated 
eosinophilia, thrombocytopenia, and mild lymphopenia was described in 21 
of 35 neonates who received both intrauterine transfusions and postnatal ex­
change transfusions and in 6 of 17 neonates who received multiple ex­
change transfusions for erythroblastosis fetalis. These infants did not pro­
gress to the typical syndrome of graft-ve/sus-host disease and were well at 
follow-up. The authors suggest that extensive immunologic investigation for 
graft-versus-host disease is not necessary unless the rash fails to improve 
within a week or there are other indications of immunodeficiency.
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Other Complications. Malfunctioning blood warmers may overheat 
blood and produce acute he-molysis, so it is prudent to verify the tempera­
ture of the water (37°C) directly with a mercury thermometer.
The unwitting use of hemoglobin SC blood produced massive in­
travascular sickling and death in one infant, suggesting the advisability of 
screening a donor for sickle-cell trait or disease.
Exchange transfusion modifies serum drug concentrations in infants 
who are being treated with various pharmacologic agents. Unless repeated 
exchange transfusions are performed, the drug loss of antibiotics after ex­
change transfusions is clinically insignificant, and the effect on digoxin lev­
els also is negligible. A double-volume exchange, however, is likely to de­
crease serum theophylline levels by 32%.
Careful attention to detail helps to avoid most of the described hazards 
of exchange transfusions, although complications related to the placement of 
a catheter and to the procedure can never be eliminated completely. This is 
particularly so because this procedure is performed on the smallest and sick­
est infants and may be responsible for problems not previously considered. 
For example, the high sodium content of CPD blood (165-170 pmol/L), al­
though of little consequence for the vigorous full-term infant, may not be be­
nign in infants who weigh less than 1500 g. In vigorous infants, exchange 
transfusion is usually a benign procedure, but necrotizing enterocolitis, in 
particular, appears to be a complication that may occur in both compromised 
and uncompromised infants.
PHOTOTHERAPY
In 1958, Cremer and colleagues observed that the exposure of prema­
ture infants to sunlight or blue fluorescent light produced a fall in serum 
bilirubin concentration. Since then, visible light for the treatment of hyper­
bilirubinemia has been used extensively throughout the world.
TERMINOLOGY
The language of phototherapy is confusing, and interpretation of 
measurements quoted in the literature is difficult because different investi­
gators use different instruments (i.e., photometers) with varying spectral re­
sponses, different filters, and different units for expressing the results. The 
irradiance, or flux, is the radiant power incident on a surface per unit area of 
that surface and is expressed in watts per square centimeter (W/cm2). Spec­
tral irradiance is the irradiance in a narrow wavelength band centered at a 
specific wavelength and is expressed as watts per square centimeter nano­
meters (W/cm2/nm). Irradiance can be converted to spectral irradiance by 
dividing the irradiance by the width of the interval (e.g., an irradiance of 
585 |xW/cm2 in the 425- to 475-nm range is equal to 585/50 or 11.7 
pW/cm2/nm). The irradiance of various lamp combinations as measured by
2 6 9
different commercially available meters has been studied by Hammerman 
and colleagues. Illuminance is the photometric analog of irradiance— 
weighted for the visual response of the eye— and is measured in foot- 
candles by the familiar photographic light meter.
EFFECTIVENESS
Phototherapy is an effective means of preventing or treating hyper­
bilirubinemia. After random assignment in the NICHHD phototherapy study, 
672 infants received phototherapy, and 667 were controls. Phototherapy was 
effective in preventing hyperbilirubinemia. Of the 462 low-birth-weight in­
fants treated with light, only 17.7% had bilirubin levels higher than 10 mg/dL 
(171 (xmol/L), compared with 62.8% of the 460 controls. Furthermore, 24.4% 
of control infants in this weight group received exchange transfusions, com­
pared with only 4.1% of infants in the phototherapy group. Phototherapy was 
also effective in controlling hyperbilirubinemia in larger infants.
In all weight groups, light treatment appeared to have its greatest im­
pact in the first 24 to 48 hours of therapy, after which efficacy decreased. The 
declining efficacy of phototherapy after 48 hours is consistent with the ob­
servation that the configurational isomer, formed during light treatment, re­
verts to natural unconjugated bilirubin in the intestine after hepatic excretion. 
Natural bilirubin is then reabsorbed through the enterohepatic circulation and 
contributes to the bilirubin load to be cleared by the liver.
Phototherapy is more effective than exchange transfusion in achiev­
ing prolonged reduction of bilirubin levels in infants with nonhemolytic 
jaundice, and it modifies the course of hyperbilirubinemia in ABO and Rh 
hemolytic disease and reduces significantly the need for exchange transfu­
sion.
Although virtually all attention has been directed toward serum 
bilirubin levels, the efficacy of phototherapy extends well beyond its ability 
to lower the plasma bilirubin concentration. Phototherapy is beneficial be­
cause it detoxifies bilirubin instantaneously and continuously, regardless of 
the serum bilirubin level.
FACTORS INFLUENCING THE EFFICIENCY OF PHOTOTHERAPY
TYPES OF LIGHT
Various types of fluorescent lights have been used for phototherapy, 
including broad-spectrum, daylight, cool white, blue, monochromatic special 
blue, green, and a quartz halide white light with a tungsten filament that has a . 
significant output in the blue spectrum. In contrast to the commonly used 
phototherapy units (i.e., a bank of fluorescent lights), the field of irradiance 
produced by the quartz halide lamp is extremely heterogeneous, with a high 
intensity in the center and a marked decrease toward the sides that may im­
pair the efficacy of these lamps in relation to the energy output.
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The first event in phototherapy is the absorption of a photon of light by 
a bilirubin molecule. Only light of certain colors or wavelengths can be ab­
sorbed by bilirubin. Because bilirubin is a yellow pigment, only violet, blue, 
and some green light can be absorbed, and when infants are treated with 
broad-spectrum white light, only a fraction of the light is acting on the 
bilirubin. Bilirubin does not absorb the different colors of light equally; blue 
light at about 450 nm is absorbed most readily, while green light is less well 
absorbed. To reach the bilirubin in an infant, however, the light must pene­
trate the skin. The depth to which light penetrates the skin depends on the 
color or wavelength of light; the longer the wavelength, the deeper the pene­
tration. Green light penetrates better than blue light, which penetrates better 
than violet light.
The efficacy of light at different wavelengths has been studied by a 
number of authors, and most studies suggest that irradiance at wavelengths 
425 to 475 nm is effective both in vitro and in vivo. Concern for potential 
mutagenic effects of light with wavelengths of 350 to 450 nm has resulted 
in the suggestion that green light (525 nm) should be used. In clinical trials, 
however, the clinical efficacy of green phototherapy lamps has been equiva­
lent or inferior to blue or daylight phototherapy. Since no one likes to look 
at green infants or work in the presence of green light, green phototherapy 
lamps cannot be recommended.
Hammerman and colleagues studied the efficacy of different combi­
nations of special blue and daylight bulbs and found that a combination of 
four special blue lamps and four daylight lamps was effective and did not 
produce discomfort in the nursery staff. Monochromatic blue light has been 
associated with discomfort and vertigo in nursery staff. In jaundiced pre­
term infants, blue light was more effective in converting bilirubin to its 
isomer (4Z, 15E-bilirubin) than was white light, even though the irradiance 
at 450 nm was the same for both light sources (12 pW/ cm2/nm). There was 
no significant difference in the percentage of lumirubin produced under 
white or blue light therapy. Note that special blue lamps are not the same as 
regular blue fluorescent lamps, although some authors fail to distinguish be­
tween the two. Special blue are narrow-spectrum lamps that carry the desig­
nation F20T12/BB, while regular blue are designated F20T12/B. Special 
blue lamps are superior to broad-spectrum white light, but no data are avail­
able to show that regular blue lamps have any advantage.
Fiberoptic light systems have been developed that deliver light from a 
high-intensity lamp to a fiberoptic pad or blanket. Two devices on the market 
are the Wallaby Phototherapy System (Fiberoptic Medical Products, Inc., 
Allentown, PA) and the BiliBlanket Phototherapy System (Ohmeda, Colum­
bia, MD). In the Wallaby system, illumination is transmitted from a halogen 
lamp source to a bundle of fiberoptic fibers contained in a cummerbund, 
which can be wrapped around the infant. Alternatively, the infant can lie on
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the blanket. In the Ohmeda system, the infant lies on a woven fiberoptic mat. 
The mat may also be tucked under the shirt while the infant is held. These 
systems have obvious advantages over conventional phototherapy systems— 
eye patches are probably unnecessary, which eliminates the possibility of na­
sal obstruction from eye pads; the equipment is less bulky than conventional 
phototherapy equipment; and infants can be held and nursed while they re­
ceive phototherapy. This is also a convenient way to deliver double photo­
therapy when it is necessary to reduce the bilirubin level as rapidly as possi­
ble. Only the Wallaby system has been tested in controlled trials, and it ap­
pears to have an efficacy similar to conventional phototherapy. There is no 
reason to believe that the Ohmeda system is not similarly effective. When 
used at home, fiberoptic phototherapy appears to be better accepted by par­
ents than conventional phototherapy.
DOSE-RESPONSE RELATION
A dear dose-response relation can be demonstrated between irradi- 
ance and the response of the serum bilirubin concentration to phototherapy. 
Tan studied nine groups of full-term infants with nonhemolytic hyper­
bilirubinemia. These infants had maximal serum bilirubin levels ranging 
from 15.7 to 17.8 mg/dL (269-304 pmol/L). A maximal decline in serum 
bilirubin level of 50% was obtained when infants were exposed to an irradi- 
ance of 34 pW/cm2/nm in the 425- to 475-nm range. This rate of decline in 
serum bilirubin indicates how effective phototherapy can be when given in 
adequate dose. Tan obtained 24-hour de-dines in serum bilirubin levels of 7 
to 8 mg/dL (120-137 pmol/L), compared with the maximal decline of less 
than 2.5 mg/dL (43 pmol/L) in the first 24 hours obtained in the NICHHD 
phototherapy study.
In the well-baby nursery at William Beaumont Hospital, I use stan­
dard fluorescent phototherapy lamps with four daylight lamps and four 
regular blue lamps. The measured irradiance when these lamps are placed 
30 to 35 cm above the infant is about 9 pW/cm2/nm. Lowering the lamp to 
within 15 cm of the infant increases the irradiance to 15 pW/cmVnm. It is 
my standard practice to place infants in bassinets and lower the photother­
apy lamps as close as possible to the infant. Occasionally, the radiant heat 
produced leads to slight temperature elevations in the infant, in which case 
the phototherapy lamp is raised slightly. This is a simple method of achiev­
ing an increase in the dose of light.
Note, however, that as the distance between lamp and infant decreases, 
there is an increase in the heterogeneity of irradiation, with a much greater 
increase in irradiance occurring at the center than at the periphery. Lining the 
incubator or bassinet with a reflecting white cloth produces greater homoge­
neity of the field of irradiance and an increase in radiant power. The lining 
also increases the amount of indirect reflected irradiance. Lining an incubator
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with a reflecting cloth may be a more effective measure for increasing the ef­
ficacy of phototherapy than moving the lamp closer to the patient.
EXPOSED BODY SURFACE AREA
The efficacy of phototherapy is also influenced by the amount of body 
surface area exposed to the light. Phototherapy systems that simultaneously 
irradiate the front and the back of the infant increase the dose by delivering 
the same amount of irradiance per square centimeter of skin to a larger skin 
area. This lowers the serum bilirubin concentration more rapidly than one­
sided systems, but these double-surface systems are impractical. The advent 
of fiberoptic phototherapy systems has made it easy to use double photother­
apy. Holtrop and colleagues performed a randomized trial comparing the ef­
ficacy of double phototherapy with conventional single phototherapy in in­
fants of less than 2500-g birth weight. Infants in the double phototherapy 
group lay on a fiberoptic phototherapy blanket with a conventional photo­
therapy light above. Those in the double phototherapy group had a 31% de­
cline in bilirubin level after 18 hours of phototherapy, compared with a 16% 
decline in the single-phototherapy group.
INTERMITTENT versu s  CONTINUOUS PHOTOTHERAPY
Clinical studies comparing intermittent with continuous phototherapy 
have produced conflicting results. Some authors found continuous photo­
therapy to be more effective than the intermittent use of light, but others did 
not. Vogl and colleagues found that 15 minutes of illumination followed by 
60 minutes with the lights off was found to be as effective as continuous il­
lumination. Lau and Fung found that a schedule of 1 in 4 hours of irradia­
tion achieved the same effect as continuous phototherapy. The interaction of 
a photon of appropriate energy with a bilirubin molecule at a skin-binding 
site probably occurs in nanoseconds. The products of this reaction then mi­
grate from the skin to the serum, while an unactivated bilirubin molecule 
assumes the skin site. The migration of bilirubin to the skin takes 1 to 3 
hours and is probably the rate-limiting step. Thus, intermittent light, timed 
to match the migration time of bilirubin, should be effective in reducing se­
rum bilirubin while minimizing the total light dosage. The observation that 
intermittent phototherapy is more deleterious than continuous phototherapy 
to the genetic material of human cells in tissue culture has raised questions 
regarding intermittent phototherapy regimens, although no such adverse ef­
fects have been documented in newborns, and the relevance of these in vitro 
observations to the human newborn is unknown.
CHOLESTYRAMINE AND AGAR
When it reaches the small bowel, the configurational isomer of 
bilirubin produced by phototherapy (4Z, 15E-bilirubin) is readily converted
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back to ordinary unconjugated bilirubin, which can be reabsorbed through the 
intestinal wall. Thus, the administration o f substances that bind bilirubin in 
the gut might decrease the enterohepatic circulation and enhance the efficacy 
of phototherapy. Mcolopoulos and colleagues found that administration of 
cholestyramine significantly reduced the duration of phototherapy. Tan and 
colleagues assigned infants to receive phototherapy or phototherapy with 
cholestyramine (1.5 g/kg/day). Infants entered the study when the serum 
bilirubin levels exceeded 15 mg/dL (257 pmol/L). There was no difference in 
the percentage decline in serum bilirubin levels after 24 hours of therapy, but 
the dose of phototherapy used by Tan was substantially higher than that used 
in most other studies. The side-effects of cholestyramine include hyper­
chloremia, hypercalcemia, acidosis, and altered stool frequency (i.e., diarrhea 
or constipation). Exposure to higher light intensities or increasing the ex­
posed surface area by double phototherapy are probably more effective and 
more tolerable methods of enhancing the efficacy of phototherapy.
HOURS
FIG. 32. Decay in energy output at 450 nm of phototherapy lamps.
Agar, like cholestyramine, can bind unconjugated bilirubin in the in­
testinal lumen and sequester it from the enterohepatic circulation. It has also 
been tested as an adjunct to phototherapy in jaundiced newborns, but its ef­
fects are slight, although the administration of Agar increased the amount of 
bile pigment excreted in the stool.
LAMP LIFE
Wide ranges in decay of energy output have been reported with pho­
totherapy lamps. Heat produces deterioration of the phosphors and shortens 
the lamp life, but with adequate cooling, effective lamp life is probably sev­
eral thousand hours. Figure 32 shows the change in blue light energy over - 
2000 hours with continuous use of a phototherapy lamp.
HOME PHOTOTHERAPY
Concerns about the dangers of hyperbilirubinemia and the economic 
and social pressures for early discharge of infants from hospital after deliv-
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ery have led to the widespread use of home phototherapy. When used ap­
propriately, phototherapy at home is as effective as that used in the hospital, 
is much cheaper, and poses no obvious hazards to the infant. When com­
pared with other infant therapies used in the home (e.g., apnea monitors, na­
sal oxygen, respirators), phototherapy ranks among the more benign. The 
use of fiberoptic systems has also made it easier to administer phototherapy 
at home. Home phototherapy reduces costs and avoids parent-child separa­
tion, and there is evidence that mothers of infants who receive phototherapy 
at home are less likely to stop breast-feeding during the period of photother­
apy and, if stopped, are more likely to resume breastfeeding than women 
whose infants are treated in hospital.
MECHANISM OF ACTION
Phototherapy is a mechanism for detoxifying bilirubin. It does this by 
converting bilirubin to photoproducts that are less lipophilic than bilirubin. 
These products partially bypass the liver's conjugating system and can be ex­
creted without further metabolism. Bilirubin is one of the few substances in 
the body that absorbs light, and when it does, one of three chemical reactions 
can occur: photooxidation, configurational isomerization, and structural 
isomerization.
PHOTOOXIDATION
If a sample of serum containing bilirubin is left exposed to sunlight, 
the bilirubin gradually disappears—one of the observations that led to the 
development of phototherapy. This bleaching phenomenon is the result of 
photooxidation of bilirubin to water-soluble, colorless products. Because 
these products are small and polar, they can be excreted in the urine. 
Photooxidation is a slow process, however, and it is probably only a minor 
contributor to the elimination of bilirubin during phototherapy.
CONFIGURATIONAL ISOMERIZATION
Isomers are substances that have different physico-chemical proper­
ties but the same molecular formula. Configurational, or geometric, isom­
erization occurs with compounds containing double bonds. Bilirubin con­
tains two symmetrically substituted double bonds, one starting at carbon 
atom C4 and the other at C l5. Therefore, there are four possible geometric 
isomers of bilirubin: 4Z, 15Z; 4Z, 15E; 4E, 15Z; and 4E, 15E. Bilirubin 
bound to human serum albumin, however, shows about a 100-fold prefer­
ence for Configurational isomerization at the double bond between C l5 and 
C16 over the double bond between C4 and C5. Thus, in infants receiving 
phototherapy, the stable 4Z,15Z isomer (i.e., the one produced in vivo by 
the breakdown of hemoglobin) is converted predominantly to only one of 
the three other isomers—the 4Z, 15E isomer (Fig. 38-26). In this reaction,
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one of the end rings undergoes a 180° rotation around the double bond at 
CIS. When this occurs, the polar N and О groups are exposed, making one 
end of the molecule polar and allowing it to be excreted in bile without con­
jugation. The formation of 4Z, 15E-bilirubin is spontaneously reversible in 
the dark, unlike photooxidation or lumirubin formation (see Structural 
Isomerization). This reverse reaction is slow when the pigment is bound to 
serum albumin but occurs rapidly in bile. Thus, the 4Z, 15E-bilirubin 
formed in the skin and excreted by the liver is readily converted back to or­
dinary unconjugated bilirubin. Furthermore, the photochemical conversion 
of the normal Z, Z isomer to the less stable 4Z, 15E isomer is reversible by 
light, and irradiation of either isomer with visible light leads to rapid forma­
tion of the other.
In rats, the process by which bilirubin isomers are formed during pho­
totherapy and then transported from the skin and excreted in the bile is ex­
ceptionally efficient. When Gunn rats are exposed to phototherapy, virtually 
instantaneous changes occur in bile composition. This process is so efficient 
that equilibrium between configurational E isomers and the natural Z,Z 
isomer is not achieved, and the photoisomers accumulate in the circulation 
only if their excretion is blocked by ligating the bile duct. Clearance of 
light-generated 4Z,15E-bilirubin isomer in jaundiced infants is slow, how­
ever, and a steady-state concentration of the two isomers is achieved (see 
Fig. 33).
FIG. 33. Z-E carbon-carbon double bond configurational isomerization of bilirubin in 
humans. (From McDonagh AF, Lightner DA. "Like a shrivelled blood orange": 
bilirubin, jaundice and phototherapy.
The absorption spectra of these isomers are similar but not identical, and 
different wavelengths (i.e., colors) of light produce different rates of the 
forward and reverse reactions. The steady-state amount of the 4Z.15E iso­
mer is dependent on the wavelength of the light used but is independent of 
intensity. Greater intensity leads to more rapid achievement of the steady- 
state concentrations but not their amounts.During phototherapy, the plasma
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concentration of 4Z.15E isomer increases to about 20% of the total bile 
pigment within less than 12 hours, and this isomer may persist for hours af­
ter phototherapy is discontinued. At the same wavelength, however, the in­
tensity of the light does not affect the steady-state concentration of the con­
figurational isomer in serum. In the jaundiced infant, therefore, the 4Z,15E 
isomer behaves "as it does in other closed systems, and although it is 
formed fastest, it has nowhere to go."13
STRUCTURAL ISOMERIZATION
In this reaction, intramolecular cyclization of bilirubin occurs in the 
presence of light to form a substance known as lumirubin (Fig. 34). 
Lumirubin is excreted in bile, without the need for conjugation, and in urine. 
During phototherapy, the serum concentration of lumirubin is about 2% to 
6% of the total serum bilirubin—considerably lower than the concentration of 
the configurational isomers (about 20% of the total bilirubin). Lumirubin is 
cleared from the serum much more rapidly than the 4Z,15E isomer. The 
mean serum half-life for lumirubin is less than 2 hours, compared with 15 
hours for the 4Z.15E isomer. Thus, although the quantum yield for the con­
figurational isomerization reaction is at least 40 times greater than that for 
any other photochemical reaction of bilirubin, the rate of elimination of the 
4Z,15E isomer is so slow that it cannot account for the decline in serum 
bilirubin observed in infants treated with phototherapy. Lumirubin formation 
is responsible for this decline. Furthermore, the formation of lumirubin is not 
a reversible reaction, so that once formed it is excreted unchanged in the bile 
and urine.
FIG. 34. Intramolecular cyclization of biirubin in presence of light to form lumirubin, 
(From McDonagh AF, Lightner DA. "Like a shrivelled blood orange": bilirubin, jaun­
dice and phototherapy.
Costarino and colleagues exposed premature infants to low-dose (6 
jtW/cm2/nm) versus high-dose (12 pW/cm2/nm) phototherapy. The lower 
light intensity was sufficient to drive the conversion of native 4Z,15Z- 
bilirubin to 4Z,15E isomer nearly to equilibrium. Doubling the irradiance 
produced no increase in the percentage of this configurational isomer. The
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proportion of Iumirubin, however, increased from 0.7% to 1.3%. In a subse­
quent study, these investigators used high-pressure chromatography to ana­
lyze bile samples obtained from premature infants during phototherapy. 
They found that the major pigment and, in some infants, the only pigment 
present in the bile was Iumirubin. The serum half-life of the Iumirubin was 
120 ± 25 minutes. These data suggest that structural isomers (i.e., 
Iumirubin), rather than the configurational isomers (i.e., E-bilirubin), are 
primarily responsible for the ability of phototherapy to lower serum 
bilirubin levels, and they account for the dose-response relation of photo­
therapy to the decrement in serum bilirubin.
Figure 35 summarizes the general mechanism of phototherapy for neo­
natal jaundice.
As McDonagh and Lightner point out,
It is important to realize that formation and excretion of bilirubin photoisomers 
are rapid processes that begin as soon as the icteric baby is exposed to light. 
Thus, detoxification starts with the flick of the light switch, although it may be 
hours before a decline in the plasma bilirubin concentration becomes evident. 
Mst as the tip of an iceberg represents only a small proportion of its mass, the 
plasma bilirubin represents only about V3 of the bilirubin in the body. Its dis­
appearance in response to phototherapy is a secondary effect. Consequently, it 
is an insensitive, tardy, and possibly misleading parameter of the effectiveness 
of phototherapy. When a baby looks jaundiced, it is because pigment molecules 
in superfidal tissues are absorbing blue light. What can be seen by eye is also 
accessible to the phototherapy lamp. . . . phototherapy is bound to accelerate 
the detoxification and elimination of bilirubin, irrespective of what the plasma 
bilirubin concentration may show.
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FIG. 35. General mechanisms of phototherapy for neonatal jaundice. Chemical reac­
tions (solid arrows) and transport processes (broken arrows) are indicated. Pigments 
may be bound to proteins in compartments other than blood. Some excretion of photoi­
somers, particularly lumirubin, in urine also occurs.
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BIOLOGIC EFFECTS AND POSSIBLE COMPLICATIONS
The extensive use of light has stimulated considerable research into its 
possible effects on the human organism. For many years, photobiologists 
have been aware of the numerous effects of light on humans and other mam­
mals. These include effects on several biologic rhythms, the pineal gland, go­
nadal function, and vitamin D synthesis. Nevertheless, no significant toxicity 
of phototherapy has been noted in over 30 years of clinical use, during which 
millions of infants have received this treatment.
TOXICITY OF PHOTOTHERAPY PRODUCTS
Human, animal, and in vitro studies suggest that the products of 
photodecomposition have no direct neurotoxic effects.
CELL DAMAGE
Exposure of cells to light intensities similar to those used in photother­
apy can produce DNA strand breaks, sister chromatid exchanges, and muta­
tions. Bilirubin appears to act as a photosensitizing agent, enhancing the level 
of DNA damage in cells exposed to phototherapy light. Intermittent illumina­
tion appears to produce more DNA damage than a similar light dosage ad­
ministered continuously, and illumination of sperm and oocytes in the 
American sea urchin produces abnormal embryos and cleavage patterns. Be­
cause it is likely that light penetrates the thin scrotal skin and perhaps even 
reaches ovaries, it has been suggested that shielding the gonads with diapers 
may be indicated during phototherapy. No chromosomal damage, however, 
was seen in lymphocyte cultures from infants receiving double phototherapy.
PHOTODYNAMIC DAMAGE
Because bilirubin is a photosensitizer, it has been suggested that it 
may act as a photodynamic agent in the presence of light and produce dam­
age. Bilirubin is a weak photosensitizer, however, and there is no evidence 
for photodynamic damage in patients receiving phototherapy. If abnormal 
levels of endogenous or exogenous photosensitizing pigments are present, 
as in some porphyrias, phototherapy is contraindicated. It is also dangerous 
to administer known photodynamic agents to infants to improve the efficacy 
of phototherapy.
INTRAVENOUS ALIMENTATION
The exposure of amino acid solutions used for intravenous alimenta­
tion to light in the blue spectrum produced a significant reduction in trypto­
phan. In addition, when a multivitamin solution was added to the amino ac­
ids, a significant reduction in methionine (40%) and histidine (22%) oc­
curred. The decrease in methionine was accompanied by an increase in me­
thionine sulfoxide. Multivitamin concentrate enhanced the generation of sin­
gle-strand DNA breaks in cells exposed to fluorescent light.
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Studies of several animal species have demonstrated the potential 
toxic effects of light on the retina. Most of these studies were performed in 
animals with pharmacologically dilated pupils and retinas that are unusually 
sensitive to phototoxicity. The effects of clinical levels of phototherapy 
(400 foot-candles) on the retinas of newborn stump-tail monkeys were stud­
ied. These animals were maintained in standard nursery incubators and were 
restrained in the supine position facing the light source. No mydriatic drops 
were used, and the monkeys could open and close their eyes as desired. One 
control eye was sutured closed and covered with a patch. Exposure to the 
phototherapy lights for 12 hours to 7 days produced severe and progressive 
damage to the retina. In a subsequent study, monkeys were exposed to light 
for 3 to 10 days, then returned to normal environments for 10 months before 
being sacrificed. Substantial recovery in retinal cytoarchitecture was evident 
if the original exposure was for less than 3 days. All the exposed retinas, 
however, showed some loss of rod and cone cells when compared with the 
controls. This loss is similar to the normal attrition of photoreceptor cells 
that occurs in the aging process in the mammalian retina. These changes 
therefore represent a form of premature aging. Thus, if an infant has suf­
fered phototoxic retinal damage (e.g., as a result of a slipped eye patch), 
visual acuity, electroretinography, and ophthalmic examination may well be 
normal in childhood, despite considerable loss of tissue.
The eyes of infants receiving phototherapy should be protected with 
appropriate eye patches. Commercially available eye patches effectively pre­
vent light transmission, but homemade devices are less effective. Displaced 
eye patches not only allow the light to reach the retina but also may obstruct 
the nares and cause respiratory distress, and the use of patches has also been 
associated with transient abdominal distention. The choice of eye patches 
should therefore take into account not only their effectiveness in preventing 
light transmission but also the simplicity and effectiveness with which they 
can be secured. In follow-up studies of infants whose eyes were adequately 
shielded, visual function as assessed clinically and electroretinographically 
was normal.
SKIN CHANGES
Because the skin becomes bleached during phototherapy, skin color 
cannot be used as a means of assessing serum bilirubin levels; they must be 
measured at regular intervals. The skin of black infants contains preformed 
melanin and may show a tanning effect from phototherapy. Exposure to some 
longwave ultraviolet and short-wave visible light (300-600nm) produces 
pigmentation without an initial erythema, which is apparently caused by re­
oxidation of preformed melanin, a process known as immediate pigment 
darkening (IPD). If this light exposure continues, the initial IPD reaction 
fades after 1 to 24 hours and is followed within 48 to 72 hours by hyper­
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pigmentation, secondary to increased melanosome synthesis. Plexiglas essen­
tially eliminates the passage of short-wave (200-280 nm) and middle-wave 
(280-320 nm) ultraviolet light but allows a significant portion of long-wave 
(320-400 nm) light to pass through. Exposure to energies in the 360- to 400- 
nm wave band may cause an increase in peripheral blood flow and has 
caused erythema in adults. At wavelengths greater than 650 nm, which in­
cludes infrared energy, most of this energy is absorbed by the Plexiglas.
BRONZE-BABY SYNDROME
Infants with cholestatic jaundice who are exposed to phototherapy may 
develop a dark grayish brown discoloration of the skin, serum, and urine. Be­
cause the bronzing effect occurs exclusively in infants with some degree of 
cholestasis, it is reasonable to assume that the color changes are produced by 
the retention of some product of phototherapy. During phototherapy, the 
duodenal bile changes from its normal color to brownish black. Onishi and 
colleagues identified an increase in serum concentrations of an "unknown 
pigment" (probably lumirubin) in infants with the bronze-baby syndrome. By 
free-radical reaction, this pigment may be polymerized to form the brown 
bilifuscin. Adults and infants with cholestasis accumulate large amounts of 
porphyrins and copper in their serum. Further confirmation of the role of 
copper-bound porphyrins was presented by Jori and colleagues. They pro­
duced an animal model of the bronze-baby syndrome by ligating the common 
bile duct in adult Wistar rats. This produced an accumulation of porphyrins 
and copper in the liver and a 20% conversion of protoporphyrin IX into 
Cu(II)-protoporphyrin IX. When exposed to phototherapy, the plasma content 
of Cu(II)-protoporphyrin increased by about 30%. The spectroscopic changes 
seen in the sera of irradiated rats whose bile ducts had been ligated were con­
sistent with the formation of products that have the typical spectrum found in 
the bronze-baby syndrome. These findings provide confirmatory evidence 
that the brown discoloration found in the bronze-baby syndrome results from 
the phototransformation of copper porphyrins subsequent to an electron 
transfer between photoexcited bilirubin and the copper iron.
Most infants with this syndrome have not suffered any deleterious 
consequences, although kernicterus was described in a full-term infant with 
the bronze-baby syndrome who died. Maximal total serum bilirubin in this 
infant was 18 mg/dL (308 pmol/L), and the direct-reacting bilirubin was 4.1 
mg/dL (17 pmol/ L). A decrease in the reserve albumin binding of bilirubin 
has been found in infants with the bronze-baby syndrome. Discontinuance 
of phototherapy generally results in the disappearance of the bronze pig­
ments.
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GASTROINTESTINAL. TRACT DISORDERS
Phototherapy is associated with an increased incidence of watery di­
arrhea, an increase in fecal water loss, and a decrease in gut transit time. Al­
though suggested in one study, the diarrhea is probably not the result of a 
phototherapy-induced lactase deficiency. During phototherapy, unconju­
gated bilirubin is excreted into the gut. Unconjugated bilirubin can induce 
intestinal secretions, and diarrhea may be a consequence of the high concen­
trations of bilirubin within the intestinal lumen. Increased concentrations of 
bile salts also have been found in the gut of neonates during phototherapy 
and may be a factor in the pathogenesis of phototherapy-associated diarrhea.
FLUID LOSSES, THERMOREGULATION, AND BLOOD FLOW
Significant increases in insensible water loss occur during photother­
apy, particularly in infants who are already under radiant warmers. In full- 
term infants, insensible water loss increases by 40%, whereas in low-birth- 
weight infants, insensible water loss may increase by as much as 80% to 
190% in nonservocontroiled incubators. This effect can be partially miti­
gated by the use of servocontrolled incubators. In addition to the previously 
noted increases in stool water loss, there is an increased fecal excretion of 
nitrogen, sodium, and potassium.
During phototherapy, there is a marked increase in skin blood flow 
(228%) and, to a lesser extent, muscle blood flow. When servocontrolled 
incubators are not used, there also is a significant increase in skin tempera­
ture from the phototherapy lamps and an increase in incubator temperature, 
heart rate, and respiration. The use of a servocontrolled incubator prevents a 
rise in skin temperature and the previously noted changes in muscle blood 
flow, respiration, and heart rate, although there remains a significant, but 
less dramatic, increase in skin blood flow (52%).
GROWTH PROBLEMS
Infants receiving phototherapy gain less weight in the first week of 
life than those not receiving phototherapy but show catch-up growth in the 
next 2 weeks. In a study of 120 infants receiving phototherapy from the 
second to sixth days of life, 44% of those receiving continuous therapy had 
regained their birth weights by the seventh day, compared with 57.6% of 
those receiving intermittent phototherapy (12 hours on, 12 hours off) and 
80% of control infants. Similar but less marked changes were seen in length 
and head circumference. The phototherapy groups had greater increases in 
weight and length during the second and third postnatal weeks. These 
growth effects may be caused by the aforementioned increases in fluid and 
caloric losses. A 2-year follow-up of these infants revealed no differences in 
weight, length, or head circumference. A 2-year follow-up of another group 
studied earlier, however, revealed significantly smaller head circumferences
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in those infants who had received phototherapy. Nevertheless, the photo­
therapy-treated infants showed no difference in developmental and neu­
rologic performance when compared with the controls. The difference in 
growth in this group of infants has not been explained. In both these studies, 
only one-half of the infants who entered the study were available for follow­
up measurements at the age of 2 years. Other studies that have followed the 
growth of infants receiving phototherapy for 2 to 6 years demonstrated no 
effect on weight, length, or head circumference.
GONADOTROPIN CHANGES
Changes have been observed in serum gonadotropins during and after 
phototherapy. Values for luteinizing hormone (LH) declined within 24 to 48 
hours after phototherapy was begun but increased significantly 6 to 9 days 
after phototherapy was discontinued. Increases in LH and follicle- 
stimulating hormone (FSH) were observed 3 to 4 weeks after phototherapy 
was administered to preterm girls. In the boys, LH increased, but FSH did 
not. These observations suggest that light may affect pituitarygonadal func­
tion in the human neonate, although the mechanism for these changes is not 
clear.
RADIANT-EMERGY EXPOSURE
Newborns are constantly exposed to the ambient nursery lighting as 
well as to light that passes through windows, which varies with the amount 
of sunlight on any particular day. An infant in an incubator near a window 
who is exposed to 6 hours of summer sunlight receives more radiant energy 
exposure in the 440- to 470-nm range than does an infant receiving 24 hours 
of phototherapy with daylight bulbs. Thus, phototherapy may be a less im­
portant source of radiant energy than sunlight in some nurseries, and it is a 
minute portion of the radiant energy exposure that an infant will receive in a 
lifetime.
ALBUMIN BINDING OF BILIRUBIN
The isomers produced during phototherapy do not compete with 
bilirubin for binding sites on albumin. Infants receiving phototherapy do not 
demonstrate any decrease in the bilirubin-binding capacity of albumin.
INFANT BEHAVIOR
During REM sleep, infants receiving phototherapy have a slight in­
crease in respiratory rate, whereas during non-REM sleep, the respiratory 
rate increases significantly. In infants who are not receiving phototherapy, 
respiratory rates in non-REM sleep decrease as serum bilirubin levels in­
crease. Other studies suggest changes in infant behavior and mother-infant 
interaction during and after phototherapy. Because infants receiving photo­
therapy are more jaundiced than control infants, however, it is difficult to
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separate the effects of the jaundice from those of phototherapy. Photother­
apy in hospital requires mother-infant separation, which may affect the in­
fant's behavior.
DEVELOPMENTAL OUTCOME .
When evaluated at 6 years of age in the NICHHD cooperative photo­
therapy study, no differences were found between children in the photother­
apy or control groups in the incidence of definite or suspect cerebral palsy, 
clumsy or abnormal movements, hypertonia, or IQ less than 70. There were 
no differences between the two groups in growth, speech, hearing loss, or 
evidence of hyperactivity.
OTHER EFFECTS
Phototherapy has been associated with an increased incidence of hy­
pocalcemia in preterm infants and in newborn rats. In one study, it was 
found that hypocalcemia in rats could be prevented by covering the entire 
head or by shielding the occiput with tape or India ink, and phototherapy- 
associated hypocalcemia persisted in blinded newborn rats but was pre­
vented by melatonin administration. On the basis of these studies, Hakanson 
and Bergstrom suggest an extraretinal photoreceptive mechanism involving 
direct transcranial photon perception by the pineal gland and a reduction of 
melatonin secretion. The resultant low serum concentration of melatonin 
permits the unopposed uptake of calcium by bone. Phototherapy does not 
appear to stimulate the photobiosynthesis of vitamin D. No effect of photo­
therapy was found on serum free fatty acid levels or leucine amino pepti­
dase values.
Light penetration has been measured through the newborn scalp and 
skull bones, something that would be expected in view of the clinical ex­
perience with transillumination of the head.
PHARMACOLOGIC TREATMENT
Pharmacologic agents used in the management of hyperbilirubinemia 
can accelerate the normal metabolic pathways for bilirubin clearance, in­
hibit the enterohepatic circulation of bilirubin, and interfere with bilirubin 
formation by either blocking the degradation of heme or inhibiting hemoly­
sis.
ACCELERATION OF NORMAL METABOLIC 
PATHWAYS FOR BILIRUBIN CLEARANCE
PHENOBARBITAL
The drug most widely tested in human studies is phenobarbital, a po­
tent inducer of microsomal enzymes that increases bilirubin conjugation and 
excretion and abolishes phase I physiologic jaundice in the newborn. In ad-
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dition, phenobarbital enhances uptake and excretion of certain compounds 
and increases bile flow. Numerous studies have demonstrated that pheno­
barbital, when given in sufficient doses to the mother, the infant, or both, is 
effective in lowering serum bilirubin levels in the first week of life. Conju­
gated bilirubin levels in cord blood are significantly higher in infants of 
mothers who receive antenatal phenobarbital compared with those who re­
ceive no therapy, demonstrating that antenatal phenobarbital enhances fetal 
bilirubin conjugation before delivery.
The possible long-term effects of antenatal phenobarbital administra­
tion are unknown. Although a 7-year follow-up of children whose mothers 
received phenobarbital in the last trimester was reassuring, at adolescence, 
the boys in the phenobarbital group were significantly taller and had a lower 
mean testicular volume than those in the control group. These observations 
are significant in view of the well-documented effects, in rats, of antenatal 
phenobarbital on growth, sex hormones, and the onset of puberty. Thus, the 
routine administration of phenobarbital to pregnant women does not appear 
justified in most Western countries, given that most infants will not develop 
significant hyperbilirubinemia. In the Far East and Greece, where the inci­
dence of severe jaundice is much higher, and in developing nations, the use 
of antenatal phenobarbital might merit consideration.
When phenobarbital was given to mothers of erythroblastotic infants 
before delivery, the treated infants had a slower postnatal rise of indirect 
bilirubin than did nontreated controls, and significantly fewer of the pheno- 
barbital-treated group required exchange transfusions. Infants with G6PD 
deficiency treated from the first day of life with phenobarbital also required 
fewer exchange transfusions than control infants. The results of the clinical 
trials involving the use of phenobarbital have been reviewed.
Combining phenobarbital with phototherapy in a newborn does not 
reduce serum bilirubin levels more rapidly than phototherapy does alone. 
Phenobarbital reduces serum bilirubin levels in patients with the type II 
Crigler-Najjar syndrome, but it has no effect on infants with the type I syn­
drome.
OTHER PHARMACOLOGIC AGENTS
Many chemicals are capable of inducing the enzymes in the hepatic 
endoplasmic reticulum and enhancing not only their own biotransformation 
but also that of many other substances.
A number of different compounds that induce UDPGT have been tried, 
including clofibrate, buculome, and zixoryn. Antenatal administration of 
ethanol and antipyrine has also been used with some success. Much more 
data are needed on the efficacy and safety of these agents before they can be 
considered for general clinical use.
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Because of speculation that reduced synthesis of uridine diphosphate 
glucuronic acid, the donor substance for UDPGT, might contribute to im­
paired conpgation of bilirubin in the newborn, orotic and aspartic acid, pre­
cursors of uridine, have been administered without apparent effect to neo­
nates.
AGENTS THAT ACT ON THE ENTEROHEPATIC CIRCULATION
Pharmacologic agents have been used in an attempt to reduce the en- 
terohepatic circulation of bilirubin. These include activated charcoal, poly­
vinyl pyrrolidine, and agar, which bind bilirubin in the intestinal lumen. The 
efficacy of agar in decreasing serum bilirubin levels has been reviewed. A 
metaanalysis of five controlled studies in infants without hemolytic disease 
suggests a possible, but small, benefit from agar. Even if further studies 
produced a more significant result, the effect size appears to be too small to 
be clinically important. No effect was found in infants with G6PD defi­
ciency.
Cholestyramine has been used as an adjuvant to phototherapy. The 
results were conflicting, and the modest benefit does not outweigh the sig­
nificant side-effects of this compound.
Bilirubin oxidase, an enzyme that degrades bilirubin, significantly 
lowers bilirubin levels when fed to Gunn rats. The presumed mechanism is 
its effect on decreasing the enterohepatic circulation of bilirubin. Bilirubin 
can also be removed from the blood by passage through a filter containing 
bilirubin oxidase.
DECREASING BILIRUBIN PRODUCTION
BY INHIBITING HEME OXYGENASE
The enzyme microsomal heme oxygenase is necessary for the conver­
sion of heme to biliverdin, one of the first steps in the formation of bilirubin 
from hemoglobin. An exciting series of observations has demonstrated that 
certain synthetic metalloporphyrins are powerful competitive inhibitors of 
heme oxygenase. Tin protoporphyrin (SnPP) and tin mesoporphyrin 
(SnMP), in contrast to other methods for controlling serum bilirubin levels, 
act by suppressing the formation of bilirubin. The inhibition of heme degra­
dation to bilirubin does not result in the accumulation of heme, which is ex­
creted in the bile in quantities that compensate for the decreased excretion 
of bilirubin. Thus, heme can be eliminated by pathways other than the for­
mation of bilirubin.
Valaes and colleagues have evaluated the contribution of the classic 
pathway (i.e., by bilirubin) and the alternative pathway of heme elimination 
in the bile and meconium from autopsies of stillbirths and neonatal deaths. 
It appears that heme excreted in the bile of fetuses and neonates is either to­
tally or partially absorbed in the bowel, either after oxidation to bilirubin by
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intestinal heme oxygenase or as intact heme. This suggests that this pathway 
predominates during fetal life and may be a mechanism for the preservation 
of iron in the fetus. In the absence of evacuation of bowel contents in the 
fetus, the enterohepatic circulation of heme may be more efficient than the 
standard bilirubin formation pathway.
One randomized controlled trial was done on the effect of SnPP on 
infants with Coombs-positive ABO hemolytic disease of the newborn. In 
the first part of the trial (i.e., study I), a single dose of 0.5 pmol/kg SnPP 
was given at 5.5 hours after birth (range, 1-11 hours). In the second phase 
(i.e., study II), the initial dose was increased to 0.75 pmol/kg, and a second 
dose was given to all infants 24 hours later. Infants whose bilirubin levels 
exceeded 10 mg/dL (171 pmol/ L) received a third dose (9 of 24 infants). 
The incremental changes in plasma bilirubin level were lower in the SnPP- 
treated groups than in the control groups. These differences were not statis­
tically significant in study I, but in study II, they became significant within 
24 to 48 hours and remained so up to 96 hours. The investigators calculated 
an area under the curve for the elevation of bilirubin above the initial 
bilirubin value for the first 96 hours of life. This measurement was signifi­
cantly lower in the SnPP-treated infants in study II. Twenty-nine percent of 
the SnPP-treated infants required phototherapy, compared with 46% of the 
control group, but these differences were not significant.
It is intriguing to contemplate the use of a drug that could eliminate 
the problem of hyperbilirubinemia in the newborn. To be effective, how­
ever, SnPP probably needs to be administered prophylactically to most in­
fants. Before that is considered, excellent documentation of its lack of toxic­
ity is needed. Transient erythema was reported in two infants in the con­
trolled trial, and other animal evidence raises concerns about possible pho­
tosensitization. In this respect, SnMP is probably as effective and less pho­
totoxic. SnPP was used to treat three patients with the type I Crigle'r-Najjar 
syndrome. Rubaltelli and colleagues described their experience with the 
treatment of an infant who was 2.5 months old. She received intermittent 
doses of SnPP (1 pmol/kg IM). They found that the duration of photother­
apy necessary to maintain the serum bilirubin concentrations below 14 tG 15 
mg/dL (239-257 pmol/L) decreased by about 85% after SnPP administra­
tion. An injection of 1 p-mol/kg given every 7 to 10 days diminished the du­
ration of phototherapy by about 56%.Galbraith and colleagues used SnMP 
in the treatment of two 17-year-old boys with type I Crigler-Najjar syn­
drome. The administration of SnMP in doses of 0.5 to 1 pmol/kg achieved a 
temporary reduction in serum bilirubin levels and a decrease in the rebound 
hyperbilirubinemia that occurs after plasmapheresis. The total-body 
bilirubin in an adolescent with type I Crigler-Najjar syndrome is many times 
greater than the bilirubin contained in the intravascular space, and the initia-
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tion of heme oxygenase inhibitor therapy in an adolescent with this disease 
would not be expected to be as effective as earlier administration.
DECREASING BILIRUBIN PRODUCTION BY INHIBITING HEMOLY­
SIS
Another interesting approach to the treatment of hemolytic disease is 
the use of high-dose intravenous immunoglobulin therapy in infants with 
isoimmune hemolytic disease. Sato and colleagues administered 1 g/kg of 
intravenous y-globulin over 6 to 8 hours to three infants. One had Rh in­
compatibility due to anti-E and anti-c, and two infants had ABO incompati­
bility. The hyperbilirubinemia was refractory to conventional phototherapy 
but responded rapidly to the administration of y-globulin. Rubo and col­
leagues conducted a controlled trial of 32 infants with Rh hemolytic disease. 
They were randomly assigned to receive conventional treatment, including 
phototherapy with or without additional intravenous •y-globulin therapy in a 
dose of 500 mg/kg given over 2 hours as soon as the diagnosis was estab­
lished. In the intravenous y-globulin group, 2 of 16 children required ex­
change transfusions, compared with 11 of 16 in the control group (p < 
0.005); and bilirubin levels were consistently lower in the intravenous y- 
globulin group, even though they had fewer exchange transfusions. Anti-D- 
coated erythrocytes are removed from the circulation through antibody- 
dependent lysis by cells of the reticuloendothelial system. The mechanism 
of action of intravenous immunoglobulin is unknown, but it is possible that 
it might alter the course of Rh hemolytic disease by blocking Fc receptors 
and thus inhibiting hemolysis. Intravenous y-globulin has been used widely 
in a variety of pediatric conditions, and significant complications are rare. 
The risks of therapy are almost certainly less than the risk of exchange 
transfusion.
PHYSIOLOGIC ROLE OF BILIRUBIN
This subject has been reviewed in depth by Mc-Donagh. In spite of its 
potential toxicity, bilirubin may have an important and positive physiologic 
role. Bilirubin, even when bound to human serum albumin, and at physiol­
ogic concentrations (1.1 mg/dL, or 19 pmol/L), protects linoleic acid from 
peroxyradical-induced oxidation in vitro. It does this by efficiently scaveng­
ing peroxyradicals and intercepting the radical chain reaction that leads to 
the destruction of unsaturated fatty acids. At low partial pressures of oxy­
gen, bilirubin is a better inhibitor of lipid peroxidation in liposomes than vi­
tamin E, which is considered to be an important antioxidant in the defense - 
against lipid peroxidation in plasma.
Unconjugated bilirubin readily diffuses through and partitions into 
biologic membranes, and the concentration of bilirubin in liver plasma 
membranes at normal adult serum bilirubin concentrations is about 0.25
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mole% (mole/100 moles phospholipid). The newborn has much higher con­
centrations of serum bilirubin, and the membrane concentration is therefore 
likely to be higher as well. In early neonatal life, bilirubin may play a role in 
preventing oxidative membrane damage. This could be important as the fe­
tus emerges from an hypoxic environment (P02 of about 30 torr) into the 
relatively hyperoxic atmosphere. Under these circumstances, oxidative 
stress may occur, particularly when the levels of antioxidant enzyme sys­
tems and endogenous vitamin E may be depressed.
Unconjugated bilirubin also reacts rapidly with another, nonradical, 
form of oxygen—singlet oxygen, the toxic intermediate thought to be re­
sponsible for the cutaneous damage seen in patients with photosensitizing 
porphyric diseases. Bilirubin may have a role as a free-radical scavenger. 
Infants with illnesses believed to enhance free-radical production (e.g., cir­
culatory failure, sepsis, asphyxia) had a significantly lower daily rise in 
mean serum bilirubin levels than control infants. These findings are consis­
tent with the hypothesis that bilirubin is consumed as an antioxidant.
Pauly and colleagues tested the hypothesis that bilirubin protects pig­
lets against oxyradical-dependent pulmonary hypertension in arterial hy­
poxemia when they are infected with group В streptococci. One group of 
animals was pretreated with a bolus of 50 mg/kg of bilirubin followed by a 
continuous infusion. There was no difference in group В streptococcus- 
induced increases in pulmonary arterial pressure or in the decrease in Pa02 
between control and bilirubin-treated animals. In this model, at least, 
bilirubin did not exhibit appreciable oxyradical-scavenging activity. 
Bilirubin may help to keep oxyradicais and their lipid peroxide reaction 
products, which are essential for other reasons, under control, although the 
physiologic significance of bilirubin's antioxidant activity to the well-being 
of the neonate is unknown.
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RENAL DISEASE
DEVELOPMENTAL PHYSIOLOGY
The kidney plays a central role in the physiologic transition from fetal 
to postnatal life. Although the neonatal kidney traditionally has been 
characterized as dysfunctional, closer analysis indicates that the kidney 
functions at a level that is appropriate to the growing infant's physiologic 
needs, except in very-low-birth-weight (VLBW) infants.
EMBRYOLOGY
Embryologic development o f the mammalian kidney proceeds 
through three sequential stages: the rudimentary pronephros, which appears 
at about week 3 of fetal life, the mesonephros, which degenerates by week 
12, and the definitive kidney, the metanephros. The ureteral bud, an off­
shoot of the mesonephros, ultimately forms the ureter, pelvis, calyces, and 
collecting ducts and induces formation of nephrons within the metanephric 
blastema. The nephroblastic cells of the blastema, on contact with the uret­
eric bud, differentiate into the glomerulus, proximal convoluted tubule, loop 
of Henie, and distal convoluted tubule.
Nephronogenesis proceeds in a centrifugal pattern. Thus, the first 
nephrons to develop are those residing in the juxtamedullary region, 
whereas the youngest are located in the superficial cortex. In the 22-week- 
old human fetus, all glomeruli present belong to juxtamedullary nephrons. 
At a conceptional age of 40 to 42 weeks, the juxtamedullary glomeruli are 
about twice the size of the outer cortical glomeruli. By 1 year of age, the 
juxtaglomerular glomeruli are only about 20% larger than cortical 
glomeruli, similar to the relationship observed in the adult.
The full complement of approximately 1 million nephrons per kidney 
in the human is achieved at a body weight of about 2300 g or 36 weeks of 
gestational age (GA). When birth occurs before 36 weeks of conceptional 
age, nephron formation continues until a full complement is achieved. Once 
complete, nephronogenesis never is resumed, even after extensive loss of 
renal tissue. Thus, the full-term newborn is born with as many nephrons as 
he or she will have for the duration of life.
Physiologic, biochemical, and enzymatic maturation of newly formed 
nephrons may lag behind anatomic maturation by weeks or months. Thus, 
the immature kidney is characterized by structural and functional heteroge­
neity arising from the concurrent presence of nephrons in diverse stages of 
differentiation.
RENAL PHYSIOLOGY
Urine produced by the metanephric kidneys of 12- to 16-week-old fe­
tuses contributes to the formation of amniotic fluid. Although renal function 
is not necessary for long-term regulation of fetal water and electrolyte ho­
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meostasis, a process assumed by the placenta, evidence indicates its impor­
tance in normal growth, lung development, and protection from acute 
changes in fetal vascular volume. The rate of urine production in normal fe­
tuses is about 10 mL/hour at 30 weeks, increasing to 28 mL/hour at 40 
weeks.
RENAL BLOOD FLOW
The effective renal plasma flow (ERPF) traditionally has been meas­
ured from the renal clearance of the organic acid paraaminohippurate 
(PAH), corrected for the fraction of PAH extracted by the kidney; the value 
for ERPF divided by (100 - hematocrit [%])/100 provides an estimate of re­
nal blood flow (RBF). The ERPF increases from 20 mL/minute/1.73 m2 at 
30 weeks of GA to 45 mL/minute/1.73 m2 by 35 weeks, and 83 
mL/minute/1.73 m2 at term. During the first 3 months of postnatal life, 
ERPF increases rapidly to 300 mL/minute/1.73 m2; by 24 months of age, 
ERPF averages 650 mL/minute/1.73 m2.
Because the renal extraction ratio for PAH varies with age, measure­
ments of ERPF must be interpreted with caution in the fetus and neonate. 
Indeed, the rate of extraction of PAH in the full-term newborn at 1 week of 
age is only about 60%, reaching 90%, the adult value, by 5 months. 
Paraaminohippurate clearance averages 148 mL/minute/1. 73 m2 in full- 
term infants at 2 weeks of life, increasing to 200 mL/minute/1.73 m2 by 2 to 
3 months. Paraaminohippurate clearance, corrected for body surface area 
(BSA), reaches adult levels sometime between 1 and 2 years of age. The in­
complete PAH extraction early in life appears to arise from the relatively 
greater blood flow to juxtamedullary nephrons and efferent arteriovenous 
shunting in cortical nephrons (see following), thereby allowing blood to by­
pass РАН-transporting segments of the nephron. In addition, the organic 
acid secretory pathways in the proximal tubule are immature early in devel­
opment. Thus, RBF and renal plasma flow (RPF) will be underestimated by 
PAH clearance alone in neonates, particularly in premature infants, in the 
absence of determination of the PAH extraction ratio.
The rate of RBF is determined by the cardiac output and the ratio of 
renal to systemic vascular resistance. Developmental changes in both deter­
minants contribute to the postnatal increase in RBF.
The two kidneys of the adult, which comprise 0.5% of the total body 
mass, receive approximately 20% of the total cardiac output, corresponding 
to a RBF of 4 mL/minute/g kidney weight. In contrast, the previable fetus 
receives only about 5% o f the cardiac output.
Although it has been proposed that imposition of functional demand 
at birth causes a dramatic increase in RBF, experimental evidence suggests 
that clamping of the umbilical cord does not in itself result in a sudden in­
crease in RBF. Indeed, RBF has been shown to increase progressively to
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6% of cardiac output by the end of the first week, reaching 15% to 18% by 
the end of the first month of life. Because further increases in the percentage 
of cardiac output received by the kidneys occur in parallel with increases in 
renal mass, the rate of RBF per unit kidney weight thereafter remains rela­
tively constant.
The intrarenal distribution of RBF in the newborn differs from that 
reported in the adult, reflecting the relative size and number of glomeruli 
present in the different regions of the kidney at that stage of development. 
The newborn kidney has a greater percentage of blood flow to the inner cor­
tical and medullary areas compared to the adult (Fig. 36). Maturation is ac­
companied by a redistribution of blood flow toward the superficial cortex, 
so that the ratio of inner cortical to outer cortical blood flow becomes pro­
gressively less than in the fetus. At maturity, about 93% of RBF goes to the 
cortex, which constitutes about 75% of the renal mass, whereas only 7% is 
distributed to the renal medulla and perirenal fat.
N e w b o r n  (n  -  5)
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FIG. 36. Postnatal changes in the intrarenal distribution of blood flow Relative rates of 
blood flow per glomerulus in the four cortical zones of the canine kidney. Zone I repre­
sents the most superficial region, and zone IV represents the deepest. The total height 
of the bars in each age group is equal At birth, the blood flow to the superficial cortex 
was lowest, with most blood flow perfusing the deep cortex By 6 weeks of age, this 
pattern was reversed. Maturation is accompanied by an increase in blood flow to the 
outer cortex, due primarily to a decrease in renal vascular resistance.
The primary factor responsible for the maturational increase in RBF 
and change in intrarenal distribution is a decrease in renal vascular resis-
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tance, the rise in cardiac output and mean arterial blood pressure (MAP) ac­
counting only partially for postnatal changes in renal hemodynamics. In­
deed, the intrarenal vascular resistance, localized both at the afferent and ef­
ferent arterioles, is much higher in the newborn than in the adult. The matu- 
rational decrease in vascular resistance in the kidney is of greater magnitude 
than in other organs.
A major contribution to the evolution of the kidney from a high- 
resistance, low-flow organ, with most of the blood supplying the inner cor­
tex, into a low-resistance, high-flow organ, with most of the blood supply­
ing the outer cortex, is provided by anatomic changes in the renal vascula­
ture. Because RBF increases during the neonatal period after volume expan­
sion, however, anatomic immaturity cannot be solely responsible for the 
low perfusion rate of the newborn kidney; a functional constraint also must 
exist.
Several vasoactive substances suggested to have a role in the regula­
tion of RBF include the renin-angiotensin system, the kallikrein-kinin sys­
tem, prostaglandins (PG), vasopressin, and atrial natriuretic peptides. The 
renal nerves and adrenergic nervous system also may play important roles in 
regulating renal vascular resistance in the neonate. These factors are consid­
ered in subsequent sections.
Anatomic Maturation o f  Vascular Structures. Experimental evidence 
indicates that the postnatal increase in RBF may be due in part to glomeru- 
logenesis or structural changes in the vascular bed, or both. Although de­
velopment and formation of new glo-meruli may continue after birth in 
premature infants of less than 34 to 36 weeks o f conceptional age, the in­
crease in RBF continues long after nephronogenesis is complete, suggesting 
that other factors are involved.
The intrarenal vascular system distal to the afferent arteriole in the 
neonate differs from that in the adult. Variability in the complexity of the 
glomerular capillary network exists early in postnatal life, with some 
glomeruli in the nephrogenic zone possessing only a single capillary loop. 
Inner cortical glomeruli at this age generally have a smaller number of cap­
illaries than the adult, although they appear similar in overall structure.
Efferent arterioles in the outer cortex of the neonatal kidney join the 
venous system by way of venous channels or sinusoids. Few of the efferent 
arterioles descend into the medulla to divide to form the vasa recta and peri­
tubular capillaries. Thus, the renal vasculature o f the neonatal kidney is 
characterized by fewer vessels and by efferent arterioles that connect di­
rectly to the venous system, thereby bypassing the proximal tubules.
Renin—Angiotensin System. The renin-angiotensin system is very ac­
tive in the fetus and newborn. The fetus produces renin as early as 17 weeks 
ot GA. Plasma renin activity (PRA) is inversely related to GA, decreasing 
from 60 ng/mL/hour at 30 weeks to about 10 to 20 ng/mL/hour at term.
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Plasma renin activity in the newborn may be 20-fold greater than in the 
adult. It increases gradually to a maximum by 3 to 6 days, then falls by 3 to 
6 weeks to a level that still exceeds normal adult levels.
The high levels of PRA in the neonate may be due to increased secre­
tion, decreased clearance, or smaller volume of distribution. Plasma renin 
activity increases as expected in response to changes in position from re­
cumbent to upright, volume depletion (e.g., hemorrhage, administration of 
furosemide), and hypoxia. Plasma renin activity levels decrease after vol­
ume expansion with isotonic saline and administration of substances such as 
the p-adrenergic antagonist propranolol, the PG synthetase inhibitor (PGSI) 
indomethacin, or vasopressin. The administration of saralasin, a competitive 
antagonist of angiotensin II (All), results in an increase in PRA, indicating a 
functional short-loop feedback mechanism in the newborn.
The high levels of PRA in the neonate are associated in general with 
levels of All and aldosterone that exceed those in the adult. Despite this, in 
contrast to the adult, systemic blood pressure is low and systemic vascular 
resistance is very low. Circulating levels of plasma All decrease during 
postnatal life in parallel with PRA.
Although the renin-angiotensin system does not appear to play a ma­
jor role in the control of basal blood flow in the fetus and newborn, the sys­
tem may be important under conditions of stress. An acute reduction in fetal 
blood volume or onset of fetal hypoxia results in significant increases in 
renin and All levels.
Kinins. Bradykinins are potent vasodilator peptides generated from 
the protein precursor kininogen by the proteolytic enzyme kallikrein. The 
kinins are inactivated by two kininases, kininase I, which is a carboxypepti- 
dase, and kininase II, which is a peptidyl dipeptide hydrolase and is also 
known as angiotensin-converting enzyme (ACE). Thus, inhibition of ACE 
not only decreases All production but also prevents breakdown of kinins.
Premature infants have undetectable levels of urinary kinins; urinary 
excretion of kallikreins and kinins is lower in newborns than older children. 
The role of these substances in modulating the function of the immature 
kidney remains unclear.
Prostaglandins. Complex interactions between PGs and the renin- 
angiotensin and kinin systems have been described, making it difficult to 
identify the specific effects of PGs on regulation of blood pressure, RBF, 
and electrolyte and water homeostasis.
Prostaglandins E2, D2, and I2 (PGE2, PGD2, PGI2) have been shown to 
reduce renal vascular resistance and increase RBF; prostaglandin F^ 
(PGF2o) and thromboxane A2 (TXA2) contribute to the vasoconstrictor tone. 
The urinary excretion of PGs, including PGE2/ PGF2a, and metabolites of 
PGI2 and TXA2, is high in the fetus, presumably reflecting a high rate of re­
nal synthesis. Urinary excretion of PGE2 and prostacyclin metabolites in the
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premature infant is 5 times that noted at term and 20 times that measured in 
older children. Although rates of excretion decrease after birth, urinary PG 
excretion remains significantly higher in neonates, especially premature in­
fants, than in children or adults.
Evidence suggests that PGs produced by the fetal kidney are involved 
in the regulation of RBF. Inhibition of PG synthesis results in reduction in 
RBF in the fetus, presumably mediated by an increase in renal vascular re­
sistance. In contrast, administration of indomethacin to the unstressed adult 
causes little change in RBF.
Urinary excretion of these substances decreases in parallel with 
changes in PRA; however, it remains unclear whether the effects on RBF 
are mediated by PGs or through their effects on the renin-angiotensin sys­
tem. Thus, in the newborn, as in the adult, PGs probably play little or no 
role in control of RBF in the normal subject at rest. Prostaglandins may, 
however, attenuate renal vasoconstriction in pathologic conditions.
Renal Nerves and the Adrenergic System. Circulating catecholamine 
levels, particularly norepinephrine, are very high just before and immedi­
ately after birth. The abrupt decrease in catecholamine release postnatally is 
not associated with any change in renal vascular resistance. It has been sug­
gested that the high vascular resistance of the maturing kidney is due to a 
high sensitivity of the neonatal renal vasculature to circulating catechola­
mines, acting directly on a-adrenergic receptors or indirectly on p- 
adrenergic receptors by means of renin-angiotensin release.
In general, the renal vascular bed of the newborn seems to be more 
sensitive, but less reactive, than that of the adult in response to renal nerve 
stimulation. The sensitivity of the newborn renal vasculature to the effects 
of the adrenergic nervous system may be related in part to differences in 
adrenergic receptor density compared to the adult. Innervation of the devel­
oping kidney is incomplete at birth, and most of the adrenergic receptors in 
the fetal and neonatal kidney are а-type. Alpha-adrenergic-mediated vaso­
constrictor effects are enhanced, whereas p-adrenergic and dopaminergic 
vasodilatory responses are decreased in the newborn compared to those in 
the adult. The gradual appearance of P-adrenergic receptors in the develop­
ing kidney may account for some vasodilation of the renal circulation.
Dopamine and Dopamine Receptors. Exogenous administration of 
dopamine, which results in an increase in RBF in the adult, has no effect in 
the young animal unless there also is an increase in systemic blood pressure 
and cardiac output. Renal cortical dopamine 1 receptor density does not ap­
pear to change with age, whereas that of dopamine 2 receptors decreases.
Arginine Vasopressin. The plasma concentration of arginine vaso­
pressin (AVP) in neonates increases abruptly after birth and is highest in in­
fants whose mothers labored before vaginal delivery. Although AVP has the 
potential to contribute to the increased renal vascular resistance characteris­
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tic of the neonate through its action on vascular and glomerular Vi recep­
tors, its role in regulating basal renal hemodynamics remains to be defined. 
Infusion of synthetic AVP does not alter RJBF and renal vascular resistance 
in fetal sheep; however, AVP may play a role in certain stress-induced re­
ductions in renal hemodynamics. For example, during hemorrhage, but not 
during hypoxemia, the marked decrease in RBF and increase in renal vascu­
lar resistance have been correlated closely with the rise in plasma AVP.
Atrial Natriuretic Factor. Atrial natriuretic peptides and messenger 
ribonucleic acids (mRNA) are present in both atria and ventricles of the fe­
tus in several species, and circulating levels of these pep-tides are signifi­
cantly elevated compared to those of the adult, due in part to decreased re­
nal clearance. Although the plasma levels of atrial natriuretic factor (ANF) 
fall to adult levels within the first few weeks of life, ANF release appears to 
respond to various stimuli that are associated with volume overload.
The role of ANF in volume and sodium homeostasis early in life re­
mains uncertain. Infusion of ANF into the renal artery of sheep results in 
renal vasodila-tion and an increase in RBF in fetal and newborn animals; 
systemic infusion causes a decline in MAP and thereby reduces RBF.
Autoregulation o f Renal Blood Flow. Autoregulation in the mature 
kidney allows for constancy of RBF as renal perfusion pressure varies over 
a wide range, from about 80 to 150 torr. Although systemic blood pressure 
in the fetus (i.e., 40-60 torr) and neonate (see Clinical Evaluation) is less 
than the lower limit of autoregulatory range defined for adults, experimental 
evidence suggests that the fetus and newborn are able efficiently to auto- 
regulate RBF at their prevailing low arterial pressure. The autoregulatory 
response probably is mediated in part by a myogenic response of the renal 
afferent arteriole, which dilates in response to a decrease in renal perfusion 
pressure, as well as by hormonal factors.
GLOMERULAR FILTRATION
Initiation of glomerular filtration in the human fetus occurs between 
weeks 9 and 12 of GA. It has been suggested that the functional demand 
placed on the neonatal kidney by cessation of placental function at birth 
stimulates glomerular filtration rate (GFR) to increase. However, accurate 
estimates of GFR, assessed by inulin clearance or true creatinine methodol­
ogy, indicate a developmental pattern of change in GFR that occurs whether 
the fetus remains in utero or is born prematurely. Specifically, GFR aver­
ages approximately 8 to 10 mL/minute/1.73 m2 at 28 weeks of GA, and in­
creases only slightly before 34 weeks of conceptional age, although body 
size and kidney weight increase appreciably during this time. After about 34 
weeks of conceptional age, at which time GFR averages 25 mL/minute/1.73 
m2, regardless of postnatal age, GFR increases rapidly, often by threefold to 
fivefold within 1 week, coincident with completion of nephronogenesis.
2 9 6
Thus, an infant born prematurely at 28 weeks of GA shows little increase in 
GFR until the infant is about 6 weeks old (i.e., until a conceptional age of 
34 weeks is attained). On the other hand, GFR increases from birth in in­
fants born at 34 weeks or beyond as it does in full-term infants. The GFR of 
neonates who are small for GA (SGA) is similar to that of infants whose 
body weight is appropriate for the same GA.
Changes in GFR immediately after birth are variable. In the human, 
however, the general pattern is one of an increase in GFR in the first 2 
hours, followed by a decrease to lower values at 4 hours.
During the first 4 months of life, GFR increases raw idly relative to 
body size, kidney weight, and surface area. Thereafter, a slower rise is noted 
until adult values, determined on the basis of BSA, are reached by 2 years 
of age. Overall, the increase in absollute GFR (in mL/minute) observed dur­
ing development is about 25-fold in a number of species.
Total-kidney GFR (TKGFR) is determined by the number of func­
tional nephrons and the rate of filtration per nephron. Increases in either one 
or both of these factors can account for the postnatal increase in GFR.
Analysis of the similar developmental pattern of change in GFR for 
several mammalian species indicates that the accelerated rate of increase in 
GFR is observed around the time nephronogenesis is complete. Thus, those 
species that complete nephronogenesis in utero, including the full-term hu­
man neonate, sheep, and guinea pig, show a rapid increase in GFR after 
birth. In contrast, premature infants continue to produce new nephrons after 
birth; GFR increases rapidly only after nephronogenesis has been com­
pleted.
Glomeruli are formed in the nephrogenic zone of the kidney, that area 
of the renal cortex directly under the renal capsule. With maturation, those 
glomeruli migrate to deeper zones of the renal cortex. At birth, the more 
mature glomeruli in the juxtamedullary cortex, nearly as large as glomeruli 
in the adult kidney, will have higher filtration rates than the most recently 
formed glomeruli in the superficial cortex, some of which may not begin fil­
tration for some time. Thus, GFR matures centrifugally. As nephrons 
enlarge and forces that regulate filtration permit, GFR increases, with most 
of the surge due to enhanced perfusion of superficial nephrons, related tem­
porally to the increase in total RBF and its centrifugal redistribution within 
the renal cortex.
The addition of newly functioning nephrons is insufficient, however, 
to account for the large increases in GFR observed during maturation. A 
substantial rise in rate of filtration per nephron also must occur. Measure­
ments of single-nephron GFR (SNGFR) and TKGFR by micropuncture 
techniques in superficial nephrons of the guinea pig show little increase in 
SNGFR in the first 2 weeks of life, followed by a surge thereafter that con­
tinues until the SNGFR of the adult, about 20 nL/minute, is reached by 4 to
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5 weeks. During this time period, TKGFR increases at a constant rate. 
These data indicate that the increase in TKGFR arises initially from an in­
crease in SNGFR of deep nephrons; superficial nephrons appear to contrib­
ute to TKGFR later.
The process of urine formation starts with ultrafiltration of plasma 
through the glomerular capillary membrane. The rate of filtration depends 
on filtration characteristics of the membrane and on the net ultrafiltration 
pressure, represented by the difference between hydrostatic pressure (i.e., 
glomerular capillary hydraulic pressure minus the Bowman space pressure) 
and colloid osmotic pressure within the capillary loop. The capillary hydro­
static pressure promotes filtration, whereas the colloid osmotic pressure of 
die blood and the hydrostatic pressure in the Bowman space oppose it.
The postnatal increase in GFR may result from changes in all of these 
variables, including surface area available for filtration, permeability of the 
filtering membrane, and effective filtration pressure. The variables that must 
be considered in describing changes in GFR are described by the following 
formula:
SNGFR = Pufx к x s,
where Puf is the net ultrafiltration pressure, к is the hydraulic conduc­
tivity of the glomerular capillary per unit surface area (i.e., index of mem­
brane permeability), and S is the surface area for filtration. The product of к 
times S is indicated by Kf.
Net Ultrafiltration Pressure. The low systemic blood pressure in the 
immediate postnatal period, substantially less than in the adult in many 
mammalian species, suggests that glomerular capillary pressure might be 
low as well. In fact, measurements of glomerular capillary pressure per­
formed in newborn guinea pigs indicate an increase from 18 to 38 torr be­
tween day 1 and 30 of life. During this same period, MAP increases from 40 
to 60 torr. Concomitantly, plasma oncotic pressure rises, as does proximal 
tubular pressure, an index of the pressure in the Bowman space. The net ef­
fect of these changes is a 2.5-fold increase in net ultrafiltration pressure be­
tween birth and 50 days of life, an increase accounting for only about 10% 
of the 25-fold increase in GFR observed with maturation.
Kf. Kf, the product of the total surface area available for filtration and 
the hydraulic conductivity of the capillary, provides an index of the net 
permeability property of the glomerular capillary. An increase in Kf appears 
to be necessary for the increases in glomerular plasma flow and SNGFR ob­
served during the later stages of maturation.
Measurements of hydraulic conductivity, or water permeability per 
unit surface area, have not been performed during development. Analysis of 
the clearance of macromolecules in dogs suggests that changes in the per­
meability characteristics of the glomerular capillary membrane play only a 
small role in the increase in GFR with development.
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Glomerular capillary surface area increases during development by an 
average of fourfold in the juxtamedullary glomeruli and by tenfold in the 
superficial glomeruli, providing a combined increase in capillary surface 
area of approximately eightfold during the first 6 weeks of life, indicating 
that the maturational increase in GFR is caused primarily by an increase in 
glomerular surface area.
Many of the vasoactive substances known to affect RBF also influ­
ence GFR. Cortisone and growth hormone have been reported to increase 
GFR concomitant with an increase in RBF. Angiotensin II, a powerful 
vasoconstrictor of both afferent and efferent arterioles, present in high 
circulating levels in the infant, is known to reduce RBF and constrict the 
glomerular mesangium, thereby reducing the surface area available for fil­
tration; thus, it may determine glomerular blood flow and hydrostatic pres­
sure within glomerular capillaries. A role for PCs in regulation of GFR has 
been suggested by the observation that administration of PGSI to newborn 
babies results in a transient decrease of GFR.
Autoregulation o f Glomerular Filtration Rate. In the adult, RBF and 
GFR are maintained over a wide range of MAPs (i.e., 60-150 torr). This 
autoregulation is accomplished primarily by changes in renal vascular resis­
tance at the afferent and efferent arteriolar level. As MAP falls, efferent ar­
teriolar resistance increases, resulting in maintenance of glomerular capil­
lary pressure and preservation of filtration rate. If MAP falls below a critical 
lower value, renal perfusion pressure and GFR decrease and prerenal az­
otemia ensues. On the other hand, as MAP increases, afferent arteriolar re­
sistance increases to limit a rise in glomerular hydrostatic pressure and thus 
protect the glomeruli from the effects of systemic hypertension. Experimen­
tal evidence indicates that the full-term newborn also can autoregulate, al­
beit at a lower range of MAP. The autoregulatory range, however, has not 
been established.
Filtration Fraction. The normal balance between GFR and RBF is 
calculated as the filtration fraction (GFR/RPF), and averages 0.2 in the adult 
kidney. Evidence indicates that the developmental increase in filtration frac­
tion appears to be determined mainly by changes in GFR. Renal blood flow 
increases in a linear fashion that parallels renal growth, whereas GFR in­
creases in a nonlinear pattern until nephronogenesis is complete.
Tubuloglomerular Feedback. Maturational relationships between tu­
bular flow and GFR (i.e., tubuloglomerular feedback) also occur with 
growth; this mechanism is thought to contribute to the autoregulatory main­
tenance of RBF and GFR. A stimulus (e.g., tubular flow rate, ion concentra­
tion) at the macula densa is transmitted to the vascular structures of the 
nephron that control GFR. The feedback system aims at maintaining a con­
stant rate of water and salt delivery to distal segments of the nephron in 
which reabsorption is regulated to maintain fluid balance. The tubuloglome-
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rular feedback mechanism (i.e., change of SNGFR induced by a given 
change in tubular flow rate) is maximally sensitive in a range that corre­
sponds to the values of SNGFR and tubular flow rate under normal condi­
tions. As GFR increases with maturation, the maximal response and flow 
range of maximum sensitivity also increase, so that the relative sensitivity 
of the tubuloglomerular feedback mechanism is unaltered during growth.
TUBULAR FUNCTION
Sodium, bicarbonate, phosphate, amino acids, and glucose are reab­
sorbed primarily by the proximal tubule. Although most filtered potassium 
also is reabsorbed proximally, net urinary potassium secretion occurs in the 
distal tubule, primarily in the cortical collecting duct. Tubular secretion of 
organic acids occurs in the proximal tubule. Hydrogen ion secretion occurs 
in both the proximal and distal tubules.
Sodium. Term infants are in a state of positive sodium balance, a req­
uisite for growth, particularly of bone. Healthy infants fed a variety of 
formulas retain approximately 30% of ingested dietary sodium. The 
magnitude of this positive balance remains relatively constant within a wide 
range of sodium intakes. The fractional excretion of sodium (FENa), which 
may be as high as 20% during fetal life, decreases progressively during 
gestation, so that the FENa in the full-term newborn generally averages 
about 0.2%. Premature infants of less than 30 weeks of GA continue to 
show elevated values of FENa, similar to those observed in the fetus, which 
may exceed 5% during the first few days of life. In these infants, excessive 
urinary sodium losses exceeding dietary sodium intake (e.g., breast milk, 
low-salt formula), often create a state of negative sodium balance and loss 
of body weight during the first 2 weeks of life (i.e., hyponatremia of 
prematurity). It has been estimated that these infants require at least 2 
mEq/kg/day of supplemental sodium to maintain a normal sodium 
concentration and remain in positive balance.
Postnatal changes in renal sodium excretion proceed in two phases, at 
least in the sheep. The first phase, which occurs within 2 hours of birth, is 
characterized by a transient increase in FENa and urinary sodium excretion 
to levels exceeding those observed during fetal life. This phenomenon may 
be related to changes in the distribution of intrarenal blood flow, changes in 
secretion of natriuretic substances and hormones that regulate sodium bal­
ance, or both. After the first few hours of postnatal life, in the second phase, 
the FENa and urinary sodium excretion decline rapidly, possibly related to 
contraction of the extracellular fluid (ECF) volume.
Studies of full-term human infants and other newborn animals dem­
onstrate parallel and proportionate increases in GFR and the reabsorptive 
capacity of the proximal tubule, thereby maintaining glomerulotubular bal­
ance. Thus, the fractional reabsorption of sodium in the proximal tubule re-
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mains constant at about 70% in euvolemic animals. A functional glomerulo­
tubular imbalance may exist in the premature infant whereby the reabsorp- 
tive capacity of the proximal tubule lags behind the capacity for glomerular 
filtration.
Clearance studies in premature infants indicate low rates of proximal 
tubular reabsorption of sodium, resulting in increased delivery to the distal 
tubule. Because the increased distal delivery is not compensated for by in­
creased distal reabsorption, despite very high circulating aldosterone levels, 
increased sodium excretion occurs. Explanations for this distal tubular limi­
tation include a relative tubular insensitivity to aldosterone in the premature 
infant, and the presence of maximal aldosterone stimulation without possi­
bility of additional effect. Conditions that may augment the FENa include 
hypoxia, respiratory distress, hyperbilirubinemia, acute tubular necrosis 
(ATN), administration of theophylline or diuretics, polycythemia, and in­
creased fluid and salt intake.
Although both term and preterm newborns can tolerate a wide range 
of salt intake, the newborn kidney is characterized by a limited capacity to 
excrete a sodium load compared to its mature counterpart. Exogenous ad­
ministration of a sodium load to an adult is followed by immediate expan­
sion of the extracellular fluid space. This signals the kidney to decrease tu­
bular sodium reabsorption, resulting in increased excretion of sodium and a 
relatively rapid return of the ECF space to the baseline condition. When 
full-term newborn infants are given a sodium load in excess of 12 
mEq/kg/day, however, they experience a rise in serum sodium levels, ab­
normal increase in weight, and generalized edema. This blunted natriuresis 
of the newborn kidney appears to be due more to enhanced sodium reab­
sorption by the distal nephron than to the low GFR.
The ability to excrete a sodium load increases with age over the first 
year of life, due to increases in filtered sodium with increased GFR and 
FENa. Paradoxically, preterm infants of 34 to 36 weeks of GA excrete a so­
dium load more efficiently than do term newborns, but not as efficiently as 
adults. In these subjects with decreased proximal reabsorption under basal 
conditions, the further depression in proximal reabsorption during saline 
loading increases distal delivery even further, presumably exceeding the re- 
absorptive capacity of this segment.
The observation that the fractional reabsorption of sodium in the 
proximal tubule of the full-term newborn is similar to that observed in the 
adult indicates that sodium retention in the infant must arise from enhanced 
reabsorption in more distal segments of the nephron. The avidity of the dis­
tal nephron for sodium reabsorption, which increases with GA, may be re­
lated to the high levels of stimulation of the renin-angiotensin-aldosterone 
system. It was showed that infants born between 30 and 32 weeks of gesta­
tion and studied at 1 week of age, while receiving 1.5 to 2.0 mEq/kg/day of
301
sodium, generally were in negative sodium balance with high urinary so­
dium excretion rates. Plasma renin activity was directly related to urinary 
sodium loss but was inversely related to plasma aldosterone concentration 
and sodium balance. There was a positive correlation between plasma aldos­
terone concentration and sodium balance, however, suggesting that prema­
ture infants can augment their PRA in response to salt wasting, but that their 
adrenals initially fail to respond adequately to this stimulation. The relative 
hypoaldosteronism results in an inability to conserve sodium, manifested 
clinically by weight loss and hyponatremia.
In addition to the renin-angiotensin-aldosterone system, regulation of 
sodium excretion during maturation is by circulating catecholamines, renal 
sympathetic innervation, ANF, and glucocorticoids. Studies in newborns in­
dicate a relatively poor natriuretic response to ANF compared to their adult 
counterparts. Renal PGE2 and PGI2 are natriuretic in the adult. Thus, ad­
ministration of indomethacin to the adult reduces sodium excretion; in con­
trast, however, this inhibitor causes a natriuresis when administered to fetal 
sheep, despite a decrease in fetal RBF. Administration of cortisol to fetal 
sheep is associated with depression of proximal sodium reabsorption.
Potassium. Potassium is transported actively across the placenta from 
mother to fetus. Indeed, fetal potassium is maintained at levels exceeding 5 
mEq/L even in the face of maternal potassium deficiency.
Unlike adults who are in zero balance, growing infants maintain a 
state of positive potassium balance. The relative conservation of potassium 
early in life generally is associated with higher plasma potassium values 
than in the adult; plasma potassium levels average 5.2 mEq/L from birth to 
age 4 months, decreasing to 4.3 mEq/L by 1 year of age. The renal clear­
ance of potassium in the infant is less than in the older child, even when 
corrected for GFR. Children and adults ingesting a regular diet containing 
sodium in excess of potassium excrete urine with a sodium-potassium ratio 
greater than one, as expected. Although the sodium-potassium ratio of 
breast milk and commercial infant formulas averages 0.5, the urinary so­
dium-potassium ratio of the newborn also is greater than one, consistent 
with significant potassium retention.
Infants, like adults, can excrete potassium at a rate that exceeds its 
glomerular filtration when given a potassium load, indicating the capacity 
for net tubular secretion; however, the rate of potassium excretion per unit 
body weight in response to exogenous potassium loading is less in newborn 
than older animals. Clearance studies in saline-expanded dogs also provide 
indirect evidence for a diminished secretory and enhanced reabsorptive ca­
pacity of the immature distal nephron to potassium.
Filtered potassium is reabsorbed almost entirely in proximal segments 
of the nephron, urinary potassium being derived predominantly from distal 
potassium secretion. Therefore, potassium balance, at least in the adult, is
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maintained by renal secretion rather than reabsorption. Approximately 50% 
of the filtered load of potassium is reabsorbed along the proximal tubule ir. 
both newborns and adults. Up to 40% of the filtered load of potassium 
reaches the superficial distal tubule of the newborn, in contrast to about 
10% in mature animals, providing evidence for functional immaturity of the 
loop of Henie.
The capacity of the immature distal tubule and collecting duct for po­
tassium transport has not been well defined. Micropuncture data indicate 
that the mass flow of potassium entering the tubular fluid between the late 
distal tubule and final urine in the newborn is less than that in the adult. Ex­
amination of single-nephron segments during postnatal development indi­
cates that the rate of potassium secretion in the cortical collecting duct, that 
segment responsible for potassium secretion in the adult, is low early in life. 
Na-K-ATPase activity in neonatal segments has been reported to be only 
50% of that measured in the mature nephron. Because the cell potassium 
content is similar in neonatal and mature collecting ducts, the limitation in 
potassium secretion at this site probably derives from an unfavorable elec­
trical gradient opposing secretion or reduced apical membrane permeability 
of this segment to potassium.
Additional factors that may limit potassium secretion early in life in­
clude the low distal flow rates characteristic of the newborn, and the unre- 
sponsive-ness of the immature nephron to mineralocorticoid stimulation. 
Plasma aldosterone concentrations in the fetus and newborn are high com­
pared to the adult's; yet, clearance studies demonstrate a relative insensitiv­
ity of the immature kidney to this hormone. Distal tubular flow rates are low 
in newborn animals, even when appropriate correction is made for the small 
tubular size. Low flow rates in the cortical collecting duct may lead to 
higher concentrations of potassium in the tubular fluid, creating a less fa­
vorable ceil-to-lumen concentration gradient, thereby limiting potassium se­
cretion. The postnatal surge in superficial SNGFR that occurs in maturing 
animals at about 3 to 4 weeks of postnatal life should increase fluid delivery 
into the cortical collecting duct and promote potassium secretion.
Acid—Base. The acid-base status of the fetus is maintained by placen­
tal function and maternal mechanisms. The fetal kidney in the second one- 
half of pregnancy, however, is able to acidify the urine. The bicarbonate 
threshold, low in the fetus, increases with GA.
Immediately after birth, the acid-base state o f the full-term newborn 
is characterized by a metabolic aci-dosis. Recovery occurs within 24 hours 
in the full-term infant, an increase accomplished in large measure through 
pulmonary excretion of C 02.
The normal range for serum bicarbonate is lower for preterm infants 
(16-20 mmol/L) and full-term infants (19-21 mEq/L) than for children and 
adults (24-28 mmol/L), presumably due to a low renal tubular bicarbonate
3 0 3
threshold. The low threshold niay arise from a relatively expanded extracel­
lular fluid compartment in the neonate or immaturity of the renal tubular re- 
absorptive capacity for bicarbonate re-absorption. Experimental evidence 
suggests that renal tubular carbonic anhydrase activity, present in the human 
fetal kidney in late gestation, does not limit the capacity of the fetal kidney 
for bicarbonate reabsorption.
The capacity of the neonatal kidney for renal acidification is limited, 
due in part to decreased excretion of urinary buffers, including phosphate 
and ammonium ions. Phosphate loading, administration of cow milk that is 
rich in protein and phosphate instead of breast milk, or high protein feeding 
enhances the ability of the newborn to excrete titratable acids and ammonia. 
Before feeding, newborns excrete 10% to 25% of H+ as titratable acid. In 1- 
week-old babies fed cow milk, net acid excretion per kilogram body weight 
is high and 60% of urinary acid is in the form of titratable acid. In contrast, 
1-week-old breast-fed babies, who ingest a milk low in phosphate and pro­
tein, excrete 60% less net acid than cow-milk-fed infants, and only 20% of 
this is titratable acid.
Term newborns generally are able to excrete a maximal acid load 
within the first 2 months of life. Premature infants born at 34 to 35 weeks of 
GA and studied 1 to 3 weeks after birth exhibit rates of excretion of net 
acid, titratable acid, and ammonium that are about 50% lower than term ba­
bies of similar postnatal age; net acid excretion increases to levels observed 
in term newborns only after 3 weeks of age. In response to acid loading with 
ammonium chloride, urinary pH of premature infants rarely decreases below 
5.9 until the second month of life. In contrast, by the end of the second 
postnatal week, urine pH values of 5.0 or lower, comparable to those in the 
adult, can be consistently achieved in term infants.
The final site of urinary acidification is the renal collecting duct. 
Functional immaturity of this segment and the acid-base transporting inter­
calated cells therein may further limit the ability of the neonate to eliminate 
an acid load.
Low rates of ammonia synthesis and excretion may contribute to the 
inability of the immature kidney to excrete acid. The rate of ammonia excre­
tion in response to acid loading in human infants does not reach mature val­
ues until 2 months of age.
Up to 10% of preterm infants develop a partially compensated hyper­
chloremic metabolic acidosis during weeks 1 to 3 of life (i.e., late metabolic 
acidosis), despite an otherwise healthy appearance. Typically, spontaneous 
remission occurs in the subsequent 2 weeks. These infants are characterized' 
further by an apparent delay in postnatal weight gain despite ample dietary 
intake, suggesting a high rate of endogenous acid formation in infants 
whose dietary intake exceeds their anabolic capacity. Although infants pro­
vided supplemental sodium bicarbonate to maintain acid-base homeostasis
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showed greater increases in length than controls, there were no differences 
in weight gain between the two groups. Because supplementation with so­
dium results in an increase in serum bicarbonate, it has been suggested that 
the late metabolic acidosis and low bicarbonate threshold results in part 
from large urinary sodium losses.
Calcium. Urinary excretion of calcium varies inversely with GA in 
the first week of life and varies directly with urine flow and sodium excre­
tion. Increased calcium excretion may contribute in part to early neonatal 
hypocalcemia, which occurs in the first 24 to 48 hours of life. The urinary 
calcium-creatinine ratio in full-term infants ranges from 0.05 to 1.2 during 
the first week of life, but may exceed 2 in premature neonates. In children 
over 1 year of age, the ratio is approximately 0.2, and in adults, less than 
0.11. Urinary calcium excretion from 1 to 15 years of age averages 2.4 
mg/kg/day, with an upper limit of 4 mg/kg/day.
The high fractional excretion of calcium in preterm infants may be re­
lated to maturational changes in the tubular handling of calcium. Approxi­
mately 50% of filtered calcium is reabsorbed along the superficial proximal 
tubule in mature rats, yet only 1% of filtered calcium is excreted. Thus, in 
the adult, almost one-half of the filtered calcium is reabsorbed at a site be­
yond the proximal tubule or in deep nephrons. The fractional reabsorption 
of calcium in the neonate has been shown to be decreased in the loop of 
Henie, as is the case for sodium, potassium, and chloride.
The roles of parathyroid hormone (PTH) and calcitonin in the regula­
tion of renal calcium excretion in the neonatal period are unclear. In mature 
animals and in adults, PTH decreases the urinary excretion of calcium, 
whereas calcitonin at high doses increases calciuria. Parathyroid hormone- 
responsive adenylate cyclase has been found in renal cortical homogenates 
from preterm rabbits and in the thick ascending loop of Henie in 2-day-old 
puppies. It has been suggested that neonatal hypocalcemia may be due to end 
organ unresponsiveness to PTH. In premature and full-term newborns, how­
ever, the administration of exogenous PTH increases urinary excretion of cy­
clic adenosine monophosphate (cAMP), results in a calcemic response but 
affects calciuria and phosphaturia only minimally. The response of the thick 
ascending limb to PTH is decreased at birth and increases with age; similar 
maturational increases are seen with calcitonin.
Magnesium. Ninety-seven percent of the filtered magnesium is reab­
sorbed by the mature nephron, largely in the loop of Henie. Although tubu­
lar reabsorption of magnesium is almost complete in the case of hypomag­
nesemia, it decreases in the case of hypermagnesemia. The administration 
of PTH results in an increase in serum concentration of magnesium.
Only limited data are available on the maturation of renal magnesium 
transport during postnatal life. Micropuncture analysis of magnesium trans­
port in developing rats showed a decrease in the fractional reabsorption of
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magnesium in the proximal tubule during maturation. In contrast, the frac­
tional reabsorption of magnesium in the loop of Henie had already reached 
mature values of about 60% in the youngest animals.
Phosphate. In contrast to most other transport processes, the capacity 
of the immature kidney to reab-sorbphosphate is greater than in the adult. 
The tubular reabsorption of phosphate increases from 85% of the filtered 
load at 28 weeks of GA to 99% at term and decreases thereafter to about 
85% between 3 and 20 months of age. An increase in phosphate load, pro­
vided by a change in formula from breast milk to cow milk, results in dou­
bling in the renal clearance of phosphate and a decrease in fractional reab­
sorption from 95% to 80%.
Clearance studies performed in infants and children suggest that 
phosphate retention in the young is due in large part to the low GFR. Stud­
ies in experimental animals, however, demonstrate enhanced tubular reab­
sorption early in life. Younger subjects have a higher maximal net reabsorp­
tion (Tm) of phosphate per unit glomerular filtrate (Tm/GFR) than adults. 
Micropuncture analysis of newborn and adult guinea pigs confirm a higher 
fractional reabsorption of phosphate in the newborn proximal tubule (75%) 
compared to the adult (65%); distal phosphate reabsorption also is higher in 
younger than older animals.
The high reabsorptive capacity of the immature kidney for phosphate 
is thought not to be related to PTH levels. Serum levels of PTH are low 
immediately after birth, increasing substantially thereafter to levels in in­
fancy exceeding those observed in later childhood. Exogenous administra­
tion of PTH to humans or experimental animals results in a blunted phos- 
phaturic effect in immature kidneys. The lack of effect may be related to 
,,oorly developed proximal tubular segments responsive to PTH or a low in­
tracellular phosphate concentration. By the end of the first week of life, 
however, full-term infants exhibit a prompt phosphaturic response and an 
increase in urinary cAMP excretion after PTH administration. The mecha­
nisms responsible for the high reabsorptive capacity of the kidney for phos­
phate early in life include developmental differences in the intrinsic proper­
ties of sodium phosphate cotransport in the luminal membrane of the tubule 
or hormonal regulation of phosphate transport between the neonate and 
adult.
Glucose. Premature infants of less than 34 weeks of GA have a higher 
urinary glucose concentration, higher fractional glucose excretion, and 
lower fractional reabsorption of filtered glucose than full-term infants and 
older children. The tubular reabsorptive capacity for glucose appears to in­
crease with increasing GA; however, the maximal reabsorption of glucose 
factored by GFR, the fractional reabsorption of glucose, is similar in full- 
term newborn infants and adults. Similar observations have been made in 
experimental animals. These results provide additional evidence for preser­
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vation of glomerulotubular balance, at least in term infants. The renal 
threshold for glucose, however, is lower in newborns than in older animals, 
suggesting a greater degree of nephron heterogeneity early in life.
Studies in the rat and guinea pig indicate that the neonatal renal tu­
bule possesses two distinct membrane transport systems for glucose, 
whereas only one, the low-affinity system, is present in adults. It is not clear 
when the high-affinity system disappears during maturation, but its presence 
early in life may enable the anatomically immature kidney to reabsorb sugar 
more efficiently from the glomerular filtrate. The single glucose transport 
system in the fetus is qualitatively similar to that of the adult; specifically, it 
is sodium dependent, electro-genie, and pH sensitive.
Organic Acids. Organic acids, including PAH (see Renal Blood Flow) 
and endogenously produced uric acid, are eliminated by filtration and 
proximal tubular secretion. Organic acids are transported from the peritubu­
lar circulation across the basolateral surface of the proximal tubule to the 
tubular fluid. The renal clearance of organic acids is low in the neonate, 
even when corrected for body size, and increases gradually with age. As 
discussed previously, the limitation in tubular excretion of weak acids may 
be due in part to the preponderance of blood flow to the juxtamedullary re­
gion, bypassing tubular secretory sites. Additional variables that may ac­
count for the low clearance of organic acids include the low GFR, reduced 
numbers of transporter sites, and limited energy for transport.
Amino Acids. The renal reabsorption of many amino acids in newborn 
animals and humans is low compared to that of adults, often resulting in 
aminoaciduria. This does not appear to be a generalized defect in amino 
acid reabsorption because other amino acids (e.g., methionine, isoleucine, 
leucine, tyrosine) are reabsorbed more completely. Specific amino acid 
transport systems have been identified in newborn kidneys. Experimental 
evidence suggests that the limitation in luminal reabsorption arises from a 
lower rate of efflux out of the cell into the peritubular circulation compared 
to the adult, a mechanism that also would account for the high intracellular 
concentrations of amino acids observed early in life.
Urinary Concentration. In mammals, fetal urine is hypotonic with re­
spect to fetal plasma. This observation may reflect a limited medullary os­
motic gradient, arising either from structural immaturity of the medulla or a 
relatively high blood flow through the vasa recta, which disperses the in- 
trarenal solute gradient normally found in the medulla of more mature ani­
mals. Another possibility is reduced sensitivity of the fetal nephron to vaso­
pressin due to reduced numbers of AVP receptors or poor coupling between 
AVP receptor binding and cAMP generation. The fetal kidney is able both 
to concentrate and to dilute urine, depending on the hydration state of the 
fetus and thus the mother. Maternal water deprivation or infusion of AVP
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into the fetus leads to a fall in fetal urine flow rate and a decrease in free 
water clearance.
Urine voided at or shortly after birth generally is hypotonic with re­
spect to plasma. Maximal urinary concentrating ability in the neonate has 
been shown to be less than that of children and adults. After fluid depriva­
tion for 12 to 24 hours, the maximal urine osmolality achieved in both pre­
mature infants and full-term newborns averages about 500 mOsm/kg, a 
value roughly 60% that observed in older children and adults. A few 1- to 2- 
month-old infants may be able to achieve a urine osmolality as high as 1000 
mOsm/kg, a maximal value generally not seen before 12 months of age.
The limited ability of infant kidneys to concentrate urine may be re­
lated to several factors, including low GFR (see Glomerular Filtration), im­
maturity of the countercurrent multiplication and exchange system thereby 
preventing buildup of a medullary gradient, and diminished responsiveness 
of the distal nephron to antidiuretic hormone (ADH).
Medullary Gradient. A direct relationship has been demonstrated in 
the rat between elongation of the loops of Henie, their penetration into the 
medulla, and the capacity to concentrate the urine. The inner medulla and 
renal papillae are poorly developed in the immature kidney. In the rat, the 
1.6-fold increase in length of the renal medulla correlates well with the 1.5- 
fold increase in urine osmolality observed between 10 and 20 days of age.
Associated with this anatomic maturation is the buildup of a high 
interstitial solute concentration gradient in the medulla. This buildup occurs 
mostly through development of two aspects of the urinary concentrating 
mechanism: the ability of the thick ascending limb of the loop of Henie to 
reabsorb sodium and the ability of this segment to sequester urea.
Antidiuretic Hormone. The decreased ability of the immature kidney 
to concentrate urine is not due to an inability of the fetus or neonate to syn­
thesize ADH. Circulating levels of ADH are elevated in preterm and term 
infants and decrease rapidly in term infants within 24 hours of birth. Studies 
in fetal and newborn animals, as well as human infants, indicate an appro­
priate response to osmolar or volume stimuli known to affect ADH release, 
similar to that observed in their mature counterparts Thus, it is likely that 
diminished end organ responsiveness to ADH in the young contributes to 
the low concentrating ability of the newborn.
Exogenous administration of A VP or l-des-amino-8-d-AVP 
(DDAVP) to healthy 1- to 3-week-old newborns leads to a response of 
shorter duration and reduced magnitude than that observed at 4 to 6 weeks. 
The diminished sensitivity of the newborn kidney to AVP may be due to a 
paucity of vasopres-sin receptors, limited activation of adenylate cyclase 
and therefore cAMP generation by AVP, or both.
Prostaglandin E2 inhibits the action of AVP on the hydraulic perme­
ability of the collecting duct. Although infants excrete more PGE2 per unit
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BSA than do older children (see Prostaglandins), inhibition of PG synthesis 
in fetal lambs has no effect on urinary concentrating ability.
Thus, the limited ability of the neonatal kidney to concentrate the 
urine is due to both structural and functional constraints that together pre­
vent generation of the requisite corticopapillary osmotic gradient.
Urinary Dilution. Premature infants (<35 weeks of GA) studied under 
conditions of maximal water diuresis decrease urine osmolality to 70 
mOsm/kg, whereas infants over 35 weeks of GA are able to reduce urine 
osmolality to 50 mOsm/kg. This is associated with a significantly greater 
osmolar clearance in the premature infants, indicating that they cannot di­
lute their urine as well as term infants or adults. Although there is greater 
proximal sodium rejection in preterm than term infants, the high avidity of 
the distal nephron for sodium reabsorption allows the neonate, especially 
the preterm infant, to generate a free water clearance greater than that in 
adults. Despite the greater capacity for free water clearance, the ability of 
the neonate to excrete a hypotonic load is limited, presumably due to the 
low GFR.
CLINICAL EVALUATION OF FUNCTION AND DISEASE
A newborn infant presenting with oligoanuria or with Potter syn­
drome, in the absence of prolonged rupture of the membranes, obviously 
has a renal problem. On the other hand, renal anomalies or malfunction can 
remain unnoticed until routine observations reveal abnormalities such as a 
mass, hypertension, an unexpectedly high gentamicin level, or a high serum 
or plasma creatinine concentration (Pcr). Temperature instability or unex­
pected jaundice may lead to the diagnosis of urinary tract infection (UTI). If 
an early diagnosis of a renal anomaly is made, several complications may be 
prevented, including those related to the kidney itself (e.g., progressive loss 
of renal function due to systemic hypertension, obstructive or reflux uropa- 
thy, or infection) and those related to other organs (e.g., cerebral hemor­
rhage, seizures or congestive heart failure [CHF] secondary to hypertension, 
ventricular arrhythmia secondary to hyperkalemia).
In this section, clinical and laboratory features that should raise suspi­
cion of a renal problem are reviewed, and an approach to establish the cor­
rect diagnosis is presented. Factors that increase the risk for renal or urinary 
tract malformations are analyzed.
INCIDENCE OF RENAL AND URINARY TRACT MALFORMATIONS
The exact incidence of major renal and urinary tract malformations in 
newborn infants can only be estimated, since a large prospective population- 
based study using ultrasonography (US) has not been reported.
Early studies using neonatal abdominal palpation as the screening method 
showed an incidence of 0.2% to 0.6%, whereas neonatal autopsy series had
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an incidence of 7% to 9%. Series using routine prenatal US have detected 
anomalies in 0.1% to 0.7% of fetuses. In two prospective studies that used 
routine US screening in a cohort of newborn infants, 1.0% of infants were 
found to have renal anomalies. However, in one of these studies, this figure 
may be an underestimation of the true incidence in a neonatal population, 
since only those infants not requiring intensive care were included. A small 
study done in a predominantly Caucasian population, using a perinatal ap­
proach that combined family history, prenatal US, physical examination, 
and case-oriented neonatal imaging showed an incidence of 1.3%. A similar 
incidence (1.4%) was found in 2- to 10-month-old infants by routine US. 
The incidence of urinary tract anomalies in males in all large series is ap­
proximately twice that in females. Whether the incidence varies with geog­
raphy or race remains to be determined.
HISTORY
FAMILY HISTORY
Positive family history should be sought for hereditary disease, in­
cluding renal cystic disease, tubular disorders, and nephrotic syndrome. 
There is a 9% incidence of asymptomatic renal malformations— most often 
unilateral renal agenesis—in the first-degree relatives of infants with agen­
esis or dysgenesis of both kidneys or agenesis of one kidney and dysgenesis 
of the other. A study using US has confirmed that in some families, bilateral 
agenesis or dysplasia is inherited as an autosomal dominant trait. The clini­
cian should be cautious not to immediately exclude a diagnosis of an auto­
somal dominant disease, since there may be variable penetrance or time of 
presentation (e.g., adult-type polycystic disease) and because of the 
possibility of a new mutation. In addition, the history for prior fetal loss 
should be carefully reviewed, with autopsy review if possible.
TERATOLOGY
The risk of renal or urinary tract malformations is increased by mater­
nal diabetes and by certain medications or drues. including alcohol, 
trimethadione, thalidomide, and cocaine, Maternal diabe­
tes, at least in the absence of tight diabetic control initiated before concep­
tion, is associated with urogenital malformations, with an incidence of 2.6%, 
compared to an incidence of 1.2% in controls, as well as with neonatal renal 
venous thrombosis. The risk for renal or urinary tract malformations is high 
when an infant of diabetic mother has either a caudal regression syndrome or 
a femoral hypoplasia-unusual fades syndrome. Fetal alcohol syndrome is as­
sociated with various types of renal malformations, including unilateral renal 
agenesis, renal hypoplasia, ureteral duplication, and hydronephrosis. The ef­
fect of maternal cocaine abuse on fetal malformations is controversial.
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PREGNANCY
Oligohydramnios should lead to the suspicion of oli-goanuria, unless 
the amniotic sac has ruptured or has been leaking. Fetal oligoanuria can re­
sult from congenital malformations of the genitourinary tract, such as bilat­
eral renal agenesis, bilateral or lower urinary tract obstruction, bilateral cys­
tic kidneys, or renal hypoplasiadysplasia, or from acquired fetal renal dis­
ease, such as that due to administration of indomethacin to the mother for 
the treatment of premature labor.
Although polyhydramnios is due most commonly to other causes, it 
may be the first clue to the diagnosis of a nephrogenic defect of urinary 
concentration. Similarly, fetal hydrops may be the first sign of congenital 
nephrotic syndrome. The diagnosis of a urologie problem may have been 
obtained by US performed as a routine examination or as a part of the work 
up for another anomaly.
Prenatal urinary indices (e.g., urinary osmolality, electrolyte concen­
tration, response of fetal urinary output to the maternal administration of fu- 
rosemide), which are obtained from amniotic fluid or, better, from aspira­
tion of urine from the fetal bladder, are not specific and sensitive enough to 
predict outcome in individual cases. A high maternal serum or amniotic a- 
fetoprotein concentration is associated with several anomalies, including 
bladder exstrophy or myelodysplasia, which are associated with urinary 
tract malformations. Increased maternal serum a-fetoprotein concentration 
is associated with pyelectasis and thick-walled bladder.
Maternal treatment with indomethacin or with ACE inhibitors has been 
associated with prenatal renal damage leading to early-onset neonatal renal 
failure with nephron dysgenesis and cystic dilatations. Severe perinatal as­
phyxia frequently is associated with oligoanuria or acute renal failure (ARF).
DYSMORPHISM
RENAL AMD URINARY TRACT ANOMALIES ASSOCIATED WITH MUL­
TIPLE CONGENITAL ANOMALIES
Any dysmorphic feature (e.g., abnormal ears) should lead the clini­
cian to look for the other anomalies and structural defects. Appendix 1-1 
lists the major signs of multiple congenital anomalies (MCA) associated 
with renal and urinary tract anomalies. The most typical sequence related to 
kidney disease is the oligohydramnios sequence, described in the next sec­
tion.
OLIGOHYDRAMNIOS SEQUENCE
The oligohydramnios sequence (i.e., Potter syndrome) can be due ci­
ther to prolonged leakage of amniotic fluid or to intrauterine oligoanuria 
secondary to bilateral renal agenesis, lower urinary tract obstruction, poly­
cystic kidneys, or renal hypoplasia-dysplasia-aplasia-dysgenesis. Severe
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oligohydramnios results in facial deformation (e.g., Potter fades character­
ized by a redundant skin, flat nose, low-set ears, bilateral ekinfolds arising 
at the inner canthus and receding chin), wrinkled skin, and malposition of 
the hands and feet, which are attributed to in utero compression, on the ba­
sis of animal studies and observations in twins discordant for renal or uri­
nary tact malformations. On the other hand, lung hypoplasia may be due to 
several factors, including fetal compression caused by oligohydramnios, ab­
normal composition of the urine that possibly includes a decrease in proline, 
and, in some cases, massive abdominal distention. The risk for lung hy­
poplasia is high during the pseudoglandular period (12-16 weeks of GA) 
and the canalicular period (17-28 weeks of GA) of lung development. Ani­
mal data suggest that the lung is more severely damaged during the latter 
period. Even a short duration of oligohydramnios (1 week) at a critical pe­
riod can induce pulmonary hypoplasia. Thus, the severity of the lung hy­
poplasia seems to depend more on the time of onset of the oligohydramnios 
than on its duration.
ASSOCIATIONS OF RENAL AND URINARY TRACT AMOMALIES WITH
SINGLE SIGNS
Although several associations have been described between upper uri­
nary tract anomalies and isolated anomalies of other body systems, such as 
abnormal vertebrae, anorectal malformations, congenital diaphragmatic her­
nia, hypospadias, lung hypoplasia, spontaneous air leak syndrome, single 
umbilical artery (UA), and supernumerary nipples, some of these associa­
tions are controversial.
LFrinary tract malformations may be present in infants with a single 
UA but an otherwise normal physical examination. Based on 35 published 
series, the minimum incidence of renal and urinary tract malformations, ex­
cluding hypospadias, in patients with a single UA is estimated to be 6.5%. In 
clinical studies, the incidence of renal and urinary tract malformation in se­
ries using a high percentage of intravenous urography (IVU) is twice that in 
the other series. In approximately 8% of those patients with a urinary tract 
malformation, the latter is isolated. The incidence of malformations in new­
born infants with a single UA is approximately seven times that seen in con­
trol infants in prospective series, and twice that seen in controls in autopsy 
series. The distribution of malformations in infants with a single UA is 
skewed toward a higher incidence of polymalformations and of isolated mal­
formations pertaining to the gastrointestinal tract. In patients with polymal­
formations, the presence of a single UA does not increase the risk of finding - 
renal or urinary tract malformations as compared to other malformed pa­
tients.
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P H Y S I C A L  E X A M I N A T I O N
VITAL SIGNS AMD GENERAL EXAMINATION
Severe cyanosis or apneic events can lead to prerenal or functional 
failure. Tachycardia, peripheral vasoconstriction, hypotension, or narrowing 
of the pulse pressure may suggest prerenal failure due to hypovolemia or 
low-output cardiac failure. Tachyarrhythmia, premature ventricular contrac­
tions, or abnormal QRS complexes on the electrocardiographic monitoring 
may be the first sign of hyperkalemia, often due to or at least related to renal 
immaturity or renal failure. Seizures or coma may be due to hypertension or 
complications of renal failure.
MEASUREMENT AND EVOLUTION OF BLOOD PRESSURE IN THE NEO­
NATAL PERIOD
Although a direct technique is the ideal method for the measurement 
of blood pressure, the transducer must be calibrated regularly and the tubing 
and the transducer dome checked for the presence of air bubbles or blood 
clots, which may result in damping of the pulse wave and falsely low meas­
urements of systolic blood pressure. On the other hand, overestimation of 
systolic blood pressure may result from a low resonant frequency system, 
which should not be used in newborn infants.
Blood pressure in normal newborn infants is obtained by the comput­
erized oscillometric or Doppler technique; either of these methods provides 
an accurate assessment of the systolic and mean blood pressure compared to 
direct measured values, unless the patient is in shock. Differences between 
direct and indirect measurements of systolic and mean blood pressure can 
be minimized by selecting an appropriate cuff size. The American Heart 
Association has recommended that the ratio between the width of the inflat­
able part (i.e., bladder) of the cuff and the arm circumference be 0.40 for 
adults and children. A larger ratio has been found to be more accurate using 
the Doppler technique in newborn infants (0.4-0.6). Similarly, the most 
appropriate ratio between the cuff width, rather than the bladder width, and 
the arm circumference for measurement of blood pressure using the 
oscillometric technique in newborn infants was found to be 0.45-0.70. The 
length of the bladder should be 80% of the arm circumference. Although 
measurements of diastolic blood pressure by indirect techniques, especially 
the Doppler technique, usually are not as accurate as systolic or mean 
pressure, excellent results may be obtained by some oscillometric devices.
The average difference between arm systolic blood pressure and thigh 
systolic blood pressure obtained by oscillometry using appropriate cuff sizes 
was found to be 0.9 ± 5.3 torr (mean ± SD) in normal full-term infants. The 
average difference in systolic blood pressure between arm and calf was 1.1 ± 
7.7 torr; the same cuff size was adequate for both limbs. Thus, statistically, 
when the systolic blood pressure in the upper limbs is more than 10 torr
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higher than that in the thigh or 15 torr higher than in the calf, coarctation of 
the aorta should be suspected.
After variable trends during the first hour of life, arterial blood pres­
sure in normal newborn infants at any GA increases by approximately 1 torr 
per day during the first week of life and then by 1 torr per week until 5 to 6 
weeks of life. It is unclear why some studies report higher blood pressure 
values than most of the other ones. The upper limit of normal systolic blood 
pressure in infancy reported in a large-scale prospective study was 113 torr. 
Interindividual differences in blood pressure are related mostly to GA, 
weight, and ponderal index. Even when considering infants of similar GA, 
size, and postnatal age, there is a wide range of normal values. Blood pres­
sure increases with awake state, knee-chest position, crying, pain, physical 
examination, and performance of procedures. In addition, a circadian blood 
pressure pattern was described in some, but not all, full-term infants. There 
is significant tracking (i.e., a trend for the same individual) of blood pres­
sure during the first months of age.
CHEST
A small chest suggests hypoplastic lungs, which can be associated 
with renal and urinary tract malformations. Congestive heart failure, patent 
ductus arteriosus, and severe respiratory distress all can cause prerenal fail­
ure.
ABDOMEN
The physical examination of a normal newborn infant should include 
bimanual palpation of the abdomen for the presence of a normal kidney in 
each flank. The examination is easiest in the delivery room, before the 
bowel is filled with gas; later on, it is facilitated by relaxation of the ab­
dominal wall musculature obtained, for instance, by eliciting the sucking 
reflex. Several characteristics of the kidneys should be evaluated, including 
their location (normally in the flank; an ectopic kidney may be located in 
the pelvis), size (the normal size in a full-term infant is 4-5 cm x 2-3 cm), 
long axis (normally cephalocaudal; a horseshoe kidney may be suspected if 
the lower pole is closer to the midline than the upper pole), consistency 
(normally firm, as opposed to a cyst or a hydronephrotic kidney, which may 
be depressible), and surface (normally smooth, as opposed to large cysts in 
multicystic or autosomal dominant poly cystic kidneys). A careful examina­
tion may raise the suspicion of ectopia, agenesis, hypoplasia, cystic dyspla­
sia, polycystic kidney, hydronephrosis, or a horseshoe kidney. Abdominal 
masses most often are of renal or urologie origin, and may correspond to 
polycystic or multicystic kidney, renal vein thrombosis, renal tumor, con­
genital hydronephrosis, or acquired hydronephrosis (e.g., fungus ball, papil­
lary necrosis); a suprapubic mass suggests bladder distention. In some ра­
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tients, one or both kidneys cannot be palpated: this may be due to a less than 
optimal examination (e.g., absence of patient relaxation, bowel distention); 
unilateral renal agenesis; renal malposition, in which case the kidney may 
be felt at another place in the abdomen; or renal hypoplasia or aplasia. Some 
abnormalities of the abdominal wall, such as bladder exstrophy, cloacal ex­
strophy, and prune-belly syndrome, are associated with renal anomalies. 
The umbilical cord should be examined for the number of umbilical arteries. 
Anorectal anomalies or ambiguous genitalia, including severe hypospadias, 
should raise the suspicion of renal or urologie malformations.
The physical examination of the abdomen also should include percus­
sion for detecting ascites or a large bladder. In the absence of hydrops fetalis, 
neonatal ascites commonly is due to the rupture of an obstructed urinary 
tract. Sphincter dysfunction may suggest an occult spinal dysraphiśm.
LIMBS
Motor and sensory dysfunction of the lower limbs suggests an occult 
spinal dysraphism. Several limb anomalies are part of syndromes or se­
quences associated with renal or urinary tract malformations, such as skele­
tal dysplasia, radial aplasia, femoral hypoplasia, rocker bottom feet, 
compression deformation, polydactyly, syndactyly, and hemihypertrophy.
HYDRATION
Body weight should be obtained on a daily basis and the net weight 
(i.e., without equipment such as arm boards, endotracheal tube, chest tubes) 
compared to the normal postnatal weight evolution. Edema may be a sign of 
renal disease, including renal failure or nephrotic syndrome, or be secondary 
to a wide variety of generalized or local problems. In newborn infants in a 
prone or supine position, generalized edema starts around the eyes, at the per­
ineum, and on the lateral sides of the trunk. Dehydration may be evident on 
the basis of weight loss, dry skin and mucosae, sunken fontanelle, sometimes 
with the signs of hypovolemia mentioned previously. Because edema fluid 
and third-space fluid do not participate in the effective ECF volume, hydra­
tion status should not be based upon weight alone. A comprehensive evalua­
tion of hydration status should include a complete history and physical ex­
amination, as well as assessment of urine output, and serum and urine bio­
chemical analysis.
CLINICAL OBSERVATIONS
TIME OF THE FIRST POSTNATAL VOIDING
The time of first voiding after birth has been analyzed by several re­
searchers. The selection criteria were mentioned in only one study. Between 
4% and 22% of infants were reported to void in the delivery room. The cu­
mulative percentage of infants who void within 24 hours after birth has in-
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creased from 92% before 1960 to 97% after 1970; this most probably results 
from an increase in total fluid intake during the first day of life. Thus, ac­
cording to the more recent studies, delayed voiding indicates that first void­
ing occurred later than 24 hours after birth. Nevertheless, the significance of 
delayed voiding, as defined above, is unclear. The most recent study failed 
to detect any difference in gender, weight, type of delivery, 5-minute Apgar 
score, time to first feeding, or incidence of respiratory distress syndrome 
(RDS), compared to infants voiding for the first time before 24 hours. In 
addition, whether urine passed in the delivery room should be included to 
assess postnatal urine output is questionable, because it is virtually impossi­
ble to exclude urination during labor. Although observation of urination in 
the delivery room is reassuring, because it demonstrates the presence of 
functional kidneys and urinary tract, it is not associated with an earlier sec­
ond urination. Urine produced in utero normally is very dilute, with an av­
erage osmolality less than 200 mOsm/ kg. Higher osmolality may result 
from obstructive urinary tract disease caused by poor tubular reabsorption 
of sodium, from administration of oxytocin or indomethacin to the mother, 
or from acute or sub-acute intrauterine asphyxia. On the other hand, urine 
produced after birth usually is isotonic or hypertonic, probably as a result of 
increased release of oxytocin and ADH.
URINE OUTPUT
The urine output depends on GFR and tubular reabsorption of water. In 
full-term infants, the urine output is low during the first day of life and in­
creases progressively in parallel with daily intake. On the other hand, in LEW 
and VLBW infants, Bidiwala and associates have described three phases in 
the early postnatal period: an oliguric phase, during which the urine output is 
always lower than the intake; a polyuric phase starting between 24 and 72 
hours of age, during which the output is always greater than the intake; and 
an adaptive phase, during which the kidney adjusts to the rate of fluid intake.
A diuretic phase was observed in most infants, whether or not the course was 
complicated by respiratory distress syndrome. Whether this triphasic pattern 
is present in most infants remains to be validated in prospective randomized 
studies using various predetermined amounts of fluid intake. The diagnosis 
and treatment of oligoanuria and polyuria are discussed elsewhere in this 
chapter.
CHARACTERISTICS OF URINATION
The baby should be observed for dribbling, urination through an ab- - 
normal location, or persistence of a large bladder after urination. Additional 
discussion can be found then.
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URINALYSIS
Urinalysis at the bedside includes the dipstick, which can help diag­
nose proteinuria, hematuria-hemoglobinuria-myoglobinuria, glucosuria and 
leukocyturia, and the measurement of urine specific gravity (SG) by refrac- 
tometry. Normal newborn infants have a physiologic proteinuria, the amount 
of which changes with GA and postnatal age. The first step in the assessment 
of hemoprotein in the urine is a microscopic examination. Glucosuria usually 
is absent until the glycemia is greater than 150 mg/dL, although mild gluco­
suria is common in VLBW infants even when glycemia is normal. Urine SG 
is inversely proportional to urine output. The relationship between SG and 
osmolarity in newborn infants is different from that in older patients. This 
may result from frequent proteinuria and glucosuria, as well as differences in 
major solutes with increasing maturity (e.g., decrease in sodium concentra­
tion, increase in urea concentration).
Pink urine may correspond to the presence of heme compounds or 
uric acidurate; the latter may be seen in some normal infants. If a dipstick is 
positive for heme compounds, the clinician first should differentiate hemo­
globinuria, myoglobinuria, and hematuria. This can be done by examining 
the urine under the microscope for the presence of erythrocytes, and the 
color of the plasma, which should be pink in the case of significant hemo­
globinuria. Definitive differentiation of hemoglobinuria and myoglobinuria 
can be obtained by electrophoresis of urinary proteins. Hemoglobinuria is 
diagnostic of a significant intravascular hemolytic process, whereas my­
oglobinuria has been observed in severely asphyxiated newborn infants, 
particularly those with birth trauma.
LABORATORY EVALUATION
MEASUREMENT OF GLOMERULAR FILTRATION RATE USING EXOGE­
NOUS SUBSTANCES
To be an adequate marker for GFR, a substance must not be metabo­
lized, must be completely filtered through the glomerulus, must not be se­
creted by the tubule, and must be eliminated from the body only by the kid­
ney, unless GFR is determined by classic clearance method. Adequate mark­
ers include inulin, polyfructosan, and 30 on. Renal clearance can be measured 
by classic clearance techniques with collection of samples of blood and urine, 
by the rate of constant infusion that is associated with a steady-state plasma 
concentration, or by a noncom-partmental analysis or a double-slope analysis 
of the plasma concentration after a single injection.
ASSESSMENT OF GLOMERULAR FILTRATION RATE USING
CREATININE CLEARANCE
In the clinical setting, GFR often is estimated by creatinine clearance 
(Ccr). Comparisons of Ccr with Cm have shown reasonable agreement, but
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the Ccr: C,n ratio tends to increase in parallel with a decrease in Cm Limita­
tions of Ccr as an assessment of GFR have been attributed to inaccurate de­
termination of Pcr, effect of maternal or diet creatinine load on creatinine 
concentration, tubular secretion of creatinine, and difficulty in obtaining 
complete urine collections in newborn infants, especially in girls.
One of the major limitations of Ccr for assessing renal function is the 
difficulty of accurately measuring Pcr. The gold standard technique is iso­
tope dilution mass spectrometry, and various high-performance liquid 
chromatography (HPLC) techniques have been proposed as reference tech­
niques. The clinician should know which technique is used in the labora­
tory, its accuracy and precision, as well as possible sources of interference.
The value of Pcr during the first days of life depends both on maternal 
creatinine load and on neonatal GFR. Cord blood creatinine concentration is 
almost equivalent to the maternal level, and the serum concentration de­
creases exponentially during the first few days of life, with a half-life of 2.1 
days in normal full-term infants. Because of this maternal load, the rate of 
decrease of P„ may be a better indicator than its absolute concentration in 
full-term infants during the first days of life, especially when the mother is 
in renal failure. The agreement between Ccr and Cjn in LEW infants during 
the first days of life suggests that creatinine secretion is minimal in imma­
ture tubules.
Obtaining an adequate urine collection is a difficult task, especially in 
girls. This often can be resolved by using either an adhesive plastic collec­
tion bag on the perineum, by bladder catheterization if hourly urine output 
measurement or bladder decompression is necessary, by using a modified 
metabolic bed or by collecting urine samples from diapers, taking care to 
limit evaporation, and correcting for diaper weight.
Several units have been used for expressing GFR (e.g., mL/minute; 
mL/minute/1.73m2 of BSA; mL/ minute/kg of weight; mL/minute/kg of 
lean body mass). Which of these units should be used in infants is contro­
versial. Indeed, the normal values of GFR corrected for 1.73m2, which are 
stable throughout childhood and midadulthood, increase significantly with 
age until 2 years of age; thus, there is no obvious advantage to correcting 
GFR for body surface area in infancy. Although correcting GFR for body 
weight (mL/minute/kg) results in more homogenization of the normal val­
ues of GFR with maturation in newborn infants, it also results in apparent 
changes in GFR due to day-to-day weight changes. It may be best to express 
GFR both in absolute units (i.e., mL/minute) and with correction for body 
size, to facilitate comparison between various studies.
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ESTIMATION OF GLOMERULAR FILTRA! ION RATE USING PLASM/'.
CREATININE CONCENTRATION
The most commonly obtained laboratory test used routinely to moni­
tor renal function is Pcr. The value should be compared to normal values for 
GA and postnatal age using the same technique of measurement. Figure 37 
shows the normal evolution of Pcr in mg/dL during the first month of life. In 
addition to the limitations of Ccr for assessing GFR, another limitation is 
relevant to the use of Pcr for this purpose. The relationship between Pcr and 
GFR results from the formula for creatinine clearance:
Ccr = V * Ucr/Pcr,
where Ccr is Ccr in mL/minute, V is urinary volume in mL/minute, (Jcr 
is the urinary creatinine concentration in mg/dL, and Pcr is Pcr in mg/dL. It is 
obvious from this formula that the relationship depends on the amount of 
creatinine excreted per unit of time into the urine; this amount depends on 
the rate of biotransformation of creatinine in striated muscle, and thus on 
the amount of muscle. Identical values of Pcr represent lower values of GFR 
for patients with less muscle per unit of body size, such as in SGA or large 
for GA (LGA) infants. As a result, a seemingly normal Pcr for age may be 
obtained in an infant with severe intrauterine growth retardation (IUGR) 
and renal failure, because of the loss in muscle mass.
To take this into account, Schwartz and colleagues have developed a 
formula designed to estimate GFR corrected for BSA:
GFR = kL/Pcr
where GFR is in mL/minute/1.73m2, the constant к is a factor corresponding 
to the rate of urinary creatinine excretion per unit of body size for a group 
of similar body habitus (mg/100 minute/cm/1.73m2), L is body length (cm), 
and Pcr is in mg/dL. The value of к was found to be 0.45 in appropriate for 
GA (AGA) full-term infants, 0.33 in LBW infants, 0.33 in SGA full-term 
infants, and 0.31 in LGA full-term infants. During the first week of life in 
LBW infants, the formula kL/Pcr gave values similar to those obtained by 
C|n. The low value of the constant к in LBW, SGA, and LGA infants is re­
lated to the lower amount of muscle mass per unit of body size compared to 
full-term AGA infants. Within each group, the coefficient of variation of the 
value of к was 30% to 35%; for LBW infants, 77% of the values of к were 
found to be within a range of 0.20 to 0.50, whereas in full-term infants, 79% 
of the values were within a range of 0.30 to 0.70.
3 1 9
POSTNATAL AGE (DAYS)
P O S TN A TA L  ■ AGE (DAYS)
FIG. 37. The normal values of plasma erc-atinine concentration (mean ± 2 SD) during the 
first month of life are shown at four gesta-tional age ranges Infants were excluded from this 
study if they had congenital heart disease, heart failure with patent ductus arteriosus, indo- 
methacin therapy within 48 hours, postasphyxic oligoanuria, renal anomalies, or muscle dis­
ease These values were obtained using a kinetic Jaffe technique with a Beckman Creatinine 
Analyzer 2. This method reportedly had no interference with bilirubin up to 400 /amol/L (23 
mg/dL), the addition of 0.1 mmol/L of pyruvate produced a rise of 5 yu.mol/L (0.06 mg/dL) in 
the creatinine value (Adapted from Rudd FT, Hughes EA, Płaczek MM, et al. Reference 
ranges for plasma creatinine during the first month of life).
Despite all the criticisms over the use of Pcr to estimate GFR in new­
born infants, several researchers have found a significant correlation be­
tween Pcr and the half-life of several medications eliminated by the kidney. 
Thus, if a reliable technique of creatinine measurement is available, the cli­
nician can use Pcr for routine, sequential evaluation of glomerular filtration 
in most newborn infants. Formal repeated measurements of Ccr or GFR are 
recommended for those patients in renal failure.
BLOOD UREA NITROGEN
The blood urea nitrogen (BUN) can increase as a result of catabolism, - 
dehydration, high protein load (e.g., oral, intravenous, gastrointestinal 
bleeding), or renal failure. On the other hand, a low value of BUN can be 
observed in association with either ECF expansion or decreased production 
of urea. The latter may result from anabolism, low protein intake, urea cycle 
disorder, liver failure, or liver immaturity.
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URIC ACID
The concentration of uric acid is higher in cord blood than in maternal 
blood. Renal handling of uric acid along the nephron includes glomerular fil­
tration, tubular reabsorption, tubular secretion, and further re-absorption dis­
tal to the secretory site. Fractional excretion of uric acid during the first 24 
hours decreases from about 70% at 29 to 31 weeks of GA to 39% ± 14% at 
38 to 40 weeks of GA, and decreases with postconceptional age, to reach less 
than 20% at 1 year of age and less than 10% in adults. This results from pro­
gressive tubular maturation. An abnormally high serum level of uric acid may 
result from a wide range of disorders associated with decreased renal excre­
tion of uric acid, including maternal toxemia, ECF contraction, renal failure, 
hypertension, medications (e.g., diuretics), and lead intoxication. Rarely, ele­
vated levels of uric acid result from increased production (e.g., leukemia). A 
very low serum level of uric acid suggests a tubular disorder.
PLASMA RENIN ACTIVITY
The most common indication for the measurement of PRA is the 
evaluation of hypertension. Normal levels of PRA are higher in the newborn 
infant than in older children or adults. This is discussed further in the sec­
tion on Hypertension.
GENETIC DIAGNOSIS
Chromosome analysis is indicated if a hereditary syndrome is sus­
pected. Molecular diagnosis using recombinant technology is available for 
an increasing number of renal diseases. For most cases with a family history 
of autosomal dominant polycystic kidney disease (ADPKD), a correct diag­
nosis can be made in the infant if there are restriction length polymorphisms 
close to the relevant gene, which is usually, but not always, on chromosome 
16.
URINARY ACIDIFICATION
Immaturity of renal tubular acidification results in a significantly 
lower value of serum bicarbonate concentration in VLBW infants than in 
full-term infants. In parallel, the serum base deficit is often between -5 and 
10 mEq/L in VLBW infants, compared with 0 to 5 mEq/L in full-term in­
fants, and the anion gap, obtained by the difference between sodium 
concentration and the sum of chloride and bicarbonate concentrations, is 
normally 15 to 22 mEq/L in premature infants, compared to 12 ± 2 mEq/L 
(<15 mEq/L) in full-term infants. In newborn infants, metabolic acidosis 
often is secondary to asphyxia, hypoxia, shock, or erythrocyte transfusion. 
If metabolic acidosis is persistent, a defect in tubular acidification, among 
other diagnoses, should be suspected, whether urine pH is low or high; a 
low urine pH suggests but does not assure that distal tubular acidification is 
normal (see Tubular Function).
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MICROSCOPIC EXAMINATION OF URINE
The shape of erythrocytes in freshly voided urine should be observed 
under the microscope. The presence of deformed cells suggests a hematuria 
from glomerular origin, whereas undeformed cells predominate in either 
massive hematuria, or in cases of lower urinary tract disease. Leukocyturia is 
common in normal infants during the first few days of life. On the other 
hand, leukocyturia may be lacking in a newborn infant with a positive urine 
culture, in contrast to older children. The presence of bacteria on a Gram 
stain may be a better predictor of UTI. The presence of erythrocyte casts in 
the urine suggests the diagnosis of glomerulopathy, whereas leukocyte casts 
can be observed during UTI.
URINE ELECTROLYTES AND OSMOLALITY
The measurement of urinary and blood osmolality, urea, creatinine, 
and electrolytes is indicated for the differential diagnosis of polyuria and for 
the early diagnosis of oligoanuria.
PROTEINURIA AND p2-MlCROGLOBULINURIA
Maturation of the infant is associated not only with a decrease in the 
daily amount of proteinuria, but also with qualitative changes that can be 
demonstrated by two-dimensional gel electrophoresis. The first voided urine 
in 22- to 28-week-old infants contains many serum proteins and peptides, 
whereas urine in full-term infants contains much less polypeptides. One of 
the identified proteins is called Tamm-Horsfall glycoprotein, which is de­
rived from the tubule.
Beta2-microglobulin is a low-molecular-weight protein (11,800 kd), 
which in the normal adult is filtered through the glomerulus and almost en­
tirely reabsorbed and catabolized by the tubule. Because the tubular reab­
sorption of p2-microglobulin increases with maturation, its fractional excre­
tion decreases until 2 years of age. Several studies have shown that the uri­
nary concentration of this and other proteins is a more sensitive indicator for 
renal damage due to asphyxia or medications, than the measurement or the 
estimation of GFR.
IMAGING OF THE KIDNEY AND THE URINARY TRACT
ULTRASONOGRAPHY
This technique is performed to screen for renal and urologie malforma­
tions or as one of the first steps in the workup of renal failure, oligoanuria, 
hypertension, UTI, and hematuria. Suggested indications for the performance 
of neonatal US are shown in Table 43. In a series using similar indications, 
71 of 1500 newborns had neonatal US performed, and 15 (21%) were found 
to have a congenital renal or urinary tract malformation. The size of the kid­
neys should be compared to normal for size, GA, and gender. The examiner
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should assess not only the kidneys but also the adrenal glands, the aorta, the 
renal arteries, the renal veins, the inferior vena cava, the ureters, and the 
bladder. The differential diagnosis of US anomalies is presented in Table 44.
Blood flow through renal vessels can be assessed by Doppler US, 
which is indicated for the evaluation of hematuria, hypertension, and ARF. 
especially in a patient with UA catheterization. Pulsed Doppler flow analysis 
(i.e., duplex scanning) allows the calculation of the ratio of end-diastolic 
minimum velocity to systolic peak velocity (i.e., diastolic-systolic ratio), 
which gives an assessment of renal artery vascular resistance.
VOIDING CYSTOURETHROGRAM
Vesicoureteral reflux (VUR) and bladder obstruction should be ruled 
out in patients with hydronephrosis, trabeculated bladder, bladder distention, 
or myelomeningocele. In patients with UT1, the voiding cystourethrogram 
(VCUG) best is delayed, because VUR, often present during a UTI, may dis ­
appear within 4 to 6 weeks. Sterile technique is imperative to prevent iatro­
genic infection; the role of prophylactic antibiotic therapy has not been 
evaluated.
Table 43
Indications for ultrasonography to rule out renal-urinary
______tract malformations and acquired renal disease in newborn infants
History*
Family history
First-degree relative with Potter syndrome (bilateral renal agenesis/dysgenesis), auto­
somal dominant polycystic kidney disease
Sibling with autosomal recessive polycystic kidney disease Abnormal prenatal ultra­
sonography (e g , kidney, bladder, ascites)
Oligohydramnios, unless normal posnatal renal function and oligohydramnios attrib­
uted to:
Prolonged rupture of the membranes 
Postdate delivery, subacute fetal distress 
Physical Examination or Evidence for Other Congenital Anomalies
Syndrome, sequence, or field defect described in Appendix l - l ł
Any part of a possible VATER syndrome (i.e., vertebral anomalies, anorectal anoma­
lies, tracheoesophageal fistula)
Preauricular pits, if family history
Supernumerary nipples, if  associated anomalies or according to ethnic or geographic 
background
Congenital diaphragmatic hernia with additional anomalies
Lung hypoplasia, symptomatic spontaneous pneumothorax
Abnormal abdominal examination;
Abnormal kidney palpation 
Abdominal mass 
Bruit t
Ascites
Single umbilical artery
Second- or third-degree hypospadias___________________________  _ -
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Ambiguous genitalia 
Evidence for Renal Disease
Renal failure, oligoanuriat 
Systemic hypertension!
Urinary tract infection 
Hematuria!
Significant proteinuria
Nephrotic syndrome___________________________________________________
* The best timing of ultrasonography remains to be determined: a negative test immediately af­
ter birth does not rule out hydronephrosis or vesicoureteral reflux; a repeat test should be ob­
tained within a few weeks or earlier if clinically indicated
t  The frequency of urinary tract anomalies in many of these entities has not been determined. 
Since a cost-benefit analysis has not been performed, the indication for neonatal ultrasono­
graphic (US) screening should be decided on an individual basis The frequency of fetal uri­
nary tract anomalies in association with maternal diabetes or cocaine use probably is too low 
to justify neonatal US in asymptomatic infants 
t  These patients also should have a Doppler ultrasonography.
RENAL RADIONUCLIDE SCAN
The most commonly used radionuclides in the study of newborn infants 
include 99mTc, which is preferred because it is a pure y-ray emitter and has a 
half-life of only 6 hours, and 123I, which also emits x-rays and has a half-life of 
13 hours. I3I1 should be avoided in infants because of its long half-life. 99mTc- 
DTPA is eliminated mostly by glomerular filtration and very little by tubular 
secretion; analysis of the radioactivity due to that compound can be used for 
assessing renal perfusion if measurements are taken immediately after the in­
jection, renal mass if measurements are taken within 1 to 3 minutes after the 
injection, and GFR if using a double-compartment analysis of radioactivity in 
sequential blood measurements or convolution analysis after a single injection, 
as well as for visualizing the urinary tract. In normal newborn infants, how­
ever, routinely measuring GFR using radionuclides is not ethically justifiable, 
even though the amount of radioactivity is minimal. Therefore, normal values 
for age are not available. On the other hand, 99mTc-dimercaptosuccinic acid 
(DMSA) binds to the tubules and is only minimally excreted into the urine; it 
is preferred for the analysis of renal morphology and differential function. 
Typical indications for radionuclide studies include renovascular hypertension, 
lack of visualization of a kidney by US, preoperative evaluation of the severity 
of urinary tract obstruction, and evaluation of differential renal function.
INTRAVENOUS UROGRAPHY
In newborn infants, IVU largely has been replaced by US, because of 
the improved resolution of the new generations of US probes, increased rec- - 
ognition of the nephrotoxicity of standard radiopaque products, and the poor 
contrast obtained, which is due to the low GFR during the first weeks of life. 
If needed, a low-osmolality contrast material is preferred (see Nephrotoxic­
ity). Optimally, the procedure is delayed a few weeks, at which time im­
proved renal function usually results in better visualization.
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_____________Renal ultrasonographic patterns in newborn infants_______
Normal Appearance 
Prerenal failure 
Renal artery thrombosis
Congenital renal disease (e g., renal tubular acidosis)
Renal cystic disease, in which cysts develop late 
Developing hydronephrosis or vesicoureteral reflux 
Increased Cortical Echogenicity 
With increased corticomedullary differentiation in large kidneys 
Beckwith-Wiedemann syndrome 
With normal corticomedullary differentiation 
Prerenal failure 
Renal ischemia 
Mild renal dysplasia
Congenital nephrotic syndrome, Finnish type 
With loss of corticomedullary differentiation in normal-to-small kidneys*
Severe renal dysplasia
Pyelonephritis, including renal candidiasis, which often is heterogeneous 
Renal tubular dysgenesis or glomerular dysgenesisf 
With loss of corticomedullary differentiation in large kidneys*
Renal vein thrombosis
Edema results in decreased echoes 
Hemorrhage results in increased echoes 
Corticomedullary necrosist 
Autosomal recessive polycystic kidney disease 
Renal glomerular dysgenesis or tubular dysgenesis 
Benign transient nephromegaly 
Contrast nephropathy 
Lymphangioma 
Mesoblastic nephroma5 
Cysts ||
See Appendix 1-3
Increased Medullary Echogenicity
Nephrocalcinosis 
Medullary cystic disease
Tamm-Horsfall proteinuria, acute tubular necrosis 
Medullary sponge kidney 
Intrapyelic Echogenicity 
Renal candidiasis (i.e., fungus ball)
Lithiasis
______ Hydronephrosis________________ ___________________________ _________
This list does not include findings shown by Doppler ultrasonography.
* Diffuse or heterogeneous hyperechogenicity of cortex or whole kidney, 
f  The kidney may be enlarged, 
t The kidney may be normal or enlarged.
s A solid mass that causes distorsion of the intrarenal collecting system, with occasional cys­
tic areas corresponding to necrosis or hemorrhage.
^The absence of cysts visualized at ultrasound does not rule out a renal cystic disease in a 
newborn infant. Some entities result in development of cysts later in life, while others (e.g., 
autosomal recessive polycystic kidney disease) result in hyperechogenicity.
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PERCUTANEOUS ANTEGRADE PYELOGRAPHY
This technique may be diagnostic in some cases of cystic disease or 
urinary tract obstruction.
ANGIOGRAM
The frequency of this procedure, mostly used during cardiac 
catheterization, has decreased dramatically since the development of two- 
dimensional echocardiography. The anatomy of the kidneys always should be 
examined during cardiac catheterization. Angiography may be indicated in 
case of an abdominal tumor, renovascular hypertension, or an aortic 
thrombus.
COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING
Computed tomography (CT) and magnetic resonance imaging (MRI) 
are indicated in case of an abdominal tumor. In addition, MRI may be a use­
ful technique to exclude a spina bifida occulta. Using MRI, we have diag­
nosed a tethered cord in a patient with bladder distention who had a normal 
US and neither VUR nor urethral stenosis with VCUG.
RENAL PATHOLOGY
Renal biopsy is indicated in cases of nephrotic syndrome and may be 
indicated in polycystic kidney disease, hematuria, or persistent severe renal 
failure when the workup has failed to lead to a definitive diagnosis. Major 
contraindications to renal biopsy include bleeding diathesis, anticoagulant 
therapy, moderate or severe hypertension, solitary kidney, and intrarenal 
tumor. The technique includes visualization of the kidney using US, radio­
isotope, or radiopaque contrast. The most common complication is macro­
scopic hematuria, which occurs in 5% to 7% of biopsies.
ACUTE RENAL FAILURE AND OLIGOANURIA
Acute renal failure, usually defined as an acute deterioration in the 
ability of the kidneys to maintain the homeostasis of body fluids, is associ­
ated with an acute decrease in the rate of glomerular filtration, as opposed to 
isolated acute tubular dysfunction. Since the placenta fulfills that role in 
utero, congenital malformations associated with limitation of renal function 
will not lead to renal failure until birth.
INCIDENCE
The incidence of intrinsic oliguric ARF in newborn infants admitted to 
the neonatal intensive care unit (NICU) ranges between 1% and 6% in retro­
spective studies, and between 6% and 8% in prospective studies. In a pro­
spective study on 314 NICU admissions, Norman and Assadi found 72 in­
fants (23%) with azotemia (i.e., BUN > 20 mg/dL) and urine output equal to 
or less than 25 mL/kg/day for at least 24 hours. Administration of a fluid and 
diuretic challenge resulted in normalization of the urine output in 52 of 72
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patients (72%). Thus, in that series, the incidence of prerenal failure was 
17%, whereas that of intrinsic renal failure was 6%. Stapleton and colleagues 
found an incidence of oliguric renal failure (i.e., urine output < 1 mL/kg/hour 
unresponsive to fluid challenge, accompanied by a Pcr greater than 1.5 
mg/dL) of 8% in N1CU patients. In a subsequent prospective study on 186 
patients including systematic determinations of Pcr these researchers found an 
incidence of 8% (14 of 186); during the same study period, only one patient 
had a nonoliguric renal failure. In other series, 30% to 50% of newborn in­
fants with renal failure were not oliguric.
DIAGNOSIS
Intrauterine oligoanuria can be suspected when oligohydramnios de­
velops in the absence of rupture of the amniotic membranes; it can be due to 
a congenital urinary tract anomaly (e.g., urinary tract obstruction, renal agen­
esis, dysgenesis), to toxins (e.g., ACE inhibitors, indomethacin), or to intrau­
terine asphyxia. If urine output alone is used to assess renal function, ARE 
often will be both overlooked and overdiagnosed. Indeed, normal urine out­
put is found in approximately one third of neonates with ARF, and anuria 
may occur as a result of the syndrome of inappropriate antidiuretic hormone 
secretion, in the absence of ARF. Renal function should be evaluated, for 
possible ARF, in infants who have been subjected to perinatal asphyxia, 
shock, hypoxemia, and various nephrotoxins (Fig. 38). Clinical signs of ARF 
include syndromes or signs suggestive of renal or urogenital malformations, 
oligoanuria, polyuria, hematuria, proteinuria, fluid overload, dehydration, 
cardiac arrhythmia, and systemic hypertension. Other signs include decreased 
activity, seizures, anemia, vomiting, and anorexia. Sometimes ARF is sus­
pected on the basis of electrolyte abnormalities or elevated plasma levels of 
medications (e.g., aminoglycosides).
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FIG. 38. Proposed approach for monitoring urinary output and preventing prerenal failure, 
(ad lib - a d  libitum , BUN - blood area nitrogen; CHD - congenital heart disease; CPAP - con­
tinuous positive airway pressure, Pcr - plasma creatinine concentration; PDA - patent ductus 
arterosus, q - every; SIADHS - syndrome of inappropriate antidiuretic hormone secretion; US 
- ultrasonography, VCUG - voiding cystourethrogram).
Acute renal failure is characterized by decreased GFR and renal tubular 
function compared to normal values for either postconceptional age or GA 
and postnatal age. Although the diagnosis of ARF is strongly suggested by a
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Pcr that is above the upper limit of normal, during the first days of life such an 
elevation also may result from abnormal maternal renal function. Thus, 
measuring GFR or following Pc, over time is required to diagnose ART in a 
newborn infant during the first days of life. Because renal tubular function 
changes with maturation, it is important to use criteria appropriate for age; 
indices developed for more mature subjects are not indicative of intrinsic re­
nal failure in VLBW infants.
ETIOLOGY
A wide variety of malformations and prenatal, perinatal, and postnatal 
events may cause neonatal renal failure (Table 45). The most common type 
of acute intrinsic renal failure is ATN, which is discussed in the next section.
Table 45.
_____________Etiologie classification of acute neonatal renal failure_______
Parenchymal Malformation*
Renal agenesis 
Renal hypoplasia 
Simple hypoplasia 
Oligoncphronic hypoplasia 
Renal dysplasia 
Multicystic 
Hypoplastic 
Aplastic
Associated with urinary tract obstruction or VUR 
Nephron dysgenesis
Tubular dysgenesis: congenital hypernephronic nephromegaly with tubular dys­
genesis = congenital tubular dysgenesis = isolated congenital renal tubular 
immaturity
Glomerular dysgenesis:
Idiopathic
Secondary to maternal administration of indomethacin or angiotensin­
converting enzyme inhibitors 
Polycystic kidney disease 
Adult type (i.e., autosomal dominant)
Infant type (i.e., autosomal recessive)
Others
Acquired Renal Dysfunction or Lesion*
Asphyxia/hypoxia/ischemia
Functional (may lead to prerenal or intrinsic renal failure):
Prenatal, perinatal, or postnatal asphyxia 
Respiratory distress, hypoxemia 
Sepsis
Surgery (e.g., cardiopulmonary bypass, shock)
Heart failure
Patent ductus arteriosus
Hypovolemia, shock, and severe dehydration__________________________
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Hyperviscosity, polycythemia 
Severe anemia 
Vascular
Arterial or arteriolar thrombosis, embolism, stenosis 
Cortical or medullary necrosis, renal infarction 
Venous thrombosis
Urinary tract obstruction, massive VUR 
Urinary tract infection 
Disseminated intravascular coagulation 
Drugs
Antibiotics (e.g., aminoglycosides, amphotericin, acyclovir)
Indomethacin 
Tolazoline 
ft-Adrenergic agents
Angiotensin converting enzyme inhibitors 
Radiocontrast agents 
Cyclosporine 
Toxins
Hemoglobinuria 
Myoglobinuria 
Hyperoxaluria 
Benzyl alcohol
Intravenous tocopherol (polysorbate probably responsible)
Uric acid nephropathy 
Glomerular disease
Membranous glomerulonephritis (IgG-mediated)
Congenital syphilis
Diffuse mesangial sclerosis__________________________________________
* May not cause acute renal failure until after the neonatal period, t  May occur in utero, V(JR- 
vesicoureteral reflex.
PATHOPHYSIOLOGY OF ACUTE TUBULAR NECROSIS
The evolution of ATN, the most common cause of ARF, is character­
ized by three successive phases: initiation, maintenance, and recovery. Al­
though ATN may be precipitated by a single event, its development is multi­
factorial and involves vascular (i.e., hemodynamic), nephronal, and cellular 
(i.e., metabolic) factors. The relative importance of these various factors may 
vary according to the etiology; specific aspects of toxic ATN are described in 
the section on Nephrotoxicity,
VASCULAR FACTORS
Vascular changes, characterized by vasoconstriction of the afferent ar­
terioles, play a major role in the initiation phase of ATN, even in the absence 
of shock. The kidney can be protected before the initiating event by the ad­
ministration of vasodilator compounds. Tubular damage due to any factor 
will result in increased amounts of solutes in the tubule; this stimulates the
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release of vasoactive compounds by the juxtaglomerular apparatus. Despite 
high PRA, the stimulation of the renin-angiotensin system alone cannot ex­
plain all the findings at this stage. Renal vasoconstriction may result from 
systemic or local changes in the relative concentrations of vasoconstrictive 
agents such as PRA, adenosine, thromboxane, and platelet activating factor, 
and vasodilator agents such as PCs and prostacyclin.
NEPHRONAL FACTORS
Nephronal factors play a major role during the maintenance phase of 
ARF. A decrease in GFR and in tubular flow may result from obstruction of 
the tubule by cellular debris, and from backleak of fluid and solutes secon­
dary to loss of integrity of the tubule. Although an increase in proximal tu­
bule pressure has been demonstrated only in animals, tubular cell casts also 
are evident in humans with ARF. Backleak has been demonstrated in hu­
mans, and its localization has been shown in animal data to be the proximal 
tubule. In addition, glomerular membrane permeability may decrease during 
ARF.
CELLULAR FACTORS
During both the initiation and the maintenance phase of ARF, several 
disturbances may occur in tubular cells. They can be classified into four 
groups, the respective importance of which, however, is unclear: cessation of 
oxidative phosphorylation, which results in depletion of adenosine triphos­
phate (ATP) and diphosphate; disruption of several major cellular functions, 
including Na+/K+-ATPase and cell swelling; formation of free radicals, lipid 
alterations, and membrane damage; and calcium influx.
During the recovery phase, GFR initially increases in parallel with a 
decrease in intratubular pressure and in intratubular casts; GFR then increases 
in parallel with PRF and urine output. Slowing of the recovery or even sec­
ondary deterioration of renal function may occur if hypovolemia results from 
lack of replacement of the large amounts of urine lost during the polyuric 
phase.
PREVENTION OF PRERENAL FAILURE AND EARLY DIAGNOSIS OF 
ACUTE RENAL FAILURE
The first step in prevention is to identify infants at high risk for renal 
failure or oligoanuria immediately after birth (Fig. 38). In these infants, care­
ful observation of urine output using a urine collection bag should be initiated 
immediately after delivery, and serial assessment of vital signs, electrolytes, 
and renal function should be initiated as indicated. If urinary tract anomalies 
are suspected on the basis of prenatal diagnosis, associated risk factors or 
other clinical evidence, a complete urologie workup should be considered. 
Decompression of the urinary tract by bladder catheterization, surgical inter­
vention, or both is indicated if obstruction or massive VUR is demonstrated.
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Prevention of prerenal failure includes correction of any abnormality in 
and maintenance of adequate oxygenation, ventilation, blood pressure, blood 
glucose, and hematocrit. Fluid intake should be initiated immediately, 60 to 
120 mL/kg/day, according to size, maturity, and environment. Assessment of 
hydration status and renal function should be made on a routine schedule 
(i.e., every shift or every day) according to the status of the infant, and the 
intake of fluid and electrolytes should be adjusted. An increase of plasma so­
dium concentration within the first 8 to 12 hours, assuming that no sodium 
has been administered, may be the first sign of progressive dehydration in a 
VLBW infant; it most often indicates that the fluid intake should be in­
creased. Prevention and rapid correction of respiratory failure, cyanosis, hy­
potension, poor cardiac output, dehydration, peritonitis, hypoglycemia, symp­
tomatic hypocalcemia, symptomatic polycythemia, and sepsis are essential.
URINE OUTPUT
In stable, low-risk, full-term infants, low or even absent urine output 
during the first 24 hours of life is a normal event and does not by itself re­
quire any workup. These infants should be evaluated carefully for significant 
history or physical signs such as bladder distention, dehydration (e.g., exces­
sive weight loss, dry mucosae), hypotension, excessive weight gain, or heart 
failure. If any of these conditions is present, further workup and treatment 
should be initiated. In other cases, intake and urine output should be moni­
tored, and breast-feeding should be supplemented if necessary, but invasive 
and other therapeutic procedures may be avoided. If spontaneous urination is 
not observed within an additional 12 to 24 hours (i.e., at 36-48 hours of life), 
suprapubic pressure (i.e., Crede maneuver) should be performed, to assess the 
possibility of bladder distention or of oligoanuria. If bladder distention is 
suspected, bladder and renal US should be performed. If no urine is obtained 
by suprapubic pressure, the bladder should be catheterized. If little or no 
urine is obtained by catheterization, oligoanuria is suspected, and further 
workup should be initiated.
In contrast, in high-risk infants, urine output should be followed care­
fully from birth. If possible, a urine dipstick test should be obtained before 
catheterization; this may provide the first evidence for hematuria or myoglo­
binuria. If urine output is less than 1 mL/kg/hour and is not increased by su­
prapubic pressure, bladder catheterization should be performed and a full 
evaluation should be obtained (see Fig. 38).
If polyuria develops during the first day, possible diagnoses include 
hypervolemia, tubular dysfunction, diabetes insipidus, glucose overload, 
polyuric phase of ATN, and polyuric phase of postrenal failure (e.g., after de­
compression of the bladder by catheterization).
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PERINATAL ASPHYXIA
Early diagnosis of ARF secondary to perinatal asphyxia is suggested 
by the finding of increased tubular proteinuria (see Hematuria and Proteinu­
ria) immediately after birth, specifically p2-microglobulin, retinol-bmding 
protein (>27,000 pg/mmol creatinine) or myoglobin (>1500 pg/mmol 
creatinine). Asphyxiated infants with a urine output less than 1 mL/kg/hour 
for 36 hours usually have high urinary concentration of p2-microglobulin as 
well as clinical signs of hypoxic-ischemic encephalopathy and often have 
long-term neurologic deficits. Oligoanuria in infants with hypoxic-ischemic 
encephalopathy may result from prerenal (i.e., functional) failure, intrinsic 
renal failure, and SIADHS. One additional factor that may contribute to ARP 
in some neonates with severe asphyxia and birth trauma is rhabdomyolysis, 
which may result in significant myoglobinemia and oliguric ARF. Myoglo­
binuria may result both from increased filtered load and decreased tubular re­
absorption. This is discussed further elsewhere in the chapter (see Nephrotox­
icity). i
One prospective randomized study showed that infusion of dopamine 
at low dose (2-5 pg/kg/minute) in severely asphyxiated newborn infants in­
creased systolic blood pressure and urine output, and decreased the incidence 
of abnormal PCT. In premature hypotensive infants (29-34 weeks of GA) with 
RDS, the infusion of dopamine at a rate of 0.5-2 pg/kg/minute resulted in a 
transient elevation in blood pressure compared to controls, followed by an 
increase in urine output, creatinine clearance, and natriuresis. In another se­
ries, the administration of low-dose dopamine to premature infants with RDS 
increased blood pressure and natriuresis, but the increase in GFR and urine 
output did not reach significance. Low-dose dopamine may stimulate PRA in 
the absence of any change in blood pressure.
INDOMETHACIN
Renal side-effects of the administration of indomethacin to premature 
infants with patent ductus arteriosus (PDA) can be prevented by the 
simultaneous administration of furosemide. Other specific preventive 
measures are discussed elsewhere in the chapter.
GENERAL APPROACH IN OLIGOANURIA
The diagnosis of oligoanuria (i.e., urinary output < 0.5-1.0 
mL/kg/hour) should be confirmed by reviewing the chart and demonstrating 
absence of urine by suprapubic pressure and by bladder catheterization per­
formed under sterile conditions, using a 3.5- or 5-Fr lubricated feeding tube, 
which then is left in place and connected to a sterile system for accurate 
measurement of the hourly urine output. Delayed micturition has been de­
scribed in association with transient bladder distention attributed to severe
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perinatal asphyxia. Bladder puncture should be avoided, because of the high 
likelihood of causing trauma.
Once oligoanuria is confirmed, the history should be reviewed for se­
vere asphyxia, respiratory failure, hypotension, shock, and renal toxins. In­
take and output over the last few days should be reviewed. The patient should 
be evaluated for possible central nervous system disease, such as meningitis, 
which may be associated with SIADHS. The physical examination should 
seek evidence of weight loss, dehydration, malformations, respiratory failure, 
CHF, shock, hypotension, and central nervous system disease. General care 
should be optimized, including ventilation using artificial means if required, 
oxygenation, cardiac output, functional circulatory volume, and extracellular 
volume.
URINE AND BLOOD ANAL YS IS
The differential diagnosis of oligoanuria includes not only renal failure 
but also SIADHS and decreased urine production secondary to the admini­
stration of ADH or its analogues (Table 46). The differentiation between pre- 
renal and true renal ARF is presented in Table 47.
Urine should be examined promptly for protein, cellular elements, 
electrolytes, creatinine, and SG or osmolality. A blood sample should be ob­
tained for hematocrit, electrolytes, creatinine, BUN, and glucose. Plasma os­
molality can be either measured, or calculated from the following formula:
Posm(mOsm/kg)=2xNa(mEq/L)+glucose(mg/dL)/18 + BUN(mg/dL)/2.8.
Use of this formula is not recommended for infants with a birth weight 
less than 1000 g, in whom it may substantially underestimate true osmolality.
While waiting for the results of these tests and ordering a renal US, and 
in some instances a renal scan, an initial therapeutic decision often can be 
made on the basis of the history and physical examination. This is especially 
important in patients in whom no urine can be obtained for analysis. Prerenal 
failure is a reasonable presumptive diagnosis in the presence of respiratory 
failure, CHF, dehydration, or shock, if osmolality or SG is high in the ab­
sence of casts in the urine. Rapid correction of the problem may be the only 
therapeutic intervention needed. The syndrome of inappropriate antidiuretic 
hormone secretion can be suspected on the basis of severe neurologic dys­
function, pneumothorax, or pleural effusion, with weight gain, oligoanuria, 
and high urinary SG.
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Tabic 46
'__________ Differential diagnosis of oligoanuria__________
Renal Failure
Prerenal: see Table 45 
Intrinsic: see Table 45 
Postrenal 
Bladder retention 
Urethral valves
Meningomyelocele, tethered cord 
Massive vesicoureteral reflux 
Bilateral ureteral obstruction
Ureteropelvic junction obstruction 
Ureterovesical junction obstruction, ureterocele 
Lithiasis 
Fungus ball 
Extrinsic compression 
Uroascites (i.e., ruptured urinary tract)
Secondary to urinary tract obstruction 
Bladder perforation due to umbilical artery catheteriza­
tion or direct bladder trauma
Syndrome of Inappropriate Secretion of Antidiuretic Hormone
Exogenous administration to mother or newborn infant 
Antidiuretic hormone, desmopressin 
Oxytocin 
Indomethacin
Acute Bladder Distension Without Renal Failure
Curarization 
Neurogenic bladder
Hematoma of the anterior wall of the bladder (i.e., traumatic suprapubic aspiration)
The urine obtained initially (i.e., before any diuretic or fluid challenge) 
should be sent for urinalysis and urine chemistry for the assessment of tubu­
lar function. Various indices and tests have been proposed to differentiate 
ATN from prerenal or functional failure, by the presence of tubular dysfunc­
tion in ATN. Fractional excretion of sodium is the preferred index; it is ob­
tained from the following formula:
F e N a  = m x u ju a
P J P ,
where UNa is the urinary concentration of sodium (mEq/L), U„ is the 
urinary concentration of creatinine (mg/dL), PNa is the plasma sodium con­
centration (mEq/L), and Pcr is the plasma creatinine concentration (mg/dL).
3 3 5
Table 47
Differential diagnosis: prerenal versus intrinsic oliguric renal failure*
Prerenal Intrinsic
FeNa <2.5% >3%
^Na <20 > 5 0
Uosm &350 <3 00
U/P osm ' >1 .2 0 .8 -1 .2
>1012 <1014
U rine  re tino l b in d in g  p ro te in* < 2 0  m g /m m o l c rea tin ine > 2 7  m grm m ol creatinine
Urine m yog lob in* <0 .5  m g /m m o l crea tin ine > 1 .5  m g im m o l creating
U ltrasonography N orm al M ay be abnormal*
BUN;’P „ > 3 0 <20
Response to  ch a lle nge5 UO >  2m L /kg /h No increase in U0
* Indices using urine sodium, osmolality, and specific gravity are not useful for the differential 
diagnosis between prerenal and intrinsic renal failure (falsely suggesting an intrinsic renal fail 
ure) after diuretic administration or volume expansion, or in case of glycosuria, adrenal insuffi 
ciency, or gestational age less than 28 weeks. In case of urinary tract obstruction, indices most 
oten are similar to intrinsic renal failure.
* Although plasma osmolality can be estimated using the formula Posm: 2 x PN, (mEq/L) + gl 
(mg/dL)/!8 + BUN (mg/dL)/2.8, the measured value of Posm is preferable, especially in criti­
cally ill patients, because of large differences in the case of sick cell syndrome (i.e., leaking cel­
lular membranes), and in infants with a birth weight less than 1000 g.
t  Transient tubular dysfunction secondary to neonatal asphyxia is characterized by moderate 
proteinuria with normal or mildly decreased GFR and normal or mildly increased FeNa, it is 
shown here in the prerenal category. Very high urine levels of myoglobin or retinol-binding 
protein may in some cases precede the increase in FeNa of intrinsic renal failure.
* Ultrasonography in intrinsic renal failure may show increased echogenicity of the pyramids, 
which probably corresponds to precipitation of Tamm-Horsfall protein, signs of renal vein 
thrombosis, renal artery thrombosis, adrenal hemorrhage, hydronephrosis, cystic kidney dis­
ease, renal dysplasia or hypoplasia, or other pathology (see Table 4Ц у , -
* The challenge corresponds to the administration of 20 mL/kg of crystalloid (more should be 
given if there is evidence of hypovolemia) and/or 1 mg/kg of furosemide. Normalization of the 
urine output after such a challenge may correspond to a prerenal failure or to the polyuric phase 
following an oliguric renal failure.
BUN/P„ - ratio of blood urea nitrogen to plasma creatinine concentration; FeNa - fractional ex­
cretion of sodium; PNj - plasma sodium concentration GFR - glomerular filtration rate; g -, gly- 
cemia; U\., - urinary sodium concentration; UO - urine output; Uosm - urine osmolality; U/P 
osm - ratio of urine to plasma osmolality; Usg - urine specific gravity.
The FENa is the ratio of the sodium clearance to the creatinine clear­
ance, expressed as a percent. A FENa greater than 3%, low urinary osmo­
lality, or low SG, suggests a diagnosis of intrinsic or postrenal failure (i.e., 
obstruction), but also can be observed in prerenal failure in patients younger 
than 28 weeks of GA or postconceptional age with adrenal insufficiency, or 
after the administration of diuretics, volume expansion, or an episode of os­
motic diuresis. Asphyxiated newborn infants may manifest transient tubular 
dysfunction associated with a normal or mildly decreased GFR and a normal 
or decreased urine output. Their tubular dysfunction is characterized by a 
positive dipstick test for blood, moderate tubular proteinuria (i.e., p2-
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microglobulin, myoglobin, retinol-binding globulin, and N-acetyl-P-D- 
glucos-aminidase [NAG]), and a FENa that is either normal or mildly in­
creased. On the other hand, ATN is associated with marked proteinuria, 
markedly decreased GFR, and often oligoanuria. Urinary concentration of 
myoglobin and retinol-binding protein, but not NAG, can be used to differen­
tiate between normal, transient tubular dysfunction and ATN; p2- 
microglobulin has not been assessed for that purpose. Emergency renal and 
bladder US may establish a diagnosis of urinary tract obstruction, uroascites, 
renal cystic disease, suggest renal vein or artery thrombosis, adrenal hemor­
rhage, or show abnormal cortical, medullary, or pyelocalicial echogenicity. 
One common finding is increased echogenicity of the pyramids, which may 
correspond to the precipitation of Tamm-Horsfall protein in patients with 
ATN.
The diagnosis of SIADHS can be suspected on the basis of plasma os­
molality less than 280 mOsm/kg, a ratio of urinary to plasma osmolality that 
is greater than 1, high urine SG, and an inappropriate increase in weight. It is 
important to note that the strict criteria used for the diagnosis of SIADHS in 
adults rarely are met in newborn infants. In most instances, inappropriate lev­
els of ADH are found in patients with abnormal renal function, because as­
phyxia is a common cause of both problems. The treatment of SIADHS usu­
ally includes severe fluid restriction, with a normal sodium intake. In some 
cases, more rapid correction is necessary because of either severe CHF sec­
ondary to fluid overload, severe hypoglycemia secondary to drastic fluid re­
striction during treatment of SIADHS, or central nervous system signs (e.g., 
seizures, coma) associated with severe hyponatremia. In these cases, the 
treatment includes the administration of furosemide, followed by careful re­
placement of the sodium lost in the urine.
CHALLENGE TEST
A challenge test is indicated only if the etiology of the renal failure is 
not evident from the assessment of risk factors, clinical signs, US, and urine 
indices (see Table 47). This can be a fluid challenge (20 mL/kg of crystalloid 
solution, such as 5% glucose, isotonic saline, or any combination of the two) 
or a diuretic challenge (usually furosemide 1 mg/kg intravenously). Although 
patients who fail to respond to furosemide may respond to bumetanide (5 
pg/kg/ dose intravenously), a more potent loop diuretic, this medication has 
not been evaluated prospectively in acute neonatal oligoanuria. Whereas the 
use of mannitol (1 g/kg) has been recommended, its administration has re­
sulted in ARF in adult patients, and may enhance the risk for intraventricular 
hemorrhage in VLBW infants through an acute increase in serum osmolality. 
Thus, mannitol cannot be recommended for routine use in newborn infants 
with oligoanuria and is contraindicated in premature infants.
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Which challenge test (i.e., diuretic administration versus fluid chal­
lenge) to be used depends first on the best judgment of the probability of hy­
povolemia versus hypervolemia. If no satisfactory response, defined by a nor­
mal urine output, is obtained after the first challenge test, the other test 
should be considered. Although normalization of the urine output in response 
to a fluid challenge is most commonly observed in prerenal failure, it also is 
compatible with the beginning of the polyuric phase after oliguric intrinsic 
renal failure, and with transformation of an incipient oliguric renal failure 
into nonoliguric renal failure. Although the FENa often is not useful in clari­
fying this differential diagnosis because either ECF expansion secondary to 
fluid challenge or diuretic administration may cause a high FENa, US and the 
subsequent development of polyuria may suggest the correct diagnosis. In 
any of these situations, renal function is expected to improve, and the prog­
nosis usually is good. In contrast, if anuria persists despite optimization of 
general care and double-challenge test, the diagnosis of intrinsic renal failure 
is likely, severe fluid restriction is indicated, and the prognosis is guarded.
Nonrandomized studies in adult patients with oliguria and azotemia 
suggest that the administration of low-dose dopamine may result in the im­
provement of urine output and creatinine clearance, even in patients who 
failed to respond to fiirosemide. A prospective study is required to evaluate 
the possible role of dopamine in the early management of diuretic-resistant 
oliguria in newborn infants.
DIAGNOSIS OF NONOLIGURIC RENAL FAILURE
Nonoliguric renal failure is characterized by a sudden decrease in GFR 
and tubular function in the absence of oligoanuria. It may be overlooked in 
the absence of routine measurement of blood chemistries and urinalysis. As 
mentioned previously, it may be confused initially with the polyuric phase of 
an intrinsic or postrenal renal failure, especially after an undiagnosed oligoa- 
nuric episode, or with prerenal failure that has been treated by the administra­
tion of fluids or low-dose dopamine for shock or hypovolemia. Although the 
evolution of nonoliguric renal failure usually is better than oliguric renal fail­
ure, it can be complicated by symptomatic hyperkalemia.
TREATMENT OF ACUTE RENAL FAILURE
In our experience, prevention of ARF and of its complications avoids 
the need for renal replacement therapy (e.g., dialysis, hemo[dia]filtration) in 
most patients. Some researchers argue that early institution of replacement 
therapy may result in improvement in mortality and morbidity.
SUPPORTIVE TREATMENT AND PREVENTION OF COMPLICATIONS
Supportive treatment of infants with ARF, whether oliguric or nono­
liguric, includes the establishment and maintenance of adequate fluid and
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electrolyte balance, as well as the adjustment of the dosage of medications 
that are eliminated by the kidney.
Many complications of ARF, such as water or medication intoxication 
and hyperkalemia, may be prevented by early suspicion of ARF and by care­
ful monitoring of intake and output and appropriate adjustment of therapy to 
renal function and to serum levels. The prognosis of ARF depends not only 
on the severity and the duration of the renal injury, but also, and perhaps 
mainly, on the overall status of the patient.
Fluid and Electrolytes
Water and Sodium. In the presence of oligoanuria refractory to the ini­
tial fluid and diuretic challenge, fluid restriction is indicated. Fluid intake is 
limited to ongoing losses (e.g., gastrointestinal losses, urinary output, third- 
space losses, drainage), plus 25 mL/kg/ 24 hours in a full-term infant, and 50 
to 75 mL/kg/24 hours in a LEW or VLBW infant. If fluid restriction is not 
initiated early in the course of ARF, fluid overload will result, with potential 
CHF, pulmonary edema, and pulmonary hemorrhage. If massive fluid over­
load leads to severe CHF, hemo(dia)filtration may be indicated. Neither so­
dium nor potassium should be administered routinely during this phase. On 
the other hand, high doses of calcium may be required to treat hypocalcemia 
or for the electrocardiographic consequences of hyperkalemia.
Hyperkalemia
Diagnosis. The most common electrolyte abnormality observed in pa­
tients with acute renal failure is hyperkalemia, which can be defined either as 
a plasma potassium concentration greater than 7 mEq/L or on the basis of 
electrocardiographic abnormalities. True hyperkalemia can be diagnosed only 
on a nonhemolyzed plasma sample that is not obtained from a heparin-coated 
umbilical catheter. Factitious hyperkalemia can result from hemolysis or clot 
formation during sampling (i.e., release of potassium from erythrocytes or 
platelets) or interference with the measurement of potassium concentration 
by benzalkonium released from a heparin-coated umbilical catheter.
Treatment. The treatment of hyperkalemia includes discontinuing po­
tassium intake from sources such as unwashed erythrocytes, antibiotics, and 
intravenous solutions; discontinuing any medication that could cause hyper­
kalemia (e.g., indomethacin, ACE inhibitors, potassium-sparing diuretics); 
and correcting hypovolemia using isotonic saline to promote tubular secre­
tion of potassium. Several modalities are available to treat hyperkalemia (Ta­
ble 48) each has potential side-effects that may limit or preclude its repetitive 
administration. Simultaneous administration of several forms of therapy often 
is required for the acute treatment of life-threatening hyperkalemia.
If electrocardiographic changes are associated with hyperkalemia, ad­
ministration of calcium chloride or calcium gluconate is indicated; this will
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rapidly, but only transiently, decrease myocardial cell excitability, and will 
not decrease potassium concentration (see Table 48). Thus, the administra­
tion of calcium should be followed immediately by at least one other method 
to decrease the potassium concentration.
Cellular uptake of potassium can be induced by an infusion of sodium 
bicarbonate, the combination of glucose and insulin, or salbutamol. Because 
their mechanisms are different, more than one method may be used; none has 
been shown to be superior to the others. If glucose and insulin are infused, 
the initial ratio for VLBW infants (500-1000 g) should be approximately 2.2 
g/unit; the ratio should be adjusted (range, 1-3 g/unit) according to the evolu­
tion of the glycemia. European data have shown that salbutamol infusion also 
is effective in treating hyperkalemia; its action is mediated by an induction of 
Na+/K+-ATPase through cAMP and is independent of insulin or aldosterone.
Table 48
Treatment of hyperkalemia in renal failure
Medication
Dose (Intravenous 
Unless Otherwise 
Specified) Mechanism
Onset 
of Action Duration
C alcium  ch lo ride  
C alc ium  g lucona te
0 .2 5 -0  5 m E q/kg  over 
5 -1 0  m in
0 .5 -1  m Eq.'kg over 5 -1 0  m in
M odifies m yocard ia l e x c it­
ab ility
1 -3  m in 30-60 miru'
’ ' '-1
S od ium  b ica rbonate 1 m E q/kg  over 10 -3 0  m in In trace llu la r up take o f К 5 -1 0  m in 2 h  Й
Glucose and insu lin 0.5 g /k g /h
1 U/2.2 g g lucose  (1 -3 )"
In trace llu la r up take o f К 30 m in 4 -6  h
S albutam ol (a lbutero l) 4 y ig /kg  over 20 m in u tes ' In trace llu la r up take o f К 40 m in >123 min
C a lion-exchange resin 
(Na/Ca po lystyrene 
su lfonate)
1 g /k g  in tra re c ta lly  q 6 hr* Exchange o f К fo r  Na o r Ca 1 -2  h 6 h  ::4
‘ ' p '4
Exchange tran s fus ion washed erythrocytes recon­
s titu te d  w ith  5% a lbum in
Uptake o f К  by ery throcytes M inutes5 >12 n
Peritoneal d ia lysis Use a d ia iysate w ith  low  
К  conce n tra tion
Dialysis M inutes5 No lim it '
H em ofiltra tion  and 
hem odialysis
F iltra tion , d ia lys is M inutes5 Days
* The preparation of an insulin drip requires saturating the plastic tubing with the insulin solu­
tion before infusing to the patient. The average ratio of glucose to insulin associated with main­
tenance of normal glycemia in VLBW infants is 2.2 ± 0.6 g/unit (mean ± SD).
t  The intravenous preparation is not available in the United States. Salbutamol also is efficient 
by aerosol, but no experience is available in newborn infants.
t  Oral administration of polystyrene resin should be avoided in VLBW infants and those with 
poor peristalsis because they may be at risk for concretions. Substantial load of calcium or so­
dium may result from the respective resin. The effect on potassium concentration is slower than 
glucose insulin combination.
§ These techniques are both rapid and extremely effective in correcting potassium levels. The 
time to set them up may be the limiting factor; other techniques may be used to stabilize the in­
fant initially
VLBW, very low birth weight.
Adapted from Smith JD, Bia MJ, DeFronzo RA. Clinical disorders of potassium metabolism. 
In: Arieff Al, DeFronzo RA, eds. Fluid, electrolyte, and acid-base disorders.
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Although an enema with cation-exchange resin offers the potential ad­
vantage of removing potassium from the body rather than moving potassium 
from the extracellular into the intracellular compartment, resin used alone has 
a much slower effect than infusion of glucose and insulin. One prospective 
randomized study showed that using a cation-exchange resin alone for the 
treatment of hyperkalemia resulted in greater mortality than using glucose- 
insulin. One potential problem associated with the use of cation-exchange 
resin is excessive sodium load; this complication may be avoided by using a 
resin with calcium instead of sodium. Oral administration of cation-exchange 
resins is not recommended.
If these techniques fail to correct hyperkalemia, exchange transfusion 
with washed, packed erythrocytes reconstituted with plasma or albumin is ex­
tremely efficient in normalizing potassium concentration for as long as 12 
hours; it is the treatment of choice in those patients in whom renal replace­
ment therapy is contraindicated by peritonitis or cardiovascular instability. 
Renal replacement therapy, especially hemo(dia)filtration, is the procedure of 
choice for the infant with severe oliguric ARF.
If hyperkalemia is associated with hyponatremia, hypoglycemia, and 
hypotension, a diagnosis of adrenal insufficiency should be considered. This 
most often results either from congenital adrenal hyperplasia or from bilateral 
adrenal hemorrhage, which may be suspected on the basis of anemia with 
thrombocytopenia, jaundice, and bilateral abdominal masses.
Acid-Base and Mineral Disturbances
Metabolic acidosis develops rapidly in most infants with ARF. It may 
require the administration of large doses of sodium bicarbonate, which may 
aggravate fluid overload.
Hypocalcemia will develop rapidly in almost all patients with ARF. It 
may result from hyperphosphatemia and increased deposition of calcium in 
injured tissues, especially in rhabdomyolysis; skeletal resistance to PTH, 
which results from decreased production of 25-hydroxyvitamin D and 1,25- 
dihydroxyvitamin D (l,25[OH]2D); and, in aminoglycoside-induced ARF, 
parathyroid dysfunction secondary to hypomagnesemia, which is due to in­
creased tubular loss. Hypercalcemia may occur as a late complication of 
rhabdomyolysis, as a result of re-absorption of calcium deposited in necrotic 
tissues. Hyperphosphatemia is due to tissue damage (e.g., severe asphyxia, 
shock, rhabdomyolysis) and decreased urine excretion. In addition, ARF usu­
ally causes hypermagnesemia, which may result from decreased excretion 
and from shift from the intracellular space. The polyuric phase of ATN is as­
sociated with increased urinary excretion of phosphate and magnesium.
Hypocalcemia should be prevented or treated with early intravenous 
administration of calcium gluconate or chloride. During the oliguric phase,
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no intake of magnesium (e.g., antacids) or phosphate should be provided, to 
limit both hypermagnesemia and hyperphosphatemia.
Polyuric Phase
The oliguric phase of ARF is followed by a polyuric phase, during 
which continuous replacement of ongoing losses is essential. Because of in­
dividual variability and the change over time in electrolyte content of the 
urine, serial measurements of urine electrolytes and hourly monitoring of the 
urine output are imperative. This will permit accurate replacement of urinary 
losses and prevent dehydration, hyponatremia, and hypokalemia. In some 
cases, bicarbonate, phosphate, and magnesium need to be given to replace 
urinary losses. When GFR approaches normal levels, fluid intake should be 
decreased gradually and carefully, while following weight, serum chemis­
tries, and urine output. Replacing the urine output volume for volume for an 
indefinite duration would cause an adaptive persistence of the polyuria. In 
contrast, some patients may not recover a normal urinary concentrating abil­
ity despite normalization of GFR; these patients need to continue to receive 
higher fluid intake.
Nutrition. If fluid restriction is required, glucose intake often is mini­
mal, and severe hypoglycemia may develop, unless a hypertonic solution of 
glucose is infused through a central venous catheter. If refractory hypogly­
cemia occurs despite an adequate glucose intake per kilogram and per min­
ute, the infant should be evaluated for possible hormonal anomalies, and spe­
cific treatment should be initiated, if indicated. Otherwise, steroids or an in­
fusion of glucagon can be given. If this is unsuccessful, hemofiltration should 
be considered. This technique will allow increased fluid and glucose intake 
while rapidly correcting the hypervolemia.
The importance of adequate nutrition results from the fact that renal 
load decreases with anabolism. Breast milk or low-protein formula should be 
initiated as soon as possible; if the infant cannot be fed, total parenteral nutri­
tion (TPN) should be initiated. If the ARF is severe, the usual amino acid so­
lution should be replaced by essential L-amino acids supplemented with L- 
histidine (Levamin Essential; Leiras, Turku, Finland), initially given at a dose 
of 0.5 to 1 g/kg/day.
Hematologic Disturbances. Anemia associated with ARF may result 
from several factors, including decreased erythropoietin production, abnor­
mal or ineffective erythropoiesis, impaired iron use, and shortened erythro­
cyte survival. Transfusion of packed erythrocytes may be necessary. Bleed­
ing tendency may result from abnormal platelet function and, in some pa­
tients (e.g., those with renal venous thrombosis), from thrombocytopenia.
Adjustment of Medication Dosage. Adjustment of the dosage of 
medications with renal elimination must be done to avoid toxic levels. The 
interval of administration should be prolonged, unless renal replacement
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therapy that removes the particular drug is initiated. Toxic levels of some 
drugs may in turn increase the severity of the renal failure (e.g., aminoglyco­
sides, acyclovir, amphotericin B, cyclosporine; see Nephrotoxicity). In new­
born infants, the commonly used drugs of concern include antibiotics (e.g., 
aminoglycosides, vancomycin, penicillins, cephalosporins, amphotericin B, 
acyclovir), paralyzing agents (e.g., vecuronium), tolazoline, theophylline, an­
tiepileptic drugs, and digoxin. Although there are insufficient data to calcu­
late adjustment of dosage in newborn infants, predictions can be made from 
the relationship between serum creatinine concentration and the half-life of 
serum concentration of a particular drug. Further adjustments can be made by 
monitoring drug levels. When possible, medications with minimal or no renal 
toxicity should be chosen.
RENAL REPLACEMENT THERAPY
Renal replacement therapy is indicated only if aggressive symptomatic 
treatment fails to manage life-threatening complications due to massive fluid 
overload, hyperkalemia, or hypertension. Hemodialysis has been replaced 
largely by peritoneal dialysis, hemofiltration, and hemodiafiltration. Avail­
ability of large-bore intravascular catheters in a patient on extracorporeal 
membrane oxygenation (ECMO) makes the latter two techniques particularly 
easy to initiate. Hemo(dia)filtration is the technique of choice for the treat­
ment of massive fluid overload. Although these techniques offer excellent 
potential renal replacement in newborn infants, their use has remained lim­
ited for several reasons.
Peritoneal dialysis is contraindicated in patients with respiratory fail­
ure, shock, peritonitis, or necrotizing enterocolitis, although it can be used in 
some cases after abdominal surgery. In patients with liver failure, lactate con­
tained in standard dialysis solution may result in the accumulation of lactic 
acid; a dialysis solution containing bicarbonate should then be used. The 
other techniques usually require heparinization, which is contraindicated in 
premature infants because of the risk of intraventricular hemorrhage. Never­
theless, efficient continuous arteriovenous hemofiltration has been performed 
in premature infants with ARF and fluid overload, using prostacyclin instead 
of heparin to prevent hemofilter clotting. If MAP is less than 40 torr, or if ar­
terial access is impossible, hemo(dia)filtration requires a pump to be effi­
cient. Renal transplantation is not an available option; this is discussed in 
greater detail elsewhere in the chapter, Before renal replacement therapy is 
initiated, serious consideration should be given to the possibility that the pa­
tient has a dysmorphic syndrome consistent with a fatal disease or one asso­
ciated with a very poor future quality of life, or the possibility that the patient 
is suffering from severe, irreversible multi-organ failure, secondary to pro­
found immaturity or asphyxia, including irreversible neurologic damage or 
severe lung compromise (Table 49).
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P R O G N O S IS
SHORT-TERM
The short-term prognosis for neonatal ARF depends on the general 
condition of the infant and the status of all major organs and systems (see 
Table 49). It is essential to assess the whole patient, not only the renal condi­
tion.
Immediate mortality of infants with congenital urinary tract malforma­
tions depends primarily on the presence of respiratory failure associated with 
pulmonary hypoplasia and oligohydramnios. Infants with severe pulmonary 
hypoplasia, often associated with typical Potter syndrome, die within the first 
postnatal hours or days; after certainty of the diagnosis, resuscitation or ac­
tive intervention appears futile and therefore inappropriate. In patients with 
prenatal diagnosis of urinary tract anomalies, satisfactory renal function is 
observed more frequently in association with a normal volume of amniotic 
fluid, absence of cortical cysts, fetal urinary sodium concentration less than 
100 mEq/L, СГ less than 90 mEq/L, osmolality less than 210 mOsm/kg, and 
urine output greater than 2 mL/hour. The reliability of these indicators to 
prognosticate in individual cases, however, has not been established.
In one series, the mortality rate in patients with oliguric ARF was 60% 
in ARF due to acquired conditions (i.e., asphyxia and sepsis) and even higher 
in those with congenital heart disease. A similar mortality rate (61%) was ob­
served in a series of infants requiring peritoneal dialysis in the first 60 days of 
life. For newborn infants in whom ARF develops while on ECMO, the prog­
nosis is grim. In contrast, the prognosis for nonoliguric renal failure or for 
pre-renal failure is excellent, unless major arrhythmia secondary to hyper­
kalemia develops or multiorgan failure develops.
LONG-TERM
A team approach to management is crucial and should include a neona- 
tologist, nephrologist, urologist, geneticist, and radiologist.
Long-term abnormalities in GFR and in tubular function are common 
in acquired as well as congenital causes of ARF. In one series, limited uri­
nary concentrating ability tested using DDAVP was observed at 1 to 36 
months of age in 11% of patients who had a neonatal Pcr greater or equal to
1.5 mg/dL. Fanconi syndrome has been reported as a sequela of renovascular 
accident in the neonatal period. The presence of bilateral renal parenchymal 
disease is the major factor predicting poor renal function in cases with con­
genital renal or urinary tract malformations. Chronic renal failure (CRF) may 
develop despite early surgical intervention for urinary tract obstruction or re­
flux (i.e., in utero or immediately after birth).
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Table 49
____________ Prognostic factors in renal-urinary tract malformations_______
Poor Prognosis for Survival or for Future Quality o f Life
General condition
Dysmorphic syndrome associated with poor prognosis 
(e.g., trisomy 13, severe oligohydramnios or Potter 
sequence)
Severe immaturity
Multiorgan failure (e.g., asphyxia, ARF in a patient on ECMO, 
overwhelming sepsis)
Other major organs and systems 
Severe pulmonary hypoplasia or oligohydramnios 
Severe, irreversible neurologic damage 
Refractory cardiac output failure, major arrhythmia 
Sepsis
Renal function*
Oligoanuria unresponsive to general treatment and to fluid and diu­
retic challenge
Poor Prognosis for Renal Function
Severe bilateral renal parenchymal disease (e.g., agenesis, hypoplasia, 
aplasia, dysplasia, severe PKD)
Late diagnosis of obstruction, reflux, or infection
* Although fetal urinary Na concentration < 100 mEq/L, Cl concentration < 90 mEq/L, osmo­
lality < 210 mOsm/kg, and urinary output > 2 mL/kg/h all are statistically associated with good 
prognosis, none of these tests is reliable in individual cases
ARE - acute renal failure; ECMO - extracorporeal membrane oxygenation; PKD - polycystic 
kidney disease.
SPECIAL CONSIDERATIONS
NEPHRON DYSGENESIS: TUBULAR OR GLOMERULAR IMMATURITY
Several cases of perinatal ARF have been described in association with 
immature nephrons, either predominantly with glomerular lesions or pre­
dominantly with tubular lesions. Oligohydramnios developed in most patients 
during the second trimester, and they died in utero or soon after birth. 
Whether these cases represent a spectrum of presentations due to the same 
pathophysiology or several different entities has not been determined. In any 
case, we propose to call this syndrome nephron dysgenesis and its two main 
subtypes tubular dysgenesis and glomerular dysgenesis.
Congenital Tubular Dysgenesis. Congenital tubular dysgenesis (i.e., 
congenital oligomeganephronic nephromegaly with tubular dysgenesis, con­
genital renal tubular immaturity) has been described in 1% of 500 consecu­
tive perinatal autopsies. This syndrome, probably autosomal recessive, is 
characterized by short and undifferentiated tubules and lack of identifiable 
proximal tubules by lectin staining, contrasting to the presence of numerous
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glomeruli. The size of the kidneys usually is normal or slightly enlarged, but 
in some instances the kidneys are hypoplastic. Renal US shows normal or in­
creased cortical echogenicity and decreased corticomedullary differentiation. 
Oligohydramnios develops during the second trimester, usually after 20 
weeks of gestation, and results in Potter sequence and perinatal death. Some 
cases have been described in association with twin-to-twin transfusion or po- 
lymalformations.
Glomerular Dysgenesis. Glomerular dysgenesis is characterized by 
immature glomeruli, often with dilation of the Bowman space. It has been re­
ported mostly in association with prenatal administration of indomethacin or 
ACE inhibitors, but also in the absence of prenatal therapy. In contrast to tu­
bular dysgenesis, glomerular dysgenesis may be associated with hematuria 
and casts.
Administration of indomethacin for the prevention of premature labor 
can result in fetal oligoanuria and oligohydramnios; this effect of indometha­
cin on fetal urine output has been used for the treatment of polyhydramnios. 
Six infants have been reported who presented with persistent oligoanuria af­
ter prenatal administration of indomethacin; these infants eventually died and 
had either massive cortical necrosis (1 patient) or ischemic changes in the 
cortex associated with cystic dilation of the superficial nephrons and in­
creased intrarenal renin. Indomethacin also may cause milder forms of 
nephron dysgenesis, as suggested by one case report of a monozygotic twin 
pregnancy with polyhydramnios in which prolonged indomethacin admini­
stration resulted in severe oligohydramnios in one of the twins.
The administration of ACE inhibitors during pregnancy can result in 
oligohydramnios, lung hypopla-sia, neonatal renal failure with oligoanuria 
for 3 to 9 days, hypotension, hypoplasia of the calvaria, and, in many cases, 
perinatal death. Pathologic examination may show nephron dysgenesis with 
immature glomeruli and dilation of glomerular spaces, convoluted tubules, 
and collecting ducts.
RENAL ARTERY THROMBOSIS
The clinical presentation of renal artery thrombosis may include sys­
temic hypertension, high PRA, and hematuria, as well as severe oligoanuric 
ARF if the lesion is bilateral. In some patients, the presence of a major aortic 
thrombus may be suspected from loss of femoral pulses and of blood flow to 
the lower extremities. The diagnosis of renal artery thrombosis should be 
suspected, especially in a newborn infant who has or has had a UA catheter. 
The incidence of thrombi in infants with a UA catheter in place ranges be­
tween 24% and 95%. These thrombi may become symptomatic when mas­
sive or when embolism occurs. Whether the incidence of UA line complica­
tions, including hypertension, can be minimized by specific position in the
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aorta or by continuous heparinization remains controversial. Renal throm­
boembolism may occur in the absence of UA catheterization.
Renal US may be normal or show increased cortical echogenicity or 
nephromegaly. Real-time US may show a blood clot in the aorta or a renal 
artery, and Doppler flow studies may show decreased renal arterial flow. Iso­
topic renogram may show absence of renal blood flow or a localized defect. 
If the UA catheter is still in place, angiography may be performed, preferably 
using a low-osmolality radiocontrast agent.
Acute renal failure associated with bilateral renal artery thrombosis 
may require prolonged replacement therapy (e.g., peritoneal dialysis). The 
indications for surgical treatment of aortic or renal thromboembolism are not 
clear. Whereas at one time nephrectomy or thrombectomy was recom­
mended, success has been reported by several researchers using a selective 
approach. Thrombolysis and, if it fails, thrombectomy, should be considered 
for patients with refractory hypertension and those with massive aortic 
thrombus resulting in major complications (e.g., compromised limb perfusion 
or anuria). The other patients usually can be treated with antihypertensive 
agents and symptomatic management of the complications of ARF; heparini­
zation may help to limit further extension of the thrombus The therapeutic 
decision should take into account the risk of disseminated bleeding and of in­
traventricular hemorrhage, especially in premature infants.
Although renal artery thrombosis often results in localized or diffuse 
renal hypotrophy, renal function often improves to a level that is close to nor­
mal, and hypertension resolves in most patients within a few months. Fanconi 
syndrome may occur in rare patients.
RENAL VENOUS THROMBOSIS
Neonatal renal venous thrombosis is an uncommon condition. It may 
be associated with polycythemia; severe perinatal asphyxia; severe dehydra­
tion, sometimes with shock; maternal diabetes; angiography for congenital 
cyanotic heart disease; and adrenal hemorrhage. Suboptimal fibrinolysis in 
stressed newborn infants may be an important factor. Renal venous thrombo­
sis presents clinically as the association of a unilateral or bilateral palpable 
flank mass with hematuria, proteinuria, and, in some cases, oligoanuria. Ul­
trasonography and Doppler studies show whether the renal venous thrombo­
sis extends to the inferior vena cava. Ultrasonography of the kidney shows a 
typical image, characterized by enlargement of the kidney, loss of definition 
of the corticomedullary junction, abnormal focal or generalized increase in 
echo amplitude of the renal parenchyma, and some diminution of the size and 
echo amplitude of the central echo complex. The acute complications of renal 
venous thrombosis include ARF, systemic hypertension, and disseminated 
intravascular coagulation (DIG); it ultimately may result in renal atrophy.
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Whereas nephrectomy used to be recommended in all cases, some se­
ries report good results using a conservative approach, except in the most se­
vere cases. In the presence of consumption coagulopathy, administration of 
heparin may be considered. In cases associated with bilateral renal venous 
thrombosis or inferior vena cava thrombosis, similar results have been re­
ported using either thrombectomy or thrombolysis.
CORTICAL NECROSIS ADD MEDULLARY NECROSIS
Renal cortical or medullary necrosis is the most severe type of ARF. 
The most common causes of renal necrosis include severe asphyxia and 
shock. A rare cause of renal infarction is idiopathic arterial calcification. The 
symptomatology is not specific and includes oligoanuric ARF, proteinuria, 
and hematuria that is often grossly apparent. The kidneys often are enlarged; 
renal US shows homogeneously hyper-echoic kidneys, with loss of sharp cor- 
ticomedullary definition. The renal scan either will show very poor renal 
function or will not visualize the kidneys. Calcifications may become visible 
both on the US and the abdominal radiography. The treatment is similar to 
that described previously for ATN. The prognosis of bilateral global cortical 
necrosis is dismal; the diagnosis has been made most often at autopsy. Pa­
tients with focal or unilateral necrosis may recover, but often have chronic 
hypertension and CRF. Infants with medullary necrosis typically have persis­
tent limitations in urinary concentrating ability.
POSTRENAL FAILURE
The medical treatment of postrenal failure is similar to that of intrinsic 
renal failure. Decompression of the urinary tract often results in an increase 
in GFR as well as a polyuric phase that usually is transient. During the polyu- 
ric phase, severe dehydration, hyponatremia, and hyperkalemia may develop 
despite adequate increase of serum aldosterone levels. Careful sequential as­
sessment of fluid balance and serum electrolytes is imperative to prevent or 
limit such complications, some of which may result from ECF contraction 
due to insufficient replacement of urine losses. As mentioned previously, 
when GFR comes to baseline within 1 week after surgery, fluid intake should 
be reduced slowly and carefully, taking into account the fact that limited 
urine-concentrating ability is expected in association with dysplastic kidneys. 
The evolution of renal function depends on the degree of renal dysplasia, 
which is very common in congenital urinary tract obstruction, and the fre­
quency of UTI, which is related to VUR, urinary stasis, and the presence of 
an indwelling catheter.
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N E P H R O T O X I C I T Y :  D R U G S  A N D  T O X IN S
PATHOPHYSIOLOGY
Several drugs that cross the placenta can damage the fetal kidney, in­
cluding aminoglycosides, heavy metals, alcohol, and organic solvents (Table 
50). Chapters 16 and 56 provide a discussion of the relevant pharmacokinet­
ics. Although high doses often are required to produce toxicity in animal 
models, once the threshold is reached, the pathologic and pathophysiologic 
processes often are similar to those observed in human toxicology.
Table 50
Nephrotoxic effects of various drugs and toxins
Substance R e na l S ide -Effects
Drugs
Aminoglycosides Proteinuria, increased urinary excretion of Na, K. Mg, and glucose,
Fanconl syndrome, myelin figures, decreased concentrating ability,
decreased RBF, polyuric ARF, ATN, interstitial nephritis
f^etWciliin Interstitial nephritis
Amphotericin В
Uf-'"
Hyperkaliuria, hyposthenuria. NDI, hypernatriuria. ATN, oliguria, RTA,
nephrocalcinosis
Acyclovir Crystalluria, obstructive nephropathy
fenethadn Decreased RBF. ATN, oligoanuria, hyponatremia, hyperkalemia in
C<-; ■ ulero nephron dysgenesis, oligohydramnios
Watolinę Hypotension and hypoxemia resulting in decreased GFR, ATN, oliguria.
. hematuria
(г-Adrenergic agents Decreased RBF, ATN
ACE inhibitors Hypotension, decreased RBF, AIN, in utero nephron dysgenesis
■ Radiocontrast agents Decreased R3F, oliguric ATN, Tamm-Horsfalt proteinuria, nephro-
fT
megaty with US similar to ARPKO, increased urinary excretion of uric
acid
: Cyclosporine Renal vasoconstriction, decreased RBF and GFR. interstitial nephritis
. loop diuretics 
: Toxins
Nephrocalcinosis, nephrolithiasis
„Heragiobin ATN
plpglobin ATN
’ Oxalate Nephrocalcinosis, nephrolithiasis, oxalosis with ARF
; Benzyl alcohol Cardiovascular collapse. ATN
Jfeiysorbate in intravenous tocopherol ATN
; Uric acid Crystalluria, ATN
pgaitic solvents (e.g.. toluene) Fanconi syndrome, aminoaciduria, hyperchloremic acidosis
Ш Л о: (In ulero) Distal RTA
ACE - angiotensin-converting enzyme; ART - acute renal failure; ARPKD - autosomal reces­
sive polycystic kidney disease, ATN - acute tubular necrosis; GFR - glomerular filtration rate; 
NDI - nephrogenic diabetes insipidus; RBF - renal blood flow, RTA - renal tubular acidosis; 
US - ultrasound
Depending on the compound and its dose, nephrotoxicity may result 
either from direct cytotoxicity or from renal ischemia; the latter mechanism 
may be especially important during the initial phase. Direct cytotoxicity is 
related to the concentration of drug or metabolite in renal tubular cells, which 
depends on the concentration of free drug in the plasma, GFR, and the char­
acteristics of tubular transport.
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CLINICAL PRESENTATION AND DIAGNOSIS
Nephrotoxicity may present as oligoanuria, ARF, drug toxicity caused 
by decreased clearance of a medication with renal excretion, hypotension, 
hematuria, proteinuria, renal tubular acidosis (RTA), nephrocalcinosis or 
nephrolithiasis, polyuria, abnormal plasma electrolyte concentrations, or car­
diac arrhythmia (see Table 50). Methods of screening for nephrotoxicity de­
pend on the drug or toxin and may include urinalysis, measurement of uri­
nary concentration of low-molecular-weight proteins, sequential measure­
ments of Pcr, GFR, or serum drug levels, urine output, or renal US. Since 
most NICU patients also are exposed to multiple drugs as well to episodes of 
hypoxemia and ischemia, it often is very difficult to determine whether a par­
ticular drug is the major renal offender.
PREVENTION AND TREATMENT
Prevention of nephrotoxicity includes avoiding teratogens (e.g., ACE 
inhibitors), adjusting the interval of administration of nephrotoxic agents 
(e.g., aminoglycosides, acyclovir) according to measured or predicted GFR, 
avoiding known toxins (e.g., methicillin, benzyl alcohol, polysorbate), select­
ing drugs with the best risk-benefit ratio (e.g., choosing a thiazide rather than 
furosemide for chronic oral therapy of bronchopulmonary dysplasia [BPD] 
except in refractory patients), and avoiding, if possible, synergistic nephro­
toxic combinations. In addition, the dosage of all these medications should be 
adjusted to renal function, which is predicted from GA during the first day of 
life and estimated from PCT afterward. Treatment of nephrotoxicity is symp­
tomatic; the dosage of all medications with renal elimination should be ad­
justed to renal function and to drug levels, fluid and electrolyte disturbances 
should be corrected, and, if appropriate, the toxic medication should be re­
placed by a less toxic one.
SPECIFIC CONSIDERATIONS
AMINOGLYCOSIDES
Fathophysiology. Aminoglycoside nephrotoxicity results from renal 
vasoconstriction and from direct cellular toxicity, especially in the proximal 
tubule, Within the same species, there is a dose-effect relationship and a 
characteristic time course. In the dog, low doses of gentamicin induce suc­
cessively an increase in urinary excretion of PGE2, a decrease in urinary os­
molality, a rise in PRA, and finally, after I weeks or more, a sudden decrease 
in PGE2 followed immediately by polyuric ARF with high FENa and tubu­
lointerstitial nephritis; higher doses result in hypokalemia, hypocalcemia, and 
a more prominent decrease in GFR. Continuous exposure to gentamicin after 
tubular necrosis and regeneration is associated with aminoglycoside insensi­
tivity, which is characterized by normalization of GFR, but only partial re-
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covery of renal concentrating ability. At that stage, pathologic examination 
discloses chronic tubulointerstitial changes in the medulla.
Rerial vasoconstriction associated with aminoglycoside administration 
may be mediated by an increase in TX synthesis. Indeed, inhibition of TX 
synthesis or volume expansion with isotonic saline diminishes aminoglyco­
side-induced nephrotoxicity; furthermore, the enhanced nephrotoxicity of the 
association of gentamicin, captopril, and potassium depletion is dependent 
largely on an increase in TXB2 synthesis. Prostaglandins may limit that vaso­
constriction, as suggested by the natural history of gentamicin nephrotoxicity 
in the dog, and by enhanced nephrotoxicity resulting from the association of 
indomethacin with gentamicin.
Aminoglycoside nephrotoxicity is predominantly a proximal tubular 
disease. Histopathologic features include a loss of brush border, an increase 
in number and size of lysosomes, and formation of myeloid bodies. In the 
proximal tubule, the aminoglycoside is absorbed by pinocytosis and stored in 
lysosomes. Cellular uptake of aminoglycoside results in inhibition of ly­
sosomal enzymes, including cathepsins and phospholipase A|, which leads to 
the development of myeloid figures; inhibition of endocytosis, mitochondrial 
Ca2+ uptake, and Na+/K+-ATPase; and alterations of membrane phospholip­
ids. Cellular uptake may explain two pharmacologic findings, the presence of 
a "tissue compartment" and the fact that plasma clearance of gentamicin is 
greater than its urinary clearance.
Functional tubular changes include decreased glucose, electrolyte, and 
fluid absorption in the proximal tubule, decreased maximum PAH secretion, 
decreased urea and sodium concentration in the papillary tip, and decreased 
fluid absorption in the papillary duct. Proteinuria is mediated by two mecha­
nisms: decreased tubular reabsorption, which results in urinary excretion of 
low-molecular-weight proteins, and loss of integrity and desquamation of 
cells, which results in urinary excretion of cytoplasmic enzymes (e.g., lactate 
dehydrogenase, alanine aminopeptidase) and lysosomal enzymes (e.g., 
NAG). Eventually, tubular necrosis, tubular atrophy, intratubular myeloid 
bodies, and interstitial nephritis may be apparent.
Several mechanisms are involved in the decrease in GFR associated 
with aminoglycoside use. In rats, low doses of gentamicin may induce a mild 
reduction in GFR secondary to a decrease in ultrafiltration coefficient, 
whereas high doses induce a severe reduction in GFR secondary to a decrease 
in RBF, ultrafiltration coefficient, and transglomerular hydraulic pressure; the 
latter is associated with tubular lesions. High doses of gentamicin also may 
induce a reduction in the number and size of the glomerular endothelial 
fenestrae, which may further decrease the ultrafiltration coefficient.
Risk Factors. Gentamicin, kanamycin, and tobra-mycin are more 
nephrotoxic than amikacin or netilmicin, several factors may enhance ami­
noglycoside nephrotoxicity under experimental conditions. In subtotally
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nephrectomized dogs, morphologic and functional (i.e., GFR) measures of 
nephrotoxicity are less severe when the interval of administration is adjusted 
with a fixed dose than when the dose is adjusted with a fixed administration 
interval. Nephrotoxic effects of aminoglycosides may be enhanced by re­
duced renal mass; ischemia; metabolic acidosis; sodium or potassium deple­
tion; pyelonephritis; endotoxemia; indomethacin; ACE inhibition, especially 
in association with potassium depletion; and furosemide. Although vancomy­
cin has been reported to increase aminoglycoside-induced nephrotoxicity in 
adult patients, several studies in newborn rats, infants, and children have 
failed to confirm an additive toxicity. Renal susceptibility to aminoglycosides 
also depends on renal maturity. In mongrel dogs, newborn puppies are less 
susceptible to gentamicin nephrotoxicity than older puppies or adult animals.
Clinical Presentation and Diagnosis. Aminoglycoside nephrotoxicity 
most commonly presents either as isolated proteinuria or polyuric ARF with 
a high FENa. Laboratory findings may include proteinuria, decreased GFR, 
decreased urine-concentrating ability, glucosuria, increased natriuresis and 
ka-liuresis, and alterations in tubular transport of organic adds; hypomagne­
semia secondary to increased urinary excretion has been reported. A reversi­
ble Fanconi syndrome has developed rarely in children receiving gentamicin, 
either within a few days or after prolonged therapy.
The diagnosis of aminoglycoside toxicity should be suspected if tubu­
lar or glomerular damage disappears after the medication is stopped. During 
the first days of therapy, the most sensitive indicator of nephrotoxicity is an 
increase in urinary excretion of low-molecular-weight proteins (i.e., (32- 
microglobu-lin, retinol-binding protein, lysozyme), whereas after 1 week of 
therapy, the most common indicator is an increase in urinary excretion of 
NAG. Neither low-molecular-weight proteinuria nor NAG enzymuria is spe­
cific. On the other hand, the presence of myelin figures in the urinary sedi­
ment is associated with nephrotoxicity related to cationic amphophilic com­
pounds (e.g., aminoglycosides) but not with ischemic nephropathy; however, 
their detection requires electron microscopy.
Prevention and Treatment. Serum aminoglycoside levels should be 
obtained at least weekly. Plasma creatinine concentration, serum electrolytes, 
urinaly-sis, and urine output should be followed serially in high-risk patients. 
The interval of administration of medications such as digoxin, indomethacin, 
and the aminoglycoside itself may have to be adjusted according to Ри and to 
respective plasma levels, which should be kept within the therapeutic range 
(for gentamicin: peak level, 4-10 pg/mL; trough level, 1-2 pg/mL). Sodium 
and potassium intake should be adequate to prevent depletion of either elec-- 
trolyte. If severe Fanconi syndrome or polyuric ARF develops, the aminogly­
coside should be replaced by another antibiotic, and nonspecific treatment 
should be given.
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INDOMETHACIN
Pathophysiology. Because the half-life of indomethacin depends on 
GA, similar doses result in higher levels for longer duration in more imma­
ture patients. Indomethacin, which is a cyclooxygenase inhibitor, blocks the 
synthesis of PG. Since renal synthesis of PCs already occurs in fetuses who 
are 22 weeks of GA, it is not surprising that indomethacin may cause renal 
side-effects at all ages.
Indomethacin administration acutely decreases RBF. Although in pre­
mature infants with symptomatic PDA, RBF decreases only transiently after 
each dose of indomethacin (0.2 mg/kg), in some patients it may result in tran­
sient renal dysfunction. The latter is associated with suppression of PG syn­
thesis, a fall of PRA from the high levels that are attributed to renal hypoper­
fusion before closure of the PDA, and a transient rise in the plasma level of 
AVP. During prolonged administration of indomethacin (i.e., up to 1 week), 
hormonal levels normalize, and renal function tends to improve.
Indomethacin and its glucuronide are excreted into the urine almost en­
tirely through the organic secretory pathway of the proximal tubule, involv­
ing active transport at the basolateral surface. Indomethacin induces a marked 
reduction in microsomal enzymes (e.g., cytochrome P450), increased reab­
sorption of solutes in the proximal part of the nephron, increased corticome- 
dullary gradient, and enhanced hydroosmotic effect of antidiuretic hormone. 
The latter two changes result in an increased ratio of urine to plasma osmo­
lality and decreased free water clearance; water retention and dilutional hy­
ponatremia develop in some patients. The effect of indomethacin administra­
tion on urinary electrolyte excretion is variable; in some premature infants it 
may result in decreased natriuresis. Indomethacin-mediated hyperkalemia is 
due to decreased renal K+ excretion, which may result from hyporeninemic 
hypoaldosteronism, decreased Na+ delivery to the distal tubule, or ARF, but 
is not due to alteration of the extrarenal handling of K+. Simultaneous ad­
ministration of PG prevents all renal side-effects of indomethacin, except for 
NAG enzymuria.
An indomethacin-mediated decrease in RBF may result in ARF in 
some patients. Papillary necrosis, nephrotic syndrome, and interstitial nephri­
tis have been described in animals and adult humans treated with nonster­
oidal antiinflammatory agents, such as indomethacin, but not in newborn in­
fants.
Risk Factors. The risk of nephrotoxicity is increased by the combina­
tion of indomethacin with other nephrotoxins, such as aminoglycosides or cy­
closporine.
Clinical Presentation. Maternal administration of indomethacin, 
which has been used for the prevention of premature labor and for the treat­
ment of poly-hydramnios, results in equivalent plasma indomethacin concen­
trations in fetal and maternal circulations. Maternal indomethacin administra-
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tion may induce nephron dysgenesis (see Acute Renal Failure), oligohydram­
nios, and neonatal renal failure.
Renal side-effects of postnatal administration of indomethacin include 
decreased free water clearance and oligoanuria, which can cause dilutional 
hypona-tremia; hyperkalemia; ARF; and decreased digoxin clearance.
Prevention and Treatment. Indomethacin is con-traindicated if Pcr is 
elevated (i.e., usual criterion is Pcr > 1.8 mg/dL) and in the presence of oli­
goanuria or hyperkalemia. The incidence of indomethacin-related nephrotox­
icity can be decreased by volume expansion for a few hours before its ad­
ministration, or by simultaneous administration of furosemide.
Because GFR decreases frequently in association with indomethacin 
administration, Pcr, serum electrolyte concentrations, and urine output should 
be monitored. In addition, the interval of drug administration should be ad­
justed according to Pcr or GFR. The digoxin administration interval should be 
increased preventively. Treatment of indomethacin-induced ARF or hyper­
kalemia is symptomatic. Dilutional hyponatremia can be prevented by adjust­
ing fluid intake to urine output. If oligoanuria develops, a challenge dose of 
furosemide should be given; fluid restriction should be initiated if oligoanuria 
persists.
TOLAZOLINE
Pathophysiology and Risk Factors. Administration of tolazoline to 
hypoxic animals induces systemic hypotension and a more severe decrease in 
RBF and GFR and increase in FENa than hypoxia alone. In newborn infants 
with pulmonary hypertension, tolazoline has predominantly a nonspecific 
vasodilator effect (i.e., acting or both the pulmonary and the systemic vascu­
lature presumably as an а-antagonist). Whether tolazoline has a specific ac­
tion on the renal vasculature or renal function in newborn infants has not 
been investigated; it may be that the renal side-effects of tolazoline are medi­
ated through ischemia caused by tolazoline-induced systemic hypotension.
Because tolazoline is excreted unchanged into the urine, both by 
glomerular filtration and by tubular secretion, its half-life is expected to in­
crease in parallel with decreasing renal function. Very little information is 
available about the pharmacokinetics of tolazoline in the newborn infant. In 
one study, a 2 mg/kg loading dose given in 3 minutes followed by a mainte­
nance dose of 2 mg/kg/hour resulted in plasma levels of 5 to 20 pg/mL at a 
GA of 27 to 41 weeks. The data suggested that these levels were higher than 
optimal (<14 pg/mL). The half-life of tolazoline ranged between 3 and 10 
hours in all patients, with the exception of one who was hypertensive and in 
whom the half-life was 33 hours.
Clinical Presentation. Renal complications, including oliguria, tran­
sient oliguric ARF, and hematu-ria, are common in newborn infants with
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pulmonary hypertension in whom systemic hypotension and persistent hy­
poxemia develop after tolazoline administration.
Prevention and Treatment. Tolazoline administration is contraindi­
cated in patients with ARF, intra-vascujar volume depletion, or low systemic 
blood pressure. We never administer tolazoline unless systolic blood pressure 
has been at least 60 torr for a few hours in a full-term infant. In addition, we 
always expand the intravascular volume and initiate a low-dose dopamine in­
fusion just before and during the administration of tolazoline.
AMPHOTERICIN В
Pathophysiology. Administration of amphotericin В produces imme­
diate nephrotoxicity, which is mediated by renal vasoconstriction and by the 
affinity of amphotericin В to sterols, which are important components of cel­
lular and lysosomal membranes. Functional tubular alterations include an in­
crease in urinary pH, in fractional excretion of Na+, K+, and phosphate, and in 
NAG enzymuria. Histopathologic features after prolonged amphotericin ad­
ministration in adults include glomerular changes (e.g., subcortical atrophy, 
juxtamedullary hypertrophy), interstitial edema, focal tubular atrophy, and 
nephrocalcinosis.
Risk Factors. Glomerular and tubular toxicity of a 5-hour infusion of 
amphotericin is lower than that of a rapid intravenous injection. The degree 
of damage to renal tubular cell membranes is directly related to the choles­
terol content of the membrane. The toxicity of amphotericin to proximal tu­
bular cells in culture is decreased by its inclusion into liposomes. Preliminary 
data in adults using a liposomal formulation of amphotericin В appear prom­
ising.
Clinical Presentation. In adults, the incidence of renal damage is 40% 
after a total dose of more than 4 g and 90% after a dose of more than 5 g; 
permanent renal damage may result from even higher total doses. Acute signs 
may include decreased RBF and GFR, azotemia, oligoanuria, increased uri­
nary excretion of Na+, K+, phosphate, and bicarbonate, and hyposthenuria; 
later complications include nephrogenic diabetes insipidus (NDI), distal 
RTA, and nephrocalcinosis.
In newborn infants receiving amphotericin В at doses adjusted to se­
rum levels, the most frequent signs of nephrotoxicity include increased Per 
and BUN, and transient hypokalemia, which responds readily to additional 
K+ intake. Inadvertent administration of an amphotericin overdose has been 
reported in a handful of newborn infants, who were treated with various mo­
dalities, including exchange transfusion. Acute nephrotoxicity in these pa­
tients was limited; distal RTA developed in one patient who received a 50- 
fold overdose of amphotericin. The most adequate therapy of amphotericin 
overdose remains to be determined.
Prevention and Treatment. If TPN is used, the dose of lipid admini­
stration should be adjusted to prevent hypercholesterolemia. The interval of
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administration of amphotericin В should be adjusted to GFR during therapy. 
Serum levels may need to be monitored in VLBW infants, and compared to 
the minimum inhibitory concentration (0.2-25 pg/mL in one study) and the 
minimum fungicidal concentration (0.2-0.4 pg/mL). Supplementary K+ in­
take may help prevent hypokalemia. If oligoanuric ARF develops during am­
photericin administration, amphotericin should be withheld temporarily and 
restarted later at a lower dose.
ACYCLOVIR
Pathophysiology. Acyclovir administration may result in an increase 
in urine P2 -micr°gl°bulin and an obstructive nephropathy mediated by crys­
tal luria.
Risk Factors. The incidence of acyclovir-related nephropathy in­
creases with rapid intravenous injections and fluid restriction.
Clinical Presentation. In children, acyclovir-related nephrotoxicity is 
associated with crystalluria and increased Pcr. Acyclovir overdose in two 
well-hydrated newborn infants did not result in nephrotoxicity. Neither ex­
change transfusion nor administration of activated charcoal appeared signifi­
cantly to enhance the elimination of acyclovir.
Prevention and Treatment. Because acyclovir is excreted in the 
urine, the interval of administration should be adjusted for GA and renal 
function to prevent neurologic toxicity. If acyclovir is administered at a cor­
rect dose and interval in a slow infusion, and if sufficient fluid intake is pro­
vided to maintain adequate urinary output, the risk of clinical nephrotoxicity 
is negligible. If acyclovir is considered in a patient who also needs fluid re­
striction, the urine should be checked regularly for crystalluria and increased 
Pcr; if renal dysfunction is observed, the dose of acyclovir should be withheld 
or decreased, and fluid intake increased temporarily.
RADIOCONTRAST AGENTS
Pathophysiology. The pathophysiologic presentation of radiocontrast 
nephropathy includes a combination of ischemia, direct toxicity, and tubular 
obstruction by Tamm-Horsfall protein or by uric acid crystals resulting from 
increased uricosuria. Histo-pathologic features include vacuolization of 
proximal tubular cells, mild dilation of proximal tubules, areas of luminal in- 
spissation by waxy debris, and interstitial edema.
Risk Factors. In adult patients, risk factors for radiocontrast-induced 
increase in Pcr include a high baseline PCT and diabetes mellitus. Whether the 
incidence of radiocontrast nephropathy in adults is lower with low-osmolality, 
contrast agents than with conventional high-osmolality products is controver­
sial; no significant difference was observed in two prospective studies on sta­
ble patients with rigorous selection criteria and adequate fluid intake. Al-
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though there is no study comparing low- and high-osmolality products in in­
fants, only the latter cause a decrease in GFR in immature rabbits.
Clinical Presentation. The signs of radiocontrast nephrotoxicity may 
include poor visualization or a prolonged nephrogram, proteinuria with casts, 
and oliguric ARF. One premature infant, who had no visualization after 
injection of an iodinated product, had a transient oligoanuric ARF with a spe­
cific gravity of 1.020, low FENa, and nephromegaly; US suggested the diag­
nosis of autosomal recessive polycystic kidney disease (ARPKD).
Prevention and Treatment. Intravenous urography best is avoided in 
the neonatal period, especially during the first days of life. In newborn infants 
who need angiography or CT with contrast, a low-osmolality agent is pre­
ferred; adequate hydration should be provided before the procedure.
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Pathophysiology. Especially in association with hypovolemia, ACE 
inhibition may cause hypotension, decreased RBF, and oliguric ARF.
Risk Factors. The combination of ACE inhibitors and diuretics may 
lead to severe refractory hypotension, profound decrease in RBF, oligoanuria, 
and ARF. Angiotensin-converting enzyme inhibition enhances the renal tox­
icity of aminoglycosides.
Clinical Presentation. Maternal administration of ACE inhibitors has 
been associated with glomerular dysgenesis, oliguric ARF, hypotension, hy­
poplasia of the calvaria, and perinatal death. Neonatal administration of ACE 
inhibitors has resulted in reversible oliguric ARF, which may occur at the 
time of initiation of therapy or much later, without any precipitating event. 
The neurologic complications are of greater concern than the renal side- 
effects.
Prevention and Treatment. Angiotensin-converting enzyme inhibi­
tors never should be used during pregnancy. Because of the neurologic com­
plications associated with chronic ACE inhibition in newborn infants, ACE 
inhibitors should be used only for life-threatening refractory hypertension, 
with continuous measurement of systemic blood pressure and central venous 
pressure. Hypotension caused by ACE inhibition often responds only to mas­
sive amounts of crystalloids and colloids, and then sometimes poorly.
CYCLOSPORINE A
Cyclosporine is used infrequently in newborn infants; however, its use 
is expected to increase in parallel with the increasing frequency of cardiac 
transplantation.
Pathophysiology. Cyclosporine induces reversible renal vasoconstric­
tion, apparently through stimulation of a r receptors.
Risk Factors. Cyclosporine toxicity is enhanced by high serum levels 
of the drug, ischemia, concomitant administration of nephrotoxic drugs (e.g.,
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indomethacin), and reduced renal function. Cyclosporine toxicity is de­
creased by cotreatment with а -antagonists or spironolactone.
Clinical Presentation. Cyclosporine nephrotoxicity develops in ap­
proximately two thirds of patients receiving Cyclosporine after liver trans­
plantation. It may present as an increase in Pcr and BUN and NAG enzy- 
muria, associated with a normal renal US and Doppler flow analysis and a 
99mTc-DTPA scan that shows normal perfusion with loss of tubular function. 
The incidence of systemic hypertension with moderately decreased GFR and 
proteinuria also is very high. Acute renal failure is a less common complica­
tion.
Prevention and Treatment. The incidence and severity of cyc­
losporine nephrotoxicity may be decreased by monitoring the blood levels of 
cyclosporine and avoiding the use of other nephrotoxic drugs. Cyclosporine- 
induced nephrotoxicity, with or without hypertension, usually is easily con­
trolled medically; other immunosuppressive drugs should be considered if 
severe nephrotoxicity has appeared during cyclosporine therapy.
MYOGLOBINURIA-HEMOGLOBINURIA
Pathophysiology. Myolysis results in increased intercompartmental 
exchanges, including influx into the intracellular compartment of water, so­
dium, chloride, and calcium, which result in shock and hypocalcemia, and 
efflux of potassium, phosphate, purines, lactic acid, myoglobin, throm­
boplastin, creatine kinase, and creatinine into the ECF compartment.
The renal damage associated with rhabdomyolysis is mediated by fac­
tors observed in other types of ATN (i.e., vasomotor, obstructive, and 
nephrotoxic), as well as metabolic factors resulting from the myolysis (i.e., 
hyperphosphatemia, hyperuricemia, and the formation of thrombi in the 
glomerular capillary tufts due to DIG). The formation of intratubular hemo- 
protein casts is favored by oligoanuria and low pH. Hemoprotein catabolism 
liberates iron pigments, which may catalyze the formation of free radicals 
and peroxidation of lipids, and inhibit the vasodilation mediated by endothe­
lium-derived relaxing factors in the kidney.
Risk Factors. In contrast to the adult literature, only rare reports of 
neonatal rhabdomyolysis have been published. This low incidence may result 
from the low myoglobin content of immature muscle, especially in premature 
infants.
Clinical Presentation. Adult patients with traumatic rhabdomyolysis 
manifest the so-called crush syndrome, characterized by shock, high serum 
concentration of creatinine phosphokinase, high Pcr-BUN ratio, hyper­
kalemia, metabolic acidosis, hyperphosphatemia, hypocalcemia, hyperurice­
mia, DIG, and oligoanuric ATN. In severely asphyxiated infants, a strongly 
positive reaction for heme in the absence of microscopic hematuria suggests 
a serum myoglobin concentration greater than 200 ng/mL.
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Prevention and Treatment. In adults with crush syndrome, immedi­
ate initiation of forced alkaline diuresis, with mannitol for patients in whom 
oligoanuria develops, results in dramatic improvement in outcome; this 
treatment prevents hypovolemia and intratubular hemoprotein casts. In con­
trast, in newborn infants with profound perinatal asphyxia or massive hemo­
lysis, a similar approach cannot be recommended, because the potential bene­
fit to the kidney may be outweighed by an increased risk for brain edema, 
pulmonary edema, and PDA. The treatment of established myoglobinuric or 
hemoglobinuric ATN is nonspecific.
CHRONIC RENAL FAILURE
The definition of chronic renal insufficiency is a reduction in GFR to a 
level between 25% and 50% of normal, whereas that of CRF is a reduction in 
GFR to less than 25% of normal for at least 3 months. End-stage renal dis­
ease (ESRD) is the stage of CRF at which the patient requires chronic dialy­
sis or renal transplantation for survival.
INCIDENCE
The incidence of ESRD in children (age range, 0-16 years) is three to . 
eight cases per one million children. Only 6% of children with ESRD are un­
der 3 years of age. In 1989, of the 754 children (age range, 0-18 years) who 
received 761 renal transplants in the United States, less than 7% were under 2 
years of age, and less than 2% were under 1 year of age. Infants rarely sur­
vive the neonatal period and either have CRF or ESRD in infancy; the exact 
incidence is not known.
ETIOLOGY
Most reports of CRF in children combine patients who developed CRF 
as neonates with those in whom CRF develops as a result of a later insult to 
the kidney (Table 51). The underlying disease in recipients of renal trans­
plants changes with age. Among patients under 24 months of age there is a 
high percentage of aplastic-hypoplastic-dysplastic kidneys (34%, versus < 
23% in patients 2 years or older) and obstructive uropathy (21%, versus < 
16% in patients 6 years or older). By far the most common (29%) underlying 
disease during the first 2 years of age is renal dysplasia. Focal segmental 
glomerulosclerosis is not observed, in contrast to the experience in older age 
groups. Typically, the course in infants is characterized by slow, progressive 
deterioration of renal function.
DIAGNOSIS
History, physical examination, US, measurement of GFR using a ra­
dionuclide for the estimation of the functional level of each kidney, urinaly­
sis, and urine culture should be obtained initially. In patients with hy­
dronephrosis, meningomyelocele, or UTI, a VCUG is indicated, and a fu-
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rosemide radionuclide scan should be considered. In certain patients, an IVU, 
a percutaneous antegrade pyelography, or a renal biopsy may be indicated.
The signs and symptoms suggestive of CRF are nonspecific, especially 
in infants, and include growth failure, anorexia, vomiting, pallor, edema, sei­
zures, dehydration, heart failure, hypertension, polyuria, fever, hematuria, 
proteinuria, and pyuria. In children, symptoms such as lassitude, fatigue, 
headache, and nausea can be present. The diagnosis of CRF is confirmed by a 
persistently low GFR corrected for postconceptional age.
Table 51
Etiology of chronic renal failure in 75 patients younger than 2 years of age
D ia g n o s is N u m b e r  o f  P a t ie n ts P e rc e n ta g e
Hypoplasia 24 32
O bstructive uropathy 15 20
Oxalosis 8 11
C ongenita l nep h ro tic  syndrom e 6 8
H em olytic  u rem ic syndrom e' 4 5
C ortica l necrosis 3 4
In fan tile  polycystic kidney d isease 3 4
G lom eru lonephritis * 3 4
S tero id -resis tant nephro tic  syndrom e 2 3
Birth hypoxia w ith  renal fa ilu re 2 3
Jeune syndrom e 1 1
Drash syndrom e 1 1
A natom ical problem s 1 1
U nknow n 2 3
* These diagnoses virtually are not seen during the neonatal period.
PATHOPHYSIOLOGY AND TREATMENT
Any patient with chronic renal insufficiency should have periodic 
physical examinations, including measurement of blood pressure, regular 
monitoring of growth rate and GFR, and not only serial measurements of 
plasma or serum creatinine concentration, acid-base status, serum electro­
lytes, mineral metabolism (i.e., serum concentrations of calcium, phosphate, 
alkaline phosphatase, and PTH), hemoglobin, and hematocrit. Urinalysis, in­
cluding dipstick, urinary electrolytes, pH, and calcium, should be done seri­
ally, and UTI should be excluded on a regular basis. The treatment of CRF 
ideally should make it possible to achieve normal growth rate, hematocrit, 
and fluid and electrolyte homeostasis, while limiting the rate of progression 
of the renal disease toward ESRD. Provision is made for limitations in renal 
function, while allowing an acceptable quality of life. Although the cost- 
benefit ratio of many aspects of treatment has not been determined, therapeu- - 
tic outcome has improved, in parallel with changes in both maintenance ther- 
аРУ (e-g-. maintenance of growth) and replacement therapy (i.e., early renal 
transplantation).
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GROWTH
One major problem of CRF in childhood, especially in infancy, is se­
vere growth failure, which is multifactorial in etiology. Known causes in­
clude acidosis, reduced caloric intake, anemia, hypertension, renal osteodys­
trophy, aluminum intoxication, abnormalities of growth hormone and soma­
tomedin, recurrent episodes of fluid and electrolyte disturbances, recurrent 
infections, and administration of steroids. Ten years ago, ESRD due to con­
genital renal disease was associated with profound growth failure. Until very 
recently, only limited catch-up growth was observed, despite increased ca­
loric intake, administration of vitamin D and phosphate-binding gels, and re­
nal transplantation.
Every effort should be made to limit growth failure at the beginning of 
CRF, this is most critical in infants, who normally grow much faster than 
children. Assessment of growth is made by serially plotting the height stan­
dard deviation score (SDS) against age. Height SDS is the number of stan­
dard deviations below the mean height for age. Because bone maturation is 
delayed in CRF, height SDS corrected for bone age is preferred. Normal 
growth rate corresponds to a height SDS that is constant with age, whereas 
catch-up growth is associated with a progressive improvement in the height 
SDS. The advantages of improving the rate of growth include a reduction in 
the renal load of potassium and phosphate, accelerated weight gain, which 
allows a renal transplant at an earlier age, and achievement of improved adult 
height. Improved growth has been obtained, at least in some patients, by pro­
vision of additional caloric intake using nasogastric feeding or TPN, treat­
ment and prevention of renal osteodystrophy, elimination of aluminum in­
take, limitation of steroid dosage made possible by the use of cyclosporine, 
prevention, early diagnosis, and treatment of complications such as UTI, ad­
ministration of erythropoietin, administration of growth hormone, and early 
transplantation.
NUTRITION
Protein restriction is recommended in adults with CRF to prevent 
glomerular capillary hyperfiltration, which has been implicated in the devel­
opment of focal segmental glomerulosclerosis. Hyperfiltration corresponds to 
the increase in GFR observed after a high-protein diet in normal people and 
in those with chronic renal disease. Dietary protein restriction slows down the 
progression of renal disease in several animal models and, perhaps, in adult 
patients. Postulated mechanisms include not only a reduction in hyperfiltra­
tion but also a reduction in glomerular prostanoid production, in glomerular 
hypertrophy, in insulinlike growth factor type 1 (IGF-1), in glomerular eico- 
sanoid production, and in glomerular selectivity.
The diet should provide sufficient calories and individual nutrients for 
a normal rate of growth. The ideal amount of protein intake in infants with
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CRF has not been established. It seems prudent to follow the recommended 
dietary allowance (RDA) for norma! infants (i.e., 2.2 g/kg body weight at 0-2 
months of age, 2.0 g/kg at 2-6 months of age, and 1.8 g/kg at 6-12 months of 
age), corresponding to 8% of the RDA of calories. Breast milk, SMA (Wyeth 
Ayerst, Radnor, PA), and Similac PM 60/40 (Ross, Columbus, OH), provide 
adequate high-quality protein and minerals with limited phosphate and so­
dium content for most infants with CRF. To maintain adequate growth de­
spite decreased appetite, the caloric content of the formula often needs to be 
supplemented with carbohydrates and with medium-chain triglycerides to 
reach 120% to 180% of the RDA, and continuous nocturnal feeding through 
a nasogastric tube or a gastrostomy tube may be required. In the few patients 
who cannot tolerate enough enteral feeding (e.g., most infants with congeni­
tal nephrotic syndrome of the Finnish type), TPN should be initiated; in pa­
tients with severe CRF, only essential amino acids should be provided.
As the degree of renal failure increases (i.e., GFR < 25% of normal), 
protein intake should be decreased to maintain a BUN below 100 mg/dL, us­
ing milk with high-quality proteins that are at least 35% essential ammo ac­
ids, such as breast milk, SMA, Similac PM 60/40, or Special Formula S-29 
(Wyeth Ayerst). Patients with severe renal failure may require special diets 
that contain limited amounts of protein and are supplemented with essential 
amino acids or their corresponding keto acids.
MAINTENANCE OF ADEQUATE FLUID
AND ELECTROLYTE AND ACID-BASE BALANCE
Because the ability of the failing kidney to concentrate urine is limited, 
additional water may be required to compensate for polyuria. On the other 
hand, the failing kidney usually is able to maintain normal serum levels of 
sodium, potassium, and bicarbonate until GFR falls below 25% of normal. As 
stated previously, the electrolyte requirements should be assessed for every 
patient from the measurement of serum and urinary electrolytes. Sodium in­
take should be normal, except in patients with salt-losing nephropathy, such 
as obstructive uropathy, primary tubulointerstitial disease, and dysplastic 
kidneys, who may need sodium supplements, and those with hypertension or 
edema, who may need sodium restriction. Metabolic acidosis is common­
place in patients with CRF. Administration of bicarbonate usually is initiated 
when the serum bicarbonate concentration falls below normal. An initial dose 
of 3 mEq/kg/day is used and increased as needed to achieve a serum level of 
22 to 24 mEq/L. Citrate can be given instead of bicarbonate, unless alumi­
num intoxication is suspected. Hyperkalemia usually develops only when 
GFR is less than 25% of normal, but it may appear earlier in patients with in­
terstitial disease or secondary to exogenous potassium intake, hemolysis, or 
acidosis.
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Acute episodes of fluid or electrolyte imbalance, characterized by hy­
ponatremia, hyperkalemia, azotemia, hypocalcemia or hypercalcemia, meta­
bolic acidosis, and hyperphosphatemia can be precipitated by diarrhea, UTI, 
sepsis, or increased catabolism associated with poor nutritional intake. Rapid 
diagnosis and correction of the imbalance are critical. The treatment of dehy­
dration, hyperkalemia, hyponatremia, hypernatremia, and acidośis is similar 
to that described for ARF. Peritoneal dialysis may be needed, Hyperkalemia 
in adults with terminal renal failure requiring chronic dialysis responds 
poorly to the administration of bicarbonate infusion.
ADJUSTMENT OF MEDICATION DOSAGE
The interval of administration of medications excreted by the kidney 
needs to be modified, based on the level of renal function or their removal by 
means of dialysis. Recommendations are given in the section on Acute Renal 
Failure.
CARDIOVASCULAR SYSTEM
Rigorous control of hypertension is important to avoid its complica­
tions and its known effect in accelerating progression of renal failure.
MINERAL METABOLISM
AND RENAL OSTEODYSTROPHY
Vitamin D and Parathyroid Hormone. The two major disturbances 
of mineral metabolism associated with chronic loss of renal function are de­
creased 1-a-hydroxylation of vitamin D as a result of loss of kidney tissue, 
and an increased secretion of PTH (Table 52). Initially, the latter is an appro­
priate response to low serum ionized calcium, but in CRF the set point for the 
inhibition of PTH secretion by extracellular calcium is raised, which corre­
sponds to secondary hyperparathyroidism.
Mild decrease in GFR is associated with a decrease in ionized calcium 
concentration, which induces the secretion of PTH (see Table 52). Higher 
levels of PTH result in phosphaturia and low levels of fasting phosphatemia; 
daytime phosphatemia may be normal. At that point, the lack of increase in 
serum level of l,25(OH)2D3, despite hyperparathyroidism, is evidence for 
lack of response of renal 1-a-hydroxylase to the hypocalcemia. When GFR 
decreases further (i.e., GFR < one-half of normal), the serum concentration of 
l,25(OH)2D3 decreases. If phosphate intake is restricted, 1-a-hydroxylase is 
stimulated and PTH decreases. The decrease in PTH might be mediated by an 
increase in ionized calcium secondary to the increase in l,25(OH)2D3. When 
GFR decreases further to below 25% of normal, hyperphosphatemia devel­
ops, except in patients with a proximal tubular defect.
The radiographic signs of renal osteodystrophy include ricketslike le­
sions (i.e., radiolucent bands), as well as signs of osteitis fibrosa related to 
increased PTH secretion (i.e., subperiosteal resorption zones and metaphyseal
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changes); the latter may result in slipped epiphyses. Histologic examination 
of the metaphysis in renal osteodystrophy shows accumulation of woven 
bone, fibrous tissue, or both, rather than the accumulation of cartilage and 
chondro-osteoid seen in rickets. Although severe renal osteodystrophy, asso­
ciated with GFR less than 30 mL/minute/1.73 m2, is related to poor growth, 
the effect of mild renal osteodystrophy on growth is unclear; histologic bone 
disease can be observed at the same frequency regardless of growth status.
Aluminum Intoxication. Some of the bone changes seen in renal os­
teodystrophy are related to aluminum intoxication, resulting from aluminum- 
containing phosphate-binding gels or aluminum-containing dialysis water. In 
adults, a syndrome characterized by bone pain, proximal myopathy, fractures, 
and encephalopathy was shown to be associated with high tissue levels of 
aluminum. Radiographs show growth zone abnormalities and metaphyseal 
solid bands, and accumulation of aluminum in bone can be demonstrated in 
biopsy specimens. Similar changes are observed in rats injected with alumi­
num. Aluminum-related bone disease increases in conditions associated with 
decreased PTH secretion, such as parathyroidectomy and administration of 
vitamin D.
Aluminum was removed from dialysis fluids around 1980, and alumi­
num-containing phosphate-binding agents were replaced by calcium carbon­
ate in 1984. Because some preparations of parenteral medications (e.g., cal­
cium gluconate, potassium and sodium phosphate, 5% albumin, heparin) may 
contain substantial amounts of aluminum despite lack of evidence on the 
package label, VLBW infants on TPN may accumulate aluminum even in the 
absence of CRF, probably because of their limited GFR. The Food and Drug 
Administration intends to set upper limits on the aluminum content of intra­
venous preparations.
Aluminum intoxication in a patient with renal osteodystrophy may be 
suggested by hypercalcemia, which may occur spontaneously but most often 
happens during vitamin D administration. Hypercalcemia is associated with a 
normal alkaline phosphatase level, normal PTH levels, and metaphyseal solid 
bands, but any of these signs can be absent (see Table 51). Confirmation of 
aluminum intoxication requires the demonstration of increased aluminum 
stores, which are not evaluated reliably by serum aluminum concentration, 
unless serum aluminum level is greater than 100 pg/L. Aluminum stores are 
evaluated best by the increase in serum level after an intravenous desferriox- 
amine test, or by a bone biopsy using flameless atomic absorption spectro­
photometry.
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Table 52
Disturbances in mineral metabolism associated with chronic loss of renal 
function in children
Ionized
Stage Calcium Phosphate 1,25(OHkOj iPTH Alkaline Phosphatase
Early (1.0 ., GFR Low Low  w hen Norm al bu t H igh N orm a l-h igh
70%-80%! tasting inadequate
N orm al du ring fo r low  Ca
the daytim e
M oderate (i.e.,
GFR <  50%) 
Norm al P Low
Norm al Low High High
intake
Restricted P N orm al (low )
Low Normal Normal
intake
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l,25(OH)2D3 - serum concentration of 1,25-dihydroxy vitamin D3 or calcitriol, Ca - calcium; 
GFR - glomerular filtration rate expressed in % of normal; iPTH - serum level of immunoreac- 
tive parathyroid hormone; P - phosphate.
Treatment of Renal Osteodystrophy. Treatment includes removal of 
all sources of aluminum intake. Citrate should be used with caution in alumi­
num-intoxicated patients. Indeed, it has two opposite effects on aluminum 
balance; although it has been used as an aluminum chelator in aluminum- 
intoxicated mice, it also increases aluminum absorption by the gastrointesti­
nal tract in several species as well as in patients with CRF. The only medica­
tion that has been shown to result in efficient elimination of aluminum is des- 
ferrioxamine, which can be given intravenously during hemodialysis, or in-
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traperitoneally. Lowering calcium concentration in the dialysis fluid en­
hances the efficacy of desferrioxamine by stimulating PTH secretion.
Early detection of renal osteodystrophy requires sequential measure­
ments of serum PTH level and urinary cAMP excretion; photon absorptiome­
try is much more sensitive than bone radiography for the detection of mild 
demineralization (e.g., in osteopenia of prematurity), but no series have been 
published about its use in infants with CRF.
The treatment of renal osteodystrophy includes the administration of 
vitamin D analogues, which raises serum calcium, decreases PTH, improves 
bone changes, and may accelerate growth (Table 53). The preferred forms of 
vitamin D are l,25(OH)2D3, dihydrotachysterol, and l-a-OHD3 because of 
their potency, lack of need for 1-a -hydroxylation, and short half-life, which 
limits the duration of hypercalcemia, should it occur. The initial doses are in­
creased progressively until PTH reaches a normal level or serum or urinary 
calcium reaches the upper limit of normal. Preliminary data suggest that early 
administration of 10 to 15 ng/kg/day of l,25(OH)2D3 may efficiently prevent 
renal osteodystrophy, probably by inhibiting the development of hyperpara­
thyroidism; growth in a small group of patients appeared better when the ad­
ministration of l,25(OH)2D3 was initiated before 12 months than in patients 
in whom it was started after 21 months of age.
An additional aspect of treatment is the administration of calcium sup­
plements and the limitation of phosphate intake. Restriction of phosphate in­
take early in the course results in increased serum levels of l,25(OH)2D3 and 
limits the degree of hyperparathyroidism. This requires avoidance of cow 
milk and dairy products and using breast milk or formulas for premature in­
fants, such as PM 60/40, which has a high calcium-phosphorus ratio and lim­
ited phosphate content. Calcium carbonate not only provides calcium (40% 
on a weight basis), but also is an efficient phosphate-binding agent, which re­
duces intestinal absorption of phosphate. It should be given with meals, to in­
crease the inhibition of phosphate absorption and to decrease the absorption 
of calcium and limit the risk for hypercalcemia.
HEMATOLOGIC DISTURBANCE
Chronic renal failure is associated with a normochromic, normocytic, 
hypoproliferative anemia, resulting from many factors, including low 
erythropoietin (Epo) levels, shortened erythrocyte survival, iron and folate 
deficiency, and aluminum intoxication. Although steady-state levels of Epo 
are low relative to the degree of anemia, levels do increase in response to hy­
poxemic stress.
Erythropoietin is a glycoprotein that is synthesized, under hypoxic con­
ditions, by endothelial cells of the peritubular capillary in the renal cortex and 
the outer medulla. Even after bilateral nephrectomy, serum levels of Epo in­
crease progressively, which demonstrates that extrarenal sites take over that
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role of the kidney. Children with ESRD at one time required many transfu­
sions, which resulted in severe iron overload. Extensive experience in adults 
has proven that recombinant human Epo administration can correct the ane­
mia of ESRD and eliminate the need for transfusion in almost all patients. 
Failure to respond to Epo has been attributed to several causes, including iron 
deficiency, underlying inflammatory disease, aluminum intoxication, and 
poorly controlled hyperparathyroidism. The most common side-effects are an 
increase in blood pressure in one third of the patients and seizures in 3%; sei­
zures most often are associated with a sudden increase in blood pressure and 
hematocrit at the initiation of therapy.
The experience with the administration of Epo to children is growing 
rapidly. Epo administered subcutaneously or intravenously in children with 
ESRD resulted in an increase in hematocrit, an improvement in symptoma­
tology, and a reduction in iron overload. The response is dose dependent. 
One fourth of patients responded to the administration of 25 U/kg of Epo two 
to three times a week, whereas two thirds responded to 50 U/kg. Side-effects 
included hypertension and thromboocclusion of vascular access. Seizures and 
increase in liver enzymes occurred in only a minimal number of patients. Al­
though there is no controlled study on the administration of Epo in children 
and infants with CRF, the administration of Epo (see Table 53) should be 
strongly considered for infants in CRF with a hematocrit below 30%. Be­
cause Epo results in increased use of iron stores and decreased need for trans­
fusions, iron supplementation should be added. During the duration of the 
Epo administration, hemoglobin, hematocrit and reticulocyte count, and fer­
ritin levels should be monitored.
Table 53
Initial doses and side-effects of medications commonly used 
in chronic renal failure
Medication Initial D o se
M ineral M etabolism  
and  Growth K idney Other
Vitamin D H ypercalcem ia Renai fa ilu re  due M e tas ta tic  c a lc iti-
1,25(OH)zD3
DHT
1-o-0HD3
2 0 -6 0  n g /k g /d  
1 5 -4 0  n g /k g /d
1 - 2  f ig /k g /d
to  m etasta tic  
c a lc ifica tio n s
ca tion s
CaC03 1 0 -2 0  m g /k g /d  of 
e lem en ta l Ca
H yperca lcem ia H yperca lc iu ria
Erythropoietin 2 5 -5 0  U /kg  3 
t im e s /w k
H ypertension S eizures due  to 
h y pe rte ns ion
GROWTH HORMONE
Growth failure in CRF occurs in the absence of low levels of growth 
hormone or of total serum concentration of IGF-1, but with an increased con­
centration of the high-molecular-weight IGF-1 binding protein. The admini­
stration of supraphysiologic doses of recombinant human growth hormone
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resulted in an improvement of the ratio of 1GF-1 to its binding protein. Ad­
ministration of growth hormone for up to 4 years accelerated growth in 
growth-retarded children with ESRD, without acceleration of bone maturity 
or other side-effects. It may be that the administration of growth hormone 
could prevent growth failure in infants with CRF. This hypothesis remains to 
be investigated.
SURGICAL TREATMENT
Surgical treatment of urinary tract obstruction and of severe VUR has 
an important role but may not prevent progressive loss of renal function. In 
addition, bilateral nephrectomy is commonly performed in patients with 
CNF, and allows the preparation of the infant for the renal transplantation.
INFECTION
Infants with CRF are at risk for infections because of urinary stasis, 
malnutrition, peritoneal dialysis, and immunosuppression at the time of 
transplantation. Chemoprophylaxis for UTI is indicated in infants at in­
creased risk because of VUR, ADPKD, or urinary tract obstruction, and at 
the time of invasive procedures. The incidence of peritonitis in children re­
ceiving either continuous ambulatory peritoneal dialysis (CAPD) or continu­
ous cyclic peritoneal dialysis (CCPD) is similar, and ranges between one epi­
sode every 5 months and one every 12 months. The most common agents in­
clude Staphylococcus sp, gram-negative organisms, and Candida sp.
CENTRAL NERVOUS SYSTEM
The complications of CRF include polyneuropathy and encephalopa­
thy, which can result from aluminum intoxication, hypertension, and electro­
lyte imbalance related to uremia. In the 1970s, a dialysis encephalopathy syn­
drome was described in adults receiving hemodialysis and was shown to be 
associated with high aluminum content in the gray matter of the brain. A 
similar encephalopathy, characterized by regression of developmental mile­
stones, ataxia, seizures, myoclonus, dementia, loss of bulbar function, and 
severe renal osteodystrophy was described in children with CRF, and subse­
quently was associated with aluminum intoxication. Since , it became stan­
dard practice to remove aluminum from all dialysis fluid and to avoid alumi­
num hydroxide as phosphate-binding therapy, most acute CNS complications 
have been limited by careful monitoring of renal function; careful monitoring 
of blood pressure, especially during Epo administration; and early initiation 
of dialysis. Nevertheless, some motor and mental delay commonly is ob­
served in children with ESRD, and electroencephalogram abnormalities are 
frequent in those with significant mental delay. Successful transplantation 
may be associated with a significant improvement in mental performance and 
in an acceleration in head growth.
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DIALYSIS
Two modalities are available, hemodialysis and peritoneal dialysis. 
Since the description of CAPD in 1976, this technique rapidly has become 
the procedure of choice for infants, in whom the large peritoneal surface 
makes it more efficient than in adults. Usually, four to five exchanges are 
performed per day, using a Silastic Tenckhoff catheter. The peritoneal dialy­
sis fluid should have a low concentration of calcium, to avoid hypercalcemia. 
It should not contain aluminum; it should not contain citrate if any aluminum 
ingestion is possible. The advantages of CAPD over hemodialysis include 
better hemodynamic stability, increased serum bicarbonate concentration, de­
creased transfusion requirements, augmented caloric intake, and increased 
freedom for the patient and the family. The side-effects of CAPD are the bur­
den to the family, the risk of peritonitis, and chronic loss of protein, calcium, 
and phosphate. Another technique now available is CCPD, in which five to 
eight 2-hour exchanges are performed automatically at night. Data of the 
North American Pediatric Renal Transplant Cooperative Study suggest that 
early initiation of peritoneal dialysis, in association with nasogastric feeding 
to augment caloric intake, is the treatment of choice of ESRD in infants.
TRANSPLANTATION
Benefits and Complications of Renal Transplantation. Although no 
randomized study is available, renal transplantation in children younger than 
5 years of age with ESRD offers a potential of improving growth and devel­
opment that is not observed in patients on long-term dialysis. The success of 
renal transplantation in young children has improved progressively during the 
last two decades. This improvement has been attributed to several factors, in­
cluding improvement of the patient's preoperative condition, with nutritional 
support and dialysis, and bilateral nephrectomy in patients with CNF; im­
provement in graft survival by multiple preoperative transfusions; improve­
ment in the quality of human leukocyte antigen matching, made possible both 
by the availability of large multicenter organizations and by the increased use 
of grafts from living related donors, which offer the best success rates; im­
provement of the surgical technique, including shortened cold storage time of 
the graft; improvement of anesthetic and postoperative therapy; and introduc­
tion of various immunosuppressive drugs to prevent and to treat graft rejec­
tion. Available drugs include cyclosporme, azathioprine, steroids, antithymo­
cyte globulin, anti lymphocyte globulin, and monoclonal antibody against 
OKI3, an antigen of T lymphocytes.
The complications of renal transplantation include postoperative renal 
failure, fluid and electrolyte disturbances, hypertension, hypotension, infec­
tion, and the side-effects of the various immunosuppressive medications. Dif­
ficult problems include the early detection of rejection and differentiating re­
369
nal failure due to cyclosporine from rejection or other complications of the 
transplant.
Controversy Over Renal Transplantation Before 1 Year of Age. 
The issue of undertaking renal transplantation in infancy before or after the 
age of 1 year is controversial. Because the best results are obtained using 
grafts from living related donors, determining the best time for transplanta­
tion is critical for the family.
The results of the North American Pediatric Renal Transplant 
Cooperative Study show that the most important factor for graft survival for 
cadaveric transplants is a recipient age greater than 24 months (relative risk 
2.8, 95% confidence interval of (1.6-4.7), although the prognosis for living 
donor transplants improves as early as age 12 months with a weight of 
approximately 8 kg.
In contrast, a few centers have reported excellent results using living 
related donor kidneys in recipients as young as 6 to 7 months or weighing 5 
to 7 kg, and cadaveric transplants during the second year of life. In such cen­
ters, the size of the donor is a more important factor for deciding the time of 
transplantation: an average-sized adult kidney (i.e., 12-13 cm) is tolerated by 
the abdominal cavity of an infant with a length of 65 cm. The wide differ­
ences in reported success in infants cannot be explained. Sequential admini­
stration of several immunosuppressive medications, prophylactic suppression 
of T-lymphocyte-related immunity for cadaveric transplants, and aggressive 
intraoperative administration of colloids are potential factors. At the Univer­
sity of Minneapolis, the 1-year and 5-year related living graft survival rates in 
18 recipients less than 12 months were, respectively, 100% and 83%, with a 
patient survival rate of 94% and 71%, whereas the graft and patient survival 
rates for cadaveric transplant were 25% both at 1 year and 5 years. The actu­
arial allograft survival was similar in infants and in 1- to 5-year-old children. 
A more recent report from the same institution showed that infants (age 
range, 6 weeks-12 months) who received a graft from a living related donor, 
as well as cyclosporine A, had a 100% 1-year survival and improved growth. 
It is not clear what are the critical factors associated with the good results of 
renal transplants in these centers. It is likely that the prognosis for renal 
transplantation in young infants will improve over the next few years in other 
institutions as well, in parallel with further improvements in immunosuppres­
sive therapy.
PROGNOSIS
The prognosis for several types of diseases that cause CRF in infancy 
has improved considerably over the last two decades. The improvement in 
prognosis may have resulted in part from a change in the percentage of pa­
tients diagnosed during the neonatal period, due to prenatal and postnatal ul­
trasonography, but also from aggressive management, as described previ­
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ously. The literature contains only limited data on the long-term prognosis for 
infants born with or rapidly developing renal failure during the neonatal pe­
riod. Considerable variability in outcome remains, which depends in part on 
the severity of the renal dysfunction (e.g., the presence of renal dysplasia in 
obstructive disease). Early neonatal death is related most often to respiratory 
failure due to pulmonary hypoplasia associated with severe cases of polycys­
tic kidney disease (PKD) or renal dysplasia, whereas later death is related to 
renal failure or other complications.
The prognosis depends also on the diagnosis and the severity of the re­
nal disease (Table 54). For obstructive urinary tract disease, the presence of 
associated renal dysplasia-hypoplasia is the main prognostic factor. Despite 
early intervention and intact renal function for many years during childhood, 
progression to ESRD may occur. Isolated posterior urethral valves are asso­
ciated with a low mortality rate and a low risk of ESRD. Infants with prune- 
belly syndrome can be divided into three groups, according to the severity of 
renal dysplasia. Most deaths occur in the first group, during the neonatal pe­
riod, and are due to respiratory failure caused by pulmonary hypoplasia; the 
autopsy most often shows severe renal dysplasia involving an average of 
70% of the parenchyma in most cases. Patients in the second group have mild 
impairment o f renal function and may develop progressive CRF. Since patho­
logic examination of nephrectomy specimens in this second group shows 
evidence of pyelonephritis and obstructive or reflux nephropathy, but only 
mild renal dysplasia involving an average of 25% of the parenchyma, it ap­
pears that aggressive prevention of these complications using surgery and an­
tibiotic therapy may decrease the incidence of ESRD in some. Finally, pa­
tients in the third group, the least severe, do not have CRF and have a normal 
life expectancy.
Infants with ARPKD diagnosed at birth have a 46% survival rate at 15 
years. Those who survive the neonatal period have a high potential for sur­
vival, although portal hypertension eventually develops in one-third to one- 
half of them, which may require a portocaval shunt. Other common compli­
cations include hyponatremia and systemic hypertension. Although only lim­
ited data are available on ADPKD, the prognosis for renal function seems 
better than in ARPKD. Of five infants who survived the neonatal period and 
were followed until the age of 3.5 ± 3.4 (mean ± SD) years, ESRD developed 
only in one.
Congenital nephrotic syndrome of the Finnish type, which used to be a 
fatal disease, now has a much better prognosis, using bilateral nephrectomy 
for recovery from the nephrotic syndrome, followed by renal transplantation. 
Two-year patient and graft survival rates of 82% and 71%, respectively, have 
been reported.
Obtaining an accurate diagnosis of the etiology of the CRF is as impor­
tant for predicting later complications and for genetic counseling as for the
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management of the CRF per se. Assessment of renal function and anatomy in 
the family may clarify the type of genetic transmission and hence the prob­
able diagnosis and prognosis in the infant. In addition, assessment of the fam­
ily may result in early diagnosis of hereditary conditions, either in the parents 
or the siblings, and lead to genetic counseling.
Table 54
* This series involved 23 cases of neonatal PKD, 23 cases of infantile PKD, and 7 patients di­
agnosed after 1 year of age. Seven patients were lost to follow-up.
ARPKD - autosomal recessive polycystic kidney disease; CHF - congestive heart failure; 
ESRD - end-stage renal disease; NA - not available; PKD - polycystic kidney disease; UTI - 
urinary tract infection.
HYPERTENSION
Systemic hypertension is defined by a blood pressure that persistently 
exceeds the mean + 2 SD for normal subjects of similar GA, size, and postna­
tal age. Hypertension is very likely if the blood pressure consistently exceeds 
90/60 torr in a full-term infant or 80/50 torr in a premature infant, and is 
likely in an infant after the neonatal period if systolic blood pressure is higher 
than 113 torr. The measurement of diastolic blood pressure by indirect tech­
niques, especially the Doppler method, is only approximate.
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INCIDENCE
The reported incidence of neonatal hypertension ranges between 0.2% 
and 43%. This variability may in part result from the following factors:
The sample studied. Groups at high risk include infants who had a 
UA catheter (3%) and those in whom BPD developed (as much 
as 43%). Hypertension may develop in some patients only after 
discharge from the nursery.
The percentage of infants screened and the frequency of measure­
ment of blood pressure in the nursery.
The care taken in measuring blood pressure accurately at rest, not 
during feeding or during various examinations.
The normative values used.
ETIOLOGY AND PATHOPHYSIOLOGY
An etiology can be determined only in approximately one third of hy­
pertensive newborn infants. Although there is a weak correlation between 
neonatal blood pressure and maternal blood pressure, there is no convincing 
evidence that essential hypertension as seen in older children and adults starts 
in the neonatal period. The most common mechanisms of neonatal hyperten­
sion include iatrogenic disease, renovascular hypertension, and renal disease.
IATROGENIC HYPERTENSION
Hypertension induced by pancuronium probably is mediated by re­
lease of catecholamines, the mechanism of which is unknown. As many as 
30% of infants receiving dexamethasone for BPD manifest hypertension, 
defined as a systolic blood pressure greater than 90 torr.
Hypertension develops in 11% to 92% of newborns placed on ECMO, 
either immediately or at variable times after initiation of the procedure. Be­
cause hypertension in these infants is more common when accompanied by 
high fluid intake, and it responds well to diuretic administration, fluid over­
load may be an important mechanism. This hypothesis remains to be demon­
strated by prospective studies.
Another common cause of hypertension is BPD. Umbilical artery 
catheterization and the administration of corticosteroids are contributing fac­
tors in some infants, but the etiology in many remains unknown. Because hy­
pertension often develops after discharge from the NICU, frequent monitor­
ing of blood pressure during follow-up is important.
Hypertension may develop after surgical repair of abdominal wall de­
fects. Three of four patients in one series had edema of the lower extremities 
and normal PRA, and one had evidence for ureteropelvic obstruction and 
high PRA. The duration of hypertension in these patients ranged from 12 
days to 6 months.
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RENOVASCULAR HYPERTENSION
Hyperreninemia is present in most infants with renovascular hyper­
tension. The most common cause of neonatal renovascular hypertension is 
aortic or renal thromboembolism related to UA catheterization. Hyperten­
sion develops in approximately 3% of infants with UA catheterization. Hy­
pertension may develop either while the catheter is in place or long after its 
removal, and may be associated with a history of renal failure or hematuria. 
Associated signs may include hematuria, ARF in patients with bilateral re­
nal thromboembolism, and loss of femoral pulses and of blood flow to the 
lower extremities in patients with extensive aortic thrombosis.
Congenital vascular anomalies responsible for renovascular hyperten­
sion in newborn infants include stenosis or hypoplasia of the renal artery, 
segmental intimal hyperplasia, and idiopathic arterial calcification of infancy; 
all these anomalies may involve the aorta as well as the renal arteries. Idio­
pathic arterial calcification of infancy is a rare disorder for which there have 
been approximately 90 reported cases. It is characterized by the presence of 
calcium deposits in all layers of the arteries, including the aorta and the coro­
nary arteries, as well as in the heart valves. Some of these deposits may be 
visible on a plain radiogram. Most cases have been diagnosed at autopsy.
Other causes of renovascular hypertension include neonatal renal arte­
rial embolism in the absence of UA catheterization, intramural hematoma of 
the renal artery, renal vein thrombosis, and external compression of the renal 
artery by hydronephrosis, adrenal hemorrhage, or urinoma.
RENAL CAUSES OF HYPERTENSION
Hypertension is a common complication of renal anomalies and dis­
eases such as PKD; renal dysplasia; tumors, of which mesoblastic nephroma 
is the most common in newborn infants; hydronephrosis; and interstitial ne­
phritis. Hypertension may develop in patients with ATN as a result of fluid 
and sodium overload. Hypertension may be associated with hyperreninemia 
in some cases, especially when it occurs with renal tumors. Hyperreninemia 
can be either primary (i.e., renin within the tumor itself), or secondary (i.e., 
increased renin in hypertrophied juxtaglomerular cells adjacent to residual 
glomeruli entrapped in the tumor).
COARCTATION OF THE AORTA
Coarctation of the aorta produces hypertension limited to the upper ex­
tremities or to the right arm, with hypotension and decreased pulse volume in 
lower extremities and normal PRA.
NEUROLOGIC HYPERTENSION
Neurologic causes of hypertension include intracranial hypertension, 
drug withdrawal, seizures, and familial dysautonomia. Although seizures
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are common complications of severe hypertension, blood pressure may in­
crease transiently during seizure episodes.
ENDOCRINE HYPERTENSION
Several adrenal disturbances can induce hypertension directly. Hyper­
thyroidism is associated with systolic hypertension and sustained tachycar­
dia and, sometimes, with episodes of supraventricular tachycardia. Neural 
crest tumors are uncommon in newborn infants.
CLINICAL FEATURES
Mild to moderate hypertension may be asymptomatic. The symptoms 
associated with hypertension are nonspecific (Table 55), and may be due to 
the underlying disease, to the hypertension itself, or to its complications 
(e.g., neurologic, cardiovascular). The infant's chart should be reviewed 
carefully for the administration of excessive fluids or of medications causa­
tive of hypertension. Infants with a UA catheter may have had transient epi­
sodes of blood pressure elevation associated with an increase in Pcr and he­
maturia, all suggestive of renal artery thromboembolism.
Pertinent points of the physical examination are listed in Table 55. In­
direct ophthalmoscopy may reveal abnormalities similar to those observed in 
older patients with hypertension. Skalina and associates observed significant 
retinal changes in 11 of 21 newborn infants with a mean blood pressure 
greater than 70 torr, including increased ratio of venous to arterial caliber, 
vascular tortuosity including arteriovenous crossing changes, superficial and 
deep hemorrhages, and exudates. These anomalies appeared to resolve after 
control of the hypertension.
INVESTIGATION
The first step is to determine whether the infant is indeed hypertensive, 
or if the blood pressure rises only during periods of agitation, pain (e.g., even 
an infiltrated intravenous line may cause an increase in blood pressure), cry­
ing, feeding, or performance of procedures. All newborn infants with hyper­
tension should have a urinalysis and routine blood chemistry tests. If it ap­
pears that the hypertension is iatrogenic or secondary to drug withdrawal, 
specific therapy can be tried before additional investigations are performed.
A thorough workup should be initiated in every patient with persistent 
or severe hypertension, both to rule out cardiovascular complications and to 
reach a specific diagnosis. If myocardial dysfunction, cardiomegaly, or heart 
failure is secondary to hypertension, the blood pressure should be reduced 
rapidly. The presence of metabolic alkalosis in a hypertensive neonate sug­
gests the diagnosis of congenital adrenal hyperplasia (CAH) or primary hy­
peraldosteronism. Ambiguous genitalia in a hypertensive infant should raise 
the suspicion of CAH. If the maternal history is positive for Graves disease,
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and the infant has a goiter or is constantly tachycardic with systolic hyperten­
sion, thyroid studies should be ordered urgently.
Table 55
Signs and symptoms associated with neonatal hypertension
History and Observation Physical Examination
Growth
Vital signs 
Respiratory system
Failure to thrive
Tachypnea, fever 
Apnea, cyanosis, tachypnea
Cardiovascular system Sweating
Fluids and renal system
Gastrointestinal system 
and liver
Neurologic system
Genitalia
Edema, hematuria 
Weight loss, polyuria Ano­
rexia, abdominal dis­
tention
Irritability, lethargy, sei­
zures
Weight and length may be 
small for age
Tachypnea, tachycardia, fever 
Apnea, central cyanosis, 
tachypnea, rales 
Hyperdynamic precordium, 
heart murmur, congestive heart 
failure, tachyarrhythmia, mot­
tling, peripheral cyanosis, poor 
perfusion, abdominal bruit, in­
creased pulse, differential pulse 
in upper versus lower extremi­
ties, ischemia o f the lower ex­
tremities with absent pulse 
Edema
Abdominal mass 
Hepatomegaly
Irritability; tremors; seizures; 
lethargy; coma; bulging fon- 
tanelle; increased, decreased, or 
asymmetrical tone; facial palsy; 
abnormal reflexes; abnormal 
optic fundus
Hypogonadism (i.e., congenital 
adrenal hyperplasia)
Some of these findings are directly related to hypertension, whereas other signs are related to 
the primary cause.
If no cause is evident, or if a renal or renovascular etiology is sus­
pected, the workup usually will include a US of the kidneys, adrenals, aorta, 
and bladder, with a flow study (i.e., Doppler US with duplex scan) of the 
aorta and the renal arteries, as well as a renal scan and PRA; IVU, angiogra­
phy, MRI, or CT may be indicated in specific patients. If there is any suspi­
cion of hydronephrosis or reflux, urine obtained by suprapubic aspiration or 
bladder catheterization should be sent for both bacterial and fungal culture.
If PRA is elevated compared to age-appropriate normal values for the 
same laboratory, a perfusion renal scan should be obtained in addition to the 
renal US and Doppler, since the scan is more sensitive for the detection of 
small defects. Renal microemboli from an umbilical artery catheter, however, 
can elude detection by any of the above means. High PRA may be secondary 
to the administration of diuretics or adrenergic medications or to severe respi-
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ratory disease, and mild elevations of PRA may be seen in normal infants. In 
addition, one normal value of PRA does not exclude hyperreninemic hyper­
tension.
TREATMENT
Various modalities of treatment for neonatal hypertension have been 
recommended. Because no prospective comparative study has been per­
formed, knowledge is based on published case reports and series. Although 
malignant hypertension should be corrected immediately and vigorously to 
prevent central nervous system hemorrhage, the treatment of chronic or 
subacute hypertension usually is aimed at a rapid decrease of blood pressure 
to a level that is not less than approximately three-fourths of the initial value, 
followed by progressive normalization. A rapid decrease of blood pressure to 
a normal level, which is easily obtained by using the combination of a diu­
retic and a potent vasodilator, might place the infant at risk for both cerebral 
ischemia and renal failure, secondary to compromised central nervous system 
and renal blood flow, respectively.
NONSPECIFIC TREATMEMT
In many patients antihypertensive medications may not be required. 
In patients with sodium or volume overload, sodium restriction with or 
without diuretics may control mild hypertension. Many newborn infants in 
whom hypertension develops already are receiving diuretics, however, and 
more intensive diuretic therapy may cause dehydration and a further in­
crease in PRA. In more severe cases, the treatment may consist of hydra­
lazine, a-methyldopa, or a p-blocker. Hy-dralazine is used frequently as the 
first-line antihypertensive medication in newborn infants. Because its side- 
effects include fluid retention and tachycardia, it often is used in combina­
tion with a diuretic or a P-blocker or both, which also increases its efficacy.
Acute, severe hypertension probably is treated best with the combina­
tion of sodium and fluid restriction and a potent diuretic (e.g., furosemide, 
bumetanide), plus a potent short-term vasodilator such as diazoxide, which 
is an arteriolar vasodilator, or sodium nitroprusside, which is both an arte­
riolar and venous vasodilator. Although the effect of diazoxide on blood 
pressure is difficult to predict, the rate of administration of a nitroprusside 
drip can be titrated, with rapid and excellent control of severe hypertension. 
The major side-effect of nitroprusside is the production of cyanide and thio­
cyanate toxicity, suggested by the development of metabolic acidosis and 
increased mixed venous oxygen content secondary to decreased tissue oxy­
gen extraction. These side-effects are uncommon with short-duration infu­
sions of up to 4 days.
Labetolol has been used successfully in a limited number o f neonates 
with severe hypertension; its effect was reported to be more gradual than
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that of nitroprusside or diazoxide. It is effective even in patients with renal 
failure.
Angiotensin-converting-enzyme inhibitors (e.g., enalapril, captopril) 
are extremely potent and have been used successfully in newborn infants; 
however, they may result in prolonged and profound hypotension that re­
quires massive doses of crystalloids and colloids and is refractory to ino- 
tropes. Such hypotensive episodes often develop at the initiation of treatment 
if the patient is relatively hypovolemic after diuretic administration and if in­
appropriately high doses are being used; correct doses in newborn infants are 
much lower than those in children. The most serious reservation with the use 
of ACE inhibitors is the risk of late-onset hypotensive episodes, even after 
weeks of apparently successful and well tolerated therapy. These episodes 
may be associated with decreased cerebral blood flow and significant central 
nervous system dysfunction or even cerebral infarction. Although additional 
knowledge of ACE pharmacokinetics may lead to safer use in the future, 
ACE inhibitors seem to be indicated only for patients with refractory hyper­
tension.
SPECIFIC TREATMENTS
Iatrogenic Hypertension. If the infant is hypervolemic secondary to 
excessive administration of sodium or fluids, intake should be restricted and 
a diuretic—usually furosemide—administered. It is imperative to eliminate 
hidden sources of sodium, such as isotonic saline used to flush an arterial 
line and sodium-containing medications (e.g., antibiotics). If fluid restric­
tion is not possible, and severe hypertension with CHF is present, hemofil­
tration should be strongly considered.
If one or more medications is responsible for the hypertension, sev­
eral choices are possible. In some cases, the medication can be replaced by 
another (e.g., pancuronium can be replaced by vecuronium). In some cases, 
withholding the medication, decreasing the dose, or using an infusion in­
stead of a repeated bolus may result in the resolution of the high blood pres­
sure. On the other hand, the neonatologist may choose to use steroids in 
VLBW infants with severe BPD, even at the risk of mild hypertension that 
can be controlled by a diuretic, sodium restriction, and hydralazine. If se­
vere hypertension develops, however, the risk of IVH, CHF, and renal fail­
ure may outweigh the possible beneficial effects on the lung disease. If hy­
pertension develops in an infant on ECMO, the first step is to induce diure­
sis vigorously. There is no specific treatment for hypertension that develops 
after closure of abdominal wall defects.
Renovascular Hypertension. The choice of antihypertensive medi­
cations is controversial. Whereas ACE inhibitors are considered the drugs of 
choice for adults and children with renovascular hypertension, and some 
centers have had good success in neonates as well, many neonatologists
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have serious concerns about the potential major side-effects mentioned pre­
viously. Other medications, such as a p-blocker or, in the case of a hyper­
tensive crisis, a potent vasodilator, should be tried first. The advantage of a 
p-blocker such as propranolol is that it reduces the secretion of renin and the 
release of norepinephrine. Several side-effects of propranolol (e.g., bron- 
choconstriction, hypoglycemia) are related to absence of specificity. A more 
specific p-blocker, metoprolol, has been used in infants.
Although the treatment of aortic or renal thrombosis remains contro­
versial, a selective approach seems justified. A thrombus that compromises 
only renal perfusion usually can be treated using antihypertensive agents; 
heparinization should be considered. If hypertension cannot be controlled 
despite aggressive medical therapy, or if massive aortic thrombosis results 
in other major complications, thrombolysis should be considered, using 
urokinase, streptokinase, or thromboplastin antecedent. If severe hyperten­
sion persists despite antihypertensive treatment and thrombolysis, throm­
bectomy or nephrectomy should be considered. Although hypertension re­
solves within a few months in most patients, refractory hypertension may 
develop in rare patients, and nephrectomy ultimately may be necessary.
Patients with renovascular hypertension due to a congenital vascular 
anomaly or to external compression of the renal artery should be treated sur­
gically. Infants with unilateral renal artery disease not infrequently can be 
managed only with unilateral nephrectomy. Hypertension due to idiopathic 
arterial calcification typically fails to respond to standard antihypertensive 
medication and to nephrectomy.
Renal Causes of Hypertension. Surgical correction of hydronephro­
sis, VUR, or renal compression usually results in cure of the hypertension, 
unless there is postoperative edema with post-renal failure or renal dyspla­
sia. If hydronephrosis is present, antibiotic therapy should be initiated im­
mediately, pending results of the culture. The presence of yeast in the urine 
should lead to immediate initiation of systemic amphotericin therapy; if hy­
dronephrosis is secondary to a fungus ball, surgical relief of the obstruction 
should be followed by local irrigation with amphotericin. Hypertension due 
to PKD sometimes is severe; if medical therapy fails, ne-phrectomy may 
have to be performed.
Neurologic Hypertension. Appropriate pain relief should be given 
before undertaking procedures such as placement of a chest tube or per­
formance of a cut-down and after major surgical procedures. A discussion 
of treatment of intracranial hypertension is presented elsewhere.
PROGNOSIS
The prognosis depends mainly on etiology, although timing of the di­
agnosis, presence of neurologic complications, and response to therapy are 
important factors. Until devices became available for routine and reliable
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monitoring of blood pressure in neonates, hypertension was detected early 
only in patients with a UA line in place. Patients in whom hypertension is 
diagnosed on the basis of either neurologic, cardiovascular, or renal decom­
pensation have a high mortality rate. Nevertheless, the use of routine moni­
toring should allow early detection of most infants with mild to moderate 
hypertension, even after discharge from the nursery.
The mortality rate of patients with idiopathic calcification of the ar­
teries or with massive aortic thrombosis remains high despite aggressive 
therapy. The long-term prognosis for newborn infants with thromboem­
bolism of the renal artery or the aorta is good, often with progressive resolu­
tion of the hypertension within a year and only mild to moderate decrease in 
renal function. Most hypertensive neonates with PKD or dysplastic kidney 
sooner or later will require nephrectomy.
DIURETICS
This section reviews the major characteristics of the various types of 
diuretics, classified according to their major site of action along the 
nephron, from proximal to distal (Table 56).
TYPES OF DIURETICS
CARBONIC ANHYDRASE INHIBITORS
Carbonic anhydrase is present in a wide range of cell types. It is an 
important enzyme for the secretion of cerebrospinal fluid and for acid-base 
transport. Carbonic anhydrase inhibition reduces bicarbonate reabsorption 
by the proximal tubule; it increases the urinary excretion of Na+, K+, bicar­
bonate, and phosphate. The diuretic action of carbonic anhydrase inhibitors 
is limited by the presence of carbonic anhydrase-independent Na+ reabsorp­
tion in the proximal tubule, compensatory mechanisms forNa+ reabsorption 
in distal segments of the tubule, and the development of metabolic acidosis, 
which results from carbonic anhydrase inhibition.
Some infants with hydrocephalus respond favorably to the combina­
tion of acetazolamide and furosemide. This treatment may be indicated in 
VLBW infants with posthemorrhagic hydrocephalus, who are too small to 
tolerate a ventriculoperitoneal shunt. In our experience, the side-effects of 
acetazolamide may be minimized by increasing the dose of acetazolamide 
gradually over the course of 2 weeks while carefully monitoring serum 
chemistries and titrating the amounts of supplementary sodium bicarbonate 
and potassium acetate that are needed.
OSMOTIC DIURETICS
The administration of hypertonic mannitol causes a shift of water 
from the intracellular fluid (1CF) to the ECF, which results in dilutional hy­
ponatremia and hypochloremia, and increased total and medullary renal 
blood flow. Mannitol is filtered freely by the glomerulus. Because it is not
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reabsorbed in the tubule, its luminal concentration increases progressively 
along the nephron, which decreases tubular fluid re-absorption. This in­
creases the backflux of Na+ into the lumen, thereby decreasing net Na+ reab­
sorption. In addition, the decreased medullary solute gradient leads to de­
creased urinary concentration.
Although mannitol has been reported to decrease the incidence of ARF 
in certain surgical situations (e.g., cardiopulmonary bypass, aneurysm of the 
aorta, obstructive jaundice), in myoglobinuria-hemoglobinuria with shock, 
and in the use of radiocontrast agents in patients with CRP, and it may con­
vert oliguric to nonoliguric ARF, it has been associated with the development 
of renal failure in some patients. Mannitol-induced water shifts may induce 
hyperkalemic metabolic acidosis and, if no diuresis occurs, it may precipitate 
CHF by acute expansion of the ECF. On the other hand, brisk diuresis may 
be followed by hypematremic dehydration unless free water is provided.
Although mannitol has been used in newborn infants, its risk-benefit 
ratio has not been assessed. It is contraindicated in premature infants because 
of the risk of inducing an intraventricular hemorrhage. The efficacy of 
mannitol in the treatment of cerebral edema in newborn infants is controver­
sial; no benefit was observed in a randomized study. Thus, the use of man­
nitol in neonates is of questionable benefit.
Table 56
Effects of various types of diuretics on urinary output
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LOOP DIURETICS
Loop diuretics—diuretics with a site of action in the loop of Henie— 
include furosemide, ethacrynic acid, bumetanide, and several other drugs. 
They have multiple actions that can affect blood pressure and fluid and elec­
trolyte balance. First, they are vasodilators. They decrease peripheral vascu­
lar resistance in patients with CHF. They increase RBF and redistribute re­
nal cortical and pulmonary blood flow. The vasodilator action, observed be­
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fore any diuretic effect, is responsible for the rapid improvement of blood 
gas exchange and pulmonary compliance in patients with pulmonary edema.
Loop diuretics reach their site of action in the tubular lumen by secre­
tion by the organic transport system of the proximal tubule, which is inhib­
ited by probenecid. The major diuretic effect on the tubule results from the 
inhibition of chloride reabsorption at the cortical thick ascending loop of 
Henie, by blocking Na+-K+-2C1‘ cotransport. The increase in CH20  induced 
by loop diuretics may be useful for the treatment of situations associated
with fluid retention and hyponatremia.
A less important potential effect is a decrease in proximal tubular 
fluid reabsorption, which results in part from the weak ability to inhibit car­
bonic anhydrase activity, due to the sulfamoylbenzoic structure. In contrast 
to other loop diuretics, ethacrynic acid does not have any effect on the 
proximal tubule at doses used clinically.
Loop diuretics decrease the reabsorption of calcium, first by decreas­
ing the lumen-positive trans-epithelial potential that favors the reabsorption 
of calcium, and, second, by blocking active reabsorption of calcium at the 
cortical thick ascending limb.
Finally, loop diuretics stimulate renin secretion and PG synthesis. In­
creased PG synthesis may be an important mediator of the effects of these 
diuretics; indomethacin prevents or limits all the effects of furosemide.
Indications for loop diuretics include oligoanuria, prevention of oli- 
goanuria due to indomethacin administration, and fluid retention with hypo­
natremia (e.g., SIADHS, CHF, nephrotic syndrome, liver failure). The most 
commonly used loop diuretic is furosemide. Bumetanide is much more potent 
than furosemide on a weight basis; pharmacologic data are becoming avail­
able in neonates.
In newborn infants, a single dose of intravenous furosemide has an 
onset of action within 1 hour and a duration of approximately 6 hours. In 
infants with a postconceptional age of fewer than 31 weeks, the secretory 
clearance of furosemide is very low, suggesting that the amount of diuretic 
reaching the site of action is entirely dependent on GFR.
BENZOTHIAZIDES OR THIAZIDES
Similarly to loop diuretics, the benzothiazides (i.e., thiazides) are se­
creted into the tubule to reach their site of actionvTheir primary action is an 
inhibition of the reabsorption of СГ, coupled with that of Na , at the early 
distal convoluted tubule. A second effect of thiazides is the inhibition of 
proximal reabsorption of chloride, which may be mediated in part through 
the inhibition of carbonic anhydrase activity secondary to the sulfonamide 
moiety of the benzothiazides. Finally, thiazides decrease NaCl and fluid re­
absorption at the inner medullary collecting duct. In contrast to loop diuret­
ics, they are not vasodilators.
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Thiazides may decrease calciuria by enhancing re-absorption of cal­
cium at the level of the proximal convoluted tubule in response to ECF con­
traction, as well as at the level of the distal convoluted tubule. A positive cal­
cium balance as a result of hypocalciuria is noted during chronic thiazide 
administration, except after salt loading or during sodium replacement. Thi­
azide administration may result in a prolonged increase in total and ionized 
serum calcium concentration.
Thiazides generally are ineffective in patients with renal failure. 
There is good evidence to show that the association of a thiazide and a po­
tassium-sparing diuretic is effective in the treatment of VLBW infants with 
BPD. In addition, because of their hypocalciuric effect, they are indicated 
for the prevention and the treatment of nephrocalcinosis in patients with hy- 
percalciuria. Finally, they are used for the treatment o f NDI in association 
with a PGSI.
QUIMAZOLINE
Like the thiazides, metolazone, a quinazoline, is an inhibitor of the re­
absorption of sodium and chloride at the diluting segment, but its action is 
more complete and more prolonged. In contrast to thiazides, metolazone 
causes little or no increase in urinary potassium excretion, and its diuretic ac­
tion on the proximal tubule is independent of carbonic anhydrase, which is 
not blocked by metolazone. It also has an antihypertensive action.
Metolazone is efficient even in patients with CRF, if higher dosage is 
used. It has been used successfully in adults and children with edema refrac­
tory to furosemide and thiazides, as well as in VLBW infants with BPD in 
whom tolerance to furosemide develops.
POTASSIUM-SPARING DIURETICS
Potassium-sparing diuretics, including spironolactone, triamterene, 
and amiloride, inhibit sodium reabsorption by the principal cells of the con­
necting tubule and the cortical collecting duct and thereby decrease potas­
sium secretion. Spironolactone is a steroid analogue and competes with al­
dosterone for binding to intracellular receptor proteins. Metabolites of spi­
ronolactone, including canrenone, also have antimineralocorticoid activity. 
In contrast to spironolactone, the effect of the two other potassium-sparing 
diuretics is independent of aldosterone. Triamterene is hydroxylated in the 
liver and exerts its action on the basolateral side of the tubule. Amiloride is 
not metabolized; its major effect is the blockade of an electrogenic Na+ 
channel on the luminal membrane of the collecting duct, thereby reducing 
К secretion. In addition, usual doses of amiloride decrease Na+ reabsorp­
tion and completely block K+ secretion at the distal convoluted tubule, caus­
ing a mild metabolic acidosis by decreasing Na+-H+ exchange in this seg­
ment.
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In newborn infants, the most commonly used potassium-sparing diu­
retic is spironolactone. Potassium-sparing diuretics are used most often in 
addition to a thiazide. They are especially useful in situations associated with 
primary hyperaldoster-onism or hyperaldosteronism secondary to CHF, 
nephrotic syndrome, or liver failure. They also may be used for the treatment 
of Bartter syndrome and, in association with a PGSI, for the treatment of 
NDI.
STRATEGY IN USING DIURETICS
The choice of diuretic depends on the acuity of hypertension or fluid 
overload, on the adequacy of renal function, and on the expected side-effects. 
For emergencies (e.g., cardiovascular or respiratory failure as a result of fluid 
overload), loop diuretics are the best choice because of their rapidity of ac­
tion and their potency. In most patients with lung edema, fluid restriction 
should be initiated along with diuretic therapy. Since the goal of the admini­
stration of diuretics is a decrease in ECF and a decrease in body sodium con­
tent, mild hyponatremia (130-135 mEq/L) should be expected. The clinician 
should avoid the vicious cycle of diuretic-low serum sodium concentration- 
increased sodium intake-more hypertension or lung edema-more diuretic; 
however, potassium and chloride depletion should be prevented.
Both hypokalemia and hypochloremic metabolic alkalosis are com­
mon complications of thiazide or loop diuretic administration, unless the pa­
tient has renal failure or appropriate preventive therapy is initiated. Despite 
decreased reabsorption of bicarbonate related to the inhibition of carbonic 
anhydrase, acute thiazide or loop diuretic administration results in a "con­
traction" alkalosis because of a reduction of the ECF volume and a rela­
tively low bicarbonate concentration in the urine. During chronic diuretic 
administration, metabolic alkalosis results from increased distal urine acidi­
fication, which may be due to hypokalemia, mineralocorticoid excess, and 
increased delivery of Na+ to the distal convoluted tubule, where protons are 
secreted in exchange for Na+. There is serious concern about the effects of 
metabolic alkalosis associated with diuretic therapy both in adults with 
chronic obstructive pulmonary disease and in infants with BPD. Thus, both 
potassium depletion and metabolic alkalosis should be treated or, better, 
prevented by adding KC1 or a potassium-sparing diuretic as soon as diuretic 
therapy is initiated, except in the presence of renal failure.
Resolution of peripheral edema is neither an emergency nor a priority. 
An effective circulatory volume and normal blood pressure should be main­
tained carefully at all times; this is especially critical when a potent vasodila­
tor is administered to a patient with marginal circulatory volume (e.g., during 
administration of tolazoline, antihypertensive medications, general anesthe­
sia). In a patient with low circulatory volume and abnormally low serum pro­
tein concentration (e.g., postoperative phase, third space losses, nephrotic
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syndrome, hydrops fetalis) with visceral (e.g., pleural, peritoneal, pericardiac) 
fluid accumulation, the circulatory volume should be expanded with colloids 
before administration of diuretics.
During chronic diuretic therapy, the sensitivity to a single diuretic de­
creases progressively, as a result of compensatory mechanisms for solute re­
absorption at other sites of the nephron. Thus, the combination of two diuret­
ics from different groups often is required. To minimize bone calcium loss 
and prevent nephrocalcinosis and nephrolithiasis, thiazides should be used as 
first choice for chronic diuretic therapy, rather than loop diuretics. The asso­
ciation of a thiazide and spironolactone is efficient in premature infants with 
BPD; intermittent doses of furosemide can be added to this regimen when 
necessary. In refractory patients, the association of metolazone and fu- 
rosemide should be considered.
BACTERIURIA AND URINARY TRACT INFECTIONS
Until the early 1970s, significant bacteriuria was defined as a colony 
count of 105/mL or greater in specimens obtained either by bag or by clean 
catch. It was shown subsequently that such samples frequently are contami­
nated by perineal flora. There is general agreement that in infants, bacteriuria 
can be diagnosed with certainty only by culturing samples obtained by inva­
sive techniques (i.e., bladder catheterization, suprapubic aspiration). There is 
no consensus, however, about the magnitude of bacteriuria required to reach 
significance (Table 57).
In this review, only those series in which bacteriuria or candiduria was 
established by invasive technique will be considered. Bacteriuria in new­
born infants can be either asymptomatic or an indication of pyelonephritis, 
which is characterized by local and systemic inflammatory response. Lower 
UTI (i.e., cystitis) usually cannot be diagnosed on clinical grounds in new­
born infants, except when associated with hematuria.
Table 57
Methods of diagnosis of bacteriuria or urinary tract infections 
in newborn infants
Suprapubic Aspiration Bladder Cathe­
terization
Contraindi­
cations
Complications*
No clinical or US evidence for presence of urine 
in the bladder
Abdominal distension, peritonitis, organomegaly 
Hemorrhagic tendency, thrombocytopenia 
Local skin infection
Microscopic hematuria (common); gross hema­
turia, hypovolemia requiring transfusion; blad­
der wall hematoma, urinary tract obstruction; 
aspiration of bowel content; bowel perforation, 
peritonitis; perforation of abdominal organ; ab­
dominal wall abscess; sepsis, death
Hypospadias, 
phimosis, local 
skin infection
Microscopic he­
maturia (com­
mon), gross he­
maturia (rare), 
UTI
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Positive cul­
ture
Indeterminate
culture
>104 or 10’ organisms/mLy 
<102 or 10s organisms/mL
>10’ or 104 or- 
ganisms/mL* 
<104 or 10s or- 
ganisms/mL
•Except for hematuria, most complications are very rare 
ł Some authors define UTI as a count >105/mL of a single bacterial species 
US - ultrasound; UTI - urinary tract infection.
FREQUENCY IN NEWBORN INFANTS
The frequency of bacteriuria demonstrated by supra-pubic aspiration or 
bladder catheterization ranges between 0% and 2.0% in an unselected neona­
tal population and between 0.6% and 10% in aNICU population. Risk factors 
include prematurity (frequency of bacteriuria is 0%-10%), male gender 
(male-female ratio ranges from 1:1 to 9; 1 in newborn infants), and absence of 
circumcision (relative risk of UTI during the first month of life is ten times as 
high in uncircumcised as in circumcised males). The frequency of UTI in un­
circumcised male newborn infants was found to be similar to that in females. 
The frequency of UTI also is increased in infants with urinary tract anomalies 
and after invasive procedures.
PATHOPHYSIOLOGY
The risk of UTI depends on bacteriologic factors, including the size 
of the inoculum and the virulence of the organism, as well as host character­
istics. Periurethral cultures obtained in uncircumcised infants show higher 
total bacterial counts, as well as a higher prevalence of Escherichia coli 
than cultures obtained in circumcised infants. Virulence factors include the 
ability of bacteria to adhere to uroepithelial cells, the presence of specific 
antigen combinations, hemolysin, endotoxin, or colicin, and resistance to 
the bactericidal effect of the serum. The normal defense against UTI in­
cludes maintenance of an adequate flow of urine and complete emptying of 
the bladder. Either may be compromised by urinary tract obstruction or 
bladder dysfunction (e.g., neurogenic bladder). In addition, the normal anat­
omic barrier (i.e., the bladder outlet) may be compromised by urinary tract 
malformation or manipulation (e.g., prolonged or repeated bladder cathe­
terization). In the case of pyelonephritis, endocytosis of bacteria is per­
formed not only by inflammatory cells but also by proximal tubular cells; in 
parallel, an increase in cellular superoxide dismutase is observed.
PATHOLOGY
Acute pyelonephritis commonly is associated with nephromegaly. It is 
characterized by the presence of polymorphonuclear leukocytes in the 
glomeruli, tubules, and interstitium. Some glomeruli are completely de­
stroyed, whereas others are infiltrated with leukocytes and surrounded by fi­
brin. The tubules are necrotic, dilated, and their lumens are filled with poly­
morphonuclear cells and bacteria. Suppuration may develop in the kidney, 
often with multiple abscesses at autopsy, as well as other parts of the genitou­
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rinary tract. Chronic or recurrent pyelonephritis is characterized by infiltra­
tion of chronic inflammatory cells, loss or hyalinization of glomeruli, and at­
rophy of tubules, with obstruction of the lumen with colloid casts. The devel­
opment of renal scars may not occur until after 1 year of life.
CLINICAL PRESENTATION
The percentage of infections that are asymptomatic is high in some se­
ries, and low in others. The clinical presentation of UTI in newborn infants 
may include one or more of the following signs:
Growth failure and gastrointestinal symptoms. Failure to thrive, exces­
sive weight loss, poor feeding, diarrhea, and vomiting are the most 
common clinical features of neonatal UTI.
Jaundice. The hyperbilirubinemia observed in newborn infants with 
UTI may be either direct or indirect and sometimes is associated 
with hemolytic anemia. It is commonly the main clinical feature at 
presentation and may be the only sign of UTI in some infants.
Temperature instability or fever (temperature s 38°C). Urinary tract in­
fection has been reported in 7.5% to 11% of febrile infants present­
ing to the emergency room during the first 8 to 12 weeks of life
Irritability, lethargy.
Abnormal urination. This includes poor urinary stream, malodorous 
urine, and polyuria, which may lead to severe dehydration.
Signs associated with bacteremia (e.g., respiratory distress) or with fo­
cal infection (e.g., mucocutaneous candidiasis, omphalitis).
Hypertension. This may develop as a result of hydronephrosis associ­
ated with the UTI.
LABORATORY FEATURES
URINALYSIS
Based on specimens obtained by bladder catheterization or suprapu­
bic aspiration, only one-half of febrile outpatients with documented UTI 
during the first 3 months of life had an abnormal urinalysis defined either 
by the presence of more than five leukocytes per high power field or by the 
presence of any bacteria. The positive predictive value of pyuria on samples 
obtained by suprapubic aspiration ranges between 71% (pyuria > 10 leuko- 
cytes/mm3) and 96% (pyuria > 20 leukocytes/mm3). Thus, although the 
presence of pyuria, at least on a sample obtained by suprapubic aspiration, 
is suggestive of UTI, its absence is insufficient to rule out UTI. Microscopic 
demonstration of yeast cells in urine obtained by suprapubic aspiration or 
bladder catheterization is very suggestive of candiduria.
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URINE CULTURE
Clean voided urine or urine collected by a bag, even after cleansing 
the perineum, often yields a false-positive culture, when a simultaneous cul­
ture of urine obtained by suprapubic aspiration or bladder catheterization is 
negative. On the other hand, a negative culture of urine obtained by a non- 
invasive technique is sufficient to rule out bacteriuria; this may avoid the 
need for invasive collection of urine in a substantial number of patients. The 
validity of suprapubic aspiration and bladder catheterization for detecting 
significant bacteriuria in newborn infants was demonstrated by the fact that 
both techniques only rarely yield equivocal bacterial counts, in contrast to 
bag-collected samples. The incidence of UTI during the first 3 days of life is 
very low among infants suspected of sepsis. Thus, urine culture usually is 
part of a sepsis workup only if the infant is more than 3 days of age. If anti­
biotic therapy is to be started immediately because of suspicion of sepsis, 
urine should be obtained by suprapubic aspiration or by bladder catheteriza­
tion. In other cases, these invasive procedures can be delayed until the result 
of a culture obtained from a bag-collected specimen is positive.
COMPLICATIONS
Acute complications of UTI in newborn infants include bacteremia; 
suppuration; VUR; urinary tract obstruction, sometimes associated with hy­
pertension or acute renal failure; severe hydromineral imbalance; methemo­
globinemia; and ARF, which may be associated with urinary tract obstruction 
or massive VUR.
The incidence of bacteremia in association with UTI in infants de­
pends on the population studied. Grain and colleagues and Krober and asso­
ciates reported an incidence of 6% in infants under 2 months of age and in 
infants under 3 months of age who presented with fever in the emergency 
room. On the other hand, the incidence of bacteremia in patients with UTI 
was found to be 29% in infants under 1 month of age and 31% to 36% in 
neonates.
Suppurative complications of UTI are extremely rare in newborn in­
fants. Only one case of renal abscess in the neonatal period has been re­
ported; the predisposing factor was congenital nephrotic syndrome. Other 
sites of abscess include the perirenal area, where abscess can be caused by 
group В streptococci; the prostate; and other genitourinary organs.
Vesicoureteral reflux is observed commonly during the acute stage of 
UTI; it often decreases or disappears after treatment and may reappear at the 
time of recurrent infections. Intraparenchymal reflux is associated with a high 
risk of renal scarring.
Bacterial UTI can be associated with the development of hyperten­
sion in infants with hydronephrosis. Mycotic UTI can lead to the develop­
ment of fungus balls, which may cause obstruction in the renal pelvis or the
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bladder; this may lead to the development of an abdominal mass, systemic 
hypertension, and anuria.
INVESTIGATION
PYELONEPHRITIS versus BACTERIURIA
Once bacteriuria is documented, the clinician should differentiate be­
tween pyelonephritis, which presents a high risk for renal scarring, and as­
ymptomatic bacteriuria, which presents a low risk for renal scarring. Clinical 
and laboratory features suggesting the diagnosis of pyelonephritis include fe­
ver, an increase in leukocyte count with a left shift, an elevated sedimentation 
rate, an increase in the serum concentration of C-reactive protein, and renal 
tubular dysfunction Unfortunately, none of these tests, alone or in combina­
tion, can reliably establish the diagnosis or predict the development of renal 
scars. Although bacterial or fungal pyelonephritis may cause parenchymal 
hyperechogenicity, the sensitivity and the specificity of US to diagnose pye­
lonephritis have not been evaluated.
Since " mTc-DMSA binds to the proximal tubules and is excreted only 
minimally into the urine, it yields excellent visualization of the functioning 
parenchyma, and is therefore ideal for the detection of cortical defects. The 
presence of focal, multifocal, or diffuse areas of decreased cortical uptake 
was shown reliably to detect pathologic inflammatory changes in a piglet 
model of acute pyelonephritis. Thus, the 99m Tc-DMSA scan may be the 
most reliable indicator of acute pyelonephritis. In addition, the DMSA scan 
has a very good predictive value (80%) for the development of renal scars. 
One study included newborn as well as older infants with UTI, in whom the 
DMSA scan was performed after resolution of the infection, which was al­
ways after 1 month of age; defects detected by the DMSA scan were associ­
ated with VUR and with the development of renal scars.
SEPSIS
On diagnosing UTI, a systemic infection must be ruled out. Most of­
ten a full sepsis workup is performed.
RENAL FUNCTION
Renal glomerular and tubular function should be assessed at the time 
of the diagnosis and during treatment and follow-up. Urinary tract infection 
can be associated with transient or permanent decrease in GFR, RTA, de­
creased urine concentrating ability, or other tubular damage demonstrated by 
increased NAG enzymuria.
UNDERLYING ABNORMALITIES
Although US of the entire urinary tract should be obtained immedi­
ately, further evaluation for the presence of a congenital or acquired urinary 
tract anomaly should be performed after the infection has resolved. The rec-
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ommended approach has changed considerably over the last decade. Al­
though previously used routinely, IVU is almost never performed in the neo­
natal period because of poor visualization as a result of limited renal function 
during the first weeks of life and the risk of nephrotoxicity inherent to ra­
diopaque contrast products. Ultrasonography and VCUG have become the 
procedures of choice. Because VUR associated with UTI often decreases af­
ter resolution of infection, the VCUG most often is delayed by approximately 
1 month, unless the US demonstrates an abnormality that requires further in­
vestigation or surgical intervention.
During the last few years, the DMSA scan has become routine for the 
workup of acute UTI in infants, children, and adults. It may be reasonable to 
perform VCUG only in children with abnormal US or DMSA scan, but this 
needs further confirmation before being accepted as the standard approach.
TREATMENT
The interval of administration of the antibiotics may have to be ad­
justed during the course of therapy, since renal function may be compro­
mised both by aminoglycoside or amphotericin nephrotoxicity and by pye­
lonephritis. The interval of gentamicin administration can be modified ac­
cording to Pcr. A cephalosporin can be substituted, if renal failure develops. 
Third-generation cephalosporins, piperacillin, and aztreonam are alterna­
tives to the ampicillin-gentamicin combination and are chosen according to 
local epidemiology. A repeat urine culture should be obtained during treat­
ment and after completion of the antibiotic therapy. In the case of failure to 
respond to treatment, US should be repeated, antibiotic therapy may have to 
be adjusted, and a systemic infection or other foci should be ruled out. Low- 
dose antibiotic therapy may be indicated after the initial 10-day course until 
the VCUG or the DMSA scan is performed, at least in those patients with 
abnormal US.
Therapy for asymptomatic bacteriuria in the absence of bacteremia can 
be given orally after the first few days. It is possible that shorter courses for 
the treatment of asymptomatic bacteriuria may be adequate, but this has not 
been evaluated in newborn infants. Although most neonatologists recom­
mend treating bacteriuria in any infant during or after the neonatal period re­
gardless of the presence or absence of symptoms, growing evidence supports 
simple observation of infants and children with asymptomatic bacteriuria. 
Additional experience in newborn infants must be obtained before withhold­
ing of therapy for asymptomatic bacteriuria can be recommended.
Surgical intervention may be required for patients with severe VUR 
and those with urinary tract obstruction. If a fungus ball is associated with 
urinary tract obstruction or does not disappear during systemic treatment, 
daily washings with amphotericin В through a bladder catheter or a 
nephrostomy tube usually are a necessary addition to systemic therapy.
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LONG-TERM COMPLICATIONS AND FOLLOW-UP
In patients with pyelonephritis or urinary tract anomalies, GFR, uri­
nary concentrating ability, and tubular acidification should be assessed seri­
ally. The development of renal failure, once a common complication of UTI 
in small children, is observed only rarely, except in patients with major uri­
nary tract malformations and renal dysplasia.
Although the association between segmental hypoplasia of the kid­
ney, VUR, and UTI has been known for more than a decade the develop­
ment of renal scars remains a serious potential complication. In patients in 
whom UTI develops before 1 year of age, approximately one-half of the 
kidneys with VUR will develop renal scars, and 70% of the kidneys that 
eventually develop scars have VUR. Several risk factors for formation of 
renal scars can be identified early, including UTI associated with specific 
strains of E. coli; grades III to IV VUR, especially if complicated by recur­
rent infections; and abnormal DMSA scan at the time of the UTI. In the pig­
let model, the DMSA scan was shown to have a sensitivity of 85% and a 
specificity of 97% for detection of scars caused by VUR and UTI. Infants at 
risk for chronic renal scarring need long-term follow-up by a nephrologist 
and a urologist, including repeat urine cultures and sequential isotopic 
scans, and should be considered for prophylactic antibiotic therapy.
PREVENTION
Several epidemiologic studies have shown an association between cir­
cumcision and a higher frequency of UTI in the neonatal period and early in­
fancy. It is possible, however, that other, unassessed factors may explain 
these differences, at least in part. In one of the studies, a high incidence of 
urinary tract malformations (26%) was found in uncircumcised boys.
Intermittent bladder catheterization with anticholinergic medication is 
performed more and more frequently in infants with neurogenic bladder as­
sociated with myelodysplasia; this method has been shown to result in a 
lower frequency of long-term deterioration of the radiologic appearance of 
the kidney, despite a relatively high incidence (19%-42%) of bacteriuria- 
UTI. It appears that prophylactic antibiotic administration may reduce the 
risk for UTI, but this has not been evaluated prospectively.
Chemoprophylaxis usually is recommended after a first UTI for infants 
with VUR or other urinary tract anomalies. The role of chemoprophylaxis in 
newborn infants with prenatally diagnosed urinary tract malformations has 
not been established. In one series of 25 infants, prenatal dilation of the uri­
nary tract led to early diagnosis of VUR in the neonatal period. Chemopro­
phylaxis was associated with absence of infection in 17 infants, a single in­
fection in 3, and 2 or more infections in only 5.
3 91
TUBULAR DYSFUNCTION
In this section, tubular disorders that present commonly in the neona­
tal period are discussed, in addition to those for which early onset of treat­
ment during the neonatal period may modify or delay the evolution toward 
renal failure. The reader is referred to other sources for discussion of un­
common disorders not included here.
HYPERCALCIURIA, NEPHROCALCINOSIS, AND NEPHROLITHIASIS
There are many causes of hypercalciuria, with or without hypercal­
cemia (Table 58). Congenital disorders associated with decreased renal tu­
bular reab-sorption of calcium include distal RTA, X-linked hypophos- 
phatemic rickets during vitamin D and phosphate therapy, arthrogryposis 
multiplex congenita with renal and hepatic anomalies, Bartter syndrome, 
and hyperprostaglandinuric tubular syndrome. Prenatal development of 
nephrocalcinosis has been observed in neonatal familial hyperparathyroid­
ism associated with hypercalciuria and distal RTA, partly associated with 
proximal RTA.
In the absence of hypercalciuria, nephrocalcinosis may develop in in­
fants with cystinosis or with primary hyperoxaluria. Hypercalciuria and 
nephrocalcinosis, however, are associated most commonly with prematurity, 
which is the subject of this section.
Table 58
______ Mechanisms of nephrocalcinosis and nephrolithiasis in infancy______
Hypercalciuria
Increased calcium intake with or without hypercalcemia 
Excessive calcium intake orally or intravenously 
Rapid calcium infusion 
Hypervitaminosis D 
Low phosphate intake 
Decreased renal tubular reabsorption 
Furosemide, ethacrynic acid, aldactone 
Extracellular volume expansion 
Osmotic diuresis 
Phosphate depletion syndrome 
Distal renal tubular acidosis, type I
Arthrogryposis multiplex congenita with renal and hepatic anomalies 
Bartter syndrome
Hyperprostaglandinuric tubular syndrome with hypercalciuria and hypokalemia 
Increased bone reabsorption
Primary hyperparathyroidism, including neonatal familial hyperparathyroidism 
Secondary hyperparathyroidism 
Acidosis 
Hyperthyroidism 
Chronic corticosteroid therapy
Hypophosphatasia_____________________________________________________
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O ther M echanisms
Factors facilitating precipitation of calcium phosphate and oxalate 
Low urine output 
Alkaline urine
Absence of inhibitors (e.g., citrate, inorganic phosphate, magnesium)
X-l inked hypophosphatemic rickets during phosphate and vitamin D administra­
tion
Other causes of nephrolithiasis 
Primary oxaluria
Cystinosis____________________________
Since that first report, US has become more sensitive than plain radiog­
raphy in detection of nephrocalcinosis, and furosemide has become widely 
used for the treatment of BPD. The incidence of nephrocalcinosis or nephro­
lithiasis in premature infants (<32 weeks of GA) is 25% to 60%.
Definition. Hypercalciuria was defined in 1- to 15-year-old children 
either as urinary calcium excretion greater than 6 mg/kg/day (0.L5 
mmol/kg/day), or as a urinary calcium-creatinine ratio greater than 0.4 ± 
0.06 mg/mg (mean ± SD; 2 mmol/mmol). Although factoring urinary cal­
cium excretion for creatininuria allows the use of spot urine rather than 
timed collections, values established in children may not be adequate for 
LBW infants, because the low muscle mass in LBW infants is associated 
with a 40% lower rate of creatinine excretion than in children. Normal val­
ues of calcium-creatinine ratio in full-term infants during the first 9 days of 
life were found by Goldsmith and associates to be a maximum of 0.15 
mg/mg.
Pathophysiology. The mechanisms responsible for hypercalciuria in­
clude increased calcium intake or gastrointestinal absorption, decreased re­
nal tubular calcium reabsorption, and abnormal regulation of bone mineral 
content. Chronic use of discontinuous daily calcium infusions is associated 
with recurrent periods of hypercalcemia and hypercalciuria. High enteral 
calcium intake from using a formula associated with high calcium and 
phosphate retention may be associated with hypercalciuria in the absence of 
hypercalcemia. Chronic phosphate depletion due to insufficient phosphate 
intake may result in hypophosphatemia, hypercalcemia, hypercalciuria, and 
osteopenia of prematurity. Increased phosphate intake results in a decrease 
in calcemia and reduces calciuria.
Although infants at highest risk for nephrocalcinosis and nephrolithi­
asis are those receiving prolonged furosemide therapy for chronic lung dis­
ease, not all affected infants have received furosemide. Acute administration 
of furosemide induces a tenfold increase in calciuria in premature infants; 
this effect is related to the inhibition of calcium reabsorption at the level of 
the ascending limb of the loop of Henie. Chronic administration of fu­
rosemide is associated with a mild increase in calciuria which leads to a
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negative calcium balance. Furosemide-induced hypercalciuria may lead to 
secondary hyperparathyroid-ism and demineralization in some infants.
Hypercalciuria also is associated with administration of ethacrynic 
acid—another loop diuretic—and spironolactone. Thiazides usually increase 
tubular reabsorption of calcium, both directly and by decreasing extracellu­
lar volume. In some patients, however, thiazide administration induces an 
increase in calciuria, attributed in premature infants to increased sodium in­
take and natriuresis. Hypercalciuria associated with TPN in adults has been 
attributed to excessive calcium intake; high protein intake, which increases 
not only GFR but also fractional excretion of calcium; and the acid load. 
Addition of acetate to the TPN resulted in a significant decrease in calciuria 
in the absence of any change in serum levels of calcium, PTH, or vitamin D. 
Acute as well as chronic acid loading induces bone calcium reabsorption 
and hypercalciuria.
Because neither the level of calciuria nor the total dose of furosemide 
separates LBW infants with nephrocalcinosis or nephrolithiasis from other 
LBW infants, the development of nephrocalcinosis in an individual infant 
appears to be multifactorial. Factors in addition to those mentioned include 
low urine output and the oxalaturia that is associated with the use of TPN.
Treatment and Prognosis. Although nephrocalcinosis and nephro­
lithiasis are not associated with any specific signs or symptoms and tend to 
decrease during the first year of life, in some patients they are associated 
with compromised renal function. Follow-up to 1 to 2 years of age has 
shown signs of tubular dysfunction in patients with persistent calcifications, 
including decrease in tubular reabsorption of phosphate, increase in FENa, 
and limitation of distal renal tubular acidification.
Low-birth-weight infants with BPD should be screened by ultrasono­
graphy for nephrolithiasis and for hyperechogenicity of the renal pyramids; 
those with abnormal ultrasonography should have a measurement of calci­
uria, which is the first step in the differential diagnosis (see Table 58). Pre­
vention of hypercalciuria includes administering enough phosphate and 
avoiding chronic administration of calcium boluses and of furosemide; the 
latter should be used only when other diuretics are ineffective or contraindi­
cated. To the extent possible, thiazides should be used in place of fu­
rosemide to limit both the development of chronic renal compromise and of 
severe bone demineralization.
PRIMARY HYPEROXALURIA AND OXALOSIS
Pathophysiology. Primary hyperoxaluria is a rare disorder, two types 
of which have been described. Type I (i.e., glycolic aciduria) is an auto­
somal recessive disorder, due to a functional deficiency in the hepatic per­
oxisomal enzyme alanine glyoxylate aminotransferase, for which pyridox- 
ine is a co-factor. This defect results in excessive production of oxalate,
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glyoxylic acid, and glycolic acid. The severity of type I is related to the pro­
gressive accumulation of calcium oxalate in various tissues, a condition 
called oxalosis. Type II hyperoxaluria (i.e., ^-glyceric aciduria) is a very 
rare disorder that probably is transmitted as an autosomal recessive trait, 
and does not cause oxalosis.
Clinical Presentation and Diagnosis. Approximately 12% of pa­
tients with primary hyperoxaluria present in infancy, with anorexia, failure 
to thrive, vomiting, dehydration and fever; presentation in the neonatal pe­
riod is rare.
Treatment. In patients with type I hyperoxaluria, early administra­
tion of high doses of pyridoxine should be tried in an attempt to limit the 
development of oxalosis. Therapy includes pyridoxine, inhibitors of calcium 
oxalate precipitation, and a large fluid intake (2 L/m2/day). Aggressive ther­
apy, including dialysis, of hyperoxaluria type I does not prevent oxalosis 
and ESRD. The most severely affected infants (i.e., those with the neonatal 
form with oxalosis) usually die before the age of 1 year. Although renal 
transplantation initially may be successful, it usually is disappointing be­
cause of rapid accumulation of oxalate in the graft, leading to recurrent re­
nal failure. Combined liver-kidney transplantation has been performed suc­
cessfully in at least 22 patients. Early liver transplantation before ESRD ap­
pears to be a promising approach.
FANCONI SYNDROME
PATHOPHYSIOLOGY
Fanconi syndrome is characterized by a generalized dysfunction of the 
proximal tubule. The cardinal signs are renal glucosuria, renal phosphaturia, 
and generalized aminoaciduria; other features, present inconsistently, include 
RTA, tubular proteinuria, increased urinary excretion of urate, sodium, potas­
sium, and calcium, and decreased ability to concentrate the urine and to se­
crete PAH. In some cases, distal tubular dysfunction is present, and the dis­
ease evolves toward renal failure, with less evidence of tubular dysfunction.
Because several transport systems are deficient in this syndrome, the 
pathophysiologic process presumably involves a global disturbance such as 
an alteration of the integrity of the tubular membranes or of sulfhydryl- 
requiring enzymes.
ETIOLOGY
Idiopathic cases of Fanconi syndrome most often are sporadic, al­
though autosomal recessive, autosomal dominant, and X-linked recessive 
transmission have been described. Fanconi syndrome occurs in association 
with a variety of acquired and congenital disorders (Table 59), the most com­
mon of which is cystinosis. Disorders associated with late onset renal
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dysfunction, such as glycogenosis type I and Wilson disease, will not be re­
viewed here.
CLINICAL FEATURES AMD DLAGNOSIS
The clinical presentation of Fanconi syndrome includes polyuria, 
polydipsia, dehydration, and failure to thrive. Signs include acidosis, hypo­
phosphatemia, and rickets. The diagnosis is confirmed by the demonstration 
of glucosuria in the presence of a normal glycemia (<120-150 mg/dL), de­
creased tubular reab-sorption of phosphate, and generalized hyperamino­
aciduria. The prognosis of Fanconi syndrome depends on the underlying dis­
order.
Table 59
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Causes of Fanconi syndrome in infancy 
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AR - autosomal recessive.
TREATMENT
The treatment includes replacement therapy, usually of sodium phos­
phate, sodium citrate, and potassium citrate and, if rickets has developed, vi­
tamin D administration. Indomethacin has been given successfully in some 
patients. Specific diet therapy for fructose intolerance, galactosemia, or tyro- 
sinemia results in disappearance of the Fanconi syndrome. In many other dis­
eases, treatment serves only to slow the deterioration of renal function.
SPECIAL CONSIDERATIONS
Cystinosis. The reported incidence of cystinosis ranges between 
1:20,000 and 1:326,000. It is an autosomal recessive lysosomal storage dis­
ease, due to a defect in the carrier-mediated transport of cystine from the ly- 
sosomes to the cytosol. The infantile (i.e., nephropathic) type of cystinosis 
is the most severe form.
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At birth, patients with cystinosis appear normal except for lighter skin 
and hair pigmentation than in siblings. Signs of Fanconi syndrome appear by 
3 to 12 months of age. In some patients, the initial presentation may suggest a 
diagnosis of Bartter syndrome or of NDI. Patients also have photophobia, 
which is secondary to retinopathy; the latter is characterized by generalized, 
often patchy, depigmentation of the peripheral retina and pigment clumps, 
and may be detected within the first weeks of life. In contrast, characteristic 
corneal opacities appear only after 1 year.
Laboratory findings include urinary excretion of typical cystine crys­
tals, generalized hyperaminoaciduria, mild to moderate glucosuria, severe 
phosphaturia, RTA, marked increase in urinary excretion of nonaminated 
organic acids, and tubular or mixed glomerular and tubular proteinuria. Pro­
gressive deterioration of the GFR leads to ESRD at a median age of 9.2 
years.
The treatment of cystinosis in infancy includes the nonspecific treat­
ment of Fanconi syndrome and the administration of cysteamine (i.e., 0- 
mercaptoethyl-amine) hydrochloride. Cysteamine administration to children 
with cystinosis results in improvement of growth and delay in progression of 
the renal failure. The administration before 2 weeks of age has been shown in 
a limited number of patients to delay the progression of the renal disease. 
Tolerance of cysteamine is limited by its foul taste and odor; this may result 
in suboptimal intake of the medication and early development of ESRD. 
Phosphocysteamine, which lacks the taste and odor of cysteamine, may re­
place it in the future if collaborative trials show equivalent efficacy.
Deal Syndrome. Deal and colleagues described a new, probably 
autosomal recessive, syndrome, characterized by ichthyosis, jaundice, mus­
culoskeletal deformities, diarrhea, failure to thrive, and early onset Fanconi 
syndrome; all six patients with this syndrome have died within the first 6 
months of life.
Glycogenosis With Fanconi Syndrome. More than 20 patients have 
been described with Fanconi-Bickel syndrome (i.e., glycogenosis with Fan­
coni syndrome), an autosomal recessive disorder characterized by impaired 
use of galactose and glucose and hepatorenal glycogenosis. In the kidney, 
glycogen accumulation is limited to the proximal tubule, with maximal lev­
els in the straight part. The etiology is unknown. This syndrome should be 
differentiated from glycogenosis type I, which is due to glucose-6- 
phosphatase or glucose-6-phosphate translocase deficiency and is associated 
with late onset of proximal tubular dysfunction in approximately 15% of the 
cases.
Fever, vomiting, growth failure, and rickets develop in the patients 
within 6 weeks to 10 months of birth, followed by hepatomegaly, protuberant 
abdomen, moon-shaped face, and fat deposition around the shoulder and the 
abdomen. Laboratory findings include glucosuria on the first day of life, ga-
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lac-tosemia on the fourth day, and hypophosphatemia by the eighth week. 
The Fanconi syndrome is severe. Over time, GFR does not decrease and the 
tubular defects improve. Hepatic glycogenosis causes a tendency toward hy­
poglycemia, ketonuria, hypercholes-terolemia, and hypertriglyceridemia, but 
no lactic acidosis. The diagnosis of Fanconi-Bickel syndrome is confirmed 
by normal enzyme activity in liver or kidney biopsy.
Particular attention should be given to treating possible acute decom­
pensations at the time of surgery or infections. Hypoglycemia can be pre­
vented by frequent protein-enriched feedings. The treatment of the nephropa­
thy is nonspecific.
Galactose-l-Phosphate Uridyl Transferase Deficiency. Galacto­
semia is an autosomal recessive disorder that results in intracellular 
accumulation of galactose-1-phosphate in various tissues, including the 
kidney. Symptoms often develop in the neonatal period, soon after initiating 
lactose intake (i.e., milk), and include hypoglycemia, anorexia, vomiting, 
diarrhea, hepatomegaly, jaundice, and hypoprothrombinemia. Renal 
dysfunction develops within 2 weeks after initiation of galactose intake; it is 
characterized by severe proteinuria, generalized aminoaciduria, and a sig­
nificant defect in transport of phosphate, bicarbonate, and PAH. Lactose 
intake leads to galactosuria, which produces a positive test for reducing 
substances but no glucosuria. Removing lactose and galactose from the diet 
results in rapid resolution.
Hereditary Fructose Intolerance. Hereditary fructose intolerance is 
an autosomal recessive disorder due to deficiency in fructose-1-phosphate 
aldolase which normally is present in the liver, small intestine, and renal 
cortex. In patients with fructose intolerance, ingestion of fructose results in 
the accumulation of fructose-1-phosphate in these tissues. Other tissues ei­
ther possess another isoenzyme of the aldolase (e.g., muscle, brain) or lack 
the enzymes required to metabolize fructose (e.g., renal medulla) and there­
fore are not involved. Although fructose is not part of the normal diet in the 
neonatal period, the routine use of sucrose has been recommended for seda­
tion during neonatal procedures such as circumcision.
A single dose of fructose immediately will induce hypophosphatemia, 
generalized hyperaminoaciduria, RTA, proteinuria, and phosphaturia; mild 
glucosuria may be present. Liver failure may result in high plasma concen­
trations of tyrosine and methionine, and thereby in a pattern of amino­
aciduria similar to that seen in tyrosinemia. Removal of fructose and su­
crose from the diet results in normalization of tubular function within 2 
weeks.
Hepatorenal Tyrosinemia. Hereditary tyrosinemia type I (i.e., hepa­
torenal tyrosinemia, tyrosinosis) is an autosomal recessive disorder due to a 
deficiency in fumarylacetoacetate hydrolyase (i.e., fumarylace-toacetase); 
maleylacetoacetate hydrolyase may be decreased as well. More than 100
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cases have been reported. Accumulation of succinylace-toacetate and suc- 
cinylacetone results in renal tubular dysfunction and inhibition of hepatic 
metabolism of tyrosine and of porphobilinogen synthase.
Clinical presentation includes failure to thrive, a cabbagelike odor, 
vomiting, diarrhea, severe metabolic acidosis, hepatomegaly, jaundice, 
melena, as-cites, edema, fever, and tubular dysfunction. Renal dysfunction 
includes hyperaminoaciduria, severe phosphaturia, and mild proteinuria, but 
no glucosuria. The acute form of tyrosinemia type I is associated with liver 
failure and death by the age of 1 year in most untreated patients. Removal 
of phenylalanine, tyrosine, and methionine from the diet results in normali­
zation of tubular function but does not prevent liver failure.
Oculocerebrorenal Dystrophy. More than 100 cases of Lowe syn­
drome (i.e., oculocerebrorenal dystrophy) have been reported. Fanconi syn­
drome appears in infancy, includes proteinuria, generalized aminoaciduria, 
phosphaturia, intermittent glucosuria, RTA, and carnitine wasting, and 
causes rickets and failure to thrive. Glomerular involvement develops pro­
gressively in childhood and eventually leads to renal failure. The treatment 
includes alkalinization therapy and supplements of potassium, phosphate, 
calcium, and carnitine.
NEPHROGENIC DIABETES INSIPIDUS
The differential diagnosis of polyuria in infancy includes central dia­
betes insipidus and nephrogenic defects in urinary concentration. The latter 
defects can result either from a decreased effect of ADH on tubular perme­
ability to water or from a decreased corticomedullary osmotic gradient (Ta­
ble 60). Several entities, congenital or acquired, may result in impaired uri­
nary concentration. Many of these disorders are discussed in other sections 
of this chapter or in Chapter 41; therefore, only NDI is reviewed here.
PATHOPHYSIOLOGY
Nephrogenic diabetes insipidus is characterized by lack of V2 recep­
tor-mediated response to arginine vasopressin. This disorder usually is 
transmitted as an X-linked recessive trait, but other modes of transmission 
have been proposed. The NDI gene has been mapped to the distal long arm 
of chromosome X by linkage analysis of affected kindreds with restriction 
fragment length polymorphism. The molecular basis for the disease has not 
been determined.
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Tab le  60
Etiology of nephrogenic defect in urinary concentration
Decreased Effect o f  A ntidiu­
retic Horm one on Tubular 
Permeability to W ater Gradi­
ent
Decreased Corticom edullary 
Concentration
Congenital Medullary cystic disease, polycystic kidney
Nephrogenic diabetes insipidus disease
Bilateral dysplastic kidneys
Hypokalemia 
Bartter syndrome 
Hyperprostaglandinuric tubu­
lar syndrome
Pseudohypoaldosteronism 
Proximal renal tubular acido­
sis
Duplication of the mitochon-
Urinary tract obstruction
drial genome 
Acquired
Polyuria (i.e., water/osmotic diuresis)
Drugs (e.g., PGE2, PGEj am- Obstructive disease before and after treatment
photericin, lithium) Hypo- Chronic or acute renal failure
kalemia Pyelonephritis
Hypercalcemia Nephrocalcinosis 
Medullary necrosis 
Malnutrition
PG - prostaglandin.
CLINICAL PRESENTATION AND DIAGNOSIS
Most patients with congenital NDI present with polyuria, dehydration, 
fever, and constipation. If untreated, mental retardation may develop. Perti­
nent laboratory findings include a persistently low urine osmolality, even if 
there is evidence for dehydration, and hypernatremia. There is no other evi­
dence of tubular dysfunction.
The diagnosis of NDI is confirmed by the failure to respond to intra­
nasal administration of DDAVP, in contrast to patients with central diabetes 
insipidus. The response of urinary cAMP can be compared to that seen in 
vasopressin-sensitive diabetes insipidus (i.e., 200%-250% increase). Diag­
nosis in utero can be made by linkage analysis if other family members 
have the disease. Female carriers do not present with any symptomatology, 
but they may have mild impairment of urine-concentrating ability.
TREATMENT
Thiazide diuretics result in a decrease in urine output. Prostaglandin 
synthesis inhibitors, especially indomethacin, additionally reduce urine out­
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put; successful long-term results are obtained in most patients, in associa­
tion with a decrease in urinary PGE2 excretion. The most common therapeu­
tic regimen is the combination of chlorothiazide, indomethacin, and potas­
sium supplements. Preliminary data suggest that an alternative may be the 
use of amiloride and hydrochlorothiazide, without potassium supplements.
HYPOKALEMIC ALKALOSIS
The differential diagnosis of hypokalemic alkalosis in infancy is 
given in Table 61. The discussion in this section is limited to the renal 
causes.
BARTTER SYNDROME
Bartter syndrome is a sporadic or familial disorder, characterized by 
hypokalemic alkalosis, impaired urinary-concentrating ability, hyperaldos­
teronism, hyperreninemia, hyperplasia of the juxtaglomerular apparatus, and 
normal blood pressure. The etiology presumably is a PG-independent defect 
of chloride transport at the level of the thick ascending loop of Henie. Hy- 
perkaliuria may result from the primary defect itself, from increased distal 
flow, or from secondary hyperaldosteronism. Hypokalemia stimulates PGE2 
anci prostacyclin synthesis; the latter, together with increased serum bra- 
dykinin concentration, leads to generalized vasodilation. High PRA and 
sympathoadrenal activity are critical in maintaining a normal blood pres­
sure, whereas hypersecretion of PGE2 and bradykinin results in pressor re­
sistance to angiotensin II and norepinephrine. Decreased urinary diluting 
ability results from the defect in chloride reabsorption, whereas decreased 
urinary concentrating ability results from the combination of hypokalemia, 
increased PGE2, and a decreased corticomedullary gradient. The defect in 
chloride reabsorption in the thick ascending loop of Henie could be the 
cause of decreased magnesium reabsorption in that segment. In addition, pa­
tients with Bartter syndrome have a circulating inhibitor of platelet aggrega­
tion, which results from PG metabolism disturbance.
Table 61
____________ Differential diagnosis of hypokalemic alkalosis _________
Inadequate intake 
СГ-deficient diet
Insufficient К and Cl intravenously 
Gastrointestinal losses 
Vomiting, pyloric stenosis 
Gastric suction 
СГ-diarrhea 
Kidney
Diuretics (e.g., loop diuretics, thiazides)
Hypovolemia and other cause for hypokalemia (e.g., proximal RTA, cystinosis) 
Bartter syndrome__________________________________________________
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Gitelman syndrome
Hypercalciuria syndrome with hyperprostaglandinuria 
Endocrine
Primary hyperaldosteronism
Gushing syndrome
Congenital adrenal hyperplasia with hypertension 
1 ip-Hydroxylase deficiency 
17a-Hydroxylase deficiency 
1 lP-Hydroxysteroid dehydrogenase deficiency
Cystic fibrosis_____________________________________________________
RTA - renal tubular acidosis.
Patients with Bartter syndrome typically present with failure to thrive, 
polyuria, polydipsia, and a tendency to dehydration. Bartter syndrome may 
present rarely in the neonatal period. In contrast to adults, nephrocalcinosis 
secondary to hypercalciuria develops in children with Bartter syndrome.
Laboratory abnormalities include hypokalemic, hypochloremic alka­
losis, elevated PRA, a high serum aldosterone, creatinine, and uric acid, and 
low magnesium concentration. Renal abnormalities include hyperkaliuria, 
hypercalciuria, high excretion of PGE2 and 6-keto-prostaglandin-I,a (6-keto- 
PGI|a), decreased fractional water clearance, decreased concentrating ability 
and, in some patients, high excretion of magnesium.
The treatment includes supplementation with KC1 and, if necessary, 
MgCI2. If this is insufficient, either a potassium-sparing diuretic or a PGSI 
is indicated. The administration of indomethacin decreases PG, bradykinin, 
PRA, and sympathoadrenal activity, but fails to correct the hyperkaliuria 
and the chloride reabsorption defect, as shown by persistence of impaired 
concentration and dilution ability.
HYPERPROSTAGLANDINURIC TUBULAR SYNDROME
This syndrome has also been called calcium-losing tubulopathy, hy- 
percalciuric Bartter syndrome, and congenital hypokalemia with hypercal­
ciuria. Although it was thought initially to be a neonatal variant of Bartter 
syndrome with enhanced renal and systemic formation of PGE2, the primary 
cause probably is a defect in tubular calcium reabsorption, rather than high 
secretion of PGE2 or a defect in tubular chloride reabsorption. Although the 
disorder shares several features with Bartter syndrome, hyperkaliuria is not 
as severe, and spironolactone administration results in normalization of the 
urinary excretion of potassium. In addition, the fractional excretion of water 
is normal. Prostaglandin E2 hyper-secretion contributes to increased bone 
resorption, increased renal 1-a-hydroxylase, decreased tubular reabsorption 
of calcium, and decreased urinary concentration ability.
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Clinical features include polyhydramnios, premature labor, failure to 
thrive, and episodes of fever, vomiting, diarrhea, renal electrolyte and water 
wastage, and hypercalciuria with nephrocalcinosis and osteopenia.
Laboratory abnormalities are similar to those seen in Bartter syndrome, 
except that there is no increase in prostacyclin, hypokalemia may be mild or 
intermittent, and fractional water excretion is normal.
Prolonged treatment with indomethacin results in substantial im­
provement of clinical and most biochemical features, although some degree 
of hypercalciuria persists. The response to indomethacin is much better than 
in Bartter syndrome.
GUELMAN SYNDROME
Gitelman syndrome or magnesium-losing nephropathy (i.e., primary 
renal tubular hypokalemic metabolic alkalosis with hypocalciuria and mag­
nesium deficiency) is a benign autosomal recessive disorder that frequently 
is complicated by febrile seizures and tetanic episodes. It is not associated 
with polyhydramnios, prematurity, defect in urinary concentration, or hy­
percalciuria.
RENAL TUBULAR ACIDOSIS
Metabolic acidosis in newborn infants usually is normochloremic with 
an increased serum anion gap. The most common cause is lactic acidosis re­
sulting from asphyxia, ischemia, hypoxemia, or local tissue damage. Less 
commonly, it is due to a congenital metabolic disorder or to renal failure.
Hyperchloremic metabolic acidosis results from bicarbonate losses 
through the gastrointestinal tract or the urinary tract. Increased bicar- 
bonaturia may result from either renal tubular acidosis (RTA) or a defect in 
urinary acidification attributed to a deficit in distal sodium delivery; the lat­
ter commonly is observed in association with diarrhea. In contrast to adults, 
the urinary anion gap is not a valid measurement in newborn infants.
Clinical presentation of RTA includes polyhydramnios, polyuria with 
episodes of dehydration, failure to thrive, vomiting, and serum biochemical 
disturbances. Failure to thrive appears to be a direct consequence of acido­
sis; correction of acidosis often results in catch-up growth, unless other 
complications (e.g., rickets, renal failure) have developed.
DIFFERENTIAL DIAGNOSIS
Four types of RTA have been described: classical distal (i.e., type I), 
proximal RTA (i.e., type II), hyperkalemic distal (i.e., type IV), which is the 
most common type of RTA, and mixed proximal and distal (Table 62). The 
differential diagnosis depends on the findings of hypertension, hyponatre­
mia and salt wasting, hyperkalemia, generalized proximal tubular dysfunc­
tion, decreased ability to acidify the urine, UTI, nephrocalcinosis, or urinary
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tract malformation. Further workup (e.g., measurement of urinary ammo­
nium, titratable acid, or PC02; ammonium chloride, sodium sulfate, or bi­
carbonate loading) may be required in specific cases, in consultation with a 
nephrologist.
PROXIMAL RENAL TUBULAR ACIDOSIS
Proximal RTA or type II may be caused by a defect of one of the 
mechanisms involved in bicarbonate absorption in the proximal tubule or 
occur in association with other signs of proximal tubular dysfunction (e.g., 
Fanconi syndrome). Although it may be a primary defect, it is associated 
most often with other entities. The diagnosis is suspected when the serum 
bicarbonate concentration is low for age and urinary pH is adequately low 
in the presence of mild to moderate acidosis. The diagnosis is confirmed ei­
ther by the presence of a Fanconi syndrome, or by measuring the urinary 
concentration of bicarbonate at various serum levels during a bicarbonate 
infusion.
Treatment consists in the administration of sodium bicarbonate or cit­
rate (initially at 5-10 mEq/kg/day) and potassium citrate. In some patients, 
acidosis will persist despite administration of high doses of alkali; hydro­
chlorothiazide or PGSI may be beneficial. Patients with Fanconi syndrome 
require additional therapy.
DISTAL RENAL TUBULAR ACIDOSIS
Several criteria have been proposed for the diagnosis of defects in 
distal RTA, including the inability to decrease urinary pH during metabolic 
acidosis, limited urinary ammonium concentration, limited urinary PC02, 
and decreased difference between urinary and arterial blood PC02.
Hyperkalemic Distal Renal Tubular Acidosis. Hyperkalemic distal 
RTA or type IV is the most common type of distal RTA. It results from the 
association of defects in K+ and H+ secretion at the level of the collecting 
duct.
Primary type IV RTA or early-childhood hyperkalemic RTA has been 
described in some infants and children who presented with failure to thrive 
and frequent vomiting. These patients had isolated signs of distal RTA with 
hyperkalemia, without nephrocalcinosis, and responded very well to alkali 
therapy.
Type IV RTA can be associated with a variety of disorders. These sec­
ondary cases of type IV RTA can be divided into five groups (see Table 62). 
Subtype 1 is caused by primary aldosterone deficiency or adrenal insuffi­
ciency in the absence of intrinsic renal disease. Subtypes 2 and 3 are caused 
by hyporenine-mic hypoaldosteronism secondary to advanced renal disease, 
and are very rare in infancy. Subtypes 4 and 5 are caused by unresponsive­
ness to aldosterone.
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The treatment of type IV RTA includes correction of the metabolic 
acidosis, limitation of potassium intake, and specific therapy for each spe­
cific disorder.
C lassic  D ista l R enal T u b u la r  A cidosis. In classic or type I RTA, 
there is no defect of potassium secretion; nephrocalcinosis and nephrolithi­
asis are common. The development of nephrocalcinosis is attributed to the 
association of hypercalciuria, high urine pH, and low citraturia.
Idiopathic RTA type I in infants can be associated with bicarbonate 
wastage. It can be hereditary, and may be associated with several other con­
ditions (see Table 62).
Table 62
Etiology of renal tubular acidosis in infancy 
Proximal R T A  (Type 2) Hyperkalem ic R TA  (Type 4)* D istal R TA  (Type 1) M ixed  (Type 3)
Primary
AR. AD
Sporad ic  transient
Secondary
Fancon isynd rom e 
Metachrom atic leukodystrophy^ 
M itochondrial d iseases 
Hereditary nephritis 
Tetralogy of Pallet1 
V itam n  D  deficiency 
Vascu la r accident in neonatal pe­
riod
rered itary nephritis 
Carbon ic  anhydrsse  inhibition 
Carbon ic  anhydrase  И deficiency 
with osteopetrosis iARt 
D ru g s  and toxins ( e . j , valproic 
acic, heavy metals)
Early ch ildhocd hyperkalen ic  RTA
1: Prim ary hypoaldostercnism . adre­
nal insufficiency
2 -3 :  Hyporenmemic hypoaidosier- 
cn ism  with chronic 'e m ! disease5 
A iPseudohypoa ldcste ron ism w ith  
or w ithout salt wasting 
5: Partial unrespensiveness tc a ldo­
sterone
Toxins, drugs, К -sparing diuret­
ics
Tubulointerstitial disease
Urinary tract oostn ictior, У П
Unilateral dysplastic kidney or 
PVT
D ru g s  (e.§.. KC1, К-sparing di-
W ilh  bicarbonate w asting in infancy 
and  early childhood 
А Я  with ^nso r ineu ra ! deafness 
AD. sporadic 
W ith cystic fibrosis
Hypergam maglobulinem ia (i.e., ma­
ternal Sjogren syndrom e)
Fetal alcohol syndrome 
Toluene, amphotericin L i t h i u m  
Hypercalcemic hyperthyroidism  
Vitamin D  intoxication 
Nephrocalcinosis 
Medullary sponge  kidney 
Urinary tract obstruction 
Carnitine palmitoyltransferase type 1 
deficiency '
Carbon ic  anhydrase d deficiency 
with osteopetrosis (ARj
Familial hyperparathyroidism with 
hypercalciuria and R TA  (Nishi- 
ya rna®!
V LB W  infant
Carbonic anhydrase  ii deficiency 
with osteopetrosis (AR) 
Hyperparatnyrcidism 
N ephroca lc inosis and Fanconi 
syndrom e
Renal transplaniailon
uretiCS. heparin A C E  inhibi­
tors, P 3S I.  cyclosporine)
Renal tubular acidification may also be deficient in the case of renal failure (i.e., normo- 
chloremic metabolic acidosis) or of acute diarrhea (i.e., hypochloremic metabolic acido­
sis).
* Numbers represent subtypes.
ł The only patients with this type of RTA were diagnosed after more than 12 months of 
age
t  Subtypes 2 and 3, associated with hyporeninemic hypoaldosteronism, are mostly seen in 
adults.
ACE - angiotensin-converting enzyme; AD - autosomal dominant; AR - autosomal re­
cessive; PGSI - prostaglandin synthetase inhibitor; RTA - renal tubular acidosis; RVT - 
renal venous thrombosis; UTI - urinary tract infection; VLBW - very low birth weight
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The treatment includes the administration of sodium bicarbonate or cit­
rate and potassium citrate. Administration of citrate is important for the pre­
vention of nephrolithiasis.
Mixed Renal Tubular Acidosis. In some disorders, both proximal 
and distal RTA are present; this is known as mixed RTA or type III (see Ta­
ble 62). Very-low-birth-weight infants during the first days or weeks of life 
have a mild degree of mixed tubular acidosis, with lower normal values of 
serum bicarbonate concentration and higher urine pH despite metabolic aci­
dosis.
HYPERPHOSPHATURIC SYNDROMES
Hyperphosphaturia results from decreased proximal tubular reabsorp­
tion. Whereas severe hypophosphaturia may result from hyperparathyroidism 
or Fanconi syndrome, mild hyperphosphaturia occurs in association with the 
administration of diuretics (e.g., loop diuretics, carbonic anhydrase inhibitors, 
thiazides) or proximal tubular toxicity from drugs or toxins. Other causes of 
hypophosphatemia such as vitamin D-deficiency rickets and hypophos­
phatemia of the premature infant caused by insufficient phosphate intake are 
discussed in Chapter 36.
FAMILIAL HYPOPHOSPHATEMIC RICKETS
OR VITAMIN D-RESISTANT RICKETS
This is the most common disease associated with hyperphosphaturia 
in infancy. It is transmitted most often as an X-linked disorder.
Clinical signs, including bone deformations, usually appear after the 
first year of life. Hypophosphatemia and low tubular reabsorption of phos­
phate can be detected during the first month of life when family cases are 
known.
The treatment includes oral supplementation with sodium and potas­
sium phosphate and l,25(OH)2D3.
VITAMIN D-DEPENDENT RICKETS
OR PSEUDOVITAMIN D-RESISTANT RICKETS
In this disorder, increased phosphaturia is due to hyperparathyroid­
ism. In type 1, which is the most frequent and is transmitted as an autosomal 
trait, hyperparathyroidism results from a defect of renal synthesis of 
l,25(OH)2D3 due to a defect of 1-a-hydroxylation in the proximal tubule. In 
type 2, there is a lack of sensitivity of target organs to l,25(OH)2D3 which, 
at least in some patients, is due to defective nuclear uptake of the hormone.
This disorder presents during infancy with typical signs of rickets in­
cluding hypotonia, tetany, irritability, motor retardation, deformations and 
growth failure. Some patients with type 2 have alopecia. Serum levels of 
l,25(OH)2D3 are lower than normal in type 1 and very high in type 2. At
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birth, serum calcium and phosphate levels are normal, but gastrointestinal 
absorption of calcium is decreased.
Patients with type 1 respond to the administration of physiologic 
doses of l-a-OHD3 or l,25(OH)2D3. In type 2, a response is observed only 
when extremely high doses are used.
GLUCOSURIA
Several disorders are associated with renal glucosuria: an isolated de­
fect, or primary glucosuria, which is a benign condition; congenital glucose- 
galactose malabsorption; Fanconi syndrome; and other rare entities. They 
all are associated with mild to moderate glucosuria, which does not require 
specific therapy.
In VLBW infants, the incidence of glucosuria is increased because of 
two factors: decreased tubular re-absorption of glucose and instability of gly- 
cemia. At a mean GA of 29 weeks, glucosuria appears when glycemia ex­
ceeds 152 ± 8 mg/dL. This may lead to osmotic diuresis, which is associated 
with loss of several electrolytes, especially sodium and potassium, and may 
cause severe dehydration. The treatment includes careful replacement of the 
urinary losses. Prevention of hyperglycemia is a much better approach. Gly­
cemia should be kept at a maximum of 120 to 150 mg/dL, using insulin if re­
quired in specific patients.
URIC ACID
INCREASED SERUM URIC ACID CONCENTRATION
Because the risk of uric acid precipitation is favored by a high urinary 
concentration and a low urine pH, the newborn infant is at relatively low risk 
for tubular obstruction by uric acid crystalluria, despite low ability of the 
immature renal tubule to reabsorb uric acid. Drug-induced decrease in uric 
acid excretion (e.g., secondary to diazoxide, diuretics, dopamine, etham- 
butol) may result in higher serum levels but not in renal toxicity. Uric acid 
crystalluria with tubular obstruction has been described rarely in newborn in­
fants with ARF secondary to perinatal asphyxia; the treatment is nonspecific. 
The prevention of uric acid nephropathy in patients at high risk includes 
maintaining a high tubular flow rate by the administration of high volumes of 
alkaline fluids. Allopurinol is indicated for infants with hyperuricemia secon­
dary to neoplasia.
DEFECTS OF TUBULAR HANDLING OF URIC ACID 
Increased urinary excretion of uric acid may result from various medi­
cations (e.g., ascorbic acid, glycine, citrate, and iodinated radiocontrast 
agents) and rare defects of tubular handling of uric acid. These disorders may 
be suspected on the basis of family history, low serum concentration of uric 
acid, or crystalluria. Early diagnosis may allow specific therapy and preven­
tion of urolithiasis, which may develop in childhood.
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CONGENITAL NEPHROTIC SYNDROME
Nephrotic syndrome is defined by the association of marked proteinu­
ria (>1 g/m2/day) with hypoalbuminemia (<2.5 g/dL). A nephrotic syn­
drome is called congenital if it presents within the first 3 months of life; this 
definition is based on the natural history of the Finnish type, the most com­
mon type of nephrotic syndrome in newborn infants.
FINNISH TYPE
CLINICAL PRESENTATION AND LABORATORY FINDINGS
The incidence of CNF is estimated to be 1.2 per 10,000 births in 
Finland; CNF should be suspected if there is a history of CNF in a sibling, 
hydrops fetalis or edema of the placenta (i.e., placental weight > 25% of 
birth weight), or an elevated a-fetoprotein or total protein concentration in 
the amniotic fluid. Since the disease begins in utero in all patients, an in­
creased a-fetoprotein (>10 SD above the mean amniotic fluid concentration 
during the second trimester) is a reliable indicator of the disease.
The natural history of the disease is based on experience before the 
availability of renal transplantation in young patients. The mean GA was 
36.6 ± 1.8 weeks (mean ± SD), and 42% of the infants were premature (<37 
weeks of GA). Many infants were SGA, especially those with a GA at or 
above 37 weeks. In some patients, the typical signs of nephrotic syndrome 
(i.e., edema, proteinuria, hypoalbuminemia) did not develop until the third 
month of life. The evolution of the disease was not affected by the admini­
stration of steroids or cytotoxic medications. Complications included severe 
failure to thrive and ascites in all patients, severe bacterial infections in 
85%, pyloric stenosis in 12%, and thrombotic events in 10%. An increase in 
Pcr or BUN was observed in approximately 20% of the patients, but none 
had frank uremia. One-half of the patients died by 6 months of life, and all 
of them by 4 years. The immediate cause of death appeared to be infection 
in one third. Autopsy showed thrombi in large vessels in 19%. Since this 
early report, aggressive management has considerably improved the sur­
vival rate.
The proteinuria, initially very selective (i.e., almost entirely albumin 
as a result of increased permeability of the glomerulus only for small pro­
teins), increases progressively and becomes nonselective, corresponding to 
increased sieving coefficient and to tubular damage. Blood chemistry is sig­
nificant for low serum albumin concentration and total thyroxine concentra­
tion as a result of low thyroxine-binding globulin, a normal or mildly ele­
vated Pcr, and hyperlipidemia. Ultrasonography shows enlarged kidneys, in­
creased echogenicity of the renal cortex compared to the liver and the 
spleen, decreased differentiation between cortex and medulla, and poor 
visualization of the pyramids. Tubular dilations may be misinterpreted as
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other causes of cystic disease, including ARPKD. The diagnosis is con­
firmed by renal biopsy.
HISTOPATHOLOGY
Although the basic defect in CNF is unknown, the pathologic findings 
are characteristic. Glomerular changes are seen by scanning electron micros­
copy in human fetuses at 13 to 24 weeks of GA. Renal biopsy in infancy 
shows irregularities of the glomerular basement membrane and thinning of 
the lamina densa, followed by fusion of the epithelial cell foot processes, all 
of which are similar to the findings in minimal-change, steroid-sensitive 
nephrotic syndrome. On light microscopy, the mature glomeruli initially 
typically show only minimal abnormalities, including mild mesangial hyper- 
cellularity and an increase in mesangial matrix. Immature-appearing 
glomeruli show a dilated urinary space surrounding a small glomerular tuft. 
Progressive changes include obliteration of capillary loops and glomerular 
hyalinization. Immune deposits become visible by electron microscopy 
within the mesangium only at late stages of the disease.
Except in the early stages, the biopsy frequently shows dilated tubules 
from both proximal and distal origin (e.g., microcystic disease). Although 
these tubular changes have been used by some neonatologists as a diagnostic 
criterion, they are not pathognomonic and have caused some confusion in the 
differential diagnosis. Although the etiology of the tubular dilation is un­
known, it has been attributed to the heavy proteinuria. Progressive interstitial 
fibro-sis and tubular atrophy develop; the latter is well correlated with in­
creasing proteinuria.
TREATMENT AND PROGNOSIS
Infants with CNF require intensive management, which includes re­
petitive administration of albumin and diuretics for ascites, oral and par­
enteral hyperalimentation, and the treatment of multiple complications. 
Chronic renal insufficiency develops between 6 and 23 months of age. As a 
consequence, most patients eventually receive dialysis while waiting for 
transplantation. All reported infants treated before the availability of renal 
transplantation died, mostly of infection. In one report, of the 17 patients 
who received renal transplantation, the 2-year patient and graft survival 
rates were 82% and 71%, respectively. Recurrence of nephrotic syndrome 
was not observed after transplantation. Most infants had a normal or accel­
erated growth, although the mean height remained significantly lower than 
normal. Although 16 of 17 had delayed psychomotor development at the 
time of transplantation, marked improvement was evident 1 year later, and 
12 of 15 surviving children had normal school and social performance.
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OTHER CAUSES
DIFFERENTIAL DIAGNOSIS
Several entities are associated with congenital nephrotic syndrome. 
An increase in a-fetoprotein in the amniotic fluid may be observed, but this 
is far less consistent than in CNF. Although therapy with corticosteroids and 
cytotoxic agents invariably has proven ineffective, specific therapy may be 
available for some patients (e.g., those with congenital infection). Classifi­
cation of a patient into one of the major entities may not be possible.
DIFFUSE MESANGIAL SCLEROSIS
The second most common cause of congenital nephrotic syndrome is 
diffuse mesangial sclerosis which appears to be a heterogenous group. The 
onset may be as late as 1 year of life. In contrast to CNF, CRF develops rap­
idly in these patients, and is the major cause of death in the absence of di­
alysis and renal transplantation. Renal venous thrombosis is a frequent 
complication. In most families, diffuse mesangial sclerosis is transmitted as 
an autosomal recessive trait. Histologic examination of the glomeruli shows 
mesangial cells embedded in a periodic acid-Schiff-positive and silver­
positive fibrillar network occluding the capillaries. Tubular changes are 
similar to those seen in CNF, and interstitial fibrosis is more pronounced 
than in CNF.
In some infants, diffuse mesangial sclerosis is part of a Drash syn­
drome, which also includes ambiguous genitalia—most often male pseudo­
hermaphroditism (i.e., 46XY karyotype)—and Wilms tumor. Patients present 
between 2 weeks and 33 months of age with proteinuria, with or without 
nephrotic syndrome, sometimes hematuria, often arterial hypertension and 
progressive CRF leading to ESRD within a few months to 2 years from the 
onset. Several patients have presented with incomplete forms of Drash syn­
drome (i.e., only two of the three signs of the triad).
CONGENITAL INFECTION
Nephrotic syndrome due to congenital infection is seen most com­
monly in congenital syphilis, in which case the lesion is characterized by 
epimembranous or proliferative glomerulopathy, with diffuse deposits of y- 
immunoglobulin and treponemal antigen along the glomerular capillaries 
and subepithelial electron-dense deposits. The condition responds very well 
to the administration of penicillin. The nephrotic syndrome associated with 
congenital toxo-plasmosis is less common; the lesion is characterized by the 
deposition in the glomeruli of immunoglobulins, complement, and 
Toxoplasma antigen and antibody. It may respond to administration of 
pyrimethamine, sulfadiazine, and steroid. Only one case of congenital 
nephrotic syndrome has been reported in association with congenital cy­
tomegalovirus infection; whether or not the nephrotic syndrome was medi­
ated by the infection was uncertain.
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OTHER CAUSES
Even though some infants with congenital nephrotic syndrome have 
been found to have minimal change disease on biopsy, corticosteroid and cy­
clophosphamide therapy has not proven useful. Some cases of congenital 
nephrotic syndrome are associated with dysmorphic features, such as pachy­
gyria, microcephaly, buphthalmos, or disturbances of neuronal migration.
Transient cases of congenital nephrotic syndrome have been de­
scribed due to maternal transmission, intoxication with mercury, or nail pa­
tella syndrome. One 3-month-old infant with infantile systemic lupus ery­
thematosus reportedly had steroid-responsive membranous glomerulopathy.
HEMATURIA AND PROTEINURIA
DIFFERENTIAL DIAGNOSIS OF HEMATURIA
Pink or red urine or coloration of the diaper may result from hema­
turia, hemoglobinuria, myoglobinuria, uric acid, or bile pigments. The pres­
ence of blood on the diaper may also result from rectal bleeding or vaginal 
mucoid sanguinous discharge caused by maternal hormone withdrawal. On 
a dipstick test, the reagent strip based on the orthotolidine peroxidase reac­
tion will give a positive reaction with hemoglobinuria, myoglobinuria, he­
maturia, or other oxidants, such as hydrogen peroxide and ascorbic acid. A 
dipstick can detect 5 to 20 intact erythrocytes per microliter of urine, and 
0.05 to 0.3 mg of free hemoglobin/100 mL urine, which corresponds to 2-10 
lysed erythrocytes per microliter. The diagnosis of hematuria requires the 
visualization of an excessive number of erythrocytes in an uncontaminated 
specimen of urine.
Significant hematuria in childhood has been defined as at least 5 
erythrocytes per high-power field in-the sediment of freshly centrifuged 
urine, at least 6 erythrocytes per 0.9 pL of unspun urine, or an Addis count 
of at least 129,000 to 800,000 erythrocytes per 12 hours. During the first 
week of life, Addis counts in normal full-term newborn infants do not ap­
pear to be different from those reported in older children and range between 
0 and 630,000 erythrocytes per 12 hours (mean, 90,219). Erythrocytes are 
most abundant during the first few days of life. Although most urine sam­
ples during the first week of life contain zero to four erythrocytes per micro­
liter, more than one-half of the samples do not contain any erythrocytes. Af­
ter the first week of life, erythrocytes are sparse. The presence of erythro­
cyte casts always is abnormal.
INCIDENCE
Gross hematuria during the first month of life occurred in 35 of 
132,050 admissions (0.21/1000) to a major tertiary center between 1950 and 
1967. In a more recent series, the incidence of hematuria during the first 48 
hours of life was much lower in normal full-term infants (0/63) than in pa­
tients admitted to the NICU (48/78); none of these patients, however, had
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abnormalities on physical examination or had proteinuria, hypertension, or 
abnormal values of Pcr or BUN. Transient hematuria was found in 76% of 
asphyxiated newborns. In another series, hematuria was estimated to occur 
in 62% of newborn infants with UA catheter in place and US evidence of an 
arterial clot, and in 25% in those without evidence for a dot. Hematuria was 
present in one-half of infants with ARF secondary to cardiac surgery, and in 
two thirds of newborn infants with irreversible ARF.
ETIOLOGY
Hematuria may occur in a wide variety of diseases, including bleeding 
diathesis and renal and postrenal disorders. Prostaglandin synthesis inhibitor- 
mediated hematuria may be due to platelet dysfunction, ATN, or tubular dys­
function. Congenital infections (e.g., syphilis, toxoplasmosis, cytomegalovi­
rus) may cause thrombocytopenia or, rarely, glomerulonephritis. Common 
congenital causes of hematuria include hydronephrosis, PKD, tumors, and 
sponge kidneys. Although before 1967 the only commonly recognized ac­
quired etiology of hematuria in the newborn infant was renal venous throm­
bosis, neonatal hematuria is known to be secondary often to asphyxia, coagu­
lation abnormalities, infectious and vascular disorders, and nephrotoxicity.
EVALUATION
The first step is to confirm the diagnosis of hematuria by the demon­
stration of erythrocytes in ffesh urine voided spontaneously or after suprapu­
bic pressure. Suprapubic aspiration is contraindicated, because it can cause 
microscopic or macroscopic hematuria. If the patient is anuric, despite treat­
ing any condition associated with prerenal failure and despite a diuretic chal­
lenge and a fluid challenge, the bladder should be catheterized using a lubri­
cated 3.5- to 5-Fr catheter.
The history may disclose familial nephritis, and maternal history may 
be positive for diabetes (suggesting renal venous thrombosis, infection, 
thrombocytopenia, glomerulonephritis), and autoimmune disease, or recent 
use of PGSI. The patient’s history should be reviewed, especially for as­
phyxia, sepsis, shock, hypertension, renal failure, medications, and place­
ment of a UA line. Pertinent points in the physical examination include hy­
pertension; bruising; edema suggesting ARF or glomerulonephritis; an ab­
dominal mass that may indicate hydronephrosis, cystic disease, adrenal 
hemorrhage, and, rarely, renal trauma; and bruit (suggesting renovascular 
disease). In some patients, the presumptive etiology is obvious (e.g., bleed­
ing disorder, bladder trauma, severe asphyxia, ATN, renovascular disease, 
glomerulonephritis, nephrotic syndrome).
The initial workup should include a microscopic examination of the 
urine, dipstick test, and measurement of urine output, BUN, and Pcr. In addi­
tion, most patients should have a bladder and renal US and a urine culture.
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Microscopic examination of the urine may show dysmorphic erythrocytes or 
erythrocyte casts indicating glomerulonephritis, crystalluria as a result of 
rapid administration of acyclovir to a dehydrated patient, bacteriuria, or 
yeast forms, and the dipstick may show glucosuria or proteinuria. If any of 
these is present, further, specific investigations should be obtained. If a 
glomerular disease is suspected, fresh urine should be examined using phase 
contrast microscopy, which is the method of choice for identifying the pres­
ence of dysmorphic erythrocytes. The origin of the hematuria cannot be as­
sessed by microscopic analysis when the hematuria is massive.
Transient microscopic hematuria during the first 48 hours of life may 
be insignificant, as long as the infant is asymptomatic (i.e., has no bleeding 
diathesis) and does not exhibit other evidence of a renal lesion (e.g., no fa­
milial renal disease; normal physical examination, biood pressure, Pcr, US 
and BUN; no erythrocyte casts in the urine).
In patients with macroscopic hematuria, the first diagnoses to exclude 
are bleeding disorder, trauma, and cystitis. In those patients, coagulation 
tests, platelet count, and bleeding time should be assessed, and a renal and 
bladder US should be obtained. Purpura, excessive bleeding after venipunc­
ture, or thrombocytopenia suggests that hematuria is due to a bleeding dis­
order. Specific treatment for sepsis or endocarditis and the bleeding disorder 
should be initiated. If renal function and urine output are normal, and hema­
turia disappears after resolution of the bleeding diathesis, no additional re­
nal workup is required. It should be remembered, however, that thrombocy­
topenia with hematuria may occur in association with renal diseases, such as 
renal venous thrombosis and UTI with sepsis. Macroscopic hematuria also 
may occur after suprapubic aspiration or catheterization of the bladder; if 
hematuria disappears rapidly, US is normal, and urine output, BUN and Pcr 
remain normal, no additional investigations are required. In patients with 
massive hematuria in whom a bleeding disorder has been excluded, cysto­
scopy should be performed, unless the presumptive etiology is renal.
All other patients should have a urine culture, as well as a renal and 
bladder US, which may disclose an intravascular thrombus, renal venous or 
arterial thrombosis, cystic kidney disease, iithiasis or nephrocalcinosis, hy­
dronephrosis, adrenal hemorrhage, or other anomalies. The association of 
hematuria with UA catheterization, an abdominal bruit, or blanching of the 
lower extremities, especially with hypertension, strongly suggests the diagno­
sis of a renovascular etiology. Hematuria is an unusual complication of 
nephrolithiasis or nephrocalcinosis during the neonatal period; it has been re­
ported in one 10-week-old patient with familial hypercalciuria.
Glomerulonephritis is a rare occurrence in newborn infants. It should 
be suspected if the patient has either hydrops or generalized edema with 
massive proteinuria or erythrocyte casts or dysmorphic erythrocytes. Al­
though hematuria of glomerular origin is suggested by the presence of
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erythrocyte casts, severe proteinuria, or dysmorphic erythrocytes, it is not 
excluded by their absence. These patients should be assessed for possible 
congenital syphilis, toxoplasmosis, cytomegalovirus infection, various 
causes of nephrotic syndrome, familial nephritis, and immune-mediated 
glomerulonephritis. A decrease in the serum concentration of the third frac­
tion of complement has been described in glomerulonephritis due to con­
genital syphilis and in one mother-infant pair with a benign glomeru­
lonephritis with isolated hematuria. Consultation with a pediatric nephrolo­
gist should be obtained, and a renal biopsy should be considered.
For the other patients, the differential diagnosis includes a wide range 
of diseases; US is the most important initial investigation. Further workup 
depends on the clinical presentation (e.g., hypertension, ARF) or presumed 
etiology (e.g., ATM, cystic disease, tumor). If hematuria persists without ob­
vious etiology, a renal biopsy should be considered.
DIFFERENTIAL DIAGNOSIS OF PROTEINURIA
Proteinuria may be suggested by a strongly positive dipstick test. Sig­
nificant proteinuria is diagnosed by a timed collection for quantitative pro­
teinuria. Abnormal proteinuria is defined according to normal values for 
age.
FREQUENCY
Increased proteinuria occurs frequently in newborn infants admitted to 
the NICU; it is associated with various types of renal injury. The detection of 
increased tubular proteinuria is a sensitive screening test for renal damage af­
ter perinatal asphyxia, as well as for tubular damage due to nephrotoxicity.
ETIOLOGY
The most common type of proteinuria is tubular proteinuria, which 
never is massive. It includes low-molecular-weight proteins (i.e., <60,000 
kd), which, as in the normal situation, are freely filtered through the glome­
rulus. These include p2-microglobulin, retinol-binding protein, and myoglo­
bin. In addition, in some patients, lysosomal proteins such as NAG can be 
found in the urine. Although tubular proteinuria can be isolated, it is associ­
ated most often with perinatal asphyxia or renal ischemia, UTI, ARF, Fan- 
coni syndrome, or nephrotoxicity.
In contrast, proteinuria of glomerular origin includes proteins with 
higher molecular weight such as albumin. In addition, it may become mas­
sive and lead to nephrotic syndrome.
EVALUATION
Because proteinuria occurs frequently, an extensive workup is not in­
dicated unless there is evidence for renal disease. Apart from history and 
physical examination, a major step in the differential diagnosis is the differ-
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entiation between tubular and glomerular proteinuria. This can be obtained 
by an electrophoresis of urinary proteins or by quantitative measurement of 
specific low-molecular-weight proteins and albumin (Fig. 39). In addition, 
there may be evidence of tubular damage (e.g., glucosuria, RTA). Discus­
sions of specific disorders are provided elsewhere in this chapter.
FIG. 39. Differential diagnosis of proteinuria (APR - acute renal failure, ATN - acute tubu­
lar necrosis; BUN - blood urea nitrogen; CNF - congenital nephrotic syndrome (Finnish 
type); DMS - diffuse mesangial sclerosis; Hg - mercury intoxication; Per - plasma creati­
nine concentration; RTA - renal tubular acidosis; RVT - renal venous thrombosis; SLE - 
systemic lupus erythematosus; UTI - urinary tract infection.)
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CHRONIC INFECTIONS
Maternal infections acquired shortly before conception or during ges­
tation can adversely affect pregnancy outcome indirectly through nonspe­
cific effects of severe maternal illness (e.g., increased rates of spontaneous 
abortions, stillbirths, premature births associated with measles infection dur­
ing pregnancy) or directly through microbial invasion of the fetus or neo­
nate. Pathogens can be transmitted from mothers to their infants through 
hematogenous spread across the placenta (e.g., cytomegalovirus [CMV], 
Toxoplasma gondii), ascension from an infected cervix (e.g., herpes simplex 
virus [HSV]), or intimate contact between a fetus and infected genital secre­
tions during vaginal delivery (e.g., HSV, hepatitis В virus [HBV], probably 
human immunodeficiency virus type 1 [HIV-1]). Iatrogenic fetal infections 
can occur after invasive procedures such as fetal scalp monitoring or intrau­
terine transfusions.
The outcome of a fetal or neonatal infection depends on the stage of 
pregnancy during which infection occurs, virulence of the pathogen, preex­
isting maternal immunity to the infecting agent, and efficacy of drug ther­
apy for maternal or neonatal disease. Intrauterine infections may lead to re­
sorption of the embryo, to fetal demise resulting in a spontaneous abortion 
or a stillbirth, or to the delivery of an infected neonate. Infected infants who 
are asymptomatic at birth may develop chronic problems in late infancy or 
early childhood (e.g., HIV, CMV), or during adulthood (e.g., rubella, HBV). 
Others suffer from severe acute neonatal disease such as pneumonia or 
hepatitis (e.g., HSV, syphilis), congenital malformations (e.g., CMV, ru­
bella), intrauterine growth retardation, or prematurity. The number of in­
fants born each year with these conditions is substantial, and the lifetime 
expenditures for their medical and educational needs are considerable. 
Compounding the problem is a resurgence in the incidence of congenital 
syphilis and congenital rubella after years of steady decline.
The acronym TORCH {T. gondii, "other", rubella virus, CMV, HSV) 
has long been used as a reminder that a number of pathogens can cause 
clinically indistinguishable illnesses in the neonate. These agents were 
originally grouped together because of shared clinical features (e.g., micro­
cephaly, hepatosplenomegaly, petechiae, ocular abnormalities), their ability 
to cause asymptomatic infections in the mother and newborn, and their pro­
pensity for causing long-term sequelae that are inapparent at birth. Because 
many other agents (e.g., HIV, Treponema pallidum, varicella-zoster virus 
[VZV], coxsackievirus, human parvovirus В 19, Mycobacterium tuberculo­
sis) are capable of causing similar illnesses, the diagnostic workup of in­
fants suspected of having a TORCH infection should not be restricted to the 
original four agents, as is common in medical practice. The clinical utility
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of this mnemonic is limited, and its use should be minimized or abandoned 
altogether.
The epidemiology, clinical manifestations, diagnosis, and treatment 
of maternal and fetal infections caused by Treponema pallidum subsp. pal­
lidum, Tgondii, rubella virus, HIV-1, CMV, HSV, VZV, human parvovirus 
В 19, and hepatitis В are summarized in this chapter. Strategies for the pre­
vention of maternal infection by these organisms or their vertical spread to 
the fetus or newborn infant are emphasized.
SYPHILIS
T. pallidum subsp. pallidum, the causative agent of syphilis, is a mo­
tile, nonculturable, gram-negative, microaerophilic spirochete that is too 
slender to be observed by light microscopy. The laboratory differentiation 
of T. pallidum from the other pathogenic treponemes that cause yaws (e.g., 
Treponema pallidum subsp. pertenue), endemic syphilis (e.g., Treponema 
pallidum subsp. endemicum), or pinta (e.g., Treponema carateum) is diffi­
cult. Ultrastructurally, T. pallidum has an outer cell membrane (i.e., enve­
lope), periplasmic flagella that arise at each end of the cell, cell wall, and a 
multilayer cytoplasmic membrane; a capsulelike amorphous layer coats the 
organism.
Person-to-person transmission of T. pallidum occurs primarily 
through contact with infectious lesions during sexual activity. The organism 
enters the body through sites of minor trauma that disrupt mucosal or 
epithelial barriers. Fibronectin receptors appear to mediate the attachment of 
T. pallidum to epithelial or mucosal cells. Parenteral transmission of this 
spirochete through transfusions is rare because of routine serologic screen­
ing of blood or blood products, but intravenous drug users occasionally ac­
quire syphilis by sharing needles contaminated with T. pallidum-infected 
blood. Intrauterine transmission from an infected mother to her developing 
fetus accounts for most congenitally infected infants; rarely, infection is ac­
quired at birth through contact with a genital lesion. In utero transmission 
can occur as early as 9 to 10 weeks of gestation. The most important deter­
minant for the risk of fetal infection is the maternal stage of syphilis. Moth­
ers with primary, secondary, early latent, or late latent stages of syphilis 
have at least a 50%, 50%, 40%, or 10% risk, respectively, of delivering an 
infant with congenital syphilis. Concomitant maternal infection with T. pal­
lidum and HIV may enhance the transplacental spread of either pathogen to 
the fetus.
Natural and experimental T. pallidum infections elicit complex cellu­
lar and humoral immune responses. Most antitreponemal antibodies pro­
duced during the course of a syphilitic infection cross-react with antigens 
from nonpathogenic treponemes (i.e., culturable treponemes that are part of 
the normal oral, intestinal, or genital flora) and are not pathogen specific.
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Antibodies directed against integral membrane lipoproteins with molecular 
masses of 47, 17, and 15 kd appear to be T. pallidum specific; their detec­
tion on Western immunoblot assays indicates syphilitic infection. A variety 
of other host immunologic defenses are activated after T. pallidum infec­
tion, including infiltration of inoculation sites with polymorphonuclear leu­
kocytes that contain treponemicidal peptides (i.e., defensins), T-lymphocyte 
activation and proliferation with interferon-y production, cytokine secretion, 
macrophage-mediated phagocytosis and intracellular killing of opsonized T. 
pallidum, and complement activation. A few treponemes manage to evade 
these clearance mechanisms during the acute phase of untreated infection, 
and this allows them to disseminate and establish a chronic infection.
MATERNAL SYPHILIS
EPIDEMIOLOGY
The number of primary and secondary syphilis cases in the United 
States increased steadily between 1985 and 1990, with 50,223 cases re­
ported for 1990 alone (i.e., 20.1 cases per 100,000 persons); the rates in­
creased most dramatically among African-American women (231%) and 
African-American men (126%) during this period. The number of cases re­
ported during 1991 declined for the first time in several years to 42,935 
(i.e., 17.3 cases per 100,000 persons). Although the highest syphilis rates 
are encountered in urban areas, increased T. pallidum transmission has oc­
curred in rural areas as well. Nationally, adolescents 15 to 19 years of age 
experienced a 40% increase in the incidence of primary and secondary 
syphilis from 1987 through 2001. Factors contributing to the increase in 
syphilis cases include cocaine use (especially crack cocaine) and exchange 
of drugs for sex, frequently with multiple, anonymous sex partners. Partner 
notification for diagnosis and treatment purposes is especially difficult un­
der these circumstances. Declines in resources for syphilis control programs 
and in the socioeconomic and educational levels of certain populations have 
promoted the spread of syphilis.
Pregnant women with syphilis are usually in their twenties (60%- 
80%), unmarried (65%-90%), and African American (45%-70%) or His­
panic (25%-55%). They usually receive no prenatal care (45%-65%) and are 
likely to be substance abusers (55%-70%).
CLINICAL MANIFESTATIONS
Approximately 10 to 90 days (mean, 21 days) after sexual contact 
with an infected person, a painless chancre with regional lymphadenopathy 
develops (i.e., primary syphilis). Chancres heal within 3 to 6 weeks, even 
without specific therapy.
Secondary syphilis develops after hematogenous spread of T. pal­
lidum. Its most recognizable manifestations include widely distributed
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rashes (e.g., macular, maculopapular, pustular, follicular) that typically in­
volve the palms and soles, alopecia, condyloma lata (i.e., broad, flat, 
painless, highly infectious papules found in moist areas such as the vulva or 
anus), oropharyngeal lesions (e.g., mucous patches, erosions, ulcers), con­
stitutional symptoms (e.g., low-grade fever, myalgias, sore throat, malaise, 
weight loss), and generalized painless lymphadenopathy. Asymptomatic 
central nervous system (CNS) involvement is found in 8% to 40%; head­
ache or meningismus occurs in 1% to 2%. Hepatitis, glomerulonephritis, 
nephrotic syndrome, osteitis, bursitis, and arthritis are uncommon.
Secondary syphilis can resolve spontaneously without specific treat­
ment. Untreated patients enter a latent phase of their illness, which is subdi­
vided into an early stage, defined as 1 year o f disease duration by the Cen­
ters for Disease Control and Prevention (CDC) and as 2 years by the World 
Health Organization, and a late stage. About 25% of patients in this phase 
experience relapses of secondary syphilis within 4 years, with approxi­
mately 75% of these relapses occurring during the first year.
Tertiary syphilis is a slowly progressive inflammatory process that 
develops after several years in about one-third of untreated patients. Mani­
festations include the invasion of various organs with gumma formation 
(i.e., late benign tertiary syphilis) or cardiovascular and CNS disease. Infec­
tion does not spread to the fetus during this stage.
The natural history of syphilis may be altered in patients co-infected 
with HIV. Support for this concept stems from several case reports describ­
ing unusual or florid symptoms and signs of disease, atypical skin rashes, 
and uveitis. Delayed healing of primary lesions and impaired immune re­
sponses to syphilis have been observed in HIV-infected rabbits and simian 
immunodeficiency virus-infected rhesus macaques.
Women with untreated gestational syphilis are at increased risk of 
spontaneous abortion, stillbirth, premature delivery, or neonatal death. Con­
genitally infected infants who are asymptomatic at birth subsequently de­
velop clinical manifestations if left untreated.
LABORATORY DIAGNOSIS
Several methods are currently available for the direct detection of T. 
pallidum in suspicious lesions (e.g., chancre, condyloma lata, mucous 
patch), body fluids (e.g., nasal discharge, amniotic fluid), placentas, umbili­
cal cords, and tissue biopsy or autopsy specimens. The organism can be 
visualized using darkfield microscopy, and it can be differentiated from 
nonpathogenic treponemes by its corkscrew appearance, characteristic 90° 
flexion centrally, and motility. A practical alternative to darkfield examina­
tion is the direct fluorescent antibody test for T. pallidum (DFA-TP). The 
DFA-TP uses pathogen-specific monoclonal antibodies as reagents. Another 
method involves the inoculation of animals with cerebrospinal fluid (CSF)
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or other clinical specimens (i.e., rabbit infectivity test) and examining the 
animals for evidence of a syphilitic infection over several weeks; this 
method is impractical for clinical purposes. An innovation uses the poly­
merase chain reaction (PCR) for the detection of minuscule amounts of T. 
pallidum DNA in CSF, amniotic fluid, lesion exudate, serum, or biopsy 
specimens. Polymerase chain reaction methodologies for syphilis diagnosis 
are not yet commercially available.
Serologic methods, despite their limitations, are the most popular and 
practical means of diagnosing syphilis. Two different types of antibodies 
are measured: nonspecific, nontreponemal reaginic (i.e., Wassermann) anti­
bodies and specific, antitreponemal antibodies.
Nontreponemal tests detect IgG and IgM antibodies directed against 
cardiolipin-lecithin-cholesterol antigens. The Venereal Disease Research 
Laboratory (VDRL) test and the rapid plasma reagin (RPR) 18-mm-circle 
card test are the two most popular tests in use. These flocculation tests are 
inexpensive and simple to perform, making them suitable for screening pur­
poses. Quantitative results can be obtained, and the measured titers are help­
ful in monitoring the response to therapy and in detecting reinfections. 
These antibodies are detectable in 70% to 80% of patients with primary 
syphilis and in almost 100% of those with secondary syphilis. They may 
disappear even without specific therapy in 25% of patients with latent dis­
ease. The RPR or VDRL tests may become nonreactive within 1 or 2 years 
of adequate treatment of patients with primary or secondary syphilis, re­
spectively. The length of time needed to serorevert depends on pretreatment 
titers.
False-positive VDRL or RPR test results occur for 1% to 2% of the 
general population and for about 10% of intravenous drug users. Many in­
fectious conditions (e.g., hepatitis, leptospirosis, HIV infection, infectious 
mononucleosis, bacterial endocarditis, chancroid, tuberculosis, Mycoplasma 
pneumonia, Lyme disease) and noninfectious conditions (e.g., pregnancy, 
chronic liver disease, connective tissue disease, multiple blood transfusions) 
are associated with false-positive test results, and specific treponemal tests 
are required for confirmation of the diagnosis. The titers in false-positive 
reactions are usually low (<1:8). Prozone (i.e., false-negative) reactions oc­
cur in 1% to 2% of patients with secondary syphilis because of the excess 
reaginic antibodies that prevent flocculation; diluting the serum and retest­
ing yield high RPR or VDRL titers.
Specific treponemal tests include fluorescent treponemal antibody- 
absorption (FTA-ABS), T. pallidum immobilization, microhemagglutination 
assay for antibody to T. pallidum (MHA-TP), and the hemagglutination tre­
ponemal tests for syphilis. These tests are expensive and cumbersome to 
perform and are not suitable for screening purposes. Reactive test results are 
obtained in 65% (by MHA-TP) to 85% (by FTA-ABS) of women with pri-
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mary syphilis, in 100% with secondary syphilis, and in 95% to 98% with 
later stages of disease. Because these tests remain positive indefinitely in 
most patients, they are not helpful in detecting reinfections. However, the 
FTA-ABS and MHA-TP tests have been shown to serorevert in 24% and 
13%, respectively, of patients with primary or secondary syphilis within 36 
months of adequate treatment. The specific treponemal tests are most useful 
in differentiating a syphilitic infection from a false-positive reaction on the 
VDRL or RPR tests. False-positive treponemal test reactions occur in about 
1% of the general population; these are usually transient. Conditions associ­
ated with false-positive reactions include infectious mononucleosis, leprosy, 
leptospirosis, Lyme disease, and systemic, discoid, or drug-induced lupus 
erythematosus.
Newer serologic techniques under evaluation include enzyme immu­
noassays and Western blots for the detection of IgG and IgM antibodies to 
T. pallidum and antigen-capture enzyme immunoassays. In the future, these 
tests may help differentiate active from previously treated syphilis and aid 
in the accurate diagnosis of congenital infection.
TREATMENT
Penicillin remains the drug of first choice for the treatment of mater­
nal syphilis and for the prevention of fetal infection. The dosage of the drug 
and the duration of treatment varies with the stage of the disease Early 
syphilis (i.e., primary, secondary, early latent) is treated with 2.4 million 
units of benzathine penicillin G given once intramuscularly. The cure rate 
with this regimen is about 95%. For syphilis of longer than a 1-year dura­
tion (i.e., late syphilis), 2.4 million units of benzathine penicillin G are 
given intramuscularly once weekly for 3 consecutive weeks. A variety of 
regimens are used for neurosyphilis. About 45% of treated pregnant women 
have Jarisch-Herxheimer reactions during the first 24 hours after benzathine 
penicillin therapy. This reaction consists of fever, myalgias, headache, 
tachycardia, and mild hypotension. Uterine contractions and decreased fetal 
movements are observed in two-thirds of pregnant women. The reaction is 
usually at its peak at 6 to 12 hours after therapy.
Formal recommendations for syphilis therapy are the same for HIV­
positive and HIV-negative patients; however, many reports have docu­
mented the failure of standard penicillin therapy in curing early syphilis in 
HIV-infected patients. Consequently, most experts in the field now use 
higher doses of penicillin for the HIV-positive patient.
The failure of maternal penicillin treatment to prevent congenital 
syphilis in some infants is well documented. Most of these failures occur 
when treatment is given during the last 4 weeks of pregnancy.
Antimicrobials other than penicillin are probably effective in the 
treatment of syphilis. Tetracyclines can be used in the penicillin-allergic pa­
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tient, but their use during pregnancy is contraindicated. Erythromycin has a 
lower cure rate in early syphilis compared with penicillin. It is not well tol­
erated because of gastrointestinal adverse effects, and its transplacental 
transfer is unpredictable. Congenital syphilis after maternal erythromycin 
therapy has been observed repeatedly. Limited data on the use of first- 
generation cephalosporins (e.g., cephalothin, cephalexin), ceftriaxone, naf- 
cillin, amoxicillin, and chloramphenicol suggest that they may be acceptable 
alternatives to penicillin in adults with early syphilis; information on their 
use during pregnancy is minimal. Aminoglycosides, clindamycin, and ri­
fampin are considered ineffective.
Penicillin-allergic pregnant women should be skin tested for reactions 
to major and minor penicillin determinants. If the skin tests are negative, 
penicillin can be used for the treatment of syphilis. If the skin test is posi­
tive, desensitization with oral penicillin over 3 to 4 hours should be at­
tempted and the patient subsequently treated with standard doses of the 
drug.
Follow-up of treated pregnant women is essential. Monthly nontre- 
ponemal serologic tests should be performed. A fourfold decline in titer 
should be observed within 3 months after therapy. If the decline in titer does 
not occur or if the titer rises, retreatment is recommended.
PREVENTION
Pregnant women should be tested for syphilis on their first antenatal 
visit and again at the time of delivery. For high-risk women, an additional 
test around 28 weeks of gestation is advisable. Screening is performed with 
quantitative nontreponemal tests, and positive results are confirmed with 
treponemal tests to exclude biologic false-positive reactions. Women who 
test positive for syphilis should be investigated for other sexually transmit­
ted pathogens, especially HIV.
CONGENITAL SYPHILIS
EPIDEMIOLOGY
The number of cases of congenital syphilis reported to the CDC in­
creased steadily between 1980 and 1991, reflecting a true increase in the 
number of primary and secondary maternal syphilis cases and a change 
since 1989 in the surveillance case definition for congenital syphilis. The 
new surveillance case definition was implemented to provide guidelines for 
reporting but not for making a clinical diagnosis of congenital syphilis. In 
essence, the change involved considering stillbirths and infants born to 
women with untreated syphilis as presumptively infected, regardless of 
symptoms or results of subsequent follow-up evaluations. Because vertical 
transmission of T. pallidum does not occur in all instances, the new defini­
tion leads to the inclusion of a number of uninfected infants in the "pre­
422
sumptive case" category. The older surveillance case definition led to un­
derestimates of the true incidence of congenital syphilis. Many infants in 
whom the diagnosis could not be made at birth were presumptively treated 
but not reported because the diagnosis could not be confirmed; others were 
inconsistently reported or lost to follow-up. The new case definition im­
proves sensitivity at the expense of specificity. Compared with traditional 
criteria for diagnosis, the new definition results in about a fivefold increase 
in the reported number of congenital syphilis cases.
CLINICAL MANIFESTATIONS
The pathologic and morphologic alterations of congenital syphilis are 
due to host immune and inflammatory responses to spirochetal fetal inva­
sion. The most prominent histopathologic abnormalities are vasculitis with 
resultant necrosis and fibrosis. Syphilitic stillbirths are usually macerated 
with T. pallidum-rich vesiculobullous cutaneous lesions, hepa- 
tosplenomegaly, and protuberant abdomen.
Most infants with congenital syphilis are asymptomatic at birth. In­
fants who develop clinical manifestations during the first 2 years of life are 
considered to have early congenital syphilis, while features that appear later, 
usually near puberty, comprise late congenital syphilis.
The placenta may be larger than normal. The main histopathologic 
abnormalities are a focal, proliferative villitis with necrosis and focal 
mononuclear cell infiltration; endovascular and perivascular proliferation in 
villous vessels, leading to vascular obliteration; and focal or diffuse villous 
immaturity. T. pallidum is demonstrable in the placenta using immunohisto- 
chemical stains; silver staining methods are difficult to perform and easy to 
misinterpret. The focal placental villitis and obliterative arteritis is associ­
ated with increased resistance to placental per-fusion; antenatal measure­
ments of uterine and umbilical systolic-diastolic ratios using Doppler veloc­
ity waveform analysis reveal higher mean ratios in pregnancies complicated 
by syphilis compared with non-infected controls. Necrotizing funisitis, a 
deep inflammatory process involving the matrix of the umbilical cord and 
accompanied by phlebitis and thrombosis, is common in syphilitic stillbirths 
and infants symptomatic at birth.
Clinical signs of congenital syphilis appear in approximately two- 
thirds of affected infants during the third to eighth week of life and in most 
by 3 months of age. Symptoms may be generalized and nonspecific (e.g., 
fever, lymphadenopathy, irritability, failure to thrive); alternatively, the 
highly suggestive triad of snuffles, palmar and plantar bullae, and 
splenomegaly may be apparent. The severity of the clinical illness can vary 
from mild to fulminant, life-threatening disease.
Congenitally infected infants may be small for their gestational ages. 
However, a carefully conducted study by Naeye of 36 stillborn and newborn
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infants with congenital syphilis revealed that fetal growth was almost nor­
mal despite widespread evidence of tissue destruction. The observed growth 
retardation in some reports may be related to confounding factors such as 
maternal intravenous drug use or co-infection with other pathogens.
Hepatosplenomegaly occurs in 50% to 90% of infants with early con­
genital syphilis. The enlargement is caused mainly by abundant extrame­
dullary hematopoiesis and by subacute hepatic and splenic inflammation. 
Jaundice, with direct and indirect hyperbilirubinemia, occurs in about a 
third of infants and may be contributed to by hepatitis or hemolysis. Syphi­
litic hepatitis is common and may worsen with penicillin therapy. Alkaline 
phosphatase elevation is a frequent biochemical abnormality. Transaminase 
and y-glutamyltransferase concentrations may be high at presentation and 
increase with antimicrobial therapy to levels approaching 150 times normal. 
Fulminant syphilitic hepatitis can manifest with hypoglycemia, lactic acido­
sis, encephalopathy, disseminated intravascular coagulation, and shock, 
mimicking metabolic or other infectious causes of acute liver failure. He­
patic and splenic abnormalities may persist for as long as 1 year after treat­
ment. Liver cirrhosis is uncommon.
Generalized lymphadenopathy is found in 20% to 50% of infants with 
congenital syphilis. The enlarged nodes are firm and nontender.
The mucocutaneous lesions of congenital syphilis are varied and oc­
cur in 30% to 60% of infants. The most characteristic are vesiculobullous 
eruptions that are most pronounced on the palms and soles; the blister fluid 
abounds with active spirochetes and is highly infectious. When a blister rup­
tures, it leaves behind a macerated red surface that rapidly dries and crusts. 
The most commonly encountered rash consists of oval, red, maculopapular 
lesions that are most prominent on the buttocks, back, thighs, and soles; 
they later change to a copper-brown color with superficial desquamation. 
Other lesions may be annular, circinate, petechial, purpuric, or have a blue­
berry-muffin appearance. Mucous patches involving the nares, palate, 
tongue, lips, and anus can occur; these lesions become deeply fissured and 
hemorrhagic and subsequently result in rhagades (i.e., Parrot radial scars of 
late congenital syphilis). Condyloma lata are usually encountered later in 
infancy in untreated patients. These raised, flat, moist, and wartlike lesions 
most commonly affect perioral (e.g., nares, angles of mouth) and perianal 
areas.
Rhinitis (i.e., snuffles) is encountered in 10% to 50% of infected in­
fants and usually precedes the appearance of cutaneous eruptions by 1 to 2 
weeks. The extremely contagious discharge is initially w'atery, but it later 
becomes thicker, purulent, and even hemorrhagic. Without treatment, the 
nasal cartilage ulcerates with ensuing chondritis, necrosis, and septal perfo­
ration (i.e., saddle nose deformity of late congenital syphilis). Throat in­
volvement can produce hoarseness or aphonia.
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Roentgenographic abnormalities are detected in 20% to more than 
95% of infants with early congenital syphilis. The lower rates are usually 
seen in asymptomatic infants. Multiple, symmetric bony lesions are com­
mon. The metaphyses and diaphyses of long bones, particularly those of the 
lower extremities, are most commonly affected. Radiologic changes include 
osteochondritis, periostitis, and osteitis. The earliest changes occur in the 
metaphysis and consist of transverse, serrated radiopaque bands alternating 
with zones of radiolucent osteoporotic bone. Osteochondritis becomes evi­
dent radiographically 5 weeks after fetal infection. The metaphysis may be­
come fragmented; focal erosions involving the proximal medial tibia are re­
ferred to as the Wimberger sign (Fig. 40). Periosteal reactions may consist 
of a single layer of new bone formation, of multiple layers (i.e., "onion peel 
periosteum"), or of a severe lamellar form (i.e., periostitis of Pehu). 
Periostitis is radiologically apparent after at least 16 weeks of fetal 
infection. Osteitis can give rise to a celery-stick appearance of longitudinal 
translucent lines that extend into the diaphysis or lead to a diffuse moth- 
eaten rarefaction of the shaft. Dactylitis, absence of lower extremity 
ossification centers, cranial nodules, and pathologic fractures or joint 
involvement leading to immobility of the affected limb (i.e.,
FIG. 40. Bone abnormalities in an infant with early congenital syphilis. Findings in­
clude bilateral, symmetric tibial periosteal new bone formation, and bilateral bony ero­
sions involving the proximal tibial metaphysis medially (i.e., Wimberger sign).
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Hematologic abnormalities are common and include anemia, 
leukocytosis, leukopenia, and thrombocytopenia. Anemia may be due to 
Coombs-negative hemolysis, to replacement of bone marrow by syphilitic 
granulation tissue, or to a maturation arrest in the erythroblastoid cell line. 
Thrombocytopenia is due to shortened peripheral platelet survival.
Clinically silent CNS involvement occurs in as many as 60% of in­
fants with congenital syphilis. Acute syphilitic meningitis may present with 
neck stiffness, vomiting, bulging anterior fontanelle, and a positive Kernig 
sign. Cerebrospinal fluid examination reveals a normal glucose concentra­
tion, modestly elevated protein content, and mononuclear pleocytosis (usu­
ally <200 cells/pL), a pattern consistent with aseptic meningitis. Chronic 
meningovascular syphilis develops in untreated infants and manifests in late 
infancy with progressive, communicating hydrocephalus, cranial nerve pal­
sies, optic atrophy, and cerebral infarctions leading to hemiplegia or seizure 
disorders.
Other less common pathologic changes of early congenital syphilis 
involve the eyes (e.g., salt and pepper chorioretinitis, glaucoma, chancres of 
eyelids, uveitis), lungs (e.g., pneumonia alba, interstitial scarring, extrame­
dullary hematopoiesis), and kidneys (e.g., nephrotic syndrome, glomeru­
lonephritis). Nonimmune hydrops is found in a sixth of liveborn infants 
with congenital syphilis. Myocarditis, pancreatitis, diarrhea, and malabsorp­
tion also occur.
The clinical manifestations of late congenital syphilis represent resid­
ual scars after therapy of early congenital infection or persistent inflamma­
tion in untreated persons. Abnormalities of dentition are secondary to early 
damage incurred by developing tooth buds and are preventable by penicillin 
treatment during the neonatal period or in early infancy. Unilateral or bilat­
eral interstitial keratitis occurs in about 10% of patients and is usually diag­
nosed between 5 and 20 years of age. Saddle nose deformity, high-arched 
palate, and poor maxillary growth are late consequences of syphilitic rhini­
tis. Eighth nerve deafness occurs infrequently (3% of patients) and is due to 
osteochondritis of the otic capsule and resulting cochlear degeneration. Rha- 
gades are linear scars that radiate from sites of earlier mucocutaneous 
lesions of the mouth, nares, and anus. Skeletal manifestations are caused by 
persistent or recurrent periostitis and its associated bone thickening.
DIAGNOSIS
Antenatal sonography may reveal placental thickening or fetal ab­
normalities such as hydrops, hepatomegaly, ascites, or dilated small bowel 
loops. Spirochetes can be visualized in amniotic fluid samples using dark- 
field microscopy or indirect immunofluorescent staining. The presence of T. 
pallidum or its DNA in amniotic fluid can be demonstrated by rabbit infec- 
tivity tests or PCR techniques, respectively. With the availability of umbili­
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cal blood sampling, intrauterine infection has been confirmed as early as 24 
weeks of gestation by detecting the spirochete or its DNA in fetal blood and 
by measuring specific IgM antibodies directed against the 47-kd antigen of 
T. pallidum in fetal serum.
At birth, the diagnosis o f congenital syphilis is best established by 
demonstrating the spirochete or its DNA in tissues or body fluids as previ­
ously alluded to. Serologic data obtained from cord blood or neonatal sera 
are helpful if interpreted with their limitations in mind.
Rapid plasma reagin measurements on cord blood samples yield 
false-positive and false-negative results in 10% and 5% of cases, respec­
tively. If an infant's RPR or VDRL titer is at least fourfold higher than a 
concomitantly obtained maternal titer, the diagnosis of congenital syphilis is 
likely. The RPR may be negative in infants whose mothers had acquired 
syphilis shortly before delivery. The FTA-ABS-IgM test yields false­
positive and false-negative results in 35% and 10% of cases, respectively. 
This is due to interference with test performance by rheumatoid factor (i.e., 
fetal IgM antibodies directed against maternal IgG). This problem can be 
overcome by separating the IgG and IgM fractions of the serum and then 
testing the IgG-depleted fraction with FTA-ABS-IgM. This assay is known 
as FTA-ABS-19S-IgM, and it is available through a few reference laborato­
ries and the CDC. The detection of IgM antibodies against specific T. pal­
lidum antigens, especially the 47-kd outer membrane protein antigen, by 
Western immunoblot assays is diagnostically helpful.
In addition to serologic tests for syphilis, the complete diagnostic 
evaluation of an infant with congenital syphilis should include bone radiog­
raphy, CSF examination, complete blood count, platelet count, liver func­
tion tests, and HIV antibody determination.
The diagnosis of congenital neurosyphilis is difficult to ascertain. 
Cerebrospinal fluid abnormalities such as mononuclear pleocytosis (>25 
cells/pL), elevated protein concentration (>170 mg/dL), and reactive CSF 
VDRL are widely used criteria. However, the CSF VDRL can be positive in 
the absence of neurosyphilis because of passive diffusion of nontre-ponemal 
IgG antibodies from serum to CSF and in infants with traumatic lumbar 
punctures. A specific IgM response to the T. pallidum 47-kd antigen has 
been detected in the CSF of some infants with congenial syphilis, and this 
may prove helpful for the diagnosis of neurosyphilis. Cerebrospinal fluid 
IgM reactivity can be present in infants with negative CSF VDRL test re­
sults. The presence of T. pallidum in the CSF of some infants with normal 
CSF cell counts, protein concentrations, and VDRL test results has been 
demonstrated using sensitive rabbit infectivity tests or PCR methods.
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TREATMENT
Infants should be treated at birth if they are symptomatic, if maternal 
therapy was inadequate or unknown, or if follow-up cannot be ensured. 
Adequate maternal therapy is defined as penicillin treatment at a dose ap­
propriate for the stage of syphilis and started at least 30 days before deliv­
ery.
One of two dosage regimens can be used for confirmed or presump­
tive congenital syphilis:
1. Crystalline penicillin G at a dose of 100,000 tol50,000 
U/kg/day administered intravenously in divided doses every 8 to 12 hours 
for 10 to 14 days
2. Procaine penicillin G at a dose of 50,000 U/kg/day given intra­
muscularly once daily for 10 to 14 days.
Because congenital neurosyphilis cannot be reliably excluded in 
many infants, benzathine penicillin G given as a single intramuscular dose 
of 50,000 U/kg is recommended only for infants at low risk for congenital 
infection who were born to HIV-negative mothers adequately treated for 
syphilis but in whom close follow-up cannot be guaranteed. The 10- to 14- 
day regimens of crystalline or procaine penicillin G should be used if the 
mother is HIV positive. The Jarisch-Herxheimer reaction occurs in some in­
fants within hours of initiation of penicillin therapy.
The VDRL titers should be monitored at 1,2, 4, 6, and 12 months of 
age until they become nonreactive. Untreated infants should have FTA-ABS 
tests. Passively acquired maternal antibodies usually disappear by 6 to 12 
months of age in uninfected infants. If the VDRL titers are stable or rising 
or if the FTA-ABS test result remains positive beyond 1 year of age, the in­
fant should be thoroughly reexamined and treated. The VDRL titers of ade­
quately treated infants with congenital syphilis gradually decline, but FTA- 
ABS reactivities persist. Infants with CSF abnormalities should be retested 
at 6 months of age. If the CSF VDRL is positive at that time, a second 
course of penicillin is indicated. Follow-up examinations should emphasize 
developmental assessment and a careful search for stigmata of congenital 
syphilis.
TOXOPLASMOSIS
Toxoplasmosis is a common zoonosis, afflicting approximately 1 in 3 
people worldwide. Infections of immunocompetent hosts are typically as­
ymptomatic or benign, but intrauterine infections and illnesses in immuno- 
suppressed patients can be severe or fatal. The causative organism, T. 
gondii, is an obligate intra-cellular protozoan that can be encountered in the 
form of a tachyzoite, tissue cyst, or oocyst. In addition to humans, T. gondii 
can infect other warmblooded animals such as cats, dogs, sheep, swine, and
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some birds; cats and other felines are the only known complete hosts for 
this parasite.
The life cycle of T. gondii is usually divided into an enteroepithelial, 
sexual phase that occurs only in felines and an extraintestinal, asexual phase 
that takes place in definitive (e.g., cats) and intermediate (e.g., humans) 
hosts. Susceptible cats can acquire Toxoplasma infection by ingesting oo­
cysts or parasite-harboring tissues of other animals. Some of the organisms 
released in cat intestines invade gut epithelial cells and undergo sexual dif­
ferentiation into microgametes and macrogametes; the gametocytes later 
fuse to produce a zygote. After a rigid wall forms around the zygote, it is 
excreted in feces as an oocyst. Acutely infected cats generally shed millions 
of oocysts in their feces daily for periods of 1 to 3 weeks. Parasites that do 
not undergo sexual differentiation may instead penetrate the gut wall and 
spread to other tissues by way of the blood and lymphatics; this extraintesti- 
na! or asexual stage can occur in humans and other susceptible animals as 
well.
The tachyzoite is the actively proliferating form that is encountered in 
organs during the acute stage of infection. Tachyzoites gain entry into the 
cytoplasm of host cells and multiply rapidly. Infected cells subsequently 
burst and release progeny parasites that go on to attack neighboring host 
cells; this leads to the formation of necrotic areas that are surrounded by an 
inflammatory' cellular reaction. This process is eventually curtailed by spe­
cific cellular and humoral host immune responses. In immunodeficient per­
sons, the acute infection can continue relentlessly and cause serious ill­
nesses.
After the host develops specific immunity against T. gondii, the or­
ganism can remain in organs in a viable, clinically inapparent tissue cyst 
form. T. gondii tissue cysts are most commonly found in the brain, eyes, 
myocardium, and skeletal muscles. Each cyst contains a number of slowly 
propagating or dormant parasites. Encysted organisms can reactivate and 
cause serious illnesses such as encephalitis and pneumonia in patients who 
become immunodeficient later in life because of malignancy, acquired im­
munodeficiency syndrome (AIDS), or immune suppressant therapy (e.g., 
organ transplants).
T. gondii is transmitted to humans primarily through the ingestion of 
oocyst-contaminated water or food or the consumption of cyst-containing 
raw or undercooked beef, pork, mutton, or chicken. Unwashed hands can 
serve as vehicles for the transport of contaminating oocysts from the soil, 
dust, or cat litter box material into the mouth. Transmission can occasion­
ally occur by eating raw infected eggs, by transfusion of infected blood or 
blood products, by heart or kidney transplants from seropositive donors to 
seronegative recipients, or by accidental self-inoculation of laboratory 
workers who are in contact with infected animals, needles, or glassware. Di­
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rect human-to-human transmission occurs only in the context of transpla­
cental spread of the parasite to a developing fetus.
MATERNAL TOXOPLASMOSIS
EPIDEMIOLOGY
The prevalence of anti-Toxoplasma antibodies among women of 
childbearing age varies geographically, ranging from none to more than 
90%. A seroprevalence of 39% was found in a large study of 22,845 preg­
nancies from diverse parts of the United States conducted between 1959 and 
1966. More recent surveys demonstrate the divergence of seroprevalence 
figures by region: Denver, CO, 3.3%; Palo Alto, CA, 10%; Boston, MA, 
14%; and Birmingham, AL, 30%. Seroprevalence figures for women of 
childbearing age from other countries include Australia with a rate of 4%; 
Finland, 20%; Poland, 36%; Ethiopia, 48%; Belgium, 53%; Panama, 63%; 
France, 71%; and El Salvador, 75%.
The incidence of acute T. gondii infection during pregnancy varies by 
locale. Reported frequencies per 1000 pregnancies include Alabama with 
0.6; Finland with 2.4; Australia with 5; Germany with 7.5; and Belgium 
with 14.3. The risk of infection is greatest for pregnant women leaving a re­
gion with a low incidence of toxoplasmosis to reside in an area where the 
infection is prevalent.
CLINICAL MANIFESTATIONS
Acute toxoplasmosis is asymptomatic in 80% to 90% of pregnant 
women. Those with clinically evident illnesses most commonly present with 
lymphadenopathy, primarily of the head and neck region; a single node is 
involved in about two-thirds of patients. T. gondii causes about 1% to 5% of 
infectious mononucleosis cases and should be considered a likely etiologie 
agent in patients with negative heterophile antibody test results. Complica­
tions such as hepatitis, pneumonia, myocarditis, encephalitis, and deafness 
are rare in immunocompetent women. Fulminating illnesses are common in 
immunosuppressed patients.
T. gondii spreads transplacentally to involve the developing fetus in 
25%, 54%, or 65% of pregnant women with untreated primary toxoplasmo­
sis during the first, second, or third trimesters, respectively. Proper maternal 
therapy reduces the overall incidence of fetal infection by more than 50%, 
and fewer infected infants manifest with severe congenital toxoplasmosis. 
These data underscore the importance of an accurate and timely diagnosis of 
acute toxoplasmosis in pregnant women.
DIAGNOSTIC TESTS
A clinical diagnosis of toxoplasmosis should be considered dubious 
unless supported by appropriate laboratory test results. T. gondii can be iso­
lated from infected blood, CSF, aqueous humor, amniotic fluid, or homoge­
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nized tissues (e.g., placenta, brain, muscle) by inoculating these specimens 
into the peritoneal cavities of mice or onto tissue cultures. Tissue culture 
techniques are faster (~1 week) but less sensitive than intraperitoneal inocu­
lation methods (>6 weeks); both methods are impractical for clinical pur­
poses. Tachyzoites can be visualized in tissue sections or smears of body 
fluids, especially if labeled specific ami-Toxoplasma antibodies are used for 
staining; their presence denotes acute infection. The demonstration of tissue 
cysts on histopathology can be consistent with an acute or a chronic 
Toxoplasma infection.
Other immunologic techniques that have been used for the diagnosis 
of toxoplasmosis include intra-dermal skin tests and transformation of lym­
phocytes on exposure to Toxoplasma antigens, both of which connote 
chronic infection. Toxoplasma antigens can be detected in CSF, urine, se­
rum, or amniotic fluid using enzyme-linked immunosorbent assays (ELISA) 
or immunoblotting methods. A positive antigen test result indicates that the 
infection is recent. This is particularly helpful in newborns and immuno- 
defi-cient persons, in whom antibody responses to infection may be absent 
or unpredictable. The antigen test is not available commercially. The PCR 
has been successfully used for the direct detection of T. gondii DNA in 
clinical samples by amplification of the P30 or B1 genes of the parasite.
The diagnosis of toxoplasmosis most often rests on serologic confir­
mation. The Sabin-Feldman dye test, traditionally the reference test against 
which newer methods are compared, requires the use of live parasites. Posi­
tive titers are usually in the 1:256 to 1:128,000 range. Most laboratories 
have abandoned the dye test in favor of simpler techniques that use killed 
antigens, such as the indirect fluorescent antibody (IFA), ELISA, agglutina­
tion, and indirect hemagglutination (IHA) tests.
Toxoplasma-specific IgM antibodies can be measured by IFA, 
ELISA, or IgM-immunosorbent agglutination assay (IgM-ISAGA). False­
positive IgM-IFA or IgM-ELISA are encountered in sera containing rheu­
matoid factor; this problem is circumvented if a double-sandwich IgM- 
ELISA (DS-IgM-ELISA) is performed. Specific IgM antibodies usually be­
come positive within 1 to 2 weeks of infection and continue to be detectable 
for months or years, especially when measured by very sensitive assays 
such as DS-IgM-ELISA or IgM-ISAGA. The detection of specific IgM an­
tibodies should not be considered proof that an infection is acute. High spe­
cific IgM titers suggest acute infection, especially if accompanied by high 
specific IgG titers of about 1:1000 or greater as measured by IFA or the Sa­
bin-Feldman dye test. Low specific IgM titers measured by DS-IgM-ELISA 
or IgM-ISAGA are generally encountered in patients whose infections oc­
curred several months earlier. IgM-IFA tests are considerably less sensitive 
than DS-IgM-ELISA or IgM-ISAGA and are positive in only 60% to 70% 
of patients with acute infections and 25% to 50% of infants with congenital
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toxoplasmosis. Fewer than 25% of patients are still positive by the IgM-IFA 
assay 9 months after an acute infection. It is important to know the type of 
assay used to measure specific IgM antibodies in pregnant women to cor­
rectly interpret the significance of positive and negative results.
Anti-Toxoplasma IgG antibodies usually appear early during an infec­
tion. IgG titers peak at about 2 months, gradually drop thereafter, but re­
main detectable for years. The predominant IgG antibody response is of the 
IgGl subclass. A single high specific IgG titer is considered only suggestive 
of an acute infection.
Knii-Toxoplasma IgA antibodies directed against the major surface 
protein of tachyzoites (P30) are present in over 95% of patients with acute 
infections. These antibodies are detected at the end of the first month of in­
fection and usually disappear within 4 to 7 months. Specific IgA antibodies 
are rarely found in patients with chronic infections.
Specific serum IgE antibodies are present in about 86% of women 
who seroconvert during pregnancy. They appear shortly before or concomi­
tantly with specific IgA antibodies, and they persist for less than 4 months.
Antibodies detected by IHA are different from those measured by the 
dye test, ELISA, or IFA. The titers take several weeks before becoming 
positive, making the test unsuitable for the diagnosis of acute toxoplasmosis 
during pregnancy.
SEROLOGIC DIAGNOSIS OF MATERNAL INFECTION
Acute infection in immunologically normal women can be diagnosed 
if seroconversion or a fourfold or greater rise in antibody titers occurs when 
serum samples are collected 3 to 6 weeks apart. The absence of 
Toxoplasma-specific IgM antibodies as measured by the DS-IgM-ELISA or 
IgM-ISAGA essentially excludes the diagnosis of acute toxoplasmosis; ele­
vated titers obtained by these assays are considered suggestive of the diag­
nosis, especially if specific IgG titers are high as well. Positive IgM-IFA re­
sults are more likely to represent recent infection. Specific antibodies de­
tected by IgM-ISAGA or DS-IgM-ELISA usually persist at low levels for 
months or years after infection; high levels measured many years after the 
acute infection are rare. The detection of Toxoplasma-specific serum IgA or 
IgE antibodies indicates a recent infection; conversely, absence of these an­
tibodies in a seropositive woman suggests that the infection is old.
Immunodeficient women with acute T. gondii are frequently unable to 
mount a specific IgM response, and their IgG responses may be absent or 
low. Use of the more sensitive antibody assays may be helpful, but direct 
detection of the parasite or its components (e.g., antigen, DNA) in body flu­
ids or tissues is sometimes the only means of establishing the diagnosis of 
acute toxoplasmosis.
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DIAGNOSIS OF INTRAUTERINE INFECTION
Estimation of the duration of maternal T. gondii infection is usually 
difficult, and consequently, assessment of the true risk to the fetus is often 
fraught with uncertainties. The parasite can be transmitted to the developing 
fetus at any stage of pregnancy and, in some cases, at or shortly before con­
ception. This creates considerable anxiety for parents, who may choose an 
unwarranted end to the pregnancy or unnecessary maternal chemotherapy 
with potentially toxic drugs.
Prenatal diagnosis of fetal toxoplasmosis can be achieved safely and 
reliably. Pregnant women shown to have acquired acute Toxoplasma infec­
tions during the course of their pregnancies can undergo amniocentesis and 
ultrasound-guided cordocentesis. Parasite isolation studies, if available, in­
clude inoculation of these clinical samples into mice or onto tissue cultures. 
Fetal blood should be shown to be free of maternal blood contamination, us­
ing the K.leihauer-Betke stain or hemoglobin electrophoresis, before it is as­
sayed for Toxoplasma-specific IgM antibodies or other nonspecific indica­
tors of fetal infection (e.g., leukocyte and differential cell counts, platelet 
count, total IgM content, lactic dehydrogenase level, y-glutamyltransferase 
concentration). Serial ultrasound examinations should be done at 2-week in­
tervals to detect ventricular dilation, cerebral or hepatic calcifications, as­
cites, hydrops, or other fetal abnormalities.
Daffos and colleagues applied this approach to prenatal diagnosis to 
746 women with gestational toxoplasmosis occurring within the first 25 
weeks of pregnancy. All mothers were treated with spiramycin. Fetal infec­
tion occurred in 42 pregnancies, of which 39 (93%) were successfully iden­
tified prenatally. The most sensitive test in this study proved to be parasite 
isolation from amniotic fluid or fetal blood (81%). Despite the use of the 
sensitive IgM-ISAGA assay, only 21% of infected fetuses tested positive. 
Serial ultrasound examinations showed abnormalities in 45% of fetuses. 
Among nonspecific tests, y-glutamyltransferase or total IgM contents of fe­
tal blood were elevated in more than one-half of the patients. Results of 
prenatal testing led to pregnancy terminations in 62% of cases; the diagno­
sis was confirmed postnatally in the remainder. No false-positive diagnoses 
of fetal toxoplasmosis were made in this study, although other investigators 
have encountered this problem.
Because maternal IgA and IgE antibodies do not cross the placenta, 
fetal serum IgA and IgE have been explored as possible markers for intrau­
terine T. gondii infection. Decoster and colleagues were able to detect spe­
cific IgA antibodies in fetal blood as early as 23 weeks of gestation. The 
sensitivity of the assay was only 50%, slightly higher than that for 
Toxoplasma-specific IgM. No false-positive results were obtained. Pinon 
and colleagues were unable to detect specific mti-Toxoplasma IgE antibod­
ies in fetal blood.
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Polymerase chain reaction methods have been employed in prenatal 
diagnosis of fetal toxoplasmosis. Cazenave and colleagues studied 80 
women with documented acute toxoplasmosis during pregnancy. Poly­
merase chain reaction analysis (i.e., P30 gene amplification) of the amniotic 
fluid was negative in 70 cases without intrauterine infection and positive for 
all 10 with fetal toxoplasmosis. In this study, the PCR was considerably 
more sensitive than recovering the parasite from amniotic fluid using cul­
ture methods (40%) or detection of specific fetal IgM (40%). Similarly, 
Grover and associates amplified the B1 gene and found the PCR method to 
be more sensitive than the traditional techniques used for the prenatal diag­
nosis of toxoplasmosis. The PCR can provide results within hours, com­
pared with tissue cultures which require a minimum of 4 days or animal in­
oculation techniques, which take at least 5 weeks to complete. The sensitiv­
ity of PCR analysis, coupled with its rapidity, makes it promising as a diag­
nostic tool because it can minimize the rate of late pregnancy terminations 
with their relatively increased risk.
TREATMENT
Acute toxoplasmosis in the healthy, nonpregnant woman usually re­
quires no specific therapy because of its benign, self-limited nature. Drugs 
used to treat toxoplasmosis are active against tachyzoites, but they generally 
have no effect on the encysted form of the parasite.
Pregnancy termination should be confined to women who become in­
fected during the first one-half of their pregnancy. Although the risk of 
transmission of the parasite to the fetus is at its lowest during this stage, the 
severity of fetal disease is usually at its greatest. Acutely infected women 
who elect to proceed with their pregnancies should be treated with spiramy­
cin as soon after diagnosis as possible. Spiramycin is a macrolide antibiotic 
that is active against T. gondii and can cross the placenta to enter the cord 
blood and amniotic fluid. It achieves high tissue levels, especially in the 
placenta. The main adverse effects of spiramycin are nausea, vomiting, and 
diarrhea. The drug reduces the risk of intrauterine transmission of the para­
site, but it does not alter fetal pathology after infection has developed. Spi­
ramycin is only available by request from the Food and Drug Administra­
tion; the adult dose is 2 to 4 g daily, given orally in two to four divided 
doses.
If prenatal diagnosis is attempted and a fetus is shown to be infected, 
drugs such as pyrimethamine and sulfadiazine are added. Pyrimethamine, an 
anti-malarial drug, is a folic acid antagonist. Its half-life in adults is about 
100 hours, and it achieves tissue concentrations (e.g., brain) that are higher 
than in serum. The drug causes bone marrow suppression with resultant 
anemia, granulocytopenia, and thrombocytopenia; severe pancytopenia oc­
casionally occurs. Other side-effects include a bad taste in the mouth, head­
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ache, and gastrointestinal discomfort. Pyrimethamine has been shown to be 
teratogenic in animals receiving massive doses of the drug early in organo­
genesis, and it should not be used before the fifth month of pregnancy. Sul­
fadiazine or the trisulfapyrimidines act synergistically with pyrimethamine 
against Toxoplasma tachyzoites; other sulfonamides show less synergy and 
are not used. These drugs are folic acid antagonists. Side-effects include 
bone marrow suppression, rashes, crystalluria, hematuria, and reversible 
acute renal failure. One regimen used to treat pregnant women with an in­
fected fetus incorporates 3-week courses of a combination of 
pyrimethamine (50 mg/day), sulfadiazine (3 g/day), and leucovorin supple­
ments (10 mg/day), alternating with 3 weeks of spiramycin (3 g/day). Leu­
covorin (folinic acid) is used to counteract the bone marrow suppressive ef­
fects of pyrimethamine and sulfadiazine. This treatment regimen is thought 
to reduce the occurrence of severe congenital infection and increase the 
proportion of infants born with asymptomatic toxoplasmosis. For ethical 
reasons, the study inferring that the drugs were efficacious did not include a 
control group of patients and relied on historic comparisons for its conclu­
sions.
PREVENTION
A vaccine against T. gondii is not yet available. Primary prevention 
rests on educating susceptible pregnant women on how to avoid becoming 
infected with this parasite. Cats that are kept indoors and only eat dried, 
cooked, or canned food are unlikely to get infected and shed oocysts. Con­
tact with cat feces should be avoided; disposable gloves should be worn 
when handling cat litter boxes or while gardening. Cat litter boxes should be 
emptied of cat feces daily and disinfected by adding boiling water to the 
empty box for 5 minutes. Covering children's sandboxes decreases the risk 
of contamination. Meat should be cooked at 66°C or higher temperatures, 
smoked, or cured in brine. Hands should riot touch the eyes or mouth when 
handling raw meat, and they must be washed thoroughly afterward. Kitchen 
surfaces should be cleaned carefully. Fruits and vegetables may have oo­
cysts on their surfaces and should be washed or peeled before being eaten.
Prenatal education programs can bring about changes in personal be­
havior that reduce a susceptible woman's risk of acquiring toxoplasmosis. 
Although it is generally believed that health education reduces the occur­
rence of gestational toxoplasmosis, the extent of this benefit is uncertain. 
Foulon and colleagues found that when a group of susceptible pregnant 
women in Belgium implemented these suggestions, the predicted serocon­
version rates decreased by only 34%. This is possibly a reflection of how 
difficult it is to consistently follow the instructions.
Secondary prevention entails the identification and treatment of preg­
nant women who are acutely infected. Because about 90% of patients with
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acute toxoplasmosis have minimal or no symptoms, a systematic serologic 
screening program would be needed. A national prevention program for 
congenital toxoplasmosis that mandates monthly serologic screening of all 
seronegative pregnant women has been in place since 1976 in France. A 
comparable policy for routine screening does not exist for the United States.
Women found to be seronegative early in pregnancy should be ad­
vised to follow the hygienic measures outlined earlier. Retesting at 18 to 22 
weeks of gestation can identify women who seroconverted during the first 
one-half of their pregnancy, affording them the opportunity to consider op­
tions such as maternal chemotherapy, prenatal diagnostic procedures, or 
elective pregnancy termination. Seronegative women gain from testing at 
the end of pregnancy; this helps to identify asymptomatic newborns with 
toxoplasmosis who may derive benefit from treatment during the first year 
of life.
Women found to be seropositive early in gestation should be evalu­
ated further to exclude a recent Toxoplasma infection. As a group, infants 
born to seropositive pregnant women with IHA titers of 1:256 to 1:512 have 
double the predicted frequency of deafness, a 60% increase in micro­
cephaly, and a 30% increase in the occurrence of intelligence quotients less 
than 70.
CONGENITAL TOXOPLASMOSIS
EPIDEMIOLOGY
The true incidence of congenital toxoplasmosis is unknown. Reported 
figures underestimate its occurrence. Published rates vary by locale, but 
they range from 0 to 10 per 1000 live births. Representative incidence esti­
mates per 1000 live births include New York City with 0.7, Birmingham, 
AL, with 0.12, Mexico City with 2, Paris with 3, and Austria with 8.3. As 
treatment of acutely infected pregnant women becomes more commonplace, 
the occurrence of congenital toxoplasmosis should decline. Trimester- 
specific T. gondii transmission rates have been shown to decrease with 
proper maternal chemotherapy from 25% to 8% for the first trimester, from 
54% to 19% for the second trimester, and from 65% to 44% for the third 
trimester.
CLINICAL MANIFESTATIONS
About two-thirds of infants with congenital toxoplasmosis have inap- 
parent disease at birth; however, a third of all asymptomatic neonates who 
undergo detailed examinations are found to have abnormalities such as CSF 
pleocytosis or elevated protein content (20%), chorioretinitis (15%), or in­
tracranial calcifications (10%). Several weeks or months later, untreated in­
fants develop signs or symptoms of disease.
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Symptomatic Toxoplasma infection of the newborn can be mild, 
moderate, or severe. It can involve multiple organ systems or present as iso­
lated abnormalities such as hydrocephalus, hepatosplenomegaly, or pro­
longed hyperbilirubinemia. Approximately 25% to 50% of symptomatic in­
fants are delivered prematurely. Only 10% of infected infants have severe 
disease at birth. Systemic manifestations such as fever, jaundice, anemia, 
hepatomegaly, splenomegaly, or chorioretinitis may predominate in some 
infants, and neurologic abnormalities such as encephalitis, seizures, hydro­
cephalus, or intracranial calcifications may be prominent in others. About 
10% of congenitally infected infants who have severe disease die, and most 
surviving infants are left with major neurologic sequelae, such as mental re­
tardation, seizures, spasticity, or visual deficits.
Central nervous system involvement is common. Parenchymal lesions 
may extend to surrounding blood vessels, leading to vasculitis with throm­
bosis and infarction. Substantial destruction of brain parenchyma can lead 
to obstruction of the aqueduct of Sylvius with resultant secondary enlarge­
ments of the third and lateral ventricles and, ultimately, hydrocephalus. Hy­
drocephalus can be the sole manifestation of congenital toxoplasmosis. It 
may be present at birth or develop later in infancy, and it may be static or 
gradually worsen to the point of requiring shunt placement. Diffuse intrac­
ranial calcifications occur in 10% to 15% of infants with congenital 
toxoplasmosis, but they can be found in 30% to 65% of those with sympto­
matic disease at birth (Fig. 41). They may increase in number and size over 
time. Other neurologic findings encountered in this infection include bulg­
ing anterior fontanelle, encephalitis, hydranencephaly, hypotonia or paraly­
sis, spasticity, microcephaly, opisthotonus, swallowing difficulties, and CSF 
pleocytosis. Radiologic CNS findings may be consistent with an old insult 
(e.g., hydrocephalus, porencephaly, encephalomalacia, cortical atrophy) or, 
less commonly, with an acute process (e.g., single or multiple hypodense 
lesions with contrast ring enhancement).
Manifestations of active congenital ocular toxoplasmosis may include 
chorioretinal scars, chorioretinitis, iritis, leukocoria, microphthalmia, nys­
tagmus, optic atrophy, optic coloboma, retinal folds and traction detach­
ments, granulomas in the posterior pole, strabismus, small cornea, or cata­
racts. On ophthalmoscopy, the typical findings are single or multiple yel­
low-white, fluffy necrotic lesions with indistinct margins that arise at the 
borders of preexisting, healed, hyperpigmented retinochoroidal scars. Macu­
lar involvement is common; other findings may include retinal hemor­
rhages, iridocyclitis, vitreous haziness, papillitis, and papilledema. Un­
treated infants who were asymptomatic at birth are at great risk of subse­
quent development of chorioretinitis (about 50% for patients older than 10 
years).
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FIG. 41. Computerized axial head tomogram of a 5-month-old girl with congenital 
toxoplasmosis. Notice the diffuse parenchymal calcifications and the prominent subarach­
noid space bilaterally.
Sensorineural hearing loss may occur in 15% to 25% of congenitally 
infected infants, and educationally significant hearing loss afflicts 10% to 
15% of infected infants. T. gondii has been found in the mastoid and middle 
ear at autopsy of some infants. Gastrointestinal disturbances such as feeding 
difficulties, diarrhea, and vomiting are common. The liver and spleen may 
be enlarged, and hepatic calcifications may be found. Conjugated hyper­
bilirubinemia sometimes takes months to subside. Biliary atresia associated 
with congenital toxoplasmosis has been reported in 1 infant. Myocarditis, 
nephrotic syndrome, hydrops fetalis, interstitial pneumonia, and skeletal 
metaphyseal lucencies occur infrequently. Cutaneous lesions include ec- 
chymoses, petechiae, purpura, or maculopapular rashes.
Hematologic abnormalities include anemia, eosinophilia, and throm­
bocytopenia. Transient quantitative (e.g., neutropenia) and qualitative (e.g., 
enlarged, vacuolated lymphocytes) changes in the leukocytes are common. 
Total CD4 lymphocyte counts and CD4:CD8 ratios are usually depressed. 
Compared with adults, infants with congenital toxoplasmosis have no or re­
duced lymphocyte blastogenic responses on exposure to Toxoplasma lysate 
antigens, with failure to produce interferon-y or interleukin-2; however, 
they do respond normally to nonspecific stimulators such as concanavalin 
A. The severe organ damage seen in congenital toxoplasmosis may be due 
to specific deficits in cell-mediated immune responses to Toxoplasma anti­
gens.
DIAGNOSIS
Congenital toxoplasmosis is diagnosed if the parasite is recovered 
from the placenta. T. gondii can be isolated from the blood of asymptomatic
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or symptomatic infants; isolation rates peak at 71% during the first week of 
life and then decline to 33% at 2 to 4 weeks of age. Attempts at recovering 
the parasite from the blood of older infants are generally fruitless. The de­
tection of Toxoplasma antigens or DNA in body fluids such as urine, CSF, 
or serum is considered diagnostic.
Specific IgM antibodies can be detected in the serum of 25% of con­
genitally infected infants with the IFA method and in as many as 75% with 
the DS-IgM-ELISA technique. The sensitivity of the IgM-ISAGA test is 
probably even greater. Passively transferred maternal mti-Toxoplasma IgG 
antibodies can suppress an infant's specific IgM response. Gross and col­
leagues have shown that about 5% of sera have strain-specific immune re­
sponses. Unless antigens from more than one T. gondii strain are used in the 
assay, the sera would have no detectable specific antibodies in one test but 
be positive in another. IgM antibodies can persist for over 1 year when 
measured by very sensitive assays. Rarely, intrathecal production of anti- 
Toxoplasma IgM is demonstrable despite the absence of specific antibodies 
in the serum of congenitally infected infants with CNS involvement.
Levels of anti-Toxoplasma IgG antibodies of maternal origin typically 
drop at a rate of 50% per month in the infant's serum, but they may continue 
to be detectable for about 1 year. Active congenital infection should be sus­
pected if specific IgG titers do not show the anticipated decline or if they 
increase. Untreated infants begin synthesizing their own anti-Toxoplasma 
IgG antibodies by 3 months of age. The intrathecal production of specific 
IgG is demonstrable in about 2% of infants with CNS involvement.
Toxoplasma-specific serum IgA antibodies are detectable in most 
congenitally infected infants, significantly more often than IgM antibodies. 
Specific IgA antibodies were found in the CSF of the few infants in whom it 
had been measured. Specific serum IgE antibodies can be measured from 
birth in some patients, especially infants with complications such as hydro­
cephalus or chorioretinitis.
Transformation of lymphocytes on exposure to Toxoplasma antigens 
is a sensitive and specific indicator of congenital infection if performed on 
symptomatic or asymptomatic infants 3 months of age or older. The ob­
served blastogenic response is lower in infants than in infected adults.
TREATMENT
Controlled trials examining the benefits of various treatment proto­
cols are lacking. Drug regimens have been arrived at empirically, and con­
clusions about their efficacies are based on comparisons with historic data. 
A randomized, prospective study by the Toxoplasmosis Study Group aiming 
at addressing these deficiencies is under way.
The treatment of symptomatic infants during the first 6 months of life 
usually consists of a combination of pyrimethamine, sulfadiazine, and leu-
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covorin supplements. Pyrimethamine (1 mg/kg orally; maximum, 25 mg) in 
one or two divided doses is given daily or every other day. A 75 mg/kg/day 
loading dose of sulfadiazine (maximum, 4 g/day) in two divided oral doses 
is given for the first 2 days, followed by 100 mg/kg/day (maximum, 8 
g/day) in two divided oral doses administered daily thereafter. Leucovorin 
(5 mg) is injected intramuscularly every 3 days; the dose can be increased to 
10 mg every 3 days in infants with bone marrow toxicities. After the first 6 
months of treatment are completed, the regimen is modified to include 1- 
month courses of spiramycin alternating with 1-month courses of 
pyrimethamine, sulfadiazine, and leucovorin supplements for an additional 
6 months. Spiramycin is given daily at a dose of 100 mg/kg/day (maximum, 
2-4 g/day) in two to four divided oral doses.
Corticosteroids such as prednisone or methylprednisolone (1.5 
mg/kg/day orally in two divided doses) are used in infants with chorioretini­
tis or CSF protein elevations to reduce the inflammatory response. They 
should be used concurrently with anti-Toxoplasma drugs.
Infants with asymptomatic congenital toxoplasmosis are treated for 1 
year. They receive an initial 6-week course of pyrimethamine, sulfadiazine, 
and leucovorin supplements, followed by alternating courses of spiramycin 
for 6 weeks and the pyrimethamine, sulfadiazine, and leucovorin combina­
tion for 4 weeks.
Healthy infants born to mothers with gestational toxoplasmosis can 
be treated with a 3-week course of pyrimethamine, sulfadiazine, and leuco­
vorin followed by 4 to 6 weeks of spiramycin. If the diagnosis of congenital 
toxoplasmosis is later established, chemotherapy is continued as delineated 
earlier for infants with subclinical T. gondii infection. For healthy infants 
born to mothers with high Sabin-Feldman dye test titers and undetermined 
timing of maternal infection, a 1-month course of spiramycin is usually pre­
scribed. Therapy is extended if clinical or laboratory evidence of congenital 
toxoplasmosis is uncovered.
Pyrimethamine serum levels do not vary significantly with age during 
infancy; they are comparable for infants receiving the drug daily or every 
other day. Pyrimethamine serum concentrations and half-life may be re­
duced in infants concomitantly treated with phenobarbital. The drug 
achieves CSF concentrations that are 10% to 25% of concurrently measured 
serum levels. Seizures have been observed in patients with pyrimethamine 
overdosage.
Clindamycin has been used effectively for the treatment of ocular 
toxoplasmosis in older patients because of its tendency to concentrate in the 
choroid. There are no data on its efficacy in congenital infection. Photoco­
agulation of active lesions and of normal retinal tissues immediately border­
ing chorioretinal scars may be helpful in reducing recurrences.
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Infants treated with pyrimethamine and sulfadiazine should be closely 
monitored. Weekly blood counts, platelet counts, and urine microscopic 
analysis are suggested for the early detection of adverse drug effects.
PROGNOSIS
Most infants with severe symptomatic congenital toxoplasmosis who 
survive beyond the neonatal period suffer from serious long-term residual 
problems, such as mental retardation and blindness. This grim outlook does 
not apply to all infants with congenital infection. Short-term follow-up stud­
ies indicate that maternal therapy during gestation, followed postnatally by 
treatment of all congenitally infected infants, improves prognosis by reduc­
ing the frequency and severity of late-appearing disease sequelae. In the 
study by Hohlfeld and colleagues, congenital infection remained subclinical 
in 76%. Almost all treated infants developed normally and were neurologi- 
cally normal. Peripheral chorioretinitis that did not impair vision developed 
in about 10% between 5 and 17 months of age. In another study, early insti­
tution of anti-Toxoplasma therapy may have prevented the occurrence of 
sensorineural hearing loss in congenitally infected infants. Preliminary data 
by Guerina and colleagues after only 2 years of follow-up suggest that pro­
gression of congenital toxoplasmosis can be halted for most infants by be­
ginning specific therapy early in infancy.
Long-term follow-up of infants with symptomatic or subclinical con­
genital toxoplasmosis suggest that most patients develop chorioretinitis or 
chorioretinal scars by 10 to 20 years of age, but treatment may reduce the 
frequency and severity of adverse sequelae. The rates at which other resid­
ual abnormalities, such as mental retardation or neurologic dysfunction, oc­
cur are unknown.
RUBELLA
Rubella (i.e., German measles, third disease) typically is a subclinical 
or mild exanthematous infection of children and adults. Gestational rubella 
can have deleterious effects on the fetus. The infant may have physical and 
mental abnormalities, such as cataracts, congenital heart disease, deafness, 
microcephaly, or psychomotor retardation, or present with severe neonatal 
diseases that include thrombocytopenia, bleeding, hepatosplenomegaly, 
pneumonia, and myocarditis. Some manifestations of congenital rubella in­
fection may not appear until years or decades later, even among patients as­
ymptomatic at birth.
The rubella virus is an enveloped, single-stranded RNA virus that is 
spherical and has spikelike projections containing hemagglutinin. Only one 
antigenic type of the virus is known, and man is its only natural host. It has 
three structural polypeptides; two are envelope glycoproteins (i.e., El and 
E2), and one is a nonglycosylated RNA-associated capsid protein (i.e., C).
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Different epitopes of El are responsible for viral hemagglutination and neu­
tralization, and E2 accounts for the minor differences among rubella strains.
Person-to-person transmission usually occurs by airborne spread of 
infected respiratory secretions, and direct contact with virus-containing 
urine or feces is a less likely route of infection. Although rubella virus can 
be recovered from the genital tract of infected women, vertical transmission 
during pregnancy is believed to occur almost exclusively through the pla­
centa.
On entry into the body in cases of postnatal infection, the rubella vi­
rus multiplies in nasopharyngeal epithelial cells and in local lymph nodes. 
This is followed by a period of viremia and shedding from the throat. It is 
during this maternal viremic phase that placental and fetal infection occurs. 
The frequency and nature of fetal involvement depends on the mother's im­
mune status against the virus and the timing during gestation of maternal 
rubella.
The mechanisms by which the virus ravages the fetus are not clearly 
understood. Necrotic placental vascular endothelial cells can serve as a 
source of virus-infected emboli. Damage to endothelial cells can lead to 
thrombosis of small blood vessels, resulting in hypoxic tissue damage. Ru­
bella-infected cells have diminished mitotic activity due to chromosomal 
breaks, the production of a mitosis-inhibiting protein, or damaging effects 
of the virus on actin-containing cytoskeletal filaments. Focal lysis of in­
fected cells can be seen in some organs, but inflammation is not a salient 
feature of congenital rubella. Growth-retarded infants have reduced cell 
numbers on histopathologic examination. Moreover, the virus can modify 
cell receptors for specific growth factors. Late-onset manifestations of con­
genital rubella may be due to viral persistence with ongoing cell destruction 
or to organ damage by means of a number of immune mechanisms such as 
circulating rubella-specific immune complexes, defective cytotoxic effector 
cell function, or the development of autoimmunity. Rubella virus El and E2 
structural proteins, but not the C nucleoprotein, appear to be responsible for 
autoantibody induction.
Long-lasting immunity normally develops after recovery from 
postnatal rubella. Reinfections can occur in persons with low antibody 
titers, but these are usually asymptomatic. Persons with low antibody levels 
after rubella vaccination are more prone to reinfections than persons with 
similarly low titers after natural infection.
Circulating antibodies and cell-mediated immune responses are gen­
erated after rubella infection. Rubella-specific IgM, IgG, IgA, IgD, and IgE 
antibodies are induced in response to postnatal infection. IgM antibodies 
appear early and are short lived, and they usually disappear 5 to 8 weeks af­
ter onset of illness, although rubella-specific IgM antibodies rarely persist 
for months or years. The IgM response after rubella vaccination or natural
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reinfection is generally weak and of brief duration. Specific IgD and IgE an­
tibodies appear early and then decline more slowly than specific IgM anti­
bodies. Specific IgA antibodies generally emerge within the first 10 days of 
illness, and they may continue to be measurable for periods ranging from 3 
weeks to several years. Rubella-specific IgG antibodies increase rapidly and 
persist throughout life; rubella-specific IgGl has been shown to be the prin­
cipal IgG subclass. The most vigorous antibody and lymphocyte prolifera­
tive responses in postnatal rubella are directed against glycoprotein El. Men 
and women appear to differ in the nature and magnitude of their antibody 
responses to rubella virus structural proteins. Men never produce anti-E2 
IgA and generate significantly lower levels of IgG antibodies directed 
against E2 than women. Anti-El IgM and IgG antibodies appear earlier in 
male patients, but female patients have higher levels of rubella-specific IgG 
antibodies after recovery from the illness. The observed gender differences 
in antibody responses to viral proteins may be under genetic or hormonal 
influences and may be related to the increased susceptibility of women to 
the joint complications of rubella.
Immune responses in congenitally infected infants differ from those 
observed in adults with rubella. Fetal IgM production usually begins after 
16 weeks of gestation. Rubella-specific IgM antibodies are detectable until 
6 to 12 months of age. Specific IgG antibody levels decrease over time; as 
many as 20% of affected children have no measurable antibody titers by 5 
years of age. Circulating antirubella antibodies in infants with intrauterine 
infection have lower affinities to rubella antigen than antibodies from adults 
with natural infection. Serum antibodies to the E2 glycoprotein are quantita­
tively more abundant than those directed against El in some patients with 
congenital rubella, particularly among older infants; antibody reactivities 
against the C protein are poor. Infants with congenital rubella have dimin­
ished cell-mediated immune responses on exposure to rubella antigens 
compared with children or adults with postnatal infection, and the responses 
are weakest for infants infected earlier during gestation.
MATERNAL RUBELLA
EPIDEMIOLOGY
Epidemics of rubella formerly occurred at 6- to 9-year intervals in the 
United States. The last major pandemic took place between 1964 and 1965, 
during which time 20,000 cases of congenital rubella occurred. Rubella did 
not become a notifiable disease in the United States until 1966. From 1966 
through 1971, between 45,000 and 58,000 cases of postnatal rubella were 
reported to the CDC each year. Since licensure of the rubella vaccine in 
1969, the number of rubella cases declined by more than 99%, and from 
1980 to 1988, the number of cases decreased from 3904 to 225. However, a 
resurgence of rubella was found for 1989 through 1991, and 1401 cases
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were reported for 2001 alone. Outbreaks of infection occur mostly in un­
immunized populations such as inner city children and adults, illegal aliens, 
prison inmates, and religious groups that refuse vaccination (e.g., Amish 
communities). Medical students and other health professionals serve as vec­
tors for rubella infection, placing susceptible pregnant women to whom they 
are exposed in a medical setting at significant risk.
Approximately 10% to 20% of women of childbearing age (>15 years 
of age) are susceptible to rubella, and more than 70% of cases occur among 
persons in this age group. Women delivering infants with the congenital ru­
bella syndrome (CRS) tend to be younger than the national average for 
mothers giving birth in the United States; a disproportionate number of 
these mothers are African-American or Hispanic. Rubella susceptibility 
rates for women of childbearing age in European countries are generally 
comparable to those found in the United States, but lower seropositivity 
rates are encountered among island populations such as in Hawaii and Ja­
maica and in certain tropical African countries. Significant regional differ­
ences have been found in large countries, such as India and China.
CLINICAL MANIFESTATIONS
Over 30% of postnatal rubella infections are subdinical. Illness occurs 
14 to 21 days (mean, 18 days) after exposure. A prodrome consisting of 
malaise, low-grade fever that rarely lasts beyond the first day of the exan­
them, headache, and conjunctivitis precede the rash by 1 to 5 days. The ex­
anthem consists of discrete macules or papules that initially appear on the 
face and behind the ears, spread downward over 1 to 2 days, and usually 
disappear over 3 to 5 days; rubella virus can be isolated from these skin le­
sions. Postauricular, suboccipital, and posterior cervical lymphadenopathy 
is common and may persist for several weeks. Complications of rubella de­
velop more frequently in adults. Transient arthralgias may occur in as many 
as one-third of infected women, but arthritis is uncommon. Other complica­
tions are rare and include thrombocytopenic purpura, hemolytic anemia, 
hepatitis, Guillain-Barre syndrome, encephalitis, progressive panencephali­
tis, myelitis, peripheral neuritis, myocarditis, and pericarditis.
Pregnancy has no effect on the natural course of rubella infection. 
However, rubella is associated with an increased risk of miscarriages, spon­
taneous abortions, and stillbirths.
LABORATORY DIAGNOSIS
The diagnosis of rubella on clinical grounds alone is unreliable be­
cause similar illnesses may be produced by enteroviruses, measles virus, or 
parvovirus В 19. Laboratory confirmation by virus isolation or sero-logic 
testing is thus essential in pregnant women, for whom an accurate diagnosis 
of gestational rubella is critical. Shirley and colleagues investigated 627 pa-
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tients clinically suspected of having rubella, but they could confirm this di­
agnosis in only 229 (37%). Human parvovirus B19 infection accounted for 
7%, measles for 1%, and other infectious agents for 1%; the causes for the 
remainder (54%) remained unknown.
Rubella virus is shed from the nasopharynx for 1 week before and 1 
week after onset of the rash. The virus is present in blood and urine during 
the week preceding the exanthem but disappears thereafter. Rubella virus 
isolation is impractical for diagnostic purposes because it is expensive, la­
bor intensive, and frequently unavailable to the clinician.
Serologic techniques are the most useful methods for diagnosing ru­
bella infection. Available tests include hemagglutination inhibition (HI), 
ELISA, immunofluorescence, radioimmunoassay (RIA), hemolysis in gel, 
complement fixation, passive hemagglutination, and latex agglutination 
tests. Serum specimens obtained as soon as feasible after the appearance of 
the exanthem and again 2 weeks later can prove the diagnosis if seroconver­
sion or a fourfold or greater rise in rubella-specific antibody titers can be 
documented. Paired sera are best tested in unison because of the variability 
in results of assays done on separate days or by different personnel. If 
measured by ELISA, HI, or RIA, rubella-specific IgG antibodies can be 
found as early as 1 to 2 days before the emergence of the rash; if assayed by 
the less readily available passive hemagglutination method, these antibodies 
are not detected until 15 to 50 days after onset of the exanthem, and peak 
approximately 6 to 7 months later. The detection of rubel la-specific IgM an­
tibodies within 28 days of the appearance of the rash is also diagnostic. 
Newer tests that can be used for the diagnosis of acute postnatal rubella in­
clude avidity-ELISA, in which acutely infected persons have low IgG avid­
ity compared with persons previously immune to rubella who exhibit 
greater IgG avidity. IgG produced in response to rubella vaccination shows 
low avidity to rubella antigens during the first 2 months after immunization, 
but this increases significantly over the ensuing months and remains at high 
levels thereafter. Immunoblot techniques have been developed for the sensi­
tive detection of rubella-specific IgG, IgM, and IgA antibodies.
Rubella reinfections are confirmed by a fourfold or greater rise in the 
titer of preexisting rubella-specific IgG antibodies. The specific IgM re­
sponse is absent or weak, but it is sometimes high enough to be within the 
range deemed sufficient for the diagnosis of primary rubella.
False-positive IgM reactions can occur in sera containing rheumatoid 
factor, although the IgM capture assay appears to be unaffected by its pres­
ence. Cross-reactions between rubella and human parvovirus B19 infections 
in specific IgM tests necessitate caution in interpreting low or equivocal 
levels of rubella-specific IgM antibodies.
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TREATMENT
Therapy of postnatal rubella is symptomatic. Patients with rubella 
shed the virus from the nasopharynx for 1 week after appearance of the 
rash, and they should therefore avoid contact with susceptible persons until 
the exanthem has vanished.
PREVENTION
The principal goal of rubella immunization programs is the elimina­
tion of CRS. The vaccine used in the United States is the RA 27/3 attenu­
ated live rubella virus vaccine. It is available in a monovalent form (i.e., ru­
bella only) and in combinations with measles, mumps, or both (i.e., MMR). 
The vaccine induces antirubella antibodies in more than 95% of recipients 
12 months of age or older, and its protective efficacy is greater than 90% for 
at least 15 years. Immunizing children whose pregnant mothers are suscep­
tible to rubella does not pose a threat to the mother or her fetus. The vaccine 
is recommended for all susceptible persons 12 months of age or older and is 
usually given at 15 months of age; a second booster dose is given to chil­
dren at the time of school entry.
A clinical diagnosis of rubella is considered unreliable and cannot be 
considered proof of immunity. Persons are deemed protected if they have 
serologic evidence of immunity or had previously been vaccinated on or af­
ter their first birthday.
Pregnant women whose rubella-immune status is not known should 
be tested for the presence of anti-rubella antibodies during their first prena­
tal visit. If a previously unimmunized pregnant woman with unknown anti­
body status is exposed to rubella, a blood sample should be immediately ob­
tained for rubella antibody testing. If antibody to rubella is found, the 
woman is considered immune. The risk of rubella reinfection after natural 
disease or vaccination is small, but it is more likely to occur in women with 
low specific IgG titers. Significant fetal pathology after reinfection occurs 
infrequently, despite rubella virus transmission to the fetus.
Susceptible women exposed to rubella should be informed of the risks 
to the fetus if maternal infection occurs. If the woman develops fever, lym- 
phadenopathy, or a rash within the expected incubation period, serum for 
rubella-specific IgM assay should be obtained. If a clinical illness does not 
occur, serum should be obtained 6 to 8 weeks after exposure to exclude a 
subclinical infection. For women who sero-convert or become positive for 
rubella-specific IgM, the rate of fetal infection is 81% after maternal rubella 
during the first 12 weeks of gestation, 54% at 13 to 16 weeks, 36% at 17 to 
22 weeks, 30% at 23 to 30 weeks, 60% at 31 to 36 weeks, and 100% at 
more than 36 weeks of pregnancy. Infants infected before 11 weeks of ges­
tation usually develop congenital defects, most often cardiac anomalies and 
deafness, but only 35% of infants infected at 13 to 16 weeks of gestation
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have abnormalities at birth, usually deafness. In a study of 106 infants with 
confirmed CRS in whom the timing of maternal infection was known with 
reasonable accuracy, Munro and colleagues found deafness in 58% of pa­
tients, and it was the sole abnormality in 40% of all infants; infants with 
congenital cardiac, ocular, or CNS defects were almost always deaf as well. 
The risk of deafness is small if maternal infection occurs at 17 weeks of 
gestation or later. Other investigators have confirmed that rubella virus can 
be transmitted to the fetus at any stage of pregnancy, and that the earlier the 
maternal infection during pregnancy, the greater is the severity of congeni­
tal defects.
If maternal rubella occurs during the first 5 months of pregnancy, the 
option of therapeutic pregnancy termination can be considered. Infections 
occurring after this time do not produce congenital defects. If available, an 
attempt at prenatal diagnosis can be made, because fetal involvement after 
maternal rubella is not universal. The virus has been isolated from amniotic 
fluid by culture or directly visualized using electron microscopy in a few 
cases. The low sensitivities of these methods limits their usefulness. Daffos 
and colleagues studied 18 pregnancies complicated by maternal rubella; fe­
tal blood was obtained at 20 to 26 weeks of gestation, and rubella-specific 
IgM was detected in 12 fetuses. Contamination of fetal blood specimens by 
maternal blood was excluded. Of the 6 fetuses without detectable rubella- 
specific IgM antibodies, 1 was found to be infected at birth. In another 
study, investigators were able to detect rubella-specific IgM and IgA as 
early as 22 weeks of pregnancy. The drawbacks of this method are that the 
fetus does not synthesize IgM until the fifth month of gestation, and the 
quantity produced initially may be meager and below the limits of detection 
of the assay. Despite these disadvantages, the technique has been found to 
be helpful in the management of pregnancies complicated by maternal ru­
bella.
Terry and associates detected rubella antigens and RNA sequences in 
a chorionic villus biopsy specimen obtained at 11 weeks of gestation from a 
woman with rubella in early pregnancy, and this led to pregnancy termina­
tion at week 13 of gestation; infection was verified in the aborted fetus and 
placenta by virus isolation, immunoblotting, and hybridization methods. 
Hybridization techniques appear to be more sensitive than viral isolation 
methods, and the PCR has been used successfully to enhance the yield from 
infected fetal and placental tissues. Molecular biologic techniques for the 
prenatal diagnosis of rubella are research tools and are not readily available 
for clinical use.
The administration of immunoglobulin to susceptible pregnant 
women who are exposed to rubella does not prevent maternal or fetal infec­
tion. Its use is confined to women who would not contemplate pregnancy 
termination under any circumstances.
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Pregnant women who do not have rubella antibody are usually immu­
nized in the immediate postpartum period. However, reports by a group of 
investigators from Canada have shown that acute arthritis occurs in as many 
as 8% of women receiving the rubella RA 27/3 vaccine in the postpartum 
period, and that some subsequently develop chronic arthropathy, neurologic 
abnormalities such as the carpal tunnel syndrome or paresthesias, and 
chronic rubella viremia. These women tend to transmit rubella virus to some 
of their infants through breast-feeding, and a few infected infants develop 
chronic rubella viremia. Data from the United States and elsewhere indicate 
that such complications are rare with the RA 27/3 live rubella vaccine. The 
mechanisms of rubella vaccine-induced joint disease are poorly understood, 
but they may include infection of the synovial membrane by vaccine virus 
or the deposition of rubella antigen-containing immune complexes in the 
synovium. It is advised that all susceptible pregnant women be vaccinated 
against rubella before hospital discharge. It is estimated that 40% to 55% of 
CRS cases could have been prevented had the opportunity to implement 
postpartum rubella immunization of susceptible women not been missed. 
Although rubella vaccine virus can be shed in breast milk, breastfeeding is 
not a contraindication to maternal immunization.
The rubella vaccine should not be knowingly administered during 
pregnancy because of its small risk of teratogenicity. Data for the 1979 to 
1988 period from the CDC indicate that none of 562 infants born to 683 
women inadvertently immunized with the RA 27/3 vaccine within 3 months 
of conception in the United States had malformations compatible with CRS. 
Between January 1971 and April 1989, 321 known rubella-susceptible 
women who had been immunized against rubella within 3 months before or 
after their estimated date of conception with the RA 27/3 or earlier vaccines 
(Cendehill, HPV-77) were followed by the CDC; none of the 324 infants 
born to these women had defects consistent with the CRS. The RA 27/3 ru­
bella vaccine virus, however, does cross the placenta and produces a sub- 
clinical infection in about 3% of infants; the rate of fetal infection was con­
siderably higher (20%) for the earlier rubella vaccines. The possible risk of 
serious congenital defects after accidental rubella vaccination has been cal­
culated by the CDC to be 0% to 1.6%; the observed risk has been zero. This 
risk is considerably lower than the 20% or greater risk of CRS after mater­
nal gestational infection, and it is comparable to the 2% to 3% rate of major 
birth defects observed in the absence of rubella vaccine exposure.
CONGENITAL RUBELLA
EPIDEMIOLOGY
The incidence of congenital rubella has shown a consistent decline 
since the introduction of rubella vaccination programs in the United States. 
From 1980 to 1989, the incidence of CRS decreased from 0.39 per 100,000
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live births to 0.05 per 100,000 live births. However, the number of indige­
nous and imported CRS cases for 1989, 1990, and 1991 were 3, 11, and 47, 
respectively. The observed increase was largely due to a cluster of cases 
from southern California. About one-half of the cases could have been pre­
vented by postpartum immunization of susceptible mothers after earlier 
pregnancies. Maternal risk factors for CRS include young age, African- 
American race, and Hispanic ethnicity. In the southern California cluster, 
approximately 40% of the mothers were never married and about 60% were 
primigravidas. Because of the passive nature of the CRS reporting system, it 
is estimated that the reported number of infants with CRS represents only 
20% to 30% of actual cases.
Congenital rubella syndrome continues to be a problem in other parts 
of the world. However, rubella immunization programs have been success­
ful in reducing the occurrence of CRS wherever implemented. As an exam­
ple, the incidence of CRS declined from 3.5 per 100,000 live births in 1980 
to 0.41 per 100,000 live births in 1986 in 19 European t birth defects regis­
tries.
CLINICAL MANIFESTATIONS
More than one-half of all newborns with congenital rubella are as­
ymptomatic at birth, but most later manifest with one or more signs and 
symptoms of disease. The most common abnormalities encountered in CRS 
listed in order of decreasing frequency are sensorineural hearing loss, men­
tal retardation, cardiac malformations, and ocular defects. Clinical abnor­
malities encountered in congenital rubella are summarized in Table 63.
If the findings of mental retardation and infection of neurosensory or­
gans such as the eyes or ears are combined, then CNS involvement occurs 
in more than 80% of CRS patients. Vascular abnormalities, a prominent 
pathologic characteristic of congenital rubella, contributes to the neuropa­
thology by causing ischemic necrosis of adjacent tissues. Microcephaly may 
be due to the generalized organ hypocellularity seen with rubella infection.
The development of late-onset CRS manifestations that were inappar- 
ent in early infancy may be related to persistence or reactivation of rubella 
virus infection, to the body's immune responses to the infection, or to vascu­
lar damage. Insulin-dependent diabetes mellitus occurs in about 20% of pa­
tients by 35 years of age. Rubella virus can infect human fetal pancreatic 
islet cells and can reduce secretion of insulin. About 20% of CRS patients 
and 50% to 80% of those with glucose intolerance have circulating pancre­
atic islet cell cytotoxic or surface antibodies. These autoaniibodies are trig­
gered by rubella virus and cause destruction of pancreatic (3 cells, unmask­
ing the person with a genetic susceptibility to diabetes mellitus. Thyroid ab­
normalities develop in about 5%; thyroid microsomal or thyroglobulin anti­
bodies are found more frequently in deaf CRS patients than in those who are
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hearing impaired from other causes. Rare cases of growth hormone defi­
ciency of hypothalamic origin have been described. About 10% of CRS pa­
tients incur additional forms of late-app.'earing ocular insults such as glau­
coma, keratoconus, corneal hydrops, and spontaneous lens absorption. Per­
manent damage to the vascular endothelium can induce the formation of ob­
structive lesions of major vessels such as the pulmonary and renal arteries. 
Choroidal neovascularization with significant visual loss can complicate 
CRS retinopathy. Autism and behavioral problems are usually delayed in 
appearance, and can be progressive. Progressive rubella panencephalitis is a 
rare but ultimately fatal CNS manifestation of CRS that appears late, usu­
ally in the second decade of life.
DIAGNOSIS
The CDC has established clinical and laboratory criteria for the clas­
sification of CRS cases to allow better CRS surveillance (Table 64).
The diagnosis of CRS usually is suspected on the basis of the mater­
nal history and the clinical findings. A definitive diagnosis can be achieved 
by isolating the virus from pharyngeal washings or, less commonly, from 
urine, CSF, conjunctivae, or available organs such as the lens at surgery or 
autopsy. Although nasopharyngeal shedding of rubella virus may continue 
for 6 to 12 months, the frequency of its isolation declines from about 85% 
during the first month of life to approximately !0% at 9 to 12 months of 
age. In children with congenital rubella encephalitis, the virus can be iso­
lated from the CSF for months or even years. However, viral isolation is 
seldom employed in clinical practice because of its difficulty, expense, and 
limited availability.
Rubella-specific IgM is usually present in congenitally infected in­
fants and may persist for 6 to 12 months. It can be used to make a definitive 
diagnosis of congenital rubella infection; false-positive results may be en­
countered in sera containing rheumatoid factor. Delays in obtaining serum 
for IgM measurements can introduce interpretation difficulties because of 
the possibility that the infant may have acquired rubella infection postna- 
tally. Persistence of rubella-specific IgG antibodies at 6 to 12 months of 
age, especially in high titers, provides presumptive evidence of congenital 
or early postnatal infection.
Other techniques for establishing the diagnosis of congenital rubella 
include negative virus-specific lymphocyte transformation responses in 
seropositive children younger than 3 years of age, detection of rubella- 
specific IgM in CSF, or demonstration of low avidity rubella-specific IgG in 
seropositive infants.
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Table 63
Clinical abnormalities in infants with symptomatic congenital rubella
Clinical Abnorm ality R em ark s
General
Intrauterine growth retardation Com m on  (5 0 % -8 5 % );  usually have other m anifestations of congenital 
infection; may be due to reduced num ber of body ce lls174
Postnatal growth retardation Retarded growth is most severe in infants with multiple congenital de­
fects; long-term follow-up studies indicate that m ost will have sub­
normal growth750 S1
Card iovascular system  
Patent ductus arteriosus M ost frequently encountered structural delect (30%); m ay occur with 
other heart lesions, especially pulm onary valvular o r artary stenosis2*
Pulm onary artery stenosis 
M isce llaneous delects
Second  most com m on heart defect: results from  intimal proliferation82 
Individually uncom m on; include coarctation of the aorta, atrial and ven­
tricular septal defects, myocarditis, tetralogy of Fallot, and ventricular
Hearing lo ss
aneurysm
The most com m on congenital defect; almost a lways present in infanls 
with other malformations; uncom m on if maternal rubella occurs at 
г 1 7  w eeks of gestation; usually bilateral: m ay be present at birth or 
develop later; can  be progressive5 253
Ocu lar abnormalities 
Cataract Found  in about 3 5 %  of infants; can  be unilateral o r bilateral; noted at
Retinopathy
birth or early infancy: v irus can be isolated from lens; spontaneous 
reabsorption of cataracts has been described in  rare case s254"257 
Com m on (35%); may be present at birth o r appear later in life; often 
unilateral; salt-and-pepper appearance; d oe s not affect visual acu-
jty2Se-200
C loudy cornea Rare; usually present at birth; may coexist with g laucom a; resolves 
spontaneously: rarely persists251
G laucom a O ccu rs in < 5 % ;  may be bilateral; can be found at birth o r appear later in 
life; leads to b lindness if not treated5
M icrophthalm ia 
M isce llaneous abnormalities 
Interstitial pneum onia
Com m on in infants with unilateral cataract5 
Uncom m on; includes iris hypoplasia, strabism us, and  iridocyclitis 
O ccu rs in about 5% ;  probably im m unologically mediated; may be acute, 
subacute, o r chron ic177
Central nervous system 
Meningoencephalitis O ccu rs in a s  m any a s  2 0 % ; manifests with bu lg ing  anterior fontanelle, 
hypotonia, irritability, and seizures; cerebrospinal fluid Findings in­
clude elevated protein concentration, m ononuc lear pleocytosis, and 
rubella virus isolation in 30% ; transient; most infants have neurode- 
velopmental deficits2*  252 20
M icrocephaly 
Intracranial calcifications 
E lectroencepha lograph^  abnor­
malities
Mental retardation
Uncom m on, m ay be associated with normal intelligence 
Rare254 255
O ccu rs in 36% ; usually resolves by 1 year of age200
O ccu rs in 1 0 % —20 % ; associated with other stigmate of congenital ru­
bella
Speech defects 
Behavioral d isorders 
M isce llaneous problem s
U ncom m on in absence  of hearing Impairment 
Com m on; occu rs primarily in deaf patients252 
Autism; central language  disorders; spastic quadriparesis; hydrocepha­
lus; cerebral arterial stenosis
Sk in
Blueberry-muffin spots 
C hron ic  rashes
Transient; infrequent (5%); represents dermal erythropo iesis255 
Generalized; persists for weeks; appears in Infancy; v iru s can  be isolated 
from sk in257
Dermatoglyphlc abnormalities 
Genitourinary system
M ay serve a s  marker for viral teratogenicity255 
Cryptorchidism ; testicular agenesis; polycystic kidneys: renal agenesis; 
renal artery stenosis with hypertension; hypospad ias; hydroureter; 
hydronephrosis; ureteral duplication255"272
1continued!
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CSnical A b n o rm a lity Remarks
Skeletal system
Metaphyseal rad iolucencies O ccu rs in 1 0 % -2 0 % ;  most com m on in distal fem ur and proxim al tibia: 
usually normalizes by 3 m onths of age; due  to a direct inhibitory effect 
of rubella virus on  bone  and  cartilage cells” 3-277
large anterior fontanelle Found  in the m osf severely affected infants273
Miscellaneous problem s M icrognathia: pathologic fractures; myositis
Gastrointestinal system
Hepatosplenomegafy C om m on  (>60% ); transient
Hepatitis O ccu rs in 5 % - 1 0 % ;  may not be associated with jaundice
Obstructive jaundice Infrequent (5%)
Miscellaneous p rob lem s Esophageal, jejunal, or rectal atresia; pancreatitis; chronic  diarrhea
Thrombocytopenic purpura O ccu rs in 5 % - 1 0 % ;  associated with severe disease; transient273'273
Anemia Transient273
Miscellaneous abnorm alities Hemolytic anemia; altered b lood  g ro up  expression279
Immune system
Hypogammaglobulinemia Rare; transient
Thymic hypoplasia Rare;fatal
Endocrine glands Diabetes mellitus; hypothyroidism ; hyperthyroidism ; thyroiditis; growth 
horm one deficiency; p recocious puberty5173230
Table 64
Outline of the centers for disease control criteria for the classification of con- 
___________________genital. Rubella syndrome cases___________________
I. Congenital Rubella Syndrom e Confirmed
Defects present and at least one of the following:
Isolation of rubella virus
Detection of rubella-specific IgM antibodies
Persistence of rubella-specific hemagglutination inhibition (HI) titer beyond 
the period expected from that of passively transferred maternal antibodies
II. Congenital Rubella Syndrom e Compatible
Incomplete laboratory data for confirmation of diagnosis and any two complica­
tions from A or one from A and one from B:
A. Cataracts or congenital glaucoma, congenital heart disease, hearing loss, 
pigmentary retinopathy
B. Purpura, splenomegaly, jaundice, bone radiolucencies, meningoencephali­
tis, microcephaly, mental retardation
III. Congenital Rubella Syndrom e Possible
Some compatible clinical findings but insufficient criteria for the confirmed or 
compatible categories
IV. Congenital Rubella Infection Only
No defects, but laboratory evidence of infection is found
V. Stillbirths
Stillbirths believed to be a consequence of maternal rubella infection___________
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VI. Congenital Rubella Syndrom e Excluded
At least one of the following inconsistent laboratory findings in a child without 
evidence of an immunodeficiency disease:
Absence of rubella-specific HI titer in a child <24 months of age 
Absence of rubella-specific HI titer in the mother
Decrease of rubella-specific HI titer in an infant in a manner consistent with 
that expected from passively transferred maternal antibodies (i.e., a twofold
dilution drop per month)____________________________________________
HI - hemagglutination inhibition.
TREATMENT
There is no specific therapy for CRS. A few patients have been 
treated with amantadine or interferon-a with minimal or no clinical im­
provement. Susceptible pregnant women should avoid contact with CRS pa­
tients during their first year of life. The appearance of delayed manifesta­
tions of CRS that were not present early in life underscores the importance 
of close follow-up. Congential rubella syndrome patients often require sur­
gical correction of heart or genitourinary defects, removal of dense cata­
racts, hearing aids, and special schooling.
HEPATITIS В
Hepatitis В virus afflicts nearly 200,000 to 300,000 persons in the 
United States each year, 6% to 10% of whom become chronic HBV carriers. 
Estimates from the CDC place the number of chronic, infectious HBV car­
riers in the United States at about 1 to 1.25 million people. Globally, the 
number of chronic carriers is approximately 300 million, and more than 
250,000 persons die each year from HBV-related acute and chronic hepatic 
disease. More than a fourth of all carriers develop HBV-related chronic ac­
tive hepatitis, liver cirrhosis, or hepatocellular carcinoma. Chronic carriers 
of this virus can transmit HBV to their offspring during pregnancy; as many 
as 70% to 90% of perinatally infected infants become chronic carriers them­
selves.
The complete HBV is known as the Dane particle and consists of an 
outer lipid-containing envelope and an inner core or nucleocapsid. On the 
surface of the outer coat is the hepatitis В surface antigen (HBsAg), an anti- 
genically complex glycoprotein. HBsAg has many antigenic epitopes that 
permit the identification of several HBV subtypes; the subtyping scheme is 
valuable as an epidemiologic tool, but it has no correlation with disease se­
verity. The surface envelope contains three proteins (i.e., major, middle, and 
large S proteins) coded for by the HBV DNA genome. Variations in the ma­
jor protein account for the subtype determinants, and the middle and large 
proteins are implicated in receptor-mediated virus uptake by hepatocytes.
The virus inner core consists of hepatitis В core antigen (HBcAg), 
hepatitis В e antigen (HBeAg), hepatitis В x antigen (HBxAg), a partially
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double-stranded DNA molecule, DNA-dependent DNA polymerase enzyme 
with reverse transcription activity, and a protein kinase. HBcAg is found 
primarily in the nuclei of infected hepatocytes. In serum, HBcAg is found 
only as a component of circulating Dane particles, but it is never found in 
free form. HBeAg is a prematurely terminated polypeptide product of the 
same gene that codes for HBcAg; its presence in serum indicates infectivity. 
HBxAg is probably an independent marker of infectivity. Hepatitis В virus 
DNA is a partially double-stranded DNA, and HBV DNA polymerase re­
pairs the single-stranded HBV DNA region to form a complete double- 
stranded molecule.
With very sensitive assays, HBsAg can be detected in the blood 
within 1 to 2 weeks of exposure to HBV. However, clinical disease usually 
occurs 1 to 3 months, and occasionally 6 months, after exposure. HBeAg 
can be detected late in the incubation period, usually coinciding with or 
within days of HBsAg appearance. Hepatitis В virus DNA polymerase and 
HBV DNA are measurable at this stage and generally peak by the latter part 
of the incubation period. Their concentrations fall with onset of liver dis­
ease. In patients who recover, HBsAg usually can no longer be detected at 
about the time of clinical resolution.
The earliest antibodies to appear are those directed against HBcAg 
(anti-HBc), typically 2 to 4 weeks after HBsAg is first detected. Anti-HBc 
titers increase during the acute stage of infection and persist for many years. 
Antibodies to HBeAg (anti-HBe) appear immediately after or within several 
weeks of HBeAg clearance and usually while HBsAg is still present. A win­
dow period that occasionally can be as long as 20 weeks follows HBsAg 
clearance from the circulation, during which neither HBsAg nor anti-HBs 
are detectable. However, specific IgM and IgG anti-HBc antibodies are usu­
ally present, and they may be the only laboratory indicators of an acute 
HBV infection. The patient is contagious during this period. After anti-HBs 
antibodies become measurable, their titers continue to increase for approxi­
mately 6 to 12 months. About 18% of patients have detectable HBV DNA 
in their serum for 3 to 6 months after first appearance of anti-HBs antibod­
ies. Anti-HBs antibodies persist for life and protect against future HBV re­
infections. Antibodies to HBxAg (anti-HBx) can be detected in only 17% of 
patients with acute HBV infection and usually appear 3 to 4 weeks after on­
set of clinical symptoms; their clinical significance is not yet defined.
Patients who continue to have detectable serum HBsAg for 20 weeks 
or longer, HBeAg for 10 weeks or longer, or HBV DNA for 4 weeks or 
longer are likely to become chronic HBsAg carriers; their serum anti-HBc 
titers are usually high, and IgM anti-HBc tends to persist for a long time. 
Approximately 25% to 50% of chronic carriers are HBeAg positive, and the 
remainder have anti-HBe. Persons who are positive for HBeAg, HBV DNA 
polymerase, or HBV DNA are highly contagious. Most chronic carriers re-
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main HBV-infected for life, but 1.5% to 2% of carriers spontaneously lose 
their HBsAg each year. About 25% of chronic carriers whose HBsAg re­
solves spontaneously have HBV DNA in their serum that can be detected by 
PCR and are potentially infectious to others; HBV DNA ultimately clears 
from serum.
Young age is an important risk factor for developing the chronic car­
rier state; 70% to 90% of infected newborns become carriers, compared 
with 25% to 50% of children infected before their fifth birthday, and 6% to 
10% of adults. Other risk factors include a positive HIV-1 antibody status, 
hemodialysis, immunodeficiency, Down syndrome, and male gender. Reac­
tivation of chronic HBV infection can occur during pregnancy, but this is 
rare.
CLINICAL MANIFESTATIONS
Most HBV infections are subclinical, particularly in children. Symp­
tomatic infections can be mild and an-icteric or be severe enough to produce 
encephalopathy, coagulopathy, and death. Fulminant hepatitis is more com­
mon in adults than in children and in those infected with certain mutant 
HBV strains or co-infected with the hepatitis delta virus. Extrahepatic dis­
ease may include a serum sickness-type illness in 10% to 20% of patients 
with acute infections, polyarteritis nodosa, membranous glomerulonephritis, 
cryoglobulinemia, and infantile papular aero-dermatitis.
Approximately two-thirds of chronic HBsAg carriers develop chronic 
persistent hepatitis. They are usually healthy but have persistent or recurrent 
serum transaminase elevations. The remaining third eventually develop 
chronic active hepatitis, a progressive disorder that ultimately results in 
postnecrotic liver cirrhosis. Primary hepatocellular carcinoma, a common 
malignant tumor in certain parts of the world such as Southeast Asia, Japan, 
Greece, and Italy, may be as much as 300 times more common in HBsAg- 
positive men than in their HBsAg-negative counterparts. Primary hepatocel­
lular carcinoma develops after an average of 35 years of HBsAg carriage; 
coexisting cirrhosis is found in 60% to 90%.
Most neonates and infants who acquire HBV from their mothers re­
main asymptomatic; those with symptoms typically have benign illnesses. 
Fulminant disease is rare. Most infected infants become chronic carriers and 
have a 25% or greater life-time chance of dying of primary hepatocellular 
carcinoma or liver cirrhosis.
NODES OF TRANSMISSION
HBsAg has been found in blood, blood products, urine, feces, bile, sa­
liva, tears, sweat, semen, vaginal secretions, gastric contents of newborns, 
breast milk, cord blood, CSF, synovial fluid, and wound exudate. Many 
routes for HBV spread are possible, but the most significant ones are percu-
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taneous or permucosal exposure to infected blood or body fluids during 
birth or sexual intercourse or by contaminated needles.
Hepatitis В virus-infected blood can enter the body through contami­
nated needles shared by drug users, if health care providers mistakenly 
puncture themselves, or if other persons reuse unsterilized devices in medi­
cal or dental offices, acupuncture clinics, or tattooing parlors. Contaminated 
blood can be introduced through mucous membranes, open wounds, and 
abrasions.
Screening of blood and blood products for HBsAg has almost eradi­
cated transfusion-acquired HBV infection. Nonetheless, blood that is nonre- 
active to HBsAg may still be infectious. In Taiwan, a region where 15% to 
20% of adults are chronic HBsAg carriers, a study of 206 volunteer blood 
donors who were HBsAg-negative and had normal serum transaminase ac­
tivities revealed that about 4% were positive for HBV DNA in plasma by 
using the PCR; their blood was possibly infectious to susceptible recipients. 
The frequency of HBsAg-negative, HBV DNA-positive blood in the donor 
pool of areas of low HBV endemicity is probably substantially less.
Hepatitis В virus can spread to sexual partners of chronic HBsAg car­
riers or patients with acute hepatitis B. Hepatitis В virus infection is more 
likely in persons with multiple sex partners, more years of sexual activity, 
and histories of other sexually transmitted diseases. Heterosexual transmis­
sion now accounts for 25% of new HBV cases in the United States, a 38% 
increase from the early 1980s. It is the most important risk factor for 
women, with parenteral drug abuse in second place. Close, long-term con­
tact with chronic carriers, as happens in households or institutions for the 
developmentally disabled, is a risk factor. Intrafamilial nonsexual transmis­
sion accounts for 2% of new HBV infections in the United States each year. 
Transplanted organs are uncommon vehicles of HBV spread to susceptible 
recipients. About 30% to 40% of all patients have no identifiable risk fac­
tors.
PERINATAL EPIDEMIOLOGY
About 0.2% of American Caucasians and 0.9% of African Americans 
are HBsAg positive. The prevalence is notably higher in certain high-risk 
groups, such as immigrants from areas of high HBV endemicity (13%), 
Alaskan natives or Pacific islanders (5%-15%), clients in institutions for the 
developmentally disabled (10%-20%), users of illicit parenteral drugs (7%), 
household contacts of an HBV carrier (3%-6%), health care workers with 
frequent blood contact (l%-2%), and heterosexuals with multiple partners 
(0.5%).
Perinatal HBV transmission accounts for 35% to 50% of all chronic 
carriers of this virus in high-incidence areas, such as Taiwan, and for about 
15% of those in intermediate-incidence areas, such as certain
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African countries. Vertical transmission accounts for a small fraction 
of cases of chronic infection in areas of low endemicity, such as the United 
States, where most HBV infections are acquired in adulthood.
The rate of vertical transmission from mother to infant hinges on sev­
eral factors. For women with acute HBV infection, the risk is about 76% if 
infection occurs during the third trimester or shortly after delivery, but it is 
only about 10% if it takes place during the first or second trimesters. For 
HBsAg carrier mothers, the risk of mother-to-infant transmission depends 
on their HBeAg/anti-HBe status. The rate is estimated to be 70% to 90% for 
those who are HBeAg positive, 31 % for those who are negative for HBeAg 
and anti-HBe, and 10% or less for those who are positive for anti-HBe. 
About a third of HBsAg-positive pregnant women in the United States are 
also HBeAg positive. Other variables that enhance vertical transmission are 
high maternal HBsAg and anti-HBe titers and a high HBV DNA concentra­
tion. Carrier mothers can transmit HBV to infants born after sequential 
pregnancies.
Mother-to-infant transmission occurs during delivery in most cases 
through transplacental microhemorrhages or from ingestion of contaminated 
maternal secretions. Intrauterine infection is uncommon but may account 
for 5% to 15% of cases for HBeAg-positive mothers. HBsAg is found in 
about 71% of breast milk samples from carrier mothers, but no differences 
in antigenemia rates have been found between breast-fed and bottle-fed in­
fants born to infected mothers.
Unimmunized infants who acquire HBV infection from their mothers 
usually have no detectable serum HBsAg until 1 to 4 months later. Passively 
acquired low levels of HBsAg may be detected in the peripheral blood of 
some neonates, and they do not necessarily imply HBV infection. Cord 
blood should not be used for HBsAg testing because it can be contaminated 
with maternal blood.
IMMUNOPROPHYLAXIS
Two preparations have been employed for passive immunization 
against HBV: immune serum globulin and hepatitis В immunoglobulin 
(HBIG). Immune serum globulin has anti-HBs titers of 1:16 to 1:1,000. 
Hepatitis В immunoglobulin, a hyperimmunoglobulin product, has anti-HBs 
titers of 1:100,000 to 1:250,000. Hepatitis В immunoglobulin is prepared 
from plasma obtained from HIV antibody-negative donors with a high anti- 
HBs titer, and its administration does not interfere with the host's immune 
response to hepatitis В vaccines.
Plasma-derived and recombinant hepatitis В vaccines are used for ac­
tive immunization. The plasma-derived vaccine, Heptavax-B, is no longer 
manufactured in the United States. Two recombinant hepatitis В vaccines 
are available: Recombivax HB and Engerix-B. These vaccines are prepared
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by insertion of a plasmid containing the HBsAg gene into common bakers' 
yeast, followed by lysis of yeast cells after the intra-celiular production, as­
sembly, and accumulation of HBsAg polypeptides. HBsAg is later separated 
from disrupted yeast cell components; less than 5% of the final product is 
yeast-derived protein. Recombivax HB contains 10 pg of HBsAg pro- 
tein/mL, and Engerix-B contains 20 pg/mL.
The CDC's recommended regimen for primary hepatitis В vaccination 
consists of three intramuscular doses given at 0, 1, and 6 months; an alterna­
tive schedule of four doses given at 0, 1, 2, and 12 months has been ap­
proved for Engerix-B only. The three-dose schedule induces a good anti­
body response in more than 90% of healthy adults and more than 95% of 
pediatric patients (i.e., newborn through 19 years of age). Hepatitis В vac­
cines have a protective efficacy of 80% to 95% when given to susceptible 
recipients. About 30% to 50% of vaccinees have no detectable anti-HBs 
titer after 7 years. The optimal schedule for booster doses has not been de­
fined.
Children younger than 11 years of age can be immunized with 0.5 mL 
per dose of the Engerix-B vaccine, and adolescents and adults need 1.0 mL 
per dose. The regimen for Recombivax HB consists of 0.5 mL per dose for 
infants of HBV-carrier mothers, 0.25 mL per dose for other infants and chil­
dren younger than 11 years of age, 0.5 mL per dose for adolescents 11 to 19 
years of age, and 1.0 mL per dose for adults.
Susceptible pregnant women with accidental percutaneous or permu- 
cosal exposure to HBV-infected blood or who have had sexual contact with 
a chronic HBV carrier or an acutely infected man should receive 
immunoprophylaxis. Regimens using multiple HBIG doses or vaccine alone 
are only 70% to 85% effective in preventing HBV infection if used for 
postexposure prophylaxis of otherwise healthy persons.
Pregnancy is not a contraindication to hepatitis В vaccination. How­
ever, vaccine manufacturers advise against their use during pregnancy for 
liability reasons. Avoidance of vaccination in early pregnancy (i.e., period 
of embryogenesis) is recommended by some experts. No fetal or maternal 
risks from hepatitis В vaccination are known, and the limited available data 
suggest that its use in early or late pregnancy is safe.
Immunoprophylaxis after exposure to HBV-contaminated blood 
should consist of two doses of HBIG (0.06 mL/kg given intramuscularly; 
maximum, 5 mL). The first dose of HBIG should be given as soon as possi­
ble or within 24 hours of exposure; its effectiveness when given after 7 days 
of exposure is unknown. The second dose is given 1 month later. This regi­
men has not been specifically evaluated in pregnant women, but it is about 
75% effective in preventing infection in healthy persons. If the physician 
decides to use the hepatitis В vaccine, which is the preferred approach, only 
one HBIG dose needs to be given; the vaccine should be administered in­
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tramuscularly-at a  site different from that used for HBIG, the first dose can 
be given concomitantly with HBIG or within 7 days of exposure. For sexual 
HBV exposure, the prophylactic regimen is similar, except last immuniza­
tion can begin within 14 days of the last sexual encounter.
PREVENTION OF PERINATAL HEPATITIS В VIRUS TRANSMISSION
The CDC estimates that 22,000 births per year occur to HBsAg- 
positive women in the United States and, unless immunoprophylaxis is 
given at birth, about 6000 of these newborns become chronic HBV carriers. 
The administration of HBIG and the initiation of hepatitis В vaccination is 
85% to 95% effective in preventing the development of the chronic carrier 
state in these infants.
The CDC initially recommended that all high-risk women be screened 
for HBsAg during pregnancy. However, targeting women in high-risk 
groups identifies only about 35% to 65% of HBsAg carriers. The guidelines 
were later revised, and universal prenatal screening for HBsAg is now 
recommended. All pregnant women should be routinely screened for 
HBsAg during an early prenatal visit. HBsAg-negative women at high risk 
for infection (e.g., those with other sexually transmitted diseases, illicit drug 
users) should be retested late in pregnancy. Opinions are divided regarding 
the cost-effectiveness of this approach when applied to low-risk prenatal 
populations.
Infants bom to HBsAg-positive mothers should be bathed as soon as 
possible to remove HBV-infected blood and other secretions. Suctioning of 
the stomach contents, if needed, should be performed gently to avoid muco­
sal trauma that could promote HBV entry into the blood. Delivery by elec­
tive cesarean section has been advocated by some as a way of reducing ma­
ternal-infant HBV transmission; this approach is not recommended because 
of the lack of evidence to support the practice and because of the efficacy of 
immunoprophylaxis.
Hepatitis В immunoglobulin at a dose of 0.5 mL intramuscularly 
should be given as soon as possible afterbirth and no later than 12 hours of 
life. An HBIG dose given at 12 to 48 hours of life is probably effective, but 
this has not been proved. The first vaccine dose should be given within the 
first week of life, preferably within the first 12 hours. The intramuscular 
dose is 0.5 mL, regardless of the vaccine product used. Later doses are 
given at 1 and 6 months of age. Breast-feeding should be allowed for infants 
who have started immunoprophylaxis.
The CDC and the American Academy of Pediatrics recommend uni­
versal hepatitis В vaccination of all infants, regardless of the maternal 
HBsAg status. Infants born to HBsAg-positive women are given HBIG and 
the vaccine as outlined earlier. Infants born to women admitted in labor and 
whose HBsAg status is unknown should receive the first dose of the vaccine
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within 12 hours of birth in the dosage used for those born to HBsAg- 
positive mothers (i.e., 0.5 mL of either vaccine type); maternal HBsAg test­
ing should be immediately performed, and if positive, the infant should re­
ceive HBIG (0.5 mL) as soon as feasible after birth and no later than 7 days 
of age. The second and third vaccine doses are given at 1 to 2 months and at 
6 months of age, respectively. Household contacts and sex partners of 
HBsAg-positive women should be vaccinated against hepatitis B; prevacci­
nation susceptibility testing should be done in adults whenever possible but 
is not required in children because of low rates of HBV infection in that age 
group and the lower costs of smaller individual vaccine doses.
The recommendations for infants born to HBsAg-negative mothers 
are different. These infants do not need HBIG administration. The vaccine 
dose depends on the product used. Recombivax HB is given in a dose of 
0.25 mL, and the Engerix-B dose is 0.5 mL. Two schedules for vaccine de­
livery are acceptable, but the preferred one involves giving the first vaccine 
dose to newborns before hospital discharge, the second dose 1 to 2 months 
later, and the third dose at 6 to 18 months of age. An alternative schedule 
for those not immunized at birth is to give the three vaccine doses at 2, 4, 
and 6 to 18 months of age. Hepatitis В virus vaccines can be given concur­
rently but in different syringes with poliomyelitis, diphtheria-tetanus- 
pertussis, measles-mumps-rubella, or Haemophilus influenzae type b conju­
gate vaccines.
Massive newborn immunization programs are already in place in at 
least 20 countries. In the United States, such programs have been success­
fully implemented in high-incidence areas, such as Alaska and American 
Samoa.
Infants who become infected despite immunoprophylaxis may have 
been infected in utero, or their mothers may have had a high virus load. In­
fants who fail immunoprophylaxis do not become HBsAg positive until 6 to 
9 months of age. Immunized infants born to HBsAg-positive mothers 
should be tested at the age of 9 months or later for HBsAg and anti-HBs; 
those negative for both should receive a fourth vaccine dose and be tested 
again 1 month later, and infants found to be HBsAg positive should be 
monitored closely to determine whether a chronic carrier state has devel­
oped.
HERPES SIMPLEX VIRUS INFECTIONS
Infections caused by HSV are common. Conservative estimates indi­
cate that in the United States each year almost 500,000 people have their 
first episode of genital herpes, and another 10 million have recurring genital 
lesions. Neonatal HSV infection occurs in at least 700 to 1000 newborns, 
and approximately 720,000 cesarean sections are performed annually for the 
purpose of preventing neonatal herpetic infection. The optimal management
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of women with active or suspected genital HSV infections during pregnancy 
or at labor is not well-defined.
Herpes simplex virus is a double-stranded DNA virus that can infect a 
broad range of hosts. The virus enters the body through mucosal surfaces or 
abraded skin, and it multiplies in cells of the epidermis or dermis. Sensory 
or autonomic nerve endings in its vicinity become infected, and the virus 
travels intraaxonally in a retrograde fashion to the ganglia. Herpes simplex 
virus can then continue its multiplication in the ganglia and later spread to 
other skin and mucous membrane areas through anterograde travel along pe­
ripheral sensory nerves, or it can enter a phase of latency in the ganglia. The 
virus intermittently reactivates and travels to the body surface, where it can 
produce clinical disease. Exposure to ultraviolet light, trauma to skin, or 
immunosuppression can provoke HSV reactivation. Antibody-and cell- 
mediated immune reactions are generated in response to HSV, both of 
which are important for control of the infection.
The various HSV strains found in the general population can be 
grouped into two serologic subtypes, HSV-1 and HSV-2. The two subtypes 
can be differentiated on the basis of their cell culture range, restriction en­
donuclease analysis, or by monoclonal antibody-based serologic assays.
Seven HSV glycoproteins (g) have been characterized; three (i.e., B, 
D, H) are essential for HSV replication, and four (i.e., С, E, G, I) are not es­
sential for viral multiplication but may play a role in the patho-genesis and 
spread of HSV. One of the glycoproteins, gG-2, is a highly type-specific an­
tigen and has been found to be helpful in differentiating HSV-1 from HSV- 
2 antibody responses.
MATERNAL INFECTION
EPIDEMIOLOGY
Serologic surveys conducted in the United States reveal that the 
prevalence of antibodies to HSV increases with age, and it is higher in per­
sons from lower socioeconomic strata and in groups with greater levels of 
sexual activity. Antibodies to HSV-1 may be present in 90% or more of 
adults from lower socioeconomic groups but only about 30% of college stu­
dents. Antibodies to HSV-2 are present in approximately 16.4% of the 
United States population 15 to 74 years of age and in 20.2% of the group 30 
to 44 years old. African-Americans are more likely to have antibodies 
against HSV-2 than American Caucasians. Among African Americans, 
women are twice as likely as men to be seropositive for this virus. Higher 
seropositivity rates (17%-32%) have been documented when populations of 
pregnant women were studied, and this appeared to be independent of so­
cioeconomic status. A recent survey that focused on adults in an inner-city 
community found that 62% and 33% had antibodies against HSV-1 and 
HSV-2 respectively. Herpes simplex virus type 1 seropositivity was signifi-
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cantly correlated with being Hispanic or African American, and HSV-2 
seropositivity significantly correlated with being female or African Ameri­
can or Hispanic and with low educational level and the number of lifetime 
sexual partners.
By measuring type-specific antibodies against HSV-2 gG in a group 
of 190 pregnant women and their husbands, Kulhanjian and colleagues 
found that 73% of the couples were concordant with respect to their HSV-2 
serologies (i.e., both partners were seronegative or seropositive). However, 
about 9.5% of the pregnant women were seronegative but had seropositive 
spouses, and they were therefore at risk for gestational primary HSV-2 in­
fection; 56% of these husbands had no history of previous genital HSV in­
fection. Approximately 5% of pregnant women in this particular study were 
susceptible to HSV-2 infection but were unaware of their risk for acquiring 
the virus from their seropositive spouses who gave no history of prior geni­
tal herpes.
Asymptomatic shedding of HSV occurs in 0.2% to 7.4% of pregnant 
women and in 0.2% to 4% of those at or near term. Most HSV infections 
during pregnancy represent recurrent disease. The frequency of asympto­
matic shedding increases as pregnancy advances.
CLINICAL MANIFESTATIONS
Many primary HSV infections are subclinical. Symptomatic primary 
HSV disease can include gingivostomatitis, genital herpes, herpetic whit­
low, keratitis, chorioretinitis, encephalitis, esophagitis, pneumonia, and 
hepatitis.
The most common manifestations of primary HSV-1 infections are 
gingivostomatitis and pharyngitis. Herpes simplex virus type 1 causes 7% to 
50% of primary genital herpes infections. Recurrent episodes of herpes labi- 
alis are common, and HSV-1 may be recovered from the pharynx of as 
many as 5% of asymptomatic healthy persons.
The most common clinical illness caused by HSV-2 is genital herpes. 
Most initial HSV-2 infections are subclinical or mild. Symptomatic patients 
can have extensive, painful, vesicular or ulcerative genital lesions with or 
without associated systemic manifestations. Women with recurrent disease 
typically have mild or subclinical infections. Serious complications of HSV 
infections include pneumonia, hepatitis, and encephalitis. The likelihood of 
reactivation of HSV infection is greater for genital than oral-labial disease 
and for HSV-2 than for HSV-1. Asymptomatic HSV-2 shedding occurs 
more often during the first 3 months after the primary genital HSV-2 infec­
tion than during subsequent periods.
Genital herpes infections are categorized according to HSV subtype, 
serologic evidence of past HSV-1 or HSV-2 infection, and the presence or 
absence of symptoms. This classification scheme is useful when examining
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the impact of gestational HSV infection on pregnancy outcome according to 
the type of maternal genital infection. First episode, primary HSV-1 or 
HSV-2 infection is considered if the virus is isolated from the genital tract 
of a symptomatic or asymptomatic woman who has no serologic evidence 
of prior infection with HSV-1 or HSV-2 in the acute phase serum, but she 
subsequently has antibodies to the same HSV subtype when convalescent 
serum is tested. If the acute-phase serum contains antibodies to the other 
HSV subtype (e.g., HSV-1 antibodies in a woman with an HSV-2 genital 
isolate), first episode, nonprimary genital infection is considered present. 
Recurrent HSV-1 or HSV-2 infection is diagnosed if the patient has 
antibodies to the same HSV subtype isolated from the genital tract in the 
acute- and convalescent-phase sera.
DIAGNOSIS
The diagnosis can be made by isolating the virus from tissue cultures 
of clinical specimens. The best specimen is usually vesicle fluid obtained 
within 3 days of its appearance. Positive culture results may be obtained 
within 16 hours to 7 days, depending on the viral load in the clinical speci­
men. Shell vial cultures may become positive within 16 to 48 hours. Direct 
detection of HSV antigens in exfoliated cells using a DFA stain can yield a 
positive result within 45 minutes. The Tzanck smear is a rapid and inexpen­
sive method, but it is only 60% sensitive for HSV infections. It involves 
scraping the base of a fresh vesicle with a scalpel and spreading the cells 
and debris on a glass slide. The adherent cells are stained with Giemsa, 
Sedi, or Wright stain. The slide is examined for the presence of virus- 
induced cytopathic abnormalities such as multinucleated giant cells, atypi­
cal keratinocytes with large nuclei, and ground-glass cytoplasm. A positive 
Tzanck smear cannot differentiate between VZV and HSV lesions.
Serologic diagnosis is infrequently used for the diagnosis of acute 
HSV infections. Herpes simples virus-specific IgM may be detected within 
3 to 10 days of onset of infection, and it persists for 6 to 8 weeks. 
Demonstration of seroconversion or a fourfold rise in HSV-specific IgG 
titers is significant.
Molecular biologic techniques have been applied for the diagnosis of 
HSV infection through the detection of viral DNA in clinical specimens. 
The PCR continues to detect HSV DNA in clinical specimens for several 
days after the culture becomes negative; the test is relatively rapid and can 
be completed within a few hours. The clinical relevance of culture-negative, 
PCR-positive results from genital specimens remains to be elucidated. Po­
lymerase chain reaction detection of HSV DNA in CSF specimens helps in 
the diagnosis of herpes encephalitis. Because the PCR technique is sensitive 
to even minuscule amounts of HSV, contamination from external sources, 
such as laboratory personnel, physicians, or nurses who may be shedding
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the virus, can yield false-positive results. Extreme care should be taken 
while handling the CSF specimen to avoid making an erroneous diagnosis 
of herpes encephalitis and possibly missing the true culprit.
TREATMENT
Acyclovir is the drug of choice for primary and symptomatic recur­
rent genital HSV infection. The drug inhibits the replication of HSV-1, 
HSV-2, and VZV. Acyclovir is converted in the body to its active tri­
phosphate form, initially through the action of viral thymidine kinase to the 
monophosphate form and later by cellular enzymes to the diphosphate and 
triphosphate forms. Acyclovir triphosphate concentrations are 40 to 100 
times higher in HSV-infected cells than in uninfected cells. The active form 
of the drug competes with deoxyguanosine triphosphate as a substrate for 
viral DNA polymerase and, once incorporated into viral DNA, leads to ter­
mination of HSV DNA synthesis.
The use of acyclovir during pregnancy is not approved and is gener­
ally reserved for life-threatening or severe HSV infections such as pneumo­
nia. Maternal antiviral therapy may fail to prevent fetal infection with HSV. 
Acyclovir is teratogenic in rats. It can cross the placenta, becomes concen­
trated in amniotic fluid, and can accumulate in human breast milk.
A registry of acyclovir use in pregnancy was established in June 
1984. As of June 30, 1990, 312 acyclovir-exposed pregnancies had been re­
ported and followed. Of 239 exposures that took place during the first tri­
mester, outcomes included 24 spontaneous fetal losses, 47 induced abor­
tions, 159 live births without congenital malformations, and 9 with congeni­
tal anomalies. Among 73 second- and third-trimester exposures, 1 infant 
only was born with an anomaly. These findings were not different from 
what was expected for the general population of pregnant women. Although 
the size of the cohort is relatively small, the data provide some reassurance 
for women who are inadvertently treated with acyclovir during pregnancy 
or have major HSV-related diseases such as pneumonia or encephalitis.
Acyclovir-resistant HSV strains are uncommon, except in patients 
with AIDS. The mechanism of resistance appears to be a mutation that ren­
ders the virus thymidine kinase deficient. Infections caused by these acy­
clovir-resistant HSV strains can be treated with foscarnet or vidarabine; nei­
ther drug is approved by the Food and Drug Administration for use during 
pregnancy.
FETAL AND NEONATAL INFECTION
EPIDEMIOLOGY
Most neonatal HSV infections are acquired during passage through an 
infected birth canal. Transplacental spread occurs occasionally, with major 
deleterious fetal effects. Primary HSV infections during the first one-half of
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gestation are associated with significantly greater frequencies of spontane­
ous abortions and stillbirths. About 40% of newborns with herpes are deliv­
ered before week 36 of pregnancy.
Intrapartum transmission is more likely to occur with primary mater­
nal HSV genital infection. Other risk factors for HSV acquisition by the in­
fant are cervical HSV infection, multiple genital lesions, prematurity, pro­
longed rupture of maternal membranes, intrauterine instrumentation (e.g., 
scalp electrodes), and absent or low titers of transplacentally acquired neu­
tralizing anti-HSV antibodies. The risk of vertical transmission is about 
40% to 50% for mothers with primary herpes and about 5% for those with 
recurrent infections. Postpartum HSV spread to newborns occurs infre­
quently.
CLINICAL MANIFESTATIONS
Asymptomatic HSV infections are rare in the newborn. Disease mani­
festations may be localized or widely disseminated. About 60% to 80% of 
infants with HSV infections are born to women who are asymptomatic at 
the time of delivery and who have no history of genital herpes. Infants born 
to asymptomatic women shedding HSV in early labor are 10 times more 
likely to develop neonatal HSV infection if the mother has recently experi­
enced a first episode genital herpes than neonates born to women whose 
HSV shedding is secondary to reactivated infection. Serious perinatal mor­
bidity is encountered in 40% of infants born to women who acquire primary 
genital herpes during pregnancy.
Intrauterine HSV infection is uncommon. Its hallmarks are a vesicular 
rash that is present at birth or appears shortly thereafter; associated abnor­
malities include microcephaly (60%), chorioretinitis (40%-50%), and mi­
crophthalmia (25%). The rash is more likely to be generalized than local­
ized. Other skin lesions include bullae and cutaneous scars in 10% to 15% 
of patients. The intracranial calcifications seen in 15% may be present at 
birth or evolve later in infancy. Lesions indicative of brain damage, such as 
hydranencephaly, cerebral necrosis, and brain atrophy, can be seen on com­
puted tomography (CT) scans of the head. Other findings can include radio- 
graphic bone lucencies, intrauterine growth retardation, hepa- 
tosplenomegaly, cloudy corneas, and cataracts. About 30% have seizures 
during the neonatal period. The mortality rate is 40%, and about one-half of 
the survivors are expected to have significant long-term residual problems 
such as psychomotor retardation, seizure disorders, spasticity, blindness, or 
deafness. Most cases have been caused by HSV-2.
About a fourth of infants with neonatal HSV infection become sick 
within the first day of life, and about two-thirds are ill by the end of the first 
week. Infections resulting from the intrapartum acquisition of HSV may not 
manifest until about 10 to 11 days of age with disease localized to the skin,
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eyes, or oral cavity. Cutaneous lesions include discrete vesicles, large bul­
lae, or denuded skin (Fig. 42). Recurrent mucocutaneous herpes develops in 
some of these infants. Ulcerative mouth lesions without skin disease may 
sometimes occur. Eye disease includes keratoconjunctivitis and 
chorioretinitis. Neurologic abnormalities eventually develop in 25% of these 
infants, despite the fact that CNS involvement may not have been evident 
during the acute illness.
A second group of infants may present at 15 to 17 days of age with 
localized CNS involvement, with or without skin, mouth, or ocular lesions. 
The mortality rate for this group is about 17%, and 40% of survivors suffer 
long-term sequelae.
FIG. 42. Localized cutaneous herpes simplex virus type 2 infection in a neonate. Notice 
the coalescing vesicular lesions on the back and right arm. The vesicles are surrounded 
by an erythematous border.
A third group presents at 9 to 11 days of age with disseminated dis­
ease. CNS involvement is found in about two-thirds of these infants; other 
organs that are severely affected are the adrenal glands, gastrointestinal 
tract, liver, heart, pancreas, and kidneys. Without appropriate therapy, about 
80% die. With acyclovir therapy, the mortality rate is 15% to 20%, but 40% 
to 55% of the survivors have severe neurologic impairments.
The National Institute of Allergy and Infectious. Diseases Collabora­
tive Antiviral Study Group (NIAID CASG) recently published their findings 
on 210 infants younger than 1 month of age with HSV infection. About 4% 
of infants had congenital HSV infection, and 40% had disease confined to 
the skin, eyes, or mouth. Central nervous system disease occurred in 34%, 
and 22% had disseminated infections. Two-thirds of the isolates were HSV- 
2 .
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The clinical manifestations of herpes encephalitis in the newborn in­
cludes focal or generalized seizures, lethargy, apnea, and pyramidal tract 
signs. Eventual loss of gag and suck reflexes is common. Involvement of 
other organs is frequent. Skin vesicles may be absent in about 40% of in­
fants, mandating a high index of suspicion for the diagnosis. Cerebrospinal 
fluid analysis reveals mononuclear pleocytosis and elevated protein concen­
trations (as high as 1000 mg/dL). Rarely, the CSF may show a predomi­
nance of neutrophils or be completely normal. Focal or generalized electro- 
encephalographic abnormalities are common. About 8% of surviving infants 
have CNS relapse within 1 month of completing therapy.
Ocular herpetic infection may be an isolated problem, but it is more 
likely to occur in infants with CNS disease. Eye abnormalities include 
keratitis, conjunctivitis, chorioretinitis, optic atrophy, and cataracts. Long­
term follow-up studies of survivors of neonatal HSV infection indicate that 
40% (94% in patients with neurologic impairment; 20% in patients who are 
neurologically normal) have persistent abnormalities, such as cataracts, cor­
neal scars, optic atrophy, and churioretmal scars; about 44% have disturbed 
oculomotor control.
Herpes simplex virus pneumonia usually presents between days 3 and 
14 of life with gradually worsening respiratory distress. Chest roentgeno­
grams reveal perihilar infiltrates that gradually progress into severe diffuse 
interstitial and alveolar disease (i.e., "white-out" lungs). Other findings in­
clude thrombocytopenia, neutropenia, jaundice, and hyperammonemia. The 
mortality rate of neonatal HSV pneumonia is about 80%, and almost 100% 
in infants with pneumonia and disseminated intravascular; coagulopathy.
DIAGNOSIS
Neonatal HSV infections are best diagnosed by isolating the virus 
from a vesicular lesion. The virus can be recovered from 25% to 40% of 
CSF specimens obtained from infants with CNS disease. Cultures of urine, 
feces, nasopharyngeal secretions, and conjunctivae may yield the virus in 
some patients. Serology is not useful in neonatal HSV infections. Direct 
fluorescent antibody staining of scrapings from the base of fresh vesicles 
may reveal HSV antigens. In culture-negative infants, the use of molecular 
techniques such as the PCR may establish the diagnosis.
TREATMENT
Antiviral therapy with acyclovir or vidarabine is the mainstay of 
treatment. In the NIAID CASG reports, infants treated with acyclovir or vi­
darabine had comparable morbidity and mortality rates. No deaths occurred 
among 85 infants with localized skin, eyes, or mouth disease; about 94% 
seemed developmentally normal after 1 year. The mortality rates for the en­
cephalitis and the disseminated HSV groups were 14% and 54%, respec­
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tively, and 40% to 70% of the survivors were neurologically impaired. Fac­
tors influencing mortality included level of consciousness at the start of 
treatment, prematurity, disease classification, pneumonia, and disseminated 
intravascular coagulopathy. Cutaneous HSV recurrences occurred in 46% of 
survivors by 6 months after the end of therapy, and the rates were similar 
for infants treated with acyclovir or vidarabine. Seventy-five percent of 
survivors with disease caused by HSV-2 were impaired, compared with 
27% of infants with HSV-1 infection. This is explained partially by the 
greater in vitro susceptibility of HSV-1 to acyclovir. Infants receiving 
acyclovir shed lower virus titers than those on vidarabine. Given the ease of 
administration of acyclovir compared with vidarabine, its fairly benign 
toxicity profile, and its efficacy against HSV, acyclovir (10 mg/kg/dose 
given every 8 hours intravenously) is preferred as initial therapy of 
suspected or proven neonatal HSV infections. Dosage reductions are needed 
in infants with renal or hepatic dysfunction. The optimal duration of therapy 
is unknown, but it appears that 14 days to 21 days may be preferable to the 
10-day course; higher dosage regimens (about 60 mg/kg/day) are being 
evaluated, but no data are available yet. Topical antiviral agents such as the 
ophthalmic preparations of trifluorothymidine, vidarabine, or 
iododeoxyuridine should be used in newborns with ocular involvement. The 
use of commercial intravenous y-globulin preparations for HSV 
postexposure prophylaxis or treatment of neonates is not recommended.
PREVENTION
Because of the enormous morbidity and mortality rates of neonatal 
HSV infections despite the early initiation of antiviral therapy, the focus of 
many research groups has been the development of effective prevention 
strategies. In a detailed decision analysis study, Libman and colleagues used 
published data to theoretically evaluate nine different obstetric approaches 
for the prevention of neonatal HSV disease. The investigators concluded 
that, given the state of technology, physical examination at the time of labor 
was the most reasonable strategy. This tactic would be expected to reduce 
the number of neonatal HSV cases by 36% while increasing the rate of ce- 
sar-ean sections by only 3%. The strategy of obtaining genital HSV cultures 
at weekly intervals from women with a history of recurrent genital herpes 
and then delivering by cesarean section those whose most recent culture re­
sults were positive by onset of labor would result in 547 additional cesarean 
sections performed to prevent less than one case of neonatal HSV infection 
(rates per 100,000 deliveries). Studies on women with histories of recurrent 
genital herpes have demonstrated that weekly antepartum cultures fail to 
predict the risks to their infants of HSV exposure at delivery and that most 
infants exposed to asymptomatic HSV shedding at delivery are born to 
women without a history of recurrent genital herpes infection. Use of rapid
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antigen detection methods on all women in labor would be the most effec­
tive approach in terms of preventing neonatal disease, but this would come 
at the cost of a 10-fold increase in the number of cesarean sections.
Cesarean section should be performed on women with signs and 
symptoms suggesting genital HSV infection at the onset of labor. Infants 
delivered through an infected birth canal should be isolated to protect other 
infants in the nursery. The risk of invasive HSV infection is small for in­
fants delivered vaginally to women with recurrent genital herpes who are 
asymptomatic but shedding the virus at the time of labor. Cultures of ex­
posed mucous membranes (e.g., eyes, nasopharynx) should be obtained at 
24 to 48 hours of life. Earlier positive cultures may reflect transient con­
tamination and not true infection. If the cultures are positive for HSV, anti­
viral therapy should be started, even if the infant is asymptomatic.
Numerous HSV candidate vaccines are currently in various stages of 
development. Although animal protection studies have provided encourag­
ing results, clinical trials with one vaccine type have been disappointing. 
None of the HSV vaccines are available commercially.
CYTOMEGALOVIRUS INFECTIONS
Cytomegalovirus is the most common congenital viral infection of 
humans in the United States. It is one of the most important opportunistic 
pathogens causing serious illness and death in immunocompromised pa­
tients. Cytomegalovirus infections are benign for most adults. However, 
when CMV infection occurs during pregnancy, the virus can be transmitted 
to the fetus and result in symptomatic neonatal disease or subclinical con­
genital infection that may later manifest with hearing loss or learning dis­
abilities.
Cytomegalovirus is an enveloped, double-stranded DNA virus that 
belongs to the herpes family of viruses. Cytomegalovirus is not eradicated 
after resolution of the primary infection. It persists in the body in a low- 
grade chronic infection form or in a latent state with periodic reactivations. 
Cytomegalovirus transmission occurs primarily by direct or indirect person- 
to-person spread of infected oropharyngeal secretions, sexual intercourse, 
blood transfusions, or transplacental spread from mother to fetus.
MATERNAL INFECTION
Serologic surveys in the United States and Great Britain have shown 
that about 40% to 60% of adults of middle or upper socioeconomic status 
have antibodies to CMV; the seropositivity rate is about 80% for adults of 
lower socioeconomic status. The higher the prevalence of maternal CMV 
antibody in a population, the greater is the rate of congenital CMV infec­
tion. Factors correlating with CMV seropositivity m pregnant women in­
clude non-Caucasian race, unmarried status, lower educational and income
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levels, and increasing parity. Sexual activity is an important risk factor for 
CMV infection in adolescent girls, and co-infection with bacterial vagino­
sis, trichomoniasis, or gonorrhea increases the odds of intrauterine CMV 
transmission.
Intrafamilial CMV transmission from young children to their sero­
negative pregnant mothers can occur. The risk of CMV seroconversion for a 
seronegative mother with an infected child is estimated at 10% to 30% per 
year and is even higher if the child is younger than 20 months of age. An­
nual seroconversion rates for seronegative day-care providers is about 8%. 
Health care workers with CMV-infected patient contact do not appear to be 
at increased risk for CMV acquisition compared with persons without pa­
tient contact.
About 2% to 2.5% of susceptible women acquire primary CMV infec­
tion during pregnancy, a risk comparable to that of nonpregnant women. 
Seropos-itive women can reactivate their latent CMV infection during preg­
nancy or, less commonly, become reinfected by an exogenous CMV strain. 
Pregnant women may shed CMV from the cervix (8%), urinary tract (4%), 
throat (2%), and breast milk in the post-partum period (14%).
Primary and recurrent maternal CMV infection can result in transmis­
sion of the virus to the fetus. This occurs in about 40% of pregnancies com­
plicated by primary CMV infection. The presence of maternal antibodies to 
CMV in women with recurrent infection does not prevent viral transmission 
to the fetus, but it does protect against major fetal damage by CMV.
Most women (90%) with primary CMV infection are asymptomatic. 
The remainder usually have illnesses resembling infectious mononucleosis. 
Other manifestations are rare but include interstitial pneumonia, myocardi­
tis, aseptic meningitis, hepatitis, colitis, thrombocytopenia, and hemolytic 
anemia. Primary CMV infection during the first trimester of pregnancy does 
not cause fetal loss.
Infection can be documented by isolating the virus from urine, saliva, 
buffy coat, or cervical secretions. Viral isolation, however, does not differ­
entiate between primary and recurrent CMV infections. Measurement of 
CMV-specific IgM antibodies is useful for the diagnosis of primary infec­
tion, but this antibody can persist in serum for 4 to 8 months. Cyto­
megalovirus-specific IgG antibody levels are helpful if seroconversion or a 
fourfold titer rise can be demonstrated. The IFA and ELISA are the most 
practical and reliable methods for detecting CMV antibodies. Rapid diagno­
sis of CMV infection is possible using newly developed antigen assays or 
molecular biologic techniques such as the PCR.
Ganciclovir, an acyclic nucleoside analog of acyclovir, has excellent 
inhibitory activity against CMV. It has been extensively evaluated in im­
munocompromised patients (e.g., AIDS, organ transplant recipients) with 
serious CMV infections such as pneumonia or retinitis, but its use in im­
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munocompetent persons has not been examined. Foscarnet (phosphonofor- 
mate), another anti-CMV drug, inhibits the DNA polymerase of CMV. Like 
ganciclovir, foscarnet is used only in the immunosuppressed patient with 
CMV disease.
CONGENITAL INFECTION
Congenital infection with CMV occurs in 0.4% to 2.3% of all live 
births. About 10% are symptomatic, and the rest have subclinical infections. 
Infants with symptomatic congenital CMV have a mortality rate of 15% to 
30%, and most survivors have long-term sequelae. Petechiae, jaundice, and 
hepatosplenomegaly are found in two-thirds of patients; conjugated hyper­
bilirubinemia and thrombocytopenia are found in about 80% of cases. Neu­
rologic abnormalities such as seizures and hypotonia are common, and mi­
crocephaly occurs in about 50% to 75% of infants. Intracranial calcifica­
tions are seen on one-half of the patients' CT scans. At autopsy, evidence of 
multiorgan involvement is apparent. Neuropathologic findings include 
periventricular necrosis, calcifications, cerebellar hypoplasia, periventricu­
lar leukomalacia, hydrocephalus, and porencephalic cyst. Hearing loss and 
neurologic impairment (e.g., psychomotor and mental retardation) develop 
in one-half of the survivors.
Chorioretinitis is the most frequent eye abnormality, followed by op­
tic atrophy. Microphthalmia, cloudy cornea, optic nerve hypoplasia, nys­
tagmus, and strabismus also occur. Eye abnormalities are common in in­
fants with intracranial calcifications.
Unilateral or bilateral sensorineural hearing loss that can vary from 
mild to profound develops in about 30% of infants with symptoms at birth, 
and in 8% to 13% of those with subclinical infections. Hearing loss may be 
present at birth in otherwise asymptomatic infants, and it subsequently dete­
riorates in more than one-half of the patients. Some patients have normal 
hearing for the first several years of life, but they then develop sudden hear­
ing loss.
Intellectual deficits are common, particularly in infants with sympto­
matic congenital CMV. Many infants with subclinical disease may develop 
mental or behavioral problems.
Dental defects can be found in 40% of the survivors of symptomatic 
neonatal disease but in only 5% of asymptomatic cases. A variety of con­
genital anomalies have been described in infants with congenital CMV in­
fection, but these probably reflect coincidental associations rather than true 
cause-and-effect associations. Reported associations include atrial and ven­
tricular septal defects, tetralogy of Fallot, congenital mitral stenosis, ingui­
nal hernia, hip dislocation, clubfoot, esophageal atresia, megacolon, and ex­
tra-hepatic biliary atresia.
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Maternal anti-CMV antibody protects the fetus against major CMV 
pathology. Fowler and colleagues found that 18% of 125 infants born to 
women with primary CMV during pregnancy had symptomatic neonatal 
disease, compared with none of 64 infants born to women with reactivated 
CMV infection. After a 5-year follow-up period, 13% of infants born to 
mothers with primary infection had mental impairment (i.e., intelligence 
quotient < 70) compared with none in the recurrent infection group. Sen­
sorineural hearing loss was found in 15% and 5% of infants born to mothers 
with primary and recurrent CMV infections, respectively. Bilateral hearing 
loss occurred only in the primary infection group.
Congenital infection can be diagnosed by isolation of CMV from the 
urine or saliva within the first 2 weeks of life. Positive cultures from speci­
mens obtained at 3 weeks or later may reflect perinatal CMV acquisition. 
Congenitally infected infants shed CMV in their urine for many years. The 
use of shell vial cultures hastens viral isolation. Cytomegalovirus can be de­
tected in the urine by electron microscopy or ELISA. Cytomegalovirus 
DNA can be detected in a variety of clinical specimens using sensitive hy­
bridization or PCR methods. Cytomegalovirus-specific IgM antibody is de­
tected in many of the infected newborns. IgM detection by RIA or ELISA is 
superior to immunofluorescence.
Ganciclovir is being evaluated as treatment for congenital CMV dis­
ease. Ganciclovir suppresses viral replication in immunocompromised pa­
tients with serious CMV infections. Several problems are associated with 
ganciclovir use, including the resumption of viral replication on discon­
tinuation of therapy, emergence of ganciclovir-resistant CMV strains after 
prolonged use in immunosuppressed patients, and drug toxicity (e.g., neu­
tropenia, thrombocytopenia). Demmler reported preliminary data on 25 ba­
bies with symptomatic congenital CMV infections who were treated with 
ganciclovir. Urinary shedding of CMV lessened during therapy but in­
creased again after stopping the drug. More detailed descriptions appear in 
reports of 2 neonates with severe CMV pneumonia and 1 infant with CNS 
involvement. All 3 infants exhibited modest improvements during ganci­
clovir therapy, but 1 infant developed significant bone marrow depression 
and a diffuse bullous rash. The 2 infants with pneumonia died a few months 
later of long-standing pulmonary problems. Cytomegalovirus hyperimmu­
noglobulin used in conjunction with ganciclovir has improved the survival 
of bone marrow transplant recipients with CMV pneumonia. The combina­
tion was not beneficial in the 1 infant in whom it was tried. The need for 
more effective anti-CMV chemotherapeutic agents is evident. Foscarnet has 
not been tried in con-genitally infected infants.
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PERINATAL INFECTION
Infants can acquire CMV during passage through an infected birth 
canal or by ingestion of CMV-positive breast milk. In contrast to congenital 
disease, perinatally acquired CMV infection is usually benign. Most infec­
tions are subclinical. A self-limited, infantile pneumonitis is the most com­
monly encountered clinical abnormality among symptomatic term infants. 
Premature infants may have severe illness, including pneumonia, hepatitis, 
anemia, thrombocytopenia, and neutropenia. The long-term prognosis for 
intellectual abilities and intact hearing for patients with perinatal CMV in­
fection is excellent.
PREVENTION
Termination of the pregnancy can be considered for women who de­
velop a primary CMV infection during gestation. With primary infection, 
the overall risk of delivering an infant with symptomatic congenital infec­
tion is only about 5%. Prenatal diagnosis of fetal CMV infection is feasible 
but usually requires a battery of tests. Fourteen of 30 infants born to women 
with primary CMV infection during pregnancy were infected in utero. The 
amniotic fluid cultures were positive for all 14 infected fetuses and negative 
for the remaining 16 who had escaped infection. Fetal blood samples ob­
tained between weeks 21 to 28 of gestation revealed the presence of CMV- 
specific IgM antibodies in 9 (64%) of 14 infected fetuses. Cytomegalovirus 
was isolated from the fetal blood of only 1 (11%) of 9 shown to be infected 
using other tests. Abnormalities of fetal hematologic indices, liver function 
tests, and total IgM concentrations were observed in some; the prognostic 
significance of these abnormalities is uncertain. One report describes the de­
tection of CMV DNA in the amniotic fluid of a woman who later delivered 
an infant with asymptomatic congenital CMV. Isolation of CMV from the 
amniotic fluid implies intrauterine infection but does not provide informa­
tion regarding the severity of fetal disease. A false-positive amniotic fluid 
culture or PCR result is possible if contamination with maternal blood oc­
curs.
Failure to isolate the virus does not rule out fetal infection with cer­
tainty. Fetal abnormalities detected by ultrasonography in women with ges­
tational primary or recurrent CMV infection generally indicate more severe 
fetal disease. A variety of sonographic findings have been reported, includ­
ing microcephaly, ventricular dilation, ascites, hydrops, pericardial effu­
sions, oligohydramnios, and intracranial and abdominal calcifications.
Cytomegalovirus vaccines are not yet available in the United States, 
but they are being tested in special populations. Routine CMV serologic 
screening of pregnant women is not cost effective.
Because blood from seropositive donors contains leukocytes that are 
latently infected with CMV, many blood banks now screen the blood for
4 7 3
CMV antibodies (68%), use leukocyte filters, or use washed erythrocytes. 
The practice of giving only CMV-negative blood or blood products to ill 
neonates has greatly reduced or eliminated the occurrence of transfusion- 
acquired CMV infections in many nurseries. Disseminated CMV infection 
after extracorporeal membrane oxygenation has been described, and CMV 
screening of blood had not been done.
VARICELLA
Varicella (i.e., chickenpox) and herpes zoster (i.e., shingles) are 
caused by VZV. Varicella-zoster virus is an enveloped, double-stranded 
DNA virus. Only one serotype is known.
MATERNAL INFECTION
In the United States, about 95% of women of child-bearing age have 
serologic evidence of past VZV infection. The proportion of seropositive 
women is smaller in those from tropical or semitropical countries.
Varicella is a highly communicable and usually benign disease of 
childhood. Children younger than 15 years of age account for more than 
90% of cases. Fewer than 2% of reported cases occur in persons 20 years of 
age or older. The estimated incidence of gestational varicella is 1 to 7 per 
10,000 pregnancies. Zoster results from reactivation of latent VZV and is 
more frequently encountered in elderly or immunosuppressed patients. Its 
incidence in pregnancy is unknown, but it is probably lower than that of 
varicella. One estimate places the incidence at about 0.5 per 10,000 preg­
nancies.
Less than 5% of primary VZV infections are sub-clinical. Varicella 
usually becomes clinically evident 10 to 20 days after exposure of suscepti­
ble persons to VZV. The typical illness consists of fever, malaise, and a pru­
ritic rash. The exanthem is mostly truncal in distribution and is character­
ized by crops of maculopapules that rapidly evolve into vesicles. The vesi­
cles gradually crust over. New lesions continue to appear for 3 to 5 days, 
producing the distinctive finding of cutaneous lesions in various stages of 
evolution. Complications of varicella include pneumonia, encephalitis, ar­
thritis, bacterial cellulitis, and bleeding diathesis. The risk of incurring 
complications from varicella in otherwise normal adults may be up to 25- 
fold greater than that for normal children. Pregnancy is not a risk factor for 
maternal complications. Immunity after varicella is usually long lasting. 
Recurrent VZV infections can occur in immunocompetent persons who re­
spond appropriately to the virus in terms of mounting seemingly adequate 
VZV-specific humoral and cellular immune responses.
Zoster is characterized by pain localized to the area of distribution of 
one or more sensory nerve roots. The rash is unilateral in most patients and
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follows the same evolutionary pattern seen in varicella except for its re­
stricted distribution.
Varicella and herpes zoster are usually diagnosed clinically, and labo­
ratory confirmation is infrequently needed. The virus can be isolated from 
vesicular fluid by inoculating freshly collected specimens onto human dip­
loid cell lines. The VZV-specific antigens can be detected in vesicular fluid 
by immunofluorescence staining of smears of cell scrapings collected from 
the base of fresh vesicles. Varicella-zoster virus DNA can be detected in 
vesicle samples, including most crusted lesions, by PCR methodologies.
Several serologic assays are available for the detection of antibodies 
to VZV. These include complement fixation, neutralization, IHA, immune 
adherence hemagglutination, fluorescent antibody against membrane anti­
gen (FAMA), IFA, and ELISA. These tests can be used to diagnose VZV 
infections or to ascertain the susceptibility status of an individual.
Complement fixation antibodies develop within 10 days of onset of 
varicella and peak at 2 to 3 weeks. These antibodies appear earlier in herpes 
zoster. Complement fixation antibodies tend to disappear with time. By I 
year after infection, about two-thirds of persons do not have detectable 
complement fixation antibody titers. The complement fixation test is rela­
tively insensitive compared with FAMA or ELISA, and it is now rarely used 
in clinical laboratories. The FAMA test is very sensitive and is considered 
to be the gold standard for VZV antibody measurements. However, FAMA 
is arduous to perform and is not readily available. The ELISA test is being 
increasingly used for VZV antibody measurements. The IFA methods have 
been shown to be as sensitive as FAMA.
Two serum samples collected 1 to 2 weeks apart can provide a retro­
spective diagnosis of VZV infection if a fourfold or greater rise in antibody 
titer is demonstrated. If the first sample is collected late in the course of the 
illness, a single high titer indicates a recent primary or a reactivated VZV 
infection.
Measurement of VZV-specific IgM antibodies is useful for 
documenting a recent infection with this virus. The VZV-specific IgM anti­
bodies can be detected in serum for several weeks after varicella and may be 
transiently found after herpes zoster.
For uncomplicated varicella, symptomatic treatment with antipruritics 
and cleansing of lesions is adequate. Analgesics are needed for pain control 
in herpes zoster. Early therapy of varicella within the first day of illness 
with oral acyclovir (800 mg given orally five times per day for 7 days) has­
tens resolution of fever and shortens the time period to complete crusting of 
the lesions. Acyclovir is not recommended for use during pregnancy, but it 
can be given for the treatment of severe or life-threatening VZV complica­
tions such as pneumonia.
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There have been several reports of pregnant women with varicella 
pneumonia treated with acyclovir. The drug was used at doses ranging from 
5 to 18 mg/kg every 8 hours, and the treatment results have generally been 
favorable. At least 312 women have been treated with acyclovir during 
pregnancy, and there has been no evidence of a teratogenic effect.
TRANSMISSION TO THE FETUS
Varicella-zoster virus transmission to the fetus occurs primarily 
through the transplacental route. Congenital malformations after maternal 
infection during the first one-half of pregnancy occur infrequently. This, 
however, provides support for the notion of transplacental fetal VZV acqui­
sition and infection, even though attempts at isolating the virus from these 
infants have been largely unsuccessful.
About one-fourth of newborns delivered to mothers who contract 
varicella during the last 3 weeks of pregnancy develop clinical infection. 
Paryani and Arvin used several clinical and immunologic criteria to docu­
ment intrauterine transmission of VZV in 43 pregnancies complicated by 
varicella and 14 others complicated by herpes zoster. These criteria included 
malformations consistent with the congenital varicella syndrome, acute 
varicella of the newborn, detection of VZV-specific IgM in the neonatal pe­
riod, specific lymphocyte transformation to VZV antigen, persistence of 
anti-VZV IgG antibodies, and the occurrence of herpes zoster in infancy. 
The rate of intrauterine transmission was 24% after maternal varicella and 
0% after maternal herpes zoster.
FETAL INFECTION
Varicella during pregnancy is not associated with an increased inci­
dence of prematurity or fetal death. Chromosomal abnormalities have oc­
curred after VZV infections in experimentally infected human diploid fibro­
blasts and in the peripheral leukocytes of patients with acute varicella. Leu­
kocyte chromosomal breaks were described in 1 child whose mother had 
gestational varicella. An increased risk for leukemia in the offspring of 
women with gestational varicella has been found by some investigators, but 
the numbers are too small to confirm the association.
Several case reports published over the past 45 years have described 
the occurrence of congenital malformations in the progeny of women who 
acquire chickenpox during pregnancy. With the exception of 2 infants with 
congenital anomalies (e.g., skin ulcers, microcephaly, cataracts, intracranial 
calcifications) after maternal varicella at 25.5 to 28 weeks of gestation, 
these infections usually occurred between weeks 8 and 20 of pregnancy. 
Abnormalities are primarily cutaneous, musculoskeletal, neurologic, and 
ocular (Table 65).
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Cicatricial lesions are the most common skin abnormalities (Fig. 43). 
Cutaneous scars usually occur on hypoplastic extremities, but they can ex­
tend to the trunk or opposite extremity. Limb hypoplasia is usually unilat­
eral and most commonly involves the leg. The arm, mandible, or hemitho- 
rax can be affected. Rudimentary digits are common on hypoplastic ex­
tremities. Detailed clinical and histopathologic studies of some patients 
suggest that limb abnormalities after intrauterine VZV infection are proba­
bly due to a neuropathy resulting from damage to dorsal ganglia and ante­
rior columns of the spinal cord.
Central nervous system pathology is common and includes micro­
cephaly, cortical and cerebellar atrophy, psychomotor retardation, seizures, 
and focal brain calcifications. Autonomic dysfunction, manifested by loss of 
bowel and urinary sphincter control, dysphagia, intestinal obstruction, and 
Horner syndrome, is observed in some patients. Unilateral or bilateral ocu­
lar anomalies are common; the eye may be the only organ affected in fetal 
VZV infection.
The literature contains references to a few infants born with congeni­
tal malformations after maternal herpes zoster during pregnancy. Reported 
birth defects include microcephaly, microphthalmia, cataracts, and talipes 
equinovarus. These rare cases probably represent chance occurrences rather 
than true associations. Paryani and Arvin prospectively followed 14 preg­
nancies complicated by herpes zoster and were unable to uncover any clini­
cal or immunologic evidence of intrauterine VZV infection.
NEONATAL INFECTION
About 25% of newborns become infected when maternal varicella oc­
curs during the last 3 weeks of pregnancy. The most important determinant 
of the severity of neonatal disease is the time of onset of maternal varicella 
relative to delivery. If maternal infection occurs within 5 days before and 2 
days after delivery, varicella lesions in neonates usually appear at 5 to 10 
days of age. The illness may be mild with only a few cutaneous lesions or 
may become severe with fever, hemorrhagic rash, and generalized visceral 
involvement (see Table 65). The mortality rate is about 30%, and death usu­
ally is caused by severe pulmonary disease. If maternal varicella occurs 5 to 
21 days before delivery, lesions in newborns typically appear in the first 4 
days of life and the prognosis is good, with no associated mortality. The 
mild course is probably due to the production and transplacental passage of 
maternal antibodies, which modify the course of the illness in newborns. 
Passive transfer of maternal VZV antibodies across the placenta at titers 
considered to be protective can occur as early as 24 to 28 weeks of gesta­
tion.
The diagnosis can be confirmed by viral isolation or VZV antigen de­
tection. Infected newborns may have VZV-specific IgM antibodies, but
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these usually disappear shortly after birth. Newborns with varicella should 
be kept in strict isolation if they require hospitalization, Vidarabine or acy­
clovir can be used for infants with severe disease. If started early in the ill­
ness, acyclovir usually leads to more rapid resolution of disease symptoms 
and signs. Varicella-zoster immunoglobulin (VZIG) is not beneficial after 
clinical disease has developed.
Table 65
Abnormalities in newborns after maternal gestational varicella
Timing of Mitomol 
Varicella
0-20 weeks of pregnancy
Last 5 days of preg­
nancy-2 days post­
partum
Neonatal Clinical Abnormalities
Cicatricial skin lesions, denuded skin, herpes zos­
ter, limb hypoplasia, rudimentary digits, muscle 
atrophy, intrauterine growth retardation, psycho­
motor retardation, microcephaly, cerebellar and 
cortical atrophy, seizures, intracranial calcifica­
tions, sensory deficits, Homer syndrome, anal 
sphincter dysfunction, dysphagia, recurrent aspi­
ration pneumonia, clubfoot, microphthalmia, 
optic atrophy, hypoplasia of optic disc, chorioret­
initis, chorioretinal scars, cataract, nystagmus 
Fever, vesicular exanthem, hemorrhagic rash, respi­
ratory distress, cyanosis, pneumonia, widespread 
necrotic lesions of the viscera (in fatal cases)
FIG. 43. Newborn with congenital varicella after maternal infection at about week 13 of 
pregnancy. Notice the ulcerated area with surrounding scars over the knee; a second scar is 
visible distally, over the tibia Despite an otherwise normal physical examination, computer­
ized tomography of the head revealed multiple areas of cerebral infarction and diffuse in­
tracranial calcifications.
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PREVENTION
Management of persons exposed to VZV is critical because varicella 
is a highly communicable infection that can adversely affect pregnant 
women and their offspring. Exposed susceptible persons can be protected by 
passive immunization with VZ1G. Varicella-zoster immunoglobulin is pre­
pared from plasma of normal blood donors found to have high IgG antibody 
titers to VZV. Varicella-zoster immunoglobulin can prevent or modify 
clinical varicella in susceptible persons if given shortly after exposure.
A live, attenuated varicella vaccine is available but awaits licensing in 
the United States. Extensive trials have shown it to be effective and safe. 
There are no formal guidelines for its use, but adults susceptible to varicella 
are likely to benefit from the vaccine.
Pregnant women exposed to varicella who have negative or uncertain 
prior histories of this infection should be tested for VZV susceptibility if 
sensitive assays are available and the results can be rapidly obtained. About 
80% to 95% of these women are immune to varicella, as indicated by posi­
tive FAMA, IF A, or ELISA test results.
If a pregnant woman has significant exposure to varicella and is sus­
ceptible or if the laboratory test result cannot be obtained in a timely fash­
ion, VZIG should be administered for the purpose of preventing or modify­
ing the infection in the mother to avoid complications. It is not known 
whether passive maternal immunization can prevent fetal VZV infection. 
Varicella-zoster immunoglobulin is most efficacious when given as soon 
after exposure as is feasible, but not later than 96 hours.
Congenital malformations after first-trimester maternal varicella are 
estimated to occur at a rate of 5%. Balducci and colleagues found no cases 
of congenital varicella among 35 term pregnancies complicated by first- 
trimester maternal varicella. Borzyskowski and collaborators reported a set 
of female identical twins sharing a single placenta whose mother developed 
varicella at 10 weeks of gestation. The first twin was normal, and the sec­
ond had congenital defects consistent with intrauterine VZV infection.
Prenatal diagnosis by detection of VZV-specific IgM in fetal blood 
has been successful in 1 fetus evaluated at about 32 weeks of gestation, ap­
proximately 12 weeks after his mother developed chickenpox. Isada and 
colleagues attempted to diagnose intrauterine VZV infection in 2 patients by 
chorionic villus sampling and PCR. Tissues from both mothers were PCR 
positive but culture negative. One mother elected to terminate her preg­
nancy at 23 weeks; examination of the fetal brain by Southern blot hybridi­
zation was negative. The second woman continued her pregnancy to term, 
and her newborn infant was clinically normal. Tests for VZV-specific IgM 
antibody in cord blood and viral placental cultures were negative. The de­
tection of VZV DNA sequences in chorionic villus samples does not equate 
with fetal infection.
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Children born to mothers who develop varicella within 5 days before 
and 2 days after delivery should receive 125 U of VZIG as soon as possible. 
Varicella-zoster immunoglobulin does not reduce the clinical attack rate in 
treated newborns, but these infants generally contract milder infections than 
untreated neonates. Because severe varicella can develop in newborns de­
spite timely administration of VZIG, some clinicians have advocated the use 
of acyclovir prophylaxis in these infants.
Although a few cases of severe neonatal varicella after exposure to 
mothers who developed the infection more than 2 days after delivery have 
been described, routine VZIG administration is not recommended, because 
this group of infants is not regarded to be at increased risk of varicella com­
plications.
Pregnant women with varicella at the time of delivery should be iso­
lated from their newborns until all vesicles have crusted. Neonates with 
varicella lesions should be isolated from other infants but not from their 
mothers.
PARVOVIRUS B19 INFECTIONS
Human parvovirus B19 was discovered fortuitously in 1975 by Brit­
ish scientists who had been evaluating new laboratory methods for the im­
proved detection of HBsAg in blood donor sera. Since then, B19 has been 
etiologically linked to a variety of conditions, including erythema infec- 
tiosum (i.e., fifth disease), aplastic crises in sickle-cell anemia and other 
hemolytic diseases, chronic anemia in immunocompromised patients, acute 
arthritis, and fetal hydrops.
В 19 is a small, nonenveloped, single-stranded DNA virus. Despite its 
many genotypes, only one B19 antigenic type is recognized at present. The 
virus does not grow in conventional cell lines, but it can be propagated in 
erythropoietin-stimulated bone marrow explant cultures, fetal liver cells of 
erythroid lineage, a novel cell line with megakaryocytic phenotype, and in 
erythroid progenitor cells generated in vitro from peripheral human blood in 
the presence of recombinant erythropoietin and interleukin-3.
B19 causes a lytic infection of human erythroid progenitor cells. Ces­
sation of erythrocyte production, manifesting as reticulocytopenia, does not 
cause symptomatic anemia in otherwise healthy persons. However, patients 
who have reduced erythrocyte life spans (e.g., sickle-cell anemia, thalas­
semia major) may develop transient aplastic crises. Patients with congenital 
or acquired immunodeficiency disorders may fail to clear the acute B19 in­
fection, and a persistent B19 infection ensues, resulting in chronic anemia. 
The rash and arthropathy seen in B19 infections are immune-mediated phe­
nomena and are not directly related to the lytic infection of erythrocyte pro­
genitor cells.
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MATERNAL INFECTION
Serologic surveys have found 30% to 60% of adults to have serum 
antibodies against B19, indicating prior infection. The virus is transmitted 
primarily by means of B19-infected respiratory secretions. Transmission 
through transfusions of blood or blood products is uncommon. The incuba­
tion period is 4 to 14 days, but it can be as long as 20 days.
About 1 % of susceptible pregnant women without known exposure 
to B19-infected persons seroconvert each year in the United States. During 
a large erythema infectiosum outbreak in Connecticut, pregnant women 
were tested for serologic evidence of recent В 19 infection. The highest in­
fection rates among exposed susceptible pregnant women were for school­
teachers (16%), day care workers (9%), and home-makers (9%). Attack 
rates of 36% to 38% have been documented among susceptible nursing staff 
who were exposed to patients with sickle-cell anemia and aplastic crisis at a 
children's hospital.
About 20% of acute B19 infections are subclinical Erythema infec­
tiosum is the most commonly identified B19-related condition. This illness 
is seen primarily in children, and its most characteristic feature is a facial 
exanthem (i.e., slapped-cheek appearance). The rash is lacy or reticulated, 
spreads to the trunk and extremities, and fades within 2 weeks. Recrudes­
cence of the rash is observed with stimuli such as temperature changes, 
sunlight, or emotional stress. Pruritic, petechial, purpuric, vesicular, or ery­
thema multiforme types of rashes are possible with acute B19 infection.
In addition to erythema infectiosum, acute B19 infections in other­
wise healthy adults can manifest with influenza-type illnesses and symmet­
ric polyarthropathies (e.g., polyarthralgias, polyarthritis); B19-associated 
joint disease is more common in women. Rheumatoid factor may be posi­
tive transiently, and the illness could therefore be misdiagnosed as early 
rheumatoid arthritis. B19 infections in compromised patients can result in 
transient aplastic crises, chronic anemia, and viral-induced hemophagocytic 
syndrome.
A diagnosis of acute or recent B19 infection can be made by detecting 
B19-specific IgM using enzyme immunoassays. These antibodies are pre­
sent in the serum of over 90% of patients by the third day of illness. B19- 
specific IgM antibodies can persist for 4 months or longer in more than 75% 
of patients, rendering the distinction between acute or recent B19 infection 
on serologic grounds alone difficult. B19-specific IgG antibodies are usu­
ally formed by the end of the first week of the illness, and they persist for 
life. The detection of B19-specific antibodies of the IgG class with negative 
IgM test results is considered evidence of past infection and, probably, im­
munity to B19 reinfections.
B19 DNA can be detected in serum and tissues by nucleic acid hy­
bridization techniques and the PCR. В 19 DNA can be found in serum for as
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long as 2 months after the onset of illness. B19 antigens can be detected by 
immunofluorescence or enzyme immunoassays, but these methods are not 
widely available.
There is no specific treatment for B19-associated illnesses. Immuno- 
suppressed patients with chronic anemia secondary to persistent B19 infec­
tions have benefited from intravenous immunoglobulin (IVIG) administra­
tion. Patients with erythema infectiosum are not contagious to others after 
the rash is evident, and those with aplastic crises continue shedding their vi­
ruses during the first few days of their hospitalization and require contact 
isolation.
FETAL INFECTION
Maternal B19 infection during pregnancy can adversely affect preg­
nancy outcome, but most fetuses escape infection. Fetal infection can lead 
to hydrops fetalis or death. B19 is responsible for about 8% of nonimmune 
hydrops cases. The histopathology of fetal B19 infection consists princi­
pally of infected erythroblasts with intranuclear inclusions, which are found 
mostly in the liver, spleen, and bone marrow.
Gestational B19 infections are associated with a less than 10% risk of 
pregnancy loss from spontaneous abortion, stillbirth, or the delivery of a 
hydropic infant. In a British prospective study of 190 pregnant women 
found to be positive for В 19-specific IgM, the B19-related fetal death rate 
was estimated at 9%. In a case-control study conducted in the United States, 
it was shown that B19 was not a common cause of fetal death in the general 
population.
B19 suppresses fetal bone marrow erythrocyte production, leading to 
a chronic anemia. This is not well tolerated by the fetus because of its rap­
idly expanding cell volume and its immature immune system, which fails to 
rapidly contain the B19 infection. Congestive heart failure ensues, usually 
secondary to the severe anemia. Direct infection of cardiac muscles by В 19 
can occur and may contribute to cardiac dysfunction.
Congenital malformations after intrauterine В19 infections have 
rarely been described, and they may represent chance occurrences rather 
than a true teratogenic effect of B19. Hartwig and colleagues described a 9- 
week-old embryo whose tissues were positive for B19 DNA and who had 
abnormalities of the eyes and damage to skeletal and smooth muscles. Rodis 
and associates described an electively terminated pregnancy in which the 
B19-infected fetus had anencephaly. If B19 is a true teratogen, the associ­
ated risk must be small.
The diagnosis of intrauterine B19 infection in a newly born infant is 
difficult and rests on detection of B19-specific IgM in serum or B19 DNA 
in the fetal blood or tissues. Parvovirus particles can be observed in tissues 
by electron microscopy.
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Management of hydropic newborns is supportive and almost invaria­
bly includes packed erythrocyte transfusions. There are no recognized long­
term sequelae for healthy infants born to mothers with gestational В19 in­
fection.
PREVENTION
Pregnant women who sustain a significant exposure to a В19- 
associated illness at home (e.g., erythema infectiosum in a child) and whose 
В 19 antibody status is unknown can be informed that their overall risk of 
fetal death is at most 2.5%. This figure can be arrived at by multiplying the 
rate of susceptibility (about 50%), the rate at which exposed susceptible 
persons acquire B19 infection (maximum of 50%), and the estimated rate of 
death in documented infection (9%). Had the exposure taken place in a 
school or day care setting, the risk would decline to less than 1.5%.
Some investigators have suggested the use of IVIG for postexposure 
prophylaxis of B19-susceptible pregnant women. Commercial IVIG prepa­
rations contain anti-B19 IgG antibodies, and they have been shown to be 
helpful in the treatment of immunosuppressed patients with B19-induced 
chronic anemia. There are no data to support or refute the use of IVIG for 
the prevention or amelioration of В 19 infection.
If acute or recent B19 infection is confirmed in the pregnant woman 
by means of a positive B19-specific IgM assay, serial ultrasound examina­
tions should be performed for the detection of early signs indicative of fetal 
hydrops. Ultrasound examination was instrumental in diagnosing meconium 
peritonitis at 25 weeks of gestation in an infant with intrauterine B19 infec­
tion. Maternal serum a-fetoprotein elevations have been observed in preg­
nancies with B19-re!ated adverse fetal outcomes such as hydrops.
Limited published experience suggests that the prenatal diagnosis of 
fetal B19 infection is possible and accurate. В19 can be demonstrated in fe­
tal blood by electron microscopy, molecular biologic techniques, or detec­
tion of B19-specific IgM antibodies. Torok and colleagues used the sensi­
tive PCR assay to detect B19 DNA in amniotic fluid and fetal blood. Fifteen 
mothers who were positive for В 19-specific serum IgM antibodies were 
evaluated. Eight of 15 fetuses were positive for B19 DNA only, and the 
other 7 were positive for В 19 DNA and B19-specific IgM. Nine (60%) fe­
tuses had hydrops. Ten infants were born healthy, including 4 found to have 
hydrops at 17 to 23 weeks o f gestation, which resolved without specific in­
tervention. Polymerase chain reaction detected B19 DNA in the sera of 20% 
of mothers with negative В 19-specific IgM assay results, with or without 
В 19-specific IgG; one-half of the fetal specimens corresponding to this 
group of mothers were B19 DNA positive by PCR.
Some B19-infected pregnant women may remain negative for В19- 
specific IgM and IgG antibodies, despite the detection of B19 particles in
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serum and saliva using electron microscopy or the detection of В19 DNA 
with PCR or other techniques. B19 infection of their newborns may or may 
not be symptomatic.
Fetal therapy with intrauterine blood transfusions or digitalization has 
been attempted in some infants. The indications for intrauterine transfusion 
are not well defined. Fetal hydrops has been shown to resolve spontane­
ously before birth in several patients without specific intervention. All of 
these infants remained well after birth and during several months of follow­
up. This indicates that fetal hydrops is not uniformly fatal if not treated and 
that some fetuses are capable of eventually resolving their B19 infection 
and reversing the observed pathophysiologic abnormalities.
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION
Acquired immunodeficiency syndrome accounted for 49% of deaths 
due to infectious diseases and 1.1% of deaths from all causes in the United 
States during 1991; mortality rates were much higher for African Americans 
than for Caucasians (31.2 versus 8.8 per 100,000, respectively). The HIV- 
related mortality rates for all races increased between 1989 and 1991 (8.7 
versus 11.2 per 100,000, respectively). The infant mortality rate per 100,000 
live births due to HIV infection was 3.0 in 1989 (10.1 for African-American 
children; 1.6 for Caucasian children); the provisional HIV-related infant 
mortality rate for 1991 is estimated at 2.0 per 100,000 live births.
Acquired immunodeficiency syndrome in children younger than 13 
years of age (i.e., 4051 cases through September 1992) accounts for 1.7% of 
all AIDS cases in the United States. Approximately 86% of these children 
have acquired their HIV infections from their mothers. The situation is 
worse in Africa, where 80% of the global pool of HIV-infected women live; 
pediatric patients account for 20% of all AIDS cases in these regions.
Approximately 3 million women worldwide are believed to be HIV- 
infected. In the United States, women account for 10.7% of all AIDS cases. 
The proportion of AIDS cases involving female patients continues to in­
crease. As HIV continues to spread among women of childbearing age, a 
parallel rise in the number of infants born with this infection is expected.
MATERNAL INFECTION
Approximately 12% of the 242,146 AIDS cases reported to the CDC 
between 1981 and September 1992 were in female patients. African- 
Americans and Hispanics accounted for 74% of AIDS cases among women; 
only 19% of all U.S. women belong to these two minorities. About 85% of 
women with AIDS are of reproductive age (i.e., 15 to 44 years). The most 
important sources of infection are intravenous drug use (50%), heterosexual 
contact (36%), and transfusions (7%); about 7% of affected women do not 
belong to any of the recognized risk groups.
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The prevalence of HIV-1 infection among women is not known with 
certainty and shows significant geographic and racial variations. Rates can 
be less than 0.2% in a cross-sectional population of pregnant women seek­
ing care at an army base to as high as 8.3% among pregnant African- 
American women in a rural Florida community. The odds of infection 
within a given group depend on the high-risk behaviors practiced: use of 
crack cocaine, multiple sexual partners, sexual intercourse with a high-risk 
partner, and presence of other sexually transmitted diseases. Another factor 
is low levels of condom use among heterosexual partners. Nationally, only 
17% of people with multiple sexual partners use condoms; 12.6% of per­
sons with risky sexual partners use condoms.
To obtain more representative figures for the prevalence of HIV-1 
among pregnant women in the United States, Gwinn and associates ex­
ploited the fact that maternal IgG antibodies against HIV-1 can passively 
cross the placenta. This group was able to calculate that 1.5 per 1000 
women giving birth in the United States were seropositive for this virus; the 
rates were highest in large metropolitan areas along the Atlantic coast (e.g., 
New York, New Jersey, District of Columbia, Florida). This national, popu­
lation-based survey in childbearing women used residual dried-blood 
specimens on filter paper that had been collected from newborns for the 
mandatory metabolic disease screening; anti-HIV-1 antibodies were de­
tected by enzyme immunoassays and Western blots. The detection of these 
antibodies in newborn blood signifies maternal infection. Gwinn and asso­
ciates estimated that 6079 births occurred to HIV-infected women in the 
United States during 1989 and that 1800 infants were infected perinatally 
during that year.
Human immunodeficiency virus screening programs targeted at pa­
tients who acknowledge high-risk behavior generally fail to identify most 
HIV-infected pregnant women. At Grady Memorial Hospital in Atlanta, 
Georgia, a program for routine voluntary HIV screening has been in place 
for several years. The hospital provides care for a predominantly African- 
American inner-city population. About 95% of pregnant women consented 
to voluntary HIV screening after pretest counseling. The rate of seropositiv- 
ity increased from 3.5 per 1000 in 1987 to 5.3 per 1000 in 1990; the in­
crease was significantly associated with history of crack cocaine use. Only 
30% of seropositive women had acknowledged high-risk behavior before 
being tested, but an additional 26% admitted such activities after learning 
their test results. Targeting only women with self-acknowledged high-risk 
behavior for HIV testing would have missed 70% of infected women. With 
nondirective counseling about options for terminating or continuing preg­
nancy, 85% of HIV-infected women elect to continue their pregnancies.
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MOTHER-TO-INFANT TRANSMISSION
Vertical transmission of HIV can occur in utero, intra-partum, or 
postpartum. Although most investigators think that vertical HIV-1 transmis­
sion in the United States occurs chiefly through intrauterine, transplacental 
spread of the virus, a growing body of evidence indicates that intrapartum 
transmission may be a major mode of fetal infection.
Laboratory investigations of second trimester abortuses from HIV- 
infected mothers have shown that about 30% of the fetuses were infected. 
On this basis, in utero transmission could account for most perinatal infec­
tions in the United States. Another group of investigators examined 13 sec­
ond-trimester pregnancies of HIV-positive women that were scheduled for 
elective pregnancy termination. Maternal serum, amniotic fluid, and fetal 
blood samples were obtained on all patients. Although HIV antibody pat­
terns were similar in maternal and fetal sera, the P24 antigen was detected 
in serum and amniotic fluid samples of 38% of the women and from the 
sera of 23% of the fetuses. These results confirm the importance of the in­
trauterine route of HIV transmission.
The importance of resolving the controversy surrounding the major 
mode of spread cannot be overemphasized. If intrapartum transmission 
proves to be the major route of spread, as for HBV, preventive approaches 
aiming at interrupting HIV transmission can be more vigorously pursued. 
These might include the administration at birth of zidovudine or recombi­
nant soluble CD4, the administration of an HIV-hyperimmunoglobulin, or 
cesarean deliveries.
Consistent, universally applied definitions would be helpful in resolv­
ing this issue. Data collected by different investigators from around the 
world can then be compared directly and conclusions can be reached. The 
Pediatric Virology Committee of the AIDS Clinical Trials Group published 
a consensus working definition. An infant is considered to have early (i.e., 
in utero) infection if the HIV-1 genome was detected by PCR or if HIV-1 
was isolated from blood within 48 hours of birth; positive results should be 
confirmed with at least one sample obtained after the neonatal period. An 
infant is considered to have late (i.e., intrapartum) infection if diagnostic 
studies (e.g., HIV-1 isolation, PCR, serum P24 antigen assays) were nega­
tive in blood samples obtained during the first week of life but became posi­
tive during the period from day 7 to day 90, and the infant has not been 
breast fed. Care should be exercised to avoid contaminating cord blood with 
maternal blood.
In the United States, breast-feeding of infants by infected mothers is 
not recommended. Postnatal HIV transmission by breast-feeding was exam­
ined prospectively in a cohort of 219 infants born to 217 seronegative 
women at the Centre Hospitalier de Kigali, Rwanda. Among 212 mother- 
infant pairs who were seronegative, 16 mothers seroconverted within 24
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months of delivery. Nine infants born to the 16 mothers became HIV­
positive by Western blot analysis, PCR, or both before the age of 18 
months; all were breast-fed. Five of the infants seroconverted by the age of 
3 months and were more likely to have acquired the virus late in gestation 
or during delivery. Four infants became HIV-positive at 6 to 18 months of 
age and were presumably infected postnatally through breast milk. Case re­
ports describing the postnatal acquisition of HIV through breast-feeding 
have appeared from the United States, France, Zaire, and Australia.
Vertical HIV transmission has been reported to occur at various rates 
in different areas throughout the world. A report by the 19-center European 
Collaborative Study provided a rate of 14.4% among a cohort of 721 chil­
dren followed for 18 months or longer; a similar rate of 14% to 20% was 
observed in a nationwide study of a cohort of 286 children born to HIV­
positive mothers in Switzerland. The rate is about 30% in the United States. 
Rates as high as 50% have been reported from African countries such as Za­
ire and Kenya. The reason for these geographic differences are unknown, 
but they may be related to the duration and severity of maternal disease, the 
frequency of cofactors for HIV activation such as other sexually transmitted 
diseases, viral strain differences, or host genetic factors.
Maternal factors enhancing the rate at which HIV is transmitted to 
their infants may include advanced disease, low CD4-positive lymphocyte 
percentage, low absolute CD4-positive counts, higher plasma virus titers, 
P24 antigenemia, coexisting infections, viral strain differences, premature 
delivery, and obstetric factors such as prolonged rupture of maternal mem­
branes or chorioamnionitis. In the report of the European Collaborative 
Study, infants born at 33 weeks of gestation or earlier were about fourfold 
more likely to become HIV-1 infected than those born closer to term. For 
twins born to HIV-infected mothers, the first infant delivered, whether 
vaginaliy or by cesarean section, is at least twice as likely to be infected as 
the second-born twin. This may be due to more intense exposure of the first 
born to HIV-infected genital secretions. De Martino and associates could 
not confirm these observations in their studies of twins born to HIV- 
infected mothers. They did observe that, if the first-born twin became in­
fected, only 42% of their second-born siblings were infected. If the first­
born escaped HIV infection, only 13% of their second-born siblings were 
infected.
Multiple HIV variants exist in infected persons. These variants arise 
during retroviral replication through errors in reverse transcription, perhaps 
as a result of immunologic pressure, alterations in cell tropism or replication 
efficiency.
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TREATMENT
The safety and efficacy of zidovudine as a chemoprophylactic agent 
against the vertical transmission of HIV is under investigation. Zidovudine 
crosses the placenta, and its concentration in umbilical cord blood may be 
higher than maternal levels. Sperling and colleagues described a retrospec­
tive survey of 43 women who had received zidovudine (300-1200 mg/day) 
during pregnancy. Their report is flawed by missing data and errors of defi­
nition. These investigators found no increased risk for premature birth, in­
trauterine growth retardation, or neonatal asphyxia. There were no malfor­
mations in the 12 newborns exposed to zidovudine during the first trimester. 
Birth defects observed in 5 newborns showed no consistent pattern and in­
cluded one each of the following: ventricular septal defect, albinism, poly- 
dactyly, clitoral enlargement, and ureteropelvic junction obstruction. At 
least 7 newborns had hemoglobin concentrations below the lowest limit of 
normal for term infants; 3 were born prematurely. This finding is potentially 
of concern because zidovudine crosses the placental barrier and may sup­
press the bone marrow of a developing fetus. Data from larger, prospective 
studies are urgently required.
Zidovudine has a direct embryotoxic effect on pregnant mice, result­
ing in fewer fetuses and more resorptions. Zidovudine's mouse embryotox- 
icity is dose-dependent and can be reduced by concomitant treatment of the 
animals with erythropoietin, vitamin E, or interleukin-3; the relevance of 
these animal findings to the human fetus has not been examined.
FETAL AND NEONATAL INFECTION
Congenitally infected infants are usually asymptomatic during the 
neonatal period, although detectable subtle signs such as lymphadenopathy 
and hepatosplenomegaly have been observed in approximately 5% of cases, 
and some infants have been born with evidence of cerebral atrophy. The la­
tency period to development of symptoms is considerably shorter than that 
for adults, with a median age at onset of 8 months. The shorter latency does 
not appear to be caused by higher titers of replicating virus in the blood of 
vertically infected infants compared with HIV-infected adults.
The diagnosis of HIV infection during the neonatal period or early in­
fancy is difficult. Measurement of the anti-HIV-1 IgG is not useful because 
of passive transplacental passage of this antibody and its persistence for 
several months. A few infants who serorevert to an HIV-seronegative status 
in early infancy may actually be HIV-infected, and close follow-up is re­
quired. Human immunodeficiency virus cultures, P24 antigen detection, and 
HIV-specific IgM and IgA measurements are all hampered by low sensitivi­
ties in the first weeks of life. Human immunodeficiency virus cultures and 
P24 antigen measurements are about 50% sensitive in the early neonatal pe­
riod. This apparently high false-negative rate may due to poor sensitivity of
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the technique itself, tropism of the virus for organs such as the lymph nodes 
and thymus, which allows it to evade detection in blood, or to the possibility 
that many infants acquire HIV late in pregnancy or at delivery and are truly 
negative when tested at birth. A technique that dissociates HIV antibodies 
from their bound antigens can provide a rapid and sensitive means of detect­
ing HIV antigens in cord sera of infected infants by disrupting HIV antigen- 
containing immune complexes. Assays for anti-HIV IgA antibodies during 
the first month of life detect fewer than 10% of HIV-infected infants, but 
their sensitivities increase to 60% for patients at 3 months of age and to 
77% to 100% at 6 months of age or older. The PCR method detects HIV 
proviral sequences in the blood of more than one-half of the infected new­
borns. Like all the other tests, the sensitivity of the PCR improves as infants 
become older. The PCR can be falsely positive if contamination with ma­
ternal blood occurs.
More than 50% of perinatally infected children become symptomatic 
by 2 years of age. The most common AIDS-defining conditions in pediatric 
patients are Pneumocystis carinii pneumonia, lymphoid interstitial hyper­
plasia, recurrent bacterial infections, HIV wasting syndrome, candidiasis, 
and HIV encephalopathy. P.carinii prophylaxis with trimethoprim- 
sulfamethoxazole is usually started in asymptomatic HIV-infected infants 
when the CD4-positive lymphocyte count is less than 1500 cells/pL during 
the first year of life. Mycobacterium avium-intracellulare has emerged as a 
common opportunistic pathogen in AIDS patients. M.tuberculosis, includ­
ing strains with multidrug resistance patterns, has increased in prevalence 
among AIDS patients. Infusions of IVIG at 2- to 4-week intervals and initia­
tion of anti-retro viral agents such as zidovudine and 2',3'-dideoxyinosine 
reduce the frequency and severity of various complications. However, re­
ports of HIV-1 resistance to zidovudine are rapidly increasing for adults and 
children.
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ACUTE INFECTIONS
Infections are significant causes of mortality and long-term morbidity 
in neonates, especially for premature infants of very low birth weight. Tem­
poral and geographic differences in the relative frequencies of various neona­
tal pathogens are well recognized. In North America in the 1930s and 1940s, 
gram-positive cocci such as group A Д-hemolytic streptococci and Staphylo­
coccus aureus were the most common bacterial isolates from neonates with 
sepsis, with Escherichia coli accounting for most of the remaining cases. 5. 
aureus and E. coli became the major pathogens in the 1950s, but since the 
late 1960s, group В Д-hemolytic streptococci and E. coli have predominated. 
Coagulase-negative staphylococci emerged in the 1980s and have surpassed
5. aureus and gram-negative enteric bacilli as the bacteria most frequently 
associated with nosocomial infections in many neonatal intensive care units; 
this has largely been a result of the survival of very-low-birth-weight infants 
who require lengthy hospitalizations and considerable mechanical and nutri­
tional support.
The outcome of neonatal infections can be improved if illness is rec­
ognized early and appropriate antimicrobial agents are promptly adminis­
tered. This chapter presents pertinent epidemiologic and pathogenetic con­
cepts of specific infections, clinical manifestations, and diagnostic evalua­
tions of patients with these diseases with a rational approach to therapy and 
control of neonatal infections.
PHARMACOLOGIC BASIS OF ANTIMICROBIAL THERAPY
Selection of antimicrobial therapy for neonatal infections must be 
based on pharmacokinetic properties of antibiotics in newborn infants of dif­
ferent gestational and postnatal ages, antimicrobial susceptibilities of com­
monly encountered pathogens within each nursery, and the natural history of 
the infectious disease being treated.
Combining two or more antibiotics is the usual clinical practice when 
initiating therapy for presumed systemic bacterial disease (e.g., ampicillin 
and an aminoglycoside are combined to treat suspected early-onset septice­
mia or meningitis before identification of the pathogen). After a bacterium 
has been identified and its susceptibility to various antimicrobials is deter­
mined, a single appropriate antibiotic is usually satisfactory for treating most 
infections.
Although antibiotics are commonly used to prevent infection, they are 
effective prophylactically only if directed against a single pathogen.- For ex­
ample, a single dose of penicillin G given intramuscularly at birth reduces the 
colonization rate and incidence of early-onset group В streptococcal (GBS) 
disease, except in infants who acquire the infection in utero. However, if an­
tibiotics are used as broad-spectrum coverage against many potential patho-
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gens, they are rarely effective. This umbrella method of chemoprophylaxis 
encourages the emergence of resistant strains among previously susceptible 
bacteria and alters the normal flora of the gastrointestinal and respiratory 
tracts with overgrowth of potentially virulent organisms. Broad-coverage 
prophylaxis may partially suppress a bacterium, masking the development of 
clinical disease and causing neglect of important surgical measures or serious 
delay in administering more effective therapy.
EPIDEMIOLOGY
The two principal sources of newborn infection are the mother and the 
nursery environment. Infection is acquired from the mother transplacentally 
at the time of delivery or in the postnatal period. The infant may acquire in­
fection postnatally from environmental sources, such as nursery personnel, 
respiratory equipment, sinks, and incubators. Infections manifesting within 
the first week of life are usually the result of exposure to microorganisms of 
maternal origin, but infections presenting later can have a maternal or envi­
ronmental source.
Myriad aerobic and anaerobic bacteria, mycoplasmas, chlamydiae, 
fungi, viruses, and protozoa can be found in the maternal genital tract. Some 
of these organisms pose little threat to the newborn infant (e.g., Lactobacil­
lus, a-hemolytic streptococci, Veillonella), and others are infrequent causes of 
neonatal disease (e.g., Haemophilus influenzae, Streptococcus pneumoniae, 
Neisseria meningitidis) More commonly, organisms such as groups A and В 
/Miemolytic streptococci, E. coli, Listeria monocytogenes, Neissena gonor- 
rhoeae, cytomegalovirus, and herpes simplex virus are responsible for seri­
ous neonatal infections.
Within a few days after birth, a-hemolytic streptococci, Staphylococcus 
epidermidis, and gram-negative enteric bacilli colonize the throat, nose, um­
bilicus, and stool. The gastrointestinal tract of newborns becomes heavily 
colonized by lactobacilli. Infants in neonatal intensive care units tend to have 
delayed colonization, which is probably related to early antimicrobial therapy 
for possible sepsis, and are more likely to acquire nosocomial strains of 
gram-negative bacilli such as Klebsiella, Enterobacter, Citrobacter, and E. 
coli. Colonization of the scalp, axilla, and groin by coagulase-negative 
staphylococci is universal by 48 hours of age. In a prospective study of 18 
premature infants admitted to a neonatal intensive care unit, S. epidermidis as 
the only coagulase-negative staphylococcal species isolated from the axilla, 
ear, nasopharynx, and rectum was found in about 11% of infants during their 
first day of life; this increased to 100% by 4 weeks of age. None of these in­
fants had a predominant S. epidermidis bio type on the first day, compared 
with 89% by 4 weeks of age. The prevalence of slime production and mul­
tidrug resistance among isolates rose from 68% to 95% and from 32% to 
82%, respectively, during the 4-week study period.
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Postnatal fungal colonization is more likely to occur in low-birth- 
weight infants. An estimated 10% of term infants have gastrointestinal Can­
dida colonization within the first 5 days of life; infants weighing less than 
1500 g have colonization rates of about 25%. Early colonization (<2 weeks 
of age) is more common, involves the gastrointestinal and respiratory tracts, 
and is with Candida albicans or Candida tropicalis, unlike late colonization 
(>2 weeks of age), which usually involves the skin and is more likely to be 
Candida parapsilosis. Cutaneous colonization with Malassezia (Pityro- 
sporum) furfur, a lipophilic yeast best known as the cause of tinea versicolor, 
is common and is found in as many as two-thirds of all critically ill new­
borns; fewer than 3% of healthy newborns and young infants have skin colo­
nization by this fungus. .
The vagina or cervix of asymptomatic, sexually active women is colo­
nized by Ureaplasma urealyticum in 40% to 80% and by Mycoplasma 
hominis in 21% to 53%. Vertical transmission rates of from 45% to 66% for 
preterm and term neonates have been reported for U. urealyticum. By 3 
months of age, about 33% to 68% of these infants continue to have detectable 
pha-ryngeal, ocular, or vaginal colonization. Vertical transmission rates for 
infants born to women with cervical Chlamydia trachomatis infections have 
been estimated at 40% to 70%; about 35% of untreated infants continue to be 
infected at one or more sites (e.g., conjunctiva, nasopharynx, oropharynx,
rectum, vagina) at 12 months of age.
The incidence of neonatal sepsis is from 1 to 10 cases per 1000 live 
births and 1 per 250 live premature births; the incidence is higher (l%-5%) 
for infants born to mothers with chorioamnionitis. The average national inci­
dence rate for nursery-acquired infections is about 1.4%, but figures reported 
for neonatal intensive care units are considerably higher and range from 5% 
to 30%. The most important risk factor for acquiring a nosocomial infection 
is low birth weight; others include prolonged hospitalization, invasive proce­
dures, placement of indwelling devices such as central venous catheters or 
ventriculoperitoneal shunts, bacterial or fungal colonization, and over­
crowded nurseries.
INFECTION CONTROL IN THE NURSERY
M icroorganisms can be transm itted to infants through direct contact 
w ith infected or colonized persons (e.g., mother, hospital personnel), indirect 
contact with a contaminated object (e.g., resuscitation equipment, pressure 
monitoring transducers), droplet contact (e.g, coughing or sneezing by in­
fected caretakers), and contaminated products (e.g., milk, lipid emulsions, 
blood). Transmission o f  bacteria by the hands o f hospital personnel is the 
most important mode o f transm ission within nurseries.
Prevention of nosocomial infection depends on recognizing and cor- 
recting environmental risk factors. Personnel should wash their hands thor-
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oughly with a scrub brush and an antibacterial cleaning agent before and be­
tween the handling of patients. Overcrowding in nurseries and a high infant- 
nurse ratio have increased the risk of nosocomial infections by 5-to 15-fold. 
Continuous surveillance through review of patient and microbiologic records 
helps to identify changing colonization patterns, to detect newly introduced 
virulent organisms in the nursery environment, and to recognize changes in 
the antibiotic susceptibility patterns of the predominant pathogens. Repeated 
treatment with broad-spectrum antimicrobials encourages colonization of in­
fants by Candida and multiresistant bacteria. Routine neonatal surveillance 
cultures are usually inadequate predictors of future infection of newborns by 
their colonizing microorganisms, but they are useful during outbreaks be­
cause they allow cohorting of infants within the nursery to minimize spread 
of an epidemic viral or bacterial strain to uninfected patients. Invasive proce­
dures, such as endotracheal intubation, placement of fetal scalp electrodes, 
and insertion of ventriculoperitoneal shunts, are well-recognized risk factors 
for hospital-acquired infections.
Umbilical and peripheral arterial and venous indwelling catheters are 
important sources of nosocomial bacteremia. As many as 60% of umbilical 
catheters become colonized by bacteria, but the prevalence of umbilical 
catheter-related sepsis has been estimated at 3% to 16%. The most common 
causative agents are coagulase-negative staphylococci, followed by S. 
aureus; gram-negative bacilli and fungi account for about a third of all cases. 
Risk factors for umbilical arterial catheter-related sepsis include very low 
birth weight and duration of antibiotic therapy. Umbilical venous catheter- 
related sepsis occurs most often in larger infants receiving infusions of hy- 
perali-mentation solutions.
There is increasing use of central venous catheters in seriously ill in­
fants for providing prolonged, dependable vascular access for the administra­
tion of intravenous fluids, hyperalimentation solutions, and drugs. About 
30% of critically ill infants with central venous catheters develop catheter- 
related sepsis. Central venous catheter infections can be caused by contami­
nated infusates, hematogenous seeding from distant sites of infection, or con­
tamination of the catheter hub. The most important source appears to be or­
ganisms found on an infant's skin, such as coagulase-negative staphylococci, 
that travel along the central venous catheter track to the catheter tip, where 
colonization takes place.
Preventive measures designed to reduce the incidence of central ve­
nous catheter-related infections generally aim at decreasing the number of 
organisms at catheter exit sites. Disinfection of central venous catheter inser­
tion sites by repeatedly applying topical antiseptics is viewed as one of the 
most important ways of reducing the frequency of catheter-related sepsis. 
Two percent aqueous chlorhexidine has been more efficacious than 10% 
povidone-iodine or 70% alcohol for this purpose when used in adults. Chlor-
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hexidine is nontoxic to newborns, and its absorption through neonatal skin is 
minimal. The popular semipermeable transparent dressings that are applied to 
central venous catheter exit sites produce significantly heavier bacterial 
growth on the underlying skin compared with gauze dressings and result in a 
higher incidence of central venous catheter contamination.'39 The use of sil­
ver-impregnated collagen cuffs that can be attached to central venous cathe­
ters has reduced the incidence of catheter-related sepsis in adults, but this ap­
proach has not been studied in neonates.
NOSOCOMIAL BACTERIAL OUTBREAKS
When an infectious disease caused by the same organism appears in 
several infants from the same nursery in a short period, a nosocomial out­
break should be suspected. The sick infants should be isolated and cultured to 
identify the pathogen. If a specific pathogen is responsible for the outbreak, 
epidemiologic investigations to determine the source of infection must be ini­
tiated, and measures should be taken to prevent further colonization and dis­
ease. Specific typing of organisms, using techniques such as phage typing for 
S. aureus, determination of antibiotic susceptibility and biochemical profiles 
for S. epidermidis, and pyocin typing for Pseudomonas are being replaced by 
the more powerful tools of molecular biology. Plasmid fingerprinting, restric­
tion endonuclease analysis of plasmid and genomic DNA, DNA hybridiza­
tion, immunoblotting, ribosomal RNA typing, multilocus enzyme electropho­
resis, and polymerase chain reactions are increasingly used in the analysis of 
nosocomial epidemics.
Staphylococcus aureus INFECTION
In the late 1950s and early 1960s, phage group I S. aureus (i.e., phage 
types 29,52, 52A, 79, 80, and 81) caused significant hospital disease, ranging 
from pustules and cellulitis to pneumonia, septicemia, and meningitis. Al­
though most infants are colonized with the epidemic strain during outbreaks, 
staphylococcal disease occurs in only a small fraction of those infants. Dis­
ease caused by phage group I staphylococci has diminished in the past dec­
ade. Theories to explain this decline are unsatisfactory but include changes in 
the virulence of the organism, implementation of infection control techniques 
in nurseries, and introduction of the semisynthetic ^ -lactamase-resistant peni­
cillins.
Disease caused by phage group II S. aureus (i.e., phage types ЗА, 3B, 
3C, 55, and 71) in newborn and young infants has been encountered. Clinical 
manifestations caused by this organism have been broadly classified as the 
expanded scalded skin syndrome. Nursery epidemics of bullous impetigo, 
toxic epidermal necrolysis, or both caused by group II staphylococci have 
been reported. Outbreaks are usually a result of lapses in infection control 
techniques and spread of the organism to other infants through hand carriage
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by nursery personnel; a staphylococcal nasal carrier among the nursery staff 
is only rarely the source.
Methicillin-resistant S. aureus (MRSA) strains have become important 
nosocomial pathogens in the United States since 1975. The major route by 
which MRSA is spread is through hand carriage by transiently colonized per­
sonnel. Nasal MRSA carriage rates for hospital personnel caring for colo­
nized patients are from 1% to 6%. Outbreaks of disease caused by multiresis- 
tant S. aureus strains have been reported from several nurseries in North 
America. These organisms are resistant to the antistaphylococcal penicillins, 
cephalosporins, lincomycin, and aminoglycosides but are susceptible to van­
comycin, rifampin, and trimethoprim-sulfamethoxazole. Vancomycin is the 
preferred therapy.
When staphylococcal disease occurs in a nursery, the extent of infec­
tion must be determined. Cultures are obtained from all infants and personnel 
associated with the index patient and a random sampling of the other infants. 
Culture sites include the nasopharynx and umbilicus for infants and the ante­
rior nares and hands for personnel. Several measures are commonly em­
ployed to control a nursery epidemic:
Increase emphasis on hand washing by all personnel.
Isolate all symptomatic and asymptomatic infants colonized with 
the virulent staphylococcal strain, with cohorting of all exposed but not 
colonized infants and all new admissions to the nursery and cohorting of 
caretakers. Maintain infant cohorts until discharge from the nursery.
Use parenteral antistaphylococcal therapy to treat systemic dis­
ease, with application of topical agents such as triple dye (i.e., mixture 
of brilliant green, crystal violet, and proflavine hemisul-fate), bacitracin 
ointment, sulfadiazine cream, isopropyl alcohol, iodophor, chlorhexi- 
dine, or mupirocin to the umbilical stump of infants to delay or reduce 
colonization.
Initiate routine bathing with antistaphylococcal cleansing agents such 
as chlorhexidine. Iodophor detergents are not recommended because of cuta­
neous staining and the potential for trans-dermal absorption of iodine, with 
resultant suppression of neonatal thyroid function. Hexachlorophene is 
neurotoxic and should not be routinely used. This agent remains an option for 
difficult-to-contain epidemics, but it should be used in a 1:4 or 1:5 dilution in 
water and only in full-term infants.
Colonize the umbilical stump of infants with a less virulent Staphylo­
coccus species such as the 502A strain of S. aureus (i.e., bacterial interfer­
ence). Although associated with low risk if properly performed, this proce­
dure is rarely used and should be undertaken only after other control tech­
niques have failed.
Close the nursery to new admissions if an outbreak is difficult to con­
trol.
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ENTEROPATHOGENIC E s c h e r ic h ia  c o li
Because diarrhea caused by enteropathogenic strains of E. coli occurs 
rarely during the first week of life, nosocomial disease is usually confined to 
intensive and special care nurseries. The mother is frequently the source of 
infection for the index case; subsequent cases are usually transmitted from 
infant to infant by nursery personnel. The epidemiology, symptoms, treat­
ment, and control measures for enteropathogenic E. coli diarrhea are consid­
ered later.
GROUP A STREPTOCOCCAL INFECTION
Group A /?-hemolytic streptococci were a common cause of puerperal 
and neonatal sepsis in the 1930s and early 1940s. With the advent of penicil­
lin and its frequent use in maternity and nursery units, neonatal infections 
caused by this organism have become relatively uncommon. However, the 
resurgence of serious, invasive group A streptococcal disease among children 
and adults may herald an increase in the incidence of neonatal infections by 
this organism. The primary source of group A streptococci in nursery out­
breaks is a nurse or physician working in the unit or the mother. After group 
A streptococci are introduced into a nursery, many infants become colonized, 
but few develop clinical disease. The most common clinical manifestation is 
a low-grade granulating omphalitis that fails to heal despite local measures. 
However, more significant disease may occur, including extensive cellulitis, 
pneumonia, septicemia, and meningitis.
One neonate with group A streptococcal colonization is enough to war­
rant investigation of the nursery for a potential source of disease. All infants 
in close contact with the index case, a random sampling of other infants, and 
nursery personnel should be cultured. Nasopharyngeal and umbilical cultures 
from infants and nasopharyngeal, skin, and rectal cultures from personnel 
should be obtained. The epidemiologic workup should be coordinated with 
the obstetric service of the hospital.
Infants with streptococcal disease should be treated with aqueous peni­
cillin G. During nosocomial outbreaks, all asymptomatic infants colonized 
with group A streptococci should receive penicillin. The prophylactic use 
of penicillin for new admissions to the nursery may be indicated. Ben­
zathine penicillin G has been used effectively as prophylaxis against 
group A streptococcal infection in one nursery outbreak.
GRAM-NEGATIVE BACILLARY INFECTIONS
Routine nasopharyngeal and rectal cultures from normal newborn 
infants usually reveal one or several coliform organisms. These bacteria 
and others represent the normal flora of the neonate's gastrointestinal 
tract. It is likely that the gastrointestinal tract is a source of systemic neo­
natal infections caused by coliform and other gram-negative bacteria.
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Several nursery outbreaks caused by specific gram-negative bacte­
ria have been described. Among the organisms incriminated were Kleb­
siella pneumoniae, Flavobacterium meningosepticum, Serratia marcescens, 
Pseudomonas aeruginosa, Proteus mirabilis, Citrobacter diversus, Entero- 
bacter spp., Salmonella spp., and E. coli. A common feature of these out­
breaks was that most colonized infants were asymptomatic, and those 
who developed disease usually had pneumonia, septicemia, or meningi­
tis.
Infected fomites represent the single most common source of nurs­
ery outbreaks caused by gram-negative bacteria. Contaminated faucet 
aerators, sink traps, drains, suction equipment, bottles containing distilled 
water, cleansing solutions, humidification apparatus, and incubators have 
been incriminated. Contaminated formula and breast milk are infrequent 
sources. Colonized infants may act as a source o f infection, and the or­
ganism is transmitted from infant to infant by way of the hands or gowns 
of personnel. During epidemics, the rate of asymptomatic colonization of 
infants with the specific pathogen ranges from 0% to 90%.
The general approach to nursery outbreaks caused by gram­
negative organisms is similar to that for outbreaks caused by S. aureus. 
Identification of an infant in a nursery or intensive care unit with a poten­
tially virulent pathogen such as P. aeruginosa should serve as a warning. 
This infant should be segregated, preferably outside the nursery, from the 
other infants and managed appropriately. All infants in the same unit 
should be cultured. If additional infants are discovered to be asympto­
matic carriers o f the organism, they should be segregated from other in­
fants in the nursery, and an epidemiologic investigation should be initi­
ated. Resuscitation and inhalation equipment, cleansing solutions, wash­
ing facilities, and other objects in the patient's environment are cultured 
so that the source of nosocomial infection can be identified. It may be­
come necessary to close the nursery to new admissions until the source 
of infection is identified and appropriate measures have been taken to 
prevent new cases.
NOSOCOMIAL VIRAL OUTBREAKS
Several viral agents have been incriminated in nursery outbreaks of 
infection. Most viral nosocomial outbreaks tend to parallel the activity of 
the agent in the community. The original source o f infection is frequently 
the mother, who transmits the viral agent transplacentally or by direct 
contact postnatally. A second common source o f nosocomial viral dis­
ease is infected nursery personnel. Although the mechanisms accounting 
for spread of virus from infant to infant are not well defined, it appears 
likely that respiratory viruses such as influenza and parainfluenza are 
spread by the airborne route, while respiratory syncytial virus (RSV) is
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spread primarily by infected hands of personnel. Viruses causing diar­
rhea may be transferred from infant to infant by the hand-to-mouth route 
through intermediary nursery personnel. Viruses excreted in the urine in 
high concentrations may be aerosolized when diapers or sheets are 
changed.
During a nursery outbreak of viral infection, most infected infants 
are asymptomatic and serve as reservoirs for perpetuation of infection. 
Even more important, infants with minimal symptoms and signs of dis­
ease such as sneezing, stuffy nose, or several loose stools may contribute 
significantly to transmission of virus by way of the airborne or fecal-oral 
routes.
COXSACKIEVIRUSES
Coxsackievirus A is rarely incriminated in nursery epidemics. In 
one outbreak at a regular nursery in Bangkok, 48 of 598 infants devel­
oped herpangina in the first week of life. Several infants had cox­
sackievirus A5 isolated from their throat or rectum or developed rising 
antibody titers to the virus.
There have been several well-documented nursery outbreaks of the 
encephalomyocarditis syndrome associated with coxsackieviruses of the 
В group. Coxsackieviruses B1 through B5 have been etiologically associ­
ated with this illness, and the virus has been isolated from multiple or­
gans, including the myocardium, lung, brain, blood, kidney, and liver. 
The severe involvement found in many infants explains the relatively 
high mortality rate of this condition. The clinical picture is one of abrupt 
onset of fever, listlessness, and feeding difficulty. Respiratory distress 
and cyanosis are found frequently, and cardiac signs such as tachycardia, 
cardiomegaly, murmurs, and gallop rhythm are present in most patients. 
Hepatosplenomegaly is common, and signs and symptoms referable to 
central nervous system involvement affect one-third of patients. The 
newborn can apparently acquire coxsackievirus infection in utero or after 
birth. The postnatally acquired disease has been traced to direct contact 
with the mother or an infected attendant.
ECHOVIRUSES
Several echovirus types cause illness in premature and term infants. 
Although echovirus 9 is the most prevalent type, it is echovirus 11 that has 
been responsible for most nursery outbreaks caused by this group of viruses. 
Reported neonatal secondary attack rates during hospital outbreaks have been 
as high as 50%.
Mother-to-infant vertical transmission appears to be the major route of 
infection. The virus spreads to other newborns through the contaminated 
hands of nursery personnel, especially to infants requiring mouth care and
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gavage feeding. Echovirus infections acquired from the mother tend to be 
more serious than those acquired through secondary nosocomial spread; this 
may be because of the lack of passively transferred protective maternal neu­
tralizing antibodies against the offending agent in infants born to women in­
fected at or near the time of delivery.
The clinical manifestations of echovirus infection range from mild di­
arrhea to overwhelming hepatic necrosis. Separate nursery outbreaks caused 
by the same echovirus type may produce different clinical diseases. For ex­
ample, in a premature nursery outbreak, echovirus type 19 produced respira­
tory illness associated with roentgenographic findings of cystic emphysema. 
In a separate outbreak of echovirus type 19, the initial clinical picture was 
strikingly similar to that of sepsis neonatorum and was characterized by 
overwhelming infection and hepatic necrosis. This disparity in the clinical 
diseases that characterize individual nosocomial outbreaks has also been ob­
served for echovirus type 11.
During nursery outbreaks, infection control measures should include 
cohorting of cases and increased emphasis on hand washing. The use of 
gloves and gowns is helpful, especially when handling secretions and feces. 
Closure of the nursery to new admissions is sometimes needed. The admini­
stration of immune serum globulin to uninfected newborns has been tried, but 
its benefits are unproved.
HEPATITIS A
There have been several reported outbreaks of hepatitis A in neonatal 
intensive care units. The virus is transmitted primarily by person-to-person 
contact through fecal contamination and oral ingestion. Approximately 16% 
to 30% of an inoculum of hepatitis A virus can be recovered from infected 
hands after 4 hours. Indirect person-to-person transmission of infectious virus 
can also occur through contact with inanimate objects, such as hard surfaces. 
In some of the nursery outbreaks, the initial infection occurred through trans­
fusion of neonates with blood or fresh frozen plasma from donors with hepa­
titis A viremia during the prodromal phase of their illness.
Hepatitis A virus is highly communicable; in one nursery outbreak, 
20% of infants, 24% of nurses, and several non-nursing staff and household 
contacts were affected. Fecal excretion of hepatitis A virus may persist for 4 
to 5 months. Risk factors for spread of hepatitis A to other infants and nurs­
ery personnel include asymptomatic infection, prolonged fecal shedding of 
the virus, frequent contact with soiled diapers, and breaks in infection control 
measures. One study found that having long fingernails, not wearing gloves 
for certain procedures, smoking, and drinking beverages in the nursery facili­
tated direct hand-to-mouth contact. The use of intramuscular immune serum 
globulin for postexposure prophylaxis may be helpful in controlling hospital 
outbreaks. To be most effective, immune globulins in a dosage of 0.02 mL
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per 1 kg of body weight should be given as soon as possible after the last ex­
posure and within a period not exceeding 2 weeks.
ADENOVIRUSES
Neonatal adenoviral infections are infrequent but can be severe. Nurs­
ery outbreaks have been caused by adenovirus serotypes 1, 2, 3, 7, 7a, 8, and 
21. Manifestations of nosocomial adenovirus infection can include pseu­
domembranous conjunctivitis, apnea, bradycardia, tachypnea, wheezing, 
coryza, fever, hypothermia, feeding intolerance, and diarrhea. Deaths during 
nosocomial outbreaks have been described. Adenoviruses can spread by 
means of contaminated hands and fomites; fecal-oral and small-particle aero­
sol spread is also possible. Conjunctival shedding of the virus persists for 7 to 
10 days; rectal shedding is intermittent and more prolonged. Adenoviruses 
remain stable on environmental surfaces for long periods; this property en­
hances their ability to spread to susceptible infants and personnel. Outbreak 
control can be achieved through cohort-ing of infected infants, exclusion of 
ill personnel from the workplace, hand washing, and wearing of gloves and 
masks; the use of goggles is advocated by some investigators. The use of 
immune serum globulins was ineffective in preventing or modifying adenovi­
ral infection in one nursery outbreak, and the administered preparation had 
minimal neutralizing activity against the specific serotype responsible for that 
outbreak.
RESPIRATORY SYNCYTIAL VIRUS
Community outbreaks of RSV infection occur in winter and early 
spring. The virus is highly contagious; as many as 50% of personnel on pedi­
atric wards become infected during nosocomial RSV outbreaks. Shedding of 
RSV in respiratory secretions of infants usually lasts from 1 to 21 days 
(mean, 7 days) but can continue for 6 or more weeks in immunosuppressed 
patients.
Respiratory syncytial virus has caused nursery outbreaks of bronchioli­
tis and pneumonia. Infants initially demonstrated coryza and cough lasting 
several days, followed by the acute onset of dyspnea associated with roent- 
genographic evidence of pneumonia in most patients. During a community 
outbreak in Rochester, New York, 35% of infants in a nursery acquired RSV 
infection. Illness was often atypical, especially in infants younger than 3 
weeks of age, in whom lower respiratory tract involvement was less com­
mon. Four infants died; 2 infants died unexpectedly after the acute illness had 
subsided. Infection was acquired by 34% of the nursery staff, who appeared 
to be important in the spread of RSV within the nursery. Infected infants are 
at risk of respiratory arrest due to RSV-related apnea. Patients with pulmo­
nary disease, congenital heart disease, or immunodeficiency are at highest 
risk for severe and potentially fatal RSV infections. Simultaneous outbreaks
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of viral respiratory disease caused by RSV and rhinovirus or parainfluenza 
virus type 3 have been described in newborn nurseries.
Control of nosocomial RSV infection should emphasize diligent hand 
washing before and after handling infants, cohorting of RSV-infected neo­
nates, and not allowing nursery personnel to care for infected and uninfected 
infants at the same time. Gowns and masks are generally ineffective in reduc­
ing nosocomial RSV spread. The use of eye-nose goggles has reduced the 
rates of nosocomial RSV infections among infants and personnel. It is occa­
sionally necessary to close the nursery to admissions if new cases of disease 
continue to occur despite the strict infection control measures.
The use of aerosolized ribavirin for the treatment of RSV infection in 
high-risk infants should be considered. When given early in the course of an 
RSV infection, ribavirin can reduce the amount and duration of viral shed­
ding, lead to a more rapid resolution of the illness, and lower mortality rates. 
Ribavirin can be administered safely to mechanically ventilated infants if 
careful attention is paid to correcting problems resulting from drug precipita­
tion in the respirator tubing and around the expiratory valves of ventilators.
INFLUENZA
Epidemics of usually mild respiratory illness caused by influenza A vi­
rus have been described in newborn infants. Clinical findings are nonspecific 
and can be indistinguishable from bacterial sepsis. Apnea, lethargy, nasal 
congestion, and poor feeding have been observed. Interstitial pneumonia may 
be seen on chest radiographs.
SEPSIS NEONATORUM
The term sepsis neonatorum is used to describe a disease of infants 
who are younger than 1 month of age, are clinically ill, and have positive 
blood cultures. The presence of clinical manifestations differentiates this 
condition from the transient bacteremia observed in some healthy neonates.
The incidence of sepsis neonatorum is from 1 to 10 cases per 1000 live 
births and 1 per 250 live premature births. These incidence rates vary from 
nursery to nursery and depend on conditions predisposing to infection.
PATHOGENESIS
Maternal, environmental, and host factors determine which infants ex­
posed to a potentially pathogenic organism will develop sepsis, meningitis, or 
other serious invasive infections.
Many prepartum and intrapartum obstetric complications have been as­
sociated with increased risk of infection in the newborn, the most significant 
of which are premature onset of labor, prolonged rupture of fetal membranes, 
chorioamnionitis, and maternal fever. In one study of 963 pregnancies com­
plicated by premature rupture of membranes, the incidence of clinical sepsis
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increased from 2% among infants born within 23 hours of membrane rupture 
to 7% and 11% among those delivered 24 to 47 hours and 48 to 71 hours af­
ter rupture, respectively; the risk was highest for the premature, low-birth- 
weight infants. The incidence of infection has been estimated at 8.7% for in­
fants born to mothers with prolonged rupture of membranes (>24 hours) and 
clinical chorioamnionitis. Iritraamniotic infection is associated with a higher 
incidence of sepsis among infants weighing less than 2500 g at birth com­
pared with those weighing 2500 g or more (16% and 4%, respectively); death 
from sepsis is greater in the low-birth-weight group (11% and 0%, respec­
tively). Isolation of bacteria from the chorioamnion has been associated with 
an increased risk for neonatal death among preterm infants. Maternal urinary 
tract infections, coitus near the time of delivery, and the use of internal moni­
toring devices are risk factors for chorioamnionitis. Concurrent maternal and 
neonatal bacteremia has been documented for many microorganisms.
With improved supportive care of the sick neonate has come increased 
opportunity for microorganisms of relatively low virulence to cause systemic 
disease. The use of arterial and venous umbilical catheters, central venous 
catheters, and endotracheal tubes provides access to the debilitated infant for 
organisms in the respiratory or gastrointestinal tract, on the skin, or in 
respiratory support equipment.
Bacterial colonization of the skin and mucosal surfaces precedes inva­
sive disease in most infants with sepsis. Type III strains of GBS, the ones 
most commonly associated with early-onset septicemia and with meningitis 
at any age in early infancy, adhere better to vaginal and neonatal buccal 
epithelial cells m vitro than do other GBS strains. Bloodstream invasion gen­
erally follows local multiplication of the organism at sites of colonization. 
Aspiration of infected amniotic fluid is another proposed route for fetal infec­
tion among infants born to mothers with chorioamnionitis.
Animals have been used to define the host-bacteria interactions that de­
termine pathogenesis of disease. Bloodstream infection in infant rats or mice 
caused by E. coli K1 or any of the GBS serotypes can be prevented by pre- 
treatment with type-specific capsular polysaccharide antibody. The orogastric 
route for E. coli K1 in the infant rat and the intratracheal installation of GBS 
in the rhesus monkey or rat produce illnesses that closely parallel the human 
syndromes.
Several investigations of the host-parasite association of humans with 
group В streptococci have focused on measurement of specific antibody in 
the serum of infected and colonized persons. Protective concentrations of an­
tibody to GBS serotype III were found in 73% of women whose newborn in­
fants were well but in only 17% of women whose neonates developed sepsis 
or meningitis caused by this organism. The amount of antibody to GBS sero­
type III was considerably lower in ill infants than in healthy neonates bom to 
mothers with vaginal colonization. Levels of GBS serotype III antibodies
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correlate with in vitro opsonic activity and in vivo protection of animals ex­
perimentally infected with these strains. The administration of standard intra­
venous immunoglobulin preparations with activities against GBS, of human 
GBS monoclonal antibodies, or of GBS hyperimmune polyclonal antibodies 
provides significant protection to animals experimentally infected with this 
pathogen. Asymptomatic colonization is also associated with antibody forma­
tion. Although less extensively studied, similar observations have been made 
for other GBS serotypes.
Evidence suggests that antibodies to the KI E. coli antigen are protec­
tive against infection by this organism, but this is not firmly established. 
Neonatal serum has been shown to be inefficient in killing E. coli because of 
a deficiency of non-IgG serum components, such as complement factor 9.
Physiologic deficiencies of the classic and alternative pathways of 
complement activation in neonates contribute to inefficient bacterial opsoni­
zation. Organisms such as GBS and E. coli with a high capsular sialic acid 
content tend to be poor activators of the alternative complement pathway.
Fibronectin is a multifunctional glycoprotein found in the plasma and 
on the surface of certain epithelial cells, basement membranes, and connec­
tive tissues. In plasma, fibronectin acts as a nonspecific opsonin that en­
hances clearance of invading bacteria. Fibronectin is deficient in neonatal 
plasma, and its concentration varies inversely with gestational age. Septic in­
fants have been shown to have significantly lower plasma concentrations of 
this glycoprotein than healthy, age-matched controls. The soluble form of fi­
bronectin binds poorly to GBS. Fibronectin enhances phagocyte function in 
vitro and in vivo.
Quantitative and qualitative deficiencies in neonatal neutrophils con­
tribute to the immaturity of the immune system of newborns. The abnormali­
ties become most pronounced at times of stress or during infections and in­
clude impaired chemotaxis, decreased deformability, reduced C3bi receptor 
expression, depressed bacterial killing by phagocytes, and oxidative meta­
bolic abnormalities. The neutrophil storage pool of neonates is markedly de­
pleted compared with that of adults. Stem cell proliferative rates are near 
maximal capacity and cannot increase appreciably in response to infection.
CLINICAL MANIFESTATIONS
Most infants with septicemia present with nonspecific signs and symp­
toms that are usually first observed by the nurse or mother rather than by the 
physician. The most common of these vague signs are temperature instability, 
lethargy, apnea, and poor feeding. Although hypothermia is more common, a 
temperature elevation above 37.8°C is significant in the neonate and fre­
quently associated with bacterial infections, especially with temperatures 
above 39°C. The signs and symptoms in some infants may suggest respira­
tory or gastrointestinal disease (e.g., tachypnea and cyanosis or vomiting, di­
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arrhea, abdominal distention). Septicemia must always be included in the dif­
ferential diagnosis when evaluating an infant with these findings.
Although it is tempting to recommend a workup for septicemia in all 
infants with nonspecific clinical manifestations, this is impractical and un­
necessary in many cases. A complete history and physical examination, cou­
pled with clinical experience, are the best guides in determining the extent of 
the workup. If doubt exists, a blood culture should be obtained. Hepa- 
tosplenomegaly, jaundice, and petechiae are classic signs of neonatal infec­
tion but represent late manifestations.
STREPTOCOCCAL DISEASE
Group В p-hemolytic streptococcus is the most common gram-positive 
bacterium isolated from blood of infants with septicemia in North America. 
The epidemiology, pathogenesis, and clinical features of GBS disease have 
been defined. The organism is a common inhabitant of the female genital 
tract and can be isolated from vaginal and anorectal cultures of as many as 
35% of asymptomatic pregnant women. Risk factors for maternal GBS colo­
nization include lower parity, higher frequency of intercourse, multiple sex­
ual partners, and concurrent colonization with Candida spp. Peripartum GBS 
colonization of the lower urogenital tract has been associated with several 
maternal complications including preterm labor, premature rupture of mem­
branes, endometritis, chorioamnionitis, urinary tract infection, intrapartum or 
postpartum fever, late abortions, and invasive infections, such as bacteremia 
or meningitis. The identical serotype can be isolated frequently from urethral 
cultures of the sexual partners of these culture-positive women. Although 
most infected pregnant women have normal, healthy infants, 1% to 2% of 
pregnancies involving maternal infection result in stillbirths or infants with 
neonatal disease. Vertical transmission of group В organisms occurs in ap­
proximately 50% to 70% of mother-infant pairs, resulting in neonatal coloni­
zation rates of from 8% to 25%; transmission is most likely to occur among 
infants born to heavily colonized mothers.
The early-onset GBS syndrome occurs within the first 72 hours of life 
(mean age of onset, 20 hours), and 65% of reported cases involve premature 
infants. There is often a history of other maternal obstetric complications. 
Onset is sudden and follows a fulminant course with the primary focus of in­
flammation in the lungs, although meningitis can develop. Respiratory dis­
tress is the most common initial sign among infants with early-onset menin­
gitis. Apnea, hypotension, and disseminated intravascular coagulation cause 
rapid deterioration and often lead to the patient's demise within 24 hours. It is 
difficult to identify the infant with respiratory distress caused by GBS infec­
tion, because in 60% of infected patients, the chest radiograph shows a 
reticulogranular pattern with air bronchograms indistinguishable from that 
seen with uncomplicated hyaline membrane disease. The mortality rate is ap­
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proximately 20% and is inversely correlated with birth weight. All five GBS 
serotypes have been incriminated in early-onset disease in roughly similar 
proportions. A similar syndrome has been associated with groups D and G 
streptococci.
A late-onset syndrome caused by GBS or L. monocytogenes occurs 
most frequently at 2 to 4 weeks of age, but it may be seen as late as 16 weeks. 
The onset is insidious; poor feeding and fever are the most frequent present­
ing symptoms. A fulminant illness with rapid onset and progressive 
deterioration is occasionally encountered. Meningitis is seen in 
approximately 60% of infants with the late-onset syndrome, and GBS 
serotype III accounts for 93% of these cases. Rarely, infants with late-onset 
meningitis caused by group В streptococci present with hydrocephalus. These 
infants may appear to have uncomplicated hydrocephalus with normal 
lumbar cerebrospinal fluid (CSF). Examination of ventricular fluid reveals 
pleocytosis, and the organism is recovered on culture. Spinal fluid cultures of 
infants with meningitis caused by gram-positive organisms are usually sterile 
within 24 to 36 hours of therapy, and the mortality rate is 10% to 15%.
Approximately 20% of neonatal infections caused by GBS do not fit 
into the early- or late-onset syndromes and extend over a broad clinical spec­
trum involving many different organ systems. Several manifestations have 
been observed:
• cellulitis
• scalp abscess
• impetigo
• breast abscess
• adenitis
• supraglottitis
• conjunctivitis
• orbital cellulitis
• ethmoiditis
• otitis media
• pneumonia complicated by empyema
• endocarditis
• hepatitis
• septic arthritis
• osteomyelitis
• urinary tract infection
• omphalitis
• asymptomatic transient bacteremia
The transient bacteremia is remarkable because these infants appear 
clinically well and are cultured because of a history of maternal obstetric 
complications. A repeat blood culture before the institution of antibiotic ther­
apy is frequently sterile.
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COAGULASE-POSITIVE STAPHYLOCOCCAL DISEASE
The phage group I S. aureus, which was common in the late 1950s, 
still exists in some nurseries and occasionally causes serious systemic neona­
tal disease. The pathogenicity of this organism is based on its ability to in­
vade the skin and musculoskeletal system, producing furuncles, breast ab­
scesses, adenitis, and osteomyelitis. Septicemia is usually secondary to local 
invasion. After S. aureus is recovered from blood cultures of neonates, a 
careful search should be made for a primary focus. Some group I S. aureus 
strains produce toxic shock syndrome toxin-1, formerly known as enterotoxin 
F or pyrogenic toxin C, and have caused toxic shock syndrome in older neo­
nates. Clinical characteristics of this disease include the sudden onset of fe­
ver, diarrhea, shock, mucous membrane hyperemia, and a diffuse erythema­
tous macular rash with subsequent desquamation of the hands and feet, com­
mencing on about the fifth or sixth day of illness.
In the early 1970s, phage group II coagulase-positive staphylococci 
emerged as a common cause of neonatal infection. Although this organism 
may be invasive, pathogenicity depends principally on production of an 
exotoxin (i.e., exfolatin or epidermolytic toxin). Common areas of primary 
infection include the umbilical stump, conjunctiva, and throat. Clinical dis­
ease may take one of several forms, including bullous impetigo, toxic epi­
dermal necrolysis (i.e., Ritter disease), and nonstreptococcal scarlatina. Col­
lectively, these diseases have been referred to as the expanded scalded skin 
syndrome.
The initial finding in Ritter disease is generalized erythema associated 
with edema and tenderness on palpation, usually noticed between days 3 to 
16 of life. After several days, a distinctive desquamation of large sheets of 
epidermis occurs, which is different from the fine desquamation observed in 
the second and third weeks of streptococcal scarlet fever. Large flaccid bullae 
are commonly observed in Ritter disease that, on rupture, leave a tender, 
weeping erythematous base. Some infants may appear quite toxic with the 
generalized form of disease. A rare, congenital form of staphylococcal 
scalded skin syndrome has been described.
Umbilical venous or arterial catheters and central venous lines are 
well-recognized risk factors for staphylococcal bacteremia. S. aureus is sec­
ond only to coagulase-negative staphylococci as a cause of catheter-related 
infections.
The mortality rate for neonates with S. aureus bacteremia is about 
20%. Low-birth-weight infants are at highest risk for death from this infec­
tion.
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COAGULASE-NEGATIVE STAPHYLOCOCCAL DISEASE
The isolation of coagulase-negative staphylococci from blood, CSF, or 
urine of newborns with signs and symptoms of sepsis can be significant, and 
these bacteria should not be dismissed as contaminants. Of the 21 recognized 
coagulase-negative staphylococcal species, 5. epidermidis is clinically the 
most significant for neonates. Experience indicates that these bacteria are re­
sponsible for about 10% of cases of sepsis in neonatal intensive care units. 
Coagulase-negative staphylococcal infections are nosocomial in origin and 
result in substantially longer hospitalizations for affected infants. Risk of 
infection with these organisms increases with decreasing gestational age and 
birth weight.
Clinical manifestations of coagulase-negative staphylococcal infec­
tions are similar to those caused by other pathogens and include apnea, bra­
dycardia, temperature instability (e.g., hypothermia, hyperthermia), respira­
tory distress (e.g., tachypnea, retractions, cyanosis), gastrointestinal manifes­
tations (e.g., poor feeding, abdominal distention, bloody stools), lethargy, and 
metabolic acidosis. Clinical illnesses include septicemia, meningitis with or 
without CSF abnormalities, neffotizing enterocolitis, pneumonia, omphalitis, 
soft tissue abscesses associated with persistent bacteremia, endocarditis, and 
scalp abscesses and osteomyelitis at insertion sites of fetal monitoring elec­
trodes.
Risk factors for coagulase-negative staphylococcal infections include 
the presence of foreign bodies, such as central venous lines, ventriculoperito­
neal shunts, or peritoneal dialysis catheters, and prior antibiotic therapy and 
the intravenous infusion of lipid emulsions for nutritional support. The organ­
isms travel along catheter tracks from colonization sites. They eventually ad­
here to and proliferate on certain biosynthetic materials and later cause local 
or systemic reactions. The mechanism by which adherence occurs appears to 
initially involve hydrophobic and electrostatic interactions between the bacte­
ria and the biopolymers. Once attached, a viscous exopolysaccharide referred 
to as slime is formed. Slime covers the bacteria to form a surface biofilm that 
protects them from such environmental factors as antibiotics and host de­
fenses while allowing continued access to nutrition. The density of the 
biofilm may be increased if the organisms are exposed to subinhibitory con­
centrations of antibiotics to which they are susceptible (e.g., vancomycin). 
Slime appears to inhibit neutrophil chemotaxis and phagocytosis and the 
lymphoproliferative responses of mononuclear cells to mitogens. Slime- 
producing strains account for most coagulase-negative staphylococci isolated 
from infants with invasive infections. Ineffective opsonophagocytosis due to 
intrinsic deficiencies in neonatal host defenses contributes to the increased 
susceptibility of low-birth-weight infants to infection with these organisms.
Coagulase-negative staphylococci produce a variety of toxins that may 
serve as virulence factors, including hemolysins, proteases, urease, and fibri-
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nolysin. Most fecal isolates produce a hemolysin that is functionally and im- 
munologically identical to the delta toxin produced by S. aureus. This toxin 
causes severe mucosal necrosis and hemorrhage when injected into ligated 
infant rat bowel loops and may play a role in the pathogenesis of neonatal ne­
crotizing enterocolitis.
Listeria monocytogenes DISEASE
The pathogenesis of clinical diseases caused by L. monocytogenes are 
similar to those caused by GBS. A fulminant, disseminated disease (i.e., 
granulomatosis infantiseptica) may occur during the first several days of life. 
The pathogen is acquired transplacentally or by aspiration at the time of 
vaginal delivery, and multiple organ systems are involved. The infant fre­
quently presents with hypothermia, lethargy, and poor feeding. Early passage 
of meconium in a premature infant suggests Listeria infection. A characteris­
tic rash consisting of small, salmon-colored papules scattered primarily on 
the trunk can be observed in some infants. The chest roentgenogram shows 
parenchymal infiltrates suggestive of aspiration pneumonitis in most infants. 
A miliary-type of bronchopneumonia can be seen in some cases. Listeria se­
rotypes la, lb, and IVb produce the early-onset disease, whereas serotype IVb 
is the predominant type in late-onset meningitic disease.
A delayed form of neonatal listeriosis occurs during the second 
through fifth weeks of life and primarily involves the meninges. The infected 
infant usually is the full-term product of an uncomplicated labor and delivery. 
Onset of symptoms and signs is relatively insidious and indistinguishable 
from those observed with meningitis caused by other pathogens. The source 
of the organism in late-onset disease is unclear. Although acquisition of Lis­
teria may occur during passage through an infected birth canal, it appears 
that most cases result from postpartum horizontal spread. In favor of the lat­
ter route of infection are several reported clusters of neonatal listeriosis and 
the demonstration of cross-infections between newborns using enzyme 
electrophoretic typing and DNA fingerprinting. The bacteriology laboratory 
should be forewarned of the clinical suspicion of listerial meningitis, because 
these microorganisms are occasionally discarded as contaminants because of 
their tinctorial and morphologic similarities with diphtheroids. Overnight re­
frigeration of spinal fluid specimens frequently enhance growth of this organ­
ism.
The peripheral leukocyte count usually shows a brisk leukocytosis, 
with a predominance of polymorphonuclear leukocytes in the differential 
count. A significant elevation in the number of monocytes, to 7% to 21% of 
the total leukocyte count, has been documented on admission laboratory 
evaluation of infected infants. A monocytosis of this magnitude can be dem­
onstrated in most remaining infants on repetitive testing of the peripheral 
leukocyte count, but monocytes are not typically found in the spinal fluid of
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infants infected with L. monocytogenes. Polymorphonuclear leukocytes pre­
dominate in about 75% of cases, with a relative lymphocytosis in the remain­
ing 25%. As with other pyogenic meningitides, hypoglycorrhachia and ele­
vated protein concentrations are frequent findings. Examination of the stained 
smear of spinal fluid has not been rewarding in more than 50% of cases. This 
is a reflection of the relatively low concentrations of organisms in the fluid.
ENTEROCOCCAL INFECTION
Group D streptococci are divided into enterococcal and nonenterococ- 
cal types. The enterococci are now included in the new genus Enterococcus', 
most neonatal infections are caused by Enterococcus faecalis and, to a lesser 
extent, by E. faecium.
Early-onset enterococcal disease (<7 days of age) is relatively mild and 
presents clinically with respiratory distress or diarrhea; no associations with 
underlying conditions, invasive procedures, or maternal obstetric complica­
tions have been observed. Late-onset disease (>7 days of age) most com­
monly afflicts low-birth-weight infants with complicated clinical problems 
that often require surgical procedures (e.g., bowel resection), central venous 
catheters, or prior treatment with antimicrobials. Clinical manifestations of 
late-onset disease include apnea, bradycardia, circulatory failure, meningitis, 
pneumonia, scalp abscesses, catheter-related bacteremia, and necrotizing en­
terocolitis-associated septicemia. About 20% of enterococcal blood isolates 
represent skin contamination; clinical correlation is needed to differentiate 
contamination from true infection.
Enterococci can spread rapidly within a nursery. Nosocomial outbreaks 
of enterococcal septicemia in neonatal intensive care units are well docu­
mented. The mortality rate is estimated at 6% to 11%, but it can be as high as 
17% in infants with necrotizing enterocolitis-associated septicemia.
The importance of identifying Enterococcus as the etiologie agent in 
septicemia primarily relates to selection of proper antimicrobial agents. The 
group D enterococci are moderately resistant to penicillin alone, due to cer­
tain properties of their penicillin-binding proteins. Some enterococcal strains 
have acquired new mechanisms of antibiotic resistance that include p- 
lactamase production and high-level aminoglycoside resistance (i.e., minimal 
inhibitory concentrations > 2000 pg/mL). Strains resistant to vancomycin 
have been encountered. Nonenterococcal group D streptococci continue to be 
highly susceptible to penicillin.
GRAM-NEGATIVE INFECTION
In North America, E. coli is the most common gram-negative organism 
causing septicemia during the neonatal period. Klebsiella and Enterobacter 
strains are second. In Dallas, annual incidence rates have remained reasona­
bly constant at 0.5 to 1 case per 1000 live births since 1970. In contradistinc-
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tion to illness caused by GBS and L. monocytogenes, E. coli infections do not 
fit into distinct clinical syndromes of early- and late-onset disease. Approxi­
mately 40% of E. coli strains causing septicemia possess K1 capsular anti­
gen, and strains identical with those isolated from blood cultures can usually 
be identified in the patient's nasopharynx or rectal cultures. The clinical fea­
tures of E. coli sepsis are generally similar to those observed in infants with 
disease caused by other pathogens. Localized E. coli infections have included 
breast abscess, cellulitis, pneumonia, lung abscess, empyema, osteomyelitis, 
septic arthritis, urinary tract infection, ascending cholangitis, and otitis me­
dia.
Pseudomonas septicemia may present with a characteristic violaceous 
papular lesion or lesions that, after several days, develop central necrosis. Al­
though these skin lesions are most commonly seen in Pseudomonas infection, 
they may be associated with other organisms
ANAEROBIC INFECTIONS
Anaerobes have accounted for 1% to 25% of all bacteria isolated from 
blood cultures of neonates with suspected septicemia in various studies. 
Baderoides spp., primarily Bacteroides fragilis, and clostridia are most com­
monly recovered. Peptostreptococcus spp., Veillonella spp., Propionibacte- 
rium acnes, Eubacterium spp., and Fusobacterium spp. occur relatively in­
frequently. Anaerobes are found mixed in cultures with aerobic bacteria in 
about a third of cases. Clinical illnesses include transient bacteremia, fulmi­
nant septicemia, postoperative infections, and intrauterine death associated 
with septic abortion. Localized diseases such as omphalitis, cellulitis, and ne­
crotizing fasciitis are commonly seen with clostridia. Conditions predispos­
ing to anaerobic septicemia include prolonged rupture of membranes, 
chorioamnionitis, prematurity, and gastrointestinal disease.
Anaerobes isolated from blood within the first 2 days of life are usually 
gram positive and penicillin G susceptible, but those isolated from older new­
borns tend to be gram negative and penicillin G resistant. Gram-positive 
anaerobes are more likely to be recovered from blood of infants with sepsis 
associated with chorioamnionitis, whereas gram-negative anaerobes pre­
dominate in necrotizing enterocolitis-associated bacteremia. The mortality 
rates for reported cases of anaerobic septicemia are about 35% for illnesses 
caused by Bacteroides spp., and 12% for other anaerobes.
GENITAL MYCOPLASMAS
M. hominis and U. urealyticum are occasionally isolated from the 
blood of neonates with sepsis. Cas-sell and colleagues observed concomitant 
bacteremia in 40% and 26% of preterm infants with positive endotracheal 
cultures for M. hominis and U. urealyticum, respectively. Other investigators 
have been unable to recover genital mycoplasmas from the blood or CSF of
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neonates with suspected sepsis. An association between persistent pulmonary 
hypertension and U. urealyticum sepsis and pneumonia has been observed.
FUNGAL INFECTIONS
Fungal infections occur in as many as 5% of low-birth-weight infants. 
Most cases are due to Candida spp., particularly C. albicans. C. tropicalis, C. 
pampsilosis, Candida lusitaniae, and Candida glabrata also cause systemic 
candidiasis. Congenital candidiasis is uncommon and results from ascending 
infection through intact membranes; it usually manifests with early skin le­
sions (e.g., maculopapular rash, pustules, vesicles, desquamation, skin ab­
scesses) but disseminated and life-threatening infections can occur.
Risk factors for late-onset systemic candidiasis include prematurity, 
low birth weight, use of broad-spectrum antimicrobial agents, central vascu­
lar catheters, parenteral hyperalimentation, intralipid infusions, prolonged 
endotracheal intubation, necrotizing enterocolitis, and immunologic immatur­
ity.
The most important of these factors appears to be the number of prior 
antibiotics and the duration of therapy. Low-birth-weight infants in whom 
muco-cutaneous candidiasis develops are at considerable risk for subsequent 
invasive disease. Infants with invasive candidiasis caused by C. albicans are 
more likely to have antecedent candidal thrush or perineal dermatitis and to 
die of their infection than neonates with severe C. pampsilosis infections. 
Clinical manifestations vary and are indistinguishable from those caused by 
other pathogens. A fungal cause for sepsis should be strongly considered in 
an infant weighing less than 1500 g who has been hospitalized for a pro­
longed period, is receiving parenteral hyperalimentation through a central 
vascular catheter, and has previously been treated with multiple antibiotics; a 
history of gastrointestinal disease or surgery adds to the clinical suspicion. 
Diseases caused by Candida spp. include but are not iimited to pneumonia, 
endocarditis, endophthalmitis, meningitis, cerebral abscesses, pyelonephritis, 
fungal balls in the kidney and bladder, peritonitis, hepatosplenic abscesses, 
arthritis, and osteomyelitis.
M. furfur causes invasive neonatal fungal disease. Most infections in­
volve chronically ill premature infants who are receiving lipid emulsions 
through a central venous catheter. The most commonly reported presenting 
symptoms and signs include fever (50%) and respiratory distress (50%). 
Pathologic analysis reveals mycotic thrombi around catheter tips, endocardial 
vegetations, and lung lesions that include mycotic emboli with occlusion of 
pulmonary arteries, septic thrombi, pulmonary vasculitis, and al-veolitis. In­
volvement of other organs is uncommon. Systemic infections due to other 
fungi such as Hansenula anomala, Aspergillus spp., Cryptococcus neofor- 
mans, Coccidioides immitis, Blastomyces spp., and Trichosporon beigelii are 
rare.
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LABORATORY TESTS AND FINDINGS
Since the early 1970s, several screening tests and scoring systems have 
been described that are purported to aid the physician in making the diagnosis 
of neonatal infection. Although a few are helpful in identifying the infant at 
high risk of developing infection, the diagnosis of septicemia can be made 
only by recovery of the organism from blood cultures or other normally ster­
ile body fluids. It is imperative that these cultures be obtained by strict asep­
tic technique. Blood should be obtained from a peripheral vein rather than 
from the umbilical vessels, the outer several millimeters of which are fre­
quently contaminated with bacteria. Femoral vein aspiration may result in 
cultures contaminated with coliform organisms from the perineum. Heel stick 
samples have low sensitivities. The skin above the vein to be punctured 
should be cleansed with an antiseptic solution, such as an iodophor, and al­
lowed to dry for maximal antiseptic effect. The amount of blood drawn is 
critical; 0.5 to 1 mL of blood is required for optimal results. The sensitivity of 
a single blood culture in identifying septicemia is only 80%. Obtaining blood 
cultures from multiple sites may enhance the yield and aid in identifying 
false-positive results. Quantitative blood cultures, if available, are helpful in 
differentiating true pathogens from culture contaminants.
It is frequently helpful to obtain cultures of other sites before initiating 
antimicrobial therapy. For example, percutaneous bladder aspiration of urine 
for culture can be helpful in identifying the urinary tract as the focus of infec­
tion. This is particularly true for illness occurring after the third day of life. 
Naso-pharyngeal, skin, umbilical cord, gastric, and rectal cultures are fre­
quently positive in the early septicemic form of listeriosis and GBS disease. 
However, these colonization sites are not predictive of the cause of blood­
stream infection and should not be used to guide antimicrobial therapy. All 
clinically stable infants with suspected septicemia should have CSF obtained 
for examination and culture before therapy. This practice has been challenged 
for infants younger than 7 days of age because of its low yield; the yield from 
a lumbar puncture is much higher when performed on infants older than 1 
week of age.
The peripheral leukocyte count is the most useful of the indirect indi­
cators of bacterial infection. After correction for the nucleated erythrocyte 
count, the total absolute neutrophil count and the ratio of immature to total 
neutrophilic forms are compared with normal standard values for age. In the 
absence of maternal hypertension, severe asphyxia, periventricular hemor­
rhage, maternal fever, or hemolytic disease, absolute total neutropenia and an 
elevated ratio of immature to total neutrophilic forms strongly suggest bacte­
rial infection. Infants born in high-altitude areas have higher total and imma­
ture neutrophil counts. Repeating complete blood counts within 24 hours of 
birth has been shown to enhance the value of the test as a screen for sepsis. 
Gastric aspirate stains and culture, erythrocyte sedimentation rate, C-reactive
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protein, and the nitroblue tetrazolium test have not proved useful as indica­
tors of bacterial infection, although in combination these tests may offer 
some guidance. C-reactive protein values appear not to be influenced by 
perinatal asphyxia, hyperbilirubinemia, periventricular hemorrhage, or respi­
ratory distress syndrome and may prove to be a useful marker for bacterial 
infection.
Detection of the soluble antigens of E. coli K l, GBS, H. influenzae 
type b, N. meningitidis, and 5. pneumoniae by counterimmunoelectrophoresis 
and agglutination procedures is useful for identifying the infant infected with 
these pathogens. The absence of antigen does not rule out infection by these 
organisms. Substantial sensitivity differences have been found among the 
commercially available latex particle agglutination (LPA) assays for GBS an­
tigen. False-positive LPA test results for GBS in urine specimens can result 
from contamination of bag specimens with these bacteria from perineal and 
rectal colonization, cross-reacting antigens, or absorption of antigen from the 
gastrointestinal tract. Similar false-positive test results may be obtained for 
the other bacteria. Rapid diagnosis of invasive Candida infection by detec­
tion of its circulating cell-wall (e.g., mannan) or cytoplasmic (e.g., enolase) 
antigens is possible, although the reliability of these tests is yet to be proved.
THERAPY
After septicemia is suspected, suitable cultures should be obtained and 
therapy with ampicillin and an aminoglycoside started immediately. If men­
ingitis has been excluded, ampicillin is administered intravenously or 
intramuscularly in a dosage of 50 mg/kg/ day divided in two doses for infants 
younger than 1 week of age and 100 to 150 mg/kg/day divided in three or 
four doses for infants 1 to 4 weeks of age. The selection of the aminoglyco­
side antibiotic should be based on antimicrobial susceptibilities of enteric or­
ganisms isolated from infants in each nursery. Gentamicin is the drug of 
choice for treatment of infections caused by susceptible gram-negative organ­
isms and is administered intravenously or intramuscularly in a dosage of 5 to
7.5 mg/kg/day divided in two or three doses, depending on infant's age.
Aminoglycoside-resistant E. coli have been encountered in some nurs­
eries in North America. In these nurseries or in an infant from whom an iso­
late is shown to be resistant to kanamycin or gentamicin, amikacin or cefo­
taxime should be used. Studies have demonstrated no significant ototoxicity 
in infants and children who were treated in the neonatal period with kanamy­
cin or gentamicin. However, in premature infants and in those receiving these 
drugs for prolonged periods, brain stem evoked response audiometry should 
be performed whenever possible. Serum concentrations of the aminoglyco­
sides should be monitored in the low-birth-weight premature infants because 
of erratic absorption and elimination of the drugs in these infants. Although 
cefotaxime should not be routinely used for initial empiric therapy of neona-
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ta] sepsis, it is an effective agent alone or combined with an aminoglycoside 
for infections caused by coliform bacilli.
When the type of skin lesions or historic experience suggests the pos­
sibility of Pseudomonas infection, ceftazidime or ticarcillin with or without 
an aminoglycoside is the therapy of choice. Although not approved for use in 
neonates by the Food and Drug Administration, we have successfully used 
Timentin (ticarcillin and clavulanate) for treatment of sepsis caused by mul- 
tiresistant gram-negative enteric bacilli, Pseudomonas, or anaerobic bacteria.
If staphylococcal sepsis is suspected but not proved, parenteral methi- 
cillin or nafcillin should be substituted for penicillin or ampicillin, because 
approximately 80% of staphylococci encountered in neonates are penicillin- 
resistant. Although gentamicin and kanamycin possess activity against most 
staphylococci, these agents cannot be recommended because there are no 
studies of their efficacy in neonatal staphylococcal disease. For disease 
caused by coagulase-negative staphylococci or multiresistant S. aureus 
strains, vancomycin is the preferred therapy. Peak and trough serum vanco­
mycin concentrations should be monitored because of the drug's narrow 
therapeutic index.
After the pathogen is identified and its antimicrobial susceptibilities 
are known, the most appropriate drug or drugs should be selected. As a gen­
eral rule, gentamicin alone or in combination with ampicillin, or cefotaxime 
alone or in combination with an aminoglycoside should be used for suscepti­
ble E. coli, Klebsiella spp., and Enterobacter spp.; amikacin alone or in com­
bination with cefotaxime for gentamicin-resistant coliform bacteria; cef­
tazidime, ticarcillin, or Timentin, with or without an aminoglycoside, for 
Pseudomonas', ampicillin alone or in combination with an aminoglycoside for 
P. mirabilis, enterococci, and L. monocytogenes', and penicillin for other 
gram-positive organisms, except for penicillin-resistant S. aureus, for which 
methicillin or nafcillin is the drug of choice. Vancomycin is used for coagu­
lase-negative staphylococci and MRSA. Rarely, coagulase-negative staphy­
lococcal strains that are resistant to vancomycin can emerge during treatment 
with this agent. The minimal inhibitory concentration (MIC) and minimal 
bactericidal concentration (MBC) of penicillin and ampicillin should be de­
termined for GBS because a small percentage of these organisms are tolerant 
(i.e., has an MBC: MIC ratio > 32) to these antibiotics. These strains are best 
treated with a penicillin-aminoglycoside combination. U. urealyticum infec­
tions are treated with erythromycin.
The drug of choice for systemic fungal infections is amphotericin B, 
with or without flucytosine. The half-life and serum concentrations of am­
photericin В are highly variable during the neonatal period. The drag appears 
to be better tolerated by infants than older children and adults, but renal and 
hepatic functions should be carefully monitored. The optimal daily dosage of 
amphotericin В is not universally agreed on. The most commonly employed
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dosage regimen is to begin with 0.5 mg/kg of the drug on the first day and, if 
tolerated, to increase the daily dosage to 1.0 mg/kg by the second or third day 
of treatment. The cumulative dosage of amphotericin В needed for the ade­
quate treatment of systemic Candida infection is not well defined, but it is 
estimated to be 20 to 30 mg/kg. Resistance to amphotericin В among Can­
dida species is not a major clinical problem. Amphotericin В is frequently 
combined with flucytosine for the treatment of central nervous system fungal 
infection because of flucytosine's excellent CSF penetration and the in vitro 
synergy of this drug combination against Candida. Gastrointestinal intoler­
ance, myelosuppression, and hepatotoxicity are common side-effects of flu­
cytosine. Experience with the use of liposomal amphotericin B, miconazole, 
or fluconazole in newborns is limited.
Guidelines for determining duration of therapy in the neonatal period 
are often lacking, because objective evidence of illness may be minimal. Cul­
ture of the blood should be repeated 24 to 48 hours after initiation of therapy; 
if positive, alteration of therapy may be necessary. In the absence of deep tis­
sue involvement or abscess formation, treatment is usually continued 5 to 7 
days after clinical improvement. If multiple organs are involved or clinical 
response is slow, treatment may need to be continued for 2 to 3 weeks.
Suspected central venous catheter-related bacterial sepsis can be ini­
tially managed with the intraluminal infusion of vancomycin combined with 
ceftazidime or an aminoglycoside. After infection is confirmed and the 
pathogen identified, single-drug therapy is usually sufficient. Reported cure 
rates with antibiotics alone without catheter removal have ranged from 50% 
to more than 90% for pediatric patients. Persistently positive blood cultures 
after 2 to 4 days of appropriate antimicrobial therapy warrants catheter re­
moval. A continuous infusion of a low dose of urokinase for 24 hours may 
help in clearing catheter-related infections in some infants who fail conven­
tional antibiotic therapy. Patients responding to antibiotic therapy should be 
treated for 2 to 3 weeks or at least for 10 days from the time of the first nega­
tive blood culture. Catheter-related fungal infections are rarely cured without 
catheter removal.
Immunotherapy of neonatal sepsis is discussed in in Chapter 46. Extra­
corporeal membrane oxygenation for newborns with persistent pulmonary 
hypertension due to overwhelming early-onset GBS sepsis may improve their 
survival.
PREVENTION
The identification of high-risk GBS-carrier mothers and the subsequent 
interruption of vertical transmission by intrapartum maternal chemotherapy 
can prevent many cases of early-onset neonatal GBS disease. If this approach 
is used, pregnant women should be screened for anogenital GBS carriage at 
26 to 28 weeks of gestation. Latex agglutination tests can be used at the time
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of delivery for women with no prenatal care. Culture-positive women with 
onset of labor or rupture of membranes before 37 weeks of gestation, fever 
during labor, rupture of membranes for more than 12 hours, a history of GBS 
bacteriuria during pregnancy, or a history of having previously delivered an 
infant with GBS disease should be treated intravenously with ampicillin until 
delivery. The management of infants bom to women given intrapartum an­
timicrobial prophylaxis depends on their clinical status and culture results; 
most premature infants are treated with ampicillin and an aminoglycoside for 
36 to 72 hours unless sepsis becomes evident. Immunologic approaches to 
prevention include passive or active immunization of mothers, with transpla­
cental passage of protective antibodies to the fetus, but immunoprophylaxis is 
not a clinically available option.
MENINGITIS
BACTERIAL MENINGITIS
The incidence of bacterial meningitis is 0.4 per 1000 live births, but 
rates as high as 1 per 1000 live births have been reported in a few nurseries. 
The disease is seen more commonly in premature infants, male infants, and 
infants born to mothers with complicated pregnancies or deliveries.
ETIOLOGY
The bacteria causing neonatal meningitis are similar to those causing 
sepsis neonatorum. Group В p-hemolytic streptococci and E. coli presently 
account for approximately 75% of all cases. The next most common etiologie 
agent is L. monocytogenes.
PATHOLOGY
The pathologic findings in cases of neonatal meningitis are similar, re­
gardless of the bacterial agent. The most consistent finding at necropsy is a 
purulent exudate coating the meninges and ependymal surfaces of the ventri­
cles. Perivascular inflammation is observed. The inflammatory response of 
neonates is similar to that in adults with meningitis, with the exception that 
babies show a relative sparsity of plasma cells and lymphocytes during the 
subacute stage of meningeal reactions. Hydrocephalus and a noninfectious 
encephalopathy can be demonstrated in approximately 50% of infants dying 
of meningitis. Subdural effusions occur rarely in neonates. Various degrees 
of phlebitis and arteritis of intracranial vessels can be found in all infants. 
Thrombophlebitis with occlusions of veins may occur in the subependymal 
zone. Ventriculitis can be demonstrated in virtually all infants dying of men­
ingitis and in approximately 75% of infants at the time of diagnosis.
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CLINICAL MANIFESTATIONS
The signs and symptoms of central nervous system infection are fre­
quently indistinguishable from those associated with neonatal septicemia. 
Lethargy, feeding problems, and altered temperature are the most frequent 
presenting complaints, and respiratory distress, vomiting, diarrhea, and ab­
dominal distention are common findings. Seizures are observed frequently 
and may be caused by direct central nervous system inflammation or may be 
associated with hypoglycemia or hypocalcemia. Signs suggesting meningeal 
involvement, such as a bulging anterior fontanelle, neck stiffness, or opist­
hotonus, are uncommon.
PATHOGENESIS
Most cases of meningitis result from bacteremia and spread from a 
contiguous infected focus is rare. Although there are more than 100 К types 
of E. coli, E. coli K1 accounts for more than 70% of meningitis cases. The 
extracellular polysaccharide capsule allows the organism to avoid host clear­
ance mechanisms. The outer membrane lipopolysaccharide (i.e., endotoxin) 
is released from dying bacteria and initiates an intense inflammatory reaction. 
Endotoxin stimulates the production of tumor necrosis factor, interleukin-1P 
(IL-P), and other mediators by monocyte-macrophage cells. Tumor necrosis 
factor and IL-ip induce phospholipase A2 activity, production of other me­
diators and receptor-ligand interactions between leukocytes and endothelia. 
Phospholipase A2 then acts on membrane phospholipids to produce a variety 
of lipid proinflammatory substances such as platelet-activating factor, leukot- 
rienes, prostaglandins, and thromboxanes. The inflammatory changes result 
in vascular injury and alterations in the permeability of the blood-brain bar­
rier, with resultant vasogenic edema. The cytokines activate adhesion- 
promoting receptors on cerebral vascular endothelial cells which leads to re­
cruitment of leukocytes to sites of stimulation. These polymorphonuclear 
leukocytes subsequently enter the subarachnoid space, release toxic sub­
stances, and cause cytotoxic edema. The net pathophysiologic effect is the 
development of increased intracranial pressure and severe brain edema. 
Cerebral edema, increased intracranial pressure, systemic hypotension, de­
creased cerebral perfusion pressure, and a variety of vascular changes result 
in global or regional reductions of cerebral blood flow and can lead to brain 
ischemia. The pathophysiologic aberrations ultimately cause focal or diffuse 
neu-ronal injury, which may be irreversible.
Among the five GBS serotypes, the Bill organisms account for more 
than 80% of cases of neonatal GBS meningitis. The presence of type-specific 
antibodies enhances opsonization of the organism in the presence of com­
plement. Cell wall components of the organism can stimulate the inflamma­
tory cascade in a manner similar to that described for endotoxins.
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LABORATORY FINDINGS
Interpretation of CSF values in newborn infants may be difficult. Any 
one or a combination of the following CSF values should alert the pediatri­
cian to the possibility of meningeal infection:
More than 32 Ieukocytes/mm3, of which more than 60% are po­
lymorphonuclear cells
CSF glucose less than 50% to 75% of a simultaneous serum glu­
cose
Protein greater than 150 mg/dL 
Microorganisms on gram-stained smears of CSF.
The upper limits of "normal" for infants with birth weights of 1500g or 
less are even higher.
It is important to carefully examine a stained smear of the CSF of 
every infant with suspected meningitis. In babies with meningitis caused by 
GBS or coliform bacteria, each oil-immersion field usually contains several 
to many bacteria. This is because there are 104 to 108 bacteria per 1 mL of 
spinal fluid (average, 107/ ml) present at the time of diagnosis. Listeria organ­
isms are often difficult to identify on stained smears because the bacterial 
counts are frequently on the order of 103/mL.
Blood and urine cultures should be obtained from every infant sus­
pected of meningitis. As many as 15% of infants with positive CSF cultures 
have sterile blood cultures.
TREATMENT
Considerable data have been gathered on the pharmacokinetic proper­
ties of antibiotics in neonates with meningitis. After an intramuscular dose of
2.5 mg/kg of gentamicin, peak levels in lumbar CSF and ventricular fluid are 
approximately 1 to 2 pg/mL. If lumbar intrathecal gentamicin is added to this 
regimen, values of 20 to 40 pg/mL or greater several hours after instillation 
may be observed in the lumbar area. Intraventricular administration of 2.5 mg 
results in ventricular fluid levels of 20 to 80 pg/mL and in lumbar spinal fluid 
values of 10 to 50 pg/mL 1 to 4 hours later. With kanamycin, peak CSF val­
ues of 6 to 10 pg/mL are observed 4 to 6 hours after an intramuscular dose of
7.5 mg/kg. However, peak values of 10 to 30 pg/mL are demonstrated in CSF 
approximately 2 to 4 hours after a 50 to 70 mg/kg/dose of ampicillin.
For the aminoglycosides, the MIC values for the common pathogens 
are frequently greater than the antibiotic levels achieved in CSF. For exam­
ple, an E. coli with a gentamicin MIC value of 2.5 or 5 pg/mL is considered 
susceptible when bloodstream infection is being treated but may be resistant 
when meningitis is being treated. This is because peak cerebrospinal and ven­
tricular fluid gentamicin levels after parenteral therapy are usually lower than 
this MIC value. Alternative therapeutic regimens must be considered, such as
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adding a second antibiotic, selecting a different antibiotic class, or changing 
the route of administration.
Ampicillin and gentamicin or ampicillin and cefo-taxime are recom­
mended for initial empiric therapy of neonatal meningitis. The dosage of am­
picillin or cefotaxime is 100 mg/kg/day in two divided doses during the first 
week of life and 200 mg/kg/day in three or four divided doses thereafter. The 
gentamicin dosage is the same as that used for septicemia. All infants should 
have repeat spinal fluid examinations and cultures at 48 hours after initiation 
of therapy. If organisms are seen on methylene blue or Gram stain of the 
fluid, the patient should be completely reevaluated with regard to making al­
terations in antimicrobial therapy and to obtaining computerized tomography 
of the head. The radiologic procedures may demonstrate the presence of a 
subdural empyema, brain abscess, or ventriculitis that requires neurosurgical 
intervention.
Cefotaxime, with or without an aminoglycoside, can be used for ther­
apy of neonatal meningitis due to susceptible gram-negative enteric organ­
isms. Although there are no large controlled trials of cefotaxime in neonates, 
accumulated experience from open studies indicates that this cephalosporin is 
effective for therapy of neonatal sepsis and meningitis.
The Neonatal Meningitis Cooperative Study group reported that there 
is no beneficial effect of lumbar intrathecal or of intraventricular instillation 
of gentamicin in the therapy of meningitis caused by gram-negative organ­
ism. The mortality rate in infants given intraventricular gentamicin was three­
fold greater than that in infants treated with systemic therapy only. The mean 
and peak ventricular CSF concentrations of endotoxin and IL-ip were sig­
nificantly higher for infants treated with intraventricular gentamicin than 
those receiving intravenous antibiotics alone. This difference may have re­
sulted from the enhanced bacterial killing achieved through higher ventricu­
lar CSF gentamicin concentrations, with the consequent increased release of 
damaging inflammatory mediators, which resulted in greater periventricular 
inflammation.
Therapy for meningitis is continued for a minimum of 2 weeks after 
sterilization of CSF cultures. This equates to 14 days of therapy for meningi­
tis caused by gram-positive organisms and a minimum of 21 days of therapy 
for meningitis caused by gram-negative pathogens.
Attention to general supportive therapy is essential in caring for infants 
with meningitis and is the single most important factor that accounts for the 
improved outcome during recent years. Disturbances of fluid and electrolyte 
balance are common, particularly in the first several days of illness when in­
appropriate antidiuretic hormone secretion may lead to fluid retention and 
hyponatremia. Hypoglycemia, hypocalcemia, and hyperbilirubinemia are fre­
quent complications. Ventilatory assistance is frequently necessary, and 
blood pressure should be carefully monitored. During the course of illness,
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hemoglobin and hematocrit values should be checked frequently because in­
fection may exaggerate and prolong the anemias of infancy, particularly in 
premature infants. Because of the frequent occurrence of bleeding diathesis, 
platelet counts, prothrombin time, and partial thromboplas-tin time should be 
followed.
PROGNOSIS
The mortality from neonatal meningitis is considerable. The overall 
mortality rate is approximately 10% to 30%, but this varies with etiologie 
agent, infant population, and the nursery or intensive care unit.
Short- and long-term sequelae of neonatal meningitis are frequent. The 
acute complications include communicating or noncommunicating hydro­
cephalus, subdural effusions, ventriculitis, and blindness. In 70% of infants 
with Citrobacter diversus meningitis, there is associated brain abscess. With 
computed tomography scanning of the head, abnormalities can be identified 
in approximately 70% of neonates with coliform meningitis. Gross retarda­
tion may be obvious immediately, but many infants appear relatively normal 
at the time of discharge. It is only after prolonged and careful follow-up that 
perceptual difficulties, reading problems, or minimal brain damage is appar­
ent. It is estimated that 30% to 50% of survivors have some evidence of neu­
rologic damage.
ASEPTIC MENINGITIS
Aseptic meningitis is an acute nonbacterial inflammatory disease of the 
meninges that is caused principally by viral agents. The illness occurs fre­
quently in older infants and children and is uncommon in newborn infants. 
Disease in young infants is sporadic or occurs in sharply defined epidemics. 
It is important to differentiate aseptic from bacterial meningitis of infancy, 
because the therapy and prognosis are different in the two conditions.
It is frequently difficult to make a clinical distinction between aseptic 
meningitis and encephalitis in young infants. The cause of viral central nerv­
ous system disease depends in part on seasonal variation, age, and immune 
status of the host. In older infants and children, the enteroviruses (e.g., cox­
sackievirus B, echoviruses) account for most cases of aseptic meningitis dur­
ing the summer months, and mumps, lymphocytic choriomeningitis, and 
other viruses are more common during the other seasons. During epidemics 
of encephalitis, such as those caused by St. Louis encephalitis virus, a mild 
aseptic meningitis may be seen in young infants and occasionally in neonates. 
The mild nature of the disease in early life may be due in part to passively 
transferred antibodies from immune mothers and the relatively isolated status 
of young infants during community outbreaks.
Certain viruses appear to cause significant disease in the very young, 
such as encephalomyocarditis caused by type В coxsackieviruses. In this dis­
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ease, brain, myocardium, blood, kidney, and liver are involved. In one nurs­
ery outbreak, coxsackievirus type B5 caused aseptic meningitis only. Echovi- 
rus type II has been etiologically associated with a nursery epidemic of asep­
tic meningitis, and sporadic cases have been caused by echoviruses 1,2, 3, 5, 
9, 11, 14, 16, 17, 18, 19, 24, 25, 30, 31, and 71.
Encephalitis, with or without involvement of the meninges, may occur 
in young infants and is caused by the aforementioned viral agents and by 
other arboviruses, principally Eastern equine encephalomyelitis virus and 
Western equine encephalomyelitis virus. St. Louis encephalomyelitis is rare 
in newborn infants. Congenital cytomegalovirus, herpes simplex virus types 
1 and 2, rubella, and varicella-zoster viruses produce encephalitis in some in­
fants.
SYMPTOMS
Poor temperature control, lethargy, irritability, loose stools, vomiting, 
diminished appetite, and "failure to thrive" are the most common symptoms. 
In some infants, a shocklike syndrome occurs associated with seizures. It 
may be difficult to differentiate this clinical illness from that of bacterial 
meningitis. In a few patients, an erythematous maculopapular eruption, with 
or without petechiae, may suggest a viral cause.
DIAGNOSIS
Aseptic meningitis should be suspected if several infants in a nursery 
develop illness over a short period or if illness is detected in an infant during 
a community outbreak of aseptic meningitis. Although the outbreak is caused 
by a single etiologie agent, the clinical manifestations may differ among in­
fected infants. Although one infant manifests respiratory symptoms primar­
ily, another may have gastrointestinal illness, and all may have findings indi­
cating involvement of the meninges. Aseptic meningitis is diagnosed in these 
infants by failure to demonstrate bacteria on stained smears and cultures of 
CSF. Although the CSF leukocyte count is usually lower than that observed 
in bacterial meningitis, high counts with predominance of polymorphonu­
clear cells may be observed early in aseptic meningitis. The CSF protein and 
sugar content are usually within normal limits. A definitive diagnosis is made 
by isolation of a viral agent from cultures of CSF or from the throat or rec­
tum, accompanied by a significant rise in serum antibody titer to the specific 
agent.
With the exception of meningoencephalitis caused by herpes simplex, 
there is no specific antiviral therapy for postnatally acquired viral aseptic 
meningitis. Acyclovir is the preferred drug for herpes CNS infections. Inten­
sive supportive care is frequently necessary, with particular attention to main­
tenance of pH and electrolyte balance, respiratory assistance, and adequate 
nutrition. It is possible, although unproved, that intravenous immunoglobu-
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lins may be beneficial in some infants with persistent viral CNS disease, es­
pecially that caused by the enteroviruses. If an infant develops illness in a 
newborn nursery, every effort should be made to define the cause and source 
of infection. The affected infants should be isolated and treated as cohorts un­
til discharge. Survivors may be at risk for development of significant neu­
rologic sequelae, especially if they had seizures during their illness.
OSTEOMYELITIS AMD SEPTIC ARTHRITIS
Because of the unique nature of the vascular supply of the neonatal 
skeletal system, osteomyelitis and septic arthritis frequently occur concomi­
tantly. During the first 12 months of life, capillaries perforate the epiphyseal 
plate of long bones and provide a communication between the metaphysis 
and the joint space. Infections originating in one anatomic location easily 
spread to the other. This is not true after approximately 1 year of age, when 
the perforating capillaries disappear.
The capsules of the hip and shoulder attach below the metaphysis of 
the femur and humerus, respectively. Infection of the epiphyseal cartilage 
may rupture through the periosteum and enter the joint space, producing pu­
rulent arthritis. Because of the capsular articulation of the hip and shoulder, 
osteomyelitis and septic arthritis may coexist, making the origin of infection 
difficult to determine.
Infections of the musculoskeletal system are uncommon in the neonate, 
but incidence figures are not available.
ETIOLOGY AND PATHOGENESIS
The infecting organisms in osteomyelitis and septic arthritis vary, but 
the predominant ones are group В streptococci, S. aureus, and gram-negative 
enteric organisms such as Klebsiella spp., Proteus spp., and E. coli. Although 
gonococcal arthritis and tenosynovitis were commonly encountered in previ­
ous decades, they are seen only occasionally today. Other etiologie agents as­
sociated with newborn bone and joint infection are Salmonella spp., Pseudo­
monas spp., and C. albicans. Hospital-acquired MRSA osteomyelitis and 
septic arthritis can develop in sick premature infants after catheter-associated 
septicemia.
Osteomyelitis and arthritis have been reported after several invasive 
procedures in newborns, including heel puncture, femoral venipuncture, ex­
change transfusions, fetal monitoring electrode placement, and umbilical ar­
tery catheterization. Osteomyelitis of cranial bones has complicated infected 
cephalhematomas. In most cases, the origin is unknown and is presumed to 
be hematogenous.
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CLINICAL PRESENTATION
Nonspecific symptoms of infection, such as lethargy, irritability and 
poor feeding, may be the initial manifestations of neonatal musculoskeletal 
infection. Diminished movement of the affected limb, unrelated temporally to 
birth trauma, is a common clinical sign. Heat, erythema, and swelling are late 
manifestations. The long bones are most commonly affected. Occasionally, 
the diagnosis is made unsuspectingly when purulent material is obtained on 
attempted aspiration of the femoral vein and the needle enters the swollen hip 
capsule. Group В streptococcal osteomyelitis is indolent and usually involves 
a single bone, most commonly the proximal humerus.
Although blood cultures are frequently positive, the infants are usually 
not clinically toxic. The exception is group A p-hemolytic streptococcal in­
fection, in which the infant may appear gravely ill.
LABORATORY TESTS AND FINDINGS
Blood cultures should be obtained from all infants with suspected in­
fection of the musculoskeletal system. A diagnostic aspiration of the joint or 
subperiosteal space should be attempted in all patients, and the material ob­
tained should be treated with Gram stain and cultured. The identification of 
the organism is particularly important, because it may be necessary to treat 
with more than one potentially nephrotoxic drug until the causative bacterium 
has been isolated.
The peripheral leukocyte count is frequently elevated, and juvenile 
forms may be seen. There is little information regarding the erythrocyte 
sedimentation rate during the neonatal period. In older infants and children, 
the sedimentation rate is accelerated in osteomyelitis; its return toward nor­
mal is a rough indicator of therapeutic success.
Radiographs of the affected bone or joint taken early in illness may be 
normal or show widening of the articular space. Later in the course of dis­
ease, subluxation and destruction of the joint are common. If osteomyelitis is 
present, the normal fat markings on roentgenograms of the deep tissues may 
be obliterated, indicating inflammation. Lifting of the periosteum from the 
bone may be observed, but cortical destruction is unusual before the second 
week of illness. A complete skeletal survey should be performed because of 
frequent involvement of multiple sites. Resolution of bone changes is consid­
erably slower than clinical improvement. Although radioisotope scans (e.g., 
technetium, gallium) of bone are useful in early diagnosis of osteomyelitis in 
older infants and children, they may be normal in newborns with proven in­
fection.
THERAPY
Selection of initial antimicrobial therapy should be based on results of 
Gram and methylene blue stains of aspirated purulent material and associated
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clinical findings, such as furuncles or cellulitis. If gram-positive cocci are ob­
served on stained smears, methicillin or nafcillin should be started. Vanco­
mycin may be preferable in nurseries with multiresistant S. aureus strains. 
Cefotaxime or gentamicin is indicated if gram-negative organisms are ob­
served. If no organisms are identified on stained smears, a combination of an 
antistaphylococcal drug and an aminoglycoside is used. After the organism 
has been identified and susceptibility studies are available, the most appro­
priate antibiotic or combination of antibiotics should be used. Direct instilla­
tion of an antimicrobial agent into the joint space is unnecessary because 
most antibiotics penetrate the inflamed synovium, and adequate concentra­
tions are achieved in purulent material. This also applies to treatment of os­
teomyelitis; direct instillation of antibiotics into infected bone is unwarranted.
As a general rule, infection of the joint space and bone should be 
drained by repeated aspiration or by surgery. Suppurative arthritis of the hip 
and shoulder is best treated with incision and drainage to prevent vascular 
compromise or extension of infection into the metaphysis. Orthopaedic con­
sultation must be obtained for all patients.
Antimicrobial therapy of neonatal musculoskeletal infections caused 
by Staphylococcus or coliform organisms should be continued for approxi­
mately 3 weeks and, in some patients, for a longer period. For gonococcal or 
streptococcal infections, 10 days of therapy are generally sufficient with ade­
quate surgical drainage. The duration of therapy must be individualized. In 
general, systemic symptoms disappear within several days of initiation of 
therapy and drainage, but local signs such as heat, erythema and swelling 
may persist for 4 to 7 days. Full range of motion of the involved limb may 
not return for several months, and physical therapy should be instituted early 
to prevent contractures. Complete resolution of roentgeno-graphic changes 
may take several months. The use of large oral dosages of antibiotics for out­
patient therapy of neonatal musculoskeletal infections has not been studied 
systematically and should be undertaken with caution.
PROGNOSIS
Death from these diseases is unusual. However, morbidity may be con­
siderable, particularly if weight-bearing joints such as the hip are involved. 
Contractures and muscle damage can be permanent.
CUTANEOUS INFECTIONS
Most infections of the skin and subcutaneous tissues in neonates are 
caused by S. aureus. There are three major presentations of superficial 
staphylococcal disease. The first and most common are pustules and furun­
cles, which may be solitary or appear in clusters during the neonatal period. 
Pustules are frequently in the periumbilical and diaper areas, and they may 
coalesce gradually and spread to other areas of the body. Bloodstream or or­
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gan invasion is unusual unless the cutaneous infection involves extensive ar­
eas. Omphalitis is usually caused by staphylococci or streptococci, and in­
fected circumcisions are usually caused by S. aureus.
The occurrence of staphylococcal skin infections in several infants 
from the same nursery should alert the physician to the possibility of noso­
comial infection caused by a single, virulent strain of S. aureus. If infections 
are caused by the same strain of Staphylococcus, prompt measures should be 
instituted so that the source of infection can be determined and further colo­
nization and disease can be prevented.
Therapy of cutaneous staphylococcal disease depends on the extent of 
the lesions and the general condition of the infant. Small, isolated pustules 
can be managed by local care with a mild cleansing agent or an antiseptic 
agent such as hexachlorophene or povidone-iodine. Infants with more exten­
sive cutaneous involvement, systemic signs and symptoms of infection, or 
both should be treated with parenteral antimicrobial agents. The selection of 
the proper penicillin is based on historic experience and antimicrobial suscep­
tibility studies of staphylococci isolated from the nursery unit.
The second form of neonatal staphylococcal disease has been de­
scribed as the expanded scalded skin syndrome. This group of illnesses in­
cludes bullous impetigo, toxic epidermal necrolysis (i.e., Ritter disease), and 
nonstreptococcal scarlatina, usually caused by phage group II staphylococci. 
The pathogenesis of these entities appears to be related to release of an 
exotoxin (i.e., exfolatin) that acts primarily on the stratum granulosa of the 
epidermis, causing a generalized erythema, edema, and tenderness, frequently 
progressing to desquamation and formation of flaccid bullae. The usual sites 
of staphylococcal infection are conjunctivae, throat, and umbilicus. Infants 
are usually afebrile. Cultures of blood, nasopharynx, eyes, and other areas 
should be obtained before therapy. Because phage group II staphylococci are 
frequently resistant to penicillin, methicillin is the initial drug of choice. Van­
comycin should be used for multiresistant strains.
The third form of staphylococcal disease is necrotizing fasciitis, which 
also can be caused by streptococci or E. coli. Necrotizing fasciitis, an unusual 
disease of newborns, is associated with surgical procedures, birth trauma, or 
cutaneous infections. In this condition, subcutaneous tissues, including mus­
cle layers, are invaded, and the organism spreads along the fascial planes. 
Overlying skin may appear violaceous, and the borders of the lesion are usu­
ally indistinct. Extensive surgery to resect the destroyed tissue is imperative 
in treating necrotizing fasciitis. Blood and tissue cultures should be obtained, 
and the patient started on methicillin or nafcillin. The necrotic fatty tissue 
may combine with calcium, resulting in tetany and convulsions.
Breast abscesses are most commonly caused by S. aureus, but gram­
negative enteric organisms can be causative. Anaerobes can be recovered 
from as many as 40% of samples, one-half of which are in mixed cultures
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with aerobic bacteria. Bacteremia is rare. The physician should attempt to es­
tablish an etiologie diagnosis by expressing fluid from the nipple after thor­
ough cleaning. Treatment is with methicillin or an aminoglycoside, depend­
ing on the results of the Gram stain and culture, and it should be continued 
for 5 to 7 days. For mild infections, antibiotic therapy is adequate; with more 
severe inflammation, incision and drainage of the abscess are required.
Scalp abscesses occur most commonly as a complication of fetal moni­
toring in which scalp electrodes are used and may occur as localized manifes­
tations of systemic disease (e.g., enterococcal sepsis). Etiologie agents in­
clude staphylococci, enterococci, gram-negative enteric bacteria, and gono­
cocci. Treatment consists of incision and drainage. If there is an associated 
cellulitis, antibiotics are given and continued for 5 to 7 days.
URINARY TRACT INFECTION
Improved methods for obtaining sterile specimens have made it possi­
ble for investigators to define more accurately the incidence of neonatal uri­
nary tract infection. Bacteriuria may be demonstrated in 0.5% to 1.0% of full- 
term infants and as many as 3% of premature infants in studies using bladder 
aspiration technique. Urinary tract infections are more common in babies 
bom to bacteriuric mothers and in male neonates, in contrast to the predomi­
nance of female infants beyond this period of life.
ETIOLOGY
E. coli is the most common etiologie agent of urinary tract infection, as 
found in older patients. Approximately 50% of causative E. coli strains be­
long to one of eight common О antigen groups. Several polysaccharide cap­
sular antigens (e.g., K l, K2, K12, K13) are found more often in infants with 
upper tract disease. This particularly pertains to the Kl antigen. Fimbriated E. 
coli can attach to specific receptors on uroepithelial cells. Glycolipids of the 
P blood group constitute a specific receptor that is believed to be associated 
with pyelonephritis in patients who do not have reflux. Klebsiella and Pseu­
domonas species are encountered less frequently. Gram-positive bacteria, 
with the exception of enterococci, are rare causes of urinary tract infections. 
Fungal cystitis and pyelonephritis are encountered in chronically ill prema­
ture infants previously treated with multiple broad-spectrum antibiotics and 
are associated with mucocutaneous candidiasis or invasive disease.
CLINICAL MANIFESTATIONS
Many infants with significant bacteriuria are asymptomatic. If clinical 
signs are present, they are usually nonspecific and consist of poor weight 
gain, altered temperature, cyanosis or gray skin color, abdominal distention, 
malodorous urine, and poor feeding. In a few patients, jaundice and hepa­
tomegaly may be the presenting features of urinary tract infection. Thrombo­
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cytopenic purpura is found in some of these infants. Localizing signs suggest­
ing urinary tract involvement are unusual; they usually consist of a weak uri­
nary stream or an abdominal tumor from bladder distention or hydronephro­
sis. The most important predisposing factor is vesicoure-teral reflux, which 
allows easy access for bacteria to ascend to the kidneys and leads to residual 
urine in the bladder.
DIAGNOSIS
The diagnosis of urinary tract infection is confirmed by examination 
and culture of urine. The result of these tests depends largely on the method 
of urine collection. Most pediatricians obtain urine with a sterile, plastic re­
ceptacle applied to the cleansed perineum. However, urine obtained by this 
method may have an elevated cell count because of recent circumcision, 
vaginal reflux of urine, or contamination from the perineum. Neonatal as­
phyxia may increase the urinary cell count. Leukocytes must be differentiated 
from round epithelial cells that appear in the urine in appreciable numbers 
during the early days of life. Although pyuria commonly accompanies sig­
nificant bacteriuria, cells can be few or absent in the presence of bacteriuria 
in as many as one-half of the patients. Direct microscopic examination of un­
centrifuged, fresh urine is useful. If bacteria are readily seen in each oil- 
immersion field, there are generally more than 10s bacteria per 1 mL. Glitter 
cells are felt by many to be diagnostic of urinary tract infections.
Quantitative urine cultures from infants with documented disease con­
tain more than 50,000 colonies per 1 mL (usually >100,000/mL), but a small 
number of organisms can be found. Any number of bacteria in a urine speci­
men obtained by percutaneous needle puncture of the bladder should be con­
sidered significant. This latter procedure is the single best source of urine for 
culture and is safe in most newborn infants; its primary complication is tran­
sient gross hematuria lasting less than 24 hours in 0.6% of patients.
TREATMENT
There are several approaches to the treatment of neonatal urinary tract 
infections. Antimicrobial agents should initially be administered parenterally, 
because septicemia is found in 15% to 30% of infants, and absorption after 
oral administration may be erratic in neonates. The physician must assume 
that there is infection of renal parenchyma resulting from hematogenous 
spread.
Antibiotic selection should be based on results of antimicrobial suscep­
tibility studies. Gentamicin is effective against the commonly encountered 
coliform bacteria. Because urinary concentrations of these drugs are consid­
erably higher than those seen in serum, the usual dosages may be halved; for 
gentamicin, 2 to 3 mg/kg/day is satisfactory, provided the initial blood cul­
tures are sterile. Ampicillin and gentamicin should be administered to symp-
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tomatic infants with pyuria before results of culture and susceptibility tests. 
Renal candidiasis should be treated systemically with amphotericin B. Blad­
der irrigation with amphotericin В for infants with uncomplicated Candida 
cystitis has not been properly evaluated, and its use cannot be recommended.
A repeat urine culture should be sterile 36 to 48 hours after initiation of 
appropriate therapy. Infants with persistent bacteriuria must be evaluated for 
possible abscess formation, with or without urinary obstruction. In the un­
complicated patient, therapy is usually continued for a period of approxi­
mately 10 days. Blood urea nitrogen and serum creatinine levels should be 
determined at the initiation of therapy. If there is evidence of renal compro­
mise, dosage and frequency of administration of the drugs, particularly the 
aminoglycosides, may need to be reduced. Approximately 1 week after ther­
apy is discontinued, a repeat urine culture is obtained. If the culture is posi­
tive, therapy is reinstituted and a thorough investigation of the urinary tract is 
made to rule out obstruction or abscess formation.
All infants with documented urinary tract infections should have ra­
diologic evaluation of the urinary tract. A renal scan or ultrasound examina­
tion is obtained sometime during therapy so that the possibility of gross con­
genital abnormalities of the urinary system can be excluded. If obstruction is 
demonstrated, urologie procedures to ensure proper drainage are mandatory if 
therapy is to be successful. A voiding cystourethrogram is usually obtained 
several weeks after therapy has been completed. Radiologic abnormalities, 
such as vesicoureteral reflux, obstructive uropathy, and renal scars, are found 
in approximately 45% of infants, especially in girls.
PROGNOSIS
It is the physician's responsibility to be certain that neonates with 
documented urinary tract infections do not have congenital abnormalities of 
the urinary system. In such patients, recurrent urinary tract infections are 
common, and physical growth may be retarded until definitive surgery for 
stage IV or V vesicoureteral reflux has been performed. Renal growth retar­
dation is common after neonatal urinary tract infections, even in patients 
without reflux. Every patient must have careful long-term follow-up studies 
to detect recurrent infections, many of which are asymptomatic. Prophylactic 
antibiotics should be provided for infants with clinically significant reflux to 
avoid new scar formation and to ensure normal renal growth.
NEONATAL OPHTHALMIA
Infections of the eye of the newborn may be caused by a variety of mi­
croorganisms, including N. gonorrhoeae, C. trachomatis, S. aureus, and P. 
aeruginosa. From a review of more than 300 cases of eye infections in new­
borns at Grady Memorial Hospital in Atlanta, it was determined that 29% 
were caused by chlamydiae, 14% by gonococci, 10% by staphylococci, 2%
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by chemical reactions, and 1% by mixed gonococcal and chlamydial infec­
tions. The causes of the remaining 44% were uncertain. This frequency dis­
tribution of etiologie agents is typical of the experience at large urban general 
hospitals.
The incidence of ophthalmia neonatorum has not paralleled the signifi­
cant increase in gonococcal disease rates among adolescents and young 
adults. This is almost certainly a result of universal neonatal gonococcal pro­
phylaxis. The invasive, destructive ophthalmitis described so vividly in old 
literature is rarely seen today. Several agents have been effective pro- 
phylactically against gonococci: 1% silver nitrate, erythromycin or tetracy­
cline ophthalmic ointments, and one dose of ceftriaxone administered intra­
muscularly.
CLINICAL MANIFESTATIONS
Gonococcal ophthalmia usually becomes apparent within the first 5 
days of life and is characterized initially by a clear, watery discharge. Con­
junctival hyperemia and chemosis are associated with a copious discharge of 
thick, white, purulent material. Both eyes are usually involved but not neces­
sarily to the same degree. Untreated gonococcal ophthalmia may extend to 
involve the cornea (i.e., keratitis) and the anterior chamber of the eye. Cor­
neal perforation and blindness may occur. Before the introduction of ade­
quate prophylactic measures, ophthalmia neonatorum was the most frequent 
cause of acquired blindness in the United States.
DIFFERENTIAL DIAGNOSIS
Any infant presenting with a conjunctival discharge should be evalu­
ated carefully to determine the cause. Three tests should be performed:
1. Gram stain of the exudate
2. Culture of the exudate
3. Direct immunofluorescent chlamydial stain ofscrapings made from the
lower palpebral conjunctiva after exudate has been wiped away.
Appropriate therapy should be instituted on the basis of the results of
the stained smears.
Conjunctivitis occurring in the first days of life can be chemical or bac­
terial. Chemical irritants, such as silver nitrate, cause transient conjunctival 
hyperemia and a watery discharge that rarely turns purulent.
If gram-negative rods are seen in the stained exudate, the greatest con­
cern is P. aeruginosa because of the virulent, necrotizing endophthalmitis 
that can result. In this condition, a relatively mild conjunctivitis can progress 
to infection of the entire globe within 12 to 24 hours. Prompt diagnosis and 
immediate institution of appropriate antimicrobial therapy are mandatory.
Conjunctivitis during the second or third week of life may be caused 
by viral, bacterial, or chlamydial agents. Viral conjunctivitis is frequently 
associated with other symptoms of respiratory tract disease, such as
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sociated with other symptoms of respiratory tract disease, such as rhinorrhea, 
cough, and rash, and several persons in the family or nursery may simultane­
ously have the disease. The discharge in viral conjunctivitis is watery or mu­
copurulent but rarely purulent. Pre-auricular adenopathy is common. Staphy­
lococci, streptococci, and occasionally gonococci cause conjunctivitis in this 
age group. A smear of purulent material helps differentiate these bacterial 
agents. However, the presence of bacteria on a gram-stained smear of exu­
date is not necessarily related etiologically to the conjunctivitis. Normal in­
habitants of the skin and mucous membranes such as Staphylococcus, diph­
theroids, and Neisseria may be observed.
Chlamydial eye infection may begin in the first days of life, but it usu­
ally does not come to the attention of the physician until the second or third 
week. Clinical manifestations of chlamydial infection vary from mild con­
junctivitis to intense inflammation and swelling of the lids, associated with 
copious purulent discharge. Pseudomembrane formation and a diffuse injec­
tion of the tarsal conjunctiva are common. The cornea is rarely affected, and 
preauricular adenopathy is unusual. In the early stages of disease, one eye 
may appear more swollen and infected than the other, but both eyes are usu­
ally involved. The physician establishes the diagnosis by scraping the tarsal 
conjunctiva and looking for typical cytoplasmic inclusions within epithelial 
cells or by direct immunofluorescent staining for chlamydial antigens.
THERAPY
Initial therapy is based on the results of stained smears of exudate and 
epithelial cells. If gonococci are seen, parenteral ceftriaxone is employed. 
Penicillin can be used in areas with a low prevalence of penicillinase- 
producing N. gonorrhoeae strains. If Staphylococci are seen, methicillin or 
another penicillinase-resistant penicillin analog is used. Topical antibiotics 
are unnecessary, because ample antibiotic to inhibit bacteria exists in the eye 
secretions.
Pseudomonas eye infection should always be treated with parenteral 
therapy consisting of ceftazidime and gentamicin. Gentamicin ophthalmic 
drops are used for simple Pseudomonas conjunctivitis, and subconjunctival 
or sub-Tenon space injections of gentamicin are given daily for 
endophthalmitis.
Ophthalmic solutions containing 1% tetracycline, erythromycin, or sul­
facetamide may be used in the treatment of chlamydial conjunctivitis. These 
are applied four times daily for 2 weeks. Topical and oral erythromycin regi­
mens are equally effective in treating this condition, but oral therapy has the 
advantage of eradicating nasopharyngeal carriage of Chlamydia spp.
Patients with gonococcal ophthalmia should be segregated, and strict 
hand-washing techniques should be employed because of the highly conta­
gious nature of the exudate. The eyes should be irrigated with saline to re­
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move the purulent material. Follow-up examination of infants treated for 
gonococcal ophthalmia is important to treat subsequent C. trachomatis oph­
thalmia, which can manifest after completion of therapy for gonococcal in­
fection.
DIARRHEAL DISEASE
Although diarrheal disease during the neonatal period is usually brief 
and self-limited, it can cause significant morbidity in some infants and repre­
sents a potential danger to other infants in the nursery unit.
ETIOLOGY AND PATHOGENESIS
The most common cause of diarrhea in young infants is alteration of 
diet and feeding practices, rather than specific bacterial or viral pathogens. Of 
the infectious causes of diarrhea, rotaviruses are important agents. Their sig­
nificance in the neonatal period has not been determined except in several 
isolated outbreaks. A study from France indicates that 32% of neonates shed 
rota virus in their stools. However, of the neonates shedding the virus, 71% in 
this study had no associated diarrhea. The finding of rotavirus in the stools of 
a neonate with diarrhea may be coincidental and not represent the true etio­
logie agent.
Enteropathogenic E. coli serotypes were once considered the most 
common bacterial agents responsible for diarrhea in young infants. These 
strains are referred to as enteroadherent or enteroaggregate on the basis of the 
purported mechanism by which they cause diarrhea. Failure to demonstrate 
enteropatho-genic serotypes of E. coli in rectal cultures does not rule out coli- 
form disease. Enterotoxigenic strains of E. coli with nonenteropathogenic se­
rotypes have been identified in nursery outbreaks of diarrheal disease. These 
organisms inhabit the small bowel, where they attach to—but do not in­
vade—the intestinal mucosa. The enterotoxin produced by these organisms 
stimulates cyclic AMP, which inhibits Na and Cl transport across the intesti­
nal wall. These salts are lost into the lumen of the upper bowel, followed pas­
sively by water, causing a net loss of stools high in electrolyte content. Vibrio 
cholerae, some E. coli sero-types (i.e., almost exclusively nonenteropatho­
genic strains), and Vibrio parahaemolyticus are examples of bacteria that 
cause diarrhea by this mechanism.
Toxigenic and nontoxigenic Clostridium difficile strains are commonly 
recovered from stool cultures of newborn infants. Their significance, how­
ever, is unknown because most culture-positive or toxin-positive infants are 
asymptomatic.
A second mechanism for bacterial diarrhea involves invasion of the in­
testinal mucosa. Shigella dysentery is the classic example of this disease. 
Colonic invasion, with subsequent destruction of the mucosa, causes an out­
pouring of polymorphonuclear cells and mucus. The resultant diarrhea is
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usually bloody and contains mucus and pus. Other organisms causing bloody 
diarrhea are Campylobacter, Yersinia, and Aeromonas species. Salmonella 
species also invade the intestinal mucosa, but extensive destruction does not 
occur. The epithelial lining is left intact and the organisms reach the lamina 
propria, where an inflammatory response is elicited.
EPIDEMIOLOGIC CONTROL
Serotyping of E. coli for identification of the traditional enteropatho- 
genic strains is no longer practiced in most hospitals. After an index case of 
enteropathogenic E. coli diarrhea is recognized in a nursery, secondary cases 
are likely to ensue. This applies to the other etiologie agents of diarrhea in 
neonates. Any nursery infant with diarrhea should be suspected of having a 
potentially communicable disease. All infants in proximity of the index case 
should have rectal swabs tested by culture or by fluorescent antibody tech­
nique, which is more sensitive for identifying asymptomatic carriers of en­
teropathogenic E. coli. Ill and healthy colonized infants should be segregated 
and treated with orally administered neomycin (100 mg/kg/day in four di­
vided doses) or with colistin sulfate (15 mg/kg/day in three divided doses) for 
5 days. Neomycin causes rapid disappearance of the organism and abbrevi­
ates the period of diarrhea, but approximately 20% of infants revert to the as­
ymptomatic carrier state after treatment. Repeated surveillance of infants is 
necessary until the pathogenic strain has been eliminated from the nursery.
CLINICAL MANIFESTATIONS
The cause of diarrhea cannot be differentiated on clinical grounds in 
newborn infants. Diarrhea caused by enteropathogenic strains of E. coli is in­
sidious in onset, is associated with seven to ten green, watery stools daily, 
and is usually without blood or mucus. The infants do not appear acutely ill. 
Complications are rare and are related primarily to dehydration and electro­
lyte disturbances. Shigella infection is uncommon, usually episodic in neo­
nates, and does not spread within nurseries. Shigellosis in the newborn may 
present as a diarrheic or dysenteric syndrome or may be evidenced only by a 
septic or toxic infant. Suppurative complications are rare, but dehydration 
and electrolyte disturbances are common and need immediate and constant 
attention. Campylobacter species can cause bloody diarrhea in an otherwise 
asymptomatic infant.
Rotavirus infection has been described in newborn infants as a spo­
radic disease or as part of a nursery outbreak. Infection may be asymptomatic 
or associated with vomiting and diarrhea. The infants are usually afebrile, but 
temperature elevation as high as 39°C can occur. Most patients vomit, and 
the diarrhea is characterized by watery stools containing mucus and no blood. 
Moderate or severe dehydration may occur, which results in significant elec­
trolyte disturbance in some infants. Fatal disease has been described in a
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small number of infants. In one report, an outbreak of necrotizing enterocoli­
tis was associated with rotavirus infection.
THERAPY
The most important aspect of therapy for diarrheal disease of newborn 
infants is maintenance of hydra-tion and electrolyte balance. Parenteral solu­
tions containing appropriate electrolytes should be administered during the 
time of active diarrhea, and the infant should be examined and weighed fre­
quently so that proper rehydration and prevention of complications are en­
sured. Estimation of fluid loss from diarrhea and vomiting should be care­
fully recorded and used as a basis for replacement therapy.
Selection of appropriate antimicrobial therapy depends in part on the 
mechanism of diarrhea. An absorbable antibiotic, such as ampicillin or 
trimethoprim-sulfamethoxazole, is indicated for disease caused by invasive 
bacteria (i.e., shigellosis), but orally administered, nonabsorbable drugs, such 
as neomycin or colistin sulfate, are used for noninvasive organisms that pro­
duce enterotoxin (e.g., strains of E. coli).
Antimicrobial therapy for Salmonella gastroenteritis is controversial. 
Antibiotics do not alter the course of illness and usually prolong intestinal 
carriage of the organism. Clinical relapse is more common in antibiotic- 
treated infants. We do not recommend antibiotic therapy for uncomplicated 
Salmonella gastroenteritis if it occurs in older infants and children. Therapy 
is probably indicated for those with prolonged illness or evidence of colitis, 
for all neonates, and for infants with systemic symptoms suggesting blood­
stream invasion. Ampicillin or amoxicillin is usually satisfactory, as are 
trimethoprim-sulfamethoxazole, cefotax-ime, or ceftriaxone.
Ampicillin was formerly the antibiotic of choice for ligellosis, but in 
recent years, significant resistance to this agent has been observed in many 
areas of the country. Most strains are susceptible in vitro to trimethoprim- 
sulfamethoxazole, and infants respond clinically and bacteriologically to a 
regimen of 10 mg trimethoprim with 50 mg sulfamethoxazole/kg/day in two 
divided doses given for 5 days. However, we have limited experience with 
this agent in newborn infants, and the drug should not be used in those with 
jaundice.
Any infant with diarrhea must be isolated from other babies in the 
nursery. Surveillance of all infants in contact with the index case and adop­
tion of strict infection control measures are mandatory.
LOWER RESPIRATORY TRACT INFECTION
Lower respiratory tract infection is an important cause of morbidity in 
the neonate and is demonstrable on postmortem examination in approxi­
mately 20% of neonatal deaths.
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Pneumonias can be divided into three categories on the basis of route 
of acquisition and age at presentation. The first is transplacental pneumonitis, 
which is acquired in utero and presents clinically in the early hours of life. 
Pneumonia may be part of a generalized congenital infection caused by cy­
tomegalovirus, herpesvirus, rubella virus, Toxoplasma spp., or L. monocyto­
genes. Treponema pallidum produces a severe, usually fatal pneumonitis (i.e., 
pneumonia alba), and mycoplasma can cause congenital pneumonia. These 
infants usually have many organ systems involved, and the pneumonitis may 
be obscured. Clinical findings may include hepatosplenomegaly, cutaneous 
manifestations such as rash or petechiae, neurologic abnormalities, and tera­
togenic effects.
The second category, aspiration pneumonia, is acquired in the immedi­
ate perinatal period, and onset of illness occurs within the first hours to days 
of life. Pathogenesis is by way of aspiration of amniotic fluid or material 
from the maternal cervix during the period immediately before or during de­
livery. Most infants with roentgenographic evidence of aspiration have not 
swallowed infected material and do not require antimicrobial therapy. This is 
also true of meconium aspiration, in which the pneumonitis is chemical. The 
bacterial pathogens most commonly encountered are the group В P-hemolytic 
streptococci, group D streptococci, pneumococci, and coliform organisms. 
Infants with these infections may present in the first 12 hours of life with 
acute respiratory distress, with or without shock. The mortality is consider­
able in this condition, even if appropriate antimicrobial therapy is instituted 
early.
The third category of pneumonias are acquired during delivery or in 
the postpartum period, usually beyond the first week of life. Acquired pneu­
monitis may be caused by viral, chlamydial, or bacterial agents and is most 
frequently bronchopneumonic or interstitial. The respiratory syncytial virus is 
the most important pathogen causing lower respiratory tract disease in young 
infants. The parainfluenza viruses, enteroviruses, rhinoviruses, and adenovi­
ruses cause bronchiolitis and pneumonia during early infancy. Herpes sim­
plex virus infection can be acquired at the time of delivery and present in the 
first week of life. Bronchiolitis, pneumonia, or both usually occur in epidem­
ics among premature and full-term nursery infants or in the community.
Documented nursery outbreaks of lower respiratory tract disease have 
been associated with RSV, adenovirus, echovirus type 22, influenza A and В 
viruses, and parainfluenza virus infections. During these outbreaks, many in­
fants are colonized with the epidemic virus strains, but only a few manifest 
clinical disease.
S. aureus and coliform organisms are the most common bacterial 
pathogens causing postnatally acquired pneumonia. Disease caused by S. 
aureus and K. pneumoniae may occur sporadically or in epidemic fashion 
during the neonatal period. Pyogenic complications, such as septicemia, os­
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teomyelitis and meningitis, are frequently associated with the epidemic form 
of these infections.
Acquisition of C. trachomatis  in the intrapartum period may result in 
conjunctivitis (i.e., inclusion blennorrhea) or in pneumonia that usually pre­
sents between the fourth and twelfth weeks of life. The pneumonia is associ­
ated with a staccato cough, often terminating in vomiting or cyanosis, and 
with tachypnea; the infants are usually afebrile. Rales are heard, and there 
may be a history of the infant having conjunctivitis in the newborn period. 
Eosinophilia affects approximately one-half of the patients. C. trachomatis 
can cause severe and chronic pneumonia in low-birth-weight infants. C. tra­
chomatis  pneumonia in otherwise healthy infants has been associated with 
long-term pulmonary function abnormalities.
Considerable data indicates that U. urealyticum  colonization of low- 
birth-weight infants is associated with the subsequent development of chronic 
lung disease. Pneumocystis carinii is an uncommon cause of pneumonia in 
the neonatal period; susceptible infants include malnourished premature 
newborns living in endemic geographic areas, infants with congenital immu­
nodeficiencies (e.g., severe combined immunodeficiency), and neonates in­
fected with the human immunodeficiency virus type 1.
CLINICAL MANIFESTATIONS
The early signs of lower respiratory tract disease in the neonate and 
young infant are frequently nonspecific and include change in feeding status, 
listlessness or irritability, and poor color. More specific findings that may not 
be present at the onset of illness are tachypnea, dyspnea, cyanosis, hypother­
mia, cough, and grunting. Accentuation of the normal irregularity of breath­
ing is a common finding in neonates.
The physical findings of pneumonia vary. Flaring of the alae nasi, 
rapid respirations, and sternal and subcostal retractions are frequently ob­
served. A cough is indicative of lower respiratory tract involvement; a brassy 
cough is frequently found in viral disease. Percussion dullness is difficult to 
demonstrate, but it is indicative of consolidation, effusion, or both. Ausculta­
tion may reveal diminished breath sounds over the affected area. Rales, 
wheezes, or both can usually be heard on deep inspiration or when the baby 
is crying, but may be absent early in the illness. The clinician is frequently 
surprised by the meager clinical signs in the face of clearly demonstrable and 
sometimes extensive roentgenographic findings of pneumonia.
DIAGNOSIS
The leukocyte count can sometimes help to differentiate viral from 
bacterial pneumonia. Infants with early-onset bacterial pneumonia with sep­
sis may have leukopenia with an increased number of band forms. Chorioąm-
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Chorioamnionitis has been demonstrated in the mothers o f some infants with 
congenital pneumonia.
Cultures of blood and material from the trachea frequently help to de­
fine the etiologie agent of neonatal pneumonia. However, results of cultures 
from the ear canal, throat, and other external sites are not helpful and may be 
misleading in newborn and young infants. Lung puncture should be consid­
ered in infants with consolidated pneumonia if the cause is unknown or the 
infant fails to respond to conventional antimicrobial therapy. Material ob­
tained at puncture should be Gram stained for direct visualization of bacteria 
and cultured. Chlamydial pneumonia is best diagnosed by direct im- 
munofluorescent staining and culture of nasopharyngeal secretions.
A chest radiograph is indicated in all infants with nonspecific signs of 
infection. There may be roentgenographic evidence of pneumonia despite the 
absence of physical findings. Although it is not usually possible to determine 
the cause of neonatal pneumonia from chest radiographs, certain roentgeno­
graphic patterns may be associated with specific diseases. A consolidating 
bronchopneumonia with pneumatoceles, with or without empyema, suggests 
staphylococcal disease. This is particularly true when the radiologic findings 
advance markedly in a few hours. If a lobar infiltrate is associated with bulg­
ing fissures on the radiograph, K. pneumoniae infection should be consid­
ered. A miliary-type of bronchopneumonia in a septic neonate is characteris­
tic of listeriosis. Group В streptococcal pneumonia is frequently indistin­
guishable radiographically from hyaline membrane disease.
A bronchopneumonic infiltrate is most commonly encountered in the 
first month of life. This can be caused by aspiration of sterile or infected am- 
niotic fluid or by viral, chlamydial, or bacterial pathogens, or it can represent 
patchy atelectasis.
Staphylococcal pneumonia is found most commonly in young in­
fants—30% of patients are younger than 3 months of age, and 70% are 
younger than 1 year of age. Epidemics of Staphylococcal disease caused by 
phage group I organisms are encountered infrequently.
Staphylococci cause a confluent bronchopneumonia, characterized by 
extensive areas of hemorrhagic necrosis and irregular areas of cavitation. The 
pleural surface is usually covered by a thick layer of fibrino-purulent exudate. 
Multiple small abscesses are scattered throughout the lungs. Rupture of a 
small sub-pleural abscess may result in a pyopneumothorax, which may 
erode into a bronchus, producing a bronchopleural fistula.
The onset of illness in Staphylococcal pneumonia is abrupt, with fever, 
cough, and respiratory distress as the major manifestations. Tachypnea, 
grunting respirations, retractions, cyanosis, and anxiety are usually observed. 
Severe dyspnea and a shocklike state may occur. Rapid progression of symp­
toms is characteristic. Moist, scattered rales, diminished breath sounds, and
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rhonchi may be heard early in the illness. With the development of pleural 
effusion, dullness on percussion is associated with diminished breath sounds.
Most patients with Staphylococcal pneumonia have roentgenographic 
evidence of bronchopneumonia early in the illness. The infiltrate may be 
patchy and limited in extent or be dense and homogeneous, involving an en­
tire lobe or hemithorax. Pleural effusion or empyema are found in most in­
fants. Pneumatoceles of various sizes are common. Although no radiographic 
change can be considered diagnostic, progression over a few hours from 
bronchopneumonia to effusion or pyopneumothorax with or without pneuma­
toceles is highly suggestive of Staphylococcal pneumonia.
TREATMENT
All diagnostic procedures and cultures should be obtained before 
initiation of therapy. Methicillin is the initial drug of choice for Staphy­
lococcal pneumonia and should be administered parenterally in a dosage of 
75 mg/kg/day, divided in two or three doses for infants younger than 1 week 
of age and in a dosage of 100 mg/kg/day divided in four doses for older 
infantif infection extends to the pleural surfaces, surgical intervention usu­
ally becomes necessary. With small amounts of effusion, repeated pleural 
taps may be successful in removing fluid, but empyema is best treated by 
closed drainage with a chest tube of the largest possible caliber.
Vancomycin is preferred for disease due to MRSA. For pneumonia 
caused by K. pneumoniae or other coli-forms, kanamycin or gentamicin 
should be used in a total dosage of 15 mg/kg/day or 5 to 7.5 mg/kg/day, re­
spectively. Alternatively, a third-generation cephalosporin, such as cefo­
taxime, can be used. Treatment for Listeria pneumonia is parenteral ampicil- 
lin in a dosage of 50 to 100 mg/kg/day, divided in two doses for infants 
younger than 1 week of age and 100 to 150 mg/kg/day divided in three doses 
for older neonates. Infants with GBS septicemia and pneumonia should be 
given penicillin in a dosage of 50,000 U/kg/day divided in two doses for in­
fants younger than 1 week of age and 75,000 to 100,000 U/kg/day divided in 
three or four doses for older infants. Larger doses are required for meningitis. 
Ampicillin or cefotaxime may be used in place of penicillin.
Chlamydial and ureaplasmal pneumonias are probably best treated 
with orally or intravenously administered erythromycin, depending on the in­
fant's clinical status. This agent has been shown to shorten the course of ill­
ness and to eradicate shedding of the organisms from the nasopharynx. 
Trimethoprim-sulfamethoxazole is the initial drug of choice for P. carinii 
pneumonia; pentamidine is reserved for treatment failures.
Pneumonia may be one manifestation of generalized congenital viral 
infections. It is important to differentiate these infections from congenital 
syphilis and bacterial pneumonias resulting from aspiration. There is no con­
vincing evidence that antiviral chemotherapy is effective in infants with con­
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genital cytomegalovirus infection. Vidarabine or acyclovir are effective if 
given early in disease caused by herpes simplex virus.
Most infants with aspiration pneumonia do not require antimicrobial 
therapy. It is frequently difficult to differentiate infants with aspiration of 
sterile amni-otic fluid from those aspirating infected materials. If doubt ex­
ists, therapy with penicillin and kanamycin or gentamicin should be initiated 
and continued until results of cultures are available.
OTITIS MEDIA
Otitis media is a frequent finding in premature infants receiving inten­
sive care and an almost universal finding in autopsy studies of infants who 
died after a period of intensive care. A principal predisposing factor for otitis 
media in the newborn is nasotracheal intubation that results in ipsilateral ob­
struction of the eustachian tube, establishing the conditions eventuating in 
middle ear infection. The diagnosis is frequently missed because pneumatic 
otoscopy is not routinely performed in neonates.
The exact incidence of this condition is unknown. In one prospective 
study of 70 infants followed from birth, 34% developed their first episode of 
otitis media before 2 months of age. Symptoms are nonspecific and include 
irritability, lethargy, fever, cough, diarrhea, vomiting, tachypnea, and ano­
rexia. An associated conjunctivitis, pneumonia, or meningitis may be found 
in one-half of the patients. The diagnosis is usually made by pneumatic oto­
scopy. Tympanometry is unreliable in neonates.
Pathogenic organisms include S. pneumoniae, H. influenzae, S. aureus, 
Moraxella catarrhalis, and coliforms. The predominant isolates vary in dif­
ferent study populations.
Tympanocentesis should be performed on all newborns with otitis me­
dia who develop illness while in the nursery or intensive care unit. This may 
yield an etiologie agent when cultures of other sites are sterile. Some infants 
have positive blood cultures. The choice of antibiotic therapy can be based on 
the results of the Gram stain and culture of the aspirated middle ear effusion. 
If no organisms are seen on the smear, treatment should be with methicillin 
and an aminoglycoside until additional information is available. Infants with 
otitis media who are seen in the clinic or office do not usually require tym­
panocentesis for etiologie diagnosis if the illness is mild and can be managed 
at home. In these infants, cefaclor or Augmentin (amoxicillin and clavu- 
Ianate) is preferred for therapy, and the patients should be reexamined 2 or 3 
days after initiation of therapy to ascertain improvement. Infants with onset 
of otitis media before 2 months of age need as long as 3 months to clear the 
effusion, and 33% of them develop chronic otitis media.
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P E R I T O N I T I S
Spontaneous bacterial (i.e., primary) peritonitis without an evident in­
traabdominal source is rare during the neonatal period. It is postulated that 
bacteria can reach the peritoneal cavity by means of hematogenous, lym­
phatic, genital, or transmural (i.e., across the gut wall) routes of spread. A 
concurrent omphalitis is common. Gram-positive bacteria (e.g., S. p n e u m o ­
niae, groups A and В streptococci) are the predominant pathogens, but gram­
negative bacilli such as Ps eu do mo na s  or Klebsiella are responsible for some 
cases.
Most infants develop peritonitis after perforation of an abdominal vis- 
cus, usually as a complication of necrotizing enterocolitis. Other predisposing 
conditions include spontaneous focal gastrointestinal perforations, wound in­
fections after abdominal surgery, traumatic perforations (e.g., feeding tube, 
rectal thermometer), ruptured omphalocele, and meconium peritonitis with 
subsequent bacterial contamination. Organisms isolated from peritoneal fluid 
cultures generally mirror the infant's gut flora and include E. coli, Klebsiella 
spp., Enterobacter  spp., Pseudomonas,  coagulase-positive and coagulase- 
negative staphylococci, streptococci, enterococci, anaerobic bacteria (e.g., 
Clostridia, Bacteroides  spp.), and Candida.
Clinical signs of peritonitis include vomiting, abdominal distention, 
abdominal wall edema or discoloration, constipation, diarrhea, grunting, tem­
perature instability (i.e., usually hypothermia), shock, and scrotal or vulvar 
swelling. Abdominal radiographs may reveal free air in the peritoneal cavity, 
indicating intestinal perforation, or patterns suggesting necrotizing 
enterocolitis (e.g., pneumatosis intestinalis) or intestinal obstruction. 
Abdominal ultrasound is helpful in visualizing peritoneal fluid. An 
abdominal paracentesis may yield pus or reveal a different cause for the 
illness (e.g., hemoperitoneum, bile peritonitis). Aerobic and anaerobic 
cultures of the peritoneal fluid and of the blood should be obtained in all 
cases. The management of peritonitis consists of supportive measures aimed 
at reversing hypovolemia, shock, and electrolyte imbalances; of surgical cor­
rection of underlying conditions; and of the administration of broad-spectrum 
antimicrobial agents. Acceptable initial antibiotic regimens include ampicil- 
lin, gentamicin and clindamycin, Timentin and an aminoglycoside, or van­
comycin, ceftazidime, and metronidazole. The broadest antibacterial cover­
age is attained by the vancomycin, ceftazidime, and metronidazole combina­
tion. Treatment can be simplified after the blood and peritoneal fluid culture 
results become available. Antibiotics are usually continued for 10 days. The 
prognosis depends on several factors, including birth weight and precipitating 
conditions, and fatality rates range from 10% to 50%.
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NEUROMUSCULAR DISEASE
The principles of rehabilitation medicine are important in the evaluation 
and treatment of infants who present with nerve or muscle problems that af­
fect tone, posture, and movement. They may be congenital or traumatic in ori­
gin. These principles include making an accurate diagnosis and recognizing its 
impact on the functional capacity of the infant; minimizing deformity that can 
become exaggerated with growth; and, if there is permanent disability, giving 
training in compensatory movements to optimize function.
Parents should be integrally involved, supported, and counseled on the 
nature of their child's disability. They should develop a reasonable level of 
comfort and be taught basic handling techniques that they can apply regularly 
to their infant. The rest of this chapter details the more common clinical disor­
ders that come under the purview of rehabilitation medicine.
TRAUMATIC PERIPHERAL NERVE PALSIES
AND SPINAL CORD INJURIES
Traumatic peripheral palsies as well as spinal cord injuries in the new­
born usually are associated with difficult deliveries. The infant's head and face 
may be subject to prolonged pressure; because of their width, the baby may 
have difficulty slipping the shoulders through the birth canal or, if presenting 
in a breech position, too much traction may be exerted on the legs and lower 
spine. There may be vigorous distraction and hyperextension of the after­
coming head. The bony spinal column may distract and not fracture, but the 
spinal cord is vulnerable to injury from traction.
FACIAL PALSY
Facial palsy may occur in association with a complicated delivery, par­
ticularly when there is extended impingement of the baby's head against the 
maternal sacrum, prolonged application of forceps, or intracra-nial bleeding 
with or without skull fracture. The infant is unable to wrinkle the forehead, 
close the eyes, or suck a nipple without dribbling the milk on the affected side 
(Fig. 44). The incidence varies from 0.05% to 1.8%.
This condition must be differentiated from congenital maldevelopment 
of the seventh nerve nucleus itself, which is frequently bilateral and associated 
with abducens palsy, as seen in the Mobius syndrome. It should not be con­
fused with persistent partial congenital palsies seen with chondrocardiac 
anomalies (e.g., Klippel-Feil syndrome, Sprengel deformity), some pho- 
comelias, and cardiac malformations reflecting maldevelopment of the visceral 
arches. Central facial palsy involves the lower portion of the face and is charac­
terized by flattening of the nasolabial fold, a droop of the involved comer of 
the mouth, and sparing of the muscles of the forehead and eye. It can be asso­
ciated with intracranial hemorrhage or in-farcts. To be distinguished from all
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others is a benign condition, described by Nelson and Eng—congenital absence 
or hypoplasia of the depressor anguli oris (i.e., triangularis) muscle (Fig. 45). 
In this condition, one comer o f the mouth does not move downward and out­
ward with the other when the baby is crying. The rest of the facial muscles are 
intact, allowing the baby to frown, close the eyes, wrinkle the nose, and suck 
without dribbling because, despite palpable thinning of the lateral portion of 
the lower lip, the orbicularis oris functions normally. It may represent the 
least remnant of a first visceral arch syndrome. Therefore, associated con­
genital cardiac lesions must be considered. As the child grows and increas­
ingly uses the smiling muscles (i.e., the risorius and zygo-maticus), the oral 
asymmetry will become less prominent
<*•
FIG. 44. Right facial palsy in a 2-week-old infant.
In birth palsy of the facial nerve, the asymmetry of facial movements 
may be profound and may not reflect the true integrity of the nerve. Clinical 
criteria that may predict prognosis (e.g., pain about the ear, associated symp­
toms such as hyperacusis and loss o f taste) cannot be evaluated in an infant. 
Fortunately, there are simple electrodiagnostic tests that can provide valuable 
information on the state of the nerve.
FIG. 45. Hypoplasia of the left depressor anguli oris muscle in a 2- month-old infant. 
NERVE EXCITABILITY TEST
This can be performed 72 hours after onset. The facial nerve is 
stimulated in front of the ear with surface electrodes using a square wave
54 1
A
pulse 0.1 to 0.2 milliseconds in duration. Visual observation of the muscle 
contraction in response to the stimulus intensity in milliamperes is com­
pared between the normal side and the affected side. If the threshold cur­
rents are the same, then neurapraxia (i.e., block o f nerve impulse secon­
dary to edema) exists, and recovery should occur in several days or 
weeks. Late degeneration of the nerve can occur; therefore, repeated test­
ing is indicated at 3- to 5-day intervals until stabilization or gradual re­
covery becomes evident.
NERVE CONDUCTION LATENCY
The facial nerve is stimulated in front o f the ear, and the impulse is 
recorded from the frontalis or levator anguli nasi muscles. If the nerve 
loses all response to electrical stimulation, the prognosis is guarded. This 
test may be done 7 to 10 days after onset.
The amplitude and duration of the evoked compound motor ac­
tion potential compared between the normal and the affected side may in­
dicate the extent of the pathologic condition and prognosis. Eliciting the 
blink reflex can give information on the more proximal portion of the facial 
nerve. The stimulus is applied to the supraorbital nerve and two responses 
are elicited, Rt, which represents a pontine pathway, and R2, which is re­
layed presumably through the pons and medulla. R2 may be elicited in only 
two thirds of neonates, according to Kimura, and mostly on the side of the 
stimulus, rarely on the contralateral side.
ELECTROMYOGRAM
This may be done 14 to 21 days after onset. Absence of motor unit ac­
tivity, and presence of fibrillation potentials and sharp waves depict a state 
of denerva-tion. Sequential studies are useful for evaluation of reinnervation 
leading to gradual improvement.
Because many infants with facial palsy recover spontaneously within 
several days to 3 weeks after delivery, the pathophysiologic process in 
these infants is undoubtedly one of mild neurapraxia. The infants who are 
referred for consultation usually are more seriously involved, yet their 
numbers are not large in the total spectrum of facial palsies affecting chil­
dren. Twenty-eight patients with facial palsy were studied over a 1-year 
period. Only 11 were seen in the newborn period; 6 had traumatic palsies, 
and 5 had congenital palsies associated with other anomalies. All but one 
infant of the six with traumatic palsies recovered spontaneously by 5 months 
of age. If there was evidence of denervation on initial electro-diagnostic stud­
ies, the nerve regenerated at approximately 2.5 cm (1 inch) each month. The 
congenital group did not change on follow-up because, in this group, there 
was agenesis of a lower branch or the entire lower division of the facial 
nerve.
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General principles of management have been formulated based on 
experience with this problem. If the clinical picture and electrodiagnosis 
suggest mild involvement or neurapraxia, no treatment is required. If par­
tial denervation exists, physical therapy, including massage and later active 
exercises, is prescribed. The use of corticosteroids to suppress edema and 
inflammation seems to hold no justification in birth palsy. Methylcellulose 
drops and taping of the involved eye to prevent excoriation of the cornea are 
the only treatments indicated. The complications of synkinesis and contrac­
ture rarely are seen in infants.
BRACHIAL PLEXUS PALSY
The brachial plexus may be injured during delivery when the infant's 
head has been delivered and the shoulders are trapped in the birth canal. 
Hyperextension o f the head may exert traction of the cervical roots and 
plexus.
Erb palsy is paralysis of the muscles of the arm supplied by compo­
nents of C5 and C6 nerve roots. It is the most common form of paralysis and 
is clinically obvious in an infant who has a one-sided Moro reflex, and whose 
affected arm hangs limply adducted and internally rotated at the shoulder, 
extended and pro-nated at the elbow, and with flexed wrist in the typical 
waiter's-tip posture. Deep tendon reflexes are diminished or absent in the 
paralyzed arm.
Klumpke paralysis affects only the muscles of the hand supplied by 
C8 to T1 nerve roots. It is seen rarely in infancy as an isolated entity after 
birth trauma. It has been associated with thoracic outlet tumors, cystic hy­
gromas, cardiac surgery, and spinal cord injury. Total plexus involvement 
affects all the muscles in the arm because the entire plexus from C5 to T1 has 
been damaged (Fig. 46). The arm lies motionless, usually devoid of sweat 
and sensation, and the hand becomes small, dry, and atrophic. The deep ten­
don reflexes are absent in the affected arm.
Intrauterine brachial plexus palsy has been described by Koenigsber- 
ger and Dunn and colleagues, and I have seen a case on one occasion. Ab­
normal intrauterine position of the fetus's arm—usually in abduction and ex­
ternal rotation at the shoulder, hand impinged behind infant's head—can re­
sult in chronic traction of the plexus. The infant's hand is usually small and 
atrophic with very simple palmar creases. Electrodiagnostic studies are ab­
normal right from birth rather than 2 to 3 weeks after delivery.
In an early report of 135 infants from the Children's National Medical 
Center, the obstetric histories were universally complicated. Long, difficult 
labors and the use of general anesthesia were the rule. The babies, with the 
exception of one, weighed between 3600 and 7000 g. The incidence of ab­
normal presentation was high. Associated defects included torticollis, facial 
palsies, subluxations of the shoulder, fracture o f the clavicle and humerus,
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slippage of the capital head of the radius, subluxation of the cervical spine 
with evidence of traction injury of the cervical cord, ipsilateral diaphragmatic 
paralysis, and even peri-adrenal hemorrhage; all suggest the traumatic nature 
of these deliveries. Homer syndrome associated with complete plexus palsy 
was seen in eight infants. Phrenic nerve paralysis may account for acute respi­
ratory compromise in some affected infants. The integrity of the nerve can be 
assessed within the first 10 to 15 days of life. Since the initial study, over 500 
patients with plexopathy have been seen and treated, which suggests that the 
relative incidence remains the same.
FIG. 46. (A) Newborn girl with 
complete brachial plexus palsy in­
volving the left arm. Atrophy of the 
pec-toralis major muscle and also the 
Homer syndrome (i.e., ptosis of the 
left lid) are present. (B) At 1 year of 
age, return of the function of the C5- 
and C6-supplied muscles has oc­
curred, but no return of function of 
the C7-, C8-, and Tl-supplied mus­
cles has taken place. The hand is 
atrophic and devoid of sensation. 
Note the persistent Homer syn­
drome.
Conduction latencies of the axillary, musculocuta-neous, median, and 
ulnar nerves, as well as ulnar and median H reflexes, and electromyography 
(EMG) are extremely useful in accurate delineation of the extent of the 
pathologic condition. The first examination can be done 2.5 to 3 weeks after 
birth. The second study should be done at 3 months of age. This second 
study is critical in assessing the integrity o f the C5- and C6-supplied mus­
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cles. If  there is no rein-nervation by 3 months into the biceps, then further 
radiographic studies are indicated. These include computed tomography 
myelography or magnetic resonance imaging of the cervical spine, and deci­
sion for surgical nerve grafting or neurotization, especially if there is dis­
ruption o f the nerves. Rupture of the nerve roots as evidenced by pseu­
domeningocele may not mean complete root avulsion, however. Even in 
these infants, reinnervation may still occur, as evidenced by improvement 
on EMG studies. Therefore, early surgical intervention remains a contro­
versial subject.
CONSERVATIVE MANAGEMENT
The initial neuritic pain may preclude immediate vigorous interven­
tion; however, gentle and meticulous movement of the joints of the para­
lyzed extremity should be started as soon as tolerated. Scapulohu-meral 
winging, limitation of internal and external rotation, abduction of the shoul­
der, loss of supination of the elbow, flexion deformity of the wrist, and tight 
adduction of the thumb quickly develop without treatment. Supportive 
splints to hold the wrist and hand in good alignment may be indicated. Elec­
trical stimulation of the denervated muscle to prevent fibrosis is a debatable 
form of treatment. To be effective, treatment should be started early, be 
applied with regularity, and be of sufficient current intensity to cause maxi­
mal muscle contraction. As recovery ensues, active exercises for strengthen­
ing the proximal shoulder girdle and arm muscles are included. The infant 
must be made aware of that extremity as a part of himself.
Sequelae, even in the mildest paralysis, include scapular winging and 
loss of shoulder abduction and elbow supination. More serious complica­
tions include loss of bone growth (Fig. 47), persistent loss of sensation, and 
total lack of awareness of the arm by the infant, even with good neuromotor 
and sensory recovery.
The differential diagnosis of brachial plexus palsy includes pseu­
doparalysis from fracture or osteomyelitis of the scapula, humerus, or other 
bones of the extremity, and hemiplegia of central origin. None of these enti­
ties usually is apparent at birth, and the deep tendon reflexes are pre­
served.
SPINAL CORD INJURY
In this era of intensive resuscitative care of asphyxiated neonates, 
those born with evidence of severe hypoxic ischemia may not only have en­
cephalopathy secondary to cortical neuronal necrosis and subcortical white 
matter injury, but also may have ischemic necrosis of spinal cord gray mat­
ter. According to Clancy and associates, depressed tone and hyporeflexia 
should alert the clinician that spinal cord involvement can coexist with
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cerebral insult. Survivors showed evidence of acute denervation on EMG in 
muscles supplied at or below the level of injury.
Spinal cord injury can occur after difficult breech extraction. Persis­
tent intrauterine hyperextension of the head can result in chronic impinge­
ment of the cervical and upper thoracic spine. Infants delivered by cesarean 
section also can sustain injury to the spinal cord, as evidenced by a case de­
scribed by Hernan-dez-Marti and colleagues, and two infants that I have 
seen. These latter two infants presented with bilateral plexus injury pre­
dominantly affecting C8-and T1-supplied muscles, resulting in partial pa­
ralysis of the trunk and lower extremities in one child, and complete cervi-
FIG. 47. (A) A 4-week-old boy with complete brachial plexus palsy involving the right 
arm. (A) The same patient at 3 years of age shows length discrepancy and loss of growth of 
the right arm. The hand intrinsic muscles are weak, and sensation is not intact.
Umbilical artery catheterization has caused spinal cord as well as 
other major organ infarctions. In such cases described in the literature, the 
tips of the catheters were located high in relation to the thoracic spinal cord, 
and thrombotic or embolic occlusion of the arterial supply to the anterior 
spinal cord presumably occurred. It has been recommended that the catheter 
be inserted to the level of the tenth thoracic vertebra or below the third lum­
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bar vertebra, recognizing that major vessel branches arise one vertebral body 
higher in infants than they do in adults.
In those infants suspected of spinal cord injury, routine radiographic 
studies are of limited value because vertebral fractures and subluxations 
rarely are seen. Somatosensory evoked potentials can be useful in cases af­
fecting the midthoracic level of the cord, but upper thoracic and cervical re­
cordings frequently are difficult to obtain even in normal infants, and scalp 
potentials overlying the somatosensory cortex may be absent in one third of 
newborns. Magnetic resonance imaging is considered superior to myelogra­
phy in its ability to define spinal cord pathology, and provides direct visuali­
zation of the spinal cord.
Management of the newborn with a spinal cord lesion requires an in­
terdisciplinary approach. The physicians must attend to the problem of spi­
nal cord stability and to pulmonary, urologie, and gastrointestinal complica­
tions. The physical and occupational therapists prevent contractures and 
malalignment, and provide appropriate developmental stimulation to the 
affected infant. The nurse tends to temperature stability, feeding, suctioning, 
prevention of skin breakdown, and instruction of parents on proper han­
dling techniques. A lightweight polypropylene body orthosis or a canvas 
jacket with flexible metal stays allow support of the trunk. Hand and 
foot splints to prevent deformity also are prescribed. An infant seat that 
provides well contoured support o f the infant also is a necessity.
Successful rehabilitation must include the parents' understanding and 
care of their disabled child. Therefore, the social service personnel should 
play an integral role in meeting parental needs and facilitating long-term 
rehabilitation options.
CONGENITAL TORTICOLLIS
Torticollis, or wry neck, is recognized in an infant who persists in 
tilting the head to one side because o f tightness of the sternocleidomastoid 
muscle or the trapezius and scalene muscles. There is asymmetry of the in­
fant's face, with flattening of the cheek and temporal region, narrowing of 
the palpebral fissure, compression o f the ear, and elevation of the shoulder 
on the side of the tight muscles, as well as flattening of the contralateral 
occiput (Fig. 48). By the second to fourth week of life, a hard fusiform 
mass (i.e., an olive) is palpable in the belly of the muscle. It may increase 
in size, then gradually disappear when the infant is between 4 and 7 
months of age, occasionally leaving a thick, fibrotic, noncontractile mus­
cle.
The birth history in an infant with torticollis is remarkable in that it 
is usually difficult, is frequently a breech presentation, and occasionally 
even necessitates a cesarean section. Despite speculation on the patho­
genesis of this problem, the reason for the torticollis probably lies in the
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fact that the sternocleidomastoid pathologic condition exists in utero, pre­
cluding engagement of the infant's head in the birth canal. The concept 
that there is a hereditary defect in the anlage of the muscle is derived from 
the discovery of anomalous muscles in relatives or of the association of 
ipsilateral hip dislocation or clubfoot in the affected infants. Intrauterine 
denervation and infection have not been substantiated by pathologic dis­
sections of the involved muscle, which usually consists of glistening 
white fibrous tissue engulfing muscle fibers, without evidence of hem­
orrhage.
Congenital torticollis must be differentiated from bony anomalies 
of the cervical spine and shoulder girdle (i.e., Klippel-Feil syndrome 
with or without Sprengel deformity) and acquired wry neck associated with 
acute trauma, pharyngotonsillitis, adenitis, cerebral irritation secondary to 
meningitis, posterior fossa tumors, visual and labyrinthine disorders, and 
postshunting for hydrocephalus. A mass in the neck may represent ade­
noma, cystic hygroma, dermoid, or rhabdomyoma.
FIG. 48. (A) Congenial torticollis affecting the right sternocleidomastoid muscle in a 
3-month-old infant. (B) Note the flattening of the left occiput and right head tilt.
In a review of 277 patients seen between 1970 and 1982, with a 2- to 
13-year follow-up, 70% of the infants had resolution of the problem by 12 
months of age. Tenotomies were required in ten children, eight having been 
first evaluated after 1 year of age. In a young baby, physical therapy is emi­
nently successful in stretching the contracted muscle. The parents are taught 
two basic exercises: stretching of the clavicular portion by lateral flexion of 
the head to the opposite side, and stretching of the sternal portion by rotation 
of the chin to the affected side. Occasionally, the trapezius and the muscles 
over the ipsilateral pelvic brim also must be stretched, because the baby 
tends to assume a long C-scoliotic curve. A soft, or a firmer, plasticized col­
lar can be made readily to hold the head in good alignment. Hanging toy mo­
biles above the baby’s head on the affected side and placing the crib so that 
the baby has to turn the head to the affected side to see what is happening in 
the room are recommended for active stretching on the infant's part. Later,
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strengthening exercises will provide balanced flexion of the head. With early 
treatment, the asymmetry lessens as the skull and facial bones are permitted 
to remold. At 2 years of age, the entire contour is appreciably improved.
TONE
Ifants frequently are examined because of problems in tone. To sepa­
rate tonal changes caused by upper motor neuron disorders from peripheral 
neuromuscular weakness, the concept of tone must be considered.
Tone is that quality in muscle that resists movement. The French call 
it extensibilite, and relate it to slow stretch while moving the muscle 
through a range of motion. It also can be described as a recoil phenomenon. 
When the muscle is stretched passively and released, it springs back to its 
original position. When there is stretch and no rebound, allowing for limp­
ness, this is hypotonia. When there is a constant resistance to stretch associ­
ated with a lead-pipe delay in relaxation, this is rigidity. Further, if there is 
stretch with too rapid rebound and too much recoil, this is spasticity.
MECHANISM
Neurophysiologists long have attempted to unravel the nervous con­
trol of posture and movement. It now appears that the у nervous system, with 
its muscle spindles, the primary and secondary endings in the spindles, the 
afferent у pathways, the у motor neurons in the ventral horn of the spinal 
cord, and the efferent у fibers back to the spindles, assumes important roles in 
the mechanism of tone. The monosynaptic connection between the group la у 
afferent fibers and the a motor neurons, which send axons to the extrafusal 
fibers, constitutes the important stretch reflex. Inhibitory potentials from an­
tagonistic muscles, as well as cutaneous and visceral afferents, affect the 
motor neuronal pathway. Supraspinal centers, through the corticospinal 
or lateral vestibulospinal tracts and reticulospinal pathways, send modify­
ing influences to both the a motor and у motor neurons.
More specifically, the muscle spindles are sensory structures. They 
are small and fusiform in shape, lying parallel to skeletal muscle fibers. 
There are two types of intrafusal fibers in the muscle spindles, a nuclear 
bag fiber and a nuclear chain fiber. Each nuclear bag and nuclear chain fiber 
has a sensory ending that unites to form the group la sensory afferent 
nerve. The secondary endings come from nuclear chain fibers and form the 
group II afferent nerve fibers. Presumably, the primary ending from the 
nuclear bag intrafusals is sensitive to the rate of change of muscle length in 
stretch, and the secondary endings are sensitive to change in length. Ac­
cording to Rushworth, group la afferent fibers not only have monosynaptic 
connections with the a motor neurons in the spinal cord of the same muscle 
but also end in motor neurons of the synergistic and antagonistic muscles. 
The exact function of the secondary endings is not clear, but they conduct
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more slowly, are polysynaptic, and are thought to facilitate flexor and in­
hibit extensor a motor neurons in the regulation o f posture.
In the ventral horn of the spinal cord, the a motor neurons send ax­
ons back to the extrafusal muscle fibers. Gamma I and у II motor neurons 
in turn send fibers that terminate in the intrafusal muscles fibers as trail 
endings and plate endings.
The у system modulates voluntary movement. According to Matthews, 
the у afferents connect with the a motor neuron by way of the spindle loop 
as a "closed-loop servomechanism" controlling the length of the muscle, 
whereas the у efferents control the "damping" of this loop and its controlled 
position.
Although Rushworth believed that overactivity of the у system re­
sulted in spasticity and rigidity, it is known that the cortex, basal ganglia, 
and cerebellum modulate brain stem structures to affect motor control. In­
terruption of the extrapyramidal fibers results in spasticity, and selective 
destruction of corticospinal tracts can result in hypotonia.
CHANGES IN TONE IN THE BRAIN-INJURED INFANT
A cerebrally damaged infant's tone may remain flaccid for days or 
weeks after delivery. The infant then progressively assumes abnormal pos­
tures and increasing stretch reflex. Tone can be modified by changing the 
infant's position. Hypotonia in prone may be hypertonia in supine and ex­
aggerated hyper-tonicity in vertical suspension. The release of descending 
vestibulospinal impulses from higher cortical control probably is responsi­
ble for these shifts in tone. Changing the position of the infant's head will 
evoke the labyrinthine reflexes that also affect tone. Hyperextension of the 
head will elicit hyperextension of the trunk and facilitate hypertonicity of the 
limbs. Flexion of the head will relieve the hypertonus and relax the limbs. Im­
posing the tonic neck reflex increases the extensor tone in the limbs on the face 
side of the infant and the flexor tone on the occipital side. There may exist a 
discrepancy between hypotonicity affecting neck and trunk muscles and hy­
pertonicity of the limb muscles. Deep tendon reflexes and infantile automa­
tisms, although important in the early assessment of the infant, frequently are 
unreliable because they again are subservient to tone.
The problem in discrimination between brain and peripheral neuro­
muscular disease lies not in the overtly cerebrally damaged infant with chang­
ing tone but in the infant with persistently depressed tone. It may be hard to 
determine whether an infant has peripheral neuromuscular disease or brain 
damage because both conditions have a similar history:
• varying degrees of intrauterine immobility
• difficult labor
• slow engagement and descent in the birth canal
•a  flaccid, immobile infant with weak cry and alow Apgar score at
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birth.
Prolonged hypotonia may be seen in the kemicteric infant after the initial 
rigid, opisthotonic state; atheto-sis may appear at the end of the first year of 
life.
Severe anoxia can produce a depressed baby for several months who 
then becomes increasingly choreoathetoid. My experience bears out Paine and 
Oppe's statement that "persistent and permanent hypotonicity of the body as a 
whole is also occasionally seen with chronic brain syndrome and may include 
hypo-or areflexia (and usually severe mental deficiency as well).
THE HYPERTONIC INFANT
Occasionally, an infant may present with too much tone. Such an in­
fant tends to be stiff in the limbs, head control is too good, and on the Lan­
dau maneuver shows too much extension of the head and legs. When placed 
on the feet, the infant jerks into full vertical extension, rearing into almost an 
opisthotonic posture. Increased jitteriness, regurgitant feeding patterns, brisk 
jaw jerks, and deep tendon reflexes may be observed. The infant usually has 
a complicated gestational history that may include maternal drug abuse, may 
be premature, or may be small for dates. As the infant grows, the rigidity may 
diminish and milestones begin to be attained readily; the infant gradually 
evolves into a perfectly normal baby by 14 to 18 months of age. On the 
other hand, the infant may become overtly spastic with delayed develop­
ment and varying degrees of psychomotor retardation. Drillien, in a pro­
spective study of 300 children of low birth weights, described "transient 
dystonia" in some of the babies in the first year of life. Mental impairment 
and hyperactivity were noted in these babies by 2 to 3 years of age com­
pared to the children who did not show abnormal neurologic signs. Those 
same children show deficits in language skills, motor perception, behavior, 
and learning when they reach school age.
THE HYPOTONIC, PERIPHERAL
NEUROMUSCULAR-DISEASED INFANT 
The hypotonic infant with lower motor neuron involvement usually as­
sumes very typical postures without changes in tone when his posture in 
space is altered. When lying supine, the arms rest slightly abducted and in­
ternally or externally rotated at the shoulder, with elbows flexed and pro- 
nated and fingers clenched in slight ulnar drift. The hips are maintained in 
an abducted externally rotated position in the pithed-frog posture. The cry 
is weak, breathing may be paradoxic with asynchronous expansion of the 
chest cage and the abdomen, and the only spontaneous movements involve 
small excursions of the fingers and toes. Deep tendon reflexes are de­
pressed and frequently absent. The Moro reflex, tonic neck reflexes, and 
crossed adductor responses usually are not elicitable. The infant may have
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an expressionless facies, but alternatively may appear vitally alert despite 
profound weakness (Fig. 49).
FIG. 49. (A) A hypotonic 3-month- 
old infant with Werdnig-Hoffinan 
disease lies in a typical immobile 
posture. He appears alert despite 
profound weakness and paradoxical 
respirations. (B) Severe head lag is 
noted when traction is exerted on the 
infant's arms.
LABORATORY AIDS IN PERIPHERAL
NEUROMUSCULAR DISORDERS
The laboratory becomes of inestimable value in the detailed study of in­
fants with hypotonia. Muscle enzymes, EMG, and muscle biopsy are impor­
tant in laboratory confirmation of the clinical impression.
MUSCLE ENZYMES
Elevated serum enzyme levels of creatine phospho-kinase, aldolase, and 
transaminases reflect muscle breakdown. They are normal in the cerebrally 
damaged infant, may be slightly elevated in neurogenic disease and some 
myopathies, and markedly elevated in muscular dystrophies. Creatine kinase 
levels are particularly specific for intrinsic muscle disease; however, they may 
be considerably elevated in normal infants during the first hours of life, 
gradually tapering to near normal levels by 5 days of age, but may persist in 
slight elevation throughout the first year of life.- Cautious interpretation of the 
enzyme levels is therefore necessary, especially when a baby with possible 
congenital Duchenne dystrophy is being considered. The enzymes should 
therefore be drawn after the end of the first week of life. It also is preferable to 
request enzymes before EMG because trauma caused by needle exploration 
may elevate the creatine kinase for 72 hours. Intramuscular injection also will 
cause a rise in creatine kinase levels.
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ELECTRODIAGNOSIS
The development of electrodiagnosis has proven a valuable adjunct to 
the neurologic differentiation of hypotonic infants. The electrical studies are well 
tolerated by neonates. They include study of neuromuscular transmission, 
nerve conduction velocity determinations, and EMG. Their application is based 
on knowledge of maturation of the infant's peripheral nervous system. In this 
regard, even the gestational age of infants can be estimated by conduction ve­
locities of their peripheral nerves. Full-term infants' nerve conduction velocities 
are approximately one-half those of adults and mature to adult levels by 3 to 5 
years of age. These nerve conduction velocity studies provide information rele­
vant to the integrity of the peripheral nerve, particularly in suspected polyneu­
ropathies.
Neuromuscular transmission likewise improves with maturation and 
deteriorates when disease states such as myasthenia gravis or botulism and 
other poisonous agents intervene.
The EMG has proven especially excellent in providing information re­
garding the muscle. The size and duration of the motor unit action potentials, 
the aggregation of these potentials and firing rate to form an interference pat­
tern, the tracing when the muscle is at rest—whether it is silent or shows fibril­
lation potentials and sharp waves—may reflect the presence or absence of a 
pathologic condition. Irritability of the muscles on needle exploration may sig­
nify sick muscles. The presence of runs of positive potentials (i.e., iterative dis­
charges) may suggest myotonia and is evidence of instability of the muscle 
membrane.
MUSCLE BIOPSY
The enzyme and electrodiagnostic data lead to necessary confirmation of 
suspected muscle disease by muscle biopsy. The importance of meticulous 
handling of the biopsy specimen cannot be overemphasized, especially when 
the possible diagnosis of a rather obscure myopathy is involved. The selection 
of the biopsy site is important. It should reflect disease that is active but not so 
advanced pathologically that all landmarks are destroyed. A muscle that has 
been recently studied by EMG or that has received intramuscular injections 
should be avoided. The biopsy then may show inflammatory reaction and fre­
quently identifiable needle tracks. A full complement of histo-chemical staining, 
electron microscopy, dystrophin assay, and interpretation by a physician ex­
perienced in muscle disorders should be available before a biopsy is attempted.
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